niacinamide has been researched along with Hepatocellular Carcinoma in 1637 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the only effective drug for advanced hepatocellular carcinoma (HCC), but few data predictive of its effectiveness are available." | 10.25 | A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. ( Kong, D; Ma, W; Song, T; Wu, Q; Zhang, W, 2011) |
| "The aim of this study is validated the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma." | 9.51 | Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study. ( Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL, 2022) |
| "This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in combination (SAM) with atorvastatin (A, 10 mg) and metformin (M, 500 mg BD) in patients with advanced hepatocellular carcinoma (HCC)." | 9.51 | Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). ( Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S, 2022) |
| "SORAMIC is a randomized controlled trial in patients with advanced hepatocellular carcinoma (HCC) undergoing sorafenib ± selective internal radiation therapy (SIRT)." | 9.51 | Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. ( Alunni-Fabbroni, M; Benckert, J; Chow, PKH; Gasbarrini, A; Kuhl, C; Malfertheiner, P; Öcal, E; Pech, M; Ricke, J; Sangro, B; Schinner, R; Shuen, TWH; Toh, HC; Wildgruber, M, 2022) |
| "For patients with advanced hepatocellular carcinoma after failure of first-line sorafenib monotherapy, second-line axitinib provides modest efficacy with tolerable toxicity." | 9.34 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. ( Chao, Y; Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Huang, PH; Hung, YP; Lee, RC; Lin, ZZ; Shao, YY; Shen, YC, 2020) |
| "Sorafenib is a current first-line treatment option for advanced hepatocellular carcinoma (HCC)." | 9.34 | Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. ( Hopkins, AM; Rowland, A; Ruanglertboon, W; Sorich, MJ, 2020) |
| "Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma." | 9.27 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. ( Baron, A; Blanc, JF; Cheng, AL; Dutcus, C; Evans, TRJ; Finn, RS; Guo, M; Han, G; Han, KH; Ikeda, K; Jassem, J; Komov, D; Kraljevic, S; Kudo, M; Lopez, C; Park, JW; Piscaglia, F; Qin, S; Ren, M; Saito, K; Tamai, T; Vogel, A, 2018) |
| "To evaluate prospectively the efficacy and safety of sorafenib, which has been the first-line treatment for advanced hepatocellular carcinoma (HCC), in Japanese HCC patients (pts) with not only Child-Pugh (C-P) A class but also C-P B class." | 9.27 | A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. ( Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K, 2018) |
| "To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.27 | A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. ( Anderton, K; Anis, M; Baron, A; Bendell, J; Bentz, T; Brisendine, A; Duddalwar, V; Edwards, A; El-Khoueiry, A; Garrett-Mayer, E; Siegel, AB; Thomas, MB; Weiss, G, 2018) |
| "To evaluate safety and efficacy of combining sorafenib with transarterial chemoembolization in patients with advanced stage hepatocellular carcinomas (HCCs)." | 9.27 | Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. ( Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T, 2018) |
| "The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma." | 9.24 | Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. ( Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J, 2017) |
| "Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts." | 9.24 | Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. ( Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS, 2017) |
| "To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE)." | 9.24 | Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. ( Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A, 2017) |
| "Sorafenib, a multi-kinase inhibitor, inhibits tumor angiogenesis and is the first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)." | 9.24 | Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. ( Aoki, Y; Arai, T; Atsukawa, M; Doi, H; Fukai, M; Itokawa, N; Kanto, T; Kimura, K; Mano, Y; Mizokami, M; Osawa, Y; Shoji, H; Sugiyama, M; Taketomi, A; Yoshio, S, 2017) |
| "To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled randomised study, assessing ramucirumab in advanced hepatocellular carcinoma (HCC) patients who received prior sorafenib." | 9.24 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. ( Abada, PB; Baron, AD; Blanc, JF; Borg, C; Bowman, L; Chau, I; Chung, HC; Cui, ZL; Girvan, AC; Kudo, M; Malfertheiner, P; Okusaka, T; Park, JO; Pastorelli, D; Peck-Radosavljevic, M; Poon, R; Ryoo, BY; Seitz, JF; Yang, L; Yen, CJ; Zhu, AX, 2017) |
| "Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC)." | 9.24 | Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. ( Abou-Alfa, GK; Bass, M; Blanc, JF; Bradley, M; Cebon, J; Ganten, T; Gupta, C; Hollywood, E; Liem, AK; Lipton, L; Litten, J; Ma, J; Miles, S; Saltz, LB; Trojan, J; Wu, B, 2017) |
| "Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease." | 9.24 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. ( Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A, 2017) |
| "There continues to be a lack of systemic options for advanced hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only approved options." | 9.24 | Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. ( Bansal, P; Fekrazad, HM; Lee, FC; Patt, Y; Rojas-Hernandez, C, 2017) |
| "The survival benefit of treatment for unresectable hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE) combined with sorafenib remains uncertain." | 9.24 | Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial. ( Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE, 2017) |
| "Previously, no therapeutic agent has been known to improve the overall survival compared with placebo in patients with hepatocellular carcinoma (HCC), who have progressed after sorafenib." | 9.24 | Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. ( Kudo, M; Nishida, N; Ueshima, K, 2017) |
| "Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma." | 9.24 | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. ( Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V, 2017) |
| "To evaluate the safety and efficacy of combined endovascular brachytherapy (EVBT), transarterial chemoembolization (TACE), and sorafenib to treat hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT)." | 9.24 | Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. ( Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH, 2017) |
| "The study assessed 314 patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib at 5 general hospitals in Kagawa Prefecture, Japan." | 9.24 | Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study. ( Ando, M; Deguchi, A; Kokudo, Y; Kubo, A; Kudo, M; Masaki, T; Matsunaka, T; Minami, Y; Morishita, A; Morita, M; Moriya, A; Nagano, T; Nishida, N; Noda, T; Ogawa, C; Omura, A; Sakurai, T; Senoh, T; Shibatoge, M; Takaguchi, K; Tamaki, H; Tani, J; Tsutsui, A; Ueshima, K; Yoneyama, H, 2017) |
| "To report the real-life results of sorafenib use in a cohort of HIV-infected patients with hepatocellular carcinoma (HCC)." | 9.24 | Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. ( Delgado-Fernández, M; Galindo, MJ; García, MA; Garcia-Deltoro, M; Ibarra, S; Merchante, N; Merino, E; Mínguez, C; Montero-Alonso, M; Pineda, JA; Revollo, B; Rivero-Juárez, A; Rodríguez-Arrondo, F; Romero-Palacios, A; Téllez, F, 2017) |
| "Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC)." | 9.24 | HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ( Chen, PT; Chen, SC; Grevel, J; Hu, CT; Jeng, LB; Le Berre, MA; Lin, SM; Liu, X; Lu, SN; Meinhardt, G; Mitchell, DY; Peña, CA; Prins, K; Yang, SS, 2017) |
| "There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment." | 9.24 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Baumhauer, A; Bodoky, G; Breder, V; Bronowicki, JP; Bruix, J; Cheng, AL; Finn, RS; Gerolami, R; Granito, A; Han, G; Huang, YH; Kudo, M; LeBerre, MA; Llovet, JM; Masi, G; Meinhardt, G; Merle, P; Ollivier-Hourmand, I; Pracht, M; Qin, S; Rosmorduc, O; Ross, PJ; Song, T; Yokosuka, O, 2017) |
| "Sorafenib is currently the first-line therapeutic regimen for patients with advanced hepatocellular carcinoma (HCC)." | 9.22 | Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. ( Bai, M; Gong, S; Guo, T; Hao, X; Lei, C; Li, X; Si, M; Song, S; Tian, H; Yang, W, 2022) |
| "This multicenter, randomized, open-label, phase II trial evaluated the efficacy and safety of AEG35156 in addition to sorafenib in patients with advanced hepatocellular carcinoma (HCC), as compared with sorafenib alone." | 9.22 | Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC). ( Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC, 2016) |
| "We report data from the final analysis of the Chinese subset of the GIDEON (the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study, which evaluated the safety and efficacy of sorafenib in Child-Pugh A, B and C patients with unresectable hepatocellular carcinoma (uHCC) in real-life clinical practice." | 9.22 | Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. ( Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J, 2016) |
| "Since the approval of sorafenib, no other agent has been proven to show survival benefits in clinical trials involving patients with advanced hepatocellular carcinoma (HCC) resistant to sorafenib." | 9.22 | Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2016) |
| "This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 1) in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 9.22 | A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. ( Bazin, I; Bondarenko, I; Ciuleanu, T; Deptala, A; Ding, M; Egger, J; Fox, NL; Giantonio, B; Gribbin, M; Humphreys, R; Kalyani, RN; Lungulescu, D; Miron, L; Rodriguez-Torres, M; Sun, W; Wissel, P, 2016) |
| "This retrospective cohort study aimed to evaluate the prognostic value of the alpha-fetoprotein (AFP) response in advanced-stage hepatocellular carcinoma (HCC) patients treated with sorafenib combined with transarterial chemoembolization." | 9.22 | The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. ( Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; He, C; Jia, J; Liu, L; Niu, J; Xia, J; Yang, M; Yin, Z; Yuan, J; Zhang, L; Zhao, Y, 2016) |
| "Currently, the only FDA-approved systemic therapy for hepatocellular carcinoma (HCC) is the multi-receptor tyrosine kinase inhibitor, sorafenib, which provides only modest clinical benefit." | 9.22 | Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. ( Brekken, RA; Cheng, X; Huang, X; Li, L; Thorpe, PE; Yopp, AC, 2016) |
| "Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for first-line systemic treatment of advanced hepatocellular carcinoma (HCC)." | 9.22 | Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). ( Bodoky, G; Buehlmann, M; Demeter, G; Dufour, JF; Feilchenfeldt, J; Horber, D; Koeberle, D; Lakatos, G; Li, Q; Montemurro, M; Peck-Radosavljevic, M; Rauch, D; Ribi, K; Roth, AD; Saletti, P; Samaras, P; Tschanz, B; Wagner, AD, 2016) |
| "No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist." | 9.22 | Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. ( Ammendola, AS; Bitzer, M; Cillo, U; Dollinger, MM; Ganten, TM; Gerken, G; Giannini, EG; Hauns, B; Henning, SW; Hentsch, B; Herz, T; Holzapfel, J; Horger, M; Lauer, UM; Mais, A; Malek, NP; Montesarchio, V; Pegoraro, S; Santoro, A; Scheulen, ME; Siveke, JT; Trevisani, F; Wege, H; Wörns, MA; Zagonel, V, 2016) |
| "To compare the impact of concurrent TACE + sorafenib versus TACE alone on overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (uHCC)." | 9.22 | Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. ( Li, H; Liu, D; Yan, D; Yao, X; Zeng, H, 2016) |
| "Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogenic escape from sorafenib may occur due to angiogenesis-associated fibroblast growth factor receptor (FGFR) pathway activation." | 9.22 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. ( Balsara, B; Chan, SL; Chao, Y; Cheng, AL; Han, G; Ikeda, M; Kang, YK; Kudo, M; Lim, HY; Numata, K; Pan, H; Poon, RT; Rodriguez, AM; Sukeepaisarnjaroen, W; Thongprasert, S; Wang, Y; Wu, CC; Yang, TS; Zhang, Y, 2016) |
| "Sorafenib is the current standard therapy for advanced hepatocellular carcinoma, but validated biomarkers predicting clinical outcomes are lacking." | 9.22 | Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. ( Evans, TR; Gane, E; Jeffers, M; Kang, YK; Meinhardt, G; Peña, CE; Rosmorduc, O; Ross, P; Santoro, A; Vogel, A; Zhu, AX, 2016) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), and to date, no combination therapy has demonstrated superior survival compared with sorafenib alone." | 9.22 | Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ( Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ, 2016) |
| "To investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC)." | 9.22 | Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. ( Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F, 2016) |
| "Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC)." | 9.22 | Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. ( Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J, 2016) |
| "Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC)." | 9.22 | Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. ( Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Ishii, H; Kaneko, S; Kojima, Y; Kudo, M; Morimoto, M; Nakamori, S; Ohmura, T; Okusaka, T; Sato, K; Sato, T; Shimizu, S; Sugimoto, R; Tahara, T; Yasui, K, 2016) |
| "To compare in a randomized controlled trial (RCT) 3-year survival of cirrhotic patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) treated with sorafenib plus percutaneous radiofrequency ablation (RFA) of both intraparenchymal HCC and PVTT (combination Group) or sorafenib alone (sorafenib-alone Group)." | 9.22 | Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial. ( Amendola, F; Calvanese, A; Coppola, C; DI Sarno, A; Gatti, P; Giorgio, A; Giorgio, V; Matteucci, P; Merola, F; Merola, MG; Montesarchio, L; Santoro, B, 2016) |
| "gov registration NCT00990860) evaluated sorafenib in combination with doxorubicin-based transarterial chemoembolization (TACE) in patients with intermediate-stage, unresectable hepatocellular carcinoma (HCC)." | 9.20 | The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. ( Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH, 2015) |
| "To prospectively assess treatment response using volumetric functional magnetic resonance imaging (MRI) metrics in patients with hepatocellular carcinoma (HCC) treated with the combination of doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) and sorafenib." | 9.20 | Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. ( Bonekamp, S; Corona-Villalobos, CP; Cosgrove, D; Geschwind, JF; Halappa, VG; Kamel, IR; Pawlik, TM; Reyes, D, 2015) |
| "This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy." | 9.20 | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. ( Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC, 2015) |
| "To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial." | 9.20 | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. ( Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX, 2015) |
| "GIDEON is a non-interventional, prospective, international study that evaluated the safety of sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in daily clinical practice, including Child-Pugh B patients." | 9.20 | [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain]. ( Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A, 2015) |
| "To assess whether urea-based cream (UBC) has prophylactic benefits on sorafenib-induced hand-foot skin reaction (HFSR) in patients with advanced hepatocellular carcinoma (HCC)." | 9.20 | Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. ( Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K, 2015) |
| "Sorafenib, an oral multikinase inhibitor, is the proved therapy method for patients with advanced hepatocellular carcinoma (HCC)." | 9.20 | Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. ( Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M, 2015) |
| "Currently there is no predictor for survival after adjuvant sorafenib in patients with hepatocellular carcinoma (HCC) who have undergone curative resection." | 9.20 | Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2015) |
| "To determine the efficacy of combined continuous sorafenib therapy and drug-eluting bead (DEB) transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC)." | 9.20 | Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. ( Cosgrove, DP; Feng, AL; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK, 2015) |
| " In this phase II study, safety and tolerability of the combination of tigatuzumab and sorafenib was evaluated in patients with advanced hepatocellular carcinoma." | 9.20 | Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. ( Austin, T; Beckman, RA; Cheng, AL; Greenberg, J; He, AR; Hung, CH; Izumi, N; Kang, YK; Kudo, M; Lim, HY; Ryoo, BY; Sheen, IS; Shiratori, S; Wang, Q, 2015) |
| " Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters." | 9.20 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. ( Abada, PB; Baron, AD; Blanc, JF; Chang, SC; Chau, I; Chung, HC; Kubackova, K; Kudo, M; Okusaka, T; Park, JO; Pastorelli, D; Pfiffer, TE; Poon, R; Ryoo, BY; Sastre, J; Schwartz, JD; Trojan, J; Yang, L; Yen, CJ; Zhu, AX, 2015) |
| "Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC)." | 9.20 | Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. ( Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S, 2015) |
| "Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation." | 9.20 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. ( Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J, 2015) |
| "We evaluated the relationship between the early clinical response after 2 weeks of sorafenib therapy and the outcomes and anti-tumor response in patients with advanced hepatocellular carcinoma." | 9.20 | Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kuzuya, T; Nakano, I, 2015) |
| "The survival benefit of combining sorafenib and transarterial chemoembolization (TACE) therapy compared with sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT) is unclear." | 9.20 | Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. ( Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y, 2015) |
| "To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC)." | 9.20 | Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. ( Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H, 2015) |
| " However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)." | 9.20 | Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015) |
| "A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis." | 9.19 | Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. ( Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Kuzuya, T; Matsuda, S; Muraoka, M; Nakanishi, H; Nakata, T; Nishimura, T; Suzuki, S; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Yasui, Y, 2014) |
| "GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials." | 9.19 | GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. ( Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2014) |
| "Sorafenib is considered a standard of care in advanced hepatocellular carcinoma (HCC)." | 9.19 | Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study. ( Ahmad, S; Khattak, J; Murad, S; Naqi, N, 2014) |
| "The aims of this study were to evaluate the frequency of dose-limiting toxicities and to find the recommended dose of combination chemotherapy with sorafenib and transcatheter arterial infusion (TAI) using cisplatin for patients with advanced hepatocellular carcinoma (HCC), for whom surgical resection, local ablation therapy, or transcatheter arterial chemoembolization were not indicated." | 9.19 | Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. ( Hagihara, A; Ikeda, M; Imanaka, K; Inaba, Y; Katayama, K; Kato, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sato, Y; Shimizu, S; Suzuki, E; Tamai, C; Ueno, H, 2014) |
| "Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC)." | 9.19 | A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. ( Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O, 2014) |
| "This phase 2 study evaluated the efficacy of radiation therapy (RT) with concurrent and sequential sorafenib therapy in patients with unresectable hepatocellular carcinoma (HCC)." | 9.19 | Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. ( Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC, 2014) |
| "To explore the efficacy and safty of sorafenib in Child-Pugh class B to class C hepatocellular carcinoma (HCC)." | 9.19 | Sorafenib in liver function impaired advanced hepatocellular carcinoma. ( Geng, CX; Ji, YX; Lan, KT; Liu, SC; Nie, KK; Sun, L; Zhang, L; Zhang, ZC; Zhang, ZF; Zhuang, XJ; Zou, X, 2014) |
| "To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT)." | 9.19 | Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. ( Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K, 2014) |
| "Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma (HCC), with demonstrated outcome benefits in randomized clinical trials." | 9.19 | Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. ( Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA, 2014) |
| "The aim of this study was to investigate the prognostic significance of blood NLR in patients with intermediate-advanced hepatocellular carcinoma (HCC) who received transcatheter arterial embolization (TAE) combined with Sorafenib." | 9.19 | Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. ( Mu, H; Song, TQ; Wang, M; Wei, K; Zhang, W, 2014) |
| "Between March 2008 and October 2010, patients with advanced pathologically proven hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A or B received sorafenib plus gemcitabine." | 9.19 | Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. ( Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S, 2014) |
| "To retrospectively analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess the prognostic impact of baseline characteristics." | 9.19 | Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. ( Luo, J; Shao, G; Zheng, J, 2014) |
| "Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma." | 9.19 | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. ( Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX, 2014) |
| "The combination of the TACE and sorafenib proved both safe and effective in the treatment of Chinese patients with unresectable hepatocellular carcinoma." | 9.17 | Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. ( Chao, Y; Feng, G; Han, G; Liu, Z; Lu, L; Shao, G; Teng, G; Wang, J; Wang, M; Yang, J; Yang, R, 2013) |
| "Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC)." | 9.17 | Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. ( Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM, 2013) |
| "Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC)." | 9.17 | A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. ( Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A, 2013) |
| "The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib." | 9.17 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013) |
| "Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC)." | 9.17 | Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. ( Brandt, U; Bruix, J; Chen, LT; Finn, RS; Gomez-Martin, C; Kang, YK; Kim, TY; Klümpen, HJ; Kunz, T; Paquet, T; Poon, RT; Rodriguez-Lope, C; Sellami, D; Yau, T, 2013) |
| "Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC)." | 9.17 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. ( Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L, 2013) |
| "Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC)." | 9.17 | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. ( Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I, 2013) |
| "We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting." | 9.17 | Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. ( Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY, 2013) |
| "Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function." | 9.17 | Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. ( Banzi, M; Boni, C; Carnaghi, C; Ceriani, R; Cortesi, E; Covini, G; De Giorgio, M; Fagiuoli, S; Fanello, S; Ferrari, D; Giordano, L; Labianca, R; Latini, L; Locopo, N; Lutman, FR; Mucciarini, C; Naimo, S; Porta, C; Pressiani, T; Rimassa, L; Salvagni, S; Santoro, A; Tommasini, MA; Torzilli, G; Tronconi, MC, 2013) |
| "To investigate the volumetric iodine-uptake (VIU) changes by dual-energy CT (DECT) in assessing the response to sorafenib treated hepatocellular carcinoma (HCC) patients, compared with AASLD (American Association for the Study of Liver Diseases) and Choi criteria." | 9.17 | Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K, 2013) |
| "Sorafenib is an oral multikinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC)." | 9.17 | Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. ( Brunello, F; Brunocilla, PR; Cantamessa, A; Carucci, P; Castiglione, A; Ciccone, G; Gaia, S; Rizzetto, M; Rolle, E, 2013) |
| "This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma." | 9.17 | Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. ( Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y, 2013) |
| "Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
| "Sorafenib is an orally active multikinase inhibitor licensed for the treatment of patients with unresectable hepatocellular carcinoma (HCC)." | 9.16 | Sorafenib in hepatocellular carcinoma - a post marketing evaluation. ( Jirillo, A; Mazurek, M; Palozzo, AC; Trojniak, MP, 2012) |
| "To investigate the safety of transarterial chemoembolisation (TACE) in combination with sorafenib in patients with hepatocellular carcinoma (HCC)." | 9.16 | Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. ( Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W, 2012) |
| "The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and South Korea - confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. ( Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J, 2012) |
| " The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection." | 9.16 | Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| "We assessed the safety and efficacy of sorafenib with cryotherapy (cryoRx) in advanced hepatocellular carcinoma (HCC)." | 9.16 | Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. ( An, L; Bai, W; Chang, X; Chen, Y; Lou, M; Lu, Y; Lv, J; Qu, J; Wang, C; Yang, Y; Zeng, Z; Zhou, L, 2012) |
| "Sorafenib is the only systemic treatment shown to be effective against advanced hepatocellular carcinoma (HCC)." | 9.16 | The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. ( Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, KH; Kim, SG; Kim, YJ; Kim, YS; Lee, JE; Lee, SH, 2012) |
| "To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post antiangiogenic treatment with sorafenib." | 9.16 | Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. ( Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K, 2012) |
| "Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC)." | 9.16 | Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. ( Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM, 2012) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 9.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "Sorafenib is presently the only effective therapy in advanced hepatocellular carcinoma (HCC)." | 9.16 | Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. ( Alexandre, J; Batteux, F; Chaussade, S; Chéreau, C; Coriat, R; Goldwasser, F; Mir, O; Nicco, C; Ropert, S; Weill, B, 2012) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 9.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "he role of serum alpha-fetoprotein (AFP) changes in predicting the treatment outcomes of advanced hepatocellular carcinoma (HCC) patients to sorafenib remains unknown." | 9.15 | The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. ( Chan, P; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T, 2011) |
| "PURPOSE To evaluate safety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) and sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 9.15 | Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. ( Bhagat, N; Cosgrove, D; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK, 2011) |
| "Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-week cycles, with efficacy measured at the end of each 6-week period." | 9.14 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. ( Burock, K; Chen, Z; Cheng, AL; Feng, J; Guan, Z; Kang, YK; Kim, JS; Liang, H; Liu, J; Luo, R; Pan, H; Qin, S; Sun, Y; Tak, WY; Tsao, CJ; Voliotis, D; Wang, J; Xu, J; Yang, TS; Ye, S; Zou, J, 2009) |
| "Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular carcinoma (HCC) and is well tolerated when combined with doxorubicin in other solid tumours." | 9.14 | Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. ( Adamietz, IA; Brendel, E; Christensen, O; Grubert, M; Hilger, RA; Kupsch, P; Ludwig, M; Richly, H; Schultheis, B; Strumberg, D, 2009) |
| "Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles." | 9.14 | Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. ( Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T, 2009) |
| "To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)." | 9.14 | [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. ( Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ, 2009) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study (ClinicalTrials." | 9.14 | Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. ( Kudo, M; Lencioni, R; Marrero, J; Venook, A; Ye, SL, 2010) |
| "To provide more evidence sources to the standard treatment for patients with advanced hepatocellular carcinoma, the writer analyze patients' time to progression (TTP) and overall survival (OS) after patients receiving transcatheter arterial chemoembolization (TACE) combined with sorafenib as a treatment of advanced hepatocellular carcinoma (HCC); observe the healing effect embolization combined with anti-angiogenic treatment for advanced hepatocellular carcinoma; and also analyze treatment of security." | 9.14 | [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma]. ( Hu, BS; Huang, GM; Huang, JW; Li, Y; Lu, LG; Shao, PJ; Wei, ZG; Zhang, L, 2010) |
| "It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma." | 9.14 | Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. ( Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010) |
| "In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease." | 9.14 | Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. ( Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB, 2010) |
| "To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)." | 9.14 | [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010) |
| "In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo." | 9.13 | Sorafenib in advanced hepatocellular carcinoma. ( Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S, 2008) |
| "Sorafenib was reported as a useful adjuvant treatment in patients with hepatocellular carcinoma who underwent surgical resection." | 9.12 | A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. ( Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L, 2021) |
| "This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients." | 9.12 | Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. ( Abou-Alfa, GK; Amadori, D; De Greve, J; Douillard, JY; Figer, A; Lathia, C; Moscovici, M; Ricci, S; Saltz, LB; Santoro, A; Schwartz, B; Schwartz, L; Taylor, I, 2006) |
| "To compare the efficacy of three types of palliative therapy for advanced hepatocellular carcinoma (HCC), including transarterial chemoembolisation (TACE) monotherapy, sorafenib alone and their combination." | 9.05 | The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. ( Cheng, Z; Guo, Y; He, L; Song, S; Song, Y; Zhang, L, 2020) |
| "Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC)." | 8.98 | Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. ( Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M, 2018) |
| "The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC." | 8.98 | Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. ( Edeline, J; Finn, RS; Galle, PR; Kudo, M; Raoul, JL; Reig, M, 2018) |
| "Transarterial chemoembolization (TACE) is the recommended treatment for hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) B-stage, whereas sorafenib is an orally administered small molecule target drug for BCLC C-stage." | 8.98 | Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y, 2018) |
| "Lenvatinib, a multi-kinase inhibitor, has demonstrated improved outcomes for patients with hepatocellular carcinoma (HCC) in clinical trials." | 8.98 | Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. ( Ikeda, M; Kaneko, S; Kobayashi, M; Tahara, M, 2018) |
| "Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and well preserved liver function." | 8.95 | Regorafenib for the treatment of unresectable hepatocellular carcinoma. ( Personeni, N; Pressiani, T; Rimassa, L; Santoro, A, 2017) |
| "It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a significant survival benefit from the sorafenib treatment, which is currently regarded as a first-line chemotherapeutic therapy in patients with advanced HCC." | 8.95 | New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. ( Chen, GG; Lai, PBS; Liu, L; Niu, L; Ren, J; Yang, S, 2017) |
| "Many studies have combined sorafenib with transcatheter arterial chemoembolization (TACE) to treat patients with advanced hepatocellular carcinoma (HCC), but the results are disputable." | 8.95 | Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. ( Cai, R; Liao, Y; Ma, H; Pang, P; Song, R; Sun, H; Wang, H; Wang, S; Yan, Y; Zhang, H; Zhou, C; Zhou, X, 2017) |
| "Introduction: Clinical markers to predict the benefit from sorafenib in patients diagnosed with hepatocellular carcinoma (HCC) are lacking." | 8.95 | Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. ( Abdel-Rahman, O; Lamarca, A, 2017) |
| "The benefits of transarterial chemoembolization plus sorafenib (TACE-S) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remain controversial." | 8.95 | Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. ( Cheng, S; Wang, K; Wang, M; Wu, M; Yang, G; Ye, X; Zhang, X, 2017) |
| "In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival." | 8.95 | Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. ( Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S, 2017) |
| "This meta-analysis aimed to analyze the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)." | 8.93 | Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. ( Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH, 2016) |
| "Combination therapy of sorafenib and transarterial chemoembolization (TACE) has shown benefits in treating advanced hepatocellular carcinoma (HCC)." | 8.93 | Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2016) |
| "Sorafenib has been approved to increase the survival in patients with advanced hepatocellular carcinoma." | 8.93 | Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature. ( Cheng, KS; Chou, JW; Huang, CW, 2016) |
| "The efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib for patients with hepatocellular carcinoma (HCC) have been explored by many studies, but the results were controversial." | 8.93 | Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. ( Lv, L; Mei, ZC; Zeng, J, 2016) |
| "Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal." | 8.91 | Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. ( Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C, 2015) |
| "To evaluate the feasibility and security of complete remission (CR) of advanced hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the previously described predictive factors in CR." | 8.91 | Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. ( Feng, X; Hu, Y; Liu, A; Liu, D; Peng, J, 2015) |
| "Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma." | 8.91 | Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. ( Cai, X; Chen, J; Huang, D; Jin, R; Liang, X; Liang, Y; Lin, H; Liu, J; Yan, H; Ying, H; Yu, H; Zhao, J; Zhou, S, 2015) |
| "Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC)." | 8.91 | Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? ( Angarano, G; Brunetti, O; Faloppi, L; Gnoni, A; Guarini, A; Licchetta, A; Lorusso, V; Lupo, L; Memeo, V; Palasciano, G; Palmieri, V; Pisconti, S; Russo, A; Santini, D; Scartozzi, M; Silvestris, N, 2015) |
| "Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is modest with low response rates and short response duration." | 8.91 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? ( Cheng, AL; Hsu, CH; Shao, YY, 2015) |
| "Sorafenib is the only and standard systematic chemotherapy drug for treatment of advanced hepatocellular carcinoma (HCC) at the current stage." | 8.91 | Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. ( Gao, JJ; Inagaki, Y; Shi, ZY; Tang, W; Xia, JF, 2015) |
| "Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven efficacy against Hepatocellular Carcinoma (HCC)." | 8.90 | New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. ( Barbare, JC; Chauffert, B; Galmiche, A, 2014) |
| "PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms "Hepatocellular carcinoma" OR "Hepatoma" or "Liver cancer" AND "systemic anticancer therapy" AND "Sorafenib" and specifying only English literature." | 8.90 | Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. ( Abdel-Rahman, O; Fouad, M, 2014) |
| "The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC)." | 8.90 | Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. ( Miyahara, K; Nouso, K; Yamamoto, K, 2014) |
| "Combination therapy of sorafenib and transarterial chemoembolization (TACE) showed benefits for hepatocellular carcinoma (HCC)." | 8.90 | Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. ( Bai, XL; Chen, YW; Fu, QH; Hu, QD; Liang, TB; Su, RG; Su, W; Zhang, Q, 2014) |
| "Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE)." | 8.90 | Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. ( Bie, P; Chen, X; Hu, P; Zhang, L, 2014) |
| "Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial." | 8.90 | Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Bai, M; Han, GH; Yang, M; Yuan, JQ, 2014) |
| "The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial." | 8.90 | An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. ( Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y, 2014) |
| "We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib." | 8.90 | [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy]. ( Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014) |
| "The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma." | 8.89 | Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. ( Salem, R; Weintraub, JL, 2013) |
| "By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine." | 8.89 | Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. ( Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ, 2013) |
| "The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory." | 8.89 | A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. ( Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Teranishi, Y, 2013) |
| "The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT)." | 8.89 | Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. ( Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 8.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| "The positive results of sorafenib have unveiled a new direction of research in the management of hepatocellular carcinoma (HCC)." | 8.88 | Management of hepatocellular carcinoma: beyond sorafenib. ( Chan, SL; Ma, BB; Mok, T, 2012) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 8.88 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. ( Spechler, SJ; Wang, DH; Xie, B, 2012) |
| "The efficacy of sorafenib in hepatocellular carcinoma (HCC) has been demonstrated in two pivotal clinical trials: the European SHARP trial and a second trial that recruited patients in the Asia-Pacific region." | 8.88 | Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). ( Hatano, E; Kokudo, N; Nakajima, J; Numata, K, 2012) |
| "Sorafenib, a receptor tyrosine kinase-inhibitor with anti-proliferative and anti-angiogenic activity, is currently the only approved systemic treatment for patients with hepatocellular carcinoma." | 8.88 | Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. ( Ebert, MP; Schott, E; Trojan, J, 2012) |
| "Sorafenib has become the standard first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 8.88 | Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. ( Fan, J; Huang, XW; Qiu, SJ; Shi, RY; Wang, WM; Wang, Z; Xu, Y; Yang, XR; Zhang, X; Zhou, J, 2012) |
| "Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results." | 8.87 | Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. ( Guan, YS; He, Q, 2011) |
| "To evaluate the effectiveness and toxicity of sorafenib for advanced hepatocellular carcinoma." | 8.87 | Sorafenib for advanced hepatocellular carcinoma: a systematic review. ( Jin-hui, T; Ke-hu, Y; Li, M; Ling-lin, Z, 2011) |
| "Since sorafenib, a multikinase inhibitor targeting angiogenesis of hepatocellular carcinoma (HCC), demonstrated survival benefits in recent clinical trials, it has changed the treatment paradigm and become the standard first-line treatment for patients with advanced HCC." | 8.87 | Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. ( Kim, HY; Park, JW, 2011) |
| "Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function." | 8.87 | Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. ( Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F, 2011) |
| "The successful approval of sorafenib has greatly stimulated the development of other molecular targeted agents in advanced hepatocellular carcinoma (HCC)." | 8.86 | Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. ( Zhu, AX, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of sorafenib according to its licensed indication for advanced hepatocellular carcinoma (HCC)." | 8.86 | Sorafenib for the treatment of advanced hepatocellular carcinoma. ( Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S, 2010) |
| "Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma." | 8.86 | Sorafenib in hepatocellular carcinoma. ( Josephs, DH; Ross, PJ, 2010) |
| "A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival = 10." | 8.86 | Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. ( Carr, BI; Carroll, S; Gondek, K; Muszbek, N, 2010) |
| "Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma." | 8.85 | Sorafenib: a review of its use in advanced hepatocellular carcinoma. ( Keating, GM; Santoro, A, 2009) |
| "Sorafenib, a multitargeted anti-VEGF receptor and raf kinase inhibitor, was recently approved by the FDA for treating unresectable hepatocellular carcinoma (HCC) based on 2 randomized phase III studies." | 8.85 | Selection of patients with hepatocellular carcinoma for sorafenib. ( Abou-Alfa, GK, 2009) |
| "Sorafenib is currently a targeted agent widely used in the treatment of advanced hepatocellular carcinoma (aHCC)." | 8.31 | A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. ( Chen, LW; Chien, CH; Chien, RN; Hu, CC; Liang, KH; Lin, CL; Lin, YH; Yeh, CT, 2023) |
| " Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy." | 8.31 | A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study. ( Atsukawa, M; Azemoto, R; Haga, Y; Ikeda, M; Inaba, Y; Inoue, M; Ito, K; Itobayashi, E; Itoh, Y; Itokawa, N; Kanogawa, N; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Maruta, S; Moriguchi, M; Morimoto, N; Nakamoto, S; Nakamura, K; Nakamura, M; Ogasawara, S; Okabe, S; Okubo, T; Ooka, Y; Seko, Y; Shiko, Y; Suzuki, E; Takatsuka, H; Watanabe, S, 2023) |
| "To compare the efficacy and safety of TACE combined with Donafenib and Toripalimab versus TACE combined with Sorafenib in the treatment of unresectable hepatocellular carcinoma (HCC), aiming to guide personalized treatment strategies for HCC and improve patient prognosis." | 8.31 | Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study. ( Liang, B; Lu, H; Xia, X; Zheng, C, 2023) |
| "To assess the cost-effectiveness of selective internal radiation therapy (SIRT) compared with sorafenib for the treatment of patients with advanced hepatocellular carcinoma in the United Kingdom, including a selected subgroup of patients who have been identified as benefiting from treatment with SIRT." | 8.12 | The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom. ( Claxton, L; Eastwood, A; Hodgson, R; Sharif-Hurst, S; Wade, R; Walton, M, 2022) |
| "The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC)." | 8.12 | Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. ( Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM, 2022) |
| "To explore the efficacy of combined therapy of Regorafenib with detoxicating and stasis softening Chinese herbal spleen tonics (DSS-splenic tonics) in mid-/late-stage hepatocellular carcinoma." | 8.12 | The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma. ( Fang, S; Li, X; Liu, G; Ma, Y; Yang, J; Yang, X; Zhao, B, 2022) |
| " The resistance of hepatocellular carcinoma (HCC) cells to sorafenib significantly limits its therapeutic effect in HCC patients." | 8.12 | FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. ( Li, J; Tan, XP; Wang, SL; Xiong, BH; Zhang, YX; Zuo, Q, 2022) |
| "The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread." | 8.12 | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. ( Chen, CT; Cheng, AL; Hsu, CH; Shao, YY, 2022) |
| "Some studies have shown that sorafenib could significantly prolong the overall survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE)." | 8.12 | Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. ( Chen, Y; He, K; Liu, X; Song, W; Wang, S; Yang, Y; Yang, Z, 2022) |
| "The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC)." | 8.02 | Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. ( Cao, G; Han, Y; Liu, B; Liu, Z; Shi, Q; Sun, B; Wang, J; Xu, H; Xu, L; Yan, D; Zhi, W; Zou, Y, 2021) |
| " The authors have therefore assessed if the concurrent use of gastric acid suppressants and sorafenib impairs outcomes in patients with advanced hepatocellular carcinoma (HCC)." | 8.02 | Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma. ( Fletcher, P; Kunene, V; Ma, YT; Razak, RA, 2021) |
| "To describe the occurrence of malabsorption (MA) in hepatocellular carcinoma (HCC) patients under sorafenib, the potential relationship with pancreatic insufficiency (PI), and the role of pancreatic enzymes supplementation." | 8.02 | Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. ( Ayuso, C; Belmonte, E; Bruix, J; Darnell, A; Díaz, A; Díaz-González, Á; Feu, F; Forner, A; Gomes da Fonseca, L; Iserte, G; Llarch, N; Reig, M; Rimola, J; Sanduzzi-Zamparelli, M; Sapena, V, 2021) |
| "Sorafenib, used for advanced-stage hepatocellular carcinoma (HCC), has an overall survival (OS) of 10 months." | 8.02 | Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Carvalhana, S; Cortez-Pinto, H; Freitas, LC; Gaio, R; Marinho, RT; Moura, M; Nogueira, PJ; Reis, D, 2021) |
| "To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)." | 8.02 | Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. ( Braghiroli, MI; da Fonseca, LG; Hoff, PM; Marta, GN; Moura, F; Sabbaga, J, 2021) |
| " Sorafenib, the first FDA-approved systemic drug for unresectable hepatocellular carcinoma (HCC), is limited by resistance." | 8.02 | Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. ( Kim, SH; Lee, HJ; Park, SC; Shin, NR; Son, Y, 2021) |
| "Recruitment of patients with advanced hepatocellular carcinoma and Child-Pugh B for sorafenib treatment and additional pharmacokinetic studies is challenging." | 7.96 | Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ( Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O, 2020) |
| " The patient had a history of psoriasis vulgaris and sorafenib (SOR) was introduced (800 mg/day) because of transcatheter arterial chemoembolization (TACE) refractoriness." | 7.96 | Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma. ( Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T, 2020) |
| "Sorafenib (SOR), a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), reveals a limited therapeutic effect due to a lack of selectivity and evident drug resistance." | 7.96 | Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. ( Deng, Y; Dong, L; Li, Y; Liu, J; Liu, TT; Shen, XZ; Sun, Y; Weng, SQ; Yu, XN; Zhang, GC; Zhu, CF; Zhu, JM, 2020) |
| "Sorafenib and lenvatinib are the first-line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events (AE) and overall survival." | 7.96 | Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. ( Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Brunet, M; Corominas, J; da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Millán, O; Reig, M; Samper, E; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F, 2020) |
| "To investigate the role of E26 transformation-specific variant 4 (ETV4) in sorafenib and cisplatin resistance in hepatocellular carcinoma (HCC)." | 7.91 | [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells ( Dehua, WU; Xiaohui, C; Xin, LI, 2019) |
| "Sorafenib is a standard treatment for patients (pts) with advanced hepatocellular carcinoma (aHCC), although the clinical benefit is heterogeneous between different pts groups." | 7.88 | An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. ( Akhoundova, D; Aparicio, J; Bruixola, G; Caballero, J; Diaz-Beveridge, R; Giménez, A; Lorente, D; Rodrigo, E; Segura, Á, 2018) |
| "Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC)." | 7.88 | A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. ( Beveridge, DJ; Brown, RM; Candy, P; Chaturvedi, V; Epis, M; Ganda, C; George, J; Kabir, TD; Kalinowski, F; Kopp, C; Leedman, PJ; Richardson, KL; Stuart, LM; Wintle, L; Yeoh, GC, 2018) |
| "The multi-kinase inhibitor regorafenib (REG) was recently demonstrated to be effective in patients with sorafenib (SOR)-resistant hepatocellular carcinoma (HCC)." | 7.88 | Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. ( Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H, 2018) |
| "For advanced hepatocellular carcinoma (HCC), surgical treatment after sorafenib induction has rarely been reported." | 7.88 | Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma. ( Arima, K; Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Higashi, T; Imai, K; Ishiko, T; Kaida, T; Nakagawa, S; Nitta, H; Okabe, H; Sasaki, Y; Takeyama, H; Taki, K; Tanaka, M, 2018) |
| " We report a hepatocellular carcinoma patient with sorafenib-induced metabolic acidosis, who showed increased hepatic uptake of C-acetate." | 7.88 | Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma. ( Bae, WK; Kim, DY; Kwon, SY; Min, JJ, 2018) |
| "Sorafenib, a multikinase inhibitor for hepatocellular carcinoma treatment, inhibits the Raf/MAPK/ERK signaling pathway." | 7.88 | Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. ( Fei, Z; Lu, M; Zhang, G, 2018) |
| "Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC)." | 7.88 | Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. ( Barbera, MA; Bernardi, M; Brandi, G; Casadei Gardini, A; De Lorenzo, S; Di Costanzo, GG; Foschi, FG; Garuti, F; Granito, A; Inghilesi, AL; Marra, F; Sacco, R; Tortora, R; Tovoli, F; Trevisani, F, 2018) |
| "Sorafenib is the only effective therapy for advanced hepatocellular carcinoma (HCC)." | 7.88 | Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. ( Bosserhoff, AK; Dietrich, P; Fritz, V; Hartmann, A; Hellerbrand, C; Koch, A, 2018) |
| "We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department." | 7.88 | The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy. ( Arakawa, Y; Bando, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Teraoku, H; Yoshimoto, T, 2018) |
| "Objective Sorafenib is a standard therapy for advanced hepatocellular carcinoma (HCC), whereas radiotherapy is effective for local control of extrahepatic spread (EHS) or macrovascular invasion (MVI)." | 7.88 | The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. ( Matsumura, T; Matsushima, H; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y; Yoshitomi, M, 2018) |
| "Sorafenib is the only Food and Drug Administration (FDA)-approved first-line therapy shown to have survival benefit for patients with advanced hepatocellular carcinoma (HCC)." | 7.88 | Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study. ( D'Addeo, K; Kaplan, DE; Mehta, R; Taddei, TH; Valderrama, A, 2018) |
| "Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy." | 7.88 | Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. ( Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018) |
| "To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with sorafenib (TACE-S)." | 7.88 | Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. ( Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS, 2018) |
| "To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 7.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "Emerging evidence indicates that combining Sorafenib with vitamin K1 (VK1) may result in a synergistic inhibition of hepatocellular carcinoma (HCC) cell migration and proliferation." | 7.88 | Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. ( Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG, 2018) |
| "The impact of transarterial chemoembolization after initiation of sorafenib (SOR) has not been prospectively compared with SOR alone in unresectable hepatocellular carcinoma (HCC)." | 7.88 | Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. ( D'Addeo, K; Gade, TP; Kaplan, DE; Mehta, R; Taddei, TH, 2018) |
| "This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients." | 7.88 | Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. ( Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J, 2018) |
| "The aim is to study the effectiveness and side effects of sorafenib administration after transarterial chemoembolization (TACE) in advanced hepatocellular carcinoma (HCC) patients." | 7.88 | Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients. ( Jian, W; Li, C; Sun, X; Xie, F; Zhang, K, 2018) |
| "Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC)." | 7.88 | Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. ( Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ, 2018) |
| "A single-center, retrospective, observational study was performed, 166 patients with intermediate-/advanced-stage hepatocellular carcinoma were treated with sorafenib and 19 with TARE." | 7.88 | Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. ( Agazzi, R; Colledan, M; Conte, G; De Giorgio, M; Fagiuoli, S; Iegri, C; Lucà, MG; Nani, R; Nicora, C; Pinelli, D; Sala, F; Sarti, D; Schranz, M; Sironi, S; Virotta, G, 2018) |
| "Purpose To determine whether texture features on pretreatment contrast material-enhanced computed tomographic (CT) images can help predict overall survival (OS) and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 7.88 | Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib. ( Costentin, C; Durot, C; Hoeffel, C; Luciani, A; Mulé, S; Rahmouni, A; Thiefin, G, 2018) |
| "In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro." | 7.88 | Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma ( Chen, CW; Hsu, FT; Kuo, YC; Pan, PJ; Tsai, JJ, 2018) |
| "To assess the inter-operator concordance and the potential sources of discordance in defining response to sorafenib in hepatocellular carcinoma (HCC)." | 7.88 | Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. ( Andreone, A; Badea, RI; Benevento, F; Brocchi, S; Ferrarini, A; Golfieri, R; Mastroroberto, M; Morselli-Labate, AM; Negrini, G; Piscaglia, F; Renzulli, M; Tovoli, F, 2018) |
| "Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and HCC refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 7.88 | Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nakahara, T; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "The present study aimed to investigate the anticancer effect of sorafenib combined with silencing of activating transcription factor 2 (ATF2) in hepatocellular carcinoma (HCC) cells and to assess the underlying molecular mechanisms." | 7.88 | Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. ( Cai, L; Luo, L; Meng, X; Tang, Z, 2018) |
| "Sorafenib is the most widely used multikinase inhibitor in patients with advanced hepatocellular carcinoma (HCC)." | 7.88 | Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. ( Kang, MK; Lee, HJ; Park, JG, 2018) |
| "To evaluate the cost-effectiveness of sorafenib treatment in combination with other therapies versus sorafenib monotherapy among patients with advanced hepatocellular carcinoma (HCC) who are enrolled in Taiwan's National Health Insurance." | 7.88 | Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. ( Chuang, PH; Ho, JC; Hsieh, ML; Hsieh, VC, 2018) |
| "The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib." | 7.88 | Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2018) |
| "Although sorafenib enhances overall survival, sorafenib resistance has been reported to be a significant limiting factor for improved prognosis in patients with hepatocellular carcinoma (HCC)." | 7.88 | Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. ( Choi, GH; Jang, SJ; Jung, Y; Kim, JS; Kim, KM; Lee, HC; Yu, ES, 2018) |
| "Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose." | 7.88 | Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. ( Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y, 2018) |
| "We report an advanced HCC patient with many lung metastases who failed sorafenib treatment." | 7.88 | The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report. ( Duo, J; Ma, X; Zhao, Y; Zhu, H, 2018) |
| "There are few efficacy and toxicity data on sorafenib for patients treated for hepatocellular carcinoma (HCC) who are not Caucasian or Asian." | 7.88 | Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. ( Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB, 2018) |
| "Sorafenib (SOR) has proved to be effective in patients with advanced hepatocellular carcinoma (HCC), since overall survival was higher in phase III clinical trials; however, disease progression can occur." | 7.88 | Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience. ( Álvares-da-Silva, MR; de Freitas, LBR; Grivicich, I; Longo, L; Santos, D, 2018) |
| "Treatment with sorafenib remains the first‑line therapy for patients with advanced stage hepatocellular carcinoma (HCC), however, it has limited effect due to the acquired resistance of HCC." | 7.88 | Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. ( Cheng, B; Du, J; Fan, Y; Li, J; Li, X; Lin, W; Ling, C; Liu, D, 2018) |
| "Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation." | 7.85 | Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. ( Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T, 2017) |
| "Drug resistance to sorafenib is common in patients with hepatocellular carcinoma(HCC)." | 7.85 | Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. ( Chen, J; Cheng, Y; Li, A; Liu, D; Liu, Y; Luo, R; Wang, B; Xu, W; Zheng, H; Zhu, Y, 2017) |
| "Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions." | 7.85 | Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. ( Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ, 2017) |
| "Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.85 | Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. ( Chen, HM; Chen, PJ; Cheng, AL; Hsu, CH; Lai, MS; Lu, LC; Shao, YY; Yeh, YC, 2017) |
| "For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines." | 7.85 | Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. ( Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2017) |
| "Sorafenib is the only standard treatment for unresectable hepatocellular carcinoma (HCC), but it provides modest survival benefits over placebo, necessitating predictive biomarkers of the response to sorafenib." | 7.85 | Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). ( Cho, EJ; Cho, Y; Cho, YY; Jun, J; Kim, H; Kim, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, S; Park, T; Yeo, I; Yoon, JH; Yu, SJ, 2017) |
| "Sorafenib is currently used to treat advanced and/or unresectable hepatocellular carcinoma (HCC), but the increase of the median survival was only 3 months." | 7.85 | Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. ( Abeni, E; Arici, B; De Petro, G; Marchina, E; Salvi, A; Traversa, M, 2017) |
| "The objective of this study was to determine the effects of sorafenib on TH levels in patients with hepatocellular carcinoma (HCC) and to evaluate possible mechanisms." | 7.85 | Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. ( Beukhof, CM; Bins, S; Chaker, L; de Herder, WW; de Rijke, YB; Mathijssen, RH; Peeters, RP; van Doorn, L; van Heerebeek, R; van Kemenade, FJ; Visser, TJ; Visser, WE, 2017) |
| "To investigate the feasibility of perfusion-CT (p-CT) measurements in quantitative assessment of hemodynamic changes related to sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 7.85 | Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. ( Franzesi, CT; Ippolito, D; Okolicsanyi, S; Querques, G; Sironi, S; Strazzabosco, M, 2017) |
| "Sorafenib is the standard of care for patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI), with limited survival." | 7.85 | Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. ( Adam, R; Amaddeo, G; Bricault, I; Calderaro, J; Cherqui, D; Costentin, CE; Decaens, T; Duvoux, C; Ganne-Carrié, N; Laurent, A; Letoublon, C; Luciani, A; Mallat, A; Nault, JC; Paule, B; Roudot-Thoraval, F; Samuel, D; Vibert, E, 2017) |
| "Molecule-targeted therapy, such as sorafenib, is one of the effectively therapeutic options for advanced hepatocellular carcinoma (HCC)." | 7.85 | Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. ( Ji, B; Liu, J; Liu, K; Liu, Y; Meng, L, 2017) |
| "Limited information is available regarding patient survival after sorafenib discontinuation in patients with hepatocellular carcinoma (HCC)." | 7.85 | Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. ( Ahn, SH; Han, KH; Heo, JY; Jang, SK; Jang, SY; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Lee, SH; Lee, YR; Park, JY; Park, SY; Tak, WY, 2017) |
| "Use of sorafenib remains debated in elderly patients treated for advanced hepatocellular carcinoma (HCC)." | 7.85 | Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. ( Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N, 2017) |
| "Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC)." | 7.85 | Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. ( Brunetti, O; Casadei Gardini, A; Cascinu, S; Di Costanzo, GG; Ercolani, G; Faloppi, L; Foschi, FG; Granata, R; Marisi, G; Palmieri, VO; Scartozzi, M; Silvestris, N; Tortora, R, 2017) |
| "Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC)." | 7.85 | Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. ( Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ, 2017) |
| "The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma (HCC) has not been established." | 7.85 | Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study. ( Hoshino, T; Ishihara, H; Kakizaki, S; Kudo, T; Naganuma, A; Sato, K; Suzuki, Y; Takagi, H; Uehara, D; Yamada, M, 2017) |
| "Purpose Sorafenib is currently the only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocellular carcinoma." | 7.85 | Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. ( D'Addeo, K; Kaplan, DE; Mamtani, R; Mehta, R; Reiss, KA; Taddei, TH; Wileyto, EP; Yu, S, 2017) |
| "Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear." | 7.85 | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. ( Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L, 2017) |
| "Sorafenib, an orally available kinase inhibitor, is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), and it exerts potent inhibitory activity against epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR) by inhibiting mitogen-activated protein kinase (MAPK) signaling in HCC." | 7.85 | Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. ( Cheng, H; Dong, J; Hu, F; Sun, W; Xu, J; Zhai, B, 2017) |
| "In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib." | 7.85 | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. ( Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U, 2017) |
| "Transcatheter arterial chemoembolization (TACE) and TACE in combination with sorafenib (TACE-sorafenib) have shown a significant survival benefit for the treatment of unresectable hepatocellular carcinoma (HCC)." | 7.85 | Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. ( Chen, KF; Li, B; Li, Q; Liu, F; Wei, YG; Zhao, RC; Zhou, J, 2017) |
| "Although sorafenib is currently used as a standard treatment for advanced hepatocellular carcinoma, low response rate, transient and limited efficacy, primary and acquired resistance and negative side-effects gain increasing attentions, suggesting the need for better efficacious combination therapy." | 7.85 | Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. ( Cai, X; Chen, J; Jin, RA; Liang, X; Lin, H; Sun, Y; Tang, M; Xu, J; Zheng, L, 2017) |
| "Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine-threonine kinases." | 7.85 | Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. ( Cai, X; Chen, J; Dai, Y; Ji, T; Liang, X; Liang, Y; Lin, H; Xie, Y; Xu, J; Yu, Q; Zhang, B, 2017) |
| "Targeted therapy is currently the standard treatment for advanced hepatocellular carcinoma (HCC), but an effective treatment after the discontinuation of sorafenib therapy remains uncertain." | 7.85 | Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. ( Chang, PY; Huang, YK; Lee, SW; Lee, TY; Shiu, SI; Yeh, HZ; Yen, CL, 2017) |
| "Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.85 | Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. ( Arai, K; Asahina, Y; Hara, Y; Hayashi, T; Honda, M; Kaneko, S; Mizukoshi, E; Nio, K; Okada, H; Sakai, Y; Suda, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T, 2017) |
| "The purpose of this study was to build prognostic models capable of estimating the outcomes of individual sorafenib-treated advanced stage hepatocellular carcinoma (HCC) patients based on specific patient and tumor factors." | 7.85 | Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. ( Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH, 2017) |
| "Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression." | 7.85 | Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. ( Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A, 2017) |
| "To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model." | 7.85 | Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. ( Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH, 2017) |
| "Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive." | 7.85 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. ( Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC, 2017) |
| "Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC)." | 7.85 | Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. ( Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG, 2017) |
| "To investigate the value of multiparametric magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) for monitoring the ultra-early (within 24 hours) treatment effect of sorafenib in human hepatocellular carcinoma (HCC) xenografts." | 7.85 | Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts. ( Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z, 2017) |
| "To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC)." | 7.85 | Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. ( Igarashi, Y; Ikehara, T; Shimizu, R; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M, 2017) |
| "Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial." | 7.85 | Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib. ( Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y, 2017) |
| "The treatment responses of sorafenib in hepatocellular carcinoma are modest which may be due to different characteristics of cancer cells or insufficient therapeutic concentrations." | 7.85 | Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. ( Chuang, WL; Lin, ZY, 2017) |
| "The multi‑kinase inhibitor sorafenib is the only drug for which randomized control trials have shown improved patient survival in advanced hepatocellular carcinoma (HCC)." | 7.85 | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. ( Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F, 2017) |
| "Sorafenib is an antitumor drug for treatment of advanced hepatocellular carcinoma (HCC)." | 7.85 | MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. ( Caraglia, M; Castiello, F; Ferri, C; Giordano, A; Mosca, N; Panella, M; Potenza, N; Russo, A; Stiuso, P; Vanacore, D; Zappavigna, S, 2017) |
| "The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized." | 7.85 | An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. ( Byun, KS; Je, JH; Kang, SH; Kim, JH; Ko, E; Lee, HJ; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2017) |
| "In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)." | 7.85 | Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017) |
| "Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC)." | 7.85 | FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. ( Gao, L; Hu, CA; Huang, S; Tang, Y; Teng, Y; Wang, X, 2017) |
| " Sorafenib, the medical treatment of reference against advanced stages of hepatocellular carcinoma (HCC), inhibits the RAF-MEK-ERK cascade in HCC cells." | 7.85 | Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. ( Galmiche, A; Giacobbi, AS; Louandre, C; Mammeri, Y; Saidak, Z; Sauzay, C, 2017) |
| "Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC)." | 7.85 | Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. ( Han, P; Jiang, H; Jiang, X; Li, H; Liu, B; Qiao, H; Sun, X; Tan, G; Zhai, B; Zhao, D, 2017) |
| "Melatonin has been shown to exert anticancer activity on hepatocellular carcinoma (HCC) through its antiproliferative and pro-apoptotic effect in both experimental and clinical studies, and sorafenib is the only approved drug for the systemic treatment of HCC." | 7.85 | Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. ( Gao, C; Herr, I; Hoffmann, K; Lin, S; Petrulionis, M; Schemmer, P, 2017) |
| "Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC)." | 7.85 | The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. ( Al-Abdulla, R; Bantel, H; Bettinger, D; Geier, A; Jahn, D; Macias, RI; Marin, JJ; Weiss, J, 2017) |
| "Response to sorafenib is highly variable in hepatocellular carcinoma (HCC)." | 7.85 | Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. ( Arizumi, T; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Toniutto, P, 2017) |
| "To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 7.85 | Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M, 2017) |
| "At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment." | 7.85 | Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. ( Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K, 2017) |
| "Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable." | 7.85 | Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. ( Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM, 2017) |
| "Purpose To identify early biomarkers for the prediction of the therapeutic response in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) and sorafenib (referred to as TACE plus sorafenib) and establish an effective prognostic nomogram." | 7.85 | Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. ( Chen, L; Ni, CF; Teng, GJ; Zhong, BY; Zhu, HD, 2017) |
| " Purpose To assess diagnostic values of intra-voxel incoherent motion (IVIM) imaging in evaluating therapeutic effects of sorafenib on hepatocellular carcinoma (HCC) using mouse xenograft model." | 7.85 | Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models. ( Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC, 2017) |
| "Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC)." | 7.85 | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. ( Cao, J; Chen, Y; Li, W; Liu, K; Shang, C; Tan, W; Zhang, L; Zhong, J; Zhu, S, 2017) |
| "Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC)." | 7.85 | Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. ( Bardeesy, N; Benes, CH; Chang, CC; Chang, CF; Chen, Y; Dima, S; Duda, DG; Duyverman, AM; Flaherty, KT; Gao, DY; Hsu, FF; Huang, P; Jain, RK; Jeng, KS; Kitahara, S; Lin, TT; Liu, CH; Liu, YC; Popescu, I; Ramjiawan, RR; Sung, YC; Zhu, AX, 2017) |
| "We studied the relation between the polymorphism of P-glycoprotein (P-gp) and of breast cancer resistance protein (BCRP), encoded by ABCB1 and ABCG2 genes, respectively, and the pharmacokinetic variability and clinical response during the treatment with sorafenib of hepatocellular carcinoma." | 7.85 | Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. ( Bonhomme-Faivre, L; Cailliez, V; Farinotti, R; Mhiri, A; Noé, G; Paule, B; Saffroy, R; Tandia, M, 2017) |
| "To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system." | 7.85 | Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. ( Ciani, O; Rognoni, C; Sommariva, S; Tarricone, R, 2017) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.83 | pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X, 2016) |
| "Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC)." | 7.83 | Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Bochereau, F; Chauffert, B; Degonville, J; Drullion, C; Fournier, E; François, C; Galmiche, A; Gicquel, A; Godin, C; Houessinon, A; Louandre, C; Nyga, R; Pluquet, O; Saidak, Z, 2016) |
| "We have previously demonstrated that isocorydine (ICD) can be served as a potential antitumor agent in hepatocellular carcinoma (HCC)." | 7.83 | Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. ( Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F, 2016) |
| "To clarify the effects of cyclin E1 suppression on antitumor efficacy of sorafenib in hepatocellular carcinoma cells and to explore the potential of combining sorafenib with cyclin-dependent kinase (CDK) inhibition in therapy." | 7.83 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. ( Cheng, AL; Cheng, YC; Feng, ZR; Hsu, C; Lin, LI; Ou, DL; Shao, YY, 2016) |
| "Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance." | 7.83 | MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. ( Huang, J; Liu, L; Luo, Y; Ma, L; Qian, C; Shan, J; Shen, J; Xu, Y; Yang, Z; Yao, C, 2016) |
| "Sorafenib is the first and currently the only standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. ( Chang, MJ; Chao, TI; Chen, KF; Chen, MH; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH, 2016) |
| "Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)." | 7.83 | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016) |
| "Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma." | 7.83 | Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. ( Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016) |
| "1, modified Response Evaluation Criteria in Solid Tumor (mRECIST), Choi and European Association for the Study of the Liver (EASL) evaluations to assess the response to sorafenib for hepatocellular carcinoma (HCC)." | 7.83 | CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus ( Ayav, A; Bronowicki, JP; Claudon, M; Gavanier, M; Laurent, V; Orry, X; Sellal, C, 2016) |
| "To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions." | 7.83 | TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016) |
| "Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear." | 7.83 | The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. ( Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y, 2016) |
| "We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression." | 7.83 | Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016) |
| "The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported." | 7.83 | MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. ( Fujimoto, S; Kimura, T; Miyamoto, H; Muguruma, N; Okamoto, K; Takayama, T; Takeishi, S; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T, 2016) |
| "Evasive mechanisms triggered by the tyrosine kinase inhibitor sorafenib reduce its efficacy in hepatocellular carcinoma (HCC) treatment." | 7.83 | Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. ( Barbero-Camps, E; Bárcena, C; Colell, A; de Gregorio, E; Fernandez-Checa, JC; García-Ruiz, C; Marí, M; Martinez-Nieto, GA; Morales, A; Moutinho, C; Stefanovic, M; Tutusaus, A; Villanueva, A, 2016) |
| "To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)." | 7.83 | Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. ( Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K, 2016) |
| " We investigated the phenomenon in 61 patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib." | 7.83 | Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. ( Bisulli, M; Casadei Gardini, A; Cascinu, S; Corbelli, J; Donati, G; Faloppi, L; Foschi, FG; Frassineti, GL; Gardini, A; Giampalma, E; La Barba, G; Marisi, G; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Veneroni, L, 2016) |
| "The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study)." | 7.83 | Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. ( Han, KH; Han, SY; Heo, J; Kim, DY; Kim, HJ; Kim, YH; Kweon, YO; Lee, BS; Lee, HC; Lee, WS; Lim, HY; Ryoo, BY; Um, SH; Woo, HY; Yoon, JH; Yoon, SK, 2016) |
| "Sorafenib (SOR) is the standard of care for patients with hepatocellular carcinoma (HCC) and portal vein invasion (PVI), based on the results of phase 3 trials." | 7.83 | A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. ( Arenas, JI; Buades-Mateu, J; Bustamante, FJ; de la Rosa, PA; de la Torre, MA; Gil, C; Iñarrairaegui, M; Lorente, S; Lué, A; Sangro, B; Serrano, MT; Testillano, M, 2016) |
| "Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009." | 7.83 | Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. ( Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T, 2016) |
| "Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016) |
| "The combination of doxorubicin (DOX) with sorafenib (SOR) has proven an effective strategy to enhance anti-hepatocellular carcinoma (HCC) efficacy." | 7.83 | iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. ( Chan, HF; Chen, M; Hu, J; Liang, G; Skibba, M; Zhang, J, 2016) |
| "We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib." | 7.83 | Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. ( Chen, D; Chen, W; Lai, J; Liang, L; Xiao, W; Yin, X; Zhang, K, 2016) |
| "Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence." | 7.83 | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016) |
| "Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares." | 7.83 | Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. ( Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B, 2016) |
| "The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 7.83 | Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. ( Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM, 2016) |
| "We aimed to determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS)with Sonazoid in the evaluation of early response to sorafenib for hepatocellular carcinoma (HCC)." | 7.83 | [Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid]. ( Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M, 2016) |
| "Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma." | 7.83 | Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016) |
| "To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)." | 7.83 | Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. ( Cai, XB; Hou, Y; Li, J; Liu, B, 2016) |
| "Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) and sorafenib resistance remain enigmatic." | 7.83 | Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. ( Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF, 2016) |
| "Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC)." | 7.83 | Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma. ( Chen, W; Dan, Y; Li, M; Li, W; Liu, K; Mo, P; Qin, L; Tong, Z; Wang, W; Yu, C, 2016) |
| "GIDEON was a prospective, global, non-interventional study evaluating the safety of sorafenib in patients with unresectable hepatocellular carcinoma in real-world practice." | 7.83 | Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. ( Furuse, J; Ikeda, M; Ito, Y; Izumi, N; Kadoya, M; Kokudo, N; Kudo, M; Numata, K; Okusaka, T; Takayama, T; Yamashita, S, 2016) |
| "Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively." | 7.83 | Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. ( Chen, SH; Chen, YY; Cheng, KS; Chou, JW; Chuang, PH; Feng, CL; Hsiao, WD; Kao, JT; Lai, HC; Peng, CY; Su, WP; Yu, CJ, 2016) |
| "Sorafenib is a multikinase inhibitor approved as the first line treatment for late stage hepatocellular carcinoma (HCC)." | 7.83 | Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. ( Cai, X; Cang, Y; Chen, J; Huang, D; Ji, T; Jin, R; Li, G; Liang, X; Lin, H; Liu, J; Liu, X; Xie, A; Zhang, J; Zhao, J, 2016) |
| "It is unknown whether the addition of locoregional therapies (LRTx) to sorafenib improves prognosis over sorafenib alone in patients with advanced hepatocellular carcinoma (HCC)." | 7.83 | The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Aycart, SN; Berger, Y; Edwards, MP; Heskel, M; Kim, E; Labow, DM; Sarpel, U; Spivack, JH; Sweeney, R, 2016) |
| "Sorafenib is an oral multikinase inhibitor that improves survival in advanced hepatocellular carcinoma (HCC)." | 7.83 | Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. ( Arachchi, N; Bell, S; Dev, A; Doyle, A; Fink, MA; Gill, R; Gow, PJ; Hong, T; Kemp, W; Knight, V; Kronborg, I; Lubel, J; Marsh, P; Mohsen, W; Nicoll, A; Roberts, S; Rodov, M; Ryan, M; Strasser, SI; Varma, P, 2016) |
| "Despite significant progress, advanced hepatocellular carcinoma (HCC) remains an incurable disease, and the overall efficacy of targeted therapy by Sorafenib remains moderate." | 7.83 | Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. ( Cui, SX; Gao, ZH; Qu, XJ; Shi, WN; Song, ZY; Wang, SQ; Yu, XF, 2016) |
| "Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC)." | 7.83 | Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. ( Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK, 2016) |
| "We evaluated radiotherapy using helical tomotherapy (HT) combined with sorafenib for treatment of pulmonary metastases from hepatocellular carcinoma (HCC)." | 7.83 | Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. ( He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S, 2016) |
| "A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma." | 7.83 | Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. ( Chan, AL; Leung, HW; Liu, CF, 2016) |
| "The Albumin-Bilirubin (ALBI) grade was proposed as an objective means to evaluate liver function in patients with Hepatocellular Carcinoma (HCC)." | 7.83 | A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. ( Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D, 2016) |
| "We investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma refractory or intolerant to sorafenib." | 7.83 | Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. ( Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T, 2016) |
| "The mechanism underlying poor prognosis and sorafenib resistance in patients with hepatocellular carcinoma (HCC) is unknown and, to date, no useful predictive biomarkers of sorafenib resistance have been identified." | 7.83 | Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. ( Cui, X; Hua, L; Liu, J; Lu, C; Ni, R; Qu, L; Shen, Z; Wu, M, 2016) |
| "hepatocellular carcinoma - HCC - BCLC - sorafenib - complete response." | 7.83 | Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. ( Macaluso, FS; Maida, M; Valenza, F; Virdone, R, 2016) |
| "This study investigates whether changes in arterial enhancement of hepatocellular carcinoma (HCC) on contrast-enhanced CT in patients treated with Sorafenib predicts overall survival." | 7.83 | Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib. ( Furlan, A; Marsh, JW; Patchett, N, 2016) |
| "To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 7.83 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016) |
| "To compare the therapeutic effect of portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined with or without sorafenib in patients for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT)." | 7.83 | [Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus]. ( Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J, 2016) |
| "The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC)." | 7.83 | Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. ( De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H, 2016) |
| "Sorafenib, a multi-kinase inhibitor, is the only standard clinical drug for patients with advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance in HCC often prevents its long-term efficacy." | 7.83 | miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. ( Azumi, J; Sakabe, T; Shiota, G; Tsubota, T, 2016) |
| "Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies." | 7.83 | Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. ( Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P, 2016) |
| "Sorafenib, a multikinase inhibitor, is currently the only approved drug for advanced hepatocellular carcinoma (HCC)." | 7.83 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. ( Cheng, AL; Feng, WC; Hsu, CH; Lin, HH; Lu, LC; Shao, YY, 2016) |
| "We examined plasma biomarkers as predictive factors for advanced hepatocellular carcinoma(ad-HCC)patients treated with sorafenib." | 7.83 | [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib]. ( Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M, 2016) |
| "Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment." | 7.83 | Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. ( Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T, 2016) |
| "Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well." | 7.83 | A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. ( Chen, X; Cui, T; Diao, X; Huang, S; Sun, J, 2016) |
| "Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC)." | 7.83 | Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells. ( Abdel-Naim, AB; Badawy, NN; El-Ahwany, E; Khalifa, AE; Liu, AW; Tolba, MF; Youssef, MM; Zada, S, 2016) |
| "Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates." | 7.83 | Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. ( Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH, 2016) |
| "Effects of sorafenib in hepatocellular carcinoma (HCC) are frequently transient due to tumor-acquired resistance, a phenotype that could be targeted by other molecules to reduce this adaptive response." | 7.83 | Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. ( Baulies, A; Fernández, A; Fernández-Checa, JC; Garcia-Ruiz, C; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Ordóñez, R; Prieto-Domínguez, N, 2016) |
| "This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China." | 7.83 | FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016) |
| "Although sorafenib is considered standard therapy for advanced hepatocellular carcinoma (HCC), actual treatments vary." | 7.83 | Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. ( Chung, YH; Ha, Y; Kang, YK; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, SR; Ryoo, BY; Ryu, MH; Shim, JH, 2016) |
| " However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects." | 7.83 | Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. ( Chen, HA; Kuo, TC; Ma, JT; Su, JL; Sung, SY; Tseng, CF; Yang, CY; Yang, ST; Yen, CJ, 2016) |
| "Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)." | 7.83 | Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. ( Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O, 2016) |
| "Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence." | 7.83 | Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. ( Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C, 2016) |
| "We explored the hypothesis that sorafenib may improve the effect of transarterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) and that longer sorafenib duration was associated with additional survival benefits." | 7.83 | Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. ( Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X, 2016) |
| "Sorafenib is the only chemotherapeutic agent currently approved for unresectable hepatocellular carcinoma (HCC)." | 7.83 | Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study. ( Abdelmageed, MM; El-Demerdash, E; El-Naga, RN; Elmazar, MM, 2016) |
| "We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 7.83 | Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. ( Casadei Gardini, A; de Stefano, G; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Negri, FV; Santini, D; Scarpi, E; Scartozzi, M; Silvestris, N; Valgiusti, M, 2016) |
| "The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC)." | 7.83 | Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2016) |
| "In patients with hepatocellular carcinoma (HCC) receiving sorafenib, drug resistance is common." | 7.83 | Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination. ( Azzariti, A; Caligiuri, A; Dituri, F; Giannelli, G; Lupo, L; Mancarella, S; Porcelli, L; Quatrale, AE, 2016) |
| "Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and a number of miRNAs contribute to this resistance." | 7.83 | An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. ( Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B, 2016) |
| " However, their effects on sorafenib resistance in hepatocellular carcinoma (HCC) are not completely understood." | 7.83 | Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. ( Ding, Y; Jiang, C; Luo, D; Qu, Z; Wu, J, 2016) |
| "Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC)." | 7.83 | Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients. ( Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma]. ( Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E, 2016) |
| "This study aimed to identify the health-related quality of life (HRQOL) domains associated with prognosis by assessing longitudinal alterations in HRQOL in patients with advanced hepatocellular carcinoma receiving sorafenib." | 7.83 | Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. ( Arase, Y; Hirose, S; Kagawa, T; Mine, T; Okabe, H; Shiraishi, K; Shomura, M; Takahira, S; Tsuruya, K, 2016) |
| " There is a lack of evidence about the prognostic value of serum LDH level in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment from hepatitis B virus endemic areas." | 7.83 | Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. ( Bi, XY; Cai, JQ; Han, Y; Huang, Z; Li, H; Li, MX; Li, ZY; Yao, XS; Zhang, YF; Zhao, DB; Zhao, H; Zhao, JJ; Zhou, JG, 2016) |
| "To provide support for combined usage of phosphoinositide 3-kinase (PI3K) inhibitors or mitogen-activated protein kinase pathway inhibitors together with sorafenib in treatment of sorafenib-resistant hepatocellular carcinoma." | 7.83 | Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor. ( Wu, CH; Wu, X; Zhang, HW, 2016) |
| " This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking." | 7.83 | Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. ( Kerbel, RS; Kuczynski, EA, 2016) |
| "The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012." | 7.81 | Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. ( Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K, 2015) |
| "Sorafenib and transarterial (90) Y-radioembolization (TARE) are possible treatments for Barcelona Clinic Liver Cancer (BCLC) intermediate-advanced stage hepatocellular carcinoma (HCC)." | 7.81 | Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. ( Bernardi, M; Bolondi, L; Cappelli, A; Cucchetti, A; Erroi, V; Fiumana, S; Golfieri, R; Gramenzi, A; Granito, A; Marinelli, S; Mosconi, C; Pettinato, C; Trevisani, F, 2015) |
| "There have been no established predictive factors of responders to sorafenib in patients with unresectable hepatocellular carcinoma (HCC)." | 7.81 | Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. ( Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y, 2015) |
| "Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC)." | 7.81 | Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. ( Döring, C; Filmann, N; Hansmann, ML; Hartmann, S; Herrmann, E; Mertens, A; Peveling-Oberhag, J; Piiper, A; Trojan, J; Welker, MW; Zeuzem, S, 2015) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 7.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| "Sorafenib is the standard of care in advanced hepatocellular carcinoma (HCC), however no criteria have been established to select patients likely to benefit from this therapy." | 7.81 | MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. ( Augello, C; Barberis, M; Bosari, S; Carnaghi, C; Di Tommaso, L; Fagiuoli, S; Faversani, A; Labianca, R; Maggioni, M; Pressiani, T; Rimassa, L; Roncalli, M; Rota Caremoli, E; Santoro, A; Spagnuolo, G; Vaira, V, 2015) |
| "The aim of this study was to assess the early response to sorafenib using ultrasound molecular imaging in a murine model of hepatocellular carcinoma (HCC)." | 7.81 | Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. ( Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L, 2015) |
| "Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.81 | Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. ( Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y, 2015) |
| "Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but it also induces the activation of Akt, which contributes to the mechanisms for the resistance to sorafenib." | 7.81 | Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. ( He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D, 2015) |
| "Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour." | 7.81 | The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. ( Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z, 2015) |
| "Prothymosin alpha (PTMA) is overexpressed in various human tumors, including hepatocellular carcinoma (HCC)." | 7.81 | Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. ( Chao, CC; Lin, YT; Lu, HP, 2015) |
| "Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 7.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
| "We aimed to evaluate the efficacy and tolerability of hepatic arterial infusion chemotherapy (HAIC) using cisplatin as an alternative to sorafenib for the treatment of hepatocellular carcinoma (HCC) patients who had not responded to transarterial chemoembolization (TACE)." | 7.81 | Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. ( Fukuda, H; Hidaka, H; Ishii, T; Kobayashi, S; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Nakazawa, T; Nozaki, A; Numata, K; Ohkawa, S; Okuse, C; Sakamaki, K; Shibuya, A; Suzuki, M; Tanaka, K, 2015) |
| "The aim of this study was to identify the prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who are refractory or intolerant to sorafenib and to exclude unsuitable candidates from subsequent therapy." | 7.81 | Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib. ( Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H, 2015) |
| "Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)." | 7.81 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival benefits." | 7.81 | CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. ( Bardeesy, N; Chen, Y; Duda, DG; Fan, C; Hato, T; Huang, P; Huang, Y; Jain, RK; Kitahara, S; Ng, MR; Ochiai, H; Ramjiawan, RR; Reddy, TP; Reiberger, T; Unan, EC; Zhu, AX, 2015) |
| "The study aimed to evaluate the tissue expression of molecules involved in intracellular signalling pathways as predictors of response to sorafenib in advanced hepatocellular carcinoma (HCC)." | 7.81 | Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. ( Ardizzoni, A; Campanini, N; Dal Bello, B; Fanello, S; Maria, SE; Missale, G; Negri, FV; Poggi, G; Porta, C; Rossi, S; Salvagni, S; Tinelli, C, 2015) |
| "Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.81 | Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. ( Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S, 2015) |
| "To compare efficacy of transarterial chemoembolization with and without radiation therapy (RT) versus sorafenib for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.81 | Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. ( Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM, 2015) |
| "To evaluate the role of antiviral therapy with nucleoside analogs (NAs) in sorafenib-treated patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)." | 7.81 | Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. ( Chen, M; Gao, H; Huang, J; Li, S; Wang, H; Xu, L; Zhang, Y; Zhou, Z, 2015) |
| "Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects." | 7.81 | Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. ( Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S, 2015) |
| " In this study, six long chain fatty acid esters of quercetin-3-O-glucoside (Q3G) acylated enzymatically and were used for determining their antiproliferative action in hepatocellular carcinoma cells (HepG2) in comparison to precursor compounds and two chemotherapy drugs (Sorafenib and Cisplatin)." | 7.81 | Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells. ( Rupasinghe, HV; Sudan, S, 2015) |
| " Sorafenib is the only drug to prolong overall survival of the patients with hepatocellular carcinoma (HCC), however, the outcome is still not satisfactory." | 7.81 | Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. ( Ishijima, N; Kanki, K; Shimizu, H; Shiota, G, 2015) |
| "This retrospective study was carried out to compare the outcomes between elderly (≥70 years of age) and nonelderly patients (<70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE)." | 7.81 | Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. ( Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015) |
| "We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment." | 7.81 | Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. ( Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G, 2015) |
| "GEMOX combined with sorafenib as first-line therapy followed by sorafenib as maintenance therapy was effective with manageable toxicity for patients with advanced hepatocellular carcinoma." | 7.81 | First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. ( Li, K; Liu, Y; Ma, N; Qiao, L; Wang, F; Wang, J; Xu, S; Yue, H, 2015) |
| "Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.81 | Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. ( Lee, HW; Park, JG; Park, SY, 2015) |
| "Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)." | 7.81 | Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015) |
| "Sorafenib is the standard of care in advanced hepatocellular carcinoma." | 7.81 | Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. ( Addario, L; Caporaso, N; Cordone, G; de Stefano, G; Di Costanzo, GG; Farella, N; Imparato, M; Lampasi, F; Lanza, AG; Tortora, R, 2015) |
| "Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC), although it is known to cause a variety of dermatologic adverse events." | 7.81 | Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma. ( Kawai, K; Minemura, M; Nakajima, T; Sugiyama, T; Tajiri, K, 2015) |
| "Sorafenib, an oral inhibitor of multiple tyrosine kinase receptors, has been widely used as a standard medical treatment for advanced hepatocellular carcinoma (HCC)." | 7.81 | Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment. ( Azuma, K; Esaki, M; Kitazono, T; Matsumoto, T; Nakamura, S; Ooho, A; Yanai, S, 2015) |
| " This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells." | 7.81 | Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. ( Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY, 2015) |
| "In the period 2005-2011, 2402 patients were diagnosed with hepatocellular carcinoma: 12% received resection and 9% sorafenib." | 7.81 | Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands. ( de Man, RA; Ijzermans, JN; Klümpen, HJ; Schrier, JG; van der Geest, LG; van Erpecum, KJ; van Meer, S, 2015) |
| "Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC)." | 7.81 | Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. ( Chao, Y; Chen, YT; Huang, YH; Huo, TI; Lee, FY; Lee, IC; Li, CP; Lin, HC; Su, CW, 2015) |
| "Retrospective analysis of consecutive hepatocellular carcinoma patients receiving metronomic capecitabine between January 2012 and November 2014." | 7.81 | Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. ( Benevento, F; Bolondi, L; Granito, A; Marinelli, S; Piscaglia, F; Renzulli, M; Terzi, E; Venerandi, L, 2015) |
| "Sorafenib increases survival of patients with advanced hepatocellular carcinoma (HCC) by inhibiting RAF kinase and receptor tyrosine kinase activity, but involvement of sorafenib in fibrosis and epithelial-mesenchymal transition (EMT) remains unclear." | 7.81 | Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. ( Ha, TY; Hong, HN; Hwang, S; Kim, N; Moon, KM; Ryoo, BY; Song, GW; Tak, E; Won, YJ, 2015) |
| " Anti-angiogenic effects of sorafenib lead to impairment of vitamin K uptake and induction of des-γ-carboxyprothrombin release by hepatocellular carcinoma (HCC) cells." | 7.81 | Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis. ( Choi, YI; Ha, TY; Hong, HN; Hwang, S; Kim, N; Ryoo, BY; Song, GW; Tak, E; Won, YJ; Yoon, SY, 2015) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | 7.81 | Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 7.81 | Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. ( Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M, 2015) |
| "Sorafenib, an oral multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma (HCC)." | 7.81 | Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. ( Dou, H; Feng, K; Jiang, X; Li, Z; Wang, T; Zhang, Y; Zhou, F, 2015) |
| "Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC)." | 7.81 | Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. ( Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO, 2015) |
| "Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib." | 7.81 | Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. ( Chen, E; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S, 2015) |
| "Sorafenib has been shown to significantly improve the overall survival of patients with advanced hepatocellular carcinoma (HCC)." | 7.81 | Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. ( Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J, 2015) |
| "The aim of this study was to determine whether skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma (HCC) that is being treated with sorafenib." | 7.81 | Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. ( Hanai, T; Ideta, T; Imai, K; Kochi, T; Miyazaki, T; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K, 2015) |
| " We investigated whether the serum TGF-β1 level was related to the outcomes of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC)." | 7.81 | High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. ( Chan, SY; Cheng, AL; Hsu, CH; Huang, CY; Lin, TH; Shao, YY, 2015) |
| "Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study." | 7.81 | [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]. ( Amoroso, D; Angelico, M; Attili, A; Barni, S; Benedetti, A; Buonadonna, A; Burlone, ME; Calvani, N; Cascinu, S; Cengarle, R; Cillo, U; Crocè, LS; Cuttone, F; D'Angelo, S; Di Costanzo, F; Erminero, C; Fava, G; Gasbarrini, A; Germano, D; Giannitrapani, L; Giovanis, P; Lencioni, R; Lorusso, V; Magini, G; Marenco, S; Marignani, M; Massa, E; Montesarchio, V; Noto, A; Palmieri, V; Picardi, A; Poggi, G; Proserpio, I; Saitta, C; Sansonno, D; Tumulo, S; Villa, E; Zolfino, T, 2015) |
| "Sorafenib (Nexabar, Bayer, Berlin, Germany), one of multikinase inhibitors, can infrequently downstage advanced hepatocellular carcinoma (HCC)." | 7.81 | Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M, 2015) |
| "While sorafenib (SFN) is the established worldwide standard therapeutic agent for advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) is also considered a favorable treatment for some advanced HCCs." | 7.81 | Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. ( Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y, 2015) |
| "This study aimed to identify the key pathways and to explore the mechanism of sorafenib in inhibiting hepatocellular carcinoma (HCC)." | 7.81 | Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array. ( Li, S; Liu, R; Liu, Y; Shen, H; Wang, P; Yin, L, 2015) |
| "The multi-kinase inhibitor sorafenib is now used as standard therapy for advanced hepatocellular carcinoma (HCC)." | 7.81 | Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. ( Izumi, N; Joko, K; Nishijima, N; Nishio, K; Orito, E; Osaki, Y; Sakai, K; Takeda, H; Uchida, Y, 2015) |
| "Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC)." | 7.81 | Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy. ( Guo, WH; Lu, J; Wang, XZ; Zhang, JX; Zheng, JF, 2015) |
| "To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed." | 7.81 | Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. ( Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K, 2015) |
| "Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib." | 7.81 | Long-term therapy with sorafenib is associated with pancreatic atrophy. ( Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 7.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
| " In this study, we investigated the ability of iRGD to improve the delivery of sorafenib and doxorubicin therapy in hepatocellular carcinoma (HCC) using established mouse models of the disease." | 7.81 | Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. ( Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S, 2015) |
| "We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib." | 7.81 | Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. ( Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S, 2015) |
| "Sorafenib (SOR) is a promising treatment for advanced hepatocellular carcinoma (HCC)." | 7.81 | Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis. ( Dong, X; Li, J; Li, T; Liu, F; Wang, F; Wang, X; Wang, Y; Wei, H; Xiu, P; Xu, Z; Zhong, J, 2015) |
| "Sorafenib is a specific adenosine triphosphate-competitive RAF inhibitor used as a first-line treatment of advanced hepatocellular carcinoma (HCC)." | 7.81 | Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. ( Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS, 2015) |
| "Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits." | 7.81 | TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. ( Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J, 2015) |
| "Sorafenib resistance remains a major obstacle for the effective treatments of hepatocellular carcinoma (HCC)." | 7.81 | MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. ( Dong, D; Dong, X; He, C; Jiang, H; Jiang, X; Li, B; Sun, X; Xu, S; Zhai, B, 2015) |
| "We compared the benefits of sorafenib with that of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (ad-HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 7.81 | [Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization]. ( Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M, 2015) |
| "In our previous studies, we reported that CD133(+) cancer stem cells (CSCs) were chemoresistant in hepatocellular carcinoma (HCC) and that isocorydine treatment decreased the percentage of CD133(+) CSCs." | 7.81 | An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. ( Chen, L; Chen, T; Cui, Y; Fang, T; Ge, C; Jiang, G; Li, H; Li, J; Li, M; Liu, J; Tian, H; Xie, H; Yao, M; Zhang, L, 2015) |
| "Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance." | 7.81 | Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress. ( Fang, T; Hu, F; Jin, X; Pan, S; Sun, X; Xu, L; Yan, H; Zhai, B; Zhao, D, 2015) |
| "Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE)." | 7.81 | Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. ( Ito, D; Kawanishi, K; Kojima, K; Ohki, T; Sato, K; Seki, M; Tagawa, K; Toda, N; Yamada, T; Yamagami, M, 2015) |
| "Sorafenib, an oral multikinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC) treatment." | 7.81 | Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. ( Aino, H; Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tajiri, N; Tanaka, M; Torimura, T, 2015) |
| "Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC)." | 7.81 | Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ( Hisamichi, K; Jin, Y; Kataoka, Y; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H, 2015) |
| " Here we provide models of human hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in vitro and in vivo to evaluate the efficacy of NFC alone and in combination with sorafenib, a kinase inhibitor approved for treatment of HCC." | 7.81 | A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. ( Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF, 2015) |
| "Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III trials." | 7.81 | Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis. ( Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Inoue, T; Iwanishi, M; Kitai, S; Kitano, M; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2015) |
| "Sorafenib is a kinase inhibitor used as anticancer drug against various human tumors, including advanced hepatocellular carcinoma (HCC)." | 7.81 | Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells. ( Chao, CC; Lin, YT, 2015) |
| "Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)." | 7.81 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015) |
| "Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC)." | 7.81 | Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. ( Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W, 2015) |
| "Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued." | 7.81 | Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma. ( BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H, 2015) |
| "SN-38 and sorafenib have synergistic anticancer activity on hepatocellular carcinoma cells in vitro with the augmentation of apoptosis." | 7.81 | [Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism]. ( Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z, 2015) |
| "Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC)." | 7.81 | [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H, 2015) |
| "We report a case of locally advanced huge hepatocellular carcinoma (HCC) invading the diaphragm and the right lung, which was controlled by sorafenib, thereby allowing curative resection." | 7.81 | [Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report]. ( Asaoka, T; Doki, Y; Eguchi, H; Kawamoto, K; Marubashi, S; Mori, M; Mukai, Y; Nagano, H; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2015) |
| "Sorafenib has been a standard therapy for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis." | 7.81 | [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report]. ( Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T, 2015) |
| "The efficacy of sorafenib for hepatocellular carcinoma (HCC) patients refractory to transcatheter arterial chemoembolization (TACE) has not yet been clarified." | 7.80 | Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. ( Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H, 2014) |
| "Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma (HCC)." | 7.80 | Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. ( Chen, KF; Chen, PJ; Chu, PY; Huang, HP; Huang, JW; Liu, CY; Shiau, CW; Tai, WT, 2014) |
| "Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 7.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
| " Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0." | 7.80 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014) |
| " We investigated the effect of EMT-related SRF, focusing on its promotion of chemoresistance against sorafenib in hepatocellular carcinoma (HCC)." | 7.80 | Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma. ( Bae, JS; Chung, MJ; Jang, KY; Kim, DG; Kim, KM; Moon, WS; Noh, SJ, 2014) |
| "Recently, the oral multikinase inhibitor sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC)." | 7.80 | Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib. ( Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2014) |
| "Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma." | 7.80 | SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. ( Chen, KF; Chen, PJ; Chen, YL; Chu, PY; Hsu, CY; Hsu, YC; Huang, JW; Li, YS; Shiau, CW; Tai, WT, 2014) |
| "1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment." | 7.80 | Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. ( Agnello, F; Brancatelli, G; Cabibbo, G; Furlan, A; Genco, C; Giannitrapani, L; Lagalla, R; Marin, D; Midiri, M; Salvaggio, G, 2014) |
| "To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 7.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
| "This study evaluated the feasibility of CT perfusion parameters for the early efficacy prediction of sorafenib in the treatment of hepatocellular carcinoma (HCC) in rats." | 7.80 | Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. ( Liu, X; Shi, G; Wang, L; Wang, Q; Wu, R, 2014) |
| "Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has demonstrated limited benefits with very low response rates." | 7.80 | Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. ( Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D, 2014) |
| "1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS)." | 7.80 | Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. ( Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N, 2014) |
| "Although sorafenib improves survival in patients with hepatocellular carcinoma (HCC), doses have to be reduced in quite a few patients because of adverse events." | 7.80 | Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma? ( Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O, 2014) |
| "To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis." | 7.80 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. ( Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D, 2014) |
| "To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC)." | 7.80 | [Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma]. ( Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K, 2014) |
| "Sorafenib is a multi-kinase inhibitor that has been proven effective for the treatment of unresectable hepatocellular carcinoma (HCC)." | 7.80 | Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. ( Chen, CL; Chen, WY; Honda, K; Kawasaki, K; Masuda, M; Miyanaga, A; Nakamura, Y; Ono, M; Sakuma, T; Yamada, T, 2014) |
| "1), may underestimate activity and does not predict survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib." | 7.80 | Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Belghiti, J; Bouattour, M; Bruno, O; Castera, L; Dreyer, C; Faivre, S; Larroque, B; Raymond, E; Ronot, M; Vilgrain, V; Wassermann, J, 2014) |
| "To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC)." | 7.80 | Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. ( Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K, 2014) |
| "Sorafenib is the first drug currently approved to treat advanced hepatocellular carcinoma (HCC)." | 7.80 | RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. ( Fan, JG; Li, GM; Pan, Q; Sun, C; Wang, J; Wang, YG, 2014) |
| "Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but the acquired resistance to sorafenib results in limited benefits." | 7.80 | Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. ( Dong, X; Hu, F; Jiang, H; Jiang, X; Liu, B; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Xu, J; Zhai, B; Zhao, D, 2014) |
| "Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation." | 7.80 | Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. ( Chen, W; Guo, E; Liu, Z; Lu, L; Peng, X; Wang, Y; Yan, T; Yang, X; Ye, L; Zhou, F, 2014) |
| "Early assessment of hepatocellular carcinoma (HCC) response during sorafenib (SO) treatment is challenging, since tumor necrosis, extension and radiological appearance can be inhomogeneous." | 7.80 | Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? ( Bargellini, I; Bartolozzi, C; Masi, G; Mismas, V; Sacco, R; Scionti, A; Vivaldi, C, 2014) |
| "Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing." | 7.80 | Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. ( Bodoky, G; Fassan, M; Gyöngyösi, B; Járay, B; Kiss, A; Schaff, Z; Székely, E; Végh, É, 2014) |
| "Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemo-embolization." | 7.80 | Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. ( Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE, 2014) |
| "Sorafenib is a promising drug for advanced hepatocellular carcinoma (HCC); however, treatment may be discontinued for multiple reasons, such as progressive disease, adverse events, or the cost of treatment." | 7.80 | Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. ( Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ, 2014) |
| "The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. ( Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z, 2014) |
| "Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor regression in patients with chronic liver diseases." | 7.80 | Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. ( Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S, 2014) |
| "Clinical trials suggest that combining transcatheter arterial chemoembolization with sorafenib in patients with advanced hepatocellular carcinoma shows a superior safety and tolerability profile." | 7.80 | Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. ( Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L, 2014) |
| "Transferrin-targeted core-shell nanomedicine encapsulating doxorubicin and sorafenib was studied as a drug delivery system against hepatocellular carcinoma, resulting in enhanced and synergistic therapeutic effects, paving the way towards potential future clinical applications of similar techniques." | 7.80 | Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. ( Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP, 2014) |
| "Sorafenib is the only drug approved by the Food and Drug Administration for metastatic hepatocellular carcinoma (HCC)." | 7.80 | Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. ( Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM, 2014) |
| "Sorafenib is the standard systemic therapy for unresectable or recurrent hepatocellular carcinoma (HCC) but adds minimal increase in survival." | 7.80 | Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. ( Ady, JW; Belin, LJ; Chen, CT; Chen, NG; Fong, Y; Heffner, J; Johnsen, C; Klein, E; Love, D; Mojica, K; Pugalenthi, A; Szalay, AA; Yu, YA, 2014) |
| "Erythema multiforme (EM) is a known side effect of sorafenib therapy in cancer patients; at onset, the causative medication should be permanently discontinued." | 7.80 | [Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma]. ( Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M, 2014) |
| "Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis." | 7.80 | The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. ( Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD, 2014) |
| " However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma (HCC) has not been demonstrated." | 7.80 | Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. ( Guo, QQ; Wang, QD; Yang, GR; Zhao, YL, 2014) |
| "The immune modulatory drug lenalidomide has shown promising anti-tumor activity in a clinical trial of patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. ( Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL, 2014) |
| "We present a 57-year-old Caucasian man with hepatocellular carcinoma (HCC) twice achieving complete remission with reduced dose sorafenib." | 7.80 | Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel. ( Tan-Shalaby, JL, 2014) |
| " Our aim was to determine whether single-nucleotide polymorphisms (SNPs) in KDR gene are associated with clinical outcomes after first-line sorafenib therapy in advanced hepatocellular carcinoma (HCC)." | 7.80 | The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. ( Fu, SR; He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhan, MX; Zhao, W; Zhao, Y; Zheng, YB, 2014) |
| "Sorafenib is the approved systemic drug of choice for advanced hepatocellular carcinoma (HCC), but has demonstrated limited benefits because of drug resistance." | 7.80 | 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. ( Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H, 2014) |
| "We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC)." | 7.80 | Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M, 2014) |
| "The aims of the present study were to examine whether unresectable hepatocellular carcinoma (HCC) patients treated with initial dose of sorafenib of 400 mg/day (half-dose group) had comparable treatment efficacy, safety and survival merit as compared with those treated with initial dose of sorafenib of 800 mg/day (standard-dose group) in a multicenter large study." | 7.80 | Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. ( Endo, M; Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y, 2014) |
| "To determine significant indicators for the efficacy of sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M, 2014) |
| " In animals and humans it was found to be quickly metabolized into 4-methylthiobutyl isothiocyanate (MTBITC, erucin) which we recently identified as strong selective apoptosis inducer in hepatocellular carcinoma (HCC) cells." | 7.80 | The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC. ( Erlacher, M; Hertrampf, A; Herz, C; Kleinhans, C; Lamy, E; Mersch-Sundermann, V; Platz, S; Rohn, S; Schüler, J; Stetter, N; Wagner, M; Zimmermann, S, 2014) |
| "Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.80 | Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, HJ; Kim, JK; Kim, SU; Kweon, YO; Lee, HW; Lee, JI; Lee, KS; Lee, S; Park, JY; Park, SY; Tak, WY, 2014) |
| "Sorafenib is the first systemic therapy to demonstrate survival benefit in advanced hepatocellular carcinoma (HCC) in randomized controlled trials with rigorous patient selection." | 7.80 | Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Barroso-Sousa, R; Bento, Ada S; Blanco, BP; da Fonseca, LG; Hoff, PM; Pfiffer, TE; Sabbaga, J; Valente, GL, 2014) |
| "To evaluate the safety and efficacy of combined therapy with transarterial chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with portal venous tumour thrombus (PVTT)." | 7.80 | Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. ( Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014) |
| "Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC)." | 7.80 | Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014) |
| "The objective of this study was to evaluate the efficacy of combined therapy using Sorafenib and radiofrequency ablation (RFA) with curative intent for all detectable lesions in patients with Barcelona Clinic Liver Cancer (BCLC) Stage 0-B1 hepatocellular carcinoma (HCC)." | 7.80 | Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. ( Dou, K; Du, X; Feng, X; Guo, C; Jia, W; Liu, T; Ma, K; Qin, X; Wang, Z; Xu, J; Xu, R; Yang, S; Zhao, H, 2014) |
| "Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC)." | 7.80 | Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. ( Kudo, M; Shimada, M; Tanaka, K, 2014) |
| "To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis." | 7.80 | [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis]. ( Chen, J; Chen, S; Wu, B; Xi, W; Yu, H, 2014) |
| "To investigate the therapeutic effect of the hepatic arterial administration of sorafenib in rabbit VX-2 hepatocellular carcinoma (HCC) model." | 7.80 | Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model. ( Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L, 2014) |
| "The aim of this study was to determine the effects of matrine (a natural alkaloid) on sorafenib-induced cytotoxicity against hepatocellular carcinoma (HCC) cells, and to explore the molecular mechanisms involved." | 7.80 | Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells. ( Jin, Y; Lin, L; Lin, Y; Tan, Y; Wang, D; Zhang, Y; Zheng, C, 2014) |
| "Sorafenib and conventional systemic cytotoxicity chemotherapy are currently being used in parallel for the patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma. ( Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J, 2014) |
| "This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib vs hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma." | 7.80 | Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study. ( Igarashi, Y; Ikehara, T; Ishii, K; Kikuchi, Y; Kogame, M; Makino, H; Matsui, T; Nagai, H; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M, 2014) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 7.80 | Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. ( Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L, 2014) |
| "Sorafenib has been proved to prolong survival of patients with advanced hepatocellular carcinoma (HCC), but with moderate efficacy." | 7.80 | The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Chen, L; Liang, S; Liu, J; Shao, H; Su, H; Xu, K, 2014) |
| "Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.79 | Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. ( Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD, 2013) |
| "Sorafenib and S-1 (one mixed formulation containing 5-FU prodrug and dihydropyrimidine dehydrogenase inhibitor) were two effective agents against hepatocellular carcinoma (HCC), but whether they had synergistic effects remained unclear." | 7.79 | Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. ( Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ, 2013) |
| "The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC)." | 7.79 | Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC, 2013) |
| "Data on the efficacy and safety of sorafenib in combination with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) are lacking." | 7.79 | Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. ( Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y, 2013) |
| " Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug." | 7.79 | Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. ( Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J, 2013) |
| "Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function." | 7.79 | Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | 7.79 | Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| "Sorafenib is currently the only medical treatment with proven efficacy against hepatocellular carcinoma (HCC)." | 7.79 | Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. ( Barbare, JC; Chatelain, D; Chauffert, B; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Henaut, L; Louandre, C; Maziere, JC; Regimbeau, JM; Sabbagh, C, 2013) |
| "Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma (HCC)." | 7.79 | Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. ( Bozzarelli, S; Carnaghi, C; Destro, A; Di Tommaso, L; Giordano, L; Ligorio, C; Personeni, N; Pressiani, T; Rimassa, L; Roncalli, M; Santoro, A; Tronconi, MC, 2013) |
| "This prospective pilot study investigated the feasibility of perfusion computed tomography parameters as surrogate markers of angiogenesis and early response following sorafenib administration in patients with advanced hepatocellular carcinoma." | 7.79 | Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. ( Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R, 2013) |
| "Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.79 | Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC, 2013) |
| " Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC)." | 7.79 | Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ( Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013) |
| "Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma, setting a new standard for first-line treatment." | 7.79 | Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. ( Dai, XF; Ding, J; Ma, CM; Ren, JH; Wu, G; Zhang, RG, 2013) |
| "Liver resection can be considered in some hepatocellular carcinoma (HCC) patients who received sorafenib." | 7.79 | Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study. ( Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P, 2013) |
| "We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2." | 7.79 | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013) |
| "To explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis." | 7.79 | [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis]. ( Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS, 2013) |
| "Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC)." | 7.79 | Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. ( Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J, 2013) |
| "The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved." | 7.79 | Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. ( Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM, 2013) |
| "Sorafenib represents the standard of care targeted therapy for patients with advanced hepatocellular carcinoma (HCC)." | 7.79 | Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. ( Chen, D; Li, SQ; Liang, LJ; Peng, BG; Xiao, WK; Yin, XY; Zhao, P, 2013) |
| "The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital, were examined." | 7.79 | [Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma]. ( Hashida, T; Inokuma, T; Kanamori, K; Kitada, N; Konishi, A; Suginoshita, Y; Tanaka, S, 2013) |
| "To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy." | 7.79 | Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. ( Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM, 2013) |
| "To evaluate the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma." | 7.79 | [The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma]. ( Fan, WZ; Huang, YH; Li, JP; Wang, Y; Yang, JY; Zhang, YQ, 2013) |
| "Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable." | 7.79 | Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013) |
| "Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.79 | Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. ( Moroni, M; Zanlorenzi, L, 2013) |
| "Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients." | 7.79 | Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. ( Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M, 2013) |
| "Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma." | 7.79 | Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. ( Cha, J; Han, KH; Kim, JW; Lee, IJ; Seong, J, 2013) |
| "A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 7.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
| "The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC)." | 7.79 | Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. ( He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB, 2013) |
| "The purpose of this study was to identify the correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib by analyzing medical records retrospectively." | 7.79 | Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib. ( Lee, YJ; Shin, SY, 2013) |
| "Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal." | 7.79 | Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. ( Ahn, SH; Chang, S; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY; Park, Y, 2013) |
| "The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species." | 7.79 | Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. ( Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013) |
| " The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC)." | 7.79 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma. ( Chang, YL; Cheng, AL; Hsu, CH; Huang, CY; Shao, YY, 2013) |
| "Sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation is a promising approach to the treatment of large, unresectable hepatocellular carcinomas." | 7.79 | Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. ( Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ, 2013) |
| "The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC)." | 7.79 | BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. ( Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY, 2013) |
| "We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy." | 7.79 | [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. ( Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H, 2013) |
| "Sorafenib currently sets the new standard for advanced hepatocellular carcinoma (HCC)." | 7.79 | Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. ( Bae, SH; Chung, YH; Kim, BI; Kim, JA; Koh, KC; Lee, D; Lee, HC; Lee, JH; Park, NH; Shim, JH; Shin, ES; Yoon, JH, 2013) |
| "Sorafenib has been shown to improve survival rate of hepatocellular carcinoma (HCC) patients significantly." | 7.79 | Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal. ( Feng, M; Liu, X; Wang, Q; Wang, Z; Yu, T; Yuan, Y; Zhuang, H, 2013) |
| "Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma, regardless of the liver functional reserve." | 7.79 | Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. ( Díaz-Rubio, E; Ladero, JM; Manzano, A; Puente, J; Sastre, J; Zugazagoitia, J, 2013) |
| "The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0." | 7.79 | FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. ( Arao, T; Arii, S; Hagiwara, S; Haji, S; Hakamada, K; Hiasa, Y; Hidaka, H; Hirooka, M; Hisai, H; Iso, Y; Izumi, N; Kanazawa, A; Kimura, H; Kubota, K; Kudo, M; Kumada, T; Kuzuya, T; Matsumoto, K; Nagai, T; Nishio, K; Sakurai, T; Sato, S; Shimada, M; Toyoda, H; Toyoki, Y; Tsuchiya, K; Ueshima, K; Utsunomiya, T; Yasui, K, 2013) |
| "Previously, we have shown that sorafenib sensitizes hepatocellular carcinoma (HCC) to apoptosis induced by TNF-related apoptosis-inducing ligand (TNFSF10; TRAIL)." | 7.79 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. ( Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Chu, PY; Ichikawa, K; Liu, CY; Shiau, CW; Tai, WT, 2013) |
| "This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 7.79 | Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. ( Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W, 2013) |
| "Sorafenib is currently the only approved systemic therapy shown to have efficacy in the treatment of advanced hepatocellular carcinoma (HCC)." | 7.79 | The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. ( Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C, 2013) |
| "Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood." | 7.79 | OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. ( Cabrera, R; Cao, M; Liu, C; Nelson, DR; Ogunwobi, OO; Puszyk, WM; Tian, C; Wang, T; Zhao, X, 2013) |
| "A multi-kinase inhibitor, sorafenib, was recently approved and is currently recommended for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.79 | Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. ( Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M, 2013) |
| "Sorafenib, an oral multikinase inhibitor, was approved for the treatment of advanced hepatocellular carcinoma (HCC), but has not been adequately evaluated for safety and effectiveness in Japanese patients with advanced HCC." | 7.79 | Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. ( Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y, 2013) |
| "Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 7.79 | The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. ( Galle, PR; Gamstätter, T; Koch, S; Marquardt, JU; Nguyen-Tat, M; Niederle, IM; Schuchmann, M; Schulze-Bergkamen, H; Weinmann, A; Wörns, MA, 2013) |
| "Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART)." | 7.79 | Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. ( Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U, 2013) |
| "Hepatocellular carcinoma (HCC) is a difficult to treat cancer characterized by poor tumor immunity with only one approved systemic drug, sorafenib." | 7.79 | Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. ( Ararat, M; Atkinson, MA; Brusko, T; Cabrera, R; Chang, LJ; Liu, C; Nelson, DR; Wasserfall, C; Xu, Y, 2013) |
| "Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC)." | 7.79 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. ( Chang, CY; Cheng, AL; Hsu, C; Lin, CY; Lin, KL; Liu, SH; Ou, DL; Shen, YC, 2013) |
| "The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study." | 7.79 | Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. ( Bruno, R; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Enea, M; Gasbarrini, A; Grieco, A; Iavarone, M; Petta, S; Villa, E; Zavaglia, C, 2013) |
| "Hypoxia induced by sustained sorafenib treatment confers sorafenib resistance to HCC through HIF-1α and NF-κB activation." | 7.79 | Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. ( Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T, 2013) |
| "Early prediction of tumour response and major adverse events (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) is essential for maximizing the clinical benefits of sorafenib." | 7.79 | Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. ( Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K, 2013) |
| "We investigated the molecular mechanisms underlying the effect of sorafenib and SC-59, a novel sorafenib derivative, on hepatocellular carcinoma (HCC)." | 7.79 | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. ( Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Lin, CS; Liu, CY; Shiau, CW; Tai, WT, 2013) |
| "To determine the value of early alterations of the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib." | 7.79 | Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M, 2013) |
| "Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic mainstay for patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. ( Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, S; Park, JY; Yoon, SH, 2012) |
| "Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. ( Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Fernández-Rodriguez, CM; Fernando, J; Lledó, JL; Sancho, P, 2012) |
| "The purpose of this study was to investigate the effect of bufalin on the anti-proliferative activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and Hep G-2 and to determine the relevant molecular mechanism." | 7.78 | Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. ( Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY, 2012) |
| "A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed according to Response Evaluation Criteria in Solid Tumors (RECIST)." | 7.78 | Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. ( Boucher, E; Edeline, J; Le Roux, C; Perrin, C; Pracht, M; Raoul, JL; Rolland, Y; Vauléon, E, 2012) |
| "Sorafenib is a multi-target oral anticancer drug used as first-line treatment for patients with advanced human hepatocellular carcinoma (HCC)." | 7.78 | Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2. ( Huang, C; Nan, K; Suo, A; Yao, Y; Zhang, L; Zhang, M; Zhang, W, 2012) |
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | 7.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Sorafenib plasma concentrations were determined by liquid chromatography, every 2 weeks, in consecutive hepatocellular carcinoma patients treated with sorafenib." | 7.78 | Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ( Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B, 2012) |
| "Retrospective evaluation of the safety and efficacy of sorafenib in patients with post-transplant hepatocellular carcinoma recurrence." | 7.78 | Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. ( Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2012) |
| "No reliable prognostic predictor is known for patients undergoing sorafenib treatment for advanced hepatocellular carcinoma (HCC)." | 7.78 | Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. ( Kondo, M; Maeda, S; Morimoto, M; Morioka, Y; Moriya, S; Nozaki, A; Numata, K; Tanaka, K, 2012) |
| "Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy." | 7.78 | Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. ( Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC, 2012) |
| "Although sorafenib has shown survival benefits in patients with hepatocellular carcinoma (HCC), many patients require discontinuation or dose reduction due to adverse events (AEs)." | 7.78 | Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. ( Chang, HM; Kang, YK; Kim, JE; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Suh, DJ, 2012) |
| "Sorafenib is currently in clinical use as an oral multikinase inhibitor that blocks tumor growth and cell proliferation in advanced hepatocellular carcinoma (HCC)." | 7.78 | Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. ( Hidaka, H; Kaneko, T; Koizumi, W; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M, 2012) |
| " However, in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC), tumor shrinkage rarely accompanies increased survival, thereby questioning the prognostic value of imaging-based Response Evaluation Criteria in Solid Tumors (RECIST)." | 7.78 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. ( Bozzarelli, S; Carnaghi, C; Giordano, L; Pedicini, V; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC, 2012) |
| "Sorafenib is the standard of care for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.78 | Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. ( Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O, 2012) |
| "Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib remain eligible for further systemic therapy." | 7.78 | Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. ( Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P, 2012) |
| "To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC)." | 7.78 | Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. ( Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W, 2012) |
| "Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma (HCC), but it is not known whether sorafenib is equally active in all HCC." | 7.78 | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. ( Barbare, JC; Chauffert, B; Diouf, M; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC; Trécherel, E, 2012) |
| "Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively." | 7.78 | The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T, 2012) |
| "Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. ( Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2012) |
| "Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma." | 7.78 | Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. ( De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2012) |
| " The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy." | 7.78 | Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2012) |
| "Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC)." | 7.78 | Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ( Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M, 2012) |
| "Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON), a global, non-interventional, surveillance study, aims to evaluate the safety of sorafenib in all patients with unresectable hepatocellular carcinoma (uHCC) under real-life practice conditions, particularly Child-Pugh B patients, who were not well represented in clinical trials." | 7.78 | First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. ( Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2012) |
| "To investigate the link between the antitumor efficacy of sorafenib and its cutaneous side effects in advanced hepatocellular carcinoma (HCC)." | 7.78 | [Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. ( He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY, 2012) |
| "The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC)." | 7.78 | The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P, 2012) |
| "Some clinical studies confirmed the efficacy and safety of sorafenib in advanced hepatocellular carcinoma(HCC), for which the standard initial dose is 400 mg twice daily." | 7.78 | [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma]. ( Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K, 2012) |
| "Prospective randomized trials have proven that sorafenib is a valid treatment option for patients with advanced-stage hepatocellular carcinoma (HCC)." | 7.78 | Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? ( Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E, 2012) |
| "To evaluate the efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma (HCC) relapse after liver transplantation." | 7.78 | [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. ( He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF, 2012) |
| "To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC)." | 7.78 | The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. ( Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C, 2012) |
| "Antiangiogenic agents can sometimes promote tumor invasiveness and metastasis, but little is known about the effects of the antiangiogenic drug sorafenib on progression of hepatocellular carcinoma (HCC)." | 7.78 | Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. ( Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY, 2012) |
| "To investigate the clinic predictors of efficacy and adverse events of sorafenib in treating with advanced hepatocellular carcinoma (HCC) patients." | 7.78 | [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients]. ( Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P, 2012) |
| "There are scarce data on the use of sorafenib for the treatment of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT)." | 7.78 | Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012) |
| "Sorafenib patient assistant program in unresectable hepatocellular carcinoma ensured compliance treatment and significantly prolonged overall survival over the historical cohort receiving palliative treatment." | 7.78 | Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients. ( Boedi, P; Ganggaiswari, A; Gani, RA; Hasan, I; Lesmana, LA; Luwia, MS; Waspodo, A, 2012) |
| "Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 7.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
| "Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for investigating its use in combination with other agents." | 7.78 | Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. ( Fang, D; Gao, J; Liu, J; Rao, Z; Zhang, A; Zhang, B; Zhang, Y; Zhao, J; Zhao, Y, 2012) |
| "This study investigates the effectiveness and safety of sorafenib in a heterogeneous cohort of Child-Pugh A, B and C patients with advanced hepatocellular carcinoma in a clinical-practice scenario." | 7.78 | Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. ( Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B, 2012) |
| "To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC)." | 7.78 | Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. ( Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M, 2012) |
| "To evaluate the efficacy of sorafenib monotherapy, we enrolled 188 patients with hepatocellular carcinoma (HCC) who had undergone sorafenib monotherapy during a 3-year period from May 2009 to June 2012." | 7.78 | Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. ( Arizumi, T; Kudo, M; Ueshima, K, 2012) |
| "There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 7.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
| "Sorafenib, a multikinase inhibitor targeting angiogenesis, cell survival, and proliferation in hepatocellular carcinoma (HCC) is a standard therapy for advanced stage disease." | 7.77 | Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. ( Aucejo, F; Kim, R; Menon, N, 2011) |
| "To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 7.77 | The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. ( Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A, 2011) |
| "Sorafenib, an orally active multi-kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC), is primarily metabolized both via cytochrome P450 3A4 isoform (CYP3A4) and UGT1A9." | 7.77 | Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ( Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M, 2011) |
| "The aim of this study was to compare tumor changes in patients with hepatocellular carcinoma receiving sorafenib using evaluation criteria of the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) as opposed to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1." | 7.77 | Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. ( Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D, 2011) |
| " Sorafenib, a VEGFR inhibitor with activity against RAF kinase, is active against hepatocellular carcinoma (HCC); however, the possible involvement of sorafenib in the EMT remains unclear." | 7.77 | Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. ( Aomatsu, K; Arao, T; Fujita, Y; Furuta, K; Kaneda, H; Kimura, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D, 2011) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. ( Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ, 2011) |
| "Sorafenib is a multi-targeted tyrosine kinase inhibitor licensed for the treatment of hepatocellular carcinoma and renal cell carcinoma." | 7.77 | Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. ( Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ, 2011) |
| "Sorafenib has become the treatment standard for patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. ( Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L, 2011) |
| "Sorafenib is a multikinase inhibitor currently used in the palliative treatment of advanced hepatocellular carcinoma." | 7.77 | Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. ( Borentain, P; Durieux, O; Garcia, S; Gérolami, R; Gregoire, E; Hardwigsen, J; Le Treut, YP, 2011) |
| "Recently, we reported that sorafenib sensitizes hepatocellular carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of transcription 3 (STAT3)." | 7.77 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. ( Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Huang, JW; Shiau, CW; Tai, WT, 2011) |
| "The purpose of this study was to describe the computed tomography (CT) findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma and to correlate the findings to the overall survival (OS)." | 7.77 | Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. ( Choi, JI; Kim, MJ; Lee, JS; Park, JW, 2011) |
| "We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection." | 7.77 | Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. ( Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M, 2011) |
| "Although sorafenib is recommended for patients with advanced hepatocellular carcinoma (HCC), a substantial portion of HCC patients in Asia are still treated with other treatments, mainly due to the prohibitive cost of sorafenib." | 7.77 | Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. ( Choi, JI; Kim, CM; Kim, HB; Kim, HK; Kim, HY; Kim, TH; Nam, BH; Park, JW, 2011) |
| "We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced hepatocellular carcinoma (HCC) patients." | 7.77 | Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. ( Abbruzzese, A; Addeo, R; Caraglia, M; Giuberti, G; Marra, M; Montella, L; Murolo, M; Naviglio, S; Prete, SD; Sperlongano, P; Stiuso, P; Vincenzi, B, 2011) |
| "Standard of practice involves using transarterial therapy for multifocal hepatocellular carcinoma (HCC) alone and sorafenib only for more advanced HCC, but the sorafenib and transarterial therapy combination may provide greater efficacy." | 7.77 | The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. ( Cabrera, R; Caridi, J; Clark, V; Firpi, RJ; George, TJ; Morelli, G; Nelson, DR; Pannu, DS; Soldevila-Pico, C; Suman, A, 2011) |
| "This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery." | 7.77 | Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. ( Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N, 2011) |
| "Sorafenib, a potent multikinase inhibitor, has been recognized as the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. ( Dai, Z; Ding, ZB; Fan, J; Gu, CY; Hui, B; Ke, AW; Peng, YF; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Zhou, J, 2011) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC)." | 7.77 | Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. ( Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ, 2011) |
| "This study compared post-transplant outcomes of patients with hepatocellular carcinoma (HCC) who took sorafenib prior to orthotopic liver transplantation (OLT) with those patients who were not treated with sorafenib." | 7.77 | Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE, 2011) |
| "A multikinase inhibitor of the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, sorafenib, is increasingly being used in the management of hepatocellular carcinoma, and its combination with conventional chemotherapeutics has stimulated particular interest." | 7.77 | Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. ( Broneshter, R; Iancu, TC; Manov, I; Pollak, Y, 2011) |
| "The purpose of this study was to evaluate the role of des-γ-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC)." | 7.77 | Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2011) |
| "Sorafenib is the new reference standard for patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Buder, R; Graziadei, I; Grünberger, B; Hucke, F; Königsberg, R; Kornek, G; Maieron, A; Matejka, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Schöniger-Hekele, M; Sieghart, W; Stauber, R; Vogel, W; Weissmann, A, 2011) |
| "A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. ( Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C, 2011) |
| "Sorafenib increases median survival and time to radiological progression in patients with advanced hepatocellular carcinoma, but its benefit for Child-Pugh B patients remains uncertain." | 7.77 | Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. ( Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S, 2011) |
| "The multi-targeted tyrosine kinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. ( Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA, 2011) |
| "A 60-year-old man with liver cirrhosis caused by hepatitis C, who was receiving warfarin anticoagulation following acute myocardial infarction, was diagnosed with advanced hepatocellular carcinoma and multiple lung metastases, and began treatment with sorafenib 200 mg daily." | 7.77 | [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma]. ( Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2011) |
| "Sorafenib, the first agent demonstrated to have efficacy to improve the survival of patients with advanced hepatocellular carcinoma (HCC), is an active multikinase inhibitor affecting angiogenesis and tumor proliferation." | 7.77 | Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. ( Hagihara, H; Ikeda, F; Kobayashi, S; Kuwaki, K; Miyahara, K; Miyake, Y; Nakamura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tomoda, T; Toshimori, J; Yamamoto, K, 2011) |
| "To investigate the inhibitory role and the underlying mechanisms of sorafenib on signal transducer and activator of transcription 3 (STAT3) activity in hepatocellular carcinoma (HCC)." | 7.77 | Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. ( Fan, J; Gao, Q; Gu, FM; Huang, XY; Jiang, JH; Li, QL; Pan, JF; Zhou, J, 2011) |
| "Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization." | 7.77 | Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011) |
| "The aim of this study was to investigate the relationships between early changes in the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y, 2011) |
| "We report here the experience of the treatment with sorafenib for advanced hepatocellular carcinoma (HCC) in our department." | 7.77 | [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T, 2011) |
| "Sorafenib is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of advanced hepatocellular carcinoma." | 7.77 | [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib]. ( Egawa, C; Kato, T; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Okishiro, M; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S, 2011) |
| "The role of sorafenib is unclear in multimodal treatment for hepatocellular carcinoma (HCC)." | 7.77 | [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. ( Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H, 2011) |
| "Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. ( Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Kudo, M; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Sekikawa, A; Takeda, H, 2011) |
| "Sorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC)." | 7.76 | Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. ( An, J; Chang, YJ; Chiou, JF; Huang, MT; Liu, TZ; Tai, CJ; Wang, YH; Wei, PL; Wu, CH, 2010) |
| "Previously we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib." | 7.76 | Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. ( Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC, 2010) |
| "An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC)." | 7.76 | Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. ( Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A, 2010) |
| "Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)." | 7.76 | Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010) |
| "Sorafenib is the standard treatment for patients with an advanced stage of hepatocellular carcinoma (HCC)." | 7.76 | Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. ( Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP, 2010) |
| "Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials." | 7.76 | Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010) |
| "Sorafenib has recently been shown to be effective for the treatment of advanced hepatocellular carcinoma in randomized controlled trials." | 7.76 | Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. ( Bechstein, WO; Engels, K; Gog, C; Herrmann, E; Lubomierski, N; Trojan, J; Vogl, TJ; Welker, MW; Zeuzem, S, 2010) |
| " One such therapy, a tyrosine kinase inhibitor (sorafenib) is now used to treat patients with advanced hepatocellular carcinoma (HCC) and metastatic renal cell carcinoma." | 7.76 | Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. ( Armstrong, C; Hull, D, 2010) |
| "To evaluate (125)I seed brachytherapy combined with sorafenib in the treatment of patients with multiple lung metastases after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC)." | 7.76 | Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. ( Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W, 2010) |
| "To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment." | 7.76 | Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. ( Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2010) |
| "to determine the efficacy and toxicities of sorafenib in the treatment of patients with multiple recurrences of hepatocellular carcinoma (HCC) after liver transplantation in a Chinese population." | 7.76 | Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. ( FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH, 2010) |
| "To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)." | 7.76 | [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L, 2010) |
| " Eight patients who underwent liver transplant for hepatocellular carcinoma between May 2007 and April 2009, and tolerated adjuvant therapy with sorafenib were matched with patients who did not receive sorafenib according to age, sex, year of transplant, tumor burden, and presence of vascular invasion." | 7.76 | Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010) |
| "Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 7.76 | Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. ( Bozorgzadeh, A; Grossman, S; Piperdi, B; Rawson, AP; Saidi, RF; Shah, SA, 2010) |
| "We analyzed the treatment outcome and effect of sorafenib in advanced hepatocellular carcinoma." | 7.76 | [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma]. ( Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M, 2010) |
| "We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC)." | 7.76 | [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y, 2010) |
| "This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection." | 7.75 | Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. ( Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH, 2009) |
| "Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis." | 7.75 | Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. ( Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A, 2009) |
| "To investigate the reversion of multidrug resistance of drug-resistant hepatocellular carcinoma (HCC) cell line BEL-7402/FU by sorafenib and the possible mechanisms." | 7.75 | [Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib]. ( Cao, MR; Li, AM; Lü, CW; Luo, RC; Su, N; Wei, L; Yan, X; Zheng, DY, 2009) |
| " For advanced hepatocellular carcinoma (HCC) a new era has recently begun by the approval of the multikinase inhibitor sorafenib." | 7.75 | Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. ( Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C, 2009) |
| " This study was to evaluate the schedule-dependent effect of sorafenib in combination with paclitaxel (TAX) on human hepatocellular carcinoma cell BEL-7402, and explore the underlying mechanism." | 7.75 | [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402]. ( Li, M; Li, N; Wu, T; Zhang, Y, 2009) |
| "The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy." | 7.75 | Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. ( Alsinet, C; Bruix, J; Cabellos, L; Chiang, DY; Deniz, K; Fiel, MI; Friedman, SL; Hoshida, Y; Lim, KH; Llovet, JM; Mazzaferro, V; Melgar-Lesmes, P; Minguez, B; Newell, P; Peix, J; Roayaie, S; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tovar, V; Villanueva, A; Yea, S, 2009) |
| "To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib." | 7.75 | UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. ( Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R, 2009) |
| "Sorafenib is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma (HCC), setting a new standard for first-line treatment." | 7.75 | Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. ( Shen, H; Wang, D; Wang, Y; Zhang, Z; Zhou, X, 2009) |
| "The approval of sorafenib and active development of many other molecularly targeted agents in hepatocellular carcinoma (HCC) have presented a challenge to understand the mechanism of action of sorafenib and identify predictive biomarkers to select patients more likely to benefit from sorafenib." | 7.75 | Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? ( Zhu, AX, 2009) |
| "Sorafenib has proved survival benefit for patients with advanced hepatocellular carcinoma (HCC)." | 7.75 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. ( Cheng, AL; Fan, HH; Hsu, C; Liang, JD; Liou, JY; Lu, YS; Ou, DL; Shen, YC; Wang, DS; Yu, SL, 2009) |
| "The objective of our study was to evaluate signal changes of advanced hepatocellular carcinoma in diffusion-weighted MRI in the early-response monitoring of oral therapy with the multikinase inhibitor sorafenib." | 7.75 | Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. ( Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF, 2009) |
| "To evaluate the safety and efficacy of the combination of transcatheter arterial chemoembolization (TACE) and sorafenib in treatment of hepatocellular carcinoma (HCC) with lung metastasis." | 7.75 | [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis]. ( Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, ZJ, 2009) |
| "To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP) on the proliferation of hepatocellular carcinoma cells and explore the molecular mechanisms." | 7.74 | [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. ( Chen, FS; Cui, YZ; Luo, RC; Wu, J; Zhang, H, 2008) |
| "To investigate the inhibitory effect of sorafenib in combination with arsenic trioxide (As2O3) on hepatocellular carcinoma cells and explore the mechanisms of the synergetic antitumor effects of the two agents." | 7.74 | [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells]. ( Cui, YZ; Luo, RC; Wu, J; Zhang, H, 2008) |
| "Sorafenib OS benefit was consistently observed across all subgroups." | 6.84 | Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. ( Bruix, J; Cheng, AL; De Sanctis, Y; Llovet, J; Meinhardt, G; Nakajima, K, 2017) |
| "Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with." | 6.84 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| " A phase I study evaluated the combination with sorafenib in HCC." | 6.84 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). ( Abou-Alfa, GK; Agajanov, T; Beylergil, V; Boisserie, F; Carrasquilo, JA; Chen, YC; Cheng, AL; Di Laurenzio, L; Frenette, C; Gansukh, B; Hsu, CH; Larson, SM; Lee, R; Lin, ZZ; Lyashchenko, SK; Ma, J; Maki, Y; Morikawa, H; O'Donoghue, J; O'Neil, B; Ohishi, N; Ohtomo, T; Pandit-Taskar, N; Ruan, S; Schwartz, L; Shao, YY; Smith-Jones, PM; Tanaka, T; Wan, P; Yen, CJ, 2017) |
| "Sorafenib was dose escalated in 2 strata: (1) low effective irradiated liver volume (veff) < 30% and (2) high veff 30%to 60%." | 6.82 | Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. ( Brade, AM; Brierley, J; Cho, C; Dawson, LA; Dinniwell, R; Kim, J; Knox, J; Ng, S; Ringash, J; Wong, RR, 2016) |
| "Treatment with sorafenib, although associated with inhibition of tumour growth and angiogenesis in in vivo studies, leads to up-regulation of pERK." | 6.82 | A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). ( Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP, 2016) |
| "Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation." | 6.82 | Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. ( Cheow, PC; Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Goh, BK; Liew, WM; Lo, RH; Low, AS; Ng, DC; Soo, KC; Tan, SB; Tay, KH; Thng, CH; Wong, JS, 2016) |
| " 47) adverse events was similar in combination-treatment arm and control arm respectively (P > 0." | 6.80 | Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. ( Bulla, K; Kolligs, F; Malfertheiner, P; Peck-Radosavljevic, M; Reimer, P; Ricke, J; Sangro, B; Schott, E; Schütte, K; Verslype, C; Walecki, J, 2015) |
| "Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15." | 6.79 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014) |
| "Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)." | 6.79 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014) |
| " Most frequent drug-related adverse events were diarrhea, rash, aspartate aminotransferase elevation, vomiting, and nausea." | 6.79 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ( Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH, 2014) |
| "Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis." | 6.79 | Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. ( Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V, 2014) |
| "Sorafenib was administered and escalated twice daily on three cohort dose levels: i) 400 mg/day, ii) 600 mg/day and iii) 800 mg/day." | 6.78 | Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. ( Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M, 2013) |
| "TACE/sorafenib cycles were repeated every 6-8 weeks." | 6.78 | Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. ( Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH, 2013) |
| "Sorafenib has been shown to significantly improve progression-free survival in adult hepatocellular carcinoma (HCC) patients." | 6.77 | Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. ( Albert, MH; Corbacioglu, S; Fröhlich, B; Graf, N; Häberle, B; Kammer, B; Kontny, U; Leuschner, I; Scheel-Walter, HG; Scheurlen, W; Schmid, I; von Schweinitz, D; Werner, S; Wiesel, T, 2012) |
| " The most common severe adverse event probably related to sorafenib was diarrhea (12." | 6.77 | Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. ( Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012) |
| "Sorafenib was given 3 days after TACE and was administered for up to 24 weeks." | 6.77 | Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. ( An, S; Choi, JI; Kim, HB; Kim, HY; Koh, YH; Nam, BH; Park, JW; Woo, SM, 2012) |
| "Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity." | 6.75 | Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. ( Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B, 2010) |
| "Sorafenib is a multikinase inhibitor with effects against tumor proliferation and angiogenesis." | 6.75 | Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I ( Chen, Z; Gu, K; Jiang, GL; Li, WT; Liu, J; Liu, LM; Ren, ZG; Xu, ZY; Zhao, JD; Zhou, ZH, 2010) |
| "Sorafenib has interesting activity and acceptable tolerability in patients with advanced HCC, including those who failed prior therapies." | 6.75 | A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. ( Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E, 2010) |
| "placebo in hepatocellular carcinoma (HCC) demonstrated that sorafenib significantly prolonged overall survival (OS) compared to placebo." | 6.73 | Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. ( Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S, 2008) |
| "Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and tyrosine kinases that are involved in tumor-cell signal transduction and tumor angiogenesis." | 6.73 | Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. ( Furuse, J; Ishii, H; Nakachi, K; Nakajima, K; Shimizu, S; Suzuki, E, 2008) |
| "The search for systemic therapies for hepatocellular carcinoma has been characterized by difficulties and failures." | 6.55 | Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. ( Barbera, MA; Biasco, G; Brandi, G; Frega, G; Garajova, I; Lorenzo, S; Palloni, A; Pantaleo, MA; Tovoli, F, 2017) |
| "Sorafenib is a small molecular inhibitor of intracellular tyrosine and serine/threonine protein kinases (VEGFR, PDGFR, CRAF and BRAF), and is thought also to induce autophagy, a chief mechanism influencing tumor growth." | 6.53 | Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. ( Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M, 2016) |
| "Sorafenib was the first drug that has shown to increase survival in patients with advanced hepatocelullar carcinoma with an adequate safety profile." | 6.53 | Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. ( Bruix, J; Reig, M; Ribeiro de Souza, A, 2016) |
| "Hepatocellular carcinoma is a challenging malignancy of global importance." | 6.52 | Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. ( Cabibbo, G; Cammà, C; Maida, M; Petta, S, 2015) |
| "Sorafenib is a molecular targeting agent used for treating hypervascular tumors." | 6.50 | Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. ( Bhargava, P; Bhosale, P; Choi, JI; Imagawa, DK; Lall, C; Seery, TE; Tirkes, T, 2014) |
| "Hepatocellular carcinoma is one of the most common cancers worldwide, and a leading cause of cancer-related death." | 6.50 | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. ( Chen, KF; Hung, MH; Shiau, CW; Tai, WT, 2014) |
| "Sorafenib has demonstrated potent anti-tumor activity in in vitro studies, preclinical xenograft models of different tumor types and human clinical trials." | 6.48 | Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. ( Gadaleta, CD; Gadaleta-Caldarola, G; Goffredo, V; Mangia, A; Patruno, R; Ranieri, G; Rizzo, A; Sciorsci, RL, 2012) |
| "The incidence of hepatocellular carcinoma is rising in many countries, including the United States." | 6.47 | What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. ( Aucejo, F; Byrne, MT; Kim, R; Tan, A, 2011) |
| "On sorafenib, treatment-emergent hypertension occurred in 9% of patients (placebo, 4%) and was grade 3 in 4% (placebo, 1%); elevated serum lipase occurred in 40% (placebo, 37%); hypophosphatemia occurred in 35% (placebo, 11%)." | 6.45 | Sorafenib for the treatment of unresectable hepatocellular carcinoma. ( Booth, B; Chattopadhyay, S; Farrell, AT; Justice, R; Kane, RC; Madabushi, R; Pazdur, R; Sridhara, R, 2009) |
| "Sorafenib has demonstrated for the first time to prolong survival in patients with advanced HCC, and it is the new reference standard for systemic treatment in these patients." | 6.44 | Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. ( Chaparro, M; González Moreno, L; Medina, J; Moreno-Otero, R; Trapero-Marugán, M, 2008) |
| "Sorafenib is an orally active multikinase inhibitor with anti-tumour activity." | 6.44 | Sorafenib: in hepatocellular carcinoma. ( Keating, GM; Simpson, D, 2008) |
| "Sorafenib is the only effective drug for advanced hepatocellular carcinoma (HCC), but few data predictive of its effectiveness are available." | 6.25 | A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. ( Kong, D; Ma, W; Song, T; Wu, Q; Zhang, W, 2011) |
| "Sorafenib is a tyrosine kinase inhibitor for the treatment of advanced-stage HCC; however, clinical trials of sorafenib failed to demonstrate long-term survival benefits due to drug resistance." | 5.91 | Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib. ( Bi, QC; Deng, ZQ; He, YQ; Liu, Y; Lv, YF; Tang, Q; Xie, CS, 2023) |
| " Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib." | 5.72 | Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. ( Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A, 2022) |
| " Other adverse events, dosing and outcome data were collected during a homogeneous protocolled follow-up." | 5.62 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. ( Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M, 2021) |
| "The aim of this study is validated the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma." | 5.51 | Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study. ( Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL, 2022) |
| "This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in combination (SAM) with atorvastatin (A, 10 mg) and metformin (M, 500 mg BD) in patients with advanced hepatocellular carcinoma (HCC)." | 5.51 | Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). ( Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S, 2022) |
| "SORAMIC is a randomized controlled trial in patients with advanced hepatocellular carcinoma (HCC) undergoing sorafenib ± selective internal radiation therapy (SIRT)." | 5.51 | Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. ( Alunni-Fabbroni, M; Benckert, J; Chow, PKH; Gasbarrini, A; Kuhl, C; Malfertheiner, P; Öcal, E; Pech, M; Ricke, J; Sangro, B; Schinner, R; Shuen, TWH; Toh, HC; Wildgruber, M, 2022) |
| "Sorafenib is an oral multi-targeted tyrosine kinase inhibitor used in cases of unresectable advanced HCC that significantly improves progression-free and overall survival." | 5.51 | [Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib]. ( Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2019) |
| "Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status." | 5.48 | Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. ( Chang, Y; Cho, EJ; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ, 2018) |
| "The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS." | 5.48 | Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA, 2018) |
| "Sorafenib was started 3-5 days after TACE, and RFA was performed 1-2 weeks after TACE." | 5.48 | Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. ( Cai, M; Chen, J; Guo, Y; Huang, J; Huang, W; Lai, L; Zhou, J; Zhu, K, 2018) |
| "Sorafenib is a potential rescue therapy in patients with TACE failure." | 5.46 | Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. ( Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY, 2017) |
| "H22-bearing liver cancer xenograft murine models were used to evaluate the biodistribution and therapeutic efficacy in vivo." | 5.46 | Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. ( Mu, S; Olerile, LD; Wang, T; Yu, X; Zhang, J; Zhang, N, 2017) |
| " The nanocomplex enhanced bioavailability of hydrophobic drugs, efficient tumor cell targeting and exhibited pH-responsive function and sustained release profile." | 5.46 | Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. ( Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G, 2017) |
| "Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation." | 5.46 | Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. ( Arizumi, T; Hagiwara, S; Kamata, K; Kudo, M; Minaga, K; Minami, Y; Nishida, N; Sakurai, T; Takenaka, M; Watanabe, T; Yada, N, 2017) |
| "However, the hepatoma arterial embolisation prognostic (HAP) score showed greater discriminative abilities than the SAP score." | 5.46 | Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. ( Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH, 2017) |
| "Sorafenib was as safe as effective in DIAB and in nDIAB patients." | 5.46 | Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. ( Addario, L; Caporaso, N; Cordone, G; Di Costanzo, GG; Falco, L; Guarino, M; Morisco, F; Tortora, R, 2017) |
| "Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options." | 5.46 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. ( Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A, 2017) |
| "Sorafenib treatment is usually administered in cases of tumor progression or poor liver function status after TACE treatment in China." | 5.46 | Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. ( He, D; Liu, F; Meng, Z; Shao, G; Wang, J; Wang, Z; Yang, J; Yip, CS, 2017) |
| "Sorafenib was equally toxic to both cell lines, but only in HepG2 was activation of caspase 3/7 activity, as a sign of apoptosis, observed." | 5.46 | Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro. ( Brauner, J; Dudeck, O; Jürgens, J; Kalinski, T; Nass, N; Powerski, M; Ricke, J; Schulz, N; Seidensticker, M; Streit, S; Wybranski, C, 2017) |
| "Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC." | 5.46 | Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. ( He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y, 2017) |
| "Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC) is a heterogeneous disease group." | 5.46 | Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis . ( Chen, B; Chen, W; Dao, H; Huang, Y; Li, N; Liu, N; Yang, J, 2017) |
| "Treatment of advanced hepatocellular carcinoma (HCC) remains a challenge due to the high tumor heterogeneity." | 5.46 | Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function. ( Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V, 2017) |
| " Oral administration of NEN to mice significantly slowed growth of genetically induced liver tumors and patient-derived xenografts, whereas niclosamide did not, coinciding with the observed greater bioavailability of NEN compared with niclosamide." | 5.46 | Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. ( Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B, 2017) |
| "Sorafenib is a potent drug for advanced HCC with multikinase inhibition activity." | 5.43 | Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. ( Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T, 2016) |
| "Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed." | 5.43 | Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016) |
| "Candida esophagitis was suspected." | 5.43 | Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. ( Chen, KH; Chou, YH; Hsieh, CH; Lu, YF; Weng, MT, 2016) |
| "Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial." | 5.43 | Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. ( Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY, 2016) |
| "Treatment of rhamnetin also reduced the expression of MDR related proteins P-GP (P-glycoprotein) and BCRP (breast cancer resistance protein)." | 5.43 | Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. ( Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP, 2016) |
| "Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used." | 5.43 | Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S, 2016) |
| "Sorafenib/OA cotreatment induces DNA fragmentation and caspase-3/7 cleavage and the addition of the pan-caspase inhibitor zVAD." | 5.43 | Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells. ( Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J, 2016) |
| "Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are not effective." | 5.43 | Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. ( Chen, JC; Chen, YC; Chien, YC; Chuang, HY; Hsu, FT; Hwang, JJ, 2016) |
| "Patients with advanced hepatocellular carcinoma (HCC) showing portal vein tumor thrombosis (PVTT) have an extremely poor prognosis." | 5.43 | Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. ( Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M, 2016) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) is dismal, underscoring the need for novel effective treatments." | 5.43 | Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells. ( Arihara, Y; Hayasaka, N; Kamihara, Y; Kato, J; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Okagawa, Y; Osuga, T; Takada, K; Usami, M, 2016) |
| "A 74-year-old man was diagnosed with hepatocellular carcinoma(HCC; S4/8)and underwent anterior segment resection of the liver in 2015." | 5.43 | [Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia]. ( Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Murakami, M; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshikawa, M, 2016) |
| " (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0." | 5.42 | Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study. ( Bazzica, M; Di Gion, P; Fucile, C; Lantieri, F; Marenco, S; Marini, V; Martelli, A; Mattioli, F; Picciotto, A; Pieri, G; Robbiano, L; Savarino, V; Stura, P; Zuccoli, ML, 2015) |
| "Sorafenib (60 mg/kg) was administered orally to NOD." | 5.42 | Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. ( Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW, 2015) |
| "Frequency of sorafenib-related adverse events was almost similar between Child-Pugh score 5, 6, and 7 patients." | 5.42 | Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015) |
| " PR-104 monotherapy elicited significant reductions in growth of Hep3B and HepG2 xenografts, and the combination with sorafenib was significantly active in all 4 xenograft models." | 5.42 | Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. ( Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR, 2015) |
| "We investigated a hepatocellular carcinoma (HCC) cell line that not only has CSC hierarchy but also shows phenotypic changes (population changes) upon differentiation of CSC during culture and can be used for screening drugs targeting CSC." | 5.42 | Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. ( Abei, M; Danjoh, I; Hyodo, I; Nakamura, Y; Shirota, R; Yamada, T; Yamashita, T, 2015) |
| "Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties." | 5.42 | Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. ( Chae, HB; Kang, HY; Kang, YW; Kim, AN; Kim, HS; Kim, SB; Kim, SH; Ko, SY; Lee, BS; Lee, ES; Lee, HY; Lee, JD; Lee, SH; Lee, TH; Noh, R; Song, IH, 2015) |
| "Many patients with advanced hepatocellular carcinoma (HCC) develop lung metastasis and available treatments are limited." | 5.42 | Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs. ( Huang, A; Shi, Y, 2015) |
| "Sorafenib has been proved to improve overall survival in advanced HCC; however, drug resistance is common." | 5.42 | CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. ( Bao, J; Che, S; Hao, C; Li, Z; Liu, J; Qian, Z; Shang, H; Wang, H; Zhang, H; Zhang, X; Zhao, H, 2015) |
| "Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival." | 5.42 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. ( Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015) |
| "Case 1: A6 4-year-old man with hepatocellular carcinoma (HCC) had received local therapy repeatedly for 20 years." | 5.42 | [Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy]. ( Hijikawa, T; Ishizaki, M; Kaibori, M; Kitade, H; Kon, M; Matsui, K; Yamada, M; Yanagida, H; Yokoigawa, N; Yoshioka, K, 2015) |
| "Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) shows a higher incidence in men, mainly because of hepatitis B X (HBx)-mediated enhancement of androgen receptor (AR) activity." | 5.42 | Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. ( Chen, DS; Chen, KF; Chen, PJ; Lin, WH; Shiau, CW; Teng, YC; Tsai, TF; Wang, SH; Yeh, SH, 2015) |
| "Sorafenib (SF) is a U." | 5.42 | Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma. ( Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS, 2015) |
| "Sorafenib treatment was initiated." | 5.42 | [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015) |
| "Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay." | 5.42 | Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. ( Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M, 2015) |
| " Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC." | 5.40 | Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. ( Chen, MS; Gao, HJ; Xu, L; Zhang, YJ, 2014) |
| "Sorafenib is a multi-kinase inhibitor of the vascular endothelial growth factor pathway and was recently introduced as a therapy for advanced HCC." | 5.40 | Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment. ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Kwon, OS; Shin, SK; Yoon, HH, 2014) |
| "Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC are limited." | 5.40 | Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. ( Andreozzi, M; Angel, P; Ben-Neriah, Y; Breuhahn, K; Finkelstein, R; Ganten, T; Grunewald, M; Hess, J; Horwitz, E; Kanarek, N; Koschny, R; Mogler, C; Nemeth, J; Pappo, O; Pikarsky, E; Porat, RM; Quagliata, L; Reuter, H; Schirmacher, P; Schweitzer, N; Shibolet, O; Shoham, A; Stein, I; Terracciano, L; Tornillo, L; Vogel, A; Zreik, F, 2014) |
| "Platelets are frequently altered in hepatocellular carcinoma (HCC) patients." | 5.40 | Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. ( Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG, 2014) |
| "Recurrence of hepatocellular carcinoma (HCC) remains a main detriment to long-term survival in liver transplants (LTx) for HCC." | 5.40 | Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. ( Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E, 2014) |
| "Hepatocellular carcinoma is the fifth most common solid cancer worldwide." | 5.40 | SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. ( Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH, 2014) |
| "Tumor growth and intrahepatic metastasis were assessed, and immunohistochemistry was applied to analyze the activation of the PI3K/Akt/Snail-dependent pathway." | 5.40 | Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. ( Chi, H; Meng, Z; Wang, H; Wang, P; Xu, L; Zhu, X, 2014) |
| "Metformin was also found to significantly inhibit the expression and secretion of MMP-9 and uPA in HCC cells, and suppress the phosphorylation of ERK1/2 and JNK1/2." | 5.40 | Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. ( Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF, 2014) |
| "Sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC." | 5.40 | Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. ( Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F, 2014) |
| "Sorafenib is a multikinase inhibitor targeting Raf and protein tyrosine kinases, which are involved in cell growth and tumor angiogenesis." | 5.40 | Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma. ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014) |
| " The most common side effect was hand-foot skin reaction." | 5.40 | Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. ( Gong, W; Liu, DJ; Liu, J; Sun, P; Xu, YT; Yu, GS; Zheng, SZ, 2014) |
| "For most patients with hepatocellular carcinoma (HCC), diagnosis is invariably done only in the advanced stages of the disease." | 5.40 | Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C). ( Fischer, K; Göke, B; Kolligs, FT; op den Winkel, M; Paprottka, PM; Rauch, B; Schmidt, L; Straub, G, 2014) |
| "Adjuvant therapy after resection of hepatocellular carcinoma (HCC) is limited." | 5.40 | Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2014) |
| "The sorafenib dose was decreased after one month to 400mg/day because of hand-foot syndrome." | 5.40 | [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration]. ( Hosoda, Y; Kakita, N; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yamada, Y; Yamasaki, M; Yasui, M, 2014) |
| "The management of hepatocellular carcinoma (HCC) in elderly patients is significantly more complicated than in younger patients because of medical comorbidities, advanced status at diagnosis, reduced liver function and altered drug pharmacokinetics." | 5.39 | Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. ( Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2013) |
| "Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC." | 5.39 | Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma? ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013) |
| "Sorafenib was used in 27 patients who finally failed to respond to HAIC (HAIC/sorafenib group)." | 5.39 | Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. ( Aikata, H; Awai, K; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Kan, H; Kawaoka, T; Kobayashi, T; Masaki, K; Miyaki, D; Naeshiro, N; Nakahara, T; Takahashi, S; Urabe, A, 2013) |
| "Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity." | 5.39 | Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. ( Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA, 2013) |
| "Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways." | 5.39 | [Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report]. ( Natori, T; Yamaguchi, M, 2013) |
| "The prognosis for hepatocellular carcinoma (HCC) is dependent upon tumour stage, performance status (PS), severity of underlying liver disease, and the availability of appropriate therapies." | 5.39 | Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. ( Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ, 2013) |
| "Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition." | 5.39 | Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. ( Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W, 2013) |
| "Sorafenib is a molecularly targeted agent that has been proven effective for treating advanced HCC with extrahepatic metastasis." | 5.39 | [A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib]. ( Cho, T; Emura, M; Igarashi, S; Kobayashi, Y; Nakamura, T; Nomizo, T; Nomura, N; Seto, R, 2013) |
| "Sorafenib is an oral multi-kinase inhibitor exerting its effects via the RAF/ MEK/ERK pathway, vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor beta (PDGFR-β) tyrosine kinases." | 5.39 | Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. ( Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N, 2013) |
| "Sorafenib was approved for advanced HCC based on trials in patients with Child-Pugh class A." | 5.39 | Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. ( Byrne, M; Estfan, B; Kim, R, 2013) |
| " Clinical outcomes and treatment-related adverse events (AEs) were compared between younger (< 70 years) and older (≥ 70 years) patients." | 5.39 | Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. ( Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2013) |
| "The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular pathogenesis remains incompletely defined in HCC." | 5.39 | αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. ( Ding, ZB; Fan, J; Huang, XY; Ke, AW; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Xiao, YS; Yan, J; Zhang, C; Zhang, X; Zhou, J, 2013) |
| "Treatment options for advanced hepatocellular cancer (HCC) are limited." | 5.38 | Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. ( Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A, 2012) |
| "Sorafenib treatment led to accumulation of autophagosomes as evidenced by conversion from LC3-I to LC3-II observed by immunoblot in Huh7, HLF and PLC/PRF/5 cells." | 5.38 | Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. ( Fujita, N; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Kanto, T; Kodama, T; Miyagi, T; Shimizu, S; Takehara, T; Tatsumi, T; Tsunematsu, H; Yoshimori, T, 2012) |
| "The Morris Hepatoma (MH) and HepG2 cells were treated in vitro with sorafenib (1-10 μM) and erlotinib (1-5 μM) and evaluated for tumor cell viability, apoptosis, and target regulation." | 5.38 | Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. ( Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W, 2012) |
| " Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%." | 5.38 | High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012) |
| "Sorafenib treatment for HCC recurrence in transplant recipients represents a challenging oncologic approach that requires further validation in prospective, multicenter studies." | 5.38 | Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. ( Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S, 2012) |
| "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 5.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC." | 5.37 | Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. ( Aucejo, F; Kim, R, 2011) |
| "Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function." | 5.37 | Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 5.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC." | 5.37 | Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. ( Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A, 2011) |
| "Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL." | 5.37 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011) |
| "Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a standard of care in advanced HCC." | 5.37 | Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. ( Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC, 2011) |
| " Treatment outcomes and related adverse events (AEs) were compared." | 5.37 | The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, RW; Poon, R; Tang, YF; Wong, H; Yao, TJ; Yau, T, 2011) |
| "Sorafenib is a multikinase inhibitor recently introduced in the therapy of patients with advanced HCC." | 5.37 | Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. ( Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A, 2011) |
| "Sorafenib treatment resulted in decreased expression of ADAM9, increased expression of membrane-bound MICA expression, and decreased levels of soluble MICA in HCC cells." | 5.36 | Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. ( Hayashi, N; Hosui, A; Ishida, H; Kohga, K; Miyagi, T; Takehara, T; Tatsumi, T, 2010) |
| "Human hepatocellular carcinoma tissues with low expression of let-7c displayed higher expression of Bcl-xL protein than those with high expression of let-7c, suggesting that low let-7 microRNA expression contributes to Bcl-xL over-expression." | 5.36 | The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. ( Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T, 2010) |
| "However, many hepatocellular carcinoma (HCC) cells show resistance to TRAIL-induced apoptosis." | 5.36 | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. ( Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Li, PK; Lin, YC; Liu, TH; Shiau, CW; Tai, WT, 2010) |
| " This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo." | 5.35 | Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. ( Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008) |
| "Hepatocellular carcinoma is rare, but increasing in prevalence in the United States." | 5.35 | Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. ( Bekaii-Saab, T; Bloomston, MA; Patel, T; So, BJ, 2008) |
| "Sorafenib was administered as salvage treatment and resulted in a rapid decline in alpha-fetoprotein (AFP) levels." | 5.35 | Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. ( Chen, CK; Chen, YJ; Hsieh, CH; Jeng, KS; Lin, CC; Lin, CP; Liu, CY; Shueng, PW; Tai, HC; Wang, CH, 2009) |
| "Dermatomyositis is a known paraneoplastic syndrome that can complicate the course of a variety of different cancers, however, the association with HCC is extremely rare." | 5.35 | Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. ( Apostolidis, L; Horstmann, S; Jäger, D; Kahlert, C; Lordick, F; Siegmund, A; Thom, R, 2009) |
| "In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not received prior systemic therapy, received either oral sorafenib (400 mg twice daily) or placebo until radiological and symptomatic progression." | 5.35 | Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. ( Rimassa, L; Santoro, A, 2009) |
| "Tumor lysis syndrome was suspected and intensive hemodialysis was performed." | 5.35 | Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. ( Huang, WS; Yang, CH, 2009) |
| "It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most challenging malignancies of worldwide importance." | 5.35 | Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. ( Zhu, AX, 2008) |
| "For patients with advanced hepatocellular carcinoma after failure of first-line sorafenib monotherapy, second-line axitinib provides modest efficacy with tolerable toxicity." | 5.34 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. ( Chao, Y; Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Huang, PH; Hung, YP; Lee, RC; Lin, ZZ; Shao, YY; Shen, YC, 2020) |
| "Sorafenib is a current first-line treatment option for advanced hepatocellular carcinoma (HCC)." | 5.34 | Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. ( Hopkins, AM; Rowland, A; Ruanglertboon, W; Sorich, MJ, 2020) |
| " In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%." | 5.33 | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. ( Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X, 2006) |
| "Well-differentiated hepatocellular carcinomas developed in nude mice given injections of the TAMH line, and these appeared similar to the primary liver tumors seen in TGF-alpha transgenic mice with regard to histology and strong expression of mouse and human TGF-alpha, insulin-like growth factor II, and alpha-fetoprotein mRNAs." | 5.29 | Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. ( Cveklova, K; Fausto, N; Merlino, G; Mosinger, B; Wu, JC, 1994) |
| "Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma." | 5.27 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. ( Baron, A; Blanc, JF; Cheng, AL; Dutcus, C; Evans, TRJ; Finn, RS; Guo, M; Han, G; Han, KH; Ikeda, K; Jassem, J; Komov, D; Kraljevic, S; Kudo, M; Lopez, C; Park, JW; Piscaglia, F; Qin, S; Ren, M; Saito, K; Tamai, T; Vogel, A, 2018) |
| "The current study aims to investigate the impact of baseline characteristics on the outcomes of sorafenib-treated advanced Hepatocellular carcinoma (HCC) patients in the setting of a clinical trial." | 5.27 | Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. ( Abdel-Rahman, O, 2018) |
| "To evaluate prospectively the efficacy and safety of sorafenib, which has been the first-line treatment for advanced hepatocellular carcinoma (HCC), in Japanese HCC patients (pts) with not only Child-Pugh (C-P) A class but also C-P B class." | 5.27 | A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. ( Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K, 2018) |
| "To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.27 | A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. ( Anderton, K; Anis, M; Baron, A; Bendell, J; Bentz, T; Brisendine, A; Duddalwar, V; Edwards, A; El-Khoueiry, A; Garrett-Mayer, E; Siegel, AB; Thomas, MB; Weiss, G, 2018) |
| "To evaluate safety and efficacy of combining sorafenib with transarterial chemoembolization in patients with advanced stage hepatocellular carcinomas (HCCs)." | 5.27 | Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. ( Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T, 2018) |
| "The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma." | 5.24 | Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. ( Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J, 2017) |
| "Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts." | 5.24 | Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. ( Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS, 2017) |
| "To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE)." | 5.24 | Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. ( Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A, 2017) |
| "Sorafenib, a multi-kinase inhibitor, inhibits tumor angiogenesis and is the first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)." | 5.24 | Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. ( Aoki, Y; Arai, T; Atsukawa, M; Doi, H; Fukai, M; Itokawa, N; Kanto, T; Kimura, K; Mano, Y; Mizokami, M; Osawa, Y; Shoji, H; Sugiyama, M; Taketomi, A; Yoshio, S, 2017) |
| "To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled randomised study, assessing ramucirumab in advanced hepatocellular carcinoma (HCC) patients who received prior sorafenib." | 5.24 | Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. ( Abada, PB; Baron, AD; Blanc, JF; Borg, C; Bowman, L; Chau, I; Chung, HC; Cui, ZL; Girvan, AC; Kudo, M; Malfertheiner, P; Okusaka, T; Park, JO; Pastorelli, D; Peck-Radosavljevic, M; Poon, R; Ryoo, BY; Seitz, JF; Yang, L; Yen, CJ; Zhu, AX, 2017) |
| "Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC)." | 5.24 | Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. ( Abou-Alfa, GK; Bass, M; Blanc, JF; Bradley, M; Cebon, J; Ganten, T; Gupta, C; Hollywood, E; Liem, AK; Lipton, L; Litten, J; Ma, J; Miles, S; Saltz, LB; Trojan, J; Wu, B, 2017) |
| "Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor." | 5.24 | Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. ( Itoh, K; Matsueda, S; Morita, M; Muroya, D; Sasada, T; Shichijo, S; Shirahama, T; Yamada, A; Yamaguchi, R; Yutani, S, 2017) |
| "Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease." | 5.24 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. ( Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A, 2017) |
| "There continues to be a lack of systemic options for advanced hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only approved options." | 5.24 | Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. ( Bansal, P; Fekrazad, HM; Lee, FC; Patt, Y; Rojas-Hernandez, C, 2017) |
| "The survival benefit of treatment for unresectable hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE) combined with sorafenib remains uncertain." | 5.24 | Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial. ( Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE, 2017) |
| "Previously, no therapeutic agent has been known to improve the overall survival compared with placebo in patients with hepatocellular carcinoma (HCC), who have progressed after sorafenib." | 5.24 | Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience. ( Kudo, M; Nishida, N; Ueshima, K, 2017) |
| "Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma." | 5.24 | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. ( Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V, 2017) |
| "To evaluate the safety and efficacy of combined endovascular brachytherapy (EVBT), transarterial chemoembolization (TACE), and sorafenib to treat hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT)." | 5.24 | Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. ( Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH, 2017) |
| "The study assessed 314 patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib at 5 general hospitals in Kagawa Prefecture, Japan." | 5.24 | Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study. ( Ando, M; Deguchi, A; Kokudo, Y; Kubo, A; Kudo, M; Masaki, T; Matsunaka, T; Minami, Y; Morishita, A; Morita, M; Moriya, A; Nagano, T; Nishida, N; Noda, T; Ogawa, C; Omura, A; Sakurai, T; Senoh, T; Shibatoge, M; Takaguchi, K; Tamaki, H; Tani, J; Tsutsui, A; Ueshima, K; Yoneyama, H, 2017) |
| "To report the real-life results of sorafenib use in a cohort of HIV-infected patients with hepatocellular carcinoma (HCC)." | 5.24 | Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. ( Delgado-Fernández, M; Galindo, MJ; García, MA; Garcia-Deltoro, M; Ibarra, S; Merchante, N; Merino, E; Mínguez, C; Montero-Alonso, M; Pineda, JA; Revollo, B; Rivero-Juárez, A; Rodríguez-Arrondo, F; Romero-Palacios, A; Téllez, F, 2017) |
| "Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC)." | 5.24 | HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. ( Chen, PT; Chen, SC; Grevel, J; Hu, CT; Jeng, LB; Le Berre, MA; Lin, SM; Liu, X; Lu, SN; Meinhardt, G; Mitchell, DY; Peña, CA; Prins, K; Yang, SS, 2017) |
| "There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment." | 5.24 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Baumhauer, A; Bodoky, G; Breder, V; Bronowicki, JP; Bruix, J; Cheng, AL; Finn, RS; Gerolami, R; Granito, A; Han, G; Huang, YH; Kudo, M; LeBerre, MA; Llovet, JM; Masi, G; Meinhardt, G; Merle, P; Ollivier-Hourmand, I; Pracht, M; Qin, S; Rosmorduc, O; Ross, PJ; Song, T; Yokosuka, O, 2017) |
| "Sorafenib is currently the first-line therapeutic regimen for patients with advanced hepatocellular carcinoma (HCC)." | 5.22 | Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. ( Bai, M; Gong, S; Guo, T; Hao, X; Lei, C; Li, X; Si, M; Song, S; Tian, H; Yang, W, 2022) |
| "This multicenter, randomized, open-label, phase II trial evaluated the efficacy and safety of AEG35156 in addition to sorafenib in patients with advanced hepatocellular carcinoma (HCC), as compared with sorafenib alone." | 5.22 | Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC). ( Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC, 2016) |
| "We report data from the final analysis of the Chinese subset of the GIDEON (the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study, which evaluated the safety and efficacy of sorafenib in Child-Pugh A, B and C patients with unresectable hepatocellular carcinoma (uHCC) in real-life clinical practice." | 5.22 | Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. ( Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J, 2016) |
| "Since the approval of sorafenib, no other agent has been proven to show survival benefits in clinical trials involving patients with advanced hepatocellular carcinoma (HCC) resistant to sorafenib." | 5.22 | Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2016) |
| "This randomized, double-blind, placebo-controlled, phase II study evaluated the efficacy and safety of mapatumumab (a human agonistic monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 1) in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 5.22 | A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. ( Bazin, I; Bondarenko, I; Ciuleanu, T; Deptala, A; Ding, M; Egger, J; Fox, NL; Giantonio, B; Gribbin, M; Humphreys, R; Kalyani, RN; Lungulescu, D; Miron, L; Rodriguez-Torres, M; Sun, W; Wissel, P, 2016) |
| "This retrospective cohort study aimed to evaluate the prognostic value of the alpha-fetoprotein (AFP) response in advanced-stage hepatocellular carcinoma (HCC) patients treated with sorafenib combined with transarterial chemoembolization." | 5.22 | The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. ( Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; He, C; Jia, J; Liu, L; Niu, J; Xia, J; Yang, M; Yin, Z; Yuan, J; Zhang, L; Zhao, Y, 2016) |
| "Currently, the only FDA-approved systemic therapy for hepatocellular carcinoma (HCC) is the multi-receptor tyrosine kinase inhibitor, sorafenib, which provides only modest clinical benefit." | 5.22 | Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. ( Brekken, RA; Cheng, X; Huang, X; Li, L; Thorpe, PE; Yopp, AC, 2016) |
| "Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for first-line systemic treatment of advanced hepatocellular carcinoma (HCC)." | 5.22 | Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). ( Bodoky, G; Buehlmann, M; Demeter, G; Dufour, JF; Feilchenfeldt, J; Horber, D; Koeberle, D; Lakatos, G; Li, Q; Montemurro, M; Peck-Radosavljevic, M; Rauch, D; Ribi, K; Roth, AD; Saletti, P; Samaras, P; Tschanz, B; Wagner, AD, 2016) |
| "No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist." | 5.22 | Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. ( Ammendola, AS; Bitzer, M; Cillo, U; Dollinger, MM; Ganten, TM; Gerken, G; Giannini, EG; Hauns, B; Henning, SW; Hentsch, B; Herz, T; Holzapfel, J; Horger, M; Lauer, UM; Mais, A; Malek, NP; Montesarchio, V; Pegoraro, S; Santoro, A; Scheulen, ME; Siveke, JT; Trevisani, F; Wege, H; Wörns, MA; Zagonel, V, 2016) |
| "To compare the impact of concurrent TACE + sorafenib versus TACE alone on overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (uHCC)." | 5.22 | Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. ( Li, H; Liu, D; Yan, D; Yao, X; Zeng, H, 2016) |
| "Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogenic escape from sorafenib may occur due to angiogenesis-associated fibroblast growth factor receptor (FGFR) pathway activation." | 5.22 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. ( Balsara, B; Chan, SL; Chao, Y; Cheng, AL; Han, G; Ikeda, M; Kang, YK; Kudo, M; Lim, HY; Numata, K; Pan, H; Poon, RT; Rodriguez, AM; Sukeepaisarnjaroen, W; Thongprasert, S; Wang, Y; Wu, CC; Yang, TS; Zhang, Y, 2016) |
| "Sorafenib is the current standard therapy for advanced hepatocellular carcinoma, but validated biomarkers predicting clinical outcomes are lacking." | 5.22 | Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. ( Evans, TR; Gane, E; Jeffers, M; Kang, YK; Meinhardt, G; Peña, CE; Rosmorduc, O; Ross, P; Santoro, A; Vogel, A; Zhu, AX, 2016) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), and to date, no combination therapy has demonstrated superior survival compared with sorafenib alone." | 5.22 | Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. ( Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ, 2016) |
| "To compare the regulation of serum angiogenic factors in patients with unresectable early hepatocellular carcinoma (HCC) treated with yttrium-90 ((90)Y) radioembolization alone vs with sorafenib." | 5.22 | Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. ( Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R, 2016) |
| "To investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC)." | 5.22 | Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. ( Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F, 2016) |
| "Sorafenib and chemoembolization of the liver (TACE) have both produced increased survival in hepatocellular carcinoma (HCC)." | 5.22 | Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. ( Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J, 2016) |
| "Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC)." | 5.22 | Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. ( Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Ishii, H; Kaneko, S; Kojima, Y; Kudo, M; Morimoto, M; Nakamori, S; Ohmura, T; Okusaka, T; Sato, K; Sato, T; Shimizu, S; Sugimoto, R; Tahara, T; Yasui, K, 2016) |
| "To compare in a randomized controlled trial (RCT) 3-year survival of cirrhotic patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) treated with sorafenib plus percutaneous radiofrequency ablation (RFA) of both intraparenchymal HCC and PVTT (combination Group) or sorafenib alone (sorafenib-alone Group)." | 5.22 | Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial. ( Amendola, F; Calvanese, A; Coppola, C; DI Sarno, A; Gatti, P; Giorgio, A; Giorgio, V; Matteucci, P; Merola, F; Merola, MG; Montesarchio, L; Santoro, B, 2016) |
| "gov registration NCT00990860) evaluated sorafenib in combination with doxorubicin-based transarterial chemoembolization (TACE) in patients with intermediate-stage, unresectable hepatocellular carcinoma (HCC)." | 5.20 | The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. ( Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH, 2015) |
| "To prospectively assess treatment response using volumetric functional magnetic resonance imaging (MRI) metrics in patients with hepatocellular carcinoma (HCC) treated with the combination of doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) and sorafenib." | 5.20 | Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. ( Bonekamp, S; Corona-Villalobos, CP; Cosgrove, D; Geschwind, JF; Halappa, VG; Kamel, IR; Pawlik, TM; Reyes, D, 2015) |
| "This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy." | 5.20 | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. ( Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC, 2015) |
| "To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial." | 5.20 | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. ( Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX, 2015) |
| "GIDEON is a non-interventional, prospective, international study that evaluated the safety of sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in daily clinical practice, including Child-Pugh B patients." | 5.20 | [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain]. ( Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A, 2015) |
| "To assess whether urea-based cream (UBC) has prophylactic benefits on sorafenib-induced hand-foot skin reaction (HFSR) in patients with advanced hepatocellular carcinoma (HCC)." | 5.20 | Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. ( Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K, 2015) |
| "Sorafenib, an oral multikinase inhibitor, is the proved therapy method for patients with advanced hepatocellular carcinoma (HCC)." | 5.20 | Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. ( Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M, 2015) |
| "Currently there is no predictor for survival after adjuvant sorafenib in patients with hepatocellular carcinoma (HCC) who have undergone curative resection." | 5.20 | Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2015) |
| "Sorafenib has become the standard therapy for patients with advanced hepatocellular carcinoma (HCC)." | 5.20 | Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance i ( Chow, LP; Feng, WC; Ho, WC; Hsu, CH; Shao, YY; Tsai, MH; Yeh, CC, 2015) |
| "To determine the efficacy of combined continuous sorafenib therapy and drug-eluting bead (DEB) transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC)." | 5.20 | Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. ( Cosgrove, DP; Feng, AL; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK, 2015) |
| " In this phase II study, safety and tolerability of the combination of tigatuzumab and sorafenib was evaluated in patients with advanced hepatocellular carcinoma." | 5.20 | Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. ( Austin, T; Beckman, RA; Cheng, AL; Greenberg, J; He, AR; Hung, CH; Izumi, N; Kang, YK; Kudo, M; Lim, HY; Ryoo, BY; Sheen, IS; Shiratori, S; Wang, Q, 2015) |
| " Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters." | 5.20 | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. ( Abada, PB; Baron, AD; Blanc, JF; Chang, SC; Chau, I; Chung, HC; Kubackova, K; Kudo, M; Okusaka, T; Park, JO; Pastorelli, D; Pfiffer, TE; Poon, R; Ryoo, BY; Sastre, J; Schwartz, JD; Trojan, J; Yang, L; Yen, CJ; Zhu, AX, 2015) |
| "Hepatotoxicity induced by sorafenib and antiviral therapy is a limitation for its continuation treatment for patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC)." | 5.20 | Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. ( Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S, 2015) |
| "Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation." | 5.20 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. ( Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J, 2015) |
| "We evaluated the relationship between the early clinical response after 2 weeks of sorafenib therapy and the outcomes and anti-tumor response in patients with advanced hepatocellular carcinoma." | 5.20 | Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kuzuya, T; Nakano, I, 2015) |
| "The survival benefit of combining sorafenib and transarterial chemoembolization (TACE) therapy compared with sorafenib monotherapy for patients with advanced hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT) is unclear." | 5.20 | Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. ( Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y, 2015) |
| "To determine the antitumor efficacy and tolerability of combination temozolomide (TMZ) and veliparib (ABT-888) in patients with advanced, sorafenib-refractory hepatocellular carcinoma (HCC)." | 5.20 | Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. ( Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H, 2015) |
| " However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)." | 5.20 | Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015) |
| "A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis." | 5.19 | Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. ( Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Kuzuya, T; Matsuda, S; Muraoka, M; Nakanishi, H; Nakata, T; Nishimura, T; Suzuki, S; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Yasui, Y, 2014) |
| "GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials." | 5.19 | GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. ( Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2014) |
| "Sorafenib is considered a standard of care in advanced hepatocellular carcinoma (HCC)." | 5.19 | Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study. ( Ahmad, S; Khattak, J; Murad, S; Naqi, N, 2014) |
| "The aims of this study were to evaluate the frequency of dose-limiting toxicities and to find the recommended dose of combination chemotherapy with sorafenib and transcatheter arterial infusion (TAI) using cisplatin for patients with advanced hepatocellular carcinoma (HCC), for whom surgical resection, local ablation therapy, or transcatheter arterial chemoembolization were not indicated." | 5.19 | Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. ( Hagihara, A; Ikeda, M; Imanaka, K; Inaba, Y; Katayama, K; Kato, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sato, Y; Shimizu, S; Suzuki, E; Tamai, C; Ueno, H, 2014) |
| "Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC)." | 5.19 | A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. ( Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O, 2014) |
| "This phase 2 study evaluated the efficacy of radiation therapy (RT) with concurrent and sequential sorafenib therapy in patients with unresectable hepatocellular carcinoma (HCC)." | 5.19 | Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. ( Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC, 2014) |
| "To explore the efficacy and safty of sorafenib in Child-Pugh class B to class C hepatocellular carcinoma (HCC)." | 5.19 | Sorafenib in liver function impaired advanced hepatocellular carcinoma. ( Geng, CX; Ji, YX; Lan, KT; Liu, SC; Nie, KK; Sun, L; Zhang, L; Zhang, ZC; Zhang, ZF; Zhuang, XJ; Zou, X, 2014) |
| "To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT)." | 5.19 | Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. ( Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K, 2014) |
| "Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma (HCC), with demonstrated outcome benefits in randomized clinical trials." | 5.19 | Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience. ( Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA, 2014) |
| "The aim of this study was to investigate the prognostic significance of blood NLR in patients with intermediate-advanced hepatocellular carcinoma (HCC) who received transcatheter arterial embolization (TAE) combined with Sorafenib." | 5.19 | Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib. ( Mu, H; Song, TQ; Wang, M; Wei, K; Zhang, W, 2014) |
| "Between March 2008 and October 2010, patients with advanced pathologically proven hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A or B received sorafenib plus gemcitabine." | 5.19 | Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. ( Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S, 2014) |
| "To retrospectively analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess the prognostic impact of baseline characteristics." | 5.19 | Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. ( Luo, J; Shao, G; Zheng, J, 2014) |
| "Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma." | 5.19 | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. ( Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX, 2014) |
| "The combination of the TACE and sorafenib proved both safe and effective in the treatment of Chinese patients with unresectable hepatocellular carcinoma." | 5.17 | Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. ( Chao, Y; Feng, G; Han, G; Liu, Z; Lu, L; Shao, G; Teng, G; Wang, J; Wang, M; Yang, J; Yang, R, 2013) |
| "Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC)." | 5.17 | Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. ( Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM, 2013) |
| "Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC)." | 5.17 | A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. ( Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A, 2013) |
| "The aim of this study was to compare radiological and pathological changes and test the adjunct efficacy of Sorafenib to Y90 as a bridge to transplantation in hepatocellular carcinoma (HCC)." | 5.17 | Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. ( Abecassis, M; Atassi, R; Baker, T; Ganger, D; Hickey, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, M; Nayar, R; Salem, R; Vouche, M; Yaghmai, V, 2013) |
| "The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib." | 5.17 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013) |
| "Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC)." | 5.17 | Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. ( Brandt, U; Bruix, J; Chen, LT; Finn, RS; Gomez-Martin, C; Kang, YK; Kim, TY; Klümpen, HJ; Kunz, T; Paquet, T; Poon, RT; Rodriguez-Lope, C; Sellami, D; Yau, T, 2013) |
| "Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC)." | 5.17 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. ( Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L, 2013) |
| "Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC)." | 5.17 | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. ( Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I, 2013) |
| "We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting." | 5.17 | Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. ( Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY, 2013) |
| "Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function." | 5.17 | Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. ( Banzi, M; Boni, C; Carnaghi, C; Ceriani, R; Cortesi, E; Covini, G; De Giorgio, M; Fagiuoli, S; Fanello, S; Ferrari, D; Giordano, L; Labianca, R; Latini, L; Locopo, N; Lutman, FR; Mucciarini, C; Naimo, S; Porta, C; Pressiani, T; Rimassa, L; Salvagni, S; Santoro, A; Tommasini, MA; Torzilli, G; Tronconi, MC, 2013) |
| "To investigate the volumetric iodine-uptake (VIU) changes by dual-energy CT (DECT) in assessing the response to sorafenib treated hepatocellular carcinoma (HCC) patients, compared with AASLD (American Association for the Study of Liver Diseases) and Choi criteria." | 5.17 | Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K, 2013) |
| "Sorafenib is an oral multikinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC)." | 5.17 | Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. ( Brunello, F; Brunocilla, PR; Cantamessa, A; Carucci, P; Castiglione, A; Ciccone, G; Gaia, S; Rizzetto, M; Rolle, E, 2013) |
| "The A(3) adenosine receptor (A(3)AR) is overexpressed in the tumor and in the peripheral blood mononuclear cells of patients with hepatocellular carcinoma (HCC)." | 5.17 | CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. ( Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM, 2013) |
| "This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma." | 5.17 | Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. ( Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y, 2013) |
| "Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
| "Sorafenib is an orally active multikinase inhibitor licensed for the treatment of patients with unresectable hepatocellular carcinoma (HCC)." | 5.16 | Sorafenib in hepatocellular carcinoma - a post marketing evaluation. ( Jirillo, A; Mazurek, M; Palozzo, AC; Trojniak, MP, 2012) |
| "To investigate the safety of transarterial chemoembolisation (TACE) in combination with sorafenib in patients with hepatocellular carcinoma (HCC)." | 5.16 | Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. ( Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W, 2012) |
| "The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and South Korea - confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. ( Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J, 2012) |
| "These subset analyses suggest that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotransferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafenib therapy." | 5.16 | Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. ( Bruix, J; Dominguez, S; Germanidis, G; Greten, TF; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Nadel, A; Raoul, JL; Ricci, S; Scherubl, H; Scheulen, ME; Sherman, M; Voliotis, D, 2012) |
| " The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection." | 5.16 | Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| "We assessed the safety and efficacy of sorafenib with cryotherapy (cryoRx) in advanced hepatocellular carcinoma (HCC)." | 5.16 | Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. ( An, L; Bai, W; Chang, X; Chen, Y; Lou, M; Lu, Y; Lv, J; Qu, J; Wang, C; Yang, Y; Zeng, Z; Zhou, L, 2012) |
| "Sorafenib is the only systemic treatment shown to be effective against advanced hepatocellular carcinoma (HCC)." | 5.16 | The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. ( Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, KH; Kim, SG; Kim, YJ; Kim, YS; Lee, JE; Lee, SH, 2012) |
| "To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post antiangiogenic treatment with sorafenib." | 5.16 | Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. ( Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K, 2012) |
| "Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC)." | 5.16 | Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. ( Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM, 2012) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 5.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "Sorafenib is presently the only effective therapy in advanced hepatocellular carcinoma (HCC)." | 5.16 | Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. ( Alexandre, J; Batteux, F; Chaussade, S; Chéreau, C; Coriat, R; Goldwasser, F; Mir, O; Nicco, C; Ropert, S; Weill, B, 2012) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 5.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| " Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma." | 5.15 | Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. ( Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O, 2011) |
| "he role of serum alpha-fetoprotein (AFP) changes in predicting the treatment outcomes of advanced hepatocellular carcinoma (HCC) patients to sorafenib remains unknown." | 5.15 | The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. ( Chan, P; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T, 2011) |
| "PURPOSE To evaluate safety and efficacy of combined transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) and sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 5.15 | Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. ( Bhagat, N; Cosgrove, D; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK, 2011) |
| "Between January, 2009 and June, 2011, 10 patients with tumor recurrence after OLT were treated with Sorafenib (group A) and another 8 recipients received no Sorafenib treatment (group B); 25 patients with hepatocellular carcinoma (HCC) also received Sorafenib treatment (group C)." | 5.15 | [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients]. ( Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J, 2011) |
| "Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-week cycles, with efficacy measured at the end of each 6-week period." | 5.14 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. ( Burock, K; Chen, Z; Cheng, AL; Feng, J; Guan, Z; Kang, YK; Kim, JS; Liang, H; Liu, J; Luo, R; Pan, H; Qin, S; Sun, Y; Tak, WY; Tsao, CJ; Voliotis, D; Wang, J; Xu, J; Yang, TS; Ye, S; Zou, J, 2009) |
| "Sorafenib, an oral multikinase inhibitor, shows efficacy in renal cell and hepatocellular carcinoma (HCC) and is well tolerated when combined with doxorubicin in other solid tumours." | 5.14 | Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. ( Adamietz, IA; Brendel, E; Christensen, O; Grubert, M; Hilger, RA; Kupsch, P; Ludwig, M; Richly, H; Schultheis, B; Strumberg, D, 2009) |
| "Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles." | 5.14 | Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. ( Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T, 2009) |
| "To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)." | 5.14 | [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma]. ( Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ, 2009) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study (ClinicalTrials." | 5.14 | Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. ( Kudo, M; Lencioni, R; Marrero, J; Venook, A; Ye, SL, 2010) |
| "To provide more evidence sources to the standard treatment for patients with advanced hepatocellular carcinoma, the writer analyze patients' time to progression (TTP) and overall survival (OS) after patients receiving transcatheter arterial chemoembolization (TACE) combined with sorafenib as a treatment of advanced hepatocellular carcinoma (HCC); observe the healing effect embolization combined with anti-angiogenic treatment for advanced hepatocellular carcinoma; and also analyze treatment of security." | 5.14 | [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma]. ( Hu, BS; Huang, GM; Huang, JW; Li, Y; Lu, LG; Shao, PJ; Wei, ZG; Zhang, L, 2010) |
| "It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma." | 5.14 | Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. ( Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010) |
| "In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease." | 5.14 | Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. ( Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB, 2010) |
| "To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)." | 5.14 | [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. ( Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010) |
| "In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo." | 5.13 | Sorafenib in advanced hepatocellular carcinoma. ( Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S, 2008) |
| "Sorafenib was reported as a useful adjuvant treatment in patients with hepatocellular carcinoma who underwent surgical resection." | 5.12 | A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. ( Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L, 2021) |
| "This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients." | 5.12 | Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. ( Abou-Alfa, GK; Amadori, D; De Greve, J; Douillard, JY; Figer, A; Lathia, C; Moscovici, M; Ricci, S; Saltz, LB; Santoro, A; Schwartz, B; Schwartz, L; Taylor, I, 2006) |
| "To compare the efficacy of three types of palliative therapy for advanced hepatocellular carcinoma (HCC), including transarterial chemoembolisation (TACE) monotherapy, sorafenib alone and their combination." | 5.05 | The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. ( Cheng, Z; Guo, Y; He, L; Song, S; Song, Y; Zhang, L, 2020) |
| "Sorafenib remains the only standard first-line drug for advanced hepatocellular carcinoma (HCC)." | 4.98 | Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. ( Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M, 2018) |
| "The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC." | 4.98 | Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. ( Edeline, J; Finn, RS; Galle, PR; Kudo, M; Raoul, JL; Reig, M, 2018) |
| "Transarterial chemoembolization (TACE) is the recommended treatment for hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) B-stage, whereas sorafenib is an orally administered small molecule target drug for BCLC C-stage." | 4.98 | Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y, 2018) |
| "Lenvatinib, a multi-kinase inhibitor, has demonstrated improved outcomes for patients with hepatocellular carcinoma (HCC) in clinical trials." | 4.98 | Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. ( Ikeda, M; Kaneko, S; Kobayashi, M; Tahara, M, 2018) |
| "Neoadjuvant therapies before liver transplantation are a common practice in the management of hepatocellular carcinoma, either in the setting of down staging or as a bridge strategy but sorafenib has been little evaluated." | 4.98 | Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review. ( Ducerf, C; Golse, N; Mabrut, JY; Merle, P; Radenne, S; Rode, A, 2018) |
| "Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and well preserved liver function." | 4.95 | Regorafenib for the treatment of unresectable hepatocellular carcinoma. ( Personeni, N; Pressiani, T; Rimassa, L; Santoro, A, 2017) |
| "It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a significant survival benefit from the sorafenib treatment, which is currently regarded as a first-line chemotherapeutic therapy in patients with advanced HCC." | 4.95 | New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. ( Chen, GG; Lai, PBS; Liu, L; Niu, L; Ren, J; Yang, S, 2017) |
| "Many studies have combined sorafenib with transcatheter arterial chemoembolization (TACE) to treat patients with advanced hepatocellular carcinoma (HCC), but the results are disputable." | 4.95 | Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. ( Cai, R; Liao, Y; Ma, H; Pang, P; Song, R; Sun, H; Wang, H; Wang, S; Yan, Y; Zhang, H; Zhou, C; Zhou, X, 2017) |
| "The multikinase inhibitor sorafenib is the first oral molecular targeted agent with proven prognostic benefit in unresectable advanced hepatocellular carcinoma (HCC)." | 4.95 | Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). ( Arizumi, T; Kudo, M, 2017) |
| "Introduction: Clinical markers to predict the benefit from sorafenib in patients diagnosed with hepatocellular carcinoma (HCC) are lacking." | 4.95 | Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. ( Abdel-Rahman, O; Lamarca, A, 2017) |
| "Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear." | 4.95 | Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. ( Berhane, S; Jackson, R; Johnson, P; Khan, H; Psarelli, EE, 2017) |
| "The benefits of transarterial chemoembolization plus sorafenib (TACE-S) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remain controversial." | 4.95 | Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. ( Cheng, S; Wang, K; Wang, M; Wu, M; Yang, G; Ye, X; Zhang, X, 2017) |
| "In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival." | 4.95 | Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. ( Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S, 2017) |
| "Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence)." | 4.95 | Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. ( Davidson, BR; Gurusamy, KS; Majumdar, A; Roccarina, D; Thorburn, D; Tsochatzis, E, 2017) |
| "This meta-analysis aimed to analyze the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)." | 4.93 | Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. ( Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH, 2016) |
| "Combination therapy of sorafenib and transarterial chemoembolization (TACE) has shown benefits in treating advanced hepatocellular carcinoma (HCC)." | 4.93 | Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. ( Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF, 2016) |
| " One of the included trials compared radioembolisation versus chemoembolization for intermediate stage hepatocellular carcinoma as classified by the Barcelona Clinic Liver Cancer (BCLC) staging system, while the other included trial was an interim analysis of a randomised trial assessing radioembolisation combined with sorafenib versus sorafenib monotherapy in participants with BCLC-advanced stage hepatocellular carcinoma." | 4.93 | Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. ( Abdel-Rahman, OM; Elsayed, Z, 2016) |
| "Sorafenib has been approved to increase the survival in patients with advanced hepatocellular carcinoma." | 4.93 | Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature. ( Cheng, KS; Chou, JW; Huang, CW, 2016) |
| "The efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib for patients with hepatocellular carcinoma (HCC) have been explored by many studies, but the results were controversial." | 4.93 | Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. ( Lv, L; Mei, ZC; Zeng, J, 2016) |
| "Sorafenib is the only drug that demonstrates a survival benefit for advanced hepatocellular carcinoma (HCC)." | 4.93 | Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. ( Itoh, Y; Moriguchi, M; Umemura, A, 2016) |
| " After the unsuccessful results with chemotherapy, sorafenib, by interfering with angiogenic pathways, has become pivotal in the treatment of hepatocellular carcinoma." | 4.93 | Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? ( Addeo, R; Del Prete, S; Montella, L; Palmieri, G, 2016) |
| "Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma." | 4.91 | Refining sorafenib therapy: lessons from clinical practice. ( Bolondi, L; Boni, C; Bruzzi, P; Cammà, C; Colombo, M; Craxi, A; Danesi, R; Daniele, B; Di Costanzo, GG; Fagiuoli, S; Santoro, A; Spandonaro, F; Trevisani, F, 2015) |
| "Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal." | 4.91 | Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. ( Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C, 2015) |
| "To evaluate the feasibility and security of complete remission (CR) of advanced hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the previously described predictive factors in CR." | 4.91 | Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib. ( Feng, X; Hu, Y; Liu, A; Liu, D; Peng, J, 2015) |
| "Sorafenib is the only approved systemic treatment for advanced hepatocellular carcinoma patients and all the recently published randomized controlled trials on new systemic drugs have been unsuccessful." | 4.91 | MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. ( Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R, 2015) |
| "Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 4.91 | Novel drugs in clinical development for hepatocellular carcinoma. ( Trojan, J; Waidmann, O, 2015) |
| "In hepatocellular carcinoma, sorafenib is the only active medical treatment validated to date." | 4.91 | [Advanced hepatocellular carcinoma: importance of clinical trials]. ( Aedo, V; Cristina, V; Faivre, S; Raymond, E, 2015) |
| "Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma." | 4.91 | Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. ( Cai, X; Chen, J; Huang, D; Jin, R; Liang, X; Liang, Y; Lin, H; Liu, J; Yan, H; Ying, H; Yu, H; Zhao, J; Zhou, S, 2015) |
| "Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC)." | 4.91 | Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? ( Angarano, G; Brunetti, O; Faloppi, L; Gnoni, A; Guarini, A; Licchetta, A; Lorusso, V; Lupo, L; Memeo, V; Palasciano, G; Palmieri, V; Pisconti, S; Russo, A; Santini, D; Scartozzi, M; Silvestris, N, 2015) |
| "Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is modest with low response rates and short response duration." | 4.91 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? ( Cheng, AL; Hsu, CH; Shao, YY, 2015) |
| "Sorafenib is the only and standard systematic chemotherapy drug for treatment of advanced hepatocellular carcinoma (HCC) at the current stage." | 4.91 | Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. ( Gao, JJ; Inagaki, Y; Shi, ZY; Tang, W; Xia, JF, 2015) |
| "Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven efficacy against Hepatocellular Carcinoma (HCC)." | 4.90 | New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. ( Barbare, JC; Chauffert, B; Galmiche, A, 2014) |
| "PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms "Hepatocellular carcinoma" OR "Hepatoma" or "Liver cancer" AND "systemic anticancer therapy" AND "Sorafenib" and specifying only English literature." | 4.90 | Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. ( Abdel-Rahman, O; Fouad, M, 2014) |
| "A large number of studies have tried to combine sorafenib with TACE for patients with unresectable hepatocellular carcinoma (HCC) and the results were controversial." | 4.90 | Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. ( Cai, G; Chen, H; Han, G; Liu, L; Qi, X; Wang, M; Zhao, Y, 2014) |
| "The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades, the introduction of novel therapies (such as sorafenib) have improved patient survival." | 4.90 | Systemic therapy of hepatocellular carcinoma: current status and future perspectives. ( Daniele, B; Germano, D, 2014) |
| "The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC)." | 4.90 | Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. ( Miyahara, K; Nouso, K; Yamamoto, K, 2014) |
| "Combination therapy of sorafenib and transarterial chemoembolization (TACE) showed benefits for hepatocellular carcinoma (HCC)." | 4.90 | Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. ( Bai, XL; Chen, YW; Fu, QH; Hu, QD; Liang, TB; Su, RG; Su, W; Zhang, Q, 2014) |
| "Liver transplantation (LT) is an established treatment for hepatocellular carcinoma (HCC), and sorafenib (SFN) is a validated treatment for patients harboring advanced tumors." | 4.90 | Sorafenib use in the transplant setting. ( Burra, P; Castelli, G; Cillo, U; Farinati, F; Giacomin, A; Senzolo, M; Vitale, A, 2014) |
| "Sorafenib is used in patients with intermediate or advanced stage hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE)." | 4.90 | Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. ( Bie, P; Chen, X; Hu, P; Zhang, L, 2014) |
| "Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial." | 4.90 | Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. ( Bai, M; Han, GH; Yang, M; Yuan, JQ, 2014) |
| "Advanced-stage hepatocellular carcinoma (HCC) has an extremely poor prognosis although sorafenib, which is the treatment of choice, has provided survival benefits." | 4.90 | Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma. ( Seong, J; Yoon, HI, 2014) |
| "The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial." | 4.90 | An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. ( Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y, 2014) |
| "We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib." | 4.90 | [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy]. ( Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014) |
| "The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma." | 4.89 | Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. ( Salem, R; Weintraub, JL, 2013) |
| "By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine." | 4.89 | Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. ( Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ, 2013) |
| "Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation." | 4.89 | Sorafenib: from literature to clinical practice. ( De Vita, F; Di Marco, V; Koskinas, J; Semela, D; Toniutto, P; Verslype, C, 2013) |
| "The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory." | 4.89 | A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. ( Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Teranishi, Y, 2013) |
| "The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT)." | 4.89 | Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. ( Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013) |
| "This analysis of both randomized and nonrandomized studies evaluating an antiangiogenic agent in HCC showed that whereas the use of sorafenib was associated with an increased risk of bleeding in HCC, this was primarily for lower-grade events and similar in magnitude to the risk encountered in RCC." | 4.89 | Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. ( Duffy, A; Greten, TF; Wilkerson, J, 2013) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 4.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| "The positive results of sorafenib have unveiled a new direction of research in the management of hepatocellular carcinoma (HCC)." | 4.88 | Management of hepatocellular carcinoma: beyond sorafenib. ( Chan, SL; Ma, BB; Mok, T, 2012) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 4.88 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. ( Spechler, SJ; Wang, DH; Xie, B, 2012) |
| "The efficacy of sorafenib in hepatocellular carcinoma (HCC) has been demonstrated in two pivotal clinical trials: the European SHARP trial and a second trial that recruited patients in the Asia-Pacific region." | 4.88 | Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®). ( Hatano, E; Kokudo, N; Nakajima, J; Numata, K, 2012) |
| "Sorafenib, a receptor tyrosine kinase-inhibitor with anti-proliferative and anti-angiogenic activity, is currently the only approved systemic treatment for patients with hepatocellular carcinoma." | 4.88 | Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. ( Ebert, MP; Schott, E; Trojan, J, 2012) |
| "Sorafenib has become the standard first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 4.88 | Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. ( Fan, J; Huang, XW; Qiu, SJ; Shi, RY; Wang, WM; Wang, Z; Xu, Y; Yang, XR; Zhang, X; Zhou, J, 2012) |
| "The approval of sorafenib as the standard of care (SOC) for advanced hepatocellular carcinoma (HCC) fostered interest to further evaluate several other targeted therapies and extend the positioning of sorafenib alone and in combination with other drugs and local therapies at earlier stages and in an adjuvant setting." | 4.87 | Novel molecular therapies in hepatocellular carcinoma. ( Bouattour, M; Faivre, S; Raymond, E, 2011) |
| "Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results." | 4.87 | Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. ( Guan, YS; He, Q, 2011) |
| "To evaluate the effectiveness and toxicity of sorafenib for advanced hepatocellular carcinoma." | 4.87 | Sorafenib for advanced hepatocellular carcinoma: a systematic review. ( Jin-hui, T; Ke-hu, Y; Li, M; Ling-lin, Z, 2011) |
| " In May 2009, sorafenib (Nexavar®) was approved in Japan for 'unresectable hepatocellular carcinoma (HCC)', and was the first molecular-targeted agent for use in HCC." | 4.87 | Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. ( Kudo, M, 2011) |
| "Since sorafenib, a multikinase inhibitor targeting angiogenesis of hepatocellular carcinoma (HCC), demonstrated survival benefits in recent clinical trials, it has changed the treatment paradigm and become the standard first-line treatment for patients with advanced HCC." | 4.87 | Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone. ( Kim, HY; Park, JW, 2011) |
| "Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function." | 4.87 | Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. ( Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F, 2011) |
| "In two pivotal randomized controlled trials, sorafenib, as compared to placebo, has been demonstrated to yield a significantly favorable disease control rate, and also favorable prolongation of progression-free survival and overall survival in patients with advanced hepatocellular carcinoma." | 4.86 | [Chemotherapy]. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Ueno, H, 2010) |
| "The successful approval of sorafenib has greatly stimulated the development of other molecular targeted agents in advanced hepatocellular carcinoma (HCC)." | 4.86 | Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma. ( Zhu, AX, 2010) |
| "The multikinase inhibitor sorafenib was the first agent to demonstrate a survival benefit for patients with locally advanced or metastatic hepatocellular carcinoma (HCC)." | 4.86 | Novel inhibitors in development for hepatocellular carcinoma. ( Galle, PR; Wörns, MA, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of sorafenib according to its licensed indication for advanced hepatocellular carcinoma (HCC)." | 4.86 | Sorafenib for the treatment of advanced hepatocellular carcinoma. ( Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S, 2010) |
| "Sorafenib, a multikinase inhibitor targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis, is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC)." | 4.86 | Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. ( Cheng, AL; Hsu, C; Shen, YC, 2010) |
| "The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease." | 4.86 | Sorafenib: where do we go from here? ( Brown, RS; Magun, A; Olsen, SK; Siegel, AB, 2010) |
| "Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma." | 4.86 | Sorafenib in hepatocellular carcinoma. ( Josephs, DH; Ross, PJ, 2010) |
| "One of the advances in recent years about the treatment of hepatocellular carcinoma is clinical evidence of the molecular target drug, sorafenib." | 4.86 | [Hepatocellular carcinoma]. ( Arai, K; Kaneko, S; Yamashita, T, 2010) |
| "A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival = 10." | 4.86 | Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. ( Carr, BI; Carroll, S; Gondek, K; Muszbek, N, 2010) |
| "Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma." | 4.85 | Sorafenib: a review of its use in advanced hepatocellular carcinoma. ( Keating, GM; Santoro, A, 2009) |
| "Sorafenib, a multitargeted anti-VEGF receptor and raf kinase inhibitor, was recently approved by the FDA for treating unresectable hepatocellular carcinoma (HCC) based on 2 randomized phase III studies." | 4.85 | Selection of patients with hepatocellular carcinoma for sorafenib. ( Abou-Alfa, GK, 2009) |
| "Sorafenib is currently a targeted agent widely used in the treatment of advanced hepatocellular carcinoma (aHCC)." | 4.31 | A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma. ( Chen, LW; Chien, CH; Chien, RN; Hu, CC; Liang, KH; Lin, CL; Lin, YH; Yeh, CT, 2023) |
| "Targeting Nicotinamide adenine dinucleotide (NAD) metabolism has emerged as a promising anti-cancer strategy; we aimed to explore the health benefits of boosting NAD levels with nicotinamide riboside (NR) on hepatocellular carcinoma (HCC)." | 4.31 | Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice. ( Chen, M; Chen, Y; Ding, Y; Fang, EF; Gu, Y; Hu, Q; Li, Q; Li, W; Pang, N; Pei, L; Sun, Y; Xiao, Y; Yang, L; Ye, M; Zhang, Z; Zhou, Y, 2023) |
| " Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy." | 4.31 | A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study. ( Atsukawa, M; Azemoto, R; Haga, Y; Ikeda, M; Inaba, Y; Inoue, M; Ito, K; Itobayashi, E; Itoh, Y; Itokawa, N; Kanogawa, N; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Maruta, S; Moriguchi, M; Morimoto, N; Nakamoto, S; Nakamura, K; Nakamura, M; Ogasawara, S; Okabe, S; Okubo, T; Ooka, Y; Seko, Y; Shiko, Y; Suzuki, E; Takatsuka, H; Watanabe, S, 2023) |
| "To compare the efficacy and safety of TACE combined with Donafenib and Toripalimab versus TACE combined with Sorafenib in the treatment of unresectable hepatocellular carcinoma (HCC), aiming to guide personalized treatment strategies for HCC and improve patient prognosis." | 4.31 | Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study. ( Liang, B; Lu, H; Xia, X; Zheng, C, 2023) |
| "Sorafenib is an oral multikinase inhibitor with regulatory approval in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and refractory differentiated thyroid carcinoma (DTC)." | 4.12 | Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. ( Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T, 2022) |
| "To assess the cost-effectiveness of selective internal radiation therapy (SIRT) compared with sorafenib for the treatment of patients with advanced hepatocellular carcinoma in the United Kingdom, including a selected subgroup of patients who have been identified as benefiting from treatment with SIRT." | 4.12 | The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom. ( Claxton, L; Eastwood, A; Hodgson, R; Sharif-Hurst, S; Wade, R; Walton, M, 2022) |
| "The combination of transcatheter arterial chemoembolization (TACE) plus sorafenib prolonged progression-free survival (PFS) and overall survival (OS) than sorafenib or TACE monotherapy for patients with hepatocellular carcinoma (HCC)." | 4.12 | Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study. ( Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM, 2022) |
| "To explore the efficacy of combined therapy of Regorafenib with detoxicating and stasis softening Chinese herbal spleen tonics (DSS-splenic tonics) in mid-/late-stage hepatocellular carcinoma." | 4.12 | The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma. ( Fang, S; Li, X; Liu, G; Ma, Y; Yang, J; Yang, X; Zhao, B, 2022) |
| "Sorafenib is currently the first-line treatment for advanced hepatocellular carcinoma (HCC)." | 4.12 | S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. ( Guo, F; Jin, X; Meng, J; Ren, D; Sun, Y; Wu, H; Zhang, H, 2022) |
| " The resistance of hepatocellular carcinoma (HCC) cells to sorafenib significantly limits its therapeutic effect in HCC patients." | 4.12 | FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. ( Li, J; Tan, XP; Wang, SL; Xiong, BH; Zhang, YX; Zuo, Q, 2022) |
| "The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread." | 4.12 | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. ( Chen, CT; Cheng, AL; Hsu, CH; Shao, YY, 2022) |
| "Some studies have shown that sorafenib could significantly prolong the overall survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE)." | 4.12 | Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. ( Chen, Y; He, K; Liu, X; Song, W; Wang, S; Yang, Y; Yang, Z, 2022) |
| "Sorafenib is an oral drug that prolongs overall survival (OS) in patients with hepatocellular carcinoma." | 4.02 | Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. ( Araki, M; Ikegami, T; Kamoshida, T; Ochi, M, 2021) |
| "The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC)." | 4.02 | Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. ( Cao, G; Han, Y; Liu, B; Liu, Z; Shi, Q; Sun, B; Wang, J; Xu, H; Xu, L; Yan, D; Zhi, W; Zou, Y, 2021) |
| " The authors have therefore assessed if the concurrent use of gastric acid suppressants and sorafenib impairs outcomes in patients with advanced hepatocellular carcinoma (HCC)." | 4.02 | Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma. ( Fletcher, P; Kunene, V; Ma, YT; Razak, RA, 2021) |
| "To describe the occurrence of malabsorption (MA) in hepatocellular carcinoma (HCC) patients under sorafenib, the potential relationship with pancreatic insufficiency (PI), and the role of pancreatic enzymes supplementation." | 4.02 | Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. ( Ayuso, C; Belmonte, E; Bruix, J; Darnell, A; Díaz, A; Díaz-González, Á; Feu, F; Forner, A; Gomes da Fonseca, L; Iserte, G; Llarch, N; Reig, M; Rimola, J; Sanduzzi-Zamparelli, M; Sapena, V, 2021) |
| "Sorafenib, used for advanced-stage hepatocellular carcinoma (HCC), has an overall survival (OS) of 10 months." | 4.02 | Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Carvalhana, S; Cortez-Pinto, H; Freitas, LC; Gaio, R; Marinho, RT; Moura, M; Nogueira, PJ; Reis, D, 2021) |
| "To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)." | 4.02 | Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. ( Braghiroli, MI; da Fonseca, LG; Hoff, PM; Marta, GN; Moura, F; Sabbaga, J, 2021) |
| " Sorafenib, the first FDA-approved systemic drug for unresectable hepatocellular carcinoma (HCC), is limited by resistance." | 4.02 | Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. ( Kim, SH; Lee, HJ; Park, SC; Shin, NR; Son, Y, 2021) |
| "Recruitment of patients with advanced hepatocellular carcinoma and Child-Pugh B for sorafenib treatment and additional pharmacokinetic studies is challenging." | 3.96 | Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ( Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O, 2020) |
| " The patient had a history of psoriasis vulgaris and sorafenib (SOR) was introduced (800 mg/day) because of transcatheter arterial chemoembolization (TACE) refractoriness." | 3.96 | Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma. ( Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T, 2020) |
| "Sorafenib (SOR), a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), reveals a limited therapeutic effect due to a lack of selectivity and evident drug resistance." | 3.96 | Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. ( Deng, Y; Dong, L; Li, Y; Liu, J; Liu, TT; Shen, XZ; Sun, Y; Weng, SQ; Yu, XN; Zhang, GC; Zhu, CF; Zhu, JM, 2020) |
| "Sorafenib and lenvatinib are the first-line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events (AE) and overall survival." | 3.96 | Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. ( Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Brunet, M; Corominas, J; da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Millán, O; Reig, M; Samper, E; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F, 2020) |
| "To investigate the role of E26 transformation-specific variant 4 (ETV4) in sorafenib and cisplatin resistance in hepatocellular carcinoma (HCC)." | 3.91 | [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells ( Dehua, WU; Xiaohui, C; Xin, LI, 2019) |
| "Oxaliplatin-based chemotherapy is an alternative systemic treatment for patients with metastatic hepatocellular carcinoma (HCC) who were refractory or intolerant to sorafenib." | 3.88 | Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. ( Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS, 2018) |
| "Sorafenib is a standard treatment for patients (pts) with advanced hepatocellular carcinoma (aHCC), although the clinical benefit is heterogeneous between different pts groups." | 3.88 | An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. ( Akhoundova, D; Aparicio, J; Bruixola, G; Caballero, J; Diaz-Beveridge, R; Giménez, A; Lorente, D; Rodrigo, E; Segura, Á, 2018) |
| "Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC)." | 3.88 | A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. ( Beveridge, DJ; Brown, RM; Candy, P; Chaturvedi, V; Epis, M; Ganda, C; George, J; Kabir, TD; Kalinowski, F; Kopp, C; Leedman, PJ; Richardson, KL; Stuart, LM; Wintle, L; Yeoh, GC, 2018) |
| "The multi-kinase inhibitor regorafenib (REG) was recently demonstrated to be effective in patients with sorafenib (SOR)-resistant hepatocellular carcinoma (HCC)." | 3.88 | Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. ( Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H, 2018) |
| " Hence, an asialoglycoprotein receptor (ASGPR)-targeting nanodrug delivery system based on mesoporous silica (MSN) nanocarrier for co-delivery of sorafenib (SO) and vascular endothelial growth factor (VEGF) targeted siRNA (siVEGF) to hepatocellular carcinoma (HCC) was successfully designed and synthesized." | 3.88 | Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. ( Chen, X; Shao, J; Shen, Z; Xu, A; Zhao, R; Zheng, G, 2018) |
| "For advanced hepatocellular carcinoma (HCC), surgical treatment after sorafenib induction has rarely been reported." | 3.88 | Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma. ( Arima, K; Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Higashi, T; Imai, K; Ishiko, T; Kaida, T; Nakagawa, S; Nitta, H; Okabe, H; Sasaki, Y; Takeyama, H; Taki, K; Tanaka, M, 2018) |
| " We report a hepatocellular carcinoma patient with sorafenib-induced metabolic acidosis, who showed increased hepatic uptake of C-acetate." | 3.88 | Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma. ( Bae, WK; Kim, DY; Kwon, SY; Min, JJ, 2018) |
| "Sorafenib, an oral multikinase inhibitor, is a recommended treatment option available for patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC)." | 3.88 | ( Bae, SH; Choi, JY; Hwang, S; Jang, JW; Park, HL; Song, MJ; Sung, PS; Yang, K; Yoo, IR; Yoon, SK, 2018) |
| "Sorafenib, a multikinase inhibitor for hepatocellular carcinoma treatment, inhibits the Raf/MAPK/ERK signaling pathway." | 3.88 | Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. ( Fei, Z; Lu, M; Zhang, G, 2018) |
| "Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC)." | 3.88 | Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. ( Barbera, MA; Bernardi, M; Brandi, G; Casadei Gardini, A; De Lorenzo, S; Di Costanzo, GG; Foschi, FG; Garuti, F; Granito, A; Inghilesi, AL; Marra, F; Sacco, R; Tortora, R; Tovoli, F; Trevisani, F, 2018) |
| "Sorafenib is the only effective therapy for advanced hepatocellular carcinoma (HCC)." | 3.88 | Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. ( Bosserhoff, AK; Dietrich, P; Fritz, V; Hartmann, A; Hellerbrand, C; Koch, A, 2018) |
| "We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department." | 3.88 | The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy. ( Arakawa, Y; Bando, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Teraoku, H; Yoshimoto, T, 2018) |
| "Objective Sorafenib is a standard therapy for advanced hepatocellular carcinoma (HCC), whereas radiotherapy is effective for local control of extrahepatic spread (EHS) or macrovascular invasion (MVI)." | 3.88 | The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. ( Matsumura, T; Matsushima, H; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y; Yoshitomi, M, 2018) |
| "Sorafenib (SFN) is an anti-angiogenic chemotherapeutic that prolongs survival of patients with hepatocellular carcinoma (HCC); its side effects, including vascular damages such as hand-foot syndrome (HFS), are a major cause of therapy discontinuation." | 3.88 | Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model. ( Abe, S; Fujisawa, K; Furutani-Seiki, M; Goto, R; Inoue, R; Kamimura, K; Koyama, N; Nagoya, T; Nishina, H; Nozawa, Y; Ogawa, K; Sakai, N; Sakaida, I; Sakamaki, A; Shinagawa-Kobayashi, Y; Sugitani, S; Terai, S; Yanagi, M; Yokoo, T, 2018) |
| "Sorafenib is the only Food and Drug Administration (FDA)-approved first-line therapy shown to have survival benefit for patients with advanced hepatocellular carcinoma (HCC)." | 3.88 | Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study. ( D'Addeo, K; Kaplan, DE; Mehta, R; Taddei, TH; Valderrama, A, 2018) |
| "Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy." | 3.88 | Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. ( Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018) |
| "To identify clinical biomarkers that could early predict improved survival in patients with advanced-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization combined with sorafenib (TACE-S)." | 3.88 | Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. ( Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS, 2018) |
| "To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 3.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "Emerging evidence indicates that combining Sorafenib with vitamin K1 (VK1) may result in a synergistic inhibition of hepatocellular carcinoma (HCC) cell migration and proliferation." | 3.88 | Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. ( Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG, 2018) |
| "The impact of transarterial chemoembolization after initiation of sorafenib (SOR) has not been prospectively compared with SOR alone in unresectable hepatocellular carcinoma (HCC)." | 3.88 | Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. ( D'Addeo, K; Gade, TP; Kaplan, DE; Mehta, R; Taddei, TH, 2018) |
| "This study aimed to investigate the safety of sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients." | 3.88 | Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. ( Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J, 2018) |
| "The aim is to study the effectiveness and side effects of sorafenib administration after transarterial chemoembolization (TACE) in advanced hepatocellular carcinoma (HCC) patients." | 3.88 | Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients. ( Jian, W; Li, C; Sun, X; Xie, F; Zhang, K, 2018) |
| "Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC)." | 3.88 | Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. ( Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ, 2018) |
| "A single-center, retrospective, observational study was performed, 166 patients with intermediate-/advanced-stage hepatocellular carcinoma were treated with sorafenib and 19 with TARE." | 3.88 | Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. ( Agazzi, R; Colledan, M; Conte, G; De Giorgio, M; Fagiuoli, S; Iegri, C; Lucà, MG; Nani, R; Nicora, C; Pinelli, D; Sala, F; Sarti, D; Schranz, M; Sironi, S; Virotta, G, 2018) |
| "Purpose To determine whether texture features on pretreatment contrast material-enhanced computed tomographic (CT) images can help predict overall survival (OS) and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 3.88 | Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib. ( Costentin, C; Durot, C; Hoeffel, C; Luciani, A; Mulé, S; Rahmouni, A; Thiefin, G, 2018) |
| "In a previous study, we showed that amentoflavone promotes sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells in vitro." | 3.88 | Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma ( Chen, CW; Hsu, FT; Kuo, YC; Pan, PJ; Tsai, JJ, 2018) |
| "To assess the inter-operator concordance and the potential sources of discordance in defining response to sorafenib in hepatocellular carcinoma (HCC)." | 3.88 | Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. ( Andreone, A; Badea, RI; Benevento, F; Brocchi, S; Ferrarini, A; Golfieri, R; Mastroroberto, M; Morselli-Labate, AM; Negrini, G; Piscaglia, F; Renzulli, M; Tovoli, F, 2018) |
| "Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and HCC refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 3.88 | Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nakahara, T; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
| "The present study aimed to investigate the anticancer effect of sorafenib combined with silencing of activating transcription factor 2 (ATF2) in hepatocellular carcinoma (HCC) cells and to assess the underlying molecular mechanisms." | 3.88 | Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. ( Cai, L; Luo, L; Meng, X; Tang, Z, 2018) |
| "Sorafenib is the most widely used multikinase inhibitor in patients with advanced hepatocellular carcinoma (HCC)." | 3.88 | Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. ( Kang, MK; Lee, HJ; Park, JG, 2018) |
| "To evaluate the cost-effectiveness of sorafenib treatment in combination with other therapies versus sorafenib monotherapy among patients with advanced hepatocellular carcinoma (HCC) who are enrolled in Taiwan's National Health Insurance." | 3.88 | Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. ( Chuang, PH; Ho, JC; Hsieh, ML; Hsieh, VC, 2018) |
| "The aim of this study was to investigate the prognostic factors associated with postprogression survival (PPS) in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib, who were not eligible for second-line treatment with regorafenib." | 3.88 | Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2018) |
| " In this study, we studied the cytotoxic effects of silibinin combined with sorafenib on hepatocellular carcinoma (HCC)." | 3.88 | Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. ( Chen, D; Chen, X; Chen, Y; Cui, T; Kabir, N; Ma, J; Mao, J; Pan, P; Yang, H; Yang, Y, 2018) |
| "Although sorafenib enhances overall survival, sorafenib resistance has been reported to be a significant limiting factor for improved prognosis in patients with hepatocellular carcinoma (HCC)." | 3.88 | Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. ( Choi, GH; Jang, SJ; Jung, Y; Kim, JS; Kim, KM; Lee, HC; Yu, ES, 2018) |
| "Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose." | 3.88 | Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. ( Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y, 2018) |
| "We report an advanced HCC patient with many lung metastases who failed sorafenib treatment." | 3.88 | The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report. ( Duo, J; Ma, X; Zhao, Y; Zhu, H, 2018) |
| "There are few efficacy and toxicity data on sorafenib for patients treated for hepatocellular carcinoma (HCC) who are not Caucasian or Asian." | 3.88 | Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. ( Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB, 2018) |
| "Sorafenib (SOR) has proved to be effective in patients with advanced hepatocellular carcinoma (HCC), since overall survival was higher in phase III clinical trials; however, disease progression can occur." | 3.88 | Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience. ( Álvares-da-Silva, MR; de Freitas, LBR; Grivicich, I; Longo, L; Santos, D, 2018) |
| "Sorafenib resistance is one of the major factors affecting the prognosis of patients with hepatocellular carcinoma (HCC)." | 3.88 | Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. ( Gu, C; Huang, Y; Liu, S; Mai, W; Nie, Y; Wang, K; Yang, H; Yu, G; Zhao, D; Zhong, Y, 2018) |
| "Treatment with sorafenib remains the first‑line therapy for patients with advanced stage hepatocellular carcinoma (HCC), however, it has limited effect due to the acquired resistance of HCC." | 3.88 | Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. ( Cheng, B; Du, J; Fan, Y; Li, J; Li, X; Lin, W; Ling, C; Liu, D, 2018) |
| "Use of the tyrosine kinase inhibitor sorafenib in patients with advanced hepatocellular carcinoma (HCC) is often hindered by the development of resistance, which has been recently shown to be associated with the emergence of a cancer stem cell (CSC) subpopulation." | 3.85 | Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. ( Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T, 2017) |
| "Drug resistance to sorafenib is common in patients with hepatocellular carcinoma(HCC)." | 3.85 | Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. ( Chen, J; Cheng, Y; Li, A; Liu, D; Liu, Y; Luo, R; Wang, B; Xu, W; Zheng, H; Zhu, Y, 2017) |
| "Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions." | 3.85 | Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. ( Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ, 2017) |
| "Sorafenib is the current standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.85 | Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. ( Chen, HM; Chen, PJ; Cheng, AL; Hsu, CH; Lai, MS; Lu, LC; Shao, YY; Yeh, YC, 2017) |
| "For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines." | 3.85 | Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. ( Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ, 2017) |
| "Sorafenib is the only standard treatment for unresectable hepatocellular carcinoma (HCC), but it provides modest survival benefits over placebo, necessitating predictive biomarkers of the response to sorafenib." | 3.85 | Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). ( Cho, EJ; Cho, Y; Cho, YY; Jun, J; Kim, H; Kim, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, S; Park, T; Yeo, I; Yoon, JH; Yu, SJ, 2017) |
| "Sorafenib is currently used to treat advanced and/or unresectable hepatocellular carcinoma (HCC), but the increase of the median survival was only 3 months." | 3.85 | Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. ( Abeni, E; Arici, B; De Petro, G; Marchina, E; Salvi, A; Traversa, M, 2017) |
| "The objective of this study was to determine the effects of sorafenib on TH levels in patients with hepatocellular carcinoma (HCC) and to evaluate possible mechanisms." | 3.85 | Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. ( Beukhof, CM; Bins, S; Chaker, L; de Herder, WW; de Rijke, YB; Mathijssen, RH; Peeters, RP; van Doorn, L; van Heerebeek, R; van Kemenade, FJ; Visser, TJ; Visser, WE, 2017) |
| "To investigate the feasibility of perfusion-CT (p-CT) measurements in quantitative assessment of hemodynamic changes related to sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 3.85 | Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. ( Franzesi, CT; Ippolito, D; Okolicsanyi, S; Querques, G; Sironi, S; Strazzabosco, M, 2017) |
| "The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high." | 3.85 | PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC. ( Choi, YK; Ham, HJ; Jang, SY; Jeon, HJ; Kim, BG; Kim, JG; Kim, JH; Kim, MJ; Lee, IK; Lee, JY; Park, KG; Park, SY, 2017) |
| "Sorafenib is the standard of care for patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI), with limited survival." | 3.85 | Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. ( Adam, R; Amaddeo, G; Bricault, I; Calderaro, J; Cherqui, D; Costentin, CE; Decaens, T; Duvoux, C; Ganne-Carrié, N; Laurent, A; Letoublon, C; Luciani, A; Mallat, A; Nault, JC; Paule, B; Roudot-Thoraval, F; Samuel, D; Vibert, E, 2017) |
| "Molecule-targeted therapy, such as sorafenib, is one of the effectively therapeutic options for advanced hepatocellular carcinoma (HCC)." | 3.85 | Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. ( Ji, B; Liu, J; Liu, K; Liu, Y; Meng, L, 2017) |
| "We investigated the functional role and clinical significance of stearoyl-CoA desaturase-1 (SCD1) mediated endoplasmic reticulum (ER) stress in regulating liver tumor-initiating cells (T-ICs) and sorafenib resistance, with the aim of developing a novel therapeutic strategy against hepatocellular carcinomas (HCCs)." | 3.85 | Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. ( Cheng, LKW; Copland, JA; Ding, J; Ho, NPY; Lau, EYT; Lee, TKW; Leung, DHW; Lin, CH; Lo, J; Lo, RCL; Ma, MKF; Ma, S; Ng, IOL, 2017) |
| "Limited information is available regarding patient survival after sorafenib discontinuation in patients with hepatocellular carcinoma (HCC)." | 3.85 | Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. ( Ahn, SH; Han, KH; Heo, JY; Jang, SK; Jang, SY; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Lee, SH; Lee, YR; Park, JY; Park, SY; Tak, WY, 2017) |
| "Use of sorafenib remains debated in elderly patients treated for advanced hepatocellular carcinoma (HCC)." | 3.85 | Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. ( Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N, 2017) |
| "Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC)." | 3.85 | Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. ( Brunetti, O; Casadei Gardini, A; Cascinu, S; Di Costanzo, GG; Ercolani, G; Faloppi, L; Foschi, FG; Granata, R; Marisi, G; Palmieri, VO; Scartozzi, M; Silvestris, N; Tortora, R, 2017) |
| "Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC)." | 3.85 | Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. ( Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ, 2017) |
| "The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma (HCC) has not been established." | 3.85 | Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study. ( Hoshino, T; Ishihara, H; Kakizaki, S; Kudo, T; Naganuma, A; Sato, K; Suzuki, Y; Takagi, H; Uehara, D; Yamada, M, 2017) |
| "Sorafenib is a multitargeted kinase inhibitor currently used in the treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment. ( Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M, 2017) |
| "Purpose Sorafenib is currently the only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocellular carcinoma." | 3.85 | Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. ( D'Addeo, K; Kaplan, DE; Mamtani, R; Mehta, R; Reiss, KA; Taddei, TH; Wileyto, EP; Yu, S, 2017) |
| "Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear." | 3.85 | The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. ( Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L, 2017) |
| "In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib for the treatment of hepatocellular carcinoma (HCC)." | 3.85 | Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation. ( Azzolina, A; Balasus, D; Cervello, M; Emma, MR; Giammona, G; Loria, GR; Pitarresi, G; Porsio, B; Puleio, R; Puleo, S; Volpe, AB, 2017) |
| "Sorafenib, an orally available kinase inhibitor, is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), and it exerts potent inhibitory activity against epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR) by inhibiting mitogen-activated protein kinase (MAPK) signaling in HCC." | 3.85 | Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. ( Cheng, H; Dong, J; Hu, F; Sun, W; Xu, J; Zhai, B, 2017) |
| "In 2015, we published a study on a small series of patients with hepatocellular carcinoma (HCC) treated chronically with metformin for type II diabetes mellitus (DM2) who showed a poorer response to sorafenib." | 3.85 | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. ( Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U, 2017) |
| "Transcatheter arterial chemoembolization (TACE) and TACE in combination with sorafenib (TACE-sorafenib) have shown a significant survival benefit for the treatment of unresectable hepatocellular carcinoma (HCC)." | 3.85 | Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. ( Chen, KF; Li, B; Li, Q; Liu, F; Wei, YG; Zhao, RC; Zhou, J, 2017) |
| "Although sorafenib is currently used as a standard treatment for advanced hepatocellular carcinoma, low response rate, transient and limited efficacy, primary and acquired resistance and negative side-effects gain increasing attentions, suggesting the need for better efficacious combination therapy." | 3.85 | Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. ( Cai, X; Chen, J; Jin, RA; Liang, X; Lin, H; Sun, Y; Tang, M; Xu, J; Zheng, L, 2017) |
| "Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine-threonine kinases." | 3.85 | Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. ( Cai, X; Chen, J; Dai, Y; Ji, T; Liang, X; Liang, Y; Lin, H; Xie, Y; Xu, J; Yu, Q; Zhang, B, 2017) |
| "Targeted therapy is currently the standard treatment for advanced hepatocellular carcinoma (HCC), but an effective treatment after the discontinuation of sorafenib therapy remains uncertain." | 3.85 | Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. ( Chang, PY; Huang, YK; Lee, SW; Lee, TY; Shiu, SI; Yeh, HZ; Yen, CL, 2017) |
| " Subsequently, we demonstrate that 1l augments the cytotoxic action of sorafenib in murine hepatocellular carcinoma cells." | 3.85 | Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist. ( Auriola, S; Bunch, L; Gynther, M; Han, L; Hansen, JC; Hansen, KB; Ishchenko, Y; Kayser, S; Larsen, Y; Malm, T; Nielsen, B; Petsalo, A; Pickering, DS; Proietti Silvestri, I, 2017) |
| " Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC)." | 3.85 | High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo. ( Fan, XG; Fu, Y; Hu, X; Huang, Y; Li, N; Quan, J; Sun, L; Xiao, Y; Zhou, P; Zhou, R, 2017) |
| "Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.85 | Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. ( Arai, K; Asahina, Y; Hara, Y; Hayashi, T; Honda, M; Kaneko, S; Mizukoshi, E; Nio, K; Okada, H; Sakai, Y; Suda, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T, 2017) |
| "The purpose of this study was to build prognostic models capable of estimating the outcomes of individual sorafenib-treated advanced stage hepatocellular carcinoma (HCC) patients based on specific patient and tumor factors." | 3.85 | Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. ( Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH, 2017) |
| "Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression." | 3.85 | Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. ( Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A, 2017) |
| "To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular carcinoma (HCC) xenograft model." | 3.85 | Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. ( Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH, 2017) |
| "Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive." | 3.85 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. ( Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC, 2017) |
| "The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC)." | 3.85 | mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. ( Bai, W; Cai, H; Fan, D; Han, G; Liu, L; Niu, J; Wang, E; Wang, W; Xia, D; Xia, J; Yang, M; Yin, Z; Zhang, L; Zhang, Z; Zhao, Y, 2017) |
| "Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. ( Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG, 2017) |
| "To investigate the value of multiparametric magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) for monitoring the ultra-early (within 24 hours) treatment effect of sorafenib in human hepatocellular carcinoma (HCC) xenografts." | 3.85 | Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts. ( Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z, 2017) |
| "Sorafenib as an effective multikinase inhibitor has been approved for the clinical treatment against advanced hepatocellular carcinoma (HCC)." | 3.85 | C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. ( An, D; Dong, M; Feng, M; Guan, Z; Jiang, S; Kuerban, K; Li, J; Peng, Y; Wang, Q; Ye, L, 2017) |
| "To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC)." | 3.85 | Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. ( Igarashi, Y; Ikehara, T; Shimizu, R; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M, 2017) |
| " We found that long non-coding RNA TUC338 is involved in the development of hepatocellular carcinoma (HCC) and sorafenib resistance." | 3.85 | Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. ( Cai, X; Chen, G; Chen, L; Fu, T; Jin, W; Ma, D; Yu, F; Yu, Z; Zhang, J; Zhang, Y, 2017) |
| "Transcatheter arterial chemoembolization (TACE) and sorafenib combination treatment for unselected hepatocellular carcinoma (HCC) is controversial." | 3.85 | Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib. ( Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y, 2017) |
| " Sorafenib, the mainstay of treatment of HCC patients, however, leads to tumour hypoxia and thereby abrogates the efficacy of anti-PD-1 treatment." | 3.85 | CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. ( Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A, 2017) |
| "The treatment responses of sorafenib in hepatocellular carcinoma are modest which may be due to different characteristics of cancer cells or insufficient therapeutic concentrations." | 3.85 | Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. ( Chuang, WL; Lin, ZY, 2017) |
| "The multi‑kinase inhibitor sorafenib is the only drug for which randomized control trials have shown improved patient survival in advanced hepatocellular carcinoma (HCC)." | 3.85 | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. ( Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F, 2017) |
| "Sorafenib is the current standard treatment for advanced hepatocellular carcinoma." | 3.85 | Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. ( Blesing, C; Braconi, C; Collins, P; Darby, S; Hubner, RA; Iwuji, C; Johnson, P; King, J; Kirkwood, A; Meyer, T; Muazzam, I; Nash, S; Nobes, J; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D, 2017) |
| "Sorafenib is an antitumor drug for treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. ( Caraglia, M; Castiello, F; Ferri, C; Giordano, A; Mosca, N; Panella, M; Potenza, N; Russo, A; Stiuso, P; Vanacore, D; Zappavigna, S, 2017) |
| "Sorafenib is a chemotherapeutic agent approved for the treatment of hepatocellular carcinoma (HCC) in China." | 3.85 | Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration. ( Chen, PC; Guo, L; Huang, Y; Kwok, HF; Li, B; Li, L; Lin, Y; Meng, C; Neves, H; Xiao, Y; Yan, W, 2017) |
| "The prognostic role of aberrant serum miRNA expression for predicting response to sorafenib treatment in advanced hepatocellular carcinoma (HCC) patients has not been well characterized." | 3.85 | An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. ( Byun, KS; Je, JH; Kang, SH; Kim, JH; Ko, E; Lee, HJ; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2017) |
| "In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4',6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging)." | 3.85 | Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. ( Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B, 2017) |
| "Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC)." | 3.85 | FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. ( Gao, L; Hu, CA; Huang, S; Tang, Y; Teng, Y; Wang, X, 2017) |
| " Sorafenib, the medical treatment of reference against advanced stages of hepatocellular carcinoma (HCC), inhibits the RAF-MEK-ERK cascade in HCC cells." | 3.85 | Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. ( Galmiche, A; Giacobbi, AS; Louandre, C; Mammeri, Y; Saidak, Z; Sauzay, C, 2017) |
| "Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC)." | 3.85 | Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. ( Han, P; Jiang, H; Jiang, X; Li, H; Liu, B; Qiao, H; Sun, X; Tan, G; Zhai, B; Zhao, D, 2017) |
| "Melatonin has been shown to exert anticancer activity on hepatocellular carcinoma (HCC) through its antiproliferative and pro-apoptotic effect in both experimental and clinical studies, and sorafenib is the only approved drug for the systemic treatment of HCC." | 3.85 | Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. ( Gao, C; Herr, I; Hoffmann, K; Lin, S; Petrulionis, M; Schemmer, P, 2017) |
| "Sorafenib is the drug of choice in the treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. ( Al-Abdulla, R; Bantel, H; Bettinger, D; Geier, A; Jahn, D; Macias, RI; Marin, JJ; Weiss, J, 2017) |
| "Response to sorafenib is highly variable in hepatocellular carcinoma (HCC)." | 3.85 | Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. ( Arizumi, T; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Toniutto, P, 2017) |
| "To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 3.85 | Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M, 2017) |
| "At advanced stages of hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only effective treatment." | 3.85 | Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. ( Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K, 2017) |
| "Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable." | 3.85 | Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. ( Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM, 2017) |
| "Purpose To identify early biomarkers for the prediction of the therapeutic response in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) and sorafenib (referred to as TACE plus sorafenib) and establish an effective prognostic nomogram." | 3.85 | Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma. ( Chen, L; Ni, CF; Teng, GJ; Zhong, BY; Zhu, HD, 2017) |
| " Purpose To assess diagnostic values of intra-voxel incoherent motion (IVIM) imaging in evaluating therapeutic effects of sorafenib on hepatocellular carcinoma (HCC) using mouse xenograft model." | 3.85 | Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models. ( Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC, 2017) |
| "Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC)." | 3.85 | Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. ( Cao, J; Chen, Y; Li, W; Liu, K; Shang, C; Tan, W; Zhang, L; Zhong, J; Zhu, S, 2017) |
| "Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC)." | 3.85 | Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. ( Bardeesy, N; Benes, CH; Chang, CC; Chang, CF; Chen, Y; Dima, S; Duda, DG; Duyverman, AM; Flaherty, KT; Gao, DY; Hsu, FF; Huang, P; Jain, RK; Jeng, KS; Kitahara, S; Lin, TT; Liu, CH; Liu, YC; Popescu, I; Ramjiawan, RR; Sung, YC; Zhu, AX, 2017) |
| "We studied the relation between the polymorphism of P-glycoprotein (P-gp) and of breast cancer resistance protein (BCRP), encoded by ABCB1 and ABCG2 genes, respectively, and the pharmacokinetic variability and clinical response during the treatment with sorafenib of hepatocellular carcinoma." | 3.85 | Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. ( Bonhomme-Faivre, L; Cailliez, V; Farinotti, R; Mhiri, A; Noé, G; Paule, B; Saffroy, R; Tandia, M, 2017) |
| "To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system." | 3.85 | Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. ( Ciani, O; Rognoni, C; Sommariva, S; Tarricone, R, 2017) |
| "The Albumin-Bilirubin (ALBI) grade is a new index to assess objectively liver function and prognosis in patients with hepatocellular carcinoma (HCC)." | 3.85 | Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. ( Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP, 2017) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.83 | pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X, 2016) |
| "Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC)." | 3.83 | Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Bochereau, F; Chauffert, B; Degonville, J; Drullion, C; Fournier, E; François, C; Galmiche, A; Gicquel, A; Godin, C; Houessinon, A; Louandre, C; Nyga, R; Pluquet, O; Saidak, Z, 2016) |
| "We have previously demonstrated that isocorydine (ICD) can be served as a potential antitumor agent in hepatocellular carcinoma (HCC)." | 3.83 | Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. ( Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F, 2016) |
| "To clarify the effects of cyclin E1 suppression on antitumor efficacy of sorafenib in hepatocellular carcinoma cells and to explore the potential of combining sorafenib with cyclin-dependent kinase (CDK) inhibition in therapy." | 3.83 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. ( Cheng, AL; Cheng, YC; Feng, ZR; Hsu, C; Lin, LI; Ou, DL; Shao, YY, 2016) |
| "Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance." | 3.83 | MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. ( Huang, J; Liu, L; Luo, Y; Ma, L; Qian, C; Shan, J; Shen, J; Xu, Y; Yang, Z; Yao, C, 2016) |
| "Sorafenib is the first and currently the only standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. ( Chang, MJ; Chao, TI; Chen, KF; Chen, MH; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH, 2016) |
| "Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)." | 3.83 | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016) |
| "Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma." | 3.83 | Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. ( Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016) |
| "Sorafenib is a multikinase inhibitor for the treatment of hepatocellular carcinoma." | 3.83 | MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. ( Cao, L; Chen, L; Ge, N; Li, J; Qian, H; Sun, B; Yin, Z; Zhai, B; Zhang, X; Zhao, L, 2016) |
| "1, modified Response Evaluation Criteria in Solid Tumor (mRECIST), Choi and European Association for the Study of the Liver (EASL) evaluations to assess the response to sorafenib for hepatocellular carcinoma (HCC)." | 3.83 | CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus ( Ayav, A; Bronowicki, JP; Claudon, M; Gavanier, M; Laurent, V; Orry, X; Sellal, C, 2016) |
| "To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions." | 3.83 | TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016) |
| "Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear." | 3.83 | The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. ( Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y, 2016) |
| "We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression." | 3.83 | Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016) |
| "The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported." | 3.83 | MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. ( Fujimoto, S; Kimura, T; Miyamoto, H; Muguruma, N; Okamoto, K; Takayama, T; Takeishi, S; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T, 2016) |
| "Evasive mechanisms triggered by the tyrosine kinase inhibitor sorafenib reduce its efficacy in hepatocellular carcinoma (HCC) treatment." | 3.83 | Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. ( Barbero-Camps, E; Bárcena, C; Colell, A; de Gregorio, E; Fernandez-Checa, JC; García-Ruiz, C; Marí, M; Martinez-Nieto, GA; Morales, A; Moutinho, C; Stefanovic, M; Tutusaus, A; Villanueva, A, 2016) |
| "To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)." | 3.83 | Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. ( Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K, 2016) |
| "PTP1B dephosphorylates PITX1 to weaken its protein stability and the transcriptional activity for p120RasGAP gene expression and acts as a determinant of the sorafenib-mediated drug effect; targeting the PITX1-p120RasGAP axis with a PTP1B inhibitor may provide a new therapy for patients with hepatocellular carcinoma." | 3.83 | Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma. ( Chen, KF; Chen, LJ; Chen, YL; Chu, PY; Huang, JW; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH, 2016) |
| " We investigated the phenomenon in 61 patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib." | 3.83 | Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. ( Bisulli, M; Casadei Gardini, A; Cascinu, S; Corbelli, J; Donati, G; Faloppi, L; Foschi, FG; Frassineti, GL; Gardini, A; Giampalma, E; La Barba, G; Marisi, G; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Veneroni, L, 2016) |
| "The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study)." | 3.83 | Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. ( Han, KH; Han, SY; Heo, J; Kim, DY; Kim, HJ; Kim, YH; Kweon, YO; Lee, BS; Lee, HC; Lee, WS; Lim, HY; Ryoo, BY; Um, SH; Woo, HY; Yoon, JH; Yoon, SK, 2016) |
| "Sorafenib (SOR) is the standard of care for patients with hepatocellular carcinoma (HCC) and portal vein invasion (PVI), based on the results of phase 3 trials." | 3.83 | A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. ( Arenas, JI; Buades-Mateu, J; Bustamante, FJ; de la Rosa, PA; de la Torre, MA; Gil, C; Iñarrairaegui, M; Lorente, S; Lué, A; Sangro, B; Serrano, MT; Testillano, M, 2016) |
| "Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009." | 3.83 | Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. ( Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T, 2016) |
| "Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016) |
| "The combination of doxorubicin (DOX) with sorafenib (SOR) has proven an effective strategy to enhance anti-hepatocellular carcinoma (HCC) efficacy." | 3.83 | iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. ( Chan, HF; Chen, M; Hu, J; Liang, G; Skibba, M; Zhang, J, 2016) |
| "We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib." | 3.83 | Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. ( Chen, D; Chen, W; Lai, J; Liang, L; Xiao, W; Yin, X; Zhang, K, 2016) |
| "Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence." | 3.83 | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016) |
| "Sorafenib has improved the median overall survival of unresectable or otherwise untreatable hepatocellular carcinoma (HCC) of ∼3 months, compared to supportive cares." | 3.83 | Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. ( Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B, 2016) |
| "To evaluate the efficacy of transcatheter arterial chemoembolisation (TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma (HCC) in patients with tumor thrombus extending to the main portal vein." | 3.83 | Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. ( Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ, 2016) |
| "The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 3.83 | Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. ( Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM, 2016) |
| "We aimed to determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS)with Sonazoid in the evaluation of early response to sorafenib for hepatocellular carcinoma (HCC)." | 3.83 | [Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid]. ( Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M, 2016) |
| "Sorafenib is an oral multiple tyrosine kinase inhibitor and is currently the only evidence-based treatment recommended for advanced hepatocellular carcinoma." | 3.83 | Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. ( Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F, 2016) |
| "To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)." | 3.83 | Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. ( Cai, XB; Hou, Y; Li, J; Liu, B, 2016) |
| "Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) and sorafenib resistance remain enigmatic." | 3.83 | Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. ( Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF, 2016) |
| "Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC)." | 3.83 | Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma. ( Chen, W; Dan, Y; Li, M; Li, W; Liu, K; Mo, P; Qin, L; Tong, Z; Wang, W; Yu, C, 2016) |
| "GIDEON was a prospective, global, non-interventional study evaluating the safety of sorafenib in patients with unresectable hepatocellular carcinoma in real-world practice." | 3.83 | Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. ( Furuse, J; Ikeda, M; Ito, Y; Izumi, N; Kadoya, M; Kokudo, N; Kudo, M; Numata, K; Okusaka, T; Takayama, T; Yamashita, S, 2016) |
| "Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively." | 3.83 | Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. ( Chen, SH; Chen, YY; Cheng, KS; Chou, JW; Chuang, PH; Feng, CL; Hsiao, WD; Kao, JT; Lai, HC; Peng, CY; Su, WP; Yu, CJ, 2016) |
| "Sorafenib is a multikinase inhibitor approved as the first line treatment for late stage hepatocellular carcinoma (HCC)." | 3.83 | Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. ( Cai, X; Cang, Y; Chen, J; Huang, D; Ji, T; Jin, R; Li, G; Liang, X; Lin, H; Liu, J; Liu, X; Xie, A; Zhang, J; Zhao, J, 2016) |
| "It is unknown whether the addition of locoregional therapies (LRTx) to sorafenib improves prognosis over sorafenib alone in patients with advanced hepatocellular carcinoma (HCC)." | 3.83 | The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Aycart, SN; Berger, Y; Edwards, MP; Heskel, M; Kim, E; Labow, DM; Sarpel, U; Spivack, JH; Sweeney, R, 2016) |
| "Sorafenib is an oral multikinase inhibitor that improves survival in advanced hepatocellular carcinoma (HCC)." | 3.83 | Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. ( Arachchi, N; Bell, S; Dev, A; Doyle, A; Fink, MA; Gill, R; Gow, PJ; Hong, T; Kemp, W; Knight, V; Kronborg, I; Lubel, J; Marsh, P; Mohsen, W; Nicoll, A; Roberts, S; Rodov, M; Ryan, M; Strasser, SI; Varma, P, 2016) |
| "Despite significant progress, advanced hepatocellular carcinoma (HCC) remains an incurable disease, and the overall efficacy of targeted therapy by Sorafenib remains moderate." | 3.83 | Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. ( Cui, SX; Gao, ZH; Qu, XJ; Shi, WN; Song, ZY; Wang, SQ; Yu, XF, 2016) |
| "To investigate feasibility, safety, and effect of transarterial chemoembolization using sorafenib on degree of tumor necrosis in a rabbit VX2 liver tumor model." | 3.83 | Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect. ( Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY, 2016) |
| "Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC)." | 3.83 | Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. ( Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK, 2016) |
| "We evaluated radiotherapy using helical tomotherapy (HT) combined with sorafenib for treatment of pulmonary metastases from hepatocellular carcinoma (HCC)." | 3.83 | Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma. ( He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S, 2016) |
| "A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma." | 3.83 | Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. ( Chan, AL; Leung, HW; Liu, CF, 2016) |
| "The Albumin-Bilirubin (ALBI) grade was proposed as an objective means to evaluate liver function in patients with Hepatocellular Carcinoma (HCC)." | 3.83 | A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. ( Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D, 2016) |
| "We investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma refractory or intolerant to sorafenib." | 3.83 | Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. ( Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T, 2016) |
| "The mechanism underlying poor prognosis and sorafenib resistance in patients with hepatocellular carcinoma (HCC) is unknown and, to date, no useful predictive biomarkers of sorafenib resistance have been identified." | 3.83 | Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. ( Cui, X; Hua, L; Liu, J; Lu, C; Ni, R; Qu, L; Shen, Z; Wu, M, 2016) |
| "hepatocellular carcinoma - HCC - BCLC - sorafenib - complete response." | 3.83 | Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. ( Macaluso, FS; Maida, M; Valenza, F; Virdone, R, 2016) |
| "This study investigates whether changes in arterial enhancement of hepatocellular carcinoma (HCC) on contrast-enhanced CT in patients treated with Sorafenib predicts overall survival." | 3.83 | Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib. ( Furlan, A; Marsh, JW; Patchett, N, 2016) |
| "Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.83 | NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. ( Augello, G; Bachvarov, D; Cancila, V; Candido, S; Cervello, M; Emma, MR; Gulino, A; Iovanna, JL; Libra, M; Loria, GR; McCubrey, JA; Montalto, G; Puleio, R, 2016) |
| "To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 3.83 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016) |
| "To compare the therapeutic effect of portal vein stenting and endovascular implantation of iodine-125 seeds strand followed by transcatheter arterial chemoembolization combined with or without sorafenib in patients for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT)." | 3.83 | [Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus]. ( Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J, 2016) |
| "The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC)." | 3.83 | Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. ( De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H, 2016) |
| "Sorafenib, a multi-kinase inhibitor, is the only standard clinical drug for patients with advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance in HCC often prevents its long-term efficacy." | 3.83 | miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. ( Azumi, J; Sakabe, T; Shiota, G; Tsubota, T, 2016) |
| "Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the treatment of these pathologies." | 3.83 | Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. ( Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P, 2016) |
| "Sorafenib, a multikinase inhibitor, is currently the only approved drug for advanced hepatocellular carcinoma (HCC)." | 3.83 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. ( Cheng, AL; Feng, WC; Hsu, CH; Lin, HH; Lu, LC; Shao, YY, 2016) |
| "We examined plasma biomarkers as predictive factors for advanced hepatocellular carcinoma(ad-HCC)patients treated with sorafenib." | 3.83 | [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib]. ( Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M, 2016) |
| "Sorafenib, a multi-kinase inhibitor, has shown its promising antitumor effect in a series of clinical trials, and has been approved as the current standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line. ( Cao, J; Cao, X; Li, D; Peng, Y; Quan, M; Ren, K; Sheng, X; Song, Z; Xiao, Q; Zeng, W; Zheng, Y; Zou, H, 2016) |
| "Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment." | 3.83 | Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. ( Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T, 2016) |
| "Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well." | 3.83 | A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. ( Chen, X; Cui, T; Diao, X; Huang, S; Sun, J, 2016) |
| "GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients." | 3.83 | Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. ( Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JH; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016) |
| "Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC)." | 3.83 | Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells. ( Abdel-Naim, AB; Badawy, NN; El-Ahwany, E; Khalifa, AE; Liu, AW; Tolba, MF; Youssef, MM; Zada, S, 2016) |
| "Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates." | 3.83 | Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. ( Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH, 2016) |
| "Effects of sorafenib in hepatocellular carcinoma (HCC) are frequently transient due to tumor-acquired resistance, a phenotype that could be targeted by other molecules to reduce this adaptive response." | 3.83 | Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. ( Baulies, A; Fernández, A; Fernández-Checa, JC; Garcia-Ruiz, C; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Ordóñez, R; Prieto-Domínguez, N, 2016) |
| "This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China." | 3.83 | FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016) |
| "Although sorafenib is considered standard therapy for advanced hepatocellular carcinoma (HCC), actual treatments vary." | 3.83 | Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. ( Chung, YH; Ha, Y; Kang, YK; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, SR; Ryoo, BY; Ryu, MH; Shim, JH, 2016) |
| " However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects." | 3.83 | Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. ( Chen, HA; Kuo, TC; Ma, JT; Su, JL; Sung, SY; Tseng, CF; Yang, CY; Yang, ST; Yen, CJ, 2016) |
| "Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)." | 3.83 | Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. ( Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O, 2016) |
| "Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence." | 3.83 | Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. ( Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C, 2016) |
| "We explored the hypothesis that sorafenib may improve the effect of transarterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) and that longer sorafenib duration was associated with additional survival benefits." | 3.83 | Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. ( Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X, 2016) |
| "Sorafenib is the only chemotherapeutic agent currently approved for unresectable hepatocellular carcinoma (HCC)." | 3.83 | Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study. ( Abdelmageed, MM; El-Demerdash, E; El-Naga, RN; Elmazar, MM, 2016) |
| "We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 3.83 | Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. ( Casadei Gardini, A; de Stefano, G; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Negri, FV; Santini, D; Scarpi, E; Scartozzi, M; Silvestris, N; Valgiusti, M, 2016) |
| "The aim of this study was to investigate the relationship between fever within 2 weeks after the start of sorafenib therapy and treatment efficacy in patients with advanced hepatocellular carcinoma (HCC)." | 3.83 | Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. ( Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I, 2016) |
| "In patients with hepatocellular carcinoma (HCC) receiving sorafenib, drug resistance is common." | 3.83 | Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination. ( Azzariti, A; Caligiuri, A; Dituri, F; Giannelli, G; Lupo, L; Mancarella, S; Porcelli, L; Quatrale, AE, 2016) |
| "Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and a number of miRNAs contribute to this resistance." | 3.83 | An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. ( Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B, 2016) |
| " However, their effects on sorafenib resistance in hepatocellular carcinoma (HCC) are not completely understood." | 3.83 | Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. ( Ding, Y; Jiang, C; Luo, D; Qu, Z; Wu, J, 2016) |
| "Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC)." | 3.83 | Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients. ( Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma]. ( Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E, 2016) |
| "This study aimed to identify the health-related quality of life (HRQOL) domains associated with prognosis by assessing longitudinal alterations in HRQOL in patients with advanced hepatocellular carcinoma receiving sorafenib." | 3.83 | Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. ( Arase, Y; Hirose, S; Kagawa, T; Mine, T; Okabe, H; Shiraishi, K; Shomura, M; Takahira, S; Tsuruya, K, 2016) |
| " There is a lack of evidence about the prognostic value of serum LDH level in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment from hepatitis B virus endemic areas." | 3.83 | Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. ( Bi, XY; Cai, JQ; Han, Y; Huang, Z; Li, H; Li, MX; Li, ZY; Yao, XS; Zhang, YF; Zhao, DB; Zhao, H; Zhao, JJ; Zhou, JG, 2016) |
| "To provide support for combined usage of phosphoinositide 3-kinase (PI3K) inhibitors or mitogen-activated protein kinase pathway inhibitors together with sorafenib in treatment of sorafenib-resistant hepatocellular carcinoma." | 3.83 | Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor. ( Wu, CH; Wu, X; Zhang, HW, 2016) |
| " This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking." | 3.83 | Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. ( Kerbel, RS; Kuczynski, EA, 2016) |
| "Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial." | 3.83 | Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. ( Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O, 2016) |
| "The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012." | 3.81 | Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. ( Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K, 2015) |
| "Sorafenib and transarterial (90) Y-radioembolization (TARE) are possible treatments for Barcelona Clinic Liver Cancer (BCLC) intermediate-advanced stage hepatocellular carcinoma (HCC)." | 3.81 | Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. ( Bernardi, M; Bolondi, L; Cappelli, A; Cucchetti, A; Erroi, V; Fiumana, S; Golfieri, R; Gramenzi, A; Granito, A; Marinelli, S; Mosconi, C; Pettinato, C; Trevisani, F, 2015) |
| "There have been no established predictive factors of responders to sorafenib in patients with unresectable hepatocellular carcinoma (HCC)." | 3.81 | Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. ( Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y, 2015) |
| "Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC)." | 3.81 | Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. ( Döring, C; Filmann, N; Hansmann, ML; Hartmann, S; Herrmann, E; Mertens, A; Peveling-Oberhag, J; Piiper, A; Trojan, J; Welker, MW; Zeuzem, S, 2015) |
| "The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 3.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
| "Sorafenib is the standard of care in advanced hepatocellular carcinoma (HCC), however no criteria have been established to select patients likely to benefit from this therapy." | 3.81 | MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. ( Augello, C; Barberis, M; Bosari, S; Carnaghi, C; Di Tommaso, L; Fagiuoli, S; Faversani, A; Labianca, R; Maggioni, M; Pressiani, T; Rimassa, L; Roncalli, M; Rota Caremoli, E; Santoro, A; Spagnuolo, G; Vaira, V, 2015) |
| "The aim of this study was to assess the early response to sorafenib using ultrasound molecular imaging in a murine model of hepatocellular carcinoma (HCC)." | 3.81 | Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. ( Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L, 2015) |
| "Existing therapies such as irradiation or sorafenib have limited success in the treatment of hepatocellular carcinoma (HCC) due to tumor recurrence and metastasis." | 3.81 | Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. ( Jeong, KY; Lee, EJ; Seong, J; Yang, SH, 2015) |
| "Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.81 | Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. ( Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y, 2015) |
| "Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but it also induces the activation of Akt, which contributes to the mechanisms for the resistance to sorafenib." | 3.81 | Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. ( He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D, 2015) |
| "Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the most frequent form of primary liver tumour." | 3.81 | The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. ( Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z, 2015) |
| "Prothymosin alpha (PTMA) is overexpressed in various human tumors, including hepatocellular carcinoma (HCC)." | 3.81 | Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis. ( Chao, CC; Lin, YT; Lu, HP, 2015) |
| "Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
| "We aimed to evaluate the efficacy and tolerability of hepatic arterial infusion chemotherapy (HAIC) using cisplatin as an alternative to sorafenib for the treatment of hepatocellular carcinoma (HCC) patients who had not responded to transarterial chemoembolization (TACE)." | 3.81 | Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. ( Fukuda, H; Hidaka, H; Ishii, T; Kobayashi, S; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Nakazawa, T; Nozaki, A; Numata, K; Ohkawa, S; Okuse, C; Sakamaki, K; Shibuya, A; Suzuki, M; Tanaka, K, 2015) |
| "The aim of this study was to identify the prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who are refractory or intolerant to sorafenib and to exclude unsuitable candidates from subsequent therapy." | 3.81 | Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib. ( Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H, 2015) |
| "Sorafenib is recommended as the treatment of choice for hepatocellular carcinoma (HCC) with extrahepatic spread (EHS)." | 3.81 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival benefits." | 3.81 | CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. ( Bardeesy, N; Chen, Y; Duda, DG; Fan, C; Hato, T; Huang, P; Huang, Y; Jain, RK; Kitahara, S; Ng, MR; Ochiai, H; Ramjiawan, RR; Reddy, TP; Reiberger, T; Unan, EC; Zhu, AX, 2015) |
| "The study aimed to evaluate the tissue expression of molecules involved in intracellular signalling pathways as predictors of response to sorafenib in advanced hepatocellular carcinoma (HCC)." | 3.81 | Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. ( Ardizzoni, A; Campanini, N; Dal Bello, B; Fanello, S; Maria, SE; Missale, G; Negri, FV; Poggi, G; Porta, C; Rossi, S; Salvagni, S; Tinelli, C, 2015) |
| "Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.81 | Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. ( Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S, 2015) |
| "To compare efficacy of transarterial chemoembolization with and without radiation therapy (RT) versus sorafenib for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.81 | Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. ( Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM, 2015) |
| "To evaluate the role of antiviral therapy with nucleoside analogs (NAs) in sorafenib-treated patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)." | 3.81 | Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. ( Chen, M; Gao, H; Huang, J; Li, S; Wang, H; Xu, L; Zhang, Y; Zhou, Z, 2015) |
| "Sorafenib is the only recommended treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)." | 3.81 | Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. ( Hsia, CY; Hsu, CY; Huang, YH; Huo, TI; Lee, RC; Lee, YH; Lin, HC; Liu, PH; Su, CW, 2015) |
| "Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects." | 3.81 | Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. ( Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S, 2015) |
| "Cyproheptadine may significantly improve survival outcomes of sorafenib-treated advanced hepatocellular carcinoma patients." | 3.81 | Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. ( Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL, 2015) |
| "Hepatocellular carcinoma (HCC) larger than ten cm belonging to Barcelona Clinic Liver Cancer (BCLC) stage B and C may benefit from hepatic resection (HR), compared to presently recommended management by transarterial chemoembolization and sorafenib, respectively." | 3.81 | Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model. ( Aguilar, G; Chan, YC; Chen, CL; Kabiling, CS; Pillai, VG; Wang, CC, 2015) |
| " In this study, six long chain fatty acid esters of quercetin-3-O-glucoside (Q3G) acylated enzymatically and were used for determining their antiproliferative action in hepatocellular carcinoma cells (HepG2) in comparison to precursor compounds and two chemotherapy drugs (Sorafenib and Cisplatin)." | 3.81 | Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells. ( Rupasinghe, HV; Sudan, S, 2015) |
| " Sorafenib is the only drug to prolong overall survival of the patients with hepatocellular carcinoma (HCC), however, the outcome is still not satisfactory." | 3.81 | Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. ( Ishijima, N; Kanki, K; Shimizu, H; Shiota, G, 2015) |
| "This retrospective study was carried out to compare the outcomes between elderly (≥70 years of age) and nonelderly patients (<70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE)." | 3.81 | Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. ( Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015) |
| "We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment." | 3.81 | Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. ( Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G, 2015) |
| "GEMOX combined with sorafenib as first-line therapy followed by sorafenib as maintenance therapy was effective with manageable toxicity for patients with advanced hepatocellular carcinoma." | 3.81 | First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. ( Li, K; Liu, Y; Ma, N; Qiao, L; Wang, F; Wang, J; Xu, S; Yue, H, 2015) |
| "Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.81 | Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. ( Lee, HW; Park, JG; Park, SY, 2015) |
| "Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC)." | 3.81 | Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC, 2015) |
| "Sorafenib is the standard of care in advanced hepatocellular carcinoma." | 3.81 | Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. ( Addario, L; Caporaso, N; Cordone, G; de Stefano, G; Di Costanzo, GG; Farella, N; Imparato, M; Lampasi, F; Lanza, AG; Tortora, R, 2015) |
| "Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC), although it is known to cause a variety of dermatologic adverse events." | 3.81 | Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma. ( Kawai, K; Minemura, M; Nakajima, T; Sugiyama, T; Tajiri, K, 2015) |
| "Sorafenib, an oral inhibitor of multiple tyrosine kinase receptors, has been widely used as a standard medical treatment for advanced hepatocellular carcinoma (HCC)." | 3.81 | Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment. ( Azuma, K; Esaki, M; Kitazono, T; Matsumoto, T; Nakamura, S; Ooho, A; Yanai, S, 2015) |
| " This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells." | 3.81 | Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. ( Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY, 2015) |
| "Tumor lysis syndrome is rare in hepatocellular carcinoma (HCC), but it has been reported more frequently recently in response to treatments such as transcatheter arterial chemoembolization (TACE), radiofrequency thermal ablation (RFTA), and sorafenib." | 3.81 | Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient. ( Choi, HS; Hahm, JS; Jun, DW; Kim, JO; Lee, HL; Lee, KN; Lee, OY; Tae, HJ; Yoon, BC, 2015) |
| "In the period 2005-2011, 2402 patients were diagnosed with hepatocellular carcinoma: 12% received resection and 9% sorafenib." | 3.81 | Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands. ( de Man, RA; Ijzermans, JN; Klümpen, HJ; Schrier, JG; van der Geest, LG; van Erpecum, KJ; van Meer, S, 2015) |
| "Sorafenib may improve progression-free survival (PFS) and overall survival (OS) of advanced hepatocellular carcinoma (HCC)." | 3.81 | Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. ( Chao, Y; Chen, YT; Huang, YH; Huo, TI; Lee, FY; Lee, IC; Li, CP; Lin, HC; Su, CW, 2015) |
| "Retrospective analysis of consecutive hepatocellular carcinoma patients receiving metronomic capecitabine between January 2012 and November 2014." | 3.81 | Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. ( Benevento, F; Bolondi, L; Granito, A; Marinelli, S; Piscaglia, F; Renzulli, M; Terzi, E; Venerandi, L, 2015) |
| "Sorafenib increases survival of patients with advanced hepatocellular carcinoma (HCC) by inhibiting RAF kinase and receptor tyrosine kinase activity, but involvement of sorafenib in fibrosis and epithelial-mesenchymal transition (EMT) remains unclear." | 3.81 | Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. ( Ha, TY; Hong, HN; Hwang, S; Kim, N; Moon, KM; Ryoo, BY; Song, GW; Tak, E; Won, YJ, 2015) |
| " Anti-angiogenic effects of sorafenib lead to impairment of vitamin K uptake and induction of des-γ-carboxyprothrombin release by hepatocellular carcinoma (HCC) cells." | 3.81 | Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis. ( Choi, YI; Ha, TY; Hong, HN; Hwang, S; Kim, N; Ryoo, BY; Song, GW; Tak, E; Won, YJ; Yoon, SY, 2015) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | 3.81 | Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC)." | 3.81 | Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. ( Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M, 2015) |
| "Sorafenib, an oral multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. ( Dou, H; Feng, K; Jiang, X; Li, Z; Wang, T; Zhang, Y; Zhou, F, 2015) |
| "Sorafenib is one of the preferred drugs for the treatment of advanced primary hepatocellular carcinoma (HCC)." | 3.81 | RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis. ( Chen, Y; Ding, J; Ding, R; Dou, K; Gao, Y; Guo, X; Liu, D; Lv, X; Ruan, B; Zhou, T, 2015) |
| "Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC)." | 3.81 | Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. ( Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO, 2015) |
| "Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib." | 3.81 | Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. ( Chen, E; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S, 2015) |
| "Sorafenib has been shown to significantly improve the overall survival of patients with advanced hepatocellular carcinoma (HCC)." | 3.81 | Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. ( Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J, 2015) |
| "The aim of this study was to determine whether skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma (HCC) that is being treated with sorafenib." | 3.81 | Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. ( Hanai, T; Ideta, T; Imai, K; Kochi, T; Miyazaki, T; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K, 2015) |
| " We investigated whether the serum TGF-β1 level was related to the outcomes of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC)." | 3.81 | High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. ( Chan, SY; Cheng, AL; Hsu, CH; Huang, CY; Lin, TH; Shao, YY, 2015) |
| "Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study." | 3.81 | [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]. ( Amoroso, D; Angelico, M; Attili, A; Barni, S; Benedetti, A; Buonadonna, A; Burlone, ME; Calvani, N; Cascinu, S; Cengarle, R; Cillo, U; Crocè, LS; Cuttone, F; D'Angelo, S; Di Costanzo, F; Erminero, C; Fava, G; Gasbarrini, A; Germano, D; Giannitrapani, L; Giovanis, P; Lencioni, R; Lorusso, V; Magini, G; Marenco, S; Marignani, M; Massa, E; Montesarchio, V; Noto, A; Palmieri, V; Picardi, A; Poggi, G; Proserpio, I; Saitta, C; Sansonno, D; Tumulo, S; Villa, E; Zolfino, T, 2015) |
| "Sorafenib (Nexabar, Bayer, Berlin, Germany), one of multikinase inhibitors, can infrequently downstage advanced hepatocellular carcinoma (HCC)." | 3.81 | Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M, 2015) |
| "While sorafenib (SFN) is the established worldwide standard therapeutic agent for advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) is also considered a favorable treatment for some advanced HCCs." | 3.81 | Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. ( Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y, 2015) |
| "This study aimed to identify the key pathways and to explore the mechanism of sorafenib in inhibiting hepatocellular carcinoma (HCC)." | 3.81 | Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array. ( Li, S; Liu, R; Liu, Y; Shen, H; Wang, P; Yin, L, 2015) |
| "The multi-kinase inhibitor sorafenib is now used as standard therapy for advanced hepatocellular carcinoma (HCC)." | 3.81 | Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. ( Izumi, N; Joko, K; Nishijima, N; Nishio, K; Orito, E; Osaki, Y; Sakai, K; Takeda, H; Uchida, Y, 2015) |
| "Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC)." | 3.81 | Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy. ( Guo, WH; Lu, J; Wang, XZ; Zhang, JX; Zheng, JF, 2015) |
| "To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed." | 3.81 | Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. ( Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K, 2015) |
| "Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib." | 3.81 | Long-term therapy with sorafenib is associated with pancreatic atrophy. ( Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 3.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
| "Patients with advanced hepatocellular carcinoma treated with sorafenib or brivanib in 2008-2011 were included in this retrospective study." | 3.81 | Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. ( Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L, 2015) |
| "Sorafenib, a multikinase inhibitor, has been used as an anti-angiogenic agent against highly vascular hepatocellular carcinoma (HCC) - yet associated with only moderate therapeutic effect and the high incidence of HCC recurrence." | 3.81 | CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. ( Chang, CC; Chen, Y; Chiang, WH; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC, 2015) |
| " In this study, we investigated the ability of iRGD to improve the delivery of sorafenib and doxorubicin therapy in hepatocellular carcinoma (HCC) using established mouse models of the disease." | 3.81 | Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. ( Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S, 2015) |
| "We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib." | 3.81 | Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. ( Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S, 2015) |
| "Sorafenib (SOR) is a promising treatment for advanced hepatocellular carcinoma (HCC)." | 3.81 | Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis. ( Dong, X; Li, J; Li, T; Liu, F; Wang, F; Wang, X; Wang, Y; Wei, H; Xiu, P; Xu, Z; Zhong, J, 2015) |
| "Sorafenib is a specific adenosine triphosphate-competitive RAF inhibitor used as a first-line treatment of advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. ( Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS, 2015) |
| "Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits." | 3.81 | TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. ( Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J, 2015) |
| "Sorafenib resistance remains a major obstacle for the effective treatments of hepatocellular carcinoma (HCC)." | 3.81 | MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. ( Dong, D; Dong, X; He, C; Jiang, H; Jiang, X; Li, B; Sun, X; Xu, S; Zhai, B, 2015) |
| "We compared the benefits of sorafenib with that of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (ad-HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 3.81 | [Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization]. ( Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M, 2015) |
| "In our previous studies, we reported that CD133(+) cancer stem cells (CSCs) were chemoresistant in hepatocellular carcinoma (HCC) and that isocorydine treatment decreased the percentage of CD133(+) CSCs." | 3.81 | An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. ( Chen, L; Chen, T; Cui, Y; Fang, T; Ge, C; Jiang, G; Li, H; Li, J; Li, M; Liu, J; Tian, H; Xie, H; Yao, M; Zhang, L, 2015) |
| "Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance." | 3.81 | Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress. ( Fang, T; Hu, F; Jin, X; Pan, S; Sun, X; Xu, L; Yan, H; Zhai, B; Zhao, D, 2015) |
| "Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia." | 3.81 | The Eltrombopag antitumor effect on hepatocellular carcinoma. ( Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW, 2015) |
| "Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE)." | 3.81 | Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. ( Ito, D; Kawanishi, K; Kojima, K; Ohki, T; Sato, K; Seki, M; Tagawa, K; Toda, N; Yamada, T; Yamagami, M, 2015) |
| "Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling. ( Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH, 2015) |
| "Sorafenib, an oral multikinase inhibitor, is approved for advanced hepatocellular carcinoma (HCC) treatment." | 3.81 | Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. ( Aino, H; Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tajiri, N; Tanaka, M; Torimura, T, 2015) |
| "Sorafenib, an oral multi-kinase inhibitor, is the final therapy prior to palliative care for advanced hepatocellular carcinoma (HCC)." | 3.81 | Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma. ( Hisamichi, K; Jin, Y; Kataoka, Y; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H, 2015) |
| " Here we provide models of human hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in vitro and in vivo to evaluate the efficacy of NFC alone and in combination with sorafenib, a kinase inhibitor approved for treatment of HCC." | 3.81 | A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. ( Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF, 2015) |
| "Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III trials." | 3.81 | Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis. ( Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Inoue, T; Iwanishi, M; Kitai, S; Kitano, M; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2015) |
| "Sorafenib is a kinase inhibitor used as anticancer drug against various human tumors, including advanced hepatocellular carcinoma (HCC)." | 3.81 | Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells. ( Chao, CC; Lin, YT, 2015) |
| "Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)." | 3.81 | Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015) |
| "Sorafenib is considered to be the first-line therapy for advanced hepatocellular carcinoma (HCC)." | 3.81 | Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma. ( Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W, 2015) |
| "Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued." | 3.81 | Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma. ( BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H, 2015) |
| "SN-38 and sorafenib have synergistic anticancer activity on hepatocellular carcinoma cells in vitro with the augmentation of apoptosis." | 3.81 | [Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism]. ( Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z, 2015) |
| "Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC)." | 3.81 | [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H, 2015) |
| "We report a case of locally advanced huge hepatocellular carcinoma (HCC) invading the diaphragm and the right lung, which was controlled by sorafenib, thereby allowing curative resection." | 3.81 | [Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report]. ( Asaoka, T; Doki, Y; Eguchi, H; Kawamoto, K; Marubashi, S; Mori, M; Mukai, Y; Nagano, H; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2015) |
| "Sorafenib has been a standard therapy for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis." | 3.81 | [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report]. ( Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T, 2015) |
| "The efficacy of sorafenib for hepatocellular carcinoma (HCC) patients refractory to transcatheter arterial chemoembolization (TACE) has not yet been clarified." | 3.80 | Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. ( Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H, 2014) |
| "Sorafenib, a multitargeted antiangiogenic tyrosine kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. ( Chen, MH; Chen, ML; Cheng, AL; Lu, WC; Yan, BS; Yang, PC; Yu, SL, 2014) |
| "Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma (HCC)." | 3.80 | Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. ( Chen, KF; Chen, PJ; Chu, PY; Huang, HP; Huang, JW; Liu, CY; Shiau, CW; Tai, WT, 2014) |
| "Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 3.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
| " Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0." | 3.80 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014) |
| " We investigated the effect of EMT-related SRF, focusing on its promotion of chemoresistance against sorafenib in hepatocellular carcinoma (HCC)." | 3.80 | Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma. ( Bae, JS; Chung, MJ; Jang, KY; Kim, DG; Kim, KM; Moon, WS; Noh, SJ, 2014) |
| "Recently, the oral multikinase inhibitor sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC)." | 3.80 | Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib. ( Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2014) |
| "Sorafenib--a broad kinase inhibitor--is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC." | 3.80 | Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. ( Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX, 2014) |
| "Sorafenib is the first approved targeted therapeutic reagent for hepatocellular carcinoma." | 3.80 | SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model. ( Chen, KF; Chen, PJ; Chen, YL; Chu, PY; Hsu, CY; Hsu, YC; Huang, JW; Li, YS; Shiau, CW; Tai, WT, 2014) |
| "1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment." | 3.80 | Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. ( Agnello, F; Brancatelli, G; Cabibbo, G; Furlan, A; Genco, C; Giannitrapani, L; Lagalla, R; Marin, D; Midiri, M; Salvaggio, G, 2014) |
| " In the present study, we investigated in vitro whether ATRA modulates the response of human hepatocellular carcinoma (HCC) cells to sorafenib, the only proven oral drug for advanced HCC, and the underlying mechanisms." | 3.80 | Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition. ( He, XD; Liu, H; Qin, SK; Tao, L; Tong, XH; Wang, ZS; Wu, Q; Yang, Y; Zheng, RS, 2014) |
| "To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 3.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
| "This study evaluated the feasibility of CT perfusion parameters for the early efficacy prediction of sorafenib in the treatment of hepatocellular carcinoma (HCC) in rats." | 3.80 | Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. ( Liu, X; Shi, G; Wang, L; Wang, Q; Wu, R, 2014) |
| "The multi-kinase inhibitor Sorafenib increases the survival of patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo. ( Bangen, JM; Gassler, N; Liedtke, C; Sonntag, R; Trautwein, C, 2014) |
| "Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has demonstrated limited benefits with very low response rates." | 3.80 | Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. ( Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D, 2014) |
| "1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS)." | 3.80 | Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. ( Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N, 2014) |
| "Although sorafenib improves survival in patients with hepatocellular carcinoma (HCC), doses have to be reduced in quite a few patients because of adverse events." | 3.80 | Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma? ( Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O, 2014) |
| "These findings suggest that MPT0E028 in combination with sorafenib has significant anti-hepatocellular carcinoma activity in preclinical models, potentially suggesting a novel therapeutic strategy for patients with advanced hepatocellular carcinoma." | 3.80 | Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. ( Chen, CH; Chen, CS; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC, 2014) |
| "To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis." | 3.80 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. ( Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D, 2014) |
| "Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)." | 3.80 | Management of sorafenib-related adverse events: a clinician's perspective. ( Brose, MS; Frenette, CT; Keefe, SM; Stein, SM, 2014) |
| "Sorafenib, a tyrosine kinase inhibitor, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC)." | 3.80 | Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. ( Grande, C; Walko, CM, 2014) |
| "To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC)." | 3.80 | [Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma]. ( Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K, 2014) |
| "Sorafenib is a multi-kinase inhibitor that has been proven effective for the treatment of unresectable hepatocellular carcinoma (HCC)." | 3.80 | Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. ( Chen, CL; Chen, WY; Honda, K; Kawasaki, K; Masuda, M; Miyanaga, A; Nakamura, Y; Ono, M; Sakuma, T; Yamada, T, 2014) |
| "1), may underestimate activity and does not predict survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib." | 3.80 | Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Belghiti, J; Bouattour, M; Bruno, O; Castera, L; Dreyer, C; Faivre, S; Larroque, B; Raymond, E; Ronot, M; Vilgrain, V; Wassermann, J, 2014) |
| "To retrospectively compare radiofrequency ablation (RFA) combined with the multikinase inhibitor sorafenib (hereafter, sorafenib-RFA) and RFA alone in the treatment of hepatocellular carcinoma (HCC)." | 3.80 | Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. ( Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K, 2014) |
| "Sorafenib is the first drug currently approved to treat advanced hepatocellular carcinoma (HCC)." | 3.80 | RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. ( Fan, JG; Li, GM; Pan, Q; Sun, C; Wang, J; Wang, YG, 2014) |
| "There are no clinical data/markers to predict improved survival in patients with hepatocellular carcinoma treated with sorafenib." | 3.80 | Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. ( Ayuso, C; Bruix, J; Darnell, A; Forner, A; LLarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2014) |
| "Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but the acquired resistance to sorafenib results in limited benefits." | 3.80 | Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. ( Dong, X; Hu, F; Jiang, H; Jiang, X; Liu, B; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Xu, J; Zhai, B; Zhao, D, 2014) |
| "The multi-kinase inhibitor (MKI) sorafenib can be an effective palliative therapy for patients with hepatocellular carcinoma (HCC)." | 3.80 | Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. ( Chen, J; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Omary, RA; Shea, LD; Sheu, AY; Zhang, Z, 2014) |
| "Sorafenib, the drug used as first line treatment for hepatocellular carcinoma (HCC), is metabolized by cytochrome P450 (CYP) 3A4-mediated oxidation and uridine diphosphate glucuronosyl transferase (UGT) 1A9-mediated glucuronidation." | 3.80 | Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. ( Chen, W; Guo, E; Liu, Z; Lu, L; Peng, X; Wang, Y; Yan, T; Yang, X; Ye, L; Zhou, F, 2014) |
| "Early assessment of hepatocellular carcinoma (HCC) response during sorafenib (SO) treatment is challenging, since tumor necrosis, extension and radiological appearance can be inhomogeneous." | 3.80 | Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? ( Bargellini, I; Bartolozzi, C; Masi, G; Mismas, V; Sacco, R; Scionti, A; Vivaldi, C, 2014) |
| "Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing." | 3.80 | Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. ( Bodoky, G; Fassan, M; Gyöngyösi, B; Járay, B; Kiss, A; Schaff, Z; Székely, E; Végh, É, 2014) |
| "Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemo-embolization." | 3.80 | Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling. ( Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE, 2014) |
| "Sorafenib is a promising drug for advanced hepatocellular carcinoma (HCC); however, treatment may be discontinued for multiple reasons, such as progressive disease, adverse events, or the cost of treatment." | 3.80 | Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. ( Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ, 2014) |
| "The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. ( Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z, 2014) |
| "Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor regression in patients with chronic liver diseases." | 3.80 | Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. ( Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S, 2014) |
| "To clarify whether histone deacetylase inhibitors histone deacetylase inhibitors (HDACIs) can sensitize hepatocellular carcinoma (HCC) cells to sorafenib treatment." | 3.80 | Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. ( Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H, 2014) |
| " This case report discusses an atypical presentation of the hand-foot syndrome in one patient treated with sorafenib." | 3.80 | Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy. ( Bella, A; Guerra, JR; Lolo, D; Suelves, AM, 2014) |
| "Clinical trials suggest that combining transcatheter arterial chemoembolization with sorafenib in patients with advanced hepatocellular carcinoma shows a superior safety and tolerability profile." | 3.80 | Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. ( Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L, 2014) |
| "Sorafenib, an oral multi-kinase inhibitor, has been approved for treatment of advanced renal-cell and hepatocellular carcinoma (HCC)." | 3.80 | A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients. ( Akasaka, K; Hisamichi, K; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H; Tsuchiya, M; Yanagi, T, 2014) |
| "Transferrin-targeted core-shell nanomedicine encapsulating doxorubicin and sorafenib was studied as a drug delivery system against hepatocellular carcinoma, resulting in enhanced and synergistic therapeutic effects, paving the way towards potential future clinical applications of similar techniques." | 3.80 | Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. ( Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP, 2014) |
| "Sorafenib is the only drug approved by the Food and Drug Administration for metastatic hepatocellular carcinoma (HCC)." | 3.80 | Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. ( Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM, 2014) |
| " Presently, Sorafenib is a first-line drug, targeted for hepatocellular carcinoma (HCC) but effective in only a small portion of patients and can induce hypoxia." | 3.80 | Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells. ( Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF, 2014) |
| "Sorafenib is the standard systemic therapy for unresectable or recurrent hepatocellular carcinoma (HCC) but adds minimal increase in survival." | 3.80 | Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently. ( Ady, JW; Belin, LJ; Chen, CT; Chen, NG; Fong, Y; Heffner, J; Johnsen, C; Klein, E; Love, D; Mojica, K; Pugalenthi, A; Szalay, AA; Yu, YA, 2014) |
| "Erythema multiforme (EM) is a known side effect of sorafenib therapy in cancer patients; at onset, the causative medication should be permanently discontinued." | 3.80 | [Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma]. ( Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M, 2014) |
| "Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis." | 3.80 | The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. ( Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD, 2014) |
| " However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma (HCC) has not been demonstrated." | 3.80 | Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. ( Guo, QQ; Wang, QD; Yang, GR; Zhao, YL, 2014) |
| "The immune modulatory drug lenalidomide has shown promising anti-tumor activity in a clinical trial of patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. ( Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL, 2014) |
| "We present a 57-year-old Caucasian man with hepatocellular carcinoma (HCC) twice achieving complete remission with reduced dose sorafenib." | 3.80 | Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel. ( Tan-Shalaby, JL, 2014) |
| " Our aim was to determine whether single-nucleotide polymorphisms (SNPs) in KDR gene are associated with clinical outcomes after first-line sorafenib therapy in advanced hepatocellular carcinoma (HCC)." | 3.80 | The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. ( Fu, SR; He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhan, MX; Zhao, W; Zhao, Y; Zheng, YB, 2014) |
| "The kinase inhibitor sorafenib is the only approved drug which is effective against late-stage hepatocellular carcinoma (HCC)." | 3.80 | Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells. ( Braeuning, A; Kirschnick, M; Muche, S; Schwarz, M, 2014) |
| "Sorafenib is the approved systemic drug of choice for advanced hepatocellular carcinoma (HCC), but has demonstrated limited benefits because of drug resistance." | 3.80 | 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. ( Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H, 2014) |
| "We compared the benefits of sorafenib therapy with continued transarterial chemoembolization (TACE) in TACE-refractory patients with intermediate-stage hepatocellular carcinoma (HCC)." | 3.80 | Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M, 2014) |
| "The aims of the present study were to examine whether unresectable hepatocellular carcinoma (HCC) patients treated with initial dose of sorafenib of 400 mg/day (half-dose group) had comparable treatment efficacy, safety and survival merit as compared with those treated with initial dose of sorafenib of 800 mg/day (standard-dose group) in a multicenter large study." | 3.80 | Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. ( Endo, M; Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y, 2014) |
| "To determine significant indicators for the efficacy of sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M, 2014) |
| " In animals and humans it was found to be quickly metabolized into 4-methylthiobutyl isothiocyanate (MTBITC, erucin) which we recently identified as strong selective apoptosis inducer in hepatocellular carcinoma (HCC) cells." | 3.80 | The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC. ( Erlacher, M; Hertrampf, A; Herz, C; Kleinhans, C; Lamy, E; Mersch-Sundermann, V; Platz, S; Rohn, S; Schüler, J; Stetter, N; Wagner, M; Zimmermann, S, 2014) |
| "Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.80 | Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, HJ; Kim, JK; Kim, SU; Kweon, YO; Lee, HW; Lee, JI; Lee, KS; Lee, S; Park, JY; Park, SY; Tak, WY, 2014) |
| "Sorafenib is the first systemic therapy to demonstrate survival benefit in advanced hepatocellular carcinoma (HCC) in randomized controlled trials with rigorous patient selection." | 3.80 | Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Barroso-Sousa, R; Bento, Ada S; Blanco, BP; da Fonseca, LG; Hoff, PM; Pfiffer, TE; Sabbaga, J; Valente, GL, 2014) |
| "To evaluate the safety and efficacy of combined therapy with transarterial chemoembolization (TACE) and sorafenib for hepatocellular carcinoma (HCC) with portal venous tumour thrombus (PVTT)." | 3.80 | Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. ( Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014) |
| "Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC)." | 3.80 | Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014) |
| "The objective of this study was to evaluate the efficacy of combined therapy using Sorafenib and radiofrequency ablation (RFA) with curative intent for all detectable lesions in patients with Barcelona Clinic Liver Cancer (BCLC) Stage 0-B1 hepatocellular carcinoma (HCC)." | 3.80 | Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. ( Dou, K; Du, X; Feng, X; Guo, C; Jia, W; Liu, T; Ma, K; Qin, X; Wang, Z; Xu, J; Xu, R; Yang, S; Zhao, H, 2014) |
| "Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma." | 3.80 | Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014) |
| "Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC)." | 3.80 | Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. ( Kudo, M; Shimada, M; Tanaka, K, 2014) |
| "To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis." | 3.80 | [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis]. ( Chen, J; Chen, S; Wu, B; Xi, W; Yu, H, 2014) |
| "To investigate the therapeutic effect of the hepatic arterial administration of sorafenib in rabbit VX-2 hepatocellular carcinoma (HCC) model." | 3.80 | Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model. ( Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L, 2014) |
| "The aim of this study was to determine the effects of matrine (a natural alkaloid) on sorafenib-induced cytotoxicity against hepatocellular carcinoma (HCC) cells, and to explore the molecular mechanisms involved." | 3.80 | Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells. ( Jin, Y; Lin, L; Lin, Y; Tan, Y; Wang, D; Zhang, Y; Zheng, C, 2014) |
| "Sorafenib and conventional systemic cytotoxicity chemotherapy are currently being used in parallel for the patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma. ( Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J, 2014) |
| "This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib vs hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma." | 3.80 | Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study. ( Igarashi, Y; Ikehara, T; Ishii, K; Kikuchi, Y; Kogame, M; Makino, H; Matsui, T; Nagai, H; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M, 2014) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 3.80 | Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. ( Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L, 2014) |
| "Sorafenib has been proved to prolong survival of patients with advanced hepatocellular carcinoma (HCC), but with moderate efficacy." | 3.80 | The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Chen, L; Liang, S; Liu, J; Shao, H; Su, H; Xu, K, 2014) |
| "Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.79 | Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. ( Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD, 2013) |
| "The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months." | 3.79 | Label-retaining liver cancer cells are relatively resistant to sorafenib. ( Ambe, CM; Anderson, AJ; Avital, I; Burka, D; Chen, JQ; Goldsmith, PK; Hari, DM; Herrmann, MA; Koizumi, T; Langan, RC; Miller, TC; Mullinax, JE; Ray, S; Rudloff, U; Stojadinovic, A; Thorgeirsson, SS; Wiegand, GW; Xin, HW, 2013) |
| "Sorafenib and S-1 (one mixed formulation containing 5-FU prodrug and dihydropyrimidine dehydrogenase inhibitor) were two effective agents against hepatocellular carcinoma (HCC), but whether they had synergistic effects remained unclear." | 3.79 | Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. ( Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ, 2013) |
| "To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib." | 3.79 | Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. ( de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A, 2013) |
| "The multikinase inhibitor sorafenib is currently the treatment of reference for advanced hepatocellular carcinoma (HCC)." | 3.79 | Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC, 2013) |
| "Data on the efficacy and safety of sorafenib in combination with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) are lacking." | 3.79 | Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. ( Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y, 2013) |
| " Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug." | 3.79 | Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. ( Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J, 2013) |
| "Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function." | 3.79 | Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | 3.79 | Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| "Sorafenib is currently the only medical treatment with proven efficacy against hepatocellular carcinoma (HCC)." | 3.79 | Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments. ( Barbare, JC; Chatelain, D; Chauffert, B; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Henaut, L; Louandre, C; Maziere, JC; Regimbeau, JM; Sabbagh, C, 2013) |
| "Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma (HCC)." | 3.79 | Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. ( Bozzarelli, S; Carnaghi, C; Destro, A; Di Tommaso, L; Giordano, L; Ligorio, C; Personeni, N; Pressiani, T; Rimassa, L; Roncalli, M; Santoro, A; Tronconi, MC, 2013) |
| "This prospective pilot study investigated the feasibility of perfusion computed tomography parameters as surrogate markers of angiogenesis and early response following sorafenib administration in patients with advanced hepatocellular carcinoma." | 3.79 | Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. ( Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R, 2013) |
| "Currently, only one drug, sorafenib, is FDA approved for the treatment of advanced hepatocellular carcinoma (HCC), achieving modest objective response rates while still conferring an overall survival benefit." | 3.79 | The evolving landscape of therapeutic drug development for hepatocellular carcinoma. ( Chong, DQ; Choo, SP; Tan, IB; Toh, HC, 2013) |
| "Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.79 | Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC, 2013) |
| " Here, we report a pharmacokinetic interaction between sorafenib and the CYP3A4 inducer prednisolone in a patient with hepatocellular carcinoma (HCC)." | 3.79 | Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ( Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013) |
| "Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma, setting a new standard for first-line treatment." | 3.79 | Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway. ( Dai, XF; Ding, J; Ma, CM; Ren, JH; Wu, G; Zhang, RG, 2013) |
| "Liver resection can be considered in some hepatocellular carcinoma (HCC) patients who received sorafenib." | 3.79 | Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study. ( Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P, 2013) |
| "Antiangiogenic therapy, specially sorafenib, has become the standard of care for patients with advanced hepatocellular carcinoma (HCC), however, the improvement in survival time is not satisfactory." | 3.79 | Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. ( Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY, 2013) |
| "We previously demonstrated the pro-metastasis effect of sorafenib in hepatocellular carcinoma (HCC), which is mediated by down-regulation of tumor suppressor HTATIP2." | 3.79 | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. ( Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD, 2013) |
| "To explore the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis." | 3.79 | [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis]. ( Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS, 2013) |
| "Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC)." | 3.79 | Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma. ( Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J, 2013) |
| "Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response." | 3.79 | Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. ( Ayuso, C; Bruix, J; Darnell, A; Forner, A; Llarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2013) |
| "The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved." | 3.79 | Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. ( Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM, 2013) |
| " We have previously observed that tetrandrine exhibits potent antitumour effects in human hepatocellular carcinoma." | 3.79 | Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling. ( Gong, K; Li, J; Li, W; Liu, T; Mei, L; Wan, J; Yu, C, 2013) |
| "Sorafenib represents the standard of care targeted therapy for patients with advanced hepatocellular carcinoma (HCC)." | 3.79 | Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. ( Chen, D; Li, SQ; Liang, LJ; Peng, BG; Xiao, WK; Yin, XY; Zhao, P, 2013) |
| "The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital, were examined." | 3.79 | [Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma]. ( Hashida, T; Inokuma, T; Kanamori, K; Kitada, N; Konishi, A; Suginoshita, Y; Tanaka, S, 2013) |
| "Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC)." | 3.79 | In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. ( Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM, 2013) |
| "To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy." | 3.79 | Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. ( Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM, 2013) |
| "To evaluate the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma." | 3.79 | [The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma]. ( Fan, WZ; Huang, YH; Li, JP; Wang, Y; Yang, JY; Zhang, YQ, 2013) |
| "Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable." | 3.79 | Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013) |
| "Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.79 | Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. ( Moroni, M; Zanlorenzi, L, 2013) |
| "Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients." | 3.79 | Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. ( Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M, 2013) |
| "Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma." | 3.79 | Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. ( Cha, J; Han, KH; Kim, JW; Lee, IJ; Seong, J, 2013) |
| "A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 3.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
| "We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 3.79 | Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. ( Hagihara, H; Honda, M; Ikeda, F; Iwadou, S; Kaneko, S; Kariyama, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Obi, S; Onishi, H; Sato, S; Sato, T; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Yamamoto, K, 2013) |
| "The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC)." | 3.79 | Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. ( He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB, 2013) |
| "The purpose of this study was to identify the correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma (HCC) patients treated with sorafenib by analyzing medical records retrospectively." | 3.79 | Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib. ( Lee, YJ; Shin, SY, 2013) |
| "Although sorafenib is accepted as the standard of care in advanced hepatocellular carcinoma (HCC), its therapeutic benefit is marginal." | 3.79 | Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. ( Ahn, SH; Chang, S; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY; Park, Y, 2013) |
| " In this study, we evaluated the role of synthetic dsRNA as a TLR3 synergist and by combining with sorafenib in anti-hepatocellular carcinoma (HCC) in vitro and in vivo." | 3.79 | A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. ( Chen, L; Qin, J; Wang, GL; Wei, YZ; Xu, YY; Zhang, YX; Zhou, JM; Zhu, YY, 2013) |
| "The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species." | 3.79 | Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. ( Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013) |
| " The current study aimed to explore whether the BIM deletion polymorphism predicts the treatment efficacy of sorafenib for advanced hepatocellular carcinoma (HCC)." | 3.79 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma. ( Chang, YL; Cheng, AL; Hsu, CH; Huang, CY; Shao, YY, 2013) |
| "Sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation is a promising approach to the treatment of large, unresectable hepatocellular carcinomas." | 3.79 | Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. ( Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ, 2013) |
| "The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC)." | 3.79 | BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. ( Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY, 2013) |
| "We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy." | 3.79 | [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. ( Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H, 2013) |
| "Sorafenib currently sets the new standard for advanced hepatocellular carcinoma (HCC)." | 3.79 | Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. ( Bae, SH; Chung, YH; Kim, BI; Kim, JA; Koh, KC; Lee, D; Lee, HC; Lee, JH; Park, NH; Shim, JH; Shin, ES; Yoon, JH, 2013) |
| "Sorafenib is a multi-kinase inhibitor currently approved in Japan for unresectable and/or metastatic renal cell carcinoma and unresectable hepatocellular carcinoma." | 3.79 | Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. ( Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H, 2013) |
| "Sorafenib has been shown to improve survival rate of hepatocellular carcinoma (HCC) patients significantly." | 3.79 | Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal. ( Feng, M; Liu, X; Wang, Q; Wang, Z; Yu, T; Yuan, Y; Zhuang, H, 2013) |
| "Sorafenib is the standard treatment of patients with advanced hepatocellular carcinoma, regardless of the liver functional reserve." | 3.79 | Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. ( Díaz-Rubio, E; Ladero, JM; Manzano, A; Puente, J; Sastre, J; Zugazagoitia, J, 2013) |
| "The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0." | 3.79 | FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. ( Arao, T; Arii, S; Hagiwara, S; Haji, S; Hakamada, K; Hiasa, Y; Hidaka, H; Hirooka, M; Hisai, H; Iso, Y; Izumi, N; Kanazawa, A; Kimura, H; Kubota, K; Kudo, M; Kumada, T; Kuzuya, T; Matsumoto, K; Nagai, T; Nishio, K; Sakurai, T; Sato, S; Shimada, M; Toyoda, H; Toyoki, Y; Tsuchiya, K; Ueshima, K; Utsunomiya, T; Yasui, K, 2013) |
| "Previously, we have shown that sorafenib sensitizes hepatocellular carcinoma (HCC) to apoptosis induced by TNF-related apoptosis-inducing ligand (TNFSF10; TRAIL)." | 3.79 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. ( Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Chu, PY; Ichikawa, K; Liu, CY; Shiau, CW; Tai, WT, 2013) |
| "This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 3.79 | Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. ( Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W, 2013) |
| "Sorafenib is currently the only approved systemic therapy shown to have efficacy in the treatment of advanced hepatocellular carcinoma (HCC)." | 3.79 | The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. ( Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C, 2013) |
| "Sorafenib has been used to treat advanced hepatocellular carcinoma (HCC), but the underlying molecular mechanisms remain controversial and why some patients do not respond to this therapy is poorly understood." | 3.79 | OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. ( Cabrera, R; Cao, M; Liu, C; Nelson, DR; Ogunwobi, OO; Puszyk, WM; Tian, C; Wang, T; Zhao, X, 2013) |
| "Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but its use is hampered by the occurrence of drug resistance." | 3.79 | Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. ( Dekervel, J; Nevens, F; Van Cutsem, E; van Malenstein, H; van Pelt, J; Verslype, C; Windmolders, P, 2013) |
| "A multi-kinase inhibitor, sorafenib, was recently approved and is currently recommended for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.79 | Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma. ( Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M, 2013) |
| "Sorafenib, an oral multikinase inhibitor, was approved for the treatment of advanced hepatocellular carcinoma (HCC), but has not been adequately evaluated for safety and effectiveness in Japanese patients with advanced HCC." | 3.79 | Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. ( Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y, 2013) |
| "Sorafenib was shown in clinical trial to enhance survival in hepatocellular carcinoma (HCC) patients, but with minimal tumor shrinkage." | 3.79 | Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. ( Carr, BI; Cavallini, A; Correale, M; D'Alessandro, R; Di Carlo, A; Iacovazzi, PA; Lippolis, C; Messa, C; Refolo, MG, 2013) |
| "Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 3.79 | The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. ( Galle, PR; Gamstätter, T; Koch, S; Marquardt, JU; Nguyen-Tat, M; Niederle, IM; Schuchmann, M; Schulze-Bergkamen, H; Weinmann, A; Wörns, MA, 2013) |
| "Few data are available on the safety and efficacy of sorafenib in HIV-infected patients with unresectable hepatocellular carcinoma (HIV-u-HCC) and concomitant highly active antiretroviral therapy (HAART)." | 3.79 | Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. ( Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U, 2013) |
| "Sorafenib is the only approved agent recommended by the American Association Study of Liver Disease guidelines for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C." | 3.79 | Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. ( Chen, CL; Cheng, YF; Hsu, HC; Kuo, YH; Lu, SN; Wang, CC; Wang, JH, 2013) |
| "Hepatocellular carcinoma (HCC) is a difficult to treat cancer characterized by poor tumor immunity with only one approved systemic drug, sorafenib." | 3.79 | Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. ( Ararat, M; Atkinson, MA; Brusko, T; Cabrera, R; Chang, LJ; Liu, C; Nelson, DR; Wasserfall, C; Xu, Y, 2013) |
| "Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC)." | 3.79 | Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. ( Chang, CY; Cheng, AL; Hsu, C; Lin, CY; Lin, KL; Liu, SH; Ou, DL; Shen, YC, 2013) |
| "The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study." | 3.79 | Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. ( Bruno, R; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Enea, M; Gasbarrini, A; Grieco, A; Iavarone, M; Petta, S; Villa, E; Zavaglia, C, 2013) |
| "Hypoxia induced by sustained sorafenib treatment confers sorafenib resistance to HCC through HIF-1α and NF-κB activation." | 3.79 | Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. ( Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T, 2013) |
| "Early prediction of tumour response and major adverse events (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) is essential for maximizing the clinical benefits of sorafenib." | 3.79 | Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. ( Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K, 2013) |
| "Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients." | 3.79 | The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. ( Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S, 2013) |
| "We investigated the molecular mechanisms underlying the effect of sorafenib and SC-59, a novel sorafenib derivative, on hepatocellular carcinoma (HCC)." | 3.79 | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. ( Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Lin, CS; Liu, CY; Shiau, CW; Tai, WT, 2013) |
| "To determine the value of early alterations of the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for predicting the outcomes of patients with advanced hepatocellular carcinoma (HCC) who receive sorafenib." | 3.79 | Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M, 2013) |
| "Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic mainstay for patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. ( Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, S; Park, JY; Yoon, SH, 2012) |
| "Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. ( Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Fernández-Rodriguez, CM; Fernando, J; Lledó, JL; Sancho, P, 2012) |
| "The purpose of this study was to investigate the effect of bufalin on the anti-proliferative activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and Hep G-2 and to determine the relevant molecular mechanism." | 3.78 | Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. ( Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY, 2012) |
| "A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed according to Response Evaluation Criteria in Solid Tumors (RECIST)." | 3.78 | Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. ( Boucher, E; Edeline, J; Le Roux, C; Perrin, C; Pracht, M; Raoul, JL; Rolland, Y; Vauléon, E, 2012) |
| "Sorafenib is a multi-target oral anticancer drug used as first-line treatment for patients with advanced human hepatocellular carcinoma (HCC)." | 3.78 | Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2. ( Huang, C; Nan, K; Suo, A; Yao, Y; Zhang, L; Zhang, M; Zhang, W, 2012) |
| " NanoHHI potently suppressed in vivo tumor growth of HCC xenografts in both subcutaneous and orthotopic milieus, and in contrast to sorafenib, resulted in significant attenuation of systemic metastases in the orthotopic setting." | 3.78 | Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. ( Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF, 2012) |
| "Patients with liver fibrosis/cirrhosis and hepatocellular carcinoma were treated with sorafenib 400 mg b." | 3.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Sorafenib plasma concentrations were determined by liquid chromatography, every 2 weeks, in consecutive hepatocellular carcinoma patients treated with sorafenib." | 3.78 | Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. ( Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B, 2012) |
| "Retrospective evaluation of the safety and efficacy of sorafenib in patients with post-transplant hepatocellular carcinoma recurrence." | 3.78 | Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. ( Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2012) |
| "Sorafenib is a multi-kinase inhibitor applicable to hepatocellular carcinoma (HCC), but its limited therapeutic effects are a major problem to be solved." | 3.78 | Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. ( Aoyagi, Y; Fujimaki, S; Kubota, M; Matsuda, Y; Ohkoshi, S; Sanpei, A; Takamura, M; Wakai, T; Yamagiwa, S; Yano, M, 2012) |
| "No reliable prognostic predictor is known for patients undergoing sorafenib treatment for advanced hepatocellular carcinoma (HCC)." | 3.78 | Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. ( Kondo, M; Maeda, S; Morimoto, M; Morioka, Y; Moriya, S; Nozaki, A; Numata, K; Tanaka, K, 2012) |
| "Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy." | 3.78 | Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. ( Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC, 2012) |
| "Although sorafenib has shown survival benefits in patients with hepatocellular carcinoma (HCC), many patients require discontinuation or dose reduction due to adverse events (AEs)." | 3.78 | Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. ( Chang, HM; Kang, YK; Kim, JE; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Suh, DJ, 2012) |
| "Sorafenib is currently in clinical use as an oral multikinase inhibitor that blocks tumor growth and cell proliferation in advanced hepatocellular carcinoma (HCC)." | 3.78 | Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. ( Hidaka, H; Kaneko, T; Koizumi, W; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M, 2012) |
| " However, in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC), tumor shrinkage rarely accompanies increased survival, thereby questioning the prognostic value of imaging-based Response Evaluation Criteria in Solid Tumors (RECIST)." | 3.78 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. ( Bozzarelli, S; Carnaghi, C; Giordano, L; Pedicini, V; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC, 2012) |
| "Sorafenib is the standard of care for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.78 | Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. ( Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O, 2012) |
| "Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib remain eligible for further systemic therapy." | 3.78 | Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. ( Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P, 2012) |
| "To compare the efficacies of transarterial chemoembolization (TACE) and sorafenib in patients with advanced-stage hepatocellular carcinoma (HCC)." | 3.78 | Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. ( Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W, 2012) |
| "Sorafenib is currently approved for advanced hepatocellular carcinoma (HCC) and is presently being studied as an adjuvant treatment for HCC following resection." | 3.78 | The effects of sorafenib on liver regeneration in a model of partial hepatectomy. ( Espat, NJ; Falanga, V; Katz, SC; Kurniali, PC; O'Gara, K; Somasundar, P; Wang, LJ; Wang, X, 2012) |
| "Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma (HCC), but it is not known whether sorafenib is equally active in all HCC." | 3.78 | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. ( Barbare, JC; Chauffert, B; Diouf, M; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC; Trécherel, E, 2012) |
| "Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively." | 3.78 | The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T, 2012) |
| "Sorafenib has been shown to improve survival of patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. ( Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2012) |
| "Sorafenib is currently the only approved systemic treatment for hepatocellular carcinoma." | 3.78 | Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. ( De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2012) |
| " The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy." | 3.78 | Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2012) |
| "Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC)." | 3.78 | Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. ( Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M, 2012) |
| "Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON), a global, non-interventional, surveillance study, aims to evaluate the safety of sorafenib in all patients with unresectable hepatocellular carcinoma (uHCC) under real-life practice conditions, particularly Child-Pugh B patients, who were not well represented in clinical trials." | 3.78 | First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. ( Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2012) |
| "To investigate the link between the antitumor efficacy of sorafenib and its cutaneous side effects in advanced hepatocellular carcinoma (HCC)." | 3.78 | [Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma]. ( He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY, 2012) |
| "The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC)." | 3.78 | The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P, 2012) |
| "Some clinical studies confirmed the efficacy and safety of sorafenib in advanced hepatocellular carcinoma(HCC), for which the standard initial dose is 400 mg twice daily." | 3.78 | [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma]. ( Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K, 2012) |
| "Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.78 | Molecular mechanisms of sorafenib action in liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G, 2012) |
| "Prospective randomized trials have proven that sorafenib is a valid treatment option for patients with advanced-stage hepatocellular carcinoma (HCC)." | 3.78 | Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? ( Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E, 2012) |
| " In the sorafenib era, other antiangiogenic targeted drugs, such as monoclonal antibodies and a new generation of tyrosine kinase inhibitors, have been shown in phase II trials to be safe and effective in the treatment of advanced hepatocellular carcinoma." | 3.78 | Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). ( Amigo, G; Antón, A; Esquerdo, G; García-Otín, AL; Lanzuela, M; Martín-Duque, P; Pazo-Cid, RA; Pérez-Gracia, JL; Trufero, JM, 2012) |
| "The Toward Integrated Treatment of Advanced Hepatocellular Carcinoma with Nexavar (TiTAN) Symposium was held in August 2010 in Tokyo, Japan, during which the position of sorafenib (Nexavar®) in the treatment of HCC in Japan (for which it received approval in 2009) was discussed by a panel of eight expert hepatologists in a session chaired by Dr Kudo." | 3.78 | Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. ( Furuse, J; Ikeda, K; Ikeda, M; Izumi, N; Kokudo, N; Kudo, M; Matsui, O; Tateishi, R; Yamashita, T, 2012) |
| "To evaluate the efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma (HCC) relapse after liver transplantation." | 3.78 | [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. ( He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF, 2012) |
| "Sixty-six patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib were enrolled in this retrospective study." | 3.78 | Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. ( Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K, 2012) |
| "To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC)." | 3.78 | The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. ( Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C, 2012) |
| "Sorafenib (Nexavar(®)), a polytyrosine kinase inhibitor, stimulates apoptosis and is thus widely used for chemotherapy in hepatocellular carcinoma (HCC)." | 3.78 | Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study. ( Bitzer, M; Föller, M; Jilani, K; Lang, E; Lang, F; Lupescu, A; Pasham, V; Plate, A; Qadri, SM; Shaik, N; Zbidah, M; Zelenak, C, 2012) |
| "Case report - 30 months surviving patient with unresectable hepatocellular carcinoma treated with sorafenib." | 3.78 | [Hepatocellular carcinoma - long-term treatable disease]. ( Fínek, J, 2012) |
| "Antiangiogenic agents can sometimes promote tumor invasiveness and metastasis, but little is known about the effects of the antiangiogenic drug sorafenib on progression of hepatocellular carcinoma (HCC)." | 3.78 | Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. ( Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY, 2012) |
| "To investigate the clinic predictors of efficacy and adverse events of sorafenib in treating with advanced hepatocellular carcinoma (HCC) patients." | 3.78 | [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients]. ( Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P, 2012) |
| "There are scarce data on the use of sorafenib for the treatment of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT)." | 3.78 | Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012) |
| "Sorafenib patient assistant program in unresectable hepatocellular carcinoma ensured compliance treatment and significantly prolonged overall survival over the historical cohort receiving palliative treatment." | 3.78 | Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients. ( Boedi, P; Ganggaiswari, A; Gani, RA; Hasan, I; Lesmana, LA; Luwia, MS; Waspodo, A, 2012) |
| "Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 3.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
| "Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for investigating its use in combination with other agents." | 3.78 | Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. ( Fang, D; Gao, J; Liu, J; Rao, Z; Zhang, A; Zhang, B; Zhang, Y; Zhao, J; Zhao, Y, 2012) |
| "The molecular mechanisms and cellular targets of sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma (HCC), remain to be fully characterized." | 3.78 | Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. ( Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P, 2012) |
| "This study investigates the effectiveness and safety of sorafenib in a heterogeneous cohort of Child-Pugh A, B and C patients with advanced hepatocellular carcinoma in a clinical-practice scenario." | 3.78 | Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. ( Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B, 2012) |
| "To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC)." | 3.78 | Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. ( Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M, 2012) |
| "To evaluate the efficacy of sorafenib monotherapy, we enrolled 188 patients with hepatocellular carcinoma (HCC) who had undergone sorafenib monotherapy during a 3-year period from May 2009 to June 2012." | 3.78 | Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. ( Arizumi, T; Kudo, M; Ueshima, K, 2012) |
| " She was diagnosed with unresectable hepatocellular carcinoma (HCC) with PVTT, and sorafenib in combination with intermittent cisplatin(CDDP) hepatic arterial infusion chemotherapy(HAIC)was performed." | 3.78 | [A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T, 2012) |
| "There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 3.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
| "Sorafenib, a multikinase inhibitor targeting angiogenesis, cell survival, and proliferation in hepatocellular carcinoma (HCC) is a standard therapy for advanced stage disease." | 3.77 | Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. ( Aucejo, F; Kim, R; Menon, N, 2011) |
| "To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 3.77 | The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. ( Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A, 2011) |
| "Sorafenib, an orally active multi-kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC), is primarily metabolized both via cytochrome P450 3A4 isoform (CYP3A4) and UGT1A9." | 3.77 | Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. ( Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M, 2011) |
| "The aim of this study was to compare tumor changes in patients with hepatocellular carcinoma receiving sorafenib using evaluation criteria of the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) as opposed to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1." | 3.77 | Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. ( Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D, 2011) |
| "Sorafenib is recommended for therapy of advanced hepatocellular carcinoma and renal cell carcinoma." | 3.77 | High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. ( Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D, 2011) |
| " Using oxamic acid, an inhibitor of lactic dehydrogenase (LDH) which hinders aerobic glycolysis, we decreased ATP levels in PLC/PRF/5 cells (a line from a hepatocellular carcinoma)." | 3.77 | Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors. ( Di Stefano, G; Fiume, L; Manerba, M; Vettraino, M, 2011) |
| " Sorafenib, a VEGFR inhibitor with activity against RAF kinase, is active against hepatocellular carcinoma (HCC); however, the possible involvement of sorafenib in the EMT remains unclear." | 3.77 | Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. ( Aomatsu, K; Arao, T; Fujita, Y; Furuta, K; Kaneda, H; Kimura, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D, 2011) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient. ( Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ, 2011) |
| "Sorafenib is a multi-targeted tyrosine kinase inhibitor licensed for the treatment of hepatocellular carcinoma and renal cell carcinoma." | 3.77 | Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. ( Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ, 2011) |
| "Sorafenib has become the treatment standard for patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. ( Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L, 2011) |
| " Sorafenib, a novel multi-kinase inhibitor, is approved for the treatment of several human cancers, including advanced hepatocellular carcinoma (HCC)." | 3.77 | Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. ( Cabrera, R; Cao, M; Gabrilovich, D; Liu, C; Nelson, DR; Xu, Y; Youn, JI; Zhang, X, 2011) |
| "Sorafenib is a multikinase inhibitor currently used in the palliative treatment of advanced hepatocellular carcinoma." | 3.77 | Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma. ( Borentain, P; Durieux, O; Garcia, S; Gérolami, R; Gregoire, E; Hardwigsen, J; Le Treut, YP, 2011) |
| "Recently, we reported that sorafenib sensitizes hepatocellular carcinoma (HCC) cells to TRAIL through the inhibition of signal transducer and activator of transcription 3 (STAT3)." | 3.77 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. ( Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Huang, JW; Shiau, CW; Tai, WT, 2011) |
| "The purpose of this study was to describe the computed tomography (CT) findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma and to correlate the findings to the overall survival (OS)." | 3.77 | Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. ( Choi, JI; Kim, MJ; Lee, JS; Park, JW, 2011) |
| "We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection." | 3.77 | Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. ( Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M, 2011) |
| "Although sorafenib is recommended for patients with advanced hepatocellular carcinoma (HCC), a substantial portion of HCC patients in Asia are still treated with other treatments, mainly due to the prohibitive cost of sorafenib." | 3.77 | Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. ( Choi, JI; Kim, CM; Kim, HB; Kim, HK; Kim, HY; Kim, TH; Nam, BH; Park, JW, 2011) |
| "We reported a relevant activity of the combination between sorafenib and octreotide long-acting release (LAR) in advanced hepatocellular carcinoma (HCC) patients." | 3.77 | Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. ( Abbruzzese, A; Addeo, R; Caraglia, M; Giuberti, G; Marra, M; Montella, L; Murolo, M; Naviglio, S; Prete, SD; Sperlongano, P; Stiuso, P; Vincenzi, B, 2011) |
| "The multi-kinase-inhibitor Sorafenib has been shown to prolong survival of patients suffering from hepatocellular carcinoma (HCC)." | 3.77 | Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. ( Hashemolhosseini, S; Hellerbrand, C; Klinger, N; Neureiter, D; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Wege, H, 2011) |
| "Standard of practice involves using transarterial therapy for multifocal hepatocellular carcinoma (HCC) alone and sorafenib only for more advanced HCC, but the sorafenib and transarterial therapy combination may provide greater efficacy." | 3.77 | The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. ( Cabrera, R; Caridi, J; Clark, V; Firpi, RJ; George, TJ; Morelli, G; Nelson, DR; Pannu, DS; Soldevila-Pico, C; Suman, A, 2011) |
| "This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery." | 3.77 | Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. ( Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N, 2011) |
| "Sorafenib is a new drug, multikinase inhibitor, which has been recently approved for the treatment of metastatic renal cell carcinoma and hepatocellular carcinoma." | 3.77 | Severe sorafenib-induced hand-foot skin reaction. ( Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F, 2011) |
| "To investigate the in vitro inhibitory effects of DC(dendritic cell)-CIK (cytokine-induced killer cell) cocultured cells combined with sorafenib against hepatocellular carcinoma cell line BEL27402." | 3.77 | [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma]. ( He, JT; Zhang, D, 2011) |
| "Sorafenib, a potent multikinase inhibitor, has been recognized as the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. ( Dai, Z; Ding, ZB; Fan, J; Gu, CY; Hui, B; Ke, AW; Peng, YF; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Zhou, J, 2011) |
| "Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "Sorafenib is an FDA-approved agent for treatment of human hepatocellular carcinoma (HCC), but tumor shrinkage is minor." | 3.77 | c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. ( Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z, 2011) |
| "Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC)." | 3.77 | Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. ( Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ, 2011) |
| "This study compared post-transplant outcomes of patients with hepatocellular carcinoma (HCC) who took sorafenib prior to orthotopic liver transplantation (OLT) with those patients who were not treated with sorafenib." | 3.77 | Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE, 2011) |
| "A multikinase inhibitor of the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, sorafenib, is increasingly being used in the management of hepatocellular carcinoma, and its combination with conventional chemotherapeutics has stimulated particular interest." | 3.77 | Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. ( Broneshter, R; Iancu, TC; Manov, I; Pollak, Y, 2011) |
| "The purpose of this study was to evaluate the role of des-γ-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC)." | 3.77 | Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2011) |
| "Sorafenib is the new reference standard for patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. ( Buder, R; Graziadei, I; Grünberger, B; Hucke, F; Königsberg, R; Kornek, G; Maieron, A; Matejka, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Schöniger-Hekele, M; Sieghart, W; Stauber, R; Vogel, W; Weissmann, A, 2011) |
| "A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. ( Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C, 2011) |
| "Sorafenib increases median survival and time to radiological progression in patients with advanced hepatocellular carcinoma, but its benefit for Child-Pugh B patients remains uncertain." | 3.77 | Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. ( Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S, 2011) |
| "The multi-targeted tyrosine kinase inhibitor sorafenib was the first agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. ( Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA, 2011) |
| "A 60-year-old man with liver cirrhosis caused by hepatitis C, who was receiving warfarin anticoagulation following acute myocardial infarction, was diagnosed with advanced hepatocellular carcinoma and multiple lung metastases, and began treatment with sorafenib 200 mg daily." | 3.77 | [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma]. ( Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2011) |
| "Sorafenib, the first agent demonstrated to have efficacy to improve the survival of patients with advanced hepatocellular carcinoma (HCC), is an active multikinase inhibitor affecting angiogenesis and tumor proliferation." | 3.77 | Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. ( Hagihara, H; Ikeda, F; Kobayashi, S; Kuwaki, K; Miyahara, K; Miyake, Y; Nakamura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tomoda, T; Toshimori, J; Yamamoto, K, 2011) |
| "To investigate the inhibitory role and the underlying mechanisms of sorafenib on signal transducer and activator of transcription 3 (STAT3) activity in hepatocellular carcinoma (HCC)." | 3.77 | Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. ( Fan, J; Gao, Q; Gu, FM; Huang, XY; Jiang, JH; Li, QL; Pan, JF; Zhou, J, 2011) |
| "Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization." | 3.77 | Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011) |
| "The aim of this study was to investigate the relationships between early changes in the tumor markers α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. ( Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y, 2011) |
| "We report here the experience of the treatment with sorafenib for advanced hepatocellular carcinoma (HCC) in our department." | 3.77 | [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T, 2011) |
| "Sorafenib is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of advanced hepatocellular carcinoma." | 3.77 | [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib]. ( Egawa, C; Kato, T; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Okishiro, M; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S, 2011) |
| "The role of sorafenib is unclear in multimodal treatment for hepatocellular carcinoma (HCC)." | 3.77 | [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. ( Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H, 2011) |
| "Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. ( Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Kudo, M; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Sekikawa, A; Takeda, H, 2011) |
| "Sorafenib is a newly established cancer drug found to be an effective systemic treatment for advanced hepatocellular carcinoma (HCC)." | 3.76 | Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. ( An, J; Chang, YJ; Chiou, JF; Huang, MT; Liu, TZ; Tai, CJ; Wang, YH; Wei, PL; Wu, CH, 2010) |
| "Previously we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib." | 3.76 | Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. ( Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC, 2010) |
| "An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC)." | 3.76 | Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. ( Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A, 2010) |
| "Hepatocellular carcinoma (HCC) is increasing in numbers worldwide, and no effective systemic treatment existed for advanced HCC until SHARP (Sorafenib in HCC Assessment Randomized Protocol) study proved sorafenib (Nexavar((R)), Bayer Pharmaceuticals, Wayne, NJ, USA) prolonged survival versus placebo." | 3.76 | Platelet count less than SHARP: what does a case series reveal? ( Saif, MW, 2010) |
| "Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)." | 3.76 | Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010) |
| "Since 2007, sorafenib is the new standard for the first-line treatment of advanced hepatocellular carcinoma (HCC), with proved effectiveness on survival, but no complete response." | 3.76 | Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? ( Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T, 2010) |
| "Sorafenib is the standard treatment for patients with an advanced stage of hepatocellular carcinoma (HCC)." | 3.76 | Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. ( Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP, 2010) |
| "Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials." | 3.76 | Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010) |
| "Sorafenib has recently been shown to be effective for the treatment of advanced hepatocellular carcinoma in randomized controlled trials." | 3.76 | Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. ( Bechstein, WO; Engels, K; Gog, C; Herrmann, E; Lubomierski, N; Trojan, J; Vogl, TJ; Welker, MW; Zeuzem, S, 2010) |
| "Tumor growth, lung metastasis, and tumor angiogenesis were observed in HCCLM3-R and SMMC7721, two human hepatocellular carcinoma xenograft nude mouse models, when treated with sorafenib (30 mg/kg daily, n = 6 per group) or a vehicle as control." | 3.76 | Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. ( Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY, 2010) |
| " One such therapy, a tyrosine kinase inhibitor (sorafenib) is now used to treat patients with advanced hepatocellular carcinoma (HCC) and metastatic renal cell carcinoma." | 3.76 | Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study. ( Armstrong, C; Hull, D, 2010) |
| " The oncogenic kinase inhibitor sorafenib can significantly prolong median survival of patients with advanced hepatocellular carcinoma (HCC), although the response is disease-stabilizing and cytostatic rather than one of tumor regression." | 3.76 | The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. ( Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T, 2010) |
| "To evaluate (125)I seed brachytherapy combined with sorafenib in the treatment of patients with multiple lung metastases after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC)." | 3.76 | Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. ( Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W, 2010) |
| "To evaluate the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) after progression under sorafenib treatment." | 3.76 | Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. ( Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2010) |
| "to determine the efficacy and toxicities of sorafenib in the treatment of patients with multiple recurrences of hepatocellular carcinoma (HCC) after liver transplantation in a Chinese population." | 3.76 | Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. ( FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH, 2010) |
| "To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)." | 3.76 | [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L, 2010) |
| " Eight patients who underwent liver transplant for hepatocellular carcinoma between May 2007 and April 2009, and tolerated adjuvant therapy with sorafenib were matched with patients who did not receive sorafenib according to age, sex, year of transplant, tumor burden, and presence of vascular invasion." | 3.76 | Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010) |
| "Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 3.76 | Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. ( Bozorgzadeh, A; Grossman, S; Piperdi, B; Rawson, AP; Saidi, RF; Shah, SA, 2010) |
| "We analyzed the treatment outcome and effect of sorafenib in advanced hepatocellular carcinoma." | 3.76 | [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma]. ( Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M, 2010) |
| "We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC)." | 3.76 | [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y, 2010) |
| "The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC)." | 3.76 | Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. ( Carr, BI; Hyslop, T; Wang, M; Wang, Z; Wei, G, 2010) |
| "This study was conducted to assess the efficacy and safety of sorafenib monotherapy in clinical practice settings for Korean patients with hepatocellular carcinoma (HCC) related primarily to HBV infection." | 3.75 | Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. ( Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH, 2009) |
| "Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis." | 3.75 | Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. ( Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A, 2009) |
| "To investigate the reversion of multidrug resistance of drug-resistant hepatocellular carcinoma (HCC) cell line BEL-7402/FU by sorafenib and the possible mechanisms." | 3.75 | [Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib]. ( Cao, MR; Li, AM; Lü, CW; Luo, RC; Su, N; Wei, L; Yan, X; Zheng, DY, 2009) |
| "Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005." | 3.75 | Localized dyskeratotic plaque with milia associated with sorafenib. ( Burkemper, NM; Chappell, JA; Semchyshyn, N, 2009) |
| "The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses." | 3.75 | Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. ( Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009) |
| " For advanced hepatocellular carcinoma (HCC) a new era has recently begun by the approval of the multikinase inhibitor sorafenib." | 3.75 | Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. ( Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C, 2009) |
| " This study was to evaluate the schedule-dependent effect of sorafenib in combination with paclitaxel (TAX) on human hepatocellular carcinoma cell BEL-7402, and explore the underlying mechanism." | 3.75 | [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402]. ( Li, M; Li, N; Wu, T; Zhang, Y, 2009) |
| "The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy." | 3.75 | Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. ( Alsinet, C; Bruix, J; Cabellos, L; Chiang, DY; Deniz, K; Fiel, MI; Friedman, SL; Hoshida, Y; Lim, KH; Llovet, JM; Mazzaferro, V; Melgar-Lesmes, P; Minguez, B; Newell, P; Peix, J; Roayaie, S; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tovar, V; Villanueva, A; Yea, S, 2009) |
| "To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib." | 3.75 | UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. ( Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R, 2009) |
| "Sorafenib is the first agent that has demonstrated an improved overall survival benefit in advanced hepatocellular carcinoma (HCC), setting a new standard for first-line treatment." | 3.75 | Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. ( Shen, H; Wang, D; Wang, Y; Zhang, Z; Zhou, X, 2009) |
| "The approval of sorafenib and active development of many other molecularly targeted agents in hepatocellular carcinoma (HCC) have presented a challenge to understand the mechanism of action of sorafenib and identify predictive biomarkers to select patients more likely to benefit from sorafenib." | 3.75 | Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? ( Zhu, AX, 2009) |
| "Sorafenib has proved survival benefit for patients with advanced hepatocellular carcinoma (HCC)." | 3.75 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. ( Cheng, AL; Fan, HH; Hsu, C; Liang, JD; Liou, JY; Lu, YS; Ou, DL; Shen, YC; Wang, DS; Yu, SL, 2009) |
| "The objective of our study was to evaluate signal changes of advanced hepatocellular carcinoma in diffusion-weighted MRI in the early-response monitoring of oral therapy with the multikinase inhibitor sorafenib." | 3.75 | Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. ( Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF, 2009) |
| " He was diagnosed with hepatocellular carcinoma in June 2007 and began treatment with sorafenib 200 mg daily in September 2007." | 3.75 | Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. ( Montalvo, RO; Moretti, LV, 2009) |
| "To evaluate the safety and efficacy of the combination of transcatheter arterial chemoembolization (TACE) and sorafenib in treatment of hepatocellular carcinoma (HCC) with lung metastasis." | 3.75 | [Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis]. ( Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, ZJ, 2009) |
| "To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP) on the proliferation of hepatocellular carcinoma cells and explore the molecular mechanisms." | 3.74 | [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. ( Chen, FS; Cui, YZ; Luo, RC; Wu, J; Zhang, H, 2008) |
| "To investigate the inhibitory effect of sorafenib in combination with arsenic trioxide (As2O3) on hepatocellular carcinoma cells and explore the mechanisms of the synergetic antitumor effects of the two agents." | 3.74 | [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells]. ( Cui, YZ; Luo, RC; Wu, J; Zhang, H, 2008) |
| "Sorafenib OS benefit was consistently observed across all subgroups." | 2.84 | Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. ( Bruix, J; Cheng, AL; De Sanctis, Y; Llovet, J; Meinhardt, G; Nakajima, K, 2017) |
| "Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with." | 2.84 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| " A phase I study evaluated the combination with sorafenib in HCC." | 2.84 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). ( Abou-Alfa, GK; Agajanov, T; Beylergil, V; Boisserie, F; Carrasquilo, JA; Chen, YC; Cheng, AL; Di Laurenzio, L; Frenette, C; Gansukh, B; Hsu, CH; Larson, SM; Lee, R; Lin, ZZ; Lyashchenko, SK; Ma, J; Maki, Y; Morikawa, H; O'Donoghue, J; O'Neil, B; Ohishi, N; Ohtomo, T; Pandit-Taskar, N; Ruan, S; Schwartz, L; Shao, YY; Smith-Jones, PM; Tanaka, T; Wan, P; Yen, CJ, 2017) |
| "Primary liver cancer was the seventh most diagnosed cancer and the second leading cause of cancer death with about 906,000 cases and 830,000 deaths, respectively, in 2020." | 2.82 | Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery. ( Cheon, C; Kim, B; Kim, DB; Lee, DK; Ribeiro, RIMA, 2022) |
| "Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB-TACE alone." | 2.82 | Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. ( Bruix, J; Chau, GY; Del Arbol, LR; Guglielmi, A; Han, G; Kim, DY; Leberre, MA; Lencioni, R; Llovet, JM; Luca, A; Meinhardt, G; Nicholson, K; Niu, W; Paik, SW; Reig, M; Tak, WY; Yang, J, 2016) |
| "Sorafenib was dose escalated in 2 strata: (1) low effective irradiated liver volume (veff) < 30% and (2) high veff 30%to 60%." | 2.82 | Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. ( Brade, AM; Brierley, J; Cho, C; Dawson, LA; Dinniwell, R; Kim, J; Knox, J; Ng, S; Ringash, J; Wong, RR, 2016) |
| "Treatment with sorafenib, although associated with inhibition of tumour growth and angiogenesis in in vivo studies, leads to up-regulation of pERK." | 2.82 | A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). ( Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP, 2016) |
| "Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation." | 2.82 | Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. ( Cheow, PC; Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Goh, BK; Liew, WM; Lo, RH; Low, AS; Ng, DC; Soo, KC; Tan, SB; Tay, KH; Thng, CH; Wong, JS, 2016) |
| " 47) adverse events was similar in combination-treatment arm and control arm respectively (P > 0." | 2.80 | Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. ( Bulla, K; Kolligs, F; Malfertheiner, P; Peck-Radosavljevic, M; Reimer, P; Ricke, J; Sangro, B; Schott, E; Schütte, K; Verslype, C; Walecki, J, 2015) |
| "To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation." | 2.80 | Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. ( Bodoky, G; Bronowicki, JP; Croitoru, A; Daniele, B; Mathurin, P; Papandreou, C; Ratziu, V; Serejo, F; Stål, P; Turnes, J, 2015) |
| "Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15." | 2.79 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014) |
| "Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)." | 2.79 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014) |
| " Most frequent drug-related adverse events were diarrhea, rash, aspartate aminotransferase elevation, vomiting, and nausea." | 2.79 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. ( Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH, 2014) |
| "Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis." | 2.79 | Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. ( Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V, 2014) |
| "Sorafenib was administered and escalated twice daily on three cohort dose levels: i) 400 mg/day, ii) 600 mg/day and iii) 800 mg/day." | 2.78 | Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. ( Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M, 2013) |
| "TACE/sorafenib cycles were repeated every 6-8 weeks." | 2.78 | Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. ( Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH, 2013) |
| "Sorafenib has been shown to significantly improve progression-free survival in adult hepatocellular carcinoma (HCC) patients." | 2.77 | Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. ( Albert, MH; Corbacioglu, S; Fröhlich, B; Graf, N; Häberle, B; Kammer, B; Kontny, U; Leuschner, I; Scheel-Walter, HG; Scheurlen, W; Schmid, I; von Schweinitz, D; Werner, S; Wiesel, T, 2012) |
| " The most common severe adverse event probably related to sorafenib was diarrhea (12." | 2.77 | Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. ( Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012) |
| "Sorafenib was given 3 days after TACE and was administered for up to 24 weeks." | 2.77 | Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. ( An, S; Choi, JI; Kim, HB; Kim, HY; Koh, YH; Nam, BH; Park, JW; Woo, SM, 2012) |
| "Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity." | 2.75 | Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. ( Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B, 2010) |
| "Sorafenib is a multikinase inhibitor with effects against tumor proliferation and angiogenesis." | 2.75 | Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I ( Chen, Z; Gu, K; Jiang, GL; Li, WT; Liu, J; Liu, LM; Ren, ZG; Xu, ZY; Zhao, JD; Zhou, ZH, 2010) |
| "Sorafenib has interesting activity and acceptable tolerability in patients with advanced HCC, including those who failed prior therapies." | 2.75 | A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. ( Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E, 2010) |
| "placebo in hepatocellular carcinoma (HCC) demonstrated that sorafenib significantly prolonged overall survival (OS) compared to placebo." | 2.73 | Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. ( Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S, 2008) |
| "Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list." | 2.73 | Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN ( Büchler, MW; Glimm, H; Heining, C; Hoffmann, K; Jaeger, D; Radeleff, B; Richter, G; Schemmer, P; Schenkel, I; Schirrmacher, P; Schmidt, J; von Kalle, C; Zahlten-Hinguranage, A, 2008) |
| "Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and tyrosine kinases that are involved in tumor-cell signal transduction and tumor angiogenesis." | 2.73 | Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. ( Furuse, J; Ishii, H; Nakachi, K; Nakajima, K; Shimizu, S; Suzuki, E, 2008) |
| " Pharmacokinetic sampling was performed in all patients; preliminary tumor response was also assessed." | 2.71 | Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. ( Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D, 2005) |
| "Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis." | 2.55 | New knowledge of the mechanisms of sorafenib resistance in liver cancer. ( Chen, L; Wang, HY; Zheng, B; Zhu, YJ, 2017) |
| "Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis." | 2.55 | Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. ( Badrinath, N; Heo, J; Woo, HY; Yoo, SY, 2017) |
| "The search for systemic therapies for hepatocellular carcinoma has been characterized by difficulties and failures." | 2.55 | Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. ( Barbera, MA; Biasco, G; Brandi, G; Frega, G; Garajova, I; Lorenzo, S; Palloni, A; Pantaleo, MA; Tovoli, F, 2017) |
| "Sorafenib is a small molecular inhibitor of intracellular tyrosine and serine/threonine protein kinases (VEGFR, PDGFR, CRAF and BRAF), and is thought also to induce autophagy, a chief mechanism influencing tumor growth." | 2.53 | Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. ( Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M, 2016) |
| "Treatment of hepatocellular carcinoma (HCC) is guided by the tumour stage." | 2.53 | Treatment of hepatocellular carcinoma: beyond international guidelines. ( Colombo, M; Sangiovanni, A, 2016) |
| "The natural history of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal (approximately 2-4 mo), and PVTT is reportedly found in 10%-40% of HCC patients at diagnosis." | 2.53 | Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. ( Gwon, DI; Han, K; Kim, JH; Ko, GY; Sung, KB, 2016) |
| "Sorafenib is a pan-VEGF receptor inhibitor, and thus many studies have focused its antivascular effects." | 2.53 | Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. ( Duda, DG; Hato, T; Zhu, AX, 2016) |
| "Sorafenib was the first drug that has shown to increase survival in patients with advanced hepatocelullar carcinoma with an adequate safety profile." | 2.53 | Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. ( Bruix, J; Reig, M; Ribeiro de Souza, A, 2016) |
| "Hepatocellular carcinoma is becoming more common, and numerous treatment algorithms are available for this complex disease." | 2.52 | Managing localized unresectable hepatocellular carcinoma. ( Narang-Master, J; Rizzolo, D, 2015) |
| "The management of hepatocellular carcinoma (HCC) is decided according to evidence-based recommendations generated by international societies: according to these recommendations, the tumour stage, as determined by the Barcelona clinical liver cancer (BCLC) score, divides patients into five prognostic categories, each with a distinct treatment indication." | 2.52 | Treatment of hepatocellular carcinoma: beyond international guidelines. ( Colombo, M; Sangiovanni, A, 2015) |
| "Sorafenib has demonstrated definite efficacy in targeted therapy for HCC." | 2.52 | Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. ( Liu, J; Zhang, B; Zhang, X; Zhou, T, 2015) |
| "Management of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) is complex and requires an understanding of multiple therapeutic options." | 2.52 | Management of hepatocellular carcinoma with portal vein thrombosis. ( Kim, YH; Lee, EW; Quirk, M; Saab, S, 2015) |
| "Sorafenib also has distinct side effects that require close monitoring." | 2.52 | Systemic therapy of hepatocellular carcinoma: current and promising. ( Kalyan, A; Kulik, L; Nimeiri, H, 2015) |
| "Liver cancer has become the second cause of cancer-related death worldwide." | 2.52 | Liquid biopsy in liver cancer. ( Labgaa, I; Villanueva, A, 2015) |
| "Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging." | 2.52 | New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. ( Heo, J; Woo, HY, 2015) |
| "Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers." | 2.52 | Sorafenib: 10 years after the first pivotal trial. ( Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A, 2015) |
| "Most patients with hepatocellular carcinoma are still diagnosed at intermediate or advanced disease stages, where curative approaches are often not feasible." | 2.52 | New molecular therapies for hepatocellular carcinoma. ( Llovet, JM; Torrecilla, S, 2015) |
| "Hepatocellular carcinoma is a challenging malignancy of global importance." | 2.52 | Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. ( Cabibbo, G; Cammà, C; Maida, M; Petta, S, 2015) |
| "The onset of hepatocellular carcinoma (HCC) is related to the development of non-neoplastic liver disease, such as viral infections and cirrhosis." | 2.50 | Targeted therapies in hepatocellular carcinoma. ( Angarano, G; Bronte, E; Bronte, F; Bronte, G; Cicero, G; Cusenza, S; Di Marco, V; Fiorentino, E; Firenze, A; Fontana, T; Rolfo, C; Russo, A, 2014) |
| "Multiple modalities for treatment of hepatocellular carcinoma are available, depending on tumor size and number." | 2.50 | Advances in managing hepatocellular carcinoma. ( Imagawa, DK; Reataza, M, 2014) |
| "Hepatocellular carcinoma is a common malignancy with a poor prognosis." | 2.50 | Treating advanced hepatocellular carcinoma: How to get out of first gear. ( Abou-Alfa, GK; Harding, JJ, 2014) |
| "Sorafenib is a molecular targeting agent used for treating hypervascular tumors." | 2.50 | Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. ( Bhargava, P; Bhosale, P; Choi, JI; Imagawa, DK; Lall, C; Seery, TE; Tirkes, T, 2014) |
| "According to the Barcelona Clinic Liver Cancer (BCLC) algorithm, intermediate-stage HCC is defined as extensive multifocal disease without vascular invasion in patients with preserved liver function and absence of cancer-related symptoms; in this context, transarterial chemoembolization (TACE) is considered the standard treatment." | 2.50 | Treatment of intermediate-stage hepatocellular carcinoma. ( Bruix, J; Forner, A; Gilabert, M; Raoul, JL, 2014) |
| "Hepatocellular carcinoma is one of the most common cancers worldwide, and a leading cause of cancer-related death." | 2.50 | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. ( Chen, KF; Hung, MH; Shiau, CW; Tai, WT, 2014) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) has remained very poor." | 2.50 | New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms. ( Harada, M; Honma, Y, 2014) |
| "Sorafenib was demonstrated to significantly increase the survival of patients with advanced HCC in two prospective, randomized, placebo-controlled trials." | 2.49 | Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. ( Barletta, E; Cannella, L; Daniele, B; Germano, D; Tinessa, V, 2013) |
| "In western countries, hepatocellular carcinoma (HCC) is a major reason for orthotopic liver transplantation (OLT) with estimated recurrence rates between 15% and 20%." | 2.49 | Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. ( Bechstein, WO; Trojan, J; Welker, MW; Zeuzem, S, 2013) |
| "The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades." | 2.49 | Medical therapies for hepatocellular carcinoma: a critical view of the evidence. ( Hernandez-Gea, V; Llovet, JM; Villanueva, A, 2013) |
| "Hepatocellular cancer is a significant global health problem yet the prognosis for the majority of patients has not changed significantly over the past few decades." | 2.48 | Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? ( Asghar, U; Meyer, T, 2012) |
| "The clinical management of hepatocellular carcinoma (HCC) is often complicated by poor liver function." | 2.48 | Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. ( Lencioni, R, 2012) |
| "Sorafenib has demonstrated potent anti-tumor activity in in vitro studies, preclinical xenograft models of different tumor types and human clinical trials." | 2.48 | Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. ( Gadaleta, CD; Gadaleta-Caldarola, G; Goffredo, V; Mangia, A; Patruno, R; Ranieri, G; Rizzo, A; Sciorsci, RL, 2012) |
| "Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death." | 2.48 | Hepatocellular carcinoma. ( Bruix, J; Forner, A; Llovet, JM, 2012) |
| "Hepatic arterial infusion chemotherapy (HAIC) allows the long-term administration of cytotoxic drugs to the liver." | 2.48 | Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. ( Yamashita, T, 2012) |
| "Treatment with sorafenib is associated with survival gain in HCC but the responses are not durable." | 2.48 | Pathways and targets in hepatocellular carcinoma. ( Arkadopoulos, N; Dimitriadis, G; Psyrri, A; Smyrniotis, V; Vassilakopoulou, M, 2012) |
| "The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages." | 2.48 | Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. ( Bolondi, L; Burroughs, A; Dufour, JF; Galle, PR; Mazzaferro, V; Piscaglia, F; Raoul, JL; Sangro, B, 2012) |
| "Hepatocellular carcinoma (hepatocellular carcinoma, HCC) is the commonest primary liver cancer (80-90%) and represents the leading cause of cancer-related death, after lung and stomach cancer." | 2.47 | Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. ( Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M, 2011) |
| "The incidence of hepatocellular carcinoma is rising in many countries, including the United States." | 2.47 | What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. ( Aucejo, F; Byrne, MT; Kim, R; Tan, A, 2011) |
| "It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%." | 2.47 | Adjuvant therapy after curative treatment for hepatocellular carcinoma. ( Kudo, M, 2011) |
| "According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence." | 2.47 | Radiotherapeutic strategies in the management of hepatocellular carcinoma. ( Lee, IJ; Seong, J, 2011) |
| "Sorafenib has been recognized as the standard of care for patients who cannot benefit from treatments of higher priority and established efficacy, such as surgical resection, transplantation, ablation and transarterial chemoembolization." | 2.46 | Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. ( Bruix, J; Reig, M, 2010) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| "Molecular profiling of hepatocellular carcinoma (HCC), the most common cause of death among cirrhotic patients and a fast-growing malignancy in Western countries, is enabling the advancement of novel approaches to disease diagnosis and management." | 2.46 | Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. ( Forner, A; Llovet, JM; Minguez, B; Reig, M; Villanueva, A, 2010) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | 2.46 | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. ( Fehér, J; Lengyel, G, 2010) |
| "The metabolic syndrome is an increasing etiology of HCC and carcinogenesis in this context may not always require the development of formal underlying cirrhosis." | 2.46 | Hepatocellular carcinoma--what's new? ( Barbare, JC; Belghiti, J; Castaing, D; Chirica, M; Farges, O; Paradis, V; Soubrane, O; Vullierme, MP, 2010) |
| "Most of patients with hepatocellular carcinoma (HCC) cannot benefit from surgical therapies." | 2.46 | [Nonsurgical management of hepatocellular carcinoma]. ( Merle, P; Mornex, F, 2010) |
| "Primary hepatocellular cancer is the fifth most common solid tumor worldwide." | 2.46 | [Treatment of primary hepatocellular carcinoma]. ( Dank, M, 2010) |
| "The marked heterogeneity of hepatocellular carcinoma (HCC), particularly with regard to the etiology and severity of the underlying cirrhosis, makes clinical trial design in this disease very challenging." | 2.46 | Developing better treatments in hepatocellular carcinoma. ( Duffy, A; Greten, T, 2010) |
| "Sorafenib is a targeted agent with proven survival benefits as monotherapy in these patients, and ongoing studies will clarify its role in combination with other agents and in patients with impaired liver function." | 2.46 | Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? ( Chen, XP; Dagher, L; Lencioni, R; Venook, AP, 2010) |
| "On sorafenib, treatment-emergent hypertension occurred in 9% of patients (placebo, 4%) and was grade 3 in 4% (placebo, 1%); elevated serum lipase occurred in 40% (placebo, 37%); hypophosphatemia occurred in 35% (placebo, 11%)." | 2.45 | Sorafenib for the treatment of unresectable hepatocellular carcinoma. ( Booth, B; Chattopadhyay, S; Farrell, AT; Justice, R; Kane, RC; Madabushi, R; Pazdur, R; Sridhara, R, 2009) |
| "The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis." | 2.45 | Multimodal approaches to the treatment of hepatocellular carcinoma. ( Antonucci, M; Cabibbo, G; Craxì, A; Latteri, F, 2009) |
| "Treatment of hepatocellular carcinoma has dramatically changed in the last years." | 2.45 | New drugs for the treatment of hepatocellular carcinoma. ( Boucher, E; Bruix, J; Forner, A; Reig, M, 2009) |
| "Sorafenib is a small molecule that blocks cancer cell proliferation by targeting the intracellular signaling pathway at the level of Raf-1 and B-Raf serine-threonine kinases, and exerts an anti-angiogenic effect by targeting the vascular endothelial growth factor receptor-1, 2 and 3, and platelet-derived growth factor receptor-beta tyrosine kinases." | 2.45 | Molecular targeting for treatment of advanced hepatocellular carcinoma. ( Song, IH, 2009) |
| "Sorafenib has demonstrated for the first time to prolong survival in patients with advanced HCC, and it is the new reference standard for systemic treatment in these patients." | 2.44 | Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. ( Chaparro, M; González Moreno, L; Medina, J; Moreno-Otero, R; Trapero-Marugán, M, 2008) |
| "Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent with multiple targets that may also prove beneficial in other malignancies." | 2.44 | Sorafenib: delivering a targeted drug to the right targets. ( Flaherty, KT, 2007) |
| "The incidence of hepatocellular carcinoma is increasing in the United States and worldwide." | 2.44 | Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? ( Almhanna, K; Kalmadi, S; Kim, R; Pelley, R, 2007) |
| "Sorafenib is an orally active multikinase inhibitor with anti-tumour activity." | 2.44 | Sorafenib: in hepatocellular carcinoma. ( Keating, GM; Simpson, D, 2008) |
| "Sorafenib is a small molecule inhibitor of several kinases involved in tumour proliferation and tumour angiogenesis including Raf, VEGFR and platelet derived growth factor receptor." | 2.43 | Sorafenib. ( Rini, BI, 2006) |
| "Sorafenib is a tyrosine kinase inhibitor for the treatment of advanced-stage HCC; however, clinical trials of sorafenib failed to demonstrate long-term survival benefits due to drug resistance." | 1.91 | Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib. ( Bi, QC; Deng, ZQ; He, YQ; Liu, Y; Lv, YF; Tang, Q; Xie, CS, 2023) |
| "Targeted therapies for Primary liver cancer (HCC) is limited to the multi-kinase inhibitors, and not fully effective due to the resistance to these agents because of the heterogeneous molecular nature of HCC developed during chronic liver disease stages and cirrhosis." | 1.72 | Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells. ( Atalay, RC; Ersahin, T; Kahraman, DC; Koyas, A; Narci, K; Tuncbag, N, 2022) |
| " Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib." | 1.72 | Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. ( Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A, 2022) |
| " Other adverse events, dosing and outcome data were collected during a homogeneous protocolled follow-up." | 1.62 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. ( Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M, 2021) |
| "Sorafenib is an oral multi-targeted tyrosine kinase inhibitor used in cases of unresectable advanced HCC that significantly improves progression-free and overall survival." | 1.51 | [Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib]. ( Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2019) |
| "Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status." | 1.48 | Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. ( Chang, Y; Cho, EJ; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ, 2018) |
| "The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS." | 1.48 | Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA, 2018) |
| "However, the association of T2DM with liver cirrhosis and therapy response in HCC patients is not clear." | 1.48 | Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma. ( Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A, 2018) |
| "At diagnosis Barcelona Clinic Liver Cancer staging (BCLC) was 0 (8%), A (48%), B (20%), C (17%), and D (7%)." | 1.48 | Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. ( Dore, GJ; Gomaa, A; Waked, I; Waziry, R, 2018) |
| "The prognostic systems Okuda, The Cancer of the Liver Italian Program (CLIP), the Chinese University Prognostic Index (CUPI), Groupe d'Etude et de Traitément du Carcinome Hepatocellulaire (GRETCH), the modified TNM-based Japan Integrated Score (JIS) combined with alpha-fetoprotein and Child-Turcotte-Pugh (CTP), the TNM system, and the Barcelona Clinic Liver Cancer Classification (BCLC) were applied to these patients and compared through model fit measurements, likelihood scores, and the Akaike Information Criterion (AIC)." | 1.48 | Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. ( Almeida-Carvalho, SR; D'Ippolito, G; Loureiro-Matos, CA; Miziara-Gonzalez, A; Pereira-Lanzoni, V; Salzedas-Netto, AA; Souza-Silva, I; Szejnfeld, D; Tannus, RK, 2018) |
| " In conclusion, the results revealed a synergistic anti-hepatoma effect of bufalin combined with sorafenib via affecting the tumor vascular microenvironment by targeting mTOR/VEGF signaling." | 1.48 | Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. ( Chi, H; Meng, Z; Wang, H; Zhang, C, 2018) |
| "Sorafenib was started 3-5 days after TACE, and RFA was performed 1-2 weeks after TACE." | 1.48 | Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. ( Cai, M; Chen, J; Guo, Y; Huang, J; Huang, W; Lai, L; Zhou, J; Zhu, K, 2018) |
| "Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge." | 1.46 | Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. ( Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E, 2017) |
| "Apoptosis of human hepatoma cells treated with sorafenib was investigated, and the expression of Jun proto-oncogene (c-Jun) was measured." | 1.46 | Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. ( Haga, Y; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Takahashi, K; Wu, S; Yokosuka, O, 2017) |
| "Sorafenib is a potential rescue therapy in patients with TACE failure." | 1.46 | Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. ( Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY, 2017) |
| "H22-bearing liver cancer xenograft murine models were used to evaluate the biodistribution and therapeutic efficacy in vivo." | 1.46 | Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. ( Mu, S; Olerile, LD; Wang, T; Yu, X; Zhang, J; Zhang, N, 2017) |
| "Barcelona clinic liver cancer-stage C (BCLC-C) encompasses a broad spectrum of tumor burdens, liver function statuses, patient prognoses, and treatment strategies." | 1.46 | Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. ( Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, HJ; Kim, HS; Park, CH; Rew, JS; Shin, SS; Yoon, JH, 2017) |
| "Aggravated behaviors of hepatocellular carcinoma (HCC) will occur after inadequate thermal ablation." | 1.46 | Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. ( Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD, 2017) |
| " The nanocomplex enhanced bioavailability of hydrophobic drugs, efficient tumor cell targeting and exhibited pH-responsive function and sustained release profile." | 1.46 | Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. ( Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G, 2017) |
| "Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation." | 1.46 | Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. ( Arizumi, T; Hagiwara, S; Kamata, K; Kudo, M; Minaga, K; Minami, Y; Nishida, N; Sakurai, T; Takenaka, M; Watanabe, T; Yada, N, 2017) |
| "However, the hepatoma arterial embolisation prognostic (HAP) score showed greater discriminative abilities than the SAP score." | 1.46 | Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. ( Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH, 2017) |
| "The treatment approach for hepatocellular carcinoma (HCC) depends on the stage and extent of disease, the severity of the underlying liver disease, and the overall performance status of the patient." | 1.46 | The treatment path in hepatocellular carcinoma. ( El-Serag, HB; Johnson, MS; Zhu, AX, 2017) |
| "Their hematological malignancies were well-controlled at the time of liver resection." | 1.46 | Liver resection for hepatocellular carcinoma in patients with hematological malignancies. ( Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS, 2017) |
| "However, the role of KLF8 in liver cancer stem cells (LCSCs) is not known." | 1.46 | Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling. ( Cao, J; He, HG; Huang, JL; Liu, F; Lu, JH; Shen, YN; Shi, CF; Shi, Y; Wang, ZC; Wei, YP; Yang, GS; Yuan, JY; Zhu, N, 2017) |
| "Sorafenib was as safe as effective in DIAB and in nDIAB patients." | 1.46 | Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. ( Addario, L; Caporaso, N; Cordone, G; Di Costanzo, GG; Falco, L; Guarino, M; Morisco, F; Tortora, R, 2017) |
| "The Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumour burden and liver function." | 1.46 | Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. ( Baroni, GS; Bernardi, M; Biasini, E; Borzio, F; Cabibbo, G; Caturelli, E; Ciccarese, F; Di Marco, M; Farinati, F; Felder, M; Foschi, FG; Garuti, F; Gasbarrini, A; Giannini, EG; Gramenzi, A; Lenzi, B; Masotto, A; Morisco, F; Pecorelli, A; Piscaglia, F; Rapaccini, GL; Sacco, R; Trevisani, F; Virdone, R; Zoli, M, 2017) |
| "Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options." | 1.46 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. ( Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A, 2017) |
| "Sorafenib treatment is usually administered in cases of tumor progression or poor liver function status after TACE treatment in China." | 1.46 | Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. ( He, D; Liu, F; Meng, Z; Shao, G; Wang, J; Wang, Z; Yang, J; Yip, CS, 2017) |
| "Sorafenib was equally toxic to both cell lines, but only in HepG2 was activation of caspase 3/7 activity, as a sign of apoptosis, observed." | 1.46 | Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro. ( Brauner, J; Dudeck, O; Jürgens, J; Kalinski, T; Nass, N; Powerski, M; Ricke, J; Schulz, N; Seidensticker, M; Streit, S; Wybranski, C, 2017) |
| "Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes." | 1.46 | The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. ( Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C, 2017) |
| "Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC." | 1.46 | Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. ( He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y, 2017) |
| "Barcelona clinic liver cancer (BCLC) stage B hepatocellular carcinoma (HCC) is a heterogeneous disease group." | 1.46 | Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis . ( Chen, B; Chen, W; Dao, H; Huang, Y; Li, N; Liu, N; Yang, J, 2017) |
| "Treatment of advanced hepatocellular carcinoma (HCC) remains a challenge due to the high tumor heterogeneity." | 1.46 | Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function. ( Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V, 2017) |
| " Oral administration of NEN to mice significantly slowed growth of genetically induced liver tumors and patient-derived xenografts, whereas niclosamide did not, coinciding with the observed greater bioavailability of NEN compared with niclosamide." | 1.46 | Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. ( Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B, 2017) |
| "Nonalcoholic fatty liver disease (NAFLD) has emerged as an important cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC)." | 1.43 | Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. ( Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC, 2016) |
| "Effective therapies for hepatocellular carcinoma (HCC) are limited." | 1.43 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. ( Abou-Alfa, GK; Ang, C; Gamblin, TC; Gatalica, Z; He, R; Millis, SZ; Miura, JT; Reddy, SK; Xiu, J; Yee, NS, 2016) |
| "Advanced hepatocellular carcinoma (HCC) includes a wide spectrum of tumors and patients' prognosis after treatment is highly variable." | 1.43 | Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study. ( Adhoute, X; Bayle, O; Beaurain, P; Blanc, JF; Bourlière, M; Bronowicki, JP; Castellani, P; Conroy, G; Edeline, J; Monnet, O; Muller, C; Pénaranda, G; Perrier, H; Pol, B; Raoul, JL, 2016) |
| "Sorafenib is a potent drug for advanced HCC with multikinase inhibition activity." | 1.43 | Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. ( Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T, 2016) |
| "Sorafenib was confirmed to inhibit MAPK signaling in the tumor, as measured by reduced ribosomal protein S6 kinase phosphorylation." | 1.43 | Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. ( Adametz, D; Boldanova, T; Colombi, M; Dazert, E; Hall, MN; Heim, MH; Jenoe, P; Moes, S; Quagliata, L; Roth, V; Terracciano, L, 2016) |
| "Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed." | 1.43 | Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. ( Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK, 2016) |
| "Treatment with quercetin caused DNA damage in HepG2, Hep3B2." | 1.43 | New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. ( Abrantes, AM; Botelho, MF; Brito, AF; Casalta-Lopes, JE; Gonçalves, AC; Laranjo, M; Mamede, AC; Ribeiro, M; Sarmento-Ribeiro, AB; Tralhão, JG, 2016) |
| "Clinical hepatocellular carcinoma (HCC) tumor samples were assessed for PKM2 expression." | 1.43 | SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma. ( Boo, YP; Chen, KF; Chen, LJ; Chen, MH; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH, 2016) |
| "The optimal treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains controversial." | 1.43 | Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. ( Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ, 2016) |
| "Candida esophagitis was suspected." | 1.43 | Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. ( Chen, KH; Chou, YH; Hsieh, CH; Lu, YF; Weng, MT, 2016) |
| "Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC." | 1.43 | Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. ( Chen, D; Chen, R; He, W; Kang, R; Niu, X; Sun, X; Tang, D, 2016) |
| "The purpose of our study was to test the hypothesis that sorafenib-related dermatologic adverse events (AEs) as an early biomarker can predict the long-term outcomes following the combination therapy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S)." | 1.43 | Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients. ( Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y, 2016) |
| "Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial." | 1.43 | Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. ( Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY, 2016) |
| "ABSTACT Human hepatocellular carcinoma (HCC) is known to have a poor prognosis." | 1.43 | Iron depletion enhances the effect of sorafenib in hepatocarcinoma. ( Fujiwara, T; Kagawa, S; Katsube, R; Kimura, F; Matsukawa, A; Ninomiya, T; Noma, K; Nouso, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Urano, S; Yamamoto, K, 2016) |
| "Treatment of rhamnetin also reduced the expression of MDR related proteins P-GP (P-glycoprotein) and BCRP (breast cancer resistance protein)." | 1.43 | Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. ( Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP, 2016) |
| " The sorafenib group showed significantly more grade 3/4 adverse effects than the radioembolization group (P < 0." | 1.43 | Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. ( Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M, 2016) |
| "However, its role in hepatocellular carcinoma (HCC) and the underlying mechanisms remain unknown." | 1.43 | ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. ( Chen, Y; Ding, J; Fang, T; Guo, LN; Li, T; Liang, D; Lv, GS; Lv, HW; Tan, YX; Tang, L; Tang, SH; Wang, CZ; Wang, HY; Wu, FQ; Yang, W; Yu, LX, 2016) |
| "Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used." | 1.43 | Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. ( Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S, 2016) |
| "In the Barcelona Clinic Liver Cancer (BCLC) system, only sorafenib is suggested for HCC patients having performance status (PS) 1 or 2 even if they have treatable lesions." | 1.43 | Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases. ( Abdelmaksoud, AH; Attar, IE; Aziz, AO; Elbaz, TM; Nabeel, MM; Omran, D; Shousha, HI, 2016) |
| "Sorafenib-LNS were prepared by nanoprecipitation and consisted of spherical particles with a uniform size distribution (164." | 1.43 | In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer. ( Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N, 2016) |
| "To evaluated patterns and outcomes of hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation (LDLT)." | 1.43 | Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. ( Hong, TH; Kim, DG; Na, GH; You, YK, 2016) |
| "Using the human hepatoma cell lines HepG2 and Huh7, we analyzed anti-cancer activities of 6 purified havanensin type limonoids isolated from the traditional African medicinal plant Trichilia rubescens Oliv." | 1.43 | The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling. ( Lange, N; Loscher, C; Mkounga, P; Nkengfack, AE; Sass, G; Tiegs, G; Tontsa, AT; Wegscheid, C, 2016) |
| "Sorafenib/OA cotreatment induces DNA fragmentation and caspase-3/7 cleavage and the addition of the pan-caspase inhibitor zVAD." | 1.43 | Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells. ( Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J, 2016) |
| "However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive." | 1.43 | Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma. ( Chen, B; Chen, Y; Hu, B; Hua, L; Liu, J; Wu, M; Yan, D; Zhang, C; Zhang, X; Zhao, F; Zhou, H, 2016) |
| "Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are not effective." | 1.43 | Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. ( Chen, JC; Chen, YC; Chien, YC; Chuang, HY; Hsu, FT; Hwang, JJ, 2016) |
| "Patients with advanced hepatocellular carcinoma (HCC) showing portal vein tumor thrombosis (PVTT) have an extremely poor prognosis." | 1.43 | Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. ( Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M, 2016) |
| "The prognosis of advanced hepatocellular carcinoma (HCC) is dismal, underscoring the need for novel effective treatments." | 1.43 | Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells. ( Arihara, Y; Hayasaka, N; Kamihara, Y; Kato, J; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Okagawa, Y; Osuga, T; Takada, K; Usami, M, 2016) |
| "A 74-year-old man was diagnosed with hepatocellular carcinoma(HCC; S4/8)and underwent anterior segment resection of the liver in 2015." | 1.43 | [Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia]. ( Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Murakami, M; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshikawa, M, 2016) |
| "Sorafenib was administered orally once the local lesion was under control." | 1.43 | [A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment]. ( Akahori, T; Hokuto, D; Kanehiro, H; Kawaguchi, C; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiwada, S; Nomi, T; Obara, S; Sho, M; Yamada, T; Yamato, I; Yasuda, S; Yoshikawa, T, 2016) |
| "Management of late-stage hepatocellular carcinoma is difficult." | 1.42 | Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. ( Fan, W; Huang, Y; Ke, S; Li, J; Ran, H; Wang, W; Wang, Y; Yang, J; Zhang, F; Zhang, Y, 2015) |
| " (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0." | 1.42 | Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study. ( Bazzica, M; Di Gion, P; Fucile, C; Lantieri, F; Marenco, S; Marini, V; Martelli, A; Mattioli, F; Picciotto, A; Pieri, G; Robbiano, L; Savarino, V; Stura, P; Zuccoli, ML, 2015) |
| "Sorafenib (60 mg/kg) was administered orally to NOD." | 1.42 | Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. ( Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW, 2015) |
| "According to the Barcelona Clinic Liver Cancer staging system, 60." | 1.42 | [Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice]. ( Artaza Varasa, T; de la Cruz Pérez, G; Gómez Rodríguez, R; González de Frutos, C; Muñoz López, D; Romero Gutiérrez, M; Ruano Díaz, L; Sánchez Ruano, JJ, 2015) |
| "A total of 89 patients with hepatocellular carcinoma (HCC) were recruited in 3 groups: Group I, 30 HCC patients receiving sorafinib; Group II, 30 HCC patients with best supportive care; and Group III include 29 patients undergoing transcatheter arterial chemoembolization (TACE)." | 1.42 | Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma. ( Ali, LA; Elmashad, N; Elmashad, W; Farouk, M; Ibrahim, WS; Mayah, WW; Taha, A, 2015) |
| "Genistein (GNT) is a phytoestrogen abundant in soybean that exerts its genomic effects through Estrogen-Receptors and Pregnane-X-Receptor (PXR), which are involved in the regulation of the above-mentioned transporters." | 1.42 | Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. ( Arias, A; Catania, VA; Ceballos, MP; Ciriaci, N; Ghanem, CI; Luquita, MG; Mottino, AD; Rigalli, JP; Ruiz, ML; Villanueva, SS, 2015) |
| "PHY906 may potentiate the anti-hepatoma activity of Sorafenib by multiple mechanisms targeting on the inflammatory state of microenvironment of tumor tissue through two major ingredients (P and S) of PHY906." | 1.42 | PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. ( Bussom, S; Cheng, YC; Guan, F; Hu, R; Huang, X; Jiang, Z; Lam, W; Liu, SH; Wang, J; Yen, Y; Zhao, H, 2015) |
| "Frequency of sorafenib-related adverse events was almost similar between Child-Pugh score 5, 6, and 7 patients." | 1.42 | Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015) |
| " PR-104 monotherapy elicited significant reductions in growth of Hep3B and HepG2 xenografts, and the combination with sorafenib was significantly active in all 4 xenograft models." | 1.42 | Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. ( Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR, 2015) |
| "We investigated a hepatocellular carcinoma (HCC) cell line that not only has CSC hierarchy but also shows phenotypic changes (population changes) upon differentiation of CSC during culture and can be used for screening drugs targeting CSC." | 1.42 | Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. ( Abei, M; Danjoh, I; Hyodo, I; Nakamura, Y; Shirota, R; Yamada, T; Yamashita, T, 2015) |
| "Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties." | 1.42 | Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. ( Chae, HB; Kang, HY; Kang, YW; Kim, AN; Kim, HS; Kim, SB; Kim, SH; Ko, SY; Lee, BS; Lee, ES; Lee, HY; Lee, JD; Lee, SH; Lee, TH; Noh, R; Song, IH, 2015) |
| "Many patients with advanced hepatocellular carcinoma (HCC) develop lung metastasis and available treatments are limited." | 1.42 | Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs. ( Huang, A; Shi, Y, 2015) |
| "Sorafenib has been proved to improve overall survival in advanced HCC; however, drug resistance is common." | 1.42 | CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. ( Bao, J; Che, S; Hao, C; Li, Z; Liu, J; Qian, Z; Shang, H; Wang, H; Zhang, H; Zhang, X; Zhao, H, 2015) |
| "Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival." | 1.42 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. ( Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015) |
| "Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of hepatocellular and advanced renal carcinoma." | 1.42 | Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. ( Calucci, L; Cappello, V; Ciofani, G; de Julian Fernandez, C; Forte, C; Gemmi, M; Grillone, A; Innocenti, C; Mattoli, V; Mondini, A; Moscato, S; Riva, ER; Ronca, F; Sacco, R, 2015) |
| "Sorafenib is a first multi-kinase inhibitor and one of the most widely used small-molecule oral-targeted drugs." | 1.42 | 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases. ( Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK, 2015) |
| "The incidence of hepatocellular carcinoma (HCC), a common neoplasm, is rising and the prognosis is poor." | 1.42 | [Hepatocellular Carcinoma: therapeutic options 2015]. ( Bettinger, D; Brunner, TB; Neeff, HP; Schultheiß, M; Thimme, R, 2015) |
| "The occurrence of hepatocellular carcinoma (HCC) is closely associated with viral hepatitis or alcoholic hepatitis." | 1.42 | Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm. ( Chun, HG; Chun, HJ; Hong, SH; Hwang, SW; Jung, ES; Lee, JE; Lee, JM; Lee, MA; Lee, SH, 2015) |
| "Case 1: A6 4-year-old man with hepatocellular carcinoma (HCC) had received local therapy repeatedly for 20 years." | 1.42 | [Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy]. ( Hijikawa, T; Ishizaki, M; Kaibori, M; Kitade, H; Kon, M; Matsui, K; Yamada, M; Yanagida, H; Yokoigawa, N; Yoshioka, K, 2015) |
| "Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) shows a higher incidence in men, mainly because of hepatitis B X (HBx)-mediated enhancement of androgen receptor (AR) activity." | 1.42 | Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1. ( Chen, DS; Chen, KF; Chen, PJ; Lin, WH; Shiau, CW; Teng, YC; Tsai, TF; Wang, SH; Yeh, SH, 2015) |
| "Sorafenib (SF) is a U." | 1.42 | Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma. ( Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS, 2015) |
| "Sorafenib treatment was initiated." | 1.42 | [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015) |
| "Real life management of hepatocellular carcinoma occasionally deviates from guidelines for recommended therapy." | 1.42 | Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy. ( Alkhatib, A; Allam, N; Gomaa, A; Rewisha, E; Waked, I, 2015) |
| "Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay." | 1.42 | Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. ( Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M, 2015) |
| "Mean survival in hepatocellular carcinoma remains low." | 1.42 | Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon. ( Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F, 2015) |
| "Advanced hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies." | 1.40 | Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. ( Harada, M; Honma, Y; Shimizu, S; Takehara, T, 2014) |
| " Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC." | 1.40 | Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. ( Chen, MS; Gao, HJ; Xu, L; Zhang, YJ, 2014) |
| "Sorafenib is a multi-kinase inhibitor of the vascular endothelial growth factor pathway and was recently introduced as a therapy for advanced HCC." | 1.40 | Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment. ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Kwon, OS; Shin, SK; Yoon, HH, 2014) |
| "Hepatocellular carcinoma is a major cause of death among patients with cirrhosis." | 1.40 | Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. ( Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M, 2014) |
| "Human hepatoma cells stably expressing short hairpin RNA targeting AR and cells over-expressing AR were generated." | 1.40 | Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. ( Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O, 2014) |
| "Sorafenib is a multikinase inhibitor with activity against several receptor tyrosine kinases." | 1.40 | Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. ( Liang, JY; Lü, MD; Pan, FS; Xie, XY; Xu, M; Zheng, SG; Zheng, YL, 2014) |
| "Death rates from hepatocellular carcinoma (HCC) are steadily increasing, yet therapeutic options for advanced HCC are limited." | 1.40 | Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. ( Andreozzi, M; Angel, P; Ben-Neriah, Y; Breuhahn, K; Finkelstein, R; Ganten, T; Grunewald, M; Hess, J; Horwitz, E; Kanarek, N; Koschny, R; Mogler, C; Nemeth, J; Pappo, O; Pikarsky, E; Porat, RM; Quagliata, L; Reuter, H; Schirmacher, P; Schweitzer, N; Shibolet, O; Shoham, A; Stein, I; Terracciano, L; Tornillo, L; Vogel, A; Zreik, F, 2014) |
| "Platelets are frequently altered in hepatocellular carcinoma (HCC) patients." | 1.40 | Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. ( Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG, 2014) |
| "Recurrence of hepatocellular carcinoma (HCC) remains a main detriment to long-term survival in liver transplants (LTx) for HCC." | 1.40 | Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. ( Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E, 2014) |
| "Hepatocellular carcinoma is the fifth most common solid cancer worldwide." | 1.40 | SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. ( Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH, 2014) |
| "Tumor growth and intrahepatic metastasis were assessed, and immunohistochemistry was applied to analyze the activation of the PI3K/Akt/Snail-dependent pathway." | 1.40 | Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. ( Chi, H; Meng, Z; Wang, H; Wang, P; Xu, L; Zhu, X, 2014) |
| "Metformin was also found to significantly inhibit the expression and secretion of MMP-9 and uPA in HCC cells, and suppress the phosphorylation of ERK1/2 and JNK1/2." | 1.40 | Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. ( Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF, 2014) |
| "Sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC." | 1.40 | Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. ( Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F, 2014) |
| "In an application to data from hepatocellular carcinoma patients, the coupled stepwise approach is seen to facilitate joint interpretation of the different cause-specific Cox models." | 1.40 | Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry. ( Binder, H; Elsäßer, A; Schmidtmann, I; Weinmann, A, 2014) |
| "Sorafenib is a multikinase inhibitor targeting Raf and protein tyrosine kinases, which are involved in cell growth and tumor angiogenesis." | 1.40 | Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma. ( Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N, 2014) |
| " The most common side effect was hand-foot skin reaction." | 1.40 | Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. ( Gong, W; Liu, DJ; Liu, J; Sun, P; Xu, YT; Yu, GS; Zheng, SZ, 2014) |
| "For most patients with hepatocellular carcinoma (HCC), diagnosis is invariably done only in the advanced stages of the disease." | 1.40 | Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C). ( Fischer, K; Göke, B; Kolligs, FT; op den Winkel, M; Paprottka, PM; Rauch, B; Schmidt, L; Straub, G, 2014) |
| "Adjuvant therapy after resection of hepatocellular carcinoma (HCC) is limited." | 1.40 | Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2014) |
| "The sorafenib dose was decreased after one month to 400mg/day because of hand-foot syndrome." | 1.40 | [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration]. ( Hosoda, Y; Kakita, N; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yamada, Y; Yamasaki, M; Yasui, M, 2014) |
| "It is overexpressed in hepatocellular carcinoma (HCC) with a clinical significance that remains obscure." | 1.39 | Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. ( Chen, L; Gu, J; He, H; Liu, H; Liu, J; Liu, W; Liu, Y; Pan, D; Wang, S; Wu, Q; Xu, J; Xu, L; Zhang, H; Zhu, Y, 2013) |
| "Sorafenib-treated Mϕ increased cytolytic NK cell function against K562, Raji, and HepG2 target cells in a dose-dependent manner." | 1.39 | Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. ( Ackermann, K; Friess, H; Galle, PR; Hartmann, D; Heikenwalder, M; Otto, G; Protzer, U; Puschnik, A; Reisinger, F; Ringelhan, M; Schiemann, M; Schuchmann, M; Sprinzl, MF; Weinmann, A, 2013) |
| "The management of hepatocellular carcinoma (HCC) in elderly patients is significantly more complicated than in younger patients because of medical comorbidities, advanced status at diagnosis, reduced liver function and altered drug pharmacokinetics." | 1.39 | Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. ( Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B, 2013) |
| "Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC." | 1.39 | Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma? ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013) |
| "Sorafenib and SPIONs were loaded into polymeric micelles." | 1.39 | Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. ( Gong, F; Ma, J; Shen, J; Zhang, F; Zhang, L; Zhang, P, 2013) |
| "Sorafenib (SOR) is a multi-kinase inhibitor that is approved for the treatment of unresectable HCC." | 1.39 | Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. ( Aloia, TA; Boktour, M; Burroughs, SG; Frenette, CT; Gaber, AO; Galati, J; Ghobrial, RM; Kaseb, A; Monsour, H, 2013) |
| "Sorafenib is a multi-kinase inhibitor shown to have survival benefits in advanced HCC." | 1.39 | Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation. ( Harada, M; Honma, Y, 2013) |
| "The medical oncologist's perspective on hepatocellular carcinoma (HCC) is unique compared with their view on other solid tumors." | 1.39 | Hepatocellular carcinoma: perspective of an oncologist. ( Stein, SM, 2013) |
| "Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells." | 1.39 | Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G, 2013) |
| "Recurrence and chemoresistance of liver cancer has been attributed to the existence of liver tumor-initiating cells (T-ICs)." | 1.39 | Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling. ( Cao, D; Chen, C; Chen, SZ; Ding, J; Feng, GS; Han, T; Huang, L; Sun, W; Tang, L; Wang, HY; Wang, X; Wen, W; Wu, MC; Xiang, DM, 2013) |
| "Sorafenib was used in 27 patients who finally failed to respond to HAIC (HAIC/sorafenib group)." | 1.39 | Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. ( Aikata, H; Awai, K; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Kan, H; Kawaoka, T; Kobayashi, T; Masaki, K; Miyaki, D; Naeshiro, N; Nakahara, T; Takahashi, S; Urabe, A, 2013) |
| "Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity." | 1.39 | Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. ( Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA, 2013) |
| "Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways." | 1.39 | [Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report]. ( Natori, T; Yamaguchi, M, 2013) |
| "The prognosis for hepatocellular carcinoma (HCC) is dependent upon tumour stage, performance status (PS), severity of underlying liver disease, and the availability of appropriate therapies." | 1.39 | Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. ( Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ, 2013) |
| "Sorafenib has demonstrated a significant survival advantage in these patients." | 1.39 | Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. ( Finn, RS; Gish, RG; Marrero, JA, 2013) |
| "Hepatocellular carcinoma is generally diagnosed at advanced stages, for which only palliative treatments are possible by intra-arterial route or by targeted therapies." | 1.39 | In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results. ( Ardisson, V; Audrain, O; Boucher, E; Clement, B; Edeline, J; Garin, E; Lenoir, L; Lepareur, N; Pracht, M; Raoul, JL, 2013) |
| "Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition." | 1.39 | Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. ( Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W, 2013) |
| "Sorafenib is a molecularly targeted agent that has been proven effective for treating advanced HCC with extrahepatic metastasis." | 1.39 | [A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib]. ( Cho, T; Emura, M; Igarashi, S; Kobayashi, Y; Nakamura, T; Nomizo, T; Nomura, N; Seto, R, 2013) |
| "Sorafenib is an oral multi-kinase inhibitor exerting its effects via the RAF/ MEK/ERK pathway, vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor beta (PDGFR-β) tyrosine kinases." | 1.39 | Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. ( Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N, 2013) |
| "Sorafenib was approved for advanced HCC based on trials in patients with Child-Pugh class A." | 1.39 | Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. ( Byrne, M; Estfan, B; Kim, R, 2013) |
| "Ixabepilone was more potent than doxorubicin." | 1.39 | In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. ( Chang, AY; Wang, M, 2013) |
| " Clinical outcomes and treatment-related adverse events (AEs) were compared between younger (< 70 years) and older (≥ 70 years) patients." | 1.39 | Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. ( Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2013) |
| "The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular pathogenesis remains incompletely defined in HCC." | 1.39 | αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. ( Ding, ZB; Fan, J; Huang, XY; Ke, AW; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Xiao, YS; Yan, J; Zhang, C; Zhang, X; Zhou, J, 2013) |
| "Treatment options for advanced hepatocellular cancer (HCC) are limited." | 1.38 | Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. ( Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A, 2012) |
| "A rare population of hepatocellular cancer stem cells (HSCs) holds the extensive proliferative and self-renewal potential necessary to form a liver tumour." | 1.38 | Functional analysis of microRNAs in human hepatocellular cancer stem cells. ( Alpini, G; Cleary, JP; DeMorrow, S; Francis, H; Glaser, SS; Han, Y; Hubble, L; Kumar, P; Liu, CG; Liu, X; Meng, F; Passarini, JD; Priester, S; Sharma, J; Staloch, D; Stokes, A; Venter, J, 2012) |
| "Using a highly invasive hepatoma SK-Hep-1 cell line, we investigated the possible synergistic anti-metastatic efficacy of a combination of sorafenib (SF), a multi-kinase inhibitor, and β-ionone (BI), a precursor of carotenoids." | 1.38 | Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells. ( Hu, ML; Huang, CS; Lyu, SC, 2012) |
| "Sorafenib treatment led to accumulation of autophagosomes as evidenced by conversion from LC3-I to LC3-II observed by immunoblot in Huh7, HLF and PLC/PRF/5 cells." | 1.38 | Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. ( Fujita, N; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Kanto, T; Kodama, T; Miyagi, T; Shimizu, S; Takehara, T; Tatsumi, T; Tsunematsu, H; Yoshimori, T, 2012) |
| "In the human hepatocellular carcinoma cell lines Hep3B and HepG2, a combination of LS081 and ferric ammonium citrate (LS081/FeAC) inhibited HIF-1α protein expression but did not inhibit HIF-1α mRNA expression." | 1.38 | Iron facilitator LS081 reduces hypoxia-inducible factor-1α protein and functions as anticancer agent in hepatocellular carcinoma. ( Addo, L; Akutsu, H; Fujiya, M; Glass, J; Ikuta, K; Kohgo, Y; Li, Z; Nakamura, M; Ohtake, T; Sasaki, K; Tanaka, H; Torimoto, Y, 2012) |
| "Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulin-like growth factor (IGF)-1 levels." | 1.38 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. ( Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY, 2012) |
| "The Morris Hepatoma (MH) and HepG2 cells were treated in vitro with sorafenib (1-10 μM) and erlotinib (1-5 μM) and evaluated for tumor cell viability, apoptosis, and target regulation." | 1.38 | Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. ( Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W, 2012) |
| "This report describes a positive experience of adverse event (AE) management of a multidisciplinary clinical team and 18 patients with late-stage renal cell carcinoma and hepatocellular carcinoma attending the Day Hospital Unit of the 'Centro Catanese di Oncologia Humanitas' (Italy) over a 2-year period." | 1.38 | Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. ( Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM, 2012) |
| " Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%." | 1.38 | High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012) |
| "Sorafenib treatment for HCC recurrence in transplant recipients represents a challenging oncologic approach that requires further validation in prospective, multicenter studies." | 1.38 | Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. ( Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S, 2012) |
| "To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 1.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
| "Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC." | 1.37 | Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. ( Aucejo, F; Kim, R, 2011) |
| "Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function." | 1.37 | Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 1.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "Treatment by sorafenib, at the contrary of gemcitabine alone or with oxaliplatine, resulted in a significant reduction in tumor volumes and prolongation of actuarial survival." | 1.37 | [Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. ( Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D, 2011) |
| "Sorafenib is a multikinase inhibitor with activity against B-raf, C-raf, VEGFR2, PDGFRβ and FGFR1." | 1.37 | Population pharmacokinetic analysis of sorafenib in patients with solid tumours. ( Dahut, WL; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Mould, DR; Venitz, J; Woo, S; Yarchoan, R, 2011) |
| "More than 50% of the worldwide cases of hepatocellular carcinoma occur in China, and this malignancy currently represents the country's second leading cause of cancer death in cities and the leading cause in rural areas." | 1.37 | Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. ( Chen, M; Orsini, LS; Qiao, YL; Therneau, T, 2011) |
| "Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC." | 1.37 | Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. ( Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A, 2011) |
| "Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL." | 1.37 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011) |
| "Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a standard of care in advanced HCC." | 1.37 | Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. ( Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC, 2011) |
| " Treatment outcomes and related adverse events (AEs) were compared." | 1.37 | The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, RW; Poon, R; Tang, YF; Wong, H; Yao, TJ; Yau, T, 2011) |
| "The practice guideline for hepatocellular carcinoma (HCC) in Korea was revised in 2009." | 1.37 | Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. ( Choi, JY, 2011) |
| "Sorafenib is a multikinase inhibitor recently introduced in the therapy of patients with advanced HCC." | 1.37 | Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. ( Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A, 2011) |
| "We used polarized hepatoma cell lines and the recently described infectious HCV Japanese fulminant hepatitis (JFH)-1 cell culture system to study the role of VEGF in regulating hepatoma permeability and HCV infection." | 1.36 | Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. ( Ahmed, A; Balfe, P; Bicknell, R; Farquhar, MJ; Harris, HJ; Hu, K; Maurel, P; McKeating, JA; Mee, CJ; Ramma, W, 2010) |
| "Sorafenib treatment resulted in decreased expression of ADAM9, increased expression of membrane-bound MICA expression, and decreased levels of soluble MICA in HCC cells." | 1.36 | Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. ( Hayashi, N; Hosui, A; Ishida, H; Kohga, K; Miyagi, T; Takehara, T; Tatsumi, T, 2010) |
| "Human hepatocellular carcinoma tissues with low expression of let-7c displayed higher expression of Bcl-xL protein than those with high expression of let-7c, suggesting that low let-7 microRNA expression contributes to Bcl-xL over-expression." | 1.36 | The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. ( Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T, 2010) |
| "Sorafenib is a multikinase inhibitor that has been reported to induce cell growth inhibition through the Raf-MAPK signaling pathway." | 1.36 | Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. ( Carr, BI; Wang, M; Wang, Z, 2010) |
| "Sorafenib therapy was then resumed without further symptoms." | 1.36 | A case of variant angina in a patient under chronic treatment with sorafenib. ( Crea, F; Landolfi, R; Leo, A; Miele, L; Pompili, M; Porto, I, 2010) |
| "Yttrium 90 is a safe microembolization treatment that can be used as an alternative to TACE in patients with advanced liver only disease or in case of portal vein thrombosis." | 1.36 | Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. ( Abou-Alfa, GK; Geschwind, JF; Krishnan, S; Salem, R; Schwarz, RE; Venook, AP, 2010) |
| "Hepatocellular carcinoma is a malignant tumor responsible for approximately 600,000-700,000 deaths worldwide, and is becoming more prevalent not only in South-East Asia and Africa, but also in Western countries; therefore, interest in hepatocellular carcinoma has mounted in recent years in the West, where little or no interest was evident 10-20 years ago." | 1.36 | Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. ( Kudo, M, 2010) |
| "However, many hepatocellular carcinoma (HCC) cells show resistance to TRAIL-induced apoptosis." | 1.36 | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. ( Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Li, PK; Lin, YC; Liu, TH; Shiau, CW; Tai, WT, 2010) |
| "A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report." | 1.36 | Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. ( Halff, G; Speeg, KV; Wang, Y; Washburn, WK, 2010) |
| " In order to maximize the benefit of sorafenib and other investigational agents for patients with advanced disease, effective interventions have been designed to mitigate their associated adverse events, such as hand-foot skin reactions and hypertension." | 1.36 | Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. ( Abou-Alfa, GK; Gish, RG; Tong, MJ, 2010) |
| " This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo." | 1.35 | Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. ( Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008) |
| "Hepatocellular carcinoma is rare, but increasing in prevalence in the United States." | 1.35 | Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. ( Bekaii-Saab, T; Bloomston, MA; Patel, T; So, BJ, 2008) |
| "Sorafenib was administered as salvage treatment and resulted in a rapid decline in alpha-fetoprotein (AFP) levels." | 1.35 | Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. ( Chen, CK; Chen, YJ; Hsieh, CH; Jeng, KS; Lin, CC; Lin, CP; Liu, CY; Shueng, PW; Tai, HC; Wang, CH, 2009) |
| "Dermatomyositis is a known paraneoplastic syndrome that can complicate the course of a variety of different cancers, however, the association with HCC is extremely rare." | 1.35 | Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib. ( Apostolidis, L; Horstmann, S; Jäger, D; Kahlert, C; Lordick, F; Siegmund, A; Thom, R, 2009) |
| "In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not received prior systemic therapy, received either oral sorafenib (400 mg twice daily) or placebo until radiological and symptomatic progression." | 1.35 | Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. ( Rimassa, L; Santoro, A, 2009) |
| "Patients with advanced stages of hepatocellular carcinoma (HCC) face a poor prognosis." | 1.35 | Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. ( Balabanov, S; Benten, D; Braig, M; Brummendorf, TH; Gontarewicz, A; Keller, G; Lohse, AW; Moll, J; Quaas, A; Schrader, J; Wege, H, 2009) |
| "Tumor lysis syndrome was suspected and intensive hemodialysis was performed." | 1.35 | Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. ( Huang, WS; Yang, CH, 2009) |
| "It is well appreciated that hepatocellular carcinoma (HCC) represents one of the most challenging malignancies of worldwide importance." | 1.35 | Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. ( Zhu, AX, 2008) |
| "Lastly, the first effective medical treatment of hepatocellular carcinoma has been presented." | 1.35 | [News in digestive oncology]. ( Di Fiore, F; Michel, P, 2008) |
| " In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%." | 1.33 | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. ( Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X, 2006) |
| "Well-differentiated hepatocellular carcinomas developed in nude mice given injections of the TAMH line, and these appeared similar to the primary liver tumors seen in TGF-alpha transgenic mice with regard to histology and strong expression of mouse and human TGF-alpha, insulin-like growth factor II, and alpha-fetoprotein mRNAs." | 1.29 | Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. ( Cveklova, K; Fausto, N; Merlino, G; Mosinger, B; Wu, JC, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (0.55) | 18.7374 |
| 1990's | 1 (0.06) | 18.2507 |
| 2000's | 111 (6.78) | 29.6817 |
| 2010's | 1455 (88.88) | 24.3611 |
| 2020's | 61 (3.73) | 2.80 |
| Authors | Studies |
|---|---|
| Ochi, M | 2 |
| Kamoshida, T | 2 |
| Araki, M | 1 |
| Ikegami, T | 2 |
| Han, Y | 4 |
| Cao, G | 2 |
| Sun, B | 3 |
| Wang, J | 19 |
| Yan, D | 4 |
| Xu, H | 4 |
| Shi, Q | 1 |
| Liu, Z | 8 |
| Zhi, W | 1 |
| Xu, L | 15 |
| Liu, B | 9 |
| Zou, Y | 1 |
| Lien, RY | 1 |
| Tung, HH | 1 |
| Wu, SL | 1 |
| Hu, SH | 1 |
| Lu, LC | 4 |
| Lu, SF | 1 |
| Chen, WT | 2 |
| Lin, SM | 3 |
| Lee, WC | 1 |
| Wu, TJ | 1 |
| Lin, CC | 5 |
| Shen, CH | 2 |
| Chang, ML | 1 |
| Lin, CL | 2 |
| Yeh, CT | 3 |
| Famularo, S | 1 |
| Donadon, M | 1 |
| Cipriani, F | 1 |
| Giuliante, F | 1 |
| Ferri, S | 1 |
| Celsa, C | 1 |
| Ferrero, A | 1 |
| Foschi, FG | 9 |
| Baiocchi, GL | 1 |
| Biasini, E | 2 |
| Campani, C | 1 |
| Valle, RD | 1 |
| Pelizzaro, F | 1 |
| Baroni, GS | 2 |
| Raimondo, G | 1 |
| Mega, A | 1 |
| Chiarelli, M | 1 |
| Maestri, M | 1 |
| Gasbarrini, A | 8 |
| Jovine, E | 1 |
| Grazi, GL | 1 |
| Rapaccini, GL | 3 |
| Ruzzenente, A | 1 |
| Morisco, F | 3 |
| Sacco, R | 15 |
| Memeo, R | 1 |
| Crespi, M | 1 |
| Antonucci, A | 1 |
| Bernasconi, DP | 1 |
| Romano, F | 1 |
| Griseri, G | 1 |
| Aldrighetti, L | 1 |
| Torzilli, G | 2 |
| Trevisani, F | 10 |
| Song, S | 2 |
| Bai, M | 2 |
| Li, X | 9 |
| Gong, S | 1 |
| Yang, W | 4 |
| Lei, C | 1 |
| Tian, H | 4 |
| Si, M | 1 |
| Hao, X | 1 |
| Guo, T | 1 |
| Habiba, YH | 1 |
| Omran, GA | 1 |
| Helmy, MW | 1 |
| Houssen, ME | 1 |
| Ostwal, V | 1 |
| Ramaswamy, A | 1 |
| Gota, V | 1 |
| Bhargava, PG | 1 |
| Srinivas, S | 1 |
| Shriyan, B | 1 |
| Jadhav, S | 1 |
| Goel, M | 1 |
| Patkar, S | 1 |
| Mandavkar, S | 1 |
| Naughane, D | 1 |
| Daddi, A | 1 |
| Nashikkar, C | 1 |
| Shetty, N | 1 |
| Ankathi, SK | 1 |
| Banavali, SD | 1 |
| Narci, K | 1 |
| Kahraman, DC | 1 |
| Koyas, A | 1 |
| Ersahin, T | 1 |
| Tuncbag, N | 1 |
| Atalay, RC | 1 |
| Oya, M | 1 |
| Kaneko, S | 14 |
| Imai, T | 1 |
| Tsujino, T | 1 |
| Sunaya, T | 2 |
| Okayama, Y | 2 |
| Claxton, L | 1 |
| Walton, M | 1 |
| Sharif-Hurst, S | 1 |
| Wade, R | 1 |
| Eastwood, A | 1 |
| Hodgson, R | 1 |
| Chapin, WJ | 1 |
| Hwang, WT | 1 |
| Karasic, TB | 1 |
| McCarthy, AM | 1 |
| Kaplan, DE | 4 |
| Li, JX | 2 |
| Deng, WX | 1 |
| Huang, ST | 1 |
| Lin, XF | 1 |
| Long, MY | 1 |
| Zhang, J | 11 |
| Su, TS | 1 |
| Li, LQ | 4 |
| Pang, YD | 1 |
| Liang, CF | 1 |
| Zhou, HM | 1 |
| Lu, HY | 1 |
| Liang, SX | 1 |
| Xiang, BD | 3 |
| Shuen, TWH | 1 |
| Alunni-Fabbroni, M | 1 |
| Öcal, E | 1 |
| Malfertheiner, P | 5 |
| Wildgruber, M | 1 |
| Schinner, R | 1 |
| Pech, M | 1 |
| Benckert, J | 1 |
| Sangro, B | 8 |
| Kuhl, C | 1 |
| Chow, PKH | 1 |
| Toh, HC | 6 |
| Ricke, J | 5 |
| Ma, Y | 4 |
| Liu, G | 2 |
| Yang, J | 18 |
| Yang, X | 8 |
| Fang, S | 2 |
| Zhao, B | 1 |
| Siddharth, S | 1 |
| Kuppusamy, P | 1 |
| Wu, Q | 6 |
| Nagalingam, A | 1 |
| Saxena, NK | 1 |
| Sharma, D | 1 |
| Sun, Y | 9 |
| Zhang, H | 10 |
| Meng, J | 1 |
| Guo, F | 1 |
| Ren, D | 1 |
| Wu, H | 2 |
| Jin, X | 2 |
| Tan, XP | 1 |
| Xiong, BH | 1 |
| Zhang, YX | 2 |
| Wang, SL | 1 |
| Zuo, Q | 1 |
| Li, J | 25 |
| Chai, MY | 1 |
| Kou, BX | 1 |
| Fu, Z | 3 |
| Wei, FL | 1 |
| Dou, SS | 1 |
| Chen, DX | 1 |
| Liu, XN | 1 |
| Chen, CT | 2 |
| Hsu, CH | 19 |
| Cheng, AL | 43 |
| Shao, YY | 16 |
| Peng, TR | 1 |
| Wu, CC | 3 |
| Chang, SY | 1 |
| Chen, YC | 3 |
| Wu, TW | 1 |
| Hsu, CS | 1 |
| Taha, AM | 1 |
| Aboulwafa, MM | 1 |
| Zedan, H | 1 |
| Helmy, OM | 1 |
| Kim, DB | 1 |
| Lee, DK | 1 |
| Cheon, C | 1 |
| Ribeiro, RIMA | 1 |
| Kim, B | 2 |
| Zhou, J | 20 |
| Feng, J | 5 |
| Wu, Y | 5 |
| Dai, HQ | 3 |
| Zhu, GZ | 3 |
| Chen, PH | 3 |
| Wang, LM | 3 |
| Lu, G | 4 |
| Liao, XW | 3 |
| Lu, PZ | 3 |
| Su, WJ | 3 |
| Hooi, SC | 3 |
| Ye, XP | 3 |
| Shen, HM | 3 |
| Peng, T | 3 |
| Lu, GD | 3 |
| Kurma, K | 1 |
| Zeybek Kuyucu, A | 1 |
| Roth, GS | 1 |
| Sturm, N | 1 |
| Mercey-Ressejac, M | 1 |
| Abbadessa, G | 2 |
| Yu, Y | 4 |
| Lerat, H | 1 |
| Marche, PN | 1 |
| Decaens, T | 5 |
| Macek Jilkova, Z | 1 |
| Weng, PW | 1 |
| Chen, MY | 1 |
| Setiawan, SA | 1 |
| Yadav, VK | 1 |
| Wu, ATH | 1 |
| Tzeng, DTW | 1 |
| Gong, JX | 1 |
| Yang, Z | 6 |
| Tzeng, YM | 2 |
| He, K | 1 |
| Liu, X | 10 |
| Yang, Y | 13 |
| Song, W | 1 |
| Wang, S | 5 |
| Chen, Y | 20 |
| Liang, KH | 1 |
| Hu, CC | 1 |
| Chien, CH | 1 |
| Chen, LW | 1 |
| Chien, RN | 1 |
| Lin, YH | 1 |
| Pang, N | 1 |
| Hu, Q | 1 |
| Zhou, Y | 2 |
| Xiao, Y | 4 |
| Li, W | 9 |
| Ding, Y | 3 |
| Ye, M | 1 |
| Pei, L | 1 |
| Li, Q | 14 |
| Gu, Y | 2 |
| Fang, EF | 1 |
| Chen, M | 6 |
| Zhang, Z | 7 |
| Yang, L | 6 |
| Bi, QC | 1 |
| Deng, ZQ | 1 |
| Lv, YF | 1 |
| Liu, Y | 20 |
| Xie, CS | 1 |
| He, YQ | 1 |
| Tang, Q | 1 |
| Kobayashi, K | 3 |
| Ogasawara, S | 12 |
| Maruta, S | 1 |
| Okubo, T | 2 |
| Itokawa, N | 3 |
| Haga, Y | 2 |
| Seko, Y | 1 |
| Moriguchi, M | 2 |
| Watanabe, S | 1 |
| Shiko, Y | 1 |
| Takatsuka, H | 1 |
| Kanzaki, H | 1 |
| Koroki, K | 1 |
| Inoue, M | 2 |
| Nakamura, M | 3 |
| Kiyono, S | 1 |
| Kanogawa, N | 8 |
| Kondo, T | 1 |
| Suzuki, E | 13 |
| Ooka, Y | 10 |
| Nakamoto, S | 3 |
| Inaba, Y | 5 |
| Ikeda, M | 16 |
| Okabe, S | 1 |
| Morimoto, N | 1 |
| Itoh, Y | 2 |
| Nakamura, K | 2 |
| Ito, K | 1 |
| Azemoto, R | 1 |
| Atsukawa, M | 3 |
| Itobayashi, E | 1 |
| Kato, N | 3 |
| Lu, H | 2 |
| Liang, B | 1 |
| Xia, X | 1 |
| Zheng, C | 2 |
| Yamazaki, K | 1 |
| Doi, T | 1 |
| Okusaka, T | 15 |
| Schueler, A | 1 |
| Watanabe, M | 12 |
| Ohtsu, A | 1 |
| Xiaohui, C | 1 |
| Xin, LI | 1 |
| Dehua, WU | 1 |
| Labeur, TA | 2 |
| Achterbergh, R | 1 |
| Takkenberg, B | 1 |
| Van Delden, O | 1 |
| Mathôt, R | 1 |
| Klümpen, HJ | 3 |
| Elsayed, MM | 1 |
| Mostafa, ME | 1 |
| Alaaeldin, E | 1 |
| Sarhan, HA | 1 |
| Shaykoon, MS | 1 |
| Allam, S | 1 |
| Ahmed, AR | 1 |
| Elsadek, BE | 1 |
| Tang, ST | 1 |
| Liang, GL | 1 |
| Sanduzzi-Zamparelli, M | 4 |
| Sapena, V | 3 |
| Bruix, J | 40 |
| Reig, M | 19 |
| Berhane, S | 3 |
| Johnson, PJ | 6 |
| Chen, J | 19 |
| Duda, DG | 5 |
| Díaz-González, Á | 3 |
| da Fonseca, LG | 4 |
| Di Costanzo, GG | 8 |
| Alves, R | 1 |
| Iavarone, M | 7 |
| Leal, C | 1 |
| Matilla, AM | 1 |
| Hernández-Guerra, M | 2 |
| Aballay Soteras, G | 1 |
| Wörns, MA | 10 |
| Pinter, M | 7 |
| Varela, M | 6 |
| Ladekarl, M | 2 |
| Chagas, AL | 2 |
| Mínguez, B | 7 |
| Arenas, JI | 2 |
| Granito, A | 7 |
| Sánchez-Torrijos, Y | 1 |
| Rojas, Á | 1 |
| Rodríguez de Lope, C | 1 |
| Alvares-da-Silva, MR | 3 |
| Pascual, S | 2 |
| Rimassa, L | 10 |
| Lledó, JL | 2 |
| Huertas, C | 1 |
| Giannini, EG | 3 |
| Delgado, M | 2 |
| Vergara, M | 2 |
| Perelló, C | 1 |
| Lue, A | 2 |
| Sala, M | 2 |
| Gallego, A | 1 |
| Coll, S | 1 |
| Hernáez, T | 1 |
| Piñero, F | 1 |
| Pereira, G | 1 |
| França, A | 1 |
| Marín, J | 1 |
| Anders, M | 1 |
| Mello, V | 1 |
| Lozano, M | 1 |
| Nault, JC | 3 |
| Menéndez, J | 1 |
| García Juárez, I | 1 |
| Lin, ZZ | 6 |
| Chen, BB | 3 |
| Hung, YP | 1 |
| Huang, PH | 1 |
| Shen, YC | 8 |
| Lee, RC | 3 |
| Chao, Y | 11 |
| Hsu, C | 14 |
| Arora, SP | 1 |
| Ananth, S | 1 |
| Ketchum, N | 1 |
| Gelfond, J | 1 |
| Michalek, J | 1 |
| Mahalingam, D | 1 |
| Ruanglertboon, W | 1 |
| Sorich, MJ | 1 |
| Rowland, A | 1 |
| Hopkins, AM | 1 |
| Adachi, T | 2 |
| Hiraoka, A | 3 |
| Okazaki, H | 1 |
| Nagamatsu, K | 1 |
| Izumoto, H | 1 |
| Yoshino, T | 1 |
| Tsuruta, M | 1 |
| Aibiki, T | 1 |
| Okudaira, T | 1 |
| Yamago, H | 1 |
| Iwasaki, R | 1 |
| Suga, Y | 1 |
| Mori, K | 1 |
| Miyata, H | 1 |
| Tsubouchi, E | 1 |
| Ninomiya, T | 2 |
| Michitaka, K | 2 |
| Razak, RA | 1 |
| Fletcher, P | 1 |
| Kunene, V | 1 |
| Ma, YT | 7 |
| Belmonte, E | 2 |
| Darnell, A | 4 |
| Díaz, A | 1 |
| Gomes da Fonseca, L | 1 |
| Llarch, N | 4 |
| Iserte, G | 2 |
| Ayuso, C | 6 |
| Forner, A | 14 |
| Feu, F | 1 |
| Rimola, J | 3 |
| Harding, JJ | 3 |
| Kelley, RK | 6 |
| Tan, B | 1 |
| Capanu, M | 2 |
| Do, GK | 1 |
| Shia, J | 1 |
| Chou, JF | 1 |
| Ferrer, CS | 1 |
| Boussayoud, C | 1 |
| Muenkel, K | 1 |
| Yarmohammadi, H | 1 |
| El Dika, I | 1 |
| Khalil, DN | 1 |
| Ruiz, C | 1 |
| Rodriguez-Lee, M | 1 |
| Kuhn, P | 2 |
| Wilton, J | 1 |
| Iyer, R | 1 |
| Abou-Alfa, GK | 15 |
| Kim, R | 7 |
| Tan, E | 1 |
| Wang, E | 3 |
| Mahipal, A | 1 |
| Chen, DT | 1 |
| Cao, B | 1 |
| Masawi, F | 1 |
| Machado, C | 1 |
| Yu, J | 2 |
| Kim, DW | 1 |
| Aby, ES | 1 |
| Sultan, A | 1 |
| Bane, A | 1 |
| Wondifraw, Z | 1 |
| Debes, JD | 1 |
| Rawat, D | 1 |
| Chhonker, SK | 1 |
| Naik, RA | 1 |
| Koiri, RK | 1 |
| Cheng, Z | 3 |
| He, L | 3 |
| Guo, Y | 2 |
| Song, Y | 2 |
| Zhang, L | 16 |
| Villani, R | 1 |
| Cavallone, F | 1 |
| Sangineto, M | 1 |
| Fioravanti, G | 1 |
| Romano, AD | 1 |
| Serviddio, G | 1 |
| Zhang, GC | 1 |
| Liu, J | 27 |
| Yu, XN | 1 |
| Deng, Y | 1 |
| Liu, TT | 1 |
| Dong, L | 2 |
| Zhu, CF | 1 |
| Shen, XZ | 1 |
| Zhu, JM | 1 |
| Weng, SQ | 1 |
| Li, Y | 19 |
| Boix, L | 1 |
| Brunet, M | 1 |
| Torres, F | 3 |
| Samper, E | 1 |
| Millán, O | 1 |
| Corominas, J | 1 |
| Mammatas, LH | 1 |
| Yaqub, M | 1 |
| Hendrikse, NH | 1 |
| Hoekstra, OS | 1 |
| Honeywell, RJ | 1 |
| Schuit, RC | 1 |
| Meijerink, M | 1 |
| Schwarte, LA | 1 |
| Peters, GJ | 1 |
| Verheul, HMW | 1 |
| Lammertsma, AA | 1 |
| Menke-van der Houven van Oordt, CW | 1 |
| Reis, D | 1 |
| Moura, M | 1 |
| Freitas, LC | 1 |
| Carvalhana, S | 1 |
| Nogueira, PJ | 1 |
| Gaio, R | 1 |
| Marinho, RT | 2 |
| Cortez-Pinto, H | 1 |
| Blanc, JF | 14 |
| Khemissa, F | 1 |
| Bronowicki, JP | 11 |
| Monterymard, C | 1 |
| Perarnau, JM | 2 |
| Bourgeois, V | 1 |
| Obled, S | 1 |
| Abdelghani, MB | 1 |
| Mabile-Archambeaud, I | 1 |
| Faroux, R | 1 |
| Seitz, JF | 5 |
| Locher, C | 1 |
| Senellart, H | 1 |
| Villing, AL | 1 |
| Audemar, F | 1 |
| Costentin, C | 5 |
| Deplanque, G | 1 |
| Manfredi, S | 1 |
| Edeline, J | 14 |
| Marta, GN | 1 |
| Braghiroli, MI | 1 |
| Moura, F | 1 |
| Hoff, PM | 2 |
| Sabbaga, J | 2 |
| Wang, H | 10 |
| Hou, W | 1 |
| Perera, A | 1 |
| Bettler, C | 1 |
| Beach, JR | 1 |
| Ding, X | 2 |
| Denning, MF | 1 |
| Dhanarajan, A | 1 |
| Cotler, SJ | 1 |
| Joyce, C | 1 |
| Yin, J | 1 |
| Ahmed, F | 1 |
| Roberts, LR | 4 |
| Qiu, W | 2 |
| Carballo-Folgoso, L | 1 |
| Álvarez-Velasco, R | 1 |
| Lorca, R | 1 |
| Castaño-García, A | 1 |
| Cuevas, J | 1 |
| González-Diéguez, ML | 1 |
| Martín, M | 1 |
| Álvarez-Navascués, C | 1 |
| Cadahía, V | 1 |
| Morís, C | 1 |
| Rodríguez, M | 3 |
| Son, Y | 1 |
| Shin, NR | 1 |
| Kim, SH | 3 |
| Park, SC | 2 |
| Lee, HJ | 4 |
| Huang, S | 5 |
| Li, D | 2 |
| Zhuang, L | 1 |
| Sun, L | 6 |
| Wu, J | 8 |
| Bockorny, B | 1 |
| Bullock, AJ | 1 |
| Abrams, TA | 1 |
| Faintuch, S | 1 |
| Alsop, DC | 1 |
| Goldberg, SN | 1 |
| Ahmed, M | 1 |
| Miksad, RA | 1 |
| Martin, RC | 1 |
| Bruenderman, E | 1 |
| Cohn, A | 1 |
| Piperdi, B | 2 |
| Miksad, R | 1 |
| Geschwind, JF | 15 |
| Goldenberg, A | 1 |
| Sanyal, A | 1 |
| Zigmont, E | 1 |
| Babajanyan, S | 1 |
| Foreman, P | 1 |
| Mantry, P | 1 |
| McGuire, B | 1 |
| Gholam, P | 2 |
| Giovannini, C | 3 |
| Baglioni, M | 3 |
| Baron Toaldo, M | 5 |
| Cescon, M | 2 |
| Bolondi, L | 15 |
| Gramantieri, L | 3 |
| Kanda, T | 2 |
| Sasaki, R | 1 |
| Takahashi, K | 1 |
| Wu, S | 3 |
| Yokosuka, O | 12 |
| Lee, S | 9 |
| Kang, JH | 1 |
| Kim, DY | 16 |
| Ahn, SH | 7 |
| Park, JY | 9 |
| Kim, BK | 6 |
| Kim, SU | 6 |
| Han, KH | 19 |
| Wang, T | 10 |
| Mu, S | 1 |
| Olerile, LD | 1 |
| Yu, X | 2 |
| Zhang, N | 3 |
| Zhu, YJ | 1 |
| Zheng, B | 1 |
| Wang, HY | 7 |
| Chen, L | 14 |
| Ye, SL | 14 |
| Chen, X | 10 |
| Bie, P | 6 |
| Zhang, S | 8 |
| Liu, F | 7 |
| Liu, L | 15 |
| Dou, K | 5 |
| Yip, CS | 3 |
| Ye, S | 3 |
| Zhao, XY | 1 |
| Hu, XG | 1 |
| Li, T | 5 |
| Xu, QR | 1 |
| Yang, HM | 1 |
| Huang, DS | 1 |
| Lu, AQ | 1 |
| Lv, B | 1 |
| Qiu, F | 1 |
| Wang, XY | 3 |
| Cao, XH | 1 |
| Lee, M | 3 |
| Jo, A | 1 |
| Kim, JB | 2 |
| Chang, Y | 4 |
| Nam, JY | 2 |
| Cho, H | 2 |
| Cho, YY | 4 |
| Cho, EJ | 6 |
| Lee, JH | 15 |
| Yu, SJ | 6 |
| Yoon, JH | 14 |
| Kim, YJ | 10 |
| Huang, M | 3 |
| Chen, C | 11 |
| Geng, J | 1 |
| Han, D | 1 |
| Xie, T | 1 |
| Wang, L | 14 |
| Wang, Y | 21 |
| Wang, C | 5 |
| Lei, Z | 1 |
| Chu, X | 1 |
| Chen, SC | 3 |
| Yang, MH | 1 |
| Ohki, T | 2 |
| Kondo, M | 6 |
| Karasawa, Y | 1 |
| Kawamura, S | 1 |
| Maeshima, S | 1 |
| Kojima, K | 3 |
| Seki, M | 2 |
| Toda, N | 2 |
| Shioda, Y | 1 |
| Tagawa, K | 2 |
| Chou, WC | 1 |
| Lee, CL | 1 |
| Yang, TS | 5 |
| Huang, CY | 4 |
| Teng, W | 1 |
| Tseng, YT | 1 |
| Chen, JS | 1 |
| Lin, YC | 2 |
| Hou, MM | 1 |
| Chang, HH | 1 |
| Chia-Hsun Hsieh, J | 1 |
| Zheng, M | 1 |
| Liao, XH | 1 |
| Chen, CP | 1 |
| Zhang, AL | 1 |
| Lu, W | 1 |
| Yang, D | 2 |
| Liu, H | 9 |
| Zhou, XZ | 1 |
| Lu, KP | 1 |
| Best, J | 1 |
| Schotten, C | 1 |
| Lohmann, G | 1 |
| Gerken, G | 4 |
| Dechêne, A | 1 |
| Kishore, S | 1 |
| Friedman, T | 1 |
| Madoff, DC | 1 |
| Cheng, Y | 2 |
| Luo, R | 2 |
| Zheng, H | 1 |
| Wang, B | 3 |
| Liu, D | 7 |
| Xu, W | 1 |
| Li, A | 2 |
| Zhu, Y | 3 |
| Li, R | 2 |
| Yanjiao, G | 1 |
| Wubin, H | 1 |
| Yue, W | 1 |
| Jianhua, H | 1 |
| Huachuan, Z | 1 |
| Rongjian, S | 1 |
| Zhidong, L | 1 |
| Verslype, C | 5 |
| Cohn, AL | 1 |
| Su, WC | 1 |
| Burris, H | 1 |
| Braiteh, F | 1 |
| Vogelzang, N | 1 |
| Spira, A | 1 |
| Foster, P | 1 |
| Lee, Y | 2 |
| Van Cutsem, E | 2 |
| Galle, PR | 16 |
| Won, JK | 1 |
| Hwang, CY | 1 |
| Cho, SH | 1 |
| Park, SM | 1 |
| Kim, K | 1 |
| Choi, WM | 1 |
| Lee, KB | 2 |
| Suh, KS | 2 |
| Jang, JJ | 2 |
| Kim, CY | 1 |
| Cho, KH | 1 |
| Jun, CH | 2 |
| Cho, E | 2 |
| Shin, SS | 1 |
| Cho, SB | 3 |
| Kim, HJ | 4 |
| Park, CH | 1 |
| Kim, HS | 5 |
| Choi, SK | 2 |
| Rew, JS | 1 |
| Mancuso, A | 7 |
| Maringhini, A | 1 |
| Mir, N | 1 |
| Jayachandran, A | 1 |
| Dhungel, B | 1 |
| Shrestha, R | 1 |
| Steel, JC | 1 |
| Huo, Q | 1 |
| Ge, C | 3 |
| Sun, J | 7 |
| Cui, M | 1 |
| Li, H | 15 |
| Zhao, F | 6 |
| Chen, T | 2 |
| Xie, H | 2 |
| Cui, Y | 4 |
| Yao, M | 4 |
| Lo Re, O | 1 |
| Panebianco, C | 1 |
| Porto, S | 1 |
| Cervi, C | 1 |
| Rappa, F | 1 |
| Di Biase, S | 1 |
| Caraglia, M | 6 |
| Pazienza, V | 1 |
| Vinciguerra, M | 2 |
| Hua, L | 3 |
| Hu, B | 4 |
| Shen, Y | 2 |
| Shen, C | 1 |
| Chen, B | 5 |
| Cui, X | 2 |
| Chen, PJ | 14 |
| Yeh, YC | 1 |
| Chen, HM | 2 |
| Lai, MS | 1 |
| Wei, X | 2 |
| Pu, J | 1 |
| Guo, Z | 3 |
| Zhu, D | 1 |
| Wu, Z | 3 |
| Lee, SJ | 3 |
| Lim, HY | 16 |
| Sanoff, HK | 2 |
| Lund, JL | 2 |
| O'Neil, BH | 3 |
| Dusetzina, SB | 2 |
| Yoo, SY | 2 |
| Badrinath, N | 1 |
| Woo, HY | 8 |
| Heo, J | 11 |
| Yoo, JJ | 1 |
| Chung, GE | 1 |
| Lee, JM | 5 |
| Lee, DH | 4 |
| Kim, HY | 7 |
| Cho, Y | 2 |
| Yi, NJ | 1 |
| Lee, KW | 1 |
| Solms, A | 1 |
| Reinecke, I | 1 |
| Fiala-Buskies, S | 1 |
| Keunecke, A | 1 |
| Drenth, HJ | 1 |
| Meinhardt, G | 10 |
| Cleton, A | 1 |
| Ploeger, B | 1 |
| Kim, H | 4 |
| Yeo, I | 1 |
| Jun, J | 1 |
| Park, T | 1 |
| Kim, Y | 2 |
| Shoji, H | 1 |
| Yoshio, S | 1 |
| Mano, Y | 1 |
| Doi, H | 1 |
| Sugiyama, M | 1 |
| Osawa, Y | 1 |
| Kimura, K | 1 |
| Arai, T | 2 |
| Aoki, Y | 1 |
| Fukai, M | 1 |
| Taketomi, A | 2 |
| Mizokami, M | 1 |
| Kanto, T | 3 |
| Abeni, E | 2 |
| Salvi, A | 2 |
| Marchina, E | 1 |
| Traversa, M | 1 |
| Arici, B | 2 |
| De Petro, G | 2 |
| Beukhof, CM | 1 |
| van Doorn, L | 2 |
| Visser, TJ | 2 |
| Bins, S | 1 |
| Visser, WE | 1 |
| van Heerebeek, R | 1 |
| van Kemenade, FJ | 1 |
| de Rijke, YB | 1 |
| de Herder, WW | 1 |
| Chaker, L | 1 |
| Mathijssen, RH | 2 |
| Peeters, RP | 2 |
| Pressiani, T | 8 |
| Personeni, N | 4 |
| Santoro, A | 19 |
| Ippolito, D | 1 |
| Querques, G | 1 |
| Okolicsanyi, S | 1 |
| Franzesi, CT | 1 |
| Strazzabosco, M | 1 |
| Sironi, S | 2 |
| Kim, MJ | 3 |
| Choi, YK | 1 |
| Park, SY | 9 |
| Jang, SY | 2 |
| Lee, JY | 1 |
| Ham, HJ | 1 |
| Kim, BG | 2 |
| Jeon, HJ | 1 |
| Kim, JH | 9 |
| Kim, JG | 1 |
| Lee, IK | 1 |
| Park, KG | 1 |
| Chau, I | 2 |
| Peck-Radosavljevic, M | 11 |
| Borg, C | 2 |
| Park, JO | 5 |
| Ryoo, BY | 13 |
| Yen, CJ | 6 |
| Kudo, M | 58 |
| Poon, R | 4 |
| Pastorelli, D | 4 |
| Chung, HC | 3 |
| Baron, AD | 2 |
| Bowman, L | 1 |
| Cui, ZL | 1 |
| Girvan, AC | 1 |
| Abada, PB | 3 |
| Zhu, AX | 18 |
| Miles, S | 1 |
| Ganten, T | 3 |
| Trojan, J | 9 |
| Cebon, J | 1 |
| Liem, AK | 1 |
| Lipton, L | 1 |
| Gupta, C | 1 |
| Wu, B | 3 |
| Bass, M | 1 |
| Hollywood, E | 1 |
| Ma, J | 4 |
| Bradley, M | 1 |
| Litten, J | 1 |
| Saltz, LB | 3 |
| Eggert, T | 1 |
| Greten, TF | 9 |
| Costentin, CE | 1 |
| Laurent, A | 2 |
| Paule, B | 2 |
| Letoublon, C | 1 |
| Luciani, A | 5 |
| Calderaro, J | 2 |
| Adam, R | 2 |
| Bricault, I | 1 |
| Amaddeo, G | 1 |
| Cherqui, D | 1 |
| Mallat, A | 2 |
| Samuel, D | 2 |
| Duvoux, C | 2 |
| Ganne-Carrié, N | 1 |
| Roudot-Thoraval, F | 1 |
| Vibert, E | 1 |
| Yutani, S | 1 |
| Shirahama, T | 1 |
| Muroya, D | 1 |
| Matsueda, S | 1 |
| Yamaguchi, R | 1 |
| Morita, M | 2 |
| Shichijo, S | 1 |
| Yamada, A | 1 |
| Sasada, T | 1 |
| Itoh, K | 1 |
| Meng, L | 1 |
| Liu, K | 6 |
| Ji, B | 3 |
| Yuan, X | 1 |
| Qu, Y | 1 |
| Wu, G | 5 |
| Li, C | 3 |
| Zu, X | 1 |
| Yang, N | 3 |
| Ke, X | 1 |
| Xie, N | 1 |
| Xu, X | 3 |
| Liu, S | 8 |
| Zhang, W | 20 |
| Ma, MKF | 1 |
| Lau, EYT | 1 |
| Leung, DHW | 1 |
| Lo, J | 2 |
| Ho, NPY | 1 |
| Cheng, LKW | 1 |
| Ma, S | 1 |
| Lin, CH | 1 |
| Copland, JA | 1 |
| Ding, J | 7 |
| Lo, RCL | 1 |
| Ng, IOL | 1 |
| Lee, TKW | 1 |
| Meyer, T | 7 |
| Fox, R | 1 |
| Ross, PJ | 7 |
| James, MW | 1 |
| Sturgess, R | 1 |
| Stubbs, C | 1 |
| Stocken, DD | 1 |
| Wall, L | 1 |
| Watkinson, A | 1 |
| Hacking, N | 1 |
| Evans, TRJ | 2 |
| Collins, P | 3 |
| Hubner, RA | 4 |
| Cunningham, D | 1 |
| Primrose, JN | 1 |
| Palmer, DH | 8 |
| Lee, HW | 3 |
| Jeon, MY | 1 |
| Heo, JY | 1 |
| Lee, YR | 1 |
| Jang, SK | 1 |
| Lee, SH | 7 |
| Tak, WY | 13 |
| Labenz, C | 1 |
| Prenosil, V | 1 |
| Koch, S | 4 |
| Huber, Y | 1 |
| Marquardt, JU | 3 |
| Schattenberg, JM | 2 |
| Weinmann, A | 9 |
| Al-Shamsi, HO | 1 |
| Abdel-Wahab, R | 1 |
| Hassan, MM | 1 |
| Shalaby, AS | 1 |
| Dahbour, I | 1 |
| Lacin, S | 1 |
| Mahvash, A | 1 |
| Odisio, BC | 1 |
| Murthy, R | 1 |
| Avritscher, R | 1 |
| Abdelsalam, ME | 1 |
| Rashid, A | 1 |
| Vauthey, JN | 1 |
| Aloia, TA | 2 |
| Conrad, C | 1 |
| Chun, YS | 1 |
| Krishnan, S | 2 |
| Das, P | 1 |
| Koay, EJ | 1 |
| Amin, HM | 1 |
| Yao, JC | 1 |
| Kaseb, AO | 1 |
| Sun, D | 2 |
| Dai, X | 2 |
| Zheng, X | 1 |
| Yan, J | 3 |
| Wei, R | 1 |
| Fu, X | 1 |
| Shen, A | 1 |
| Huang, X | 4 |
| Geng, M | 1 |
| Nakajima, K | 9 |
| De Sanctis, Y | 1 |
| Llovet, J | 2 |
| Patt, Y | 1 |
| Rojas-Hernandez, C | 1 |
| Fekrazad, HM | 1 |
| Bansal, P | 1 |
| Lee, FC | 1 |
| Tovoli, F | 4 |
| Lorenzo, S | 1 |
| Barbera, MA | 2 |
| Garajova, I | 1 |
| Frega, G | 1 |
| Palloni, A | 1 |
| Pantaleo, MA | 1 |
| Biasco, G | 4 |
| Brandi, G | 5 |
| Ganten, TM | 6 |
| Stauber, RE | 1 |
| Schott, E | 4 |
| Buder, R | 2 |
| Göhler, T | 1 |
| Walther, M | 1 |
| Koschny, R | 5 |
| Zhang, R | 2 |
| Ma, M | 2 |
| Dong, G | 1 |
| Yao, RR | 1 |
| Li, JH | 1 |
| Zheng, QD | 1 |
| Dong, YY | 1 |
| Ma, H | 2 |
| Gao, DM | 5 |
| Cui, JF | 2 |
| Ren, ZG | 4 |
| Chen, RX | 2 |
| Williet, N | 2 |
| Clavel, L | 1 |
| Bourmaud, A | 1 |
| Verot, C | 1 |
| Bouarioua, N | 1 |
| Roblin, X | 1 |
| Merle, P | 4 |
| Phelip, JM | 1 |
| Han, JK | 1 |
| Yao, W | 3 |
| Ba, Q | 1 |
| Yuan, Y | 4 |
| Wang, F | 5 |
| Duan, X | 2 |
| Kollmann, D | 1 |
| Selzner, N | 1 |
| Selzner, M | 1 |
| Zhao, R | 2 |
| Zheng, G | 2 |
| Jiang, K | 1 |
| Fan, L | 1 |
| Shao, J | 2 |
| Bai, T | 3 |
| Zhao, Y | 14 |
| Zhu, R | 1 |
| Wang, W | 10 |
| Casadei Gardini, A | 9 |
| Marisi, G | 8 |
| Scartozzi, M | 11 |
| Granata, R | 1 |
| Faloppi, L | 11 |
| Cascinu, S | 10 |
| Silvestris, N | 6 |
| Brunetti, O | 4 |
| Palmieri, VO | 1 |
| Ercolani, G | 3 |
| Tortora, R | 6 |
| Sakurai, T | 11 |
| Yada, N | 7 |
| Hagiwara, S | 9 |
| Arizumi, T | 11 |
| Minaga, K | 1 |
| Kamata, K | 1 |
| Takenaka, M | 1 |
| Minami, Y | 8 |
| Watanabe, T | 4 |
| Nishida, N | 10 |
| Kang, D | 1 |
| Han, Z | 2 |
| Oh, GH | 1 |
| Joo, Y | 1 |
| Choi, HJ | 5 |
| Song, JJ | 1 |
| Brahms, A | 1 |
| Mudhasani, R | 1 |
| Pinkham, C | 1 |
| Kota, K | 1 |
| Nasar, F | 1 |
| Zamani, R | 1 |
| Bavari, S | 1 |
| Kehn-Hall, K | 1 |
| Bettinger, D | 6 |
| Spode, R | 1 |
| Glaser, N | 1 |
| Buettner, N | 1 |
| Boettler, T | 1 |
| Neumann-Haefelin, C | 1 |
| Brunner, TB | 2 |
| Gkika, E | 1 |
| Maruschke, L | 1 |
| Thimme, R | 6 |
| Schultheiss, M | 1 |
| Diaz-Beveridge, R | 1 |
| Bruixola, G | 1 |
| Lorente, D | 1 |
| Caballero, J | 1 |
| Rodrigo, E | 1 |
| Segura, Á | 1 |
| Akhoundova, D | 1 |
| Giménez, A | 1 |
| Aparicio, J | 1 |
| Ou, DL | 8 |
| Wang, MJ | 1 |
| Lou, G | 2 |
| Norton, JT | 1 |
| Kandela, I | 1 |
| Tang, S | 2 |
| Shank, NI | 1 |
| Gupta, P | 1 |
| Avram, MJ | 1 |
| Green, R | 1 |
| Mazar, A | 1 |
| Appella, D | 1 |
| Chen, Z | 6 |
| Naganuma, A | 1 |
| Hoshino, T | 1 |
| Suzuki, Y | 3 |
| Uehara, D | 1 |
| Kudo, T | 3 |
| Ishihara, H | 1 |
| Sato, K | 4 |
| Kakizaki, S | 1 |
| Yamada, M | 2 |
| Takagi, H | 2 |
| Borgia, F | 1 |
| Saitta, C | 2 |
| Vaccaro, M | 1 |
| Franzè, MS | 1 |
| Lentini, M | 1 |
| Cannavò, SP | 1 |
| Guerrini, GP | 1 |
| Berretta, M | 3 |
| Tarantino, G | 2 |
| Magistri, P | 1 |
| Pecchi, A | 1 |
| Ballarin, R | 2 |
| Di Benedetto, F | 3 |
| García Carretero, R | 1 |
| Vazquez-Gomez, O | 1 |
| Romero Brugera, M | 1 |
| Rebollo-Aparicio, N | 1 |
| Kabir, TD | 1 |
| Ganda, C | 1 |
| Brown, RM | 1 |
| Beveridge, DJ | 1 |
| Richardson, KL | 1 |
| Chaturvedi, V | 1 |
| Candy, P | 1 |
| Epis, M | 1 |
| Wintle, L | 1 |
| Kalinowski, F | 1 |
| Kopp, C | 1 |
| Stuart, LM | 1 |
| Yeoh, GC | 1 |
| George, J | 4 |
| Leedman, PJ | 1 |
| Wang, P | 4 |
| Tan, G | 5 |
| Zhu, M | 2 |
| Zhai, B | 10 |
| Sun, X | 13 |
| Li, S | 3 |
| Dai, W | 1 |
| Mo, W | 1 |
| Wu, L | 2 |
| Liu, T | 4 |
| Yu, Q | 3 |
| Xu, S | 3 |
| Lu, X | 2 |
| Zhang, Q | 6 |
| Chen, K | 3 |
| Xia, Y | 2 |
| Lu, J | 3 |
| Fan, X | 1 |
| Guo, C | 2 |
| Reiss, KA | 1 |
| Yu, S | 2 |
| Mamtani, R | 1 |
| Mehta, R | 3 |
| D'Addeo, K | 3 |
| Wileyto, EP | 1 |
| Taddei, TH | 3 |
| Wu, FX | 1 |
| Zhu, SL | 1 |
| Yang, TB | 1 |
| Qi, LN | 1 |
| Zou, L | 1 |
| Li, ZH | 1 |
| Ye, JZ | 2 |
| Lee, TY | 4 |
| Chen, CY | 2 |
| Wang, TE | 1 |
| Lo, GH | 1 |
| Chang, CS | 1 |
| Cervello, M | 4 |
| Pitarresi, G | 1 |
| Volpe, AB | 1 |
| Porsio, B | 1 |
| Balasus, D | 1 |
| Emma, MR | 2 |
| Azzolina, A | 3 |
| Puleio, R | 2 |
| Loria, GR | 2 |
| Puleo, S | 1 |
| Giammona, G | 1 |
| Kaufmann, S | 1 |
| Thaiss, WM | 1 |
| Schulze, M | 1 |
| Bitzer, M | 8 |
| Lauer, U | 2 |
| Nikolaou, K | 1 |
| Horger, M | 7 |
| Dong, J | 1 |
| Sun, W | 7 |
| Hu, F | 3 |
| Cheng, H | 2 |
| Xu, J | 14 |
| Chow, PK | 4 |
| Gandhi, M | 3 |
| Gebski, V | 1 |
| Lin, H | 7 |
| Li, YS | 4 |
| Lee, YH | 2 |
| Gao, L | 2 |
| Shay, C | 1 |
| Lv, F | 1 |
| Wang, X | 8 |
| Teng, Y | 2 |
| De Matteis, S | 1 |
| Palmieri, V | 3 |
| Vespasiani-Gentilucci, U | 1 |
| Perrone, G | 1 |
| Valgiusti, M | 3 |
| Granato, AM | 1 |
| Negrini, G | 2 |
| Tamburini, E | 2 |
| Aprile, G | 1 |
| Passardi, A | 1 |
| Santini, D | 5 |
| Frassineti, GL | 6 |
| Campillo-Gimenez, B | 4 |
| King, J | 3 |
| Faluyi, O | 1 |
| Mathurin, J | 1 |
| Ghazi, S | 1 |
| Zhao, RC | 1 |
| Wei, YG | 1 |
| Chen, KF | 20 |
| Li, B | 7 |
| Thein, HH | 1 |
| Qiao, Y | 1 |
| Zaheen, A | 1 |
| Jembere, N | 1 |
| Sapisochin, G | 1 |
| Chan, KKW | 1 |
| Yoshida, EM | 2 |
| Earle, CC | 1 |
| Zheng, L | 4 |
| Jin, RA | 2 |
| Tang, M | 1 |
| Liang, X | 4 |
| Cai, X | 8 |
| Liang, Y | 4 |
| Ji, T | 2 |
| Zhang, B | 6 |
| Dai, Y | 1 |
| Xie, Y | 3 |
| El-Serag, HB | 2 |
| Johnson, MS | 1 |
| Ueshima, K | 14 |
| Kumada, T | 2 |
| Hirooka, M | 2 |
| Koizumi, Y | 1 |
| Hiasa, Y | 2 |
| Tajiri, K | 2 |
| Toyoda, H | 2 |
| Tada, T | 1 |
| Ochi, H | 1 |
| Joko, K | 4 |
| Shimada, N | 1 |
| Deguchi, A | 2 |
| Ishikawa, T | 5 |
| Imai, M | 1 |
| Tsuji, K | 5 |
| Niu, L | 1 |
| Yang, S | 7 |
| Ren, J | 2 |
| Lai, PBS | 1 |
| Chen, GG | 3 |
| Arai, J | 1 |
| Goto, K | 1 |
| Stephanou, A | 1 |
| Tanoue, Y | 1 |
| Ito, S | 1 |
| Muroyama, R | 1 |
| Matsubara, Y | 1 |
| Nakagawa, R | 1 |
| Morimoto, S | 1 |
| Kaise, Y | 1 |
| Lim, LA | 1 |
| Yoshida, H | 1 |
| Quintavalle, C | 1 |
| Hindupur, SK | 1 |
| Quagliata, L | 3 |
| Pallante, P | 1 |
| Nigro, C | 1 |
| Condorelli, G | 1 |
| Andersen, JB | 1 |
| Tagscherer, KE | 1 |
| Roth, W | 1 |
| Beguinot, F | 1 |
| Heim, MH | 3 |
| Ng, CKY | 1 |
| Piscuoglio, S | 1 |
| Matter, MS | 1 |
| Lii Cheng, A | 1 |
| Jackson, R | 2 |
| Psarelli, E | 1 |
| Lin, HC | 3 |
| Yang, YS | 1 |
| Teng, CJ | 1 |
| Jan, YG | 1 |
| Cheng, SB | 2 |
| Lin, YL | 1 |
| Huang, CC | 2 |
| P'eng, FK | 1 |
| Lin, J | 2 |
| Lu, F | 2 |
| Fu, C | 1 |
| Gu, H | 1 |
| Cai, M | 3 |
| Lin, L | 2 |
| Cao, Z | 1 |
| Zhu, K | 5 |
| Shuai, X | 1 |
| Vilgrain, V | 5 |
| Pereira, H | 2 |
| Assenat, E | 3 |
| Guiu, B | 1 |
| Ilonca, AD | 1 |
| Pageaux, GP | 1 |
| Sibert, A | 2 |
| Bouattour, M | 6 |
| Lebtahi, R | 2 |
| Allaham, W | 1 |
| Barraud, H | 1 |
| Laurent, V | 2 |
| Mathias, E | 1 |
| Tasu, JP | 1 |
| Perdrisot, R | 1 |
| Silvain, C | 1 |
| Gerolami, R | 4 |
| Mundler, O | 1 |
| Vidal, V | 1 |
| Aubé, C | 1 |
| Oberti, F | 1 |
| Couturier, O | 1 |
| Brenot-Rossi, I | 1 |
| Raoul, JL | 14 |
| Sarran, A | 1 |
| Itti, E | 1 |
| Lewin, M | 2 |
| Ronot, M | 4 |
| Dinut, A | 2 |
| Castera, L | 3 |
| Chatellier, G | 3 |
| Xu, A | 1 |
| Shen, Z | 3 |
| Takeyama, H | 1 |
| Beppu, T | 3 |
| Higashi, T | 1 |
| Kaida, T | 1 |
| Arima, K | 1 |
| Taki, K | 1 |
| Imai, K | 3 |
| Nitta, H | 3 |
| Hayashi, H | 2 |
| Nakagawa, S | 2 |
| Okabe, H | 4 |
| Hashimoto, D | 1 |
| Chikamoto, A | 3 |
| Ishiko, T | 3 |
| Tanaka, M | 8 |
| Sasaki, Y | 3 |
| Baba, H | 3 |
| Cai, R | 1 |
| Song, R | 2 |
| Pang, P | 1 |
| Yan, Y | 2 |
| Liao, Y | 1 |
| Zhou, C | 2 |
| Zhou, X | 3 |
| Sun, H | 7 |
| Kwon, SY | 1 |
| Min, JJ | 1 |
| Bae, WK | 1 |
| Sung, PS | 1 |
| Park, HL | 1 |
| Yang, K | 1 |
| Hwang, S | 4 |
| Song, MJ | 3 |
| Jang, JW | 1 |
| Choi, JY | 4 |
| Yoon, SK | 8 |
| Yoo, IR | 1 |
| Bae, SH | 7 |
| Nada, Y | 1 |
| Rashad, N | 1 |
| Eissa, M | 1 |
| Ghonaim, A | 1 |
| Farag, K | 1 |
| Saadawi, I | 1 |
| Sheha, A | 1 |
| El Gewaity, M | 1 |
| Abdel-Rahman, O | 8 |
| Lu, M | 3 |
| Fei, Z | 1 |
| Zhang, G | 2 |
| Sun, T | 2 |
| Ming, L | 1 |
| Makol, A | 1 |
| Kanthaje, S | 1 |
| Dhiman, RK | 1 |
| Kalra, N | 1 |
| Chawla, YK | 1 |
| Chakraborti, A | 1 |
| Huang, YK | 1 |
| Yen, CL | 1 |
| Shiu, SI | 1 |
| Lee, SW | 2 |
| Chang, PY | 1 |
| Yeh, HZ | 1 |
| Gynther, M | 1 |
| Proietti Silvestri, I | 1 |
| Hansen, JC | 1 |
| Hansen, KB | 1 |
| Malm, T | 1 |
| Ishchenko, Y | 1 |
| Larsen, Y | 1 |
| Han, L | 1 |
| Kayser, S | 1 |
| Auriola, S | 1 |
| Petsalo, A | 1 |
| Nielsen, B | 1 |
| Pickering, DS | 1 |
| Bunch, L | 1 |
| Zhang, ZH | 1 |
| Liu, QX | 2 |
| Ma, JQ | 1 |
| Wang, JH | 5 |
| Luo, JJ | 2 |
| Liu, LX | 2 |
| Yan, ZP | 2 |
| Fu, Y | 2 |
| Huang, Y | 11 |
| Zhou, R | 1 |
| Hu, X | 2 |
| Zhou, P | 1 |
| Quan, J | 1 |
| Li, N | 4 |
| Fan, XG | 1 |
| Garuti, F | 3 |
| De Lorenzo, S | 2 |
| Inghilesi, AL | 3 |
| Bernardi, M | 3 |
| Marra, F | 3 |
| Ogawa, C | 3 |
| Omura, A | 1 |
| Noda, T | 3 |
| Kubo, A | 1 |
| Matsunaka, T | 1 |
| Tamaki, H | 1 |
| Shibatoge, M | 1 |
| Tsutsui, A | 1 |
| Senoh, T | 1 |
| Nagano, T | 1 |
| Takaguchi, K | 2 |
| Tani, J | 1 |
| Morishita, A | 1 |
| Yoneyama, H | 1 |
| Masaki, T | 1 |
| Moriya, A | 1 |
| Ando, M | 1 |
| Kokudo, Y | 1 |
| Hayashi, T | 2 |
| Yamashita, T | 11 |
| Terashima, T | 2 |
| Suda, T | 1 |
| Okada, H | 1 |
| Asahina, Y | 3 |
| Hara, Y | 1 |
| Nio, K | 1 |
| Sunagozaka, H | 1 |
| Takatori, H | 1 |
| Arai, K | 4 |
| Sakai, Y | 2 |
| Mizukoshi, E | 2 |
| Honda, M | 3 |
| Dietrich, P | 1 |
| Koch, A | 2 |
| Fritz, V | 1 |
| Hartmann, A | 2 |
| Bosserhoff, AK | 1 |
| Hellerbrand, C | 2 |
| Yoshimoto, T | 1 |
| Imura, S | 1 |
| Morine, Y | 1 |
| Ikemoto, T | 1 |
| Arakawa, Y | 1 |
| Iwahashi, S | 1 |
| Saito, YU | 1 |
| Takasu, C | 1 |
| Ishikawa, D | 1 |
| Teraoku, H | 1 |
| Bando, Y | 1 |
| Shimada, M | 6 |
| Wada, Y | 3 |
| Takami, Y | 2 |
| Matsushima, H | 4 |
| Tateishi, M | 2 |
| Ryu, T | 2 |
| Yoshitomi, M | 1 |
| Matsumura, T | 2 |
| Saitsu, H | 2 |
| Shinagawa-Kobayashi, Y | 1 |
| Kamimura, K | 1 |
| Goto, R | 1 |
| Ogawa, K | 1 |
| Inoue, R | 1 |
| Yokoo, T | 1 |
| Sakai, N | 1 |
| Nagoya, T | 1 |
| Sakamaki, A | 1 |
| Abe, S | 1 |
| Sugitani, S | 1 |
| Yanagi, M | 1 |
| Fujisawa, K | 1 |
| Nozawa, Y | 1 |
| Koyama, N | 1 |
| Nishina, H | 1 |
| Furutani-Seiki, M | 1 |
| Sakaida, I | 1 |
| Terai, S | 1 |
| Fong, ELS | 1 |
| Toh, TB | 1 |
| Lin, QXX | 1 |
| Hooi, L | 1 |
| Mohd Abdul Rashid, MB | 1 |
| Benoukraf, T | 1 |
| Chow, EK | 1 |
| Huynh, TH | 1 |
| Yu, H | 4 |
| Valderrama, A | 1 |
| Feng, F | 3 |
| Jiang, Q | 1 |
| Cao, S | 1 |
| Cao, Y | 5 |
| Shen, L | 1 |
| Zhu, H | 4 |
| Liang, E | 1 |
| Chai, Y | 1 |
| Yang, R | 2 |
| Xin, S | 1 |
| Li, BA | 1 |
| DeWaal, D | 1 |
| Nogueira, V | 1 |
| Terry, AR | 1 |
| Patra, KC | 1 |
| Jeon, SM | 1 |
| Guzman, G | 1 |
| Au, J | 1 |
| Long, CP | 1 |
| Antoniewicz, MR | 1 |
| Hay, N | 1 |
| Peng, Z | 1 |
| Chen, S | 4 |
| Wei, M | 1 |
| Lin, M | 2 |
| Jiang, C | 3 |
| Mei, J | 1 |
| Xie, X | 1 |
| Qian, G | 1 |
| Kuang, M | 2 |
| Meng, XC | 2 |
| Chen, BH | 1 |
| Huang, JJ | 1 |
| Huang, WS | 3 |
| Cai, MY | 1 |
| Zhou, JW | 1 |
| Guo, YJ | 2 |
| Zhu, KS | 2 |
| Llovet, JM | 29 |
| Finn, RS | 14 |
| Kokudo, T | 2 |
| Kokudo, N | 4 |
| Hasegawa, K | 1 |
| Garin, E | 6 |
| Rolland, Y | 5 |
| Kodama, K | 2 |
| Kawaoka, T | 7 |
| Aikata, H | 7 |
| Uchikawa, S | 2 |
| Nishida, Y | 1 |
| Inagaki, Y | 5 |
| Hatooka, M | 5 |
| Morio, K | 5 |
| Nakahara, T | 5 |
| Murakami, E | 4 |
| Tsuge, M | 3 |
| Hiramatsu, A | 7 |
| Imamura, M | 5 |
| Kawakami, Y | 5 |
| Masaki, K | 3 |
| Honda, Y | 4 |
| Mori, N | 3 |
| Takaki, S | 4 |
| Kohno, H | 8 |
| Moriya, T | 4 |
| Nonaka, M | 3 |
| Hyogo, H | 4 |
| Aisaka, Y | 3 |
| Kimura, T | 3 |
| Nagata, Y | 1 |
| Chayama, K | 7 |
| Qin, S | 8 |
| Ikeda, K | 4 |
| Piscaglia, F | 11 |
| Baron, A | 2 |
| Park, JW | 14 |
| Han, G | 13 |
| Jassem, J | 1 |
| Vogel, A | 6 |
| Komov, D | 2 |
| Lopez, C | 1 |
| Dutcus, C | 1 |
| Guo, M | 1 |
| Saito, K | 3 |
| Kraljevic, S | 1 |
| Tamai, T | 1 |
| Ren, M | 2 |
| Zhong, J | 4 |
| Dong, X | 7 |
| Zhou, W | 3 |
| Li, L | 4 |
| Li, Z | 6 |
| Sun, P | 2 |
| Shi, X | 1 |
| D'Alessandro, R | 6 |
| Refolo, MG | 6 |
| Lippolis, C | 4 |
| Carella, N | 3 |
| Messa, C | 5 |
| Cavallini, A | 5 |
| Carr, BI | 10 |
| Yamaguchi, K | 1 |
| Sugimoto, R | 3 |
| Aramaki, T | 1 |
| Asagi, A | 1 |
| Yasui, K | 4 |
| Sano, K | 2 |
| Hosokawa, A | 1 |
| Ishii, H | 5 |
| Sato, T | 4 |
| Furuse, J | 15 |
| Gade, TP | 1 |
| Hao, C | 3 |
| Shao, G | 5 |
| Xia, Q | 2 |
| Deng, X | 2 |
| Lv, Z | 1 |
| Zhang, XP | 1 |
| Wang, K | 6 |
| Guo, WX | 2 |
| Chen, ZH | 1 |
| Cheng, SQ | 4 |
| Waziry, R | 1 |
| Gomaa, A | 2 |
| Waked, I | 2 |
| Dore, GJ | 1 |
| Zhang, K | 2 |
| Xie, F | 1 |
| Jian, W | 1 |
| Lucà, MG | 1 |
| Nani, R | 1 |
| Schranz, M | 1 |
| De Giorgio, M | 3 |
| Iegri, C | 1 |
| Agazzi, R | 1 |
| Sala, F | 1 |
| Virotta, G | 1 |
| Sarti, D | 1 |
| Conte, G | 1 |
| Pinelli, D | 1 |
| Nicora, C | 1 |
| Colledan, M | 1 |
| Fagiuoli, S | 5 |
| Mulé, S | 1 |
| Thiefin, G | 1 |
| Durot, C | 1 |
| Rahmouni, A | 1 |
| Hoeffel, C | 1 |
| Tsai, JJ | 1 |
| Hsu, FT | 3 |
| Pan, PJ | 1 |
| Chen, CW | 1 |
| Kuo, YC | 2 |
| Tannus, RK | 1 |
| Almeida-Carvalho, SR | 1 |
| Loureiro-Matos, CA | 1 |
| Miziara-Gonzalez, A | 1 |
| Salzedas-Netto, AA | 1 |
| Szejnfeld, D | 1 |
| D'Ippolito, G | 1 |
| Pereira-Lanzoni, V | 1 |
| Souza-Silva, I | 1 |
| Zhang, C | 5 |
| Chi, H | 2 |
| Meng, Z | 3 |
| Renzulli, M | 2 |
| Brocchi, S | 1 |
| Ferrarini, A | 1 |
| Andreone, A | 1 |
| Benevento, F | 2 |
| Golfieri, R | 4 |
| Morselli-Labate, AM | 1 |
| Mastroroberto, M | 1 |
| Badea, RI | 1 |
| Tsuboi, R | 1 |
| Asano, T | 1 |
| Matsuura, K | 1 |
| Asabe, S | 1 |
| Mashima, H | 1 |
| Huang, J | 4 |
| Lai, L | 2 |
| Huang, W | 2 |
| Luo, L | 2 |
| Cai, L | 1 |
| Tang, Z | 2 |
| Meng, X | 3 |
| Chang, HL | 1 |
| Chen, HA | 2 |
| Bamodu, OA | 1 |
| Lee, KF | 1 |
| Lee, WH | 1 |
| Tsai, JT | 1 |
| Kang, MK | 1 |
| Park, JG | 3 |
| Ho, JC | 1 |
| Hsieh, ML | 1 |
| Chuang, PH | 2 |
| Hsieh, VC | 1 |
| Thomas, MB | 2 |
| Garrett-Mayer, E | 1 |
| Anis, M | 1 |
| Anderton, K | 1 |
| Bentz, T | 1 |
| Edwards, A | 1 |
| Brisendine, A | 1 |
| Weiss, G | 1 |
| Siegel, AB | 2 |
| Bendell, J | 1 |
| Duddalwar, V | 1 |
| El-Khoueiry, A | 1 |
| Kuzuya, T | 7 |
| Ishigami, M | 3 |
| Ishizu, Y | 3 |
| Honda, T | 3 |
| Hayashi, K | 3 |
| Nakano, I | 3 |
| Hirooka, Y | 3 |
| Goto, H | 3 |
| Mao, J | 1 |
| Yang, H | 4 |
| Cui, T | 2 |
| Pan, P | 1 |
| Kabir, N | 1 |
| Chen, D | 6 |
| Schultheiß, M | 2 |
| Fichtner-Feigl, S | 1 |
| Kim, JS | 4 |
| Choi, GH | 3 |
| Jung, Y | 1 |
| Kim, KM | 9 |
| Jang, SJ | 1 |
| Yu, ES | 1 |
| Lee, HC | 13 |
| Saber, S | 1 |
| Mahmoud, AAA | 1 |
| Goda, R | 1 |
| Helal, NS | 1 |
| El-Ahwany, E | 2 |
| Abdelghany, RH | 1 |
| Tang, X | 1 |
| Cai, S | 1 |
| Zhang, Y | 16 |
| Jiang, Z | 2 |
| Ma, D | 2 |
| Ma, X | 1 |
| Duo, J | 1 |
| Sato, Y | 2 |
| Nishiofuku, H | 2 |
| Yasumoto, T | 1 |
| Nakatsuka, A | 1 |
| Matsuo, K | 1 |
| Kodama, Y | 1 |
| Okubo, H | 1 |
| Abo, D | 1 |
| Takaki, H | 1 |
| Yamakado, K | 2 |
| Schmidt, TM | 1 |
| Liu, LI | 1 |
| Abraham, IE | 1 |
| Uy, AB | 1 |
| Dudek, AZ | 1 |
| Longo, L | 1 |
| de Freitas, LBR | 1 |
| Santos, D | 1 |
| Grivicich, I | 1 |
| Gu, C | 1 |
| Yu, G | 1 |
| Zhao, D | 7 |
| Mai, W | 1 |
| Zhong, Y | 1 |
| Nie, Y | 1 |
| Ohkawara, A | 1 |
| Ohkawara, H | 1 |
| Kakinoki, N | 1 |
| Hirai, S | 1 |
| Yanaka, A | 1 |
| Fan, Y | 1 |
| Cheng, B | 1 |
| Lin, W | 1 |
| Du, J | 1 |
| Ling, C | 1 |
| Zhao, W | 4 |
| Wang, M | 12 |
| Hu, J | 2 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Kobayashi, M | 1 |
| Tahara, M | 1 |
| Kim, DH | 3 |
| Kim, S | 1 |
| Koh, YI | 1 |
| Sim, DW | 1 |
| Al-Gayyar, MMH | 1 |
| Bagalagel, A | 1 |
| Noor, AO | 1 |
| Almasri, DM | 1 |
| Diri, R | 1 |
| Takeda, Y | 3 |
| Ohmura, Y | 1 |
| Katsura, Y | 1 |
| Sakamoto, T | 1 |
| Nose, Y | 1 |
| Mori, R | 1 |
| Inatome, J | 1 |
| Kawai, K | 2 |
| Naito, A | 1 |
| Murakami, K | 1 |
| Kagawa, Y | 1 |
| Masuzawa, T | 1 |
| Takeno, A | 2 |
| Egawa, C | 2 |
| Murata, K | 1 |
| Musso, O | 1 |
| Beraza, N | 1 |
| de Rosa, F | 2 |
| Calzà, L | 1 |
| Girolamo, SD | 1 |
| Tufoni, M | 1 |
| Ricci, CS | 1 |
| Cirignotta, F | 1 |
| Caraceni, P | 1 |
| Zhang, QB | 4 |
| Sun, HC | 7 |
| Zhang, KZ | 2 |
| Jia, QA | 1 |
| Bu, Y | 1 |
| Chai, ZT | 3 |
| Wang, WQ | 5 |
| Kong, LQ | 5 |
| Zhu, XD | 7 |
| Lu, L | 12 |
| Wu, WZ | 6 |
| Tang, ZY | 8 |
| Xin, HW | 1 |
| Ambe, CM | 1 |
| Hari, DM | 1 |
| Wiegand, GW | 1 |
| Miller, TC | 1 |
| Chen, JQ | 1 |
| Anderson, AJ | 1 |
| Ray, S | 1 |
| Mullinax, JE | 1 |
| Koizumi, T | 1 |
| Langan, RC | 1 |
| Burka, D | 1 |
| Herrmann, MA | 1 |
| Goldsmith, PK | 1 |
| Stojadinovic, A | 1 |
| Rudloff, U | 1 |
| Thorgeirsson, SS | 1 |
| Avital, I | 1 |
| He, H | 1 |
| Liu, W | 1 |
| Pan, D | 1 |
| Gu, J | 2 |
| Sprinzl, MF | 2 |
| Reisinger, F | 1 |
| Puschnik, A | 2 |
| Ringelhan, M | 1 |
| Ackermann, K | 2 |
| Hartmann, D | 1 |
| Schiemann, M | 1 |
| Schuchmann, M | 6 |
| Friess, H | 1 |
| Otto, G | 3 |
| Heikenwalder, M | 3 |
| Protzer, U | 2 |
| Montella, L | 6 |
| Addeo, R | 6 |
| Cennamo, G | 2 |
| Vincenzi, B | 5 |
| Palmieri, R | 1 |
| Sperlongano, P | 2 |
| Sperlongano, R | 1 |
| Iodice, P | 1 |
| Russo, P | 1 |
| Del Prete, S | 4 |
| Kim, YH | 5 |
| Jiang, W | 1 |
| Zeng, ZC | 2 |
| Køstner, AH | 1 |
| Sorensen, M | 1 |
| Olesen, RK | 1 |
| Grønbæk, H | 1 |
| Lassen, U | 1 |
| Zhai, JM | 1 |
| Yin, XY | 3 |
| Lai, YR | 1 |
| Hou, X | 2 |
| Cai, JP | 1 |
| Hao, XY | 1 |
| Liang, LJ | 3 |
| Zhang, LJ | 1 |
| Vogel, W | 4 |
| Kim, EH | 2 |
| Peng, YF | 2 |
| Shi, YH | 3 |
| Ding, ZB | 3 |
| Qiu, SJ | 5 |
| Hui, B | 2 |
| Gu, CY | 2 |
| Liu, WR | 1 |
| Fan, J | 11 |
| Teng, G | 2 |
| Feng, G | 1 |
| Xia, H | 1 |
| Ooi, LL | 1 |
| Hui, KM | 2 |
| Lin, CS | 2 |
| Tai, WT | 16 |
| Hsieh, CY | 1 |
| Shiau, CW | 16 |
| Serova, M | 2 |
| de Gramont, A | 4 |
| Tijeras-Raballand, A | 2 |
| Dos Santos, C | 2 |
| Riveiro, ME | 1 |
| Slimane, K | 1 |
| Faivre, S | 9 |
| Raymond, E | 7 |
| Berasain, C | 1 |
| Sposito, C | 5 |
| Mariani, L | 1 |
| Germini, A | 3 |
| Flores Reyes, M | 1 |
| Bongini, M | 2 |
| Grossi, G | 1 |
| Bhoori, S | 3 |
| Mazzaferro, V | 13 |
| Louandre, C | 9 |
| Ezzoukhry, Z | 4 |
| Godin, C | 8 |
| Barbare, JC | 12 |
| Mazière, JC | 4 |
| Chauffert, B | 8 |
| Galmiche, A | 12 |
| Wang, WJ | 2 |
| Guan, S | 3 |
| Li, HL | 1 |
| Xu, RC | 1 |
| Wu, JB | 1 |
| Liu, JS | 1 |
| Li, HP | 1 |
| Bai, W | 6 |
| Yin, ZX | 2 |
| Fan, DM | 2 |
| Zhang, ZL | 1 |
| Han, GH | 3 |
| Nimeiri, HS | 1 |
| Munster, PN | 1 |
| Vergo, MT | 1 |
| Li, CM | 1 |
| Hwang, J | 1 |
| Mulcahy, MF | 3 |
| Yeh, BM | 1 |
| Luttgen, MS | 1 |
| Grabowsky, JA | 1 |
| Stucky-Marshall, L | 1 |
| Korn, WM | 1 |
| Ko, AH | 1 |
| Bergsland, EK | 1 |
| Benson, AB | 1 |
| Venook, AP | 8 |
| Herraez, E | 1 |
| Lozano, E | 1 |
| Macias, RI | 2 |
| Vaquero, J | 1 |
| Bujanda, L | 1 |
| Banales, JM | 1 |
| Marin, JJ | 2 |
| Briz, O | 1 |
| Honma, Y | 3 |
| Shimizu, S | 14 |
| Takehara, T | 5 |
| Harada, M | 3 |
| Villanueva, A | 13 |
| D'Angelo, S | 3 |
| Secondulfo, M | 2 |
| De Cristofano, R | 2 |
| Sorrentino, P | 2 |
| Weintraub, JL | 1 |
| Salem, R | 5 |
| Salvatore, V | 5 |
| Venerandi, L | 5 |
| Morisaki, T | 1 |
| Umebayashi, M | 1 |
| Kiyota, A | 1 |
| Koya, N | 1 |
| Tanaka, H | 5 |
| Onishi, H | 3 |
| Katano, M | 1 |
| Dupont, S | 2 |
| Chatelain, D | 3 |
| Henaut, L | 1 |
| Sabbagh, C | 2 |
| Regimbeau, JM | 3 |
| Grözinger, G | 1 |
| Plentz, R | 1 |
| Toso, C | 1 |
| Mentha, G | 1 |
| Majno, P | 1 |
| Destro, A | 1 |
| Ligorio, C | 1 |
| Tronconi, MC | 3 |
| Bozzarelli, S | 3 |
| Carnaghi, C | 5 |
| Di Tommaso, L | 2 |
| Giordano, L | 4 |
| Roncalli, M | 2 |
| Suh, SJ | 3 |
| Yim, HJ | 4 |
| Sampat, KR | 1 |
| O'Neil, B | 2 |
| Faggioni, L | 3 |
| Bargellini, I | 9 |
| Ginanni, B | 4 |
| Battaglia, V | 4 |
| Romano, A | 5 |
| Bertini, M | 5 |
| Bresci, G | 6 |
| Bartolozzi, C | 7 |
| Boni, C | 3 |
| Rota Caremoli, E | 2 |
| Foa, P | 1 |
| Salvagni, S | 3 |
| Cortesi, E | 2 |
| Chiara Tronconi, M | 1 |
| Chiara Banzi, M | 1 |
| Fanello, S | 3 |
| Romano Lutman, F | 1 |
| Kusano, H | 1 |
| Akiba, J | 1 |
| Nakayama, M | 1 |
| Ueda, K | 3 |
| Yano, H | 1 |
| Chong, DQ | 1 |
| Tan, IB | 1 |
| Choo, SP | 6 |
| Cho, JY | 4 |
| Paik, YH | 4 |
| Kim, YG | 1 |
| Lim, HK | 1 |
| Min, YW | 1 |
| Gwak, GY | 5 |
| Choi, MS | 4 |
| Koh, KC | 5 |
| Paik, SW | 7 |
| Yoo, BC | 4 |
| Gong, F | 1 |
| Zhang, F | 3 |
| Zhang, P | 8 |
| Shen, J | 3 |
| Wang, Z | 12 |
| Wu, XL | 1 |
| Zeng, WZ | 1 |
| Xu, GS | 1 |
| Weng, M | 1 |
| Hou, JN | 1 |
| Jiang, MD | 1 |
| Wilson, GS | 1 |
| Hu, Z | 1 |
| Duan, W | 1 |
| Tian, A | 1 |
| Wang, XM | 1 |
| McLeod, D | 1 |
| Lam, V | 1 |
| Qiao, L | 3 |
| Safran, H | 1 |
| Charpentier, KP | 1 |
| Kaubisch, A | 2 |
| Mantripragada, K | 1 |
| Dubel, G | 1 |
| Perez, K | 1 |
| Faricy-Anderson, K | 1 |
| Miner, T | 1 |
| Eng, Y | 1 |
| Victor, J | 1 |
| Plette, A | 1 |
| Espat, J | 1 |
| Bakalarski, P | 1 |
| Wingate, P | 1 |
| Berz, D | 1 |
| Luppe, D | 1 |
| Martel, D | 1 |
| Rosati, K | 1 |
| Aparo, S | 1 |
| Noda, S | 1 |
| Shioya, M | 2 |
| Hira, D | 1 |
| Fujiyama, Y | 2 |
| Morita, SY | 1 |
| Terada, T | 1 |
| Hamed, HA | 1 |
| Yamaguchi, Y | 1 |
| Fisher, PB | 1 |
| Grant, S | 1 |
| Dent, P | 1 |
| Dekervel, J | 2 |
| van Pelt, J | 2 |
| Dai, XF | 1 |
| Zhang, RG | 1 |
| Ren, JH | 2 |
| Ma, CM | 1 |
| Frenette, CT | 3 |
| Boktour, M | 1 |
| Burroughs, SG | 1 |
| Kaseb, A | 1 |
| Galati, J | 1 |
| Gaber, AO | 1 |
| Monsour, H | 1 |
| Ghobrial, RM | 1 |
| Vouche, M | 2 |
| Kulik, L | 4 |
| Atassi, R | 1 |
| Memon, K | 1 |
| Hickey, R | 2 |
| Ganger, D | 2 |
| Miller, FH | 1 |
| Yaghmai, V | 1 |
| Abecassis, M | 2 |
| Baker, T | 3 |
| Mulcahy, M | 1 |
| Nayar, R | 1 |
| Lewandowski, RJ | 4 |
| Poullenot, F | 1 |
| Bioulac-Sage, P | 2 |
| Laumonier, H | 1 |
| Saric, J | 1 |
| Carteret, T | 1 |
| Dufour, JF | 7 |
| De Maria, N | 1 |
| De Simone, P | 1 |
| Goulis, I | 1 |
| Di Marco, V | 2 |
| De Vita, F | 1 |
| Koskinas, J | 1 |
| Semela, D | 1 |
| Toniutto, P | 4 |
| Barbier, L | 1 |
| Fuks, D | 1 |
| Pessaux, P | 1 |
| Muscari, F | 1 |
| Le Treut, YP | 2 |
| Belghiti, J | 5 |
| Xu, HX | 4 |
| Zhang, JB | 3 |
| Zhuang, PY | 4 |
| Savić, R | 3 |
| He, X | 7 |
| Fiel, I | 1 |
| Schuchman, EH | 1 |
| Zhang, YY | 1 |
| Ao, JY | 1 |
| Li, JQ | 1 |
| Jia, N | 1 |
| Liou, I | 1 |
| Halldorson, J | 1 |
| Carithers, R | 1 |
| Perkins, J | 1 |
| Reyes, J | 1 |
| Yeh, M | 1 |
| Stohr, E | 1 |
| Rao, S | 1 |
| Lin, EH | 1 |
| Chen, JW | 1 |
| Pang, PF | 1 |
| Zhou, B | 2 |
| Shan, H | 2 |
| Stein, SM | 2 |
| Wei, Y | 1 |
| Shen, N | 1 |
| Yang, G | 3 |
| Yi, B | 2 |
| Qiu, Y | 1 |
| Wild, AT | 1 |
| Gandhi, N | 1 |
| Chettiar, ST | 1 |
| Aziz, K | 1 |
| Gajula, RP | 1 |
| Williams, RD | 1 |
| Kumar, R | 1 |
| Taparra, K | 1 |
| Zeng, J | 2 |
| Cades, JA | 1 |
| Velarde, E | 1 |
| Menon, S | 1 |
| Cosgrove, D | 3 |
| Pawlik, TM | 6 |
| Maitra, A | 3 |
| Wong, J | 1 |
| Hales, RK | 1 |
| Torbenson, MS | 1 |
| Herman, JM | 1 |
| Tran, PT | 1 |
| Gedaly, R | 6 |
| Galuppo, R | 2 |
| Musgrave, Y | 1 |
| Angulo, P | 4 |
| Hundley, J | 4 |
| Shah, M | 3 |
| Daily, MF | 5 |
| Cohen, DA | 1 |
| Spear, BT | 3 |
| Evers, BM | 4 |
| Rombolà, F | 2 |
| Spinoso, A | 2 |
| Bachvarov, D | 3 |
| Lampiasi, N | 2 |
| Cusimano, A | 2 |
| McCubrey, JA | 3 |
| Montalto, G | 3 |
| Kwon, JH | 1 |
| Lee, N | 1 |
| Yu, YS | 1 |
| Kim, JP | 1 |
| Shin, JH | 1 |
| Kim, DS | 2 |
| Joh, JW | 1 |
| Choi, KY | 1 |
| Kang, KJ | 2 |
| Kim, G | 1 |
| Moon, YH | 1 |
| Wang, HJ | 1 |
| Rodriguez-Lope, C | 3 |
| Ríos, J | 2 |
| Mitsunaga, S | 5 |
| Ohno, I | 3 |
| Takahashi, H | 3 |
| Okuyama, H | 3 |
| Kuwahara, A | 3 |
| Kondo, S | 3 |
| Morizane, C | 3 |
| Ueno, H | 3 |
| Satake, M | 1 |
| Arai, Y | 1 |
| Kapanadze, T | 1 |
| Gamrekelashvili, J | 1 |
| Ma, C | 1 |
| Chan, C | 1 |
| Hewitt, S | 1 |
| Zender, L | 4 |
| Kapoor, V | 1 |
| Felsher, DW | 1 |
| Manns, MP | 5 |
| Korangy, F | 2 |
| Joo, J | 1 |
| Woo, SM | 2 |
| Lee, WJ | 2 |
| Kim, CM | 3 |
| Takahashi, Y | 3 |
| Fukunishi, S | 1 |
| Nishikawa, T | 1 |
| Nouda, S | 1 |
| Sanomura, M | 1 |
| Umegaki, E | 1 |
| Higuchi, K | 1 |
| Wen, W | 2 |
| Han, T | 2 |
| Huang, L | 1 |
| Chen, SZ | 1 |
| Xiang, DM | 2 |
| Tang, L | 3 |
| Cao, D | 2 |
| Feng, GS | 3 |
| Wu, MC | 7 |
| Wan, J | 1 |
| Mei, L | 1 |
| Gong, K | 1 |
| Yu, C | 2 |
| Miyaki, D | 3 |
| Kan, H | 1 |
| Fujino, H | 1 |
| Urabe, A | 1 |
| Fukuhara, T | 2 |
| Kobayashi, T | 5 |
| Naeshiro, N | 3 |
| Takahashi, S | 4 |
| Ishikawa, M | 1 |
| Kakizawa, H | 1 |
| Awai, K | 1 |
| Zocco, MA | 2 |
| Garcovich, M | 1 |
| Lupascu, A | 1 |
| Di Stasio, E | 1 |
| Roccarina, D | 2 |
| Annicchiarico, BE | 1 |
| Riccardi, L | 1 |
| Ainora, ME | 1 |
| Ponziani, F | 1 |
| Caracciolo, G | 1 |
| Landolfi, R | 2 |
| Siciliano, M | 1 |
| Pompili, M | 3 |
| Grieco, A | 5 |
| Lombardo, A | 1 |
| Biolato, M | 2 |
| Chen, ML | 1 |
| Yan, BS | 1 |
| Lu, WC | 1 |
| Chen, MH | 3 |
| Yu, SL | 3 |
| Yang, PC | 1 |
| Lee, BS | 4 |
| Chang, YC | 1 |
| Lin, LI | 4 |
| Liou, JY | 3 |
| Erös de Bethlenfalva-Hora, C | 1 |
| Mertens, JC | 1 |
| Piguet, AC | 2 |
| Kettenbach, J | 1 |
| Schmitt, J | 1 |
| Terracciano, L | 3 |
| Weimann, R | 1 |
| Geier, A | 2 |
| Abdel-Wahab, M | 1 |
| Shaker, M | 2 |
| Abdel-Wahab, S | 1 |
| Elbassiony, M | 2 |
| Ellithy, M | 2 |
| Holstein, A | 1 |
| Kovacs, P | 1 |
| Beil, W | 1 |
| Zhao, P | 2 |
| Li, SQ | 1 |
| Xiao, WK | 1 |
| Peng, BG | 1 |
| Kitada, N | 1 |
| Kanamori, K | 1 |
| Konishi, A | 1 |
| Tanaka, S | 2 |
| Suginoshita, Y | 1 |
| Inokuma, T | 1 |
| Hashida, T | 1 |
| Hagihara, A | 4 |
| Teranishi, Y | 1 |
| Kawamura, E | 1 |
| Fujii, H | 2 |
| Iwai, S | 1 |
| Morikawa, H | 2 |
| Enomoto, M | 1 |
| Tamori, A | 1 |
| Kawada, N | 1 |
| Shingina, A | 1 |
| Hashim, AM | 1 |
| Haque, M | 1 |
| Suen, M | 1 |
| Gill, S | 1 |
| Donnellan, F | 1 |
| Weiss, AA | 1 |
| Yang, F | 2 |
| Li, QJ | 1 |
| Gong, ZB | 1 |
| Zhou, L | 5 |
| You, N | 1 |
| Li, XL | 1 |
| Li, JJ | 3 |
| An, JZ | 1 |
| Wang, DS | 2 |
| He, Y | 1 |
| Dou, KF | 1 |
| Natori, T | 1 |
| Yamaguchi, M | 1 |
| Shim, JH | 7 |
| Ryu, MH | 7 |
| Kang, YK | 20 |
| Shin, YM | 1 |
| Lim, YS | 7 |
| Hussain, SA | 1 |
| Smith, AJ | 1 |
| Hargreaves, S | 1 |
| Hull, D | 3 |
| Gish, RG | 4 |
| Marrero, JA | 6 |
| Zhang, YQ | 4 |
| Yang, JY | 2 |
| Huang, YH | 6 |
| Fan, WZ | 1 |
| Li, JP | 3 |
| Deng, L | 1 |
| Ren, Z | 3 |
| Jia, Q | 1 |
| Wu, W | 1 |
| Shen, H | 3 |
| Moroni, M | 1 |
| Zanlorenzi, L | 1 |
| Chu, PY | 7 |
| Huang, HP | 3 |
| Liu, CY | 7 |
| Huang, JW | 10 |
| Kermiche-Rahali, S | 1 |
| Di Fiore, A | 1 |
| Drieux, F | 1 |
| Di Fiore, F | 2 |
| François, A | 1 |
| Scotté, M | 1 |
| Cha, J | 1 |
| Seong, J | 7 |
| Lee, IJ | 2 |
| Kim, JW | 2 |
| Chen, CL | 5 |
| Tsukamoto, H | 1 |
| Liu, JC | 1 |
| Kashiwabara, C | 1 |
| Feldman, D | 1 |
| Sher, L | 1 |
| Dooley, S | 1 |
| French, SW | 1 |
| Mishra, L | 1 |
| Petrovic, L | 1 |
| Jeong, JH | 2 |
| Machida, K | 1 |
| Poon, RT | 15 |
| Yau, T | 9 |
| Chen, LT | 2 |
| Kim, TY | 2 |
| Gomez-Martin, C | 2 |
| Kunz, T | 1 |
| Paquet, T | 1 |
| Brandt, U | 1 |
| Sellami, D | 1 |
| Cucchetti, A | 3 |
| Dietrich, CF | 1 |
| Lang, H | 2 |
| Schlaak, J | 1 |
| Adair, A | 1 |
| Wigmore, SJ | 1 |
| Philip, PA | 1 |
| Hu, TH | 2 |
| Boucher, E | 10 |
| Robles-Aviña, J | 1 |
| Yan, L | 2 |
| Sobhonslidsuk, A | 1 |
| Jeng, LB | 3 |
| Ezzeddine, R | 2 |
| Walters, I | 2 |
| Chang, C | 4 |
| Boige, V | 3 |
| Mathurin, P | 3 |
| Fartoux, L | 3 |
| Lin, DY | 2 |
| Sherman, M | 4 |
| Bronte, F | 1 |
| Bronte, G | 1 |
| Cusenza, S | 1 |
| Fiorentino, E | 1 |
| Rolfo, C | 1 |
| Cicero, G | 1 |
| Bronte, E | 1 |
| Firenze, A | 1 |
| Angarano, G | 2 |
| Fontana, T | 1 |
| Russo, A | 4 |
| Vogt, A | 2 |
| Sievers, E | 1 |
| Lukacs-Kornek, V | 1 |
| Decker, G | 2 |
| Raskopf, E | 2 |
| Meumann, N | 1 |
| Büning, H | 1 |
| Sauerbruch, T | 2 |
| Strassburg, CP | 1 |
| Schmidt-Wolf, IG | 1 |
| Gonzalez-Carmona, MA | 2 |
| Mallick, R | 1 |
| Cai, J | 2 |
| Wogen, J | 1 |
| Felga, G | 1 |
| Salvalaggio, PR | 1 |
| de Rezende, MB | 1 |
| de Almeida, MD | 1 |
| Pracht, M | 6 |
| Lepareur, N | 2 |
| Lenoir, L | 3 |
| Ardisson, V | 1 |
| Clement, B | 4 |
| Audrain, O | 2 |
| Tan-Shalaby, J | 1 |
| Giordano, S | 1 |
| Columbano, A | 1 |
| Yoon, EL | 2 |
| Yeon, JE | 2 |
| Kang, SH | 2 |
| Kang, K | 1 |
| Yoo, YJ | 2 |
| Byun, KS | 2 |
| Miyahara, K | 3 |
| Nouso, K | 4 |
| Morimoto, Y | 1 |
| Takeuchi, Y | 1 |
| Hagihara, H | 2 |
| Kuwaki, K | 2 |
| Ikeda, F | 2 |
| Miyake, Y | 2 |
| Nakamura, S | 4 |
| Shiraha, H | 2 |
| Takaki, A | 2 |
| Sato, S | 3 |
| Obi, S | 2 |
| Iwadou, S | 1 |
| Kobayashi, Y | 2 |
| Kariyama, K | 1 |
| Takuma, Y | 1 |
| Takabatake, H | 1 |
| Yamamoto, K | 4 |
| Elsayed, ZA | 1 |
| Zheng, YB | 3 |
| Hu, BS | 7 |
| Lu, LG | 7 |
| Shin, SY | 1 |
| Lee, YJ | 2 |
| Song, X | 2 |
| Poggi, G | 4 |
| Omata, M | 1 |
| Pitman Lowenthal, S | 1 |
| Lanzalone, S | 1 |
| Lechuga, MJ | 1 |
| Murali, AR | 1 |
| Romero-Marrero, C | 1 |
| Aucejo, F | 5 |
| Menon, KV | 1 |
| Pfeiffenberger, J | 1 |
| Hoffmann, K | 5 |
| Mehrabi, A | 1 |
| Schmitz, A | 1 |
| Radeleff, B | 3 |
| Stremmel, W | 2 |
| Schemmer, P | 5 |
| Germano, D | 3 |
| Tinessa, V | 1 |
| Barletta, E | 1 |
| Cannella, L | 1 |
| Daniele, B | 6 |
| Ventrucci, C | 1 |
| D'Adamo, S | 1 |
| Cipone, M | 2 |
| Chieco, P | 1 |
| Tsuchiya, K | 7 |
| Matsuda, S | 1 |
| Muraoka, M | 1 |
| Nakata, T | 1 |
| Tamaki, N | 1 |
| Yasui, Y | 2 |
| Suzuki, S | 1 |
| Hosokawa, T | 2 |
| Nishimura, T | 2 |
| Nakanishi, H | 2 |
| Itakura, J | 2 |
| Kurosaki, M | 2 |
| Enomoto, N | 1 |
| Izumi, N | 11 |
| Fukudo, M | 1 |
| Ito, T | 1 |
| Mizuno, T | 1 |
| Shinsako, K | 1 |
| Hatano, E | 6 |
| Uemoto, S | 4 |
| Kamba, T | 1 |
| Yamasaki, T | 1 |
| Ogawa, O | 1 |
| Seno, H | 1 |
| Chiba, T | 10 |
| Matsubara, K | 1 |
| Park, Y | 1 |
| Chang, S | 1 |
| Chon, CY | 1 |
| Bae, JS | 1 |
| Noh, SJ | 1 |
| Jang, KY | 1 |
| Chung, MJ | 1 |
| Kim, DG | 2 |
| Moon, WS | 1 |
| Xu, YY | 1 |
| Wang, GL | 1 |
| Zhou, JM | 1 |
| Wei, YZ | 1 |
| Zhu, YY | 1 |
| Qin, J | 1 |
| Yoshiji, H | 1 |
| Noguchi, R | 1 |
| Namisaki, T | 1 |
| Moriya, K | 1 |
| Kitade, M | 1 |
| Aihara, Y | 1 |
| Douhara, A | 1 |
| Kawaratani, H | 1 |
| Nishimura, N | 1 |
| Fukui, H | 1 |
| Schmieder, R | 1 |
| Puehler, F | 1 |
| Neuhaus, R | 1 |
| Kissel, M | 1 |
| Adjei, AA | 1 |
| Miner, JN | 1 |
| Mumberg, D | 1 |
| Ziegelbauer, K | 1 |
| Scholz, A | 1 |
| Zavaglia, C | 7 |
| Bai, F | 1 |
| Puoti, M | 1 |
| Belli, LS | 3 |
| Mazzarelli, C | 2 |
| Perricone, G | 3 |
| Chang, YL | 1 |
| Nagai, H | 4 |
| Kanekawa, T | 2 |
| Mukozu, T | 3 |
| Matsui, D | 3 |
| Matsui, T | 3 |
| Kanayama, M | 2 |
| Wakui, N | 4 |
| Momiyama, K | 3 |
| Shinohara, M | 6 |
| Ishii, K | 4 |
| Igarashi, Y | 8 |
| Sumino, Y | 10 |
| Cabibbo, G | 13 |
| Maida, M | 4 |
| Cammà, C | 7 |
| Craxì, A | 6 |
| Agostini, V | 1 |
| di Girolamo, S | 2 |
| Andreone, P | 1 |
| Serra, C | 1 |
| Sama, C | 1 |
| Gramenzi, A | 4 |
| Pinna, AD | 1 |
| Liang, HY | 1 |
| Shao, PJ | 3 |
| Qin, Y | 2 |
| Lu, Y | 3 |
| Wang, R | 1 |
| Qu, X | 1 |
| Reiberger, T | 3 |
| Duyverman, AM | 2 |
| Huang, P | 3 |
| Samuel, R | 1 |
| Hiddingh, L | 1 |
| Roberge, S | 1 |
| Koppel, C | 1 |
| Lauwers, GY | 1 |
| Jain, RK | 3 |
| Chow, AK | 1 |
| Ng, L | 1 |
| Lam, CS | 1 |
| Wong, SK | 1 |
| Wan, TM | 1 |
| Cheng, NS | 1 |
| Yau, TC | 1 |
| Pang, RW | 2 |
| Ishii, T | 4 |
| Yasuchika, K | 2 |
| Taura, K | 3 |
| Seo, S | 1 |
| Chen, YL | 5 |
| Hsu, CY | 5 |
| Hsu, YC | 1 |
| Lencioni, R | 11 |
| Chen, XP | 6 |
| Dagher, L | 6 |
| de Guevara, LL | 3 |
| Papandreou, C | 6 |
| Takayama, T | 9 |
| Lehr, R | 4 |
| Heldner, S | 5 |
| Sanyal, AJ | 5 |
| Salvaggio, G | 1 |
| Furlan, A | 2 |
| Agnello, F | 1 |
| Marin, D | 1 |
| Giannitrapani, L | 2 |
| Genco, C | 3 |
| Midiri, M | 1 |
| Lagalla, R | 1 |
| Brancatelli, G | 1 |
| Emura, M | 1 |
| Nakamura, T | 1 |
| Cho, T | 1 |
| Seto, R | 1 |
| Nomura, N | 1 |
| Nomizo, T | 1 |
| Igarashi, S | 1 |
| Jeong, SW | 2 |
| Jang, JY | 3 |
| Shim, KY | 1 |
| Kim, SG | 2 |
| Cha, SW | 2 |
| Kim, YS | 4 |
| Cho, YD | 2 |
| Kim, BS | 3 |
| Kim, KH | 3 |
| Qin, SK | 1 |
| Wang, ZS | 1 |
| Zheng, RS | 1 |
| Tong, XH | 1 |
| Tao, L | 1 |
| He, XD | 1 |
| Gao, HJ | 1 |
| Zhang, YJ | 4 |
| Chen, MS | 4 |
| Conde, I | 1 |
| Grossi, I | 1 |
| Specchia, C | 1 |
| Portolani, N | 1 |
| Barlati, S | 1 |
| Naqi, N | 1 |
| Ahmad, S | 1 |
| Murad, S | 1 |
| Khattak, J | 1 |
| Tomuleasa, C | 1 |
| Giannelli, G | 3 |
| Cucuianu, A | 1 |
| Aldea, M | 1 |
| Paradiso, A | 1 |
| Berindan-Neagoe, I | 1 |
| Park, HC | 2 |
| Yu, JI | 1 |
| Sohn, W | 2 |
| Man, K | 1 |
| Metselaar, HJ | 1 |
| Janssen, HL | 1 |
| Peppelenbosch, MP | 1 |
| Pan, Q | 2 |
| Huang, WC | 1 |
| Hsieh, YL | 1 |
| Hung, CM | 1 |
| Chien, PH | 1 |
| Chien, YF | 1 |
| Chen, LC | 1 |
| Tu, CY | 1 |
| Chen, CH | 3 |
| Hsu, SC | 1 |
| Lin, YM | 1 |
| Chen, YJ | 4 |
| Komatsu, H | 1 |
| Tsukamoto, T | 4 |
| Kodai, S | 1 |
| Kanazawa, A | 5 |
| Yamazoe, S | 1 |
| Ohira, G | 1 |
| Nakajima, T | 3 |
| Nakai, T | 2 |
| Kawasaki, Y | 2 |
| Kioka, K | 2 |
| Mukai, R | 1 |
| Wada, H | 4 |
| Tomimaru, Y | 2 |
| Hama, N | 1 |
| Kawamoto, K | 3 |
| Kobayashi, S | 6 |
| Eguchi, H | 3 |
| Umeshita, K | 3 |
| Doki, Y | 4 |
| Mori, M | 6 |
| Nagano, H | 4 |
| Lee, JE | 3 |
| You, YK | 2 |
| Lee, MA | 2 |
| Kong, J | 4 |
| Kong, F | 2 |
| Gao, J | 5 |
| Dong, S | 2 |
| Gu, F | 1 |
| Ke, S | 2 |
| Pan, B | 2 |
| Shen, Q | 1 |
| Nakachi, K | 4 |
| Kojima, Y | 3 |
| Katayama, K | 1 |
| Imanaka, K | 2 |
| Tamai, C | 1 |
| Kato, M | 1 |
| Wang, Q | 5 |
| Shi, G | 1 |
| Wu, R | 1 |
| Fouad, M | 1 |
| Berk, V | 1 |
| Kaplan, MA | 1 |
| Tonyali, O | 1 |
| Buyukberber, S | 1 |
| Balakan, O | 1 |
| Ozkan, M | 1 |
| Demirci, U | 1 |
| Ozturk, T | 1 |
| Bilici, A | 1 |
| Tastekin, D | 1 |
| Ozdemir, N | 1 |
| Unal, OU | 1 |
| Oflazoglu, U | 1 |
| Turkmen, E | 1 |
| Erdogan, B | 1 |
| Uyeturk, U | 1 |
| Oksuzoglu, B | 1 |
| Cinkir, HY | 1 |
| Yasar, N | 1 |
| Gumus, M | 1 |
| Shin, SK | 1 |
| Jung, YK | 1 |
| Yoon, HH | 1 |
| Kwon, OS | 1 |
| Choi, DJ | 1 |
| Sonntag, R | 1 |
| Gassler, N | 1 |
| Bangen, JM | 1 |
| Trautwein, C | 1 |
| Liedtke, C | 1 |
| He, C | 5 |
| Jiang, X | 9 |
| Pan, S | 3 |
| Wei, Z | 2 |
| Ma, L | 6 |
| Qiao, H | 5 |
| Jiang, H | 8 |
| Meng, Q | 1 |
| Yin, Q | 1 |
| Takeda, H | 5 |
| Osaki, Y | 6 |
| Takita, M | 6 |
| Inoue, T | 8 |
| Kitai, S | 6 |
| Ramanathan, R | 1 |
| Sharma, A | 1 |
| Lee, DD | 1 |
| Behnke, M | 1 |
| Bornstein, K | 1 |
| Stravitz, RT | 1 |
| Sydnor, M | 1 |
| Fulcher, A | 1 |
| Cotterell, A | 1 |
| Posner, MP | 1 |
| Fisher, RA | 1 |
| Svegliati Baroni, G | 2 |
| Loretelli, C | 3 |
| Fava, G | 2 |
| De Minicis, S | 2 |
| Mandolesi, A | 1 |
| Bianconi, M | 2 |
| Giampieri, R | 2 |
| Facchetti, F | 2 |
| Bitetto, D | 2 |
| Marinelli, S | 6 |
| Vavassori, S | 2 |
| Gemini, S | 1 |
| D'Errico, A | 1 |
| Colombo, M | 8 |
| Bearzi, I | 1 |
| Benedetti, A | 3 |
| Qi, X | 3 |
| Jia, J | 2 |
| Fan, D | 4 |
| Motoyama, T | 7 |
| Tawada, A | 9 |
| Chen, MC | 1 |
| Wang, JC | 1 |
| Tsai, AC | 1 |
| Chen, CS | 2 |
| Liou, JP | 1 |
| Pan, SL | 1 |
| Teng, CM | 1 |
| Gores, GJ | 3 |
| Del Prete, M | 2 |
| D'Anzeo, M | 1 |
| Liu, LL | 1 |
| Zhang, MF | 1 |
| Pan, YH | 1 |
| Yun, JP | 1 |
| Zhang, CZ | 1 |
| Abdelwahab, M | 1 |
| Abdelwahab, S | 1 |
| Tanoglu, A | 1 |
| Karagoz, E | 1 |
| Gallori, D | 1 |
| Antonuzzo, L | 1 |
| Forte, P | 1 |
| Tomcikova, D | 1 |
| Arena, U | 1 |
| Colagrande, S | 2 |
| Pradella, S | 1 |
| Fani, B | 1 |
| Gianni, E | 1 |
| Boni, L | 1 |
| Laffi, G | 1 |
| Di Costanzo, F | 2 |
| Brose, MS | 1 |
| Keefe, SM | 1 |
| Walko, CM | 1 |
| Grande, C | 1 |
| Chen, LF | 1 |
| Su, HY | 1 |
| Xu, K | 5 |
| Shao, HB | 1 |
| Liang, SN | 1 |
| Miyamura, T | 1 |
| van Meer, S | 2 |
| van Erpecum, KJ | 2 |
| Schrier, GH | 1 |
| Verhoef, C | 2 |
| Verheij, J | 1 |
| de Man, RA | 2 |
| van der Geest, LG | 2 |
| Kanai, F | 6 |
| Xu, M | 1 |
| Zheng, YL | 1 |
| Xie, XY | 2 |
| Liang, JY | 1 |
| Pan, FS | 1 |
| Zheng, SG | 1 |
| Lü, MD | 1 |
| Poon, DY | 1 |
| Khin, MW | 1 |
| Singh, H | 1 |
| Han, HS | 1 |
| Goh, AS | 2 |
| Lai, HK | 1 |
| Lo, RH | 2 |
| Tay, KH | 2 |
| Lim, TG | 1 |
| Tan, SB | 2 |
| Soo, KC | 4 |
| Coppola, R | 1 |
| Zanframundo, S | 1 |
| Rinati, MV | 1 |
| Carbotti, M | 1 |
| Graziano, A | 1 |
| Galati, G | 2 |
| De Florio, L | 1 |
| Panasiti, V | 1 |
| Qiu, YQ | 1 |
| Kang, XS | 1 |
| Ding, LM | 1 |
| Yu, W | 2 |
| Tan, FL | 1 |
| Deng, DF | 1 |
| Geng, ZM | 1 |
| Jha, RK | 1 |
| Li, WZ | 1 |
| Zheng, JB | 1 |
| Huanchen, S | 1 |
| Makarova, AS | 1 |
| Lazarevich, NL | 1 |
| Masuda, M | 1 |
| Chen, WY | 1 |
| Miyanaga, A | 1 |
| Nakamura, Y | 2 |
| Kawasaki, K | 1 |
| Sakuma, T | 1 |
| Ono, M | 1 |
| Honda, K | 1 |
| Yamada, T | 4 |
| Chen, H | 4 |
| Cai, G | 1 |
| Wassermann, J | 2 |
| Bruno, O | 1 |
| Dreyer, C | 1 |
| Larroque, B | 1 |
| Chen, SW | 1 |
| Lin, LC | 1 |
| Liang, JA | 1 |
| Kuo, CC | 1 |
| Chiou, JF | 3 |
| Koppe, S | 1 |
| Habib, A | 1 |
| Karp, J | 1 |
| Al-Saden, P | 1 |
| Lacouture, M | 1 |
| Cotliar, J | 1 |
| Horwitz, E | 1 |
| Stein, I | 1 |
| Andreozzi, M | 1 |
| Nemeth, J | 1 |
| Shoham, A | 1 |
| Pappo, O | 1 |
| Schweitzer, N | 2 |
| Tornillo, L | 1 |
| Kanarek, N | 1 |
| Zreik, F | 1 |
| Porat, RM | 1 |
| Finkelstein, R | 1 |
| Reuter, H | 1 |
| Mogler, C | 1 |
| Shibolet, O | 1 |
| Hess, J | 1 |
| Breuhahn, K | 1 |
| Grunewald, M | 1 |
| Schirmacher, P | 2 |
| Angel, P | 1 |
| Ben-Neriah, Y | 1 |
| Pikarsky, E | 1 |
| Fukuda, H | 2 |
| Numata, K | 8 |
| Moriya, S | 2 |
| Shimoyama, Y | 1 |
| Nozaki, A | 3 |
| Morimoto, M | 7 |
| Maeda, S | 4 |
| Sakamaki, K | 2 |
| Morita, S | 4 |
| Tanaka, K | 8 |
| Maynard, E | 1 |
| Li, GM | 1 |
| Wang, YG | 1 |
| Fan, JG | 1 |
| Sun, C | 3 |
| Ji, YX | 1 |
| Zhang, ZF | 1 |
| Lan, KT | 1 |
| Nie, KK | 1 |
| Geng, CX | 1 |
| Liu, SC | 1 |
| Zhuang, XJ | 1 |
| Zou, X | 1 |
| Zhang, ZC | 1 |
| Xiang, Q | 1 |
| Chen, W | 8 |
| Deng, DY | 1 |
| Shang, C | 2 |
| Nam, SW | 2 |
| Park, KC | 2 |
| Choi, HS | 2 |
| Lee, B | 2 |
| Kim, SW | 2 |
| Sheu, AY | 1 |
| Omary, RA | 1 |
| Shea, LD | 1 |
| Larson, AC | 2 |
| Yokosuka, AO | 1 |
| Imedio, ER | 1 |
| Beveridge, RD | 1 |
| Urtasun, JA | 1 |
| Campos, GB | 1 |
| Estellés, DL | 1 |
| Esparcia, MF | 1 |
| Daroqui, JC | 1 |
| Huerta, ÁS | 1 |
| Ortiz, AG | 1 |
| Salcedo, JM | 1 |
| Akutsu, N | 1 |
| Sasaki, S | 1 |
| Motoya, M | 1 |
| Shitani, M | 1 |
| Igarashi, M | 1 |
| Hirayama, D | 1 |
| Wakasugi, H | 1 |
| Yamamoto, H | 1 |
| Kaneto, H | 1 |
| Yonezawa, K | 1 |
| Yawata, A | 1 |
| Hamamoto, Y | 1 |
| Shinomura, Y | 1 |
| Mosconi, C | 2 |
| Cappelli, A | 2 |
| Pettinato, C | 2 |
| Erroi, V | 1 |
| Fiumana, S | 1 |
| Raza, A | 1 |
| Sood, GK | 1 |
| Fu, QH | 2 |
| Bai, XL | 2 |
| Hu, QD | 1 |
| Su, W | 1 |
| Chen, YW | 1 |
| Su, RG | 1 |
| Liang, TB | 2 |
| Zhong, L | 1 |
| Fu, XY | 1 |
| Zou, C | 1 |
| Yang, LL | 1 |
| Zhou, S | 3 |
| Tang, Y | 2 |
| Cheng, C | 1 |
| Li, LL | 1 |
| Xiang, R | 1 |
| Chen, LJ | 3 |
| Chen, YZ | 1 |
| Wei, YQ | 1 |
| Yang, SY | 1 |
| Wei, K | 3 |
| Mu, H | 1 |
| Song, TQ | 2 |
| Ye, L | 2 |
| Guo, E | 1 |
| Peng, X | 1 |
| Yan, T | 1 |
| Zhou, F | 2 |
| Scionti, A | 1 |
| Mismas, V | 3 |
| Masi, G | 5 |
| Vivaldi, C | 4 |
| Gyöngyösi, B | 1 |
| Végh, É | 1 |
| Járay, B | 1 |
| Székely, E | 1 |
| Fassan, M | 1 |
| Bodoky, G | 4 |
| Schaff, Z | 1 |
| Kiss, A | 1 |
| Liu, YC | 3 |
| Chiang, IT | 1 |
| Liu, RS | 1 |
| Wang, HE | 1 |
| Lin, WJ | 1 |
| Hwang, JJ | 2 |
| Castelli, G | 1 |
| Burra, P | 3 |
| Giacomin, A | 1 |
| Vitale, A | 4 |
| Senzolo, M | 2 |
| Cillo, U | 6 |
| Farinati, F | 4 |
| Reataza, M | 1 |
| Imagawa, DK | 2 |
| Srimuninnimit, V | 1 |
| Sriuranpong, V | 1 |
| Suwanvecho, S | 1 |
| Fu, SR | 2 |
| Zhan, MX | 2 |
| Hu, H | 3 |
| Duan, Z | 2 |
| Long, X | 2 |
| Hertzanu, Y | 2 |
| Shi, H | 3 |
| Matsuda, Y | 4 |
| Wakai, T | 2 |
| Kubota, M | 2 |
| Osawa, M | 1 |
| Hirose, Y | 1 |
| Sakata, J | 1 |
| Fujimaki, S | 2 |
| Takamura, M | 2 |
| Yamagiwa, S | 2 |
| Aoyagi, Y | 2 |
| Narjoz, C | 1 |
| Favre, A | 1 |
| McMullen, J | 1 |
| Kiehl, P | 1 |
| Montemurro, M | 2 |
| Figg, WD | 2 |
| Beaune, P | 1 |
| de Waziers, I | 1 |
| Rochat, B | 1 |
| Yuan, H | 1 |
| Li, AJ | 1 |
| Ma, SL | 2 |
| Cui, LJ | 1 |
| Yin, L | 2 |
| Nishikawa, H | 3 |
| Taniguchi, H | 3 |
| Orito, E | 3 |
| Uchida, Y | 3 |
| Guerra, JR | 1 |
| Suelves, AM | 1 |
| Bella, A | 1 |
| Lolo, D | 1 |
| Shouval, D | 1 |
| Peng, S | 2 |
| Peng, H | 1 |
| Shen, S | 1 |
| Peng, B | 1 |
| Tremosini, S | 2 |
| Mazza, G | 1 |
| Gadaleta-Caldarola, G | 4 |
| Lombardi, G | 3 |
| Antonucci, M | 3 |
| Ai, DL | 1 |
| Fu, JL | 1 |
| Peng, XM | 1 |
| Zhang, LZ | 1 |
| Wang, JY | 1 |
| Yang, B | 3 |
| Liu, CZ | 1 |
| Wang, HM | 1 |
| Okawa, H | 2 |
| Maejima, T | 2 |
| Yanagi, T | 1 |
| Hisamichi, K | 2 |
| Matsuura, M | 2 |
| Akasaka, K | 1 |
| Tsuchiya, M | 1 |
| Kondo, Y | 3 |
| Shimosegawa, T | 2 |
| Maekawa, M | 2 |
| Suzuki, H | 3 |
| Mano, N | 2 |
| Giannuzzi, G | 1 |
| Nakazawa, T | 5 |
| Hidaka, H | 7 |
| Shibuya, A | 5 |
| Okuwaki, Y | 4 |
| Tanaka, Y | 3 |
| Takada, J | 5 |
| Minamino, T | 3 |
| Kokubu, S | 2 |
| Koizumi, W | 4 |
| Luo, X | 1 |
| Zheng, J | 1 |
| Luo, J | 1 |
| Chapiro, J | 4 |
| Duran, R | 4 |
| Bruera, G | 2 |
| Cannita, K | 1 |
| Giordano, AV | 2 |
| Manetta, R | 1 |
| Vicentini, R | 1 |
| Carducci, S | 1 |
| Saltarelli, P | 1 |
| Iapadre, N | 1 |
| Coletti, G | 1 |
| Ficorella, C | 1 |
| Ricevuto, E | 2 |
| Milazzo, M | 2 |
| Croci, L | 2 |
| Pecorelli, A | 2 |
| Palamà, C | 2 |
| Diana, A | 1 |
| Malarvizhi, GL | 1 |
| Retnakumari, AP | 1 |
| Nair, S | 1 |
| Koyakutty, M | 1 |
| Liang, XD | 1 |
| Dai, YC | 1 |
| Li, ZY | 2 |
| Gan, MF | 1 |
| Zhang, SR | 1 |
| Lu, HS | 1 |
| Cao, XQ | 1 |
| Zheng, BJ | 1 |
| Bao, LF | 1 |
| Wang, DD | 2 |
| Zhang, LM | 1 |
| Ladep, NG | 1 |
| Dona, AC | 1 |
| Lewis, MR | 1 |
| Crossey, MM | 1 |
| Lemoine, M | 1 |
| Okeke, E | 1 |
| Shimakawa, Y | 1 |
| Duguru, M | 1 |
| Njai, HF | 1 |
| Fye, HK | 1 |
| Taal, M | 1 |
| Chetwood, J | 1 |
| Kasstan, B | 1 |
| Khan, SA | 1 |
| Garside, DA | 1 |
| Wijeyesekera, A | 1 |
| Thillainayagam, AV | 1 |
| Banwat, E | 1 |
| Thursz, MR | 1 |
| Nicholson, JK | 1 |
| Njie, R | 1 |
| Holmes, E | 1 |
| Taylor-Robinson, SD | 1 |
| Agilli, M | 1 |
| Aydin, FN | 1 |
| Kurt, YG | 1 |
| Bulla, K | 1 |
| Kolligs, F | 2 |
| Reimer, P | 1 |
| Schütte, K | 2 |
| Walecki, J | 1 |
| Hu, P | 1 |
| Alsaied, OA | 1 |
| Sangwan, V | 1 |
| Banerjee, S | 1 |
| Krosch, TC | 1 |
| Chugh, R | 1 |
| Saluja, A | 1 |
| Vickers, SM | 1 |
| Jensen, EH | 1 |
| Peng, HS | 1 |
| Liao, MB | 1 |
| Zhang, MY | 1 |
| Zheng, XF | 1 |
| Chen, YF | 1 |
| Ady, JW | 1 |
| Heffner, J | 1 |
| Mojica, K | 1 |
| Johnsen, C | 1 |
| Belin, LJ | 1 |
| Love, D | 1 |
| Pugalenthi, A | 1 |
| Klein, E | 1 |
| Chen, NG | 1 |
| Yu, YA | 1 |
| Szalay, AA | 1 |
| Fong, Y | 1 |
| Peveling-Oberhag, J | 1 |
| Döring, C | 1 |
| Hartmann, S | 1 |
| Filmann, N | 1 |
| Mertens, A | 1 |
| Piiper, A | 2 |
| Herrmann, E | 2 |
| Hansmann, ML | 1 |
| Zeuzem, S | 7 |
| Welker, MW | 4 |
| Bolos, D | 1 |
| Lee, FA | 1 |
| Zee, BC | 1 |
| Cheung, FY | 1 |
| Kwong, P | 1 |
| Chiang, CL | 1 |
| Leung, KC | 1 |
| Siu, SW | 1 |
| Lee, C | 1 |
| Lai, M | 1 |
| Kwok, C | 1 |
| Chong, M | 1 |
| Jolivet, J | 1 |
| Tung, S | 1 |
| Vandewynckel, YP | 1 |
| Laukens, D | 1 |
| Geerts, A | 2 |
| Vanhove, C | 1 |
| Descamps, B | 1 |
| Colle, I | 2 |
| Devisscher, L | 1 |
| Bogaerts, E | 1 |
| Paridaens, A | 1 |
| Verhelst, X | 1 |
| Van Steenkiste, C | 1 |
| Libbrecht, L | 2 |
| Lambrecht, BN | 1 |
| Janssens, S | 1 |
| Van Vlierberghe, H | 2 |
| Alsina, AE | 1 |
| Makris, A | 1 |
| Nenos, V | 1 |
| Sucre, E | 1 |
| Arrobas, J | 1 |
| Franco, E | 1 |
| Kemmer, N | 1 |
| Sengodan, P | 1 |
| Grewal, H | 1 |
| Gandhi, S | 1 |
| Ulahannan, SV | 1 |
| Duffy, AG | 1 |
| McNeel, TS | 1 |
| Kish, JK | 1 |
| Dickie, LA | 1 |
| Rahma, OE | 1 |
| McGlynn, KA | 1 |
| Altekruse, SF | 1 |
| Nishida, A | 1 |
| Inatomi, O | 1 |
| Bamba, S | 1 |
| Sasaki, M | 3 |
| Andoh, A | 1 |
| Wu, CT | 1 |
| Liu, C | 7 |
| Long, J | 1 |
| Ni, QX | 1 |
| Yu, XJ | 2 |
| Yang, KJ | 1 |
| Song, DS | 1 |
| Chung, WJ | 2 |
| Yang, JM | 1 |
| Choi, JI | 5 |
| Bhosale, P | 1 |
| Bhargava, P | 1 |
| Tirkes, T | 1 |
| Seery, TE | 1 |
| Lall, C | 1 |
| Mao, K | 1 |
| Tan, C | 1 |
| Zeng, Y | 2 |
| Xiao, Z | 2 |
| Vaira, V | 1 |
| Faversani, A | 1 |
| Maggioni, M | 1 |
| Augello, C | 1 |
| Spagnuolo, G | 1 |
| Barberis, M | 1 |
| Labianca, R | 2 |
| Bosari, S | 1 |
| Su, JC | 2 |
| Tseng, PH | 2 |
| Wu, SH | 1 |
| Chen, IT | 1 |
| Cattan, S | 2 |
| Dorval, E | 1 |
| Jappe, A | 1 |
| Perraud, K | 1 |
| Anak, O | 1 |
| Sellami, DB | 1 |
| Lavi, O | 1 |
| Skinner, J | 1 |
| Gottesman, MM | 1 |
| Zhu, X | 4 |
| Gilabert, M | 1 |
| Yang, M | 4 |
| Yuan, JQ | 1 |
| Zhao, YL | 1 |
| Guo, QQ | 1 |
| Yang, GR | 1 |
| Wang, QD | 1 |
| Chung, YH | 6 |
| Shao, GL | 2 |
| Kim, BI | 3 |
| İlknur, T | 1 |
| Akarsu, S | 1 |
| Çarsanbali, S | 1 |
| Lebe, B | 1 |
| Fetil, E | 1 |
| Fitzmorris, P | 1 |
| Shoreibah, M | 1 |
| Anand, BS | 1 |
| Singal, AK | 1 |
| Chang, CJ | 1 |
| Jeng, YM | 2 |
| Lin, YJ | 1 |
| Gandhi, AK | 1 |
| Liao, SC | 1 |
| Huang, ZM | 1 |
| Erhardt, A | 1 |
| Dollinger, M | 1 |
| Wege, H | 5 |
| Gog, C | 2 |
| Lammert, F | 1 |
| Walter, C | 1 |
| Blondin, D | 1 |
| Ohmann, C | 1 |
| Häussinger, D | 2 |
| Tan-Shalaby, JL | 1 |
| Daoudaki, M | 1 |
| Fouzas, I | 2 |
| Francini, E | 2 |
| Bianco, V | 2 |
| Tang, W | 2 |
| Xue, R | 1 |
| Weng, S | 1 |
| Fang, Y | 1 |
| Ji, L | 2 |
| Hu, T | 1 |
| Shen, X | 1 |
| Muche, S | 1 |
| Kirschnick, M | 1 |
| Schwarz, M | 1 |
| Braeuning, A | 1 |
| Rudalska, R | 1 |
| Dauch, D | 2 |
| Longerich, T | 1 |
| McJunkin, K | 1 |
| Wuestefeld, T | 1 |
| Kang, TW | 1 |
| Hohmeyer, A | 1 |
| Pesic, M | 1 |
| Leibold, J | 1 |
| von Thun, A | 1 |
| Zuber, J | 1 |
| Weiss, KH | 1 |
| Powers, S | 1 |
| Malek, NP | 4 |
| Eilers, M | 1 |
| Sipos, B | 1 |
| Lowe, SW | 1 |
| Geffers, R | 1 |
| Laufer, S | 1 |
| Jung, HU | 1 |
| Yoo, SH | 1 |
| Yoo, KS | 1 |
| Cheong, J | 1 |
| Park, BS | 1 |
| Yun, I | 1 |
| Yoo, YH | 1 |
| Li, G | 4 |
| Ni, S | 1 |
| Jeong, KY | 1 |
| Lee, EJ | 1 |
| Yang, SH | 2 |
| Burki, TK | 1 |
| Corona-Villalobos, CP | 1 |
| Halappa, VG | 1 |
| Bonekamp, S | 1 |
| Reyes, D | 1 |
| Kamel, IR | 3 |
| Yoshikawa, M | 2 |
| Endo, M | 1 |
| Hsieh, SC | 1 |
| Tsai, JP | 1 |
| Yang, SF | 1 |
| Tang, MJ | 1 |
| Hsieh, YH | 1 |
| Hamilton, G | 1 |
| Rath, B | 1 |
| Yada, M | 1 |
| Masumoto, A | 2 |
| Motomura, K | 1 |
| Tajiri, H | 1 |
| Morita, Y | 1 |
| Senju, T | 1 |
| Koyanagi, T | 1 |
| Herz, C | 1 |
| Hertrampf, A | 1 |
| Zimmermann, S | 1 |
| Stetter, N | 1 |
| Wagner, M | 1 |
| Kleinhans, C | 1 |
| Erlacher, M | 1 |
| Schüler, J | 1 |
| Platz, S | 1 |
| Rohn, S | 1 |
| Mersch-Sundermann, V | 1 |
| Lamy, E | 1 |
| Gazzola, A | 2 |
| Di Donato, R | 2 |
| Kikuchi, L | 1 |
| Oliveira, CP | 1 |
| Tani, CM | 1 |
| Diniz, MA | 1 |
| Stefano, JT | 1 |
| Alencar, RS | 1 |
| Vezozzo, DC | 1 |
| Santos, GR | 1 |
| Campos, PB | 1 |
| Alves, VA | 1 |
| Ratziu, V | 2 |
| Carrilho, FJ | 2 |
| Han, S | 1 |
| Kim, JK | 3 |
| Kweon, YO | 4 |
| Lee, JI | 1 |
| Lee, KS | 2 |
| Barroso-Sousa, R | 1 |
| Bento, Ada S | 1 |
| Blanco, BP | 1 |
| Valente, GL | 1 |
| Pfiffer, TE | 2 |
| Fan, W | 3 |
| Ran, H | 1 |
| Lin, CY | 3 |
| Rau, KM | 2 |
| Yeo, W | 1 |
| Tay, MH | 1 |
| Hsieh, WS | 1 |
| Kappeler, C | 1 |
| Rajagopalan, P | 2 |
| Krissel, H | 1 |
| Jeffers, M | 2 |
| Pan, T | 1 |
| Li, XS | 1 |
| Xie, QK | 1 |
| Wang, JP | 1 |
| Wu, PH | 1 |
| Zhao, M | 1 |
| Albines, GS | 1 |
| Mesa, A | 1 |
| Fuentes-Martínez, N | 1 |
| Pérez, R | 1 |
| Fernández-Molina, J | 1 |
| Chiang, HC | 1 |
| Ko, CH | 2 |
| Lin, MW | 2 |
| Huan, HB | 2 |
| Lau, WY | 4 |
| Xia, F | 3 |
| Ma, KS | 2 |
| Schmidtmann, I | 1 |
| Elsäßer, A | 1 |
| Binder, H | 1 |
| Bruzzi, P | 1 |
| Danesi, R | 1 |
| Spandonaro, F | 1 |
| Liang, Q | 1 |
| Mei, X | 1 |
| Chishina, H | 4 |
| Kono, M | 4 |
| Jeng, WJ | 1 |
| Sheen, IS | 2 |
| Hung, MH | 5 |
| Feng, X | 4 |
| Xu, R | 2 |
| Du, X | 1 |
| Qin, X | 2 |
| Jia, W | 1 |
| Zhao, H | 4 |
| Ma, K | 3 |
| Mazzaroppi, S | 1 |
| Fiaschi, AI | 1 |
| Petrioli, R | 1 |
| Laera, L | 1 |
| Roviello, G | 1 |
| Pira, T | 1 |
| Pellicelli, AM | 1 |
| Matsui, O | 4 |
| Kadoya, M | 2 |
| Miyayama, S | 1 |
| Minami, T | 1 |
| Yoon, HI | 2 |
| Fucile, C | 1 |
| Marenco, S | 2 |
| Bazzica, M | 1 |
| Zuccoli, ML | 1 |
| Lantieri, F | 1 |
| Robbiano, L | 1 |
| Marini, V | 1 |
| Di Gion, P | 1 |
| Pieri, G | 1 |
| Stura, P | 1 |
| Martelli, A | 1 |
| Savarino, V | 1 |
| Mattioli, F | 1 |
| Picciotto, A | 1 |
| Marcq, I | 1 |
| Bouhlal, H | 1 |
| Lachaier, E | 1 |
| Saidak, Z | 5 |
| François, C | 4 |
| Debuysscher, V | 1 |
| Nagel, C | 1 |
| Armeanu-Ebinger, S | 1 |
| Dewerth, A | 1 |
| Warmann, SW | 1 |
| Fuchs, J | 1 |
| Seino, S | 1 |
| Tsuchiya, A | 1 |
| Musettini, G | 1 |
| Caparello, C | 1 |
| Felder, M | 2 |
| Fornaro, L | 2 |
| Lin, YT | 2 |
| Lu, HP | 2 |
| Chao, CC | 3 |
| Xu, F | 2 |
| Jia, C | 1 |
| Xu, Y | 7 |
| Dai, C | 1 |
| Schlitter, AM | 2 |
| Schad, A | 2 |
| Esposito, I | 2 |
| Abdel-Rehim, M | 1 |
| Zheng, SZ | 1 |
| Liu, DJ | 1 |
| Yu, GS | 1 |
| Xu, YT | 1 |
| Gong, W | 1 |
| Crouzet, L | 4 |
| Le Sourd, S | 2 |
| Larible, C | 1 |
| Brunot, A | 2 |
| Le Roy, F | 2 |
| Cattenoz, C | 1 |
| Latournerie, M | 1 |
| Gédouin, D | 1 |
| Guillygomarc'h, A | 3 |
| Saito, T | 4 |
| Narang-Master, J | 1 |
| Rizzolo, D | 1 |
| Cainap, C | 2 |
| Huang, WT | 1 |
| Chung, IJ | 1 |
| Pan, H | 4 |
| Gorbunova, V | 1 |
| Eskens, FA | 3 |
| Qian, J | 1 |
| McKee, MD | 2 |
| Ricker, JL | 2 |
| Carlson, DM | 1 |
| El-Nowiem, S | 1 |
| Ohkawa, S | 4 |
| Okuse, C | 3 |
| Suzuki, M | 2 |
| Romero Gutiérrez, M | 2 |
| Ruano Díaz, L | 1 |
| Muñoz López, D | 1 |
| Artaza Varasa, T | 1 |
| González de Frutos, C | 2 |
| Sánchez Ruano, JJ | 1 |
| de la Cruz Pérez, G | 2 |
| Gómez Rodríguez, R | 2 |
| Schmidt, L | 1 |
| op den Winkel, M | 1 |
| Fischer, K | 1 |
| Straub, G | 1 |
| Rauch, B | 1 |
| Paprottka, PM | 1 |
| Göke, B | 1 |
| Kolligs, FT | 1 |
| Senda, S | 1 |
| Xi, W | 1 |
| Ahn, JM | 1 |
| Sinn, DH | 2 |
| Sangiovanni, A | 4 |
| Ramjiawan, RR | 2 |
| Ng, MR | 1 |
| Hato, T | 2 |
| Ochiai, H | 1 |
| Kitahara, S | 2 |
| Unan, EC | 1 |
| Reddy, TP | 1 |
| Fan, C | 1 |
| Bardeesy, N | 2 |
| Zhao, L | 3 |
| Fang, Q | 1 |
| Zhan, C | 1 |
| Rosmorduc, O | 10 |
| Evans, TR | 3 |
| Thuluvath, PJ | 1 |
| Leberre, MA | 3 |
| Jensen, M | 1 |
| Liu, FY | 3 |
| Fu, JX | 1 |
| Duan, F | 4 |
| Fan, QS | 1 |
| Wang, MQ | 3 |
| Wei, JC | 1 |
| Meng, FD | 1 |
| Qu, K | 1 |
| Wang, ZX | 1 |
| Wu, QF | 1 |
| Zhang, LQ | 1 |
| Pang, Q | 1 |
| Hollebecque, A | 2 |
| Malka, D | 1 |
| Ferté, C | 1 |
| Ducreux, M | 1 |
| Negri, FV | 3 |
| Dal Bello, B | 1 |
| Porta, C | 6 |
| Campanini, N | 1 |
| Rossi, S | 1 |
| Tinelli, C | 1 |
| Missale, G | 1 |
| Ardizzoni, A | 1 |
| Maria, SE | 1 |
| de León, FJ | 1 |
| Blanes, MM | 1 |
| Albares, MP | 1 |
| Berbegal, L | 1 |
| Shau, WY | 1 |
| Chan, SY | 2 |
| Turnes, J | 3 |
| Díaz, R | 1 |
| Gómez, M | 1 |
| Castells, L | 2 |
| Bustamante, J | 4 |
| Espinosa, MD | 1 |
| Fernández-Castroagudín, J | 1 |
| Serrano, T | 1 |
| Rendón, P | 1 |
| Andrade, R | 1 |
| Salgado, M | 1 |
| Arenas, J | 1 |
| Polo, BA | 1 |
| Granizo, IM | 1 |
| Gonzálvez, ML | 1 |
| Viudez, A | 1 |
| Lim, S | 1 |
| Han, J | 1 |
| Kim, GM | 2 |
| Kim, GA | 1 |
| Yoon, SM | 1 |
| Jung, J | 1 |
| Lee, D | 3 |
| Lee, YS | 4 |
| Yulyana, Y | 1 |
| Ho, IA | 1 |
| Sia, KC | 1 |
| Newman, JP | 1 |
| Toh, XY | 1 |
| Endaya, BB | 1 |
| Chan, JK | 1 |
| Gnecchi, M | 1 |
| Huynh, H | 5 |
| Chung, AY | 2 |
| Lim, KH | 2 |
| Leong, HS | 1 |
| Iyer, NG | 1 |
| Lam, PY | 1 |
| Ohta, K | 1 |
| Hoshino, H | 1 |
| Ono, S | 1 |
| Iida, Y | 1 |
| Hata, K | 1 |
| Huang, SK | 1 |
| Colquhoun, S | 1 |
| Hoon, DS | 1 |
| Gao, H | 3 |
| Zhou, Z | 1 |
| Zhao, G | 2 |
| Ma, W | 3 |
| Song, T | 8 |
| Zhang, T | 5 |
| Kong, D | 3 |
| Mazzola, A | 1 |
| Enea, M | 2 |
| Galvano, A | 1 |
| Belli, L | 1 |
| Sun, G | 1 |
| Coy, DH | 1 |
| Liu, PH | 1 |
| Hsia, CY | 1 |
| Su, CW | 2 |
| Huo, TI | 2 |
| Della Corte, C | 2 |
| Barbara, M | 1 |
| Basso, M | 1 |
| Feng, YM | 1 |
| Feng, CW | 1 |
| Lu, CL | 1 |
| Lee, MY | 1 |
| Liu, A | 1 |
| Peng, J | 1 |
| Hu, Y | 3 |
| Chan, YC | 1 |
| Kabiling, CS | 1 |
| Pillai, VG | 1 |
| Aguilar, G | 1 |
| Wang, CC | 2 |
| Kang, H | 2 |
| Qu, Z | 2 |
| Shi, L | 5 |
| Bai, Y | 1 |
| Guo, X | 3 |
| Zhang, X | 12 |
| Zhou, T | 2 |
| Wen, F | 4 |
| Yan, W | 2 |
| Hao, P | 1 |
| Bi, F | 1 |
| Icard, N | 1 |
| Laffont, S | 1 |
| Mesbah, H | 1 |
| Breton, M | 1 |
| Sulpice, L | 1 |
| Boudjema, K | 2 |
| Rohou, T | 2 |
| Sudan, S | 1 |
| Rupasinghe, HV | 1 |
| Kirstein, MM | 1 |
| Schmidt, S | 1 |
| Klöpper, A | 1 |
| Ringe, KI | 1 |
| Lehmann, U | 1 |
| Wedemeyer, H | 1 |
| Ishijima, N | 1 |
| Kanki, K | 1 |
| Shimizu, H | 1 |
| Shiota, G | 2 |
| Kan, X | 1 |
| Jing, Y | 1 |
| Wan, QY | 1 |
| Pan, JC | 1 |
| Han, M | 1 |
| Liu, KH | 1 |
| Ye, X | 2 |
| Ouyang, H | 1 |
| Tao, S | 1 |
| Qiao, K | 1 |
| Fu, Q | 1 |
| Elmashad, N | 1 |
| Ibrahim, WS | 1 |
| Mayah, WW | 1 |
| Farouk, M | 1 |
| Ali, LA | 1 |
| Taha, A | 1 |
| Elmashad, W | 1 |
| Tong, X | 2 |
| Bellentani, S | 1 |
| Saccoccio, G | 1 |
| Kumar, S | 2 |
| Yue, H | 1 |
| Ma, N | 2 |
| Li, K | 1 |
| Gao, X | 1 |
| Zeng, Z | 3 |
| An, L | 2 |
| Qu, J | 2 |
| Lin, Y | 3 |
| Jin, Y | 2 |
| Wang, D | 3 |
| Tan, Y | 1 |
| Watanabe, Y | 2 |
| Nakaba, H | 1 |
| Taniguchi, E | 1 |
| Kikkawa, H | 1 |
| Tamagawa, H | 1 |
| Kitayama, T | 1 |
| Doi, Y | 1 |
| Oguchi, Y | 1 |
| Hosoda, Y | 1 |
| Kakita, N | 1 |
| Yamada, Y | 1 |
| Yamasaki, M | 1 |
| Nishino, M | 1 |
| Okano, M | 1 |
| Nagai, K | 1 |
| Yasui, M | 1 |
| Tsujinaka, T | 1 |
| Bodeau, S | 2 |
| Diouf, M | 3 |
| Conte, MA | 1 |
| Barget, N | 2 |
| Trinchet, JC | 1 |
| Ganne, N | 2 |
| de Stefano, G | 3 |
| Farella, N | 2 |
| Addario, L | 2 |
| Lampasi, F | 3 |
| Lanza, AG | 2 |
| Cordone, G | 4 |
| Imparato, M | 2 |
| Caporaso, N | 2 |
| Rigalli, JP | 1 |
| Ciriaci, N | 1 |
| Arias, A | 1 |
| Ceballos, MP | 1 |
| Villanueva, SS | 1 |
| Luquita, MG | 1 |
| Mottino, AD | 1 |
| Ghanem, CI | 1 |
| Catania, VA | 1 |
| Ruiz, ML | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Lam, W | 1 |
| Guan, F | 1 |
| Hu, R | 1 |
| Bussom, S | 1 |
| Liu, SH | 2 |
| Yen, Y | 2 |
| Cheng, YC | 2 |
| Kishikawa, T | 1 |
| Otsuka, M | 1 |
| Tan, PS | 1 |
| Ohno, M | 1 |
| Yoshikawa, T | 2 |
| Shibata, C | 1 |
| Takata, A | 2 |
| Takehana, K | 1 |
| Ohishi, M | 1 |
| Ota, S | 1 |
| Noyama, T | 1 |
| Sato, M | 1 |
| Soga, T | 1 |
| Hoshida, Y | 7 |
| Koike, K | 1 |
| Delire, B | 1 |
| Stärkel, P | 1 |
| Yanai, S | 1 |
| Ooho, A | 1 |
| Esaki, M | 1 |
| Azuma, K | 1 |
| Kitazono, T | 1 |
| Matsumoto, T | 1 |
| Quirk, M | 1 |
| Saab, S | 3 |
| Lee, EW | 1 |
| Gu, HR | 1 |
| Choi, SJ | 1 |
| Lee, JC | 1 |
| Kim, YC | 1 |
| Han, CJ | 1 |
| Kim, J | 2 |
| Yang, KY | 1 |
| Noh, GY | 1 |
| No, SH | 1 |
| Kim, JO | 2 |
| Jun, DW | 1 |
| Tae, HJ | 1 |
| Lee, KN | 1 |
| Lee, HL | 1 |
| Lee, OY | 1 |
| Yoon, BC | 1 |
| Hahm, JS | 1 |
| Schrier, JG | 1 |
| Ijzermans, JN | 1 |
| Yeh, CC | 2 |
| Ho, WC | 1 |
| Tsai, MH | 4 |
| Feng, WC | 4 |
| Chow, LP | 1 |
| Yang, T | 1 |
| Shen, YN | 2 |
| Shen, F | 2 |
| Schwartz, M | 4 |
| Lee, IC | 1 |
| Chen, YT | 1 |
| Li, CP | 1 |
| Lee, FY | 1 |
| Terzi, E | 1 |
| Ha, TY | 2 |
| Moon, KM | 1 |
| Won, YJ | 2 |
| Song, GW | 2 |
| Kim, N | 3 |
| Tak, E | 2 |
| Hong, HN | 2 |
| Choi, YI | 1 |
| Yoon, SY | 1 |
| Ogino, YU | 1 |
| Higai, K | 1 |
| Liu, N | 3 |
| Sun, HL | 1 |
| Shen, WF | 1 |
| Wang, RY | 1 |
| Li, HY | 1 |
| Cong, WM | 2 |
| Abbattista, MR | 1 |
| Jamieson, SM | 1 |
| Nickel, JE | 1 |
| Pullen, SM | 1 |
| Patterson, AV | 1 |
| Wilson, WR | 2 |
| Guise, CP | 1 |
| Ganten, MK | 2 |
| Schuessler, M | 1 |
| Bruckner, T | 1 |
| Abei, M | 1 |
| Danjoh, I | 1 |
| Shirota, R | 1 |
| Hyodo, I | 1 |
| Song, IH | 2 |
| Noh, R | 1 |
| Kang, HY | 1 |
| Kim, SB | 1 |
| Ko, SY | 1 |
| Lee, ES | 1 |
| Kim, AN | 1 |
| Chae, HB | 1 |
| Lee, TH | 1 |
| Kang, YW | 1 |
| Lee, JD | 2 |
| Lee, HY | 1 |
| Shinoda, M | 1 |
| Kishida, N | 1 |
| Itano, O | 1 |
| Ei, S | 1 |
| Ueno, A | 1 |
| Kitago, M | 1 |
| Abe, Y | 1 |
| Hibi, T | 1 |
| Yagi, H | 1 |
| Masugi, Y | 1 |
| Tanabe, M | 2 |
| Aiura, K | 1 |
| Sakamaoto, M | 1 |
| Tanimoto, A | 1 |
| Kitagawa, Y | 1 |
| Iodice, V | 1 |
| Feng, K | 1 |
| Dou, H | 1 |
| Hong, YM | 2 |
| Yoon, KT | 3 |
| Cho, M | 3 |
| Kang, DH | 3 |
| Kim, HW | 2 |
| Choi, CW | 2 |
| Park, SB | 2 |
| Lim, W | 2 |
| Lv, X | 2 |
| Ruan, B | 1 |
| Ding, R | 1 |
| Gao, Y | 2 |
| Lau, EY | 1 |
| Ching, RH | 1 |
| Cheng, BY | 1 |
| Ma, MK | 1 |
| Ng, IO | 2 |
| Lee, TK | 1 |
| Kuczynski, EA | 3 |
| Lee, CR | 3 |
| Man, S | 4 |
| Chen, E | 1 |
| Kerbel, RS | 5 |
| Facciorusso, A | 3 |
| Licinio, R | 1 |
| Di Leo, A | 2 |
| Barone, M | 2 |
| Tang, R | 1 |
| Du, Z | 1 |
| Kalyan, A | 1 |
| Nimeiri, H | 1 |
| Takai, K | 1 |
| Hanai, T | 1 |
| Ideta, T | 1 |
| Miyazaki, T | 1 |
| Kochi, T | 1 |
| Suetsugu, A | 1 |
| Shiraki, M | 1 |
| Shimizu, M | 1 |
| Muscatiello, N | 1 |
| Gotthardtp, D | 1 |
| Settmacher, U | 1 |
| Kollmar, O | 1 |
| Nadalin, S | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| von Kalle, C | 2 |
| Jäger, D | 2 |
| Büchler, MW | 3 |
| Kim, BH | 1 |
| Kim, BC | 1 |
| Shin, A | 1 |
| Hong, SH | 2 |
| Hwang, JA | 1 |
| Lee, JA | 1 |
| Nam, S | 1 |
| Bhak, J | 1 |
| Labgaa, I | 1 |
| Lin, TH | 1 |
| Ku, CY | 1 |
| Wang, YR | 1 |
| Lin, HY | 1 |
| Lu, SC | 1 |
| Lin, JY | 1 |
| Schernthaner, RE | 1 |
| Lv, Y | 2 |
| Liang, R | 1 |
| Liao, X | 1 |
| Yuan, C | 1 |
| Liao, S | 1 |
| Zolfino, T | 1 |
| Sansonno, D | 2 |
| Montesarchio, V | 3 |
| Attili, A | 1 |
| Buonadonna, A | 1 |
| Barni, S | 1 |
| Burlone, ME | 4 |
| Villa, E | 3 |
| Giovanis, P | 1 |
| Proserpio, I | 1 |
| Magini, G | 1 |
| Cengarle, R | 2 |
| Cuttone, F | 1 |
| Calvani, N | 1 |
| Angelico, M | 1 |
| Noto, A | 1 |
| Marignani, M | 1 |
| Amoroso, D | 1 |
| Massa, E | 1 |
| Crocè, LS | 1 |
| Picardi, A | 2 |
| Tumulo, S | 1 |
| Erminero, C | 1 |
| Lorusso, V | 2 |
| Groß, C | 1 |
| Steiger, K | 1 |
| Sayyed, S | 1 |
| Heid, I | 1 |
| Feuchtinger, A | 1 |
| Walch, A | 1 |
| Heß, J | 1 |
| Unger, K | 1 |
| Zitzelsberger, H | 1 |
| Settles, M | 1 |
| Dworniczak, J | 1 |
| Altomonte, J | 1 |
| Ebert, O | 1 |
| Schwaiger, M | 1 |
| Rummeny, E | 1 |
| Steingötter, A | 1 |
| Braren, R | 1 |
| Shi, Y | 2 |
| Huang, A | 1 |
| Rousseau, B | 2 |
| Payancé, A | 1 |
| Huillard, O | 1 |
| Qian, Z | 1 |
| Che, S | 1 |
| Shang, H | 1 |
| Bao, J | 1 |
| Kim, MN | 1 |
| Ro, SW | 1 |
| Kim, da Y | 1 |
| Cho, KJ | 1 |
| Park, JH | 1 |
| Grillone, A | 1 |
| Riva, ER | 1 |
| Mondini, A | 1 |
| Forte, C | 1 |
| Calucci, L | 1 |
| Innocenti, C | 1 |
| de Julian Fernandez, C | 1 |
| Cappello, V | 1 |
| Gemmi, M | 1 |
| Moscato, S | 1 |
| Ronca, F | 1 |
| Mattoli, V | 1 |
| Ciofani, G | 1 |
| Fukubayashi, K | 1 |
| Izumi, K | 1 |
| Fujie, S | 1 |
| Kawasaki, T | 1 |
| Yoshimaru, Y | 1 |
| Tateyama, M | 1 |
| Setoyama, H | 1 |
| Naoe, H | 1 |
| Kikuchi, K | 1 |
| Jia, B | 1 |
| Tan, L | 1 |
| Jin, Z | 1 |
| Liu, R | 3 |
| Sakai, K | 3 |
| Nishijima, N | 1 |
| Nishio, K | 4 |
| Albuquerque, M | 1 |
| Paradis, V | 5 |
| Neuzillet, C | 1 |
| Benhadji, KA | 1 |
| Cosgrove, DP | 1 |
| Reyes, DK | 2 |
| Feng, AL | 1 |
| He, AR | 2 |
| Hung, CH | 2 |
| Austin, T | 1 |
| Greenberg, J | 1 |
| Shiratori, S | 1 |
| Beckman, RA | 1 |
| Lu, YY | 1 |
| Wang, JJ | 1 |
| Zhang, XK | 1 |
| Li, WB | 1 |
| Guo, XL | 1 |
| Zheng, JF | 1 |
| Wang, XZ | 1 |
| Guo, WH | 1 |
| Zhang, JX | 1 |
| Fu, S | 3 |
| Kubackova, K | 1 |
| Sastre, J | 3 |
| Chang, SC | 1 |
| Schwartz, JD | 1 |
| Waidmann, O | 3 |
| Zhou, DS | 1 |
| Zhao, J | 5 |
| Spolverato, G | 1 |
| Li, SP | 1 |
| Morio, R | 2 |
| Waki, K | 3 |
| Siao, FY | 1 |
| Yen, HH | 2 |
| Azmi, AN | 1 |
| Chan, WK | 1 |
| Goh, KL | 2 |
| Aedo, V | 1 |
| Cristina, V | 1 |
| Shiozawa, K | 7 |
| Ikehara, T | 5 |
| Kogame, M | 4 |
| Okano, N | 2 |
| Kikuchi, Y | 6 |
| Makino, H | 2 |
| Cong, N | 1 |
| Shi, C | 2 |
| Bu, W | 1 |
| Song, J | 1 |
| Croitoru, A | 1 |
| Serejo, F | 1 |
| Stål, P | 1 |
| Tang, C | 1 |
| Zhou, M | 1 |
| He, D | 2 |
| Zheng, D | 1 |
| Infusino, S | 2 |
| Divella, R | 2 |
| Ferraro, E | 2 |
| Mazzocca, A | 2 |
| De Rose, F | 1 |
| Filippelli, G | 2 |
| Abbate, I | 2 |
| Brandi, M | 2 |
| Weber, A | 1 |
| O'Connor, T | 1 |
| Jin, R | 2 |
| Ying, H | 1 |
| Yan, H | 2 |
| Huang, D | 2 |
| Shyue, SK | 1 |
| Feng, ZR | 2 |
| Fan, HH | 3 |
| Su, H | 1 |
| Shao, H | 1 |
| Liang, S | 1 |
| Neeff, HP | 1 |
| Hwang, SW | 1 |
| Chun, HG | 1 |
| Chun, HJ | 1 |
| Jung, ES | 1 |
| Kitade, H | 2 |
| Yanagida, H | 1 |
| Yokoigawa, N | 1 |
| Hijikawa, T | 1 |
| Kaibori, M | 5 |
| Matsui, K | 5 |
| Ishizaki, M | 5 |
| Yoshioka, K | 1 |
| Kon, M | 1 |
| Torrecilla, S | 3 |
| Wang, SH | 1 |
| Yeh, SH | 1 |
| Lin, WH | 1 |
| Tsai, TF | 1 |
| Teng, YC | 1 |
| Chen, DS | 1 |
| Pigneur, F | 1 |
| Nelson, AC | 1 |
| Tselikas, L | 1 |
| Katsahian, S | 1 |
| Diao, G | 1 |
| Gnoni, A | 1 |
| Licchetta, A | 1 |
| Lupo, L | 2 |
| Palasciano, G | 1 |
| Memeo, V | 1 |
| Guarini, A | 1 |
| Pisconti, S | 1 |
| Gao, DY | 3 |
| Lin, TsT | 1 |
| Sung, YC | 2 |
| Chiang, WH | 1 |
| Chang, CC | 2 |
| Liu, JY | 2 |
| Schmithals, C | 1 |
| Köberle, V | 1 |
| Korkusuz, H | 1 |
| Pleli, T | 1 |
| Kakoschky, B | 1 |
| Augusto, EA | 1 |
| Ibrahim, AA | 1 |
| Arencibia, JM | 1 |
| Vafaizadeh, V | 1 |
| Groner, B | 1 |
| Korf, HW | 1 |
| Kronenberger, B | 1 |
| Vogl, TJ | 2 |
| Kitajima, T | 1 |
| Mitsunori, Y | 2 |
| Fujimoto, Y | 1 |
| Mizumoto, M | 1 |
| Okajima, H | 1 |
| Kaido, T | 1 |
| Minamiguchi, S | 1 |
| Xiu, P | 1 |
| Wei, H | 1 |
| Xu, Z | 1 |
| Seo, MS | 1 |
| Shim, JY | 1 |
| Guan, DX | 2 |
| Shi, J | 2 |
| Zhao, JS | 1 |
| Long, LY | 1 |
| Chen, TW | 1 |
| Zhang, EB | 1 |
| Feng, YY | 1 |
| Bao, WD | 1 |
| Deng, YZ | 2 |
| Qiu, L | 1 |
| Zhang, XL | 1 |
| Koeffler, HP | 1 |
| Xie, D | 2 |
| Daniele, A | 1 |
| Sabbà, C | 1 |
| Marceglia, S | 1 |
| Chiang, T | 1 |
| Liu, CH | 2 |
| Chern, GG | 1 |
| Lin, TT | 2 |
| Ho, V | 1 |
| Lim, TS | 1 |
| Lee, J | 5 |
| Steinberg, J | 1 |
| Szmyd, R | 1 |
| Tham, M | 1 |
| Yaligar, J | 1 |
| Kaldis, P | 1 |
| Abastado, JP | 1 |
| Chew, V | 1 |
| Sima, H | 1 |
| Zhu, N | 2 |
| Dong, D | 1 |
| Thapa, RK | 1 |
| Poudel, BK | 1 |
| Hiep, TT | 1 |
| Pathak, S | 1 |
| Gupta, B | 1 |
| Choi, HG | 1 |
| Yong, CS | 1 |
| Matsukiyo, Y | 3 |
| Li, M | 5 |
| Fang, T | 3 |
| Jiang, G | 1 |
| Qiu, X | 1 |
| Guo, W | 4 |
| Yan, B | 1 |
| Kwon, YC | 1 |
| Bose, SK | 1 |
| Steele, R | 1 |
| Meyer, K | 1 |
| Di Bisceglie, AM | 1 |
| Ray, RB | 1 |
| Ray, R | 1 |
| Lu, WJ | 1 |
| Chua, MS | 2 |
| Wei, W | 2 |
| So, SK | 1 |
| Chau, GY | 2 |
| Roayaie, S | 2 |
| Makuuchi, M | 1 |
| Souza, F | 1 |
| Berre, MA | 1 |
| Kurokawa, T | 1 |
| Murata, S | 1 |
| Zheng, YW | 1 |
| Iwasaki, K | 1 |
| Kohno, K | 1 |
| Fukunaga, K | 1 |
| Ohkohchi, N | 1 |
| Petta, S | 2 |
| Katano, Y | 1 |
| Yamagami, M | 1 |
| Ito, D | 1 |
| Kawanishi, K | 1 |
| Gabrielson, A | 1 |
| Tesfaye, AA | 1 |
| Marshall, JL | 1 |
| Pishvaian, MJ | 1 |
| Smaglo, B | 1 |
| Jha, R | 1 |
| Dorsch-Vogel, K | 1 |
| Adhoute, X | 2 |
| Kanda, M | 1 |
| Sugimoto, H | 1 |
| Kodera, Y | 1 |
| Nagai, S | 1 |
| Mangus, RS | 1 |
| Kubal, CA | 1 |
| Ekser, B | 1 |
| Fridell, JA | 1 |
| Klingler, KR | 1 |
| Maluccio, MA | 2 |
| Tector, AJ | 1 |
| Sharma, R | 4 |
| Suddle, A | 3 |
| Quaglia, A | 1 |
| Peddu, P | 1 |
| Karani, J | 1 |
| Satyadas, T | 1 |
| Heaton, N | 2 |
| Kim, HR | 1 |
| Lee, HS | 2 |
| Nakagawa, T | 1 |
| Chubachi, S | 1 |
| Gon, H | 1 |
| Kido, M | 1 |
| Fukumoto, T | 1 |
| Takebe, A | 1 |
| Kuramitsu, K | 1 |
| Kinoshita, H | 1 |
| Fukushima, K | 1 |
| Urade, T | 1 |
| So, S | 2 |
| Shinzeki, M | 1 |
| Matsumoto, I | 1 |
| Ajiki, T | 1 |
| Ku, Y | 1 |
| Nakano, M | 3 |
| Kuromatsu, R | 3 |
| Nagamatsu, H | 3 |
| Tajiri, N | 2 |
| Satani, M | 3 |
| Niizeki, T | 3 |
| Aino, H | 2 |
| Okamura, S | 3 |
| Iwamoto, H | 3 |
| Shimose, S | 2 |
| Shirono, T | 2 |
| Koga, H | 3 |
| Torimura, T | 3 |
| Qin, C | 1 |
| Kataoka, Y | 1 |
| Sun, YF | 2 |
| Sun, HX | 2 |
| Zhu, QF | 2 |
| Yang, XR | 3 |
| Gao, YB | 1 |
| Tang, WG | 1 |
| Anders, RA | 2 |
| Kitano, M | 2 |
| Iwanishi, M | 1 |
| Ida, H | 1 |
| de'Angelis, N | 2 |
| Landi, F | 2 |
| Carra, MC | 1 |
| Azoulay, D | 2 |
| Zhong, JH | 2 |
| Matsunaga, K | 2 |
| Scarpi, E | 4 |
| Tamberi, S | 3 |
| Tenti, E | 2 |
| Ricca Rosellini, S | 1 |
| Ulivi, P | 3 |
| Nanni, O | 2 |
| Alkhatib, A | 1 |
| Allam, N | 1 |
| Rewisha, E | 1 |
| Ge, N | 2 |
| Qian, H | 2 |
| Wu, M | 4 |
| Yin, Z | 5 |
| Houessinon, A | 2 |
| Gicquel, A | 1 |
| Bochereau, F | 1 |
| Nyga, R | 1 |
| Degonville, J | 1 |
| Fournier, E | 1 |
| Drullion, C | 1 |
| Pluquet, O | 1 |
| Adjibade, P | 1 |
| St-Sauveur, VG | 1 |
| Quevillon Huberdeau, M | 1 |
| Fournier, MJ | 1 |
| Savard, A | 1 |
| Coudert, L | 1 |
| Khandjian, EW | 1 |
| Mazroui, R | 1 |
| Wilson, G | 1 |
| Zhou, G | 1 |
| Hebbard, L | 1 |
| Gao, JJ | 1 |
| Shi, ZY | 1 |
| Xia, JF | 1 |
| Coulouarn, C | 1 |
| Pei, Y | 1 |
| Qin, L | 2 |
| Zhu, W | 1 |
| Jia, H | 2 |
| Elleuch, N | 1 |
| Ennaifer, R | 1 |
| Romdhane, H | 1 |
| Cheikh, M | 1 |
| Hefaiedh, R | 1 |
| Bougassas, W | 1 |
| Ben Nejma, H | 1 |
| BelHadj, N | 1 |
| Mazzoccoli, G | 1 |
| Miele, L | 2 |
| Oben, J | 1 |
| Shan, J | 1 |
| Luo, Y | 1 |
| Yao, C | 1 |
| Qian, C | 1 |
| Tovar, V | 5 |
| Cornella, H | 1 |
| Moeini, A | 2 |
| Vidal, S | 1 |
| Sia, D | 3 |
| Peix, J | 2 |
| Cabellos, L | 4 |
| Alsinet, C | 5 |
| Martinez-Quetglas, I | 2 |
| Lozano, JJ | 1 |
| Desbois-Mouthon, C | 3 |
| Solé, M | 2 |
| Domingo-Domenech, J | 1 |
| Ang, C | 2 |
| Miura, JT | 1 |
| Gamblin, TC | 1 |
| He, R | 1 |
| Xiu, J | 1 |
| Millis, SZ | 1 |
| Gatalica, Z | 2 |
| Reddy, SK | 1 |
| Yee, NS | 1 |
| Zhang, JY | 1 |
| Lou, Y | 1 |
| Li, GG | 1 |
| Chen, ZL | 1 |
| Yiu, ZZ | 1 |
| Ali, FR | 1 |
| Griffiths, CE | 1 |
| Chao, TI | 1 |
| Chang, MJ | 1 |
| Pénaranda, G | 1 |
| Conroy, G | 1 |
| Perrier, H | 1 |
| Pol, B | 1 |
| Bayle, O | 1 |
| Monnet, O | 1 |
| Beaurain, P | 1 |
| Muller, C | 4 |
| Castellani, P | 1 |
| Bourlière, M | 1 |
| Zahavi, T | 1 |
| Lanton, T | 1 |
| Divon, MS | 1 |
| Salmon, A | 1 |
| Peretz, T | 1 |
| Galun, E | 1 |
| Axelrod, JH | 1 |
| Sonnenblick, A | 1 |
| Tsubota, A | 1 |
| Nakagawa, A | 1 |
| Kondo, C | 1 |
| Iwakiri, K | 1 |
| Ponziani, FR | 1 |
| Flores, M | 1 |
| Cao, L | 2 |
| Yuan-run, Z | 1 |
| Jian, C | 1 |
| Xiao-chun, Y | 1 |
| Pei-hua, L | 1 |
| Gavanier, M | 1 |
| Ayav, A | 1 |
| Sellal, C | 1 |
| Orry, X | 1 |
| Claudon, M | 1 |
| Lu, Z | 2 |
| Ladrón de Guevara, L | 3 |
| Mikagi, K | 1 |
| Mokdad, AA | 1 |
| Singal, AG | 3 |
| Yopp, AC | 3 |
| Cao, M | 4 |
| You, A | 2 |
| Zhou, H | 4 |
| Fang, F | 3 |
| Han, K | 1 |
| Ko, GY | 2 |
| Gwon, DI | 1 |
| Sung, KB | 2 |
| Hiensch, R | 1 |
| Meinhof, K | 1 |
| Nandedkar, D | 1 |
| Chun, G | 1 |
| Dua, S | 1 |
| Tomonari, T | 1 |
| Takeishi, S | 1 |
| Taniguchi, T | 1 |
| Tanaka, T | 3 |
| Fujimoto, S | 1 |
| Okamoto, K | 1 |
| Miyamoto, H | 1 |
| Muguruma, N | 1 |
| Dazert, E | 1 |
| Colombi, M | 1 |
| Boldanova, T | 1 |
| Moes, S | 1 |
| Adametz, D | 1 |
| Roth, V | 1 |
| Jenoe, P | 1 |
| Hall, MN | 1 |
| Firtina Karagonlar, Z | 1 |
| Koc, D | 1 |
| Iscan, E | 1 |
| Erdal, E | 1 |
| Atabey, N | 1 |
| Ciuleanu, T | 1 |
| Bazin, I | 1 |
| Lungulescu, D | 1 |
| Miron, L | 1 |
| Bondarenko, I | 1 |
| Deptala, A | 1 |
| Rodriguez-Torres, M | 1 |
| Giantonio, B | 1 |
| Fox, NL | 1 |
| Wissel, P | 1 |
| Egger, J | 1 |
| Ding, M | 1 |
| Kalyani, RN | 1 |
| Humphreys, R | 1 |
| Gribbin, M | 1 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Kakisaka, T | 1 |
| Orimo, T | 1 |
| Wakayama, K | 1 |
| Shimada, S | 2 |
| Tsuruga, Y | 1 |
| Kamachi, H | 1 |
| Matoba, H | 1 |
| Seta, S | 1 |
| Mukai, Y | 1 |
| Tomokuni, A | 1 |
| Asaoka, T | 2 |
| Marubashi, S | 1 |
| Deguchi, S | 2 |
| Yamamoto, S | 1 |
| Murata, A | 2 |
| Sakae, M | 2 |
| Tachimori, A | 1 |
| Tamamori, Y | 1 |
| Yamamoto, A | 1 |
| Yamashita, Y | 1 |
| Nishiguchi, Y | 1 |
| Kurihara, S | 1 |
| Tashima, T | 1 |
| Guglielmi, A | 1 |
| Luca, A | 1 |
| Del Arbol, LR | 1 |
| Niu, W | 1 |
| Nicholson, K | 1 |
| Xu, IM | 1 |
| Lai, RK | 1 |
| Lin, SH | 1 |
| Tse, AP | 1 |
| Chiu, DK | 1 |
| Koh, HY | 1 |
| Law, CT | 1 |
| Wong, CM | 1 |
| Cai, Z | 2 |
| Wong, CC | 1 |
| Stefanovic, M | 1 |
| Tutusaus, A | 1 |
| Martinez-Nieto, GA | 1 |
| Bárcena, C | 1 |
| de Gregorio, E | 1 |
| Moutinho, C | 1 |
| Barbero-Camps, E | 1 |
| Colell, A | 1 |
| Marí, M | 1 |
| García-Ruiz, C | 2 |
| Fernandez-Checa, JC | 2 |
| Morales, A | 1 |
| Hu, MD | 1 |
| Jia, LH | 1 |
| Liu, HB | 1 |
| Zhang, KH | 1 |
| Guo, GH | 1 |
| Shirota, N | 1 |
| Sugimoto, K | 3 |
| Takara, K | 1 |
| Moriyasu, F | 2 |
| Tokuuye, K | 1 |
| Niu, J | 2 |
| Yuan, J | 1 |
| Cai, H | 2 |
| Xia, J | 2 |
| Jiang, D | 1 |
| Yu, D | 1 |
| Cheng, X | 1 |
| Thorpe, PE | 1 |
| Brekken, RA | 1 |
| Wang, G | 1 |
| Zhou, SF | 1 |
| Qiu, P | 1 |
| Wen, P | 1 |
| Wen, J | 1 |
| Xiao, X | 1 |
| Brade, AM | 1 |
| Ng, S | 1 |
| Brierley, J | 1 |
| Dinniwell, R | 1 |
| Ringash, J | 1 |
| Wong, RR | 1 |
| Cho, C | 1 |
| Knox, J | 2 |
| Dawson, LA | 2 |
| Grimm, D | 1 |
| Lieb, J | 1 |
| Weyer, V | 1 |
| Vollmar, J | 1 |
| Darstein, F | 1 |
| Lautem, A | 1 |
| Hoppe-Lotichius, M | 2 |
| Zimmermann, T | 1 |
| Shih, CT | 1 |
| Yu, HC | 2 |
| Koeberle, D | 1 |
| Demeter, G | 1 |
| Ribi, K | 1 |
| Samaras, P | 1 |
| Saletti, P | 1 |
| Roth, AD | 1 |
| Horber, D | 1 |
| Buehlmann, M | 1 |
| Wagner, AD | 1 |
| Lakatos, G | 1 |
| Feilchenfeldt, J | 1 |
| Rauch, D | 1 |
| Tschanz, B | 1 |
| Donati, G | 1 |
| Giampalma, E | 1 |
| Bisulli, M | 1 |
| Corbelli, J | 2 |
| Gardini, A | 1 |
| La Barba, G | 1 |
| Veneroni, L | 1 |
| Loinaz Segurola, C | 1 |
| LIedó Navarro, JL | 1 |
| Burgos, Rde L | 1 |
| Martín Ríos, D | 1 |
| Ochando Cerdán, F | 1 |
| Alonso López, S | 1 |
| Martel Villagrán, J | 1 |
| Gutiérrez Garcia, ML | 1 |
| Fernandez Cebrián, JM | 1 |
| Fernández Rodríguez, C | 1 |
| Abdel-Rahman, OM | 1 |
| Elsayed, Z | 1 |
| Han, SY | 2 |
| Um, SH | 1 |
| Lee, WS | 1 |
| de la Torre, MA | 1 |
| Buades-Mateu, J | 1 |
| de la Rosa, PA | 1 |
| Bustamante, FJ | 1 |
| Serrano, MT | 1 |
| Testillano, M | 2 |
| Lorente, S | 1 |
| Gil, C | 1 |
| Iñarrairaegui, M | 1 |
| Gao, M | 1 |
| Kong, Q | 1 |
| Hua, H | 1 |
| Yin, Y | 1 |
| Luo, T | 1 |
| Jiang, Y | 2 |
| Zhou, SL | 1 |
| Zhou, ZJ | 1 |
| Hu, ZQ | 2 |
| Huang, XW | 3 |
| Chen, EB | 1 |
| Dai, Z | 3 |
| Matsuzaki, Y | 1 |
| Minami, H | 1 |
| Ito, Y | 2 |
| Inuyama, L | 1 |
| Okita, K | 2 |
| Ma, WL | 2 |
| Yeh, S | 2 |
| Brito, AF | 1 |
| Ribeiro, M | 1 |
| Abrantes, AM | 1 |
| Mamede, AC | 1 |
| Laranjo, M | 1 |
| Casalta-Lopes, JE | 1 |
| Gonçalves, AC | 1 |
| Sarmento-Ribeiro, AB | 1 |
| Tralhão, JG | 1 |
| Botelho, MF | 1 |
| Siveke, JT | 1 |
| Dollinger, MM | 1 |
| Scheulen, ME | 3 |
| Zagonel, V | 1 |
| Holzapfel, J | 1 |
| Herz, T | 1 |
| Ammendola, AS | 1 |
| Pegoraro, S | 1 |
| Hauns, B | 1 |
| Mais, A | 1 |
| Lauer, UM | 3 |
| Henning, SW | 1 |
| Hentsch, B | 1 |
| Zuo, B | 1 |
| Yin, H | 2 |
| Boo, YP | 1 |
| Chan, HF | 1 |
| Skibba, M | 1 |
| Liang, G | 1 |
| Xiao, W | 1 |
| Yin, X | 1 |
| Lai, J | 1 |
| Liang, L | 1 |
| Lei, J | 1 |
| Hao, J | 1 |
| Zhu, J | 2 |
| Wen, T | 1 |
| Chou, JW | 2 |
| Cheng, KS | 2 |
| Huang, CW | 1 |
| Mao, YL | 1 |
| Sun, BC | 1 |
| Meng, Y | 1 |
| Yang, YF | 1 |
| Chen, KH | 1 |
| Weng, MT | 1 |
| Chou, YH | 1 |
| Lu, YF | 1 |
| Hsieh, CH | 2 |
| Lorenzin, D | 1 |
| Pravisani, R | 1 |
| Leo, CA | 1 |
| Bugiantella, W | 1 |
| Soardo, G | 1 |
| Carnelutti, A | 1 |
| Umberto, B | 1 |
| Risaliti, A | 1 |
| Yao, X | 1 |
| Zeng, H | 1 |
| Niu, X | 1 |
| Chen, R | 1 |
| He, W | 1 |
| Kang, R | 1 |
| Tang, D | 1 |
| Rouleau, L | 1 |
| Antony, AN | 1 |
| Bisetto, S | 1 |
| Newberg, A | 1 |
| Doria, C | 1 |
| Levine, M | 1 |
| Monti, DA | 1 |
| Hoek, JB | 1 |
| Lv, W | 1 |
| Sahu, S | 1 |
| Ren, W | 1 |
| Mu, W | 1 |
| Gu, S | 1 |
| Jang, BK | 1 |
| Choi, WY | 1 |
| Choi, SM | 1 |
| Hwang, JS | 1 |
| Chauhan, AK | 1 |
| Lee, CH | 1 |
| Ye, HH | 1 |
| Xie, ZB | 1 |
| Peng, YC | 1 |
| Chen, JZ | 1 |
| Qin, HG | 1 |
| Lauletta, G | 2 |
| Neri, LM | 1 |
| Amadori, D | 2 |
| Yin, M | 1 |
| Bar-Zion, A | 1 |
| Butz, H | 1 |
| Daley, F | 1 |
| Vermeulen, PB | 1 |
| Yousef, GM | 1 |
| Foster, FS | 1 |
| Reynolds, AR | 1 |
| Camelli, V | 1 |
| Spinardi, L | 1 |
| Bucci, L | 1 |
| Thongprasert, S | 1 |
| Sukeepaisarnjaroen, W | 1 |
| Chan, SL | 4 |
| Balsara, B | 1 |
| Rodriguez, AM | 1 |
| Urano, S | 1 |
| Ohara, T | 1 |
| Noma, K | 1 |
| Katsube, R | 1 |
| Tomono, Y | 1 |
| Tazawa, H | 1 |
| Kagawa, S | 1 |
| Shirakawa, Y | 1 |
| Kimura, F | 1 |
| Matsukawa, A | 1 |
| Fujiwara, T | 1 |
| Yang, Q | 1 |
| Jiang, QY | 1 |
| Ma, HD | 1 |
| Sun, HW | 1 |
| Hou, MX | 1 |
| Yang, YP | 1 |
| Su, X | 2 |
| Leung, BC | 1 |
| Ho, RL | 2 |
| Lee, CG | 1 |
| Lai, PB | 2 |
| Hou, Y | 1 |
| Cai, XB | 1 |
| Liu, M | 2 |
| Ma, NF | 1 |
| Chow, RK | 1 |
| Chan, TH | 1 |
| Xi, S | 1 |
| Jiang, L | 1 |
| Zeng, TT | 1 |
| Yuan, YF | 2 |
| Guan, XY | 1 |
| Zhang, PF | 1 |
| Li, KS | 1 |
| Shen, YH | 1 |
| Gao, PT | 1 |
| Dong, ZR | 1 |
| Cai, JB | 1 |
| Huang, XY | 3 |
| Tian, MX | 1 |
| Ke, AW | 3 |
| Shi, GM | 3 |
| Dan, Y | 1 |
| Tong, Z | 1 |
| Mo, P | 1 |
| Yamashita, S | 1 |
| Hsiao, WD | 1 |
| Peng, CY | 1 |
| Lai, HC | 1 |
| Chen, YY | 1 |
| Yu, CJ | 1 |
| Feng, CL | 1 |
| Su, WP | 1 |
| Chen, SH | 1 |
| Kao, JT | 1 |
| Wheeler, J | 1 |
| Fu, P | 1 |
| Yamashita, M | 1 |
| Ogawa, H | 1 |
| Yamada, D | 1 |
| Gotoh, K | 1 |
| Xie, A | 1 |
| Cang, Y | 1 |
| Kim, HC | 1 |
| Chung, JW | 1 |
| Kim, do Y | 2 |
| Wu, FQ | 1 |
| Yu, LX | 1 |
| Lv, GS | 1 |
| Lv, HW | 1 |
| Liang, D | 1 |
| Wang, CZ | 1 |
| Tan, YX | 1 |
| Guo, LN | 2 |
| Tang, SH | 1 |
| Sarpel, U | 1 |
| Spivack, JH | 1 |
| Berger, Y | 1 |
| Heskel, M | 1 |
| Aycart, SN | 1 |
| Sweeney, R | 1 |
| Edwards, MP | 1 |
| Labow, DM | 1 |
| Kim, E | 1 |
| Park, W | 1 |
| Cho, S | 1 |
| Park, SJ | 1 |
| Na, K | 1 |
| Doyle, A | 1 |
| Marsh, P | 1 |
| Gill, R | 1 |
| Rodov, M | 1 |
| Mohsen, W | 1 |
| Varma, P | 1 |
| Hong, T | 1 |
| Strasser, SI | 1 |
| Bell, S | 1 |
| Ryan, M | 1 |
| Nicoll, A | 1 |
| Lubel, J | 1 |
| Gow, PJ | 1 |
| Fink, MA | 1 |
| Roberts, S | 1 |
| Kemp, W | 1 |
| Kronborg, I | 1 |
| Arachchi, N | 1 |
| Knight, V | 1 |
| Dev, A | 1 |
| Cui, SX | 1 |
| Shi, WN | 1 |
| Song, ZY | 1 |
| Wang, SQ | 1 |
| Yu, XF | 1 |
| Gao, ZH | 1 |
| Qu, XJ | 1 |
| Kim, MD | 1 |
| Won, JY | 1 |
| Park, SI | 1 |
| Lee, do Y | 1 |
| Shin, W | 1 |
| Shin, M | 1 |
| Sauzay, C | 2 |
| Mongelard, G | 1 |
| Gutierrez, L | 1 |
| Coriat, R | 7 |
| He, J | 2 |
| Zeng, M | 2 |
| Leung, HW | 1 |
| Liu, CF | 1 |
| Chan, AL | 1 |
| Kamiya, T | 1 |
| Chang, YH | 1 |
| Campana, D | 1 |
| Deng, YR | 1 |
| Liu, WB | 1 |
| Lian, ZX | 1 |
| Golse, N | 1 |
| Radenne, S | 1 |
| Rode, A | 1 |
| Ducerf, C | 1 |
| Mabrut, JY | 1 |
| Johnson, P | 6 |
| Ross, P | 3 |
| Sumpter, K | 2 |
| Darby, S | 2 |
| Evans, J | 1 |
| Iwuji, C | 2 |
| Swinson, D | 2 |
| Patel, K | 3 |
| Muazzam, I | 2 |
| Gane, E | 2 |
| Peña, CE | 2 |
| Horii, R | 1 |
| Kawaguchi, K | 1 |
| Kitamura, K | 2 |
| Shahda, S | 1 |
| Loehrer, PJ | 1 |
| Clark, RS | 1 |
| Spittler, AJ | 1 |
| Althouse, SK | 1 |
| Chiorean, EG | 2 |
| Andreoli, JM | 1 |
| Kallini, JR | 1 |
| Gabr, A | 1 |
| Kircher, S | 1 |
| Aziz, AO | 1 |
| Omran, D | 1 |
| Nabeel, MM | 1 |
| Elbaz, TM | 1 |
| Abdelmaksoud, AH | 1 |
| Attar, IE | 1 |
| Shousha, HI | 1 |
| Gorodetski, B | 1 |
| Schernthaner, R | 1 |
| Lee, H | 1 |
| Lenis, D | 1 |
| Stuart, EA | 1 |
| Nonyane, BA | 1 |
| Pekurovsky, V | 1 |
| Tamrazi, A | 1 |
| Gebauer, B | 1 |
| Schlachter, T | 1 |
| Han, ZH | 1 |
| Fu, CX | 1 |
| Lv, P | 1 |
| Zierhut, ML | 1 |
| Pithavala, YK | 1 |
| Nickens, DJ | 1 |
| Valota, O | 1 |
| Amantea, MA | 1 |
| Qu, L | 1 |
| Lu, C | 1 |
| Ni, R | 1 |
| Gong, X | 1 |
| Macaluso, FS | 1 |
| Valenza, F | 1 |
| Virdone, R | 2 |
| Patchett, N | 1 |
| Marsh, JW | 1 |
| Iovanna, JL | 1 |
| Augello, G | 1 |
| Candido, S | 1 |
| Libra, M | 1 |
| Gulino, A | 1 |
| Cancila, V | 1 |
| Lv, L | 1 |
| Mei, ZC | 1 |
| Wu, LL | 1 |
| Wen, XD | 1 |
| Li, XW | 1 |
| Borentain, P | 2 |
| Gregoire, E | 2 |
| Louis, G | 1 |
| Dinh, VY | 1 |
| Bhatia, S | 1 |
| Narayanan, G | 1 |
| Yrizarry, J | 1 |
| Savaraj, N | 1 |
| O'Brien, C | 1 |
| Martin, P | 1 |
| Feun, L | 1 |
| Li, WW | 1 |
| Dai, ZY | 1 |
| Wan, HG | 1 |
| Yao, LZ | 1 |
| Li, CL | 1 |
| Wang, XJ | 1 |
| Pan, J | 1 |
| Chen, LZ | 1 |
| Tao, NN | 1 |
| Zhou, HZ | 1 |
| Tang, H | 1 |
| Cai, XF | 1 |
| Zhang, WL | 1 |
| Li, WY | 1 |
| Yang, QX | 1 |
| Cheng, ST | 1 |
| Huang, LX | 1 |
| Huang, AL | 1 |
| Linauskiene, K | 1 |
| Malinauskiene, L | 1 |
| Vitkauskaite, E | 1 |
| Chomiciene, A | 1 |
| Blaziene, A | 1 |
| De Velasco, MA | 1 |
| Iida, H | 1 |
| Kwon, AH | 4 |
| Haji, S | 2 |
| Takemura, S | 1 |
| Kubo, S | 1 |
| Azumi, J | 1 |
| Tsubota, T | 1 |
| Sakabe, T | 1 |
| Chiadini, E | 1 |
| Delmonte, A | 2 |
| Lucchesi, A | 2 |
| Oboldi, D | 1 |
| Dubini, A | 1 |
| Umemura, A | 1 |
| Lin, HH | 1 |
| Na, GH | 1 |
| Hong, TH | 1 |
| Liao, YY | 1 |
| Peng, NF | 1 |
| Tong, TJ | 1 |
| Zou, H | 1 |
| Cao, X | 1 |
| Xiao, Q | 1 |
| Sheng, X | 1 |
| Ren, K | 1 |
| Quan, M | 1 |
| Song, Z | 1 |
| Zheng, Y | 1 |
| Zeng, W | 1 |
| Cao, J | 3 |
| Peng, Y | 2 |
| Noda, Y | 1 |
| Diao, X | 1 |
| Palmieri, G | 2 |
| Geschwind, JH | 1 |
| Youssef, MM | 1 |
| Tolba, MF | 1 |
| Badawy, NN | 1 |
| Liu, AW | 1 |
| Khalifa, AE | 1 |
| Zada, S | 1 |
| Abdel-Naim, AB | 1 |
| Jia, HL | 1 |
| Qin, LX | 2 |
| Zhou, TY | 1 |
| Zhuang, LH | 1 |
| Zhou, YL | 1 |
| Lin, WK | 1 |
| Wan, ZQ | 1 |
| Chang, LL | 1 |
| Ying, MD | 1 |
| Chen, ZB | 1 |
| Lou, JS | 1 |
| He, QJ | 1 |
| Murer, F | 1 |
| Pozzan, C | 1 |
| Peserico, G | 1 |
| He, HG | 1 |
| Yuan, JY | 1 |
| Wang, ZC | 1 |
| Shi, CF | 1 |
| Wei, YP | 1 |
| Huang, JL | 1 |
| Yang, GS | 1 |
| Lu, JH | 1 |
| Prieto-Domínguez, N | 1 |
| Ordóñez, R | 1 |
| Fernández, A | 1 |
| Méndez-Blanco, C | 1 |
| Baulies, A | 1 |
| Mauriz, JL | 1 |
| González-Gallego, J | 1 |
| Jung, I | 1 |
| Ha, Y | 1 |
| Park, SR | 1 |
| Singh, AR | 1 |
| Joshi, S | 1 |
| Burgoyne, AM | 1 |
| Sicklick, JK | 1 |
| Ikeda, S | 1 |
| Kono, Y | 1 |
| Garlich, JR | 1 |
| Morales, GA | 1 |
| Durden, DL | 1 |
| Guarino, M | 1 |
| Falco, L | 1 |
| Finkenstedt, A | 1 |
| Zoller, H | 1 |
| Lange, N | 1 |
| Tontsa, AT | 1 |
| Wegscheid, C | 1 |
| Mkounga, P | 1 |
| Nkengfack, AE | 1 |
| Loscher, C | 1 |
| Sass, G | 2 |
| Tiegs, G | 2 |
| Kuo, TC | 2 |
| Tseng, CF | 1 |
| Ma, JT | 1 |
| Yang, ST | 1 |
| Yang, CY | 1 |
| Sung, SY | 1 |
| Su, JL | 1 |
| Wakamatsu, T | 1 |
| Lamarca, A | 2 |
| Salu, I | 1 |
| McNamara, MG | 1 |
| Valle, JW | 1 |
| Lange, M | 1 |
| Abhari, BA | 1 |
| Hinrichs, TM | 1 |
| Fulda, S | 1 |
| Liese, J | 1 |
| Brizzi, MP | 1 |
| Pignataro, D | 1 |
| Tampellini, M | 1 |
| Scagliotti, GV | 1 |
| Di Maio, M | 2 |
| Kawazoe, S | 1 |
| Ukai, K | 1 |
| Tsuji, A | 1 |
| Tateishi, R | 2 |
| Sugiyama, G | 1 |
| Nencioni, M | 1 |
| Palen, A | 1 |
| Lahat, E | 1 |
| Salloum, C | 1 |
| Compagnon, P | 1 |
| Lim, C | 2 |
| Feray, C | 1 |
| Wan, X | 1 |
| Zhai, X | 1 |
| Yan, Z | 1 |
| Yang, P | 2 |
| Wu, D | 1 |
| Lenzi, B | 1 |
| Ciccarese, F | 1 |
| Di Marco, M | 1 |
| Caturelli, E | 1 |
| Zoli, M | 1 |
| Borzio, F | 1 |
| Masotto, A | 1 |
| Nakamori, S | 2 |
| Tahara, T | 2 |
| Ohmura, T | 2 |
| Ribeiro de Souza, A | 1 |
| Abdelmageed, MM | 1 |
| El-Naga, RN | 1 |
| El-Demerdash, E | 1 |
| Elmazar, MM | 1 |
| Pinyol, R | 1 |
| Portela, A | 1 |
| Rodriguez-Carunchio, L | 1 |
| Lujambio, A | 2 |
| Thung, S | 4 |
| Esteller, M | 1 |
| Brower, V | 1 |
| Ohri, N | 1 |
| Garg, M | 1 |
| Guha, C | 1 |
| Ziogas, DC | 1 |
| Papadatos-Pastos, D | 1 |
| Thillai, K | 1 |
| Korantzis, I | 1 |
| Chowdhury, R | 1 |
| O'Grady, J | 1 |
| Al-Khadimi, G | 1 |
| Allen, N | 1 |
| Sarker, D | 1 |
| Azzariti, A | 1 |
| Mancarella, S | 1 |
| Porcelli, L | 1 |
| Quatrale, AE | 1 |
| Caligiuri, A | 1 |
| Dituri, F | 1 |
| Aburas, S | 1 |
| Taliani, GG | 1 |
| Nardi, C | 1 |
| Xia, D | 1 |
| Tai, WM | 2 |
| Yong, WP | 1 |
| Low, LS | 1 |
| Tham, CK | 1 |
| Koh, TS | 1 |
| Ng, QS | 1 |
| Wang, WW | 1 |
| Wang, LZ | 1 |
| Hartano, S | 1 |
| Thng, CH | 3 |
| Lim, KT | 1 |
| Goh, BC | 2 |
| Han, P | 2 |
| Luo, D | 1 |
| Merchante, N | 1 |
| Ibarra, S | 1 |
| Revollo, B | 1 |
| Rodríguez-Arrondo, F | 1 |
| Merino, E | 1 |
| Delgado-Fernández, M | 1 |
| Montero-Alonso, M | 1 |
| Téllez, F | 1 |
| Galindo, MJ | 1 |
| Rivero-Juárez, A | 1 |
| García, MA | 1 |
| Mínguez, C | 1 |
| Romero-Palacios, A | 1 |
| Garcia-Deltoro, M | 1 |
| Pineda, JA | 1 |
| Dika, IE | 1 |
| Liu, P | 2 |
| Shen, P | 1 |
| Parikh, ND | 1 |
| Marshall, VD | 1 |
| Nathan, H | 1 |
| Lok, AS | 1 |
| Balkrishnan, R | 1 |
| Shahinian, V | 1 |
| Ma, Z | 1 |
| Liang, C | 3 |
| Giorgio, A | 1 |
| Merola, MG | 1 |
| Montesarchio, L | 1 |
| Merola, F | 1 |
| Santoro, B | 1 |
| Coppola, C | 1 |
| Gatti, P | 1 |
| Amendola, F | 1 |
| DI Sarno, A | 1 |
| Calvanese, A | 1 |
| Matteucci, P | 1 |
| Giorgio, V | 1 |
| Jiang, S | 1 |
| Feng, M | 2 |
| Guan, Z | 3 |
| An, D | 1 |
| Dong, M | 1 |
| Kuerban, K | 1 |
| M'Sadek, A | 1 |
| Duval, M | 1 |
| Ventroux, E | 1 |
| Lelievre, N | 1 |
| Laguerre, B | 1 |
| Low, AS | 1 |
| Cheow, PC | 1 |
| Goh, BK | 1 |
| Wong, JS | 1 |
| Ng, DC | 1 |
| Liew, WM | 1 |
| Elsadek, B | 1 |
| Mansour, A | 1 |
| Saleem, T | 1 |
| Warnecke, A | 1 |
| Kratz, F | 1 |
| Bhullar, M | 1 |
| Bhullar, A | 1 |
| Arachchi, NJ | 1 |
| Shomura, M | 1 |
| Kagawa, T | 1 |
| Shiraishi, K | 1 |
| Hirose, S | 1 |
| Arase, Y | 1 |
| Tsuruya, K | 1 |
| Takahira, S | 1 |
| Mine, T | 1 |
| Shimizu, R | 1 |
| Bollard, J | 1 |
| Miguela, V | 1 |
| Ruiz de Galarreta, M | 1 |
| Venkatesh, A | 1 |
| Bian, CB | 1 |
| Roberto, MP | 1 |
| Molina-Sánchez, P | 1 |
| Nguyen, CB | 1 |
| Ungerleider, N | 1 |
| Han, C | 1 |
| Yao, L | 1 |
| Wu, T | 2 |
| Chen, JC | 1 |
| Chuang, HY | 1 |
| Chien, YC | 1 |
| Jin, W | 1 |
| Fu, T | 1 |
| Yu, Z | 2 |
| Yu, F | 1 |
| Chen, G | 1 |
| Li, MX | 1 |
| Bi, XY | 1 |
| Yao, XS | 1 |
| Huang, Z | 2 |
| Zhou, JG | 1 |
| Zhao, JJ | 1 |
| Zhang, YF | 1 |
| Zhao, DB | 1 |
| Cai, JQ | 1 |
| Wu, CH | 2 |
| Wu, X | 1 |
| Zhang, HW | 1 |
| Soubrane, O | 2 |
| Zhang, HL | 1 |
| Wang, MD | 1 |
| Qin, CJ | 1 |
| Fu, GB | 1 |
| Zhao, LH | 1 |
| Yan, HX | 1 |
| Takano, M | 1 |
| Miyazaki, Y | 1 |
| Kageyama, Y | 1 |
| Takahashi, A | 1 |
| Amikura, K | 1 |
| Sakamoto, H | 1 |
| Lu, SN | 3 |
| Chen, PT | 1 |
| Hu, CT | 1 |
| Yang, SS | 1 |
| Le Berre, MA | 1 |
| Mitchell, DY | 1 |
| Prins, K | 1 |
| Grevel, J | 1 |
| Peña, CA | 1 |
| Semaan, A | 1 |
| Dietrich, D | 1 |
| Bergheim, D | 1 |
| Dietrich, J | 1 |
| Kalff, JC | 1 |
| Branchi, V | 1 |
| Matthaei, H | 1 |
| Kristiansen, G | 1 |
| Fischer, HP | 1 |
| Goltz, D | 1 |
| Stadler, N | 1 |
| Wendum, D | 1 |
| Segal-Bendirdjian, E | 1 |
| Forgez, P | 1 |
| Niu, M | 1 |
| Hong, D | 1 |
| Ma, TC | 1 |
| Chen, XW | 1 |
| Han, JH | 1 |
| Breder, V | 1 |
| Ollivier-Hourmand, I | 1 |
| Baumhauer, A | 1 |
| Lin, ZY | 1 |
| Chuang, WL | 1 |
| Reyes, R | 1 |
| Wani, NA | 1 |
| Ghoshal, K | 2 |
| Jacob, ST | 1 |
| Motiwala, T | 1 |
| Hubbard, JM | 1 |
| Mahoney, MR | 1 |
| Loui, WS | 1 |
| Smyrk, TC | 1 |
| Borad, M | 1 |
| Alberts, SR | 1 |
| Song, CQ | 1 |
| Mou, H | 1 |
| Moore, J | 1 |
| Park, A | 1 |
| Pomyen, Y | 1 |
| Hough, S | 1 |
| Kennedy, Z | 1 |
| Fischer, A | 1 |
| Anderson, DG | 1 |
| Conte, D | 1 |
| Wang, XW | 1 |
| Thorgeirsson, S | 1 |
| Weng, Z | 1 |
| Xue, W | 1 |
| Ling, S | 1 |
| Song, L | 1 |
| Fan, N | 1 |
| Feng, T | 1 |
| Tian, Y | 1 |
| Huang, Q | 1 |
| Hou, Z | 1 |
| Braconi, C | 1 |
| Nobes, J | 1 |
| Blesing, C | 1 |
| Kirkwood, A | 1 |
| Nash, S | 1 |
| Okagawa, Y | 1 |
| Takada, K | 1 |
| Arihara, Y | 1 |
| Kikuchi, S | 1 |
| Osuga, T | 1 |
| Nakamura, H | 1 |
| Kamihara, Y | 1 |
| Hayasaka, N | 1 |
| Usami, M | 1 |
| Murase, K | 1 |
| Miyanishi, K | 1 |
| Kobune, M | 1 |
| Kato, J | 1 |
| Potenza, N | 1 |
| Mosca, N | 1 |
| Zappavigna, S | 1 |
| Castiello, F | 1 |
| Panella, M | 1 |
| Ferri, C | 1 |
| Vanacore, D | 1 |
| Giordano, A | 1 |
| Stiuso, P | 2 |
| Fan, JH | 1 |
| Zhao, JX | 1 |
| Dai, XJ | 1 |
| Liu, Q | 1 |
| Shen, YJ | 1 |
| Sun, WD | 1 |
| Mishra, S | 1 |
| Katare, DP | 1 |
| Lorenzoni, G | 1 |
| Nass, N | 1 |
| Streit, S | 1 |
| Wybranski, C | 1 |
| Jürgens, J | 1 |
| Brauner, J | 1 |
| Schulz, N | 1 |
| Powerski, M | 1 |
| Kalinski, T | 1 |
| Dudeck, O | 1 |
| Seidensticker, M | 1 |
| Guo, L | 1 |
| Meng, C | 1 |
| Neves, H | 1 |
| Chen, PC | 1 |
| Kwok, HF | 1 |
| Psarelli, EE | 1 |
| Khan, H | 1 |
| Ko, E | 1 |
| Je, JH | 1 |
| Seo, YS | 1 |
| Calvisi, D | 1 |
| Eferl, R | 1 |
| Kang, M | 2 |
| Fang, H | 1 |
| Ye, Q | 1 |
| Jiang, B | 1 |
| Hocke, J | 1 |
| Loembé, AB | 1 |
| Hu, CA | 1 |
| Fornari, F | 1 |
| Pollutri, D | 1 |
| Patrizi, C | 1 |
| La Bella, T | 1 |
| Callegari, E | 1 |
| Baldassarre, M | 1 |
| Galassi, M | 1 |
| Ravaioli, M | 1 |
| Negrini, M | 1 |
| Zheng, A | 1 |
| Xie, J | 1 |
| Xue, Q | 1 |
| Pinato, DJ | 3 |
| Yen, C | 2 |
| Ramaswami, R | 3 |
| Ward, C | 1 |
| Pirisi, M | 3 |
| O'Donoghue, J | 1 |
| Beylergil, V | 1 |
| Ruan, S | 1 |
| Pandit-Taskar, N | 1 |
| Gansukh, B | 2 |
| Lyashchenko, SK | 1 |
| Wan, P | 1 |
| Frenette, C | 1 |
| Schwartz, L | 2 |
| Smith-Jones, PM | 1 |
| Ohtomo, T | 1 |
| Maki, Y | 1 |
| Ohishi, N | 1 |
| Agajanov, T | 1 |
| Boisserie, F | 1 |
| Di Laurenzio, L | 1 |
| Lee, R | 1 |
| Larson, SM | 1 |
| Carrasquilo, JA | 1 |
| Shuto, T | 1 |
| Murakami, M | 1 |
| Shimizu, J | 1 |
| Koga, C | 1 |
| Yasuyama, A | 1 |
| Kameda, C | 1 |
| Kawabata, R | 1 |
| Hirota, M | 1 |
| Noura, S | 1 |
| Hasegawa, J | 1 |
| Nomi, T | 1 |
| Hokuto, D | 1 |
| Yamato, I | 1 |
| Yasuda, S | 1 |
| Obara, S | 1 |
| Kawaguchi, C | 1 |
| Kinoshita, S | 1 |
| Nishiwada, S | 1 |
| Nagai, M | 1 |
| Akahori, T | 1 |
| Sho, M | 1 |
| Kanehiro, H | 1 |
| Nakajima, Y | 1 |
| Dao, H | 1 |
| Giacobbi, AS | 1 |
| Mammeri, Y | 1 |
| Ding, W | 1 |
| Dutta, R | 1 |
| Mahato, RI | 1 |
| Cheng, S | 1 |
| Lin, S | 1 |
| Gao, C | 1 |
| Petrulionis, M | 1 |
| Herr, I | 1 |
| Weiss, J | 1 |
| Bantel, H | 1 |
| Jahn, D | 1 |
| Al-Abdulla, R | 1 |
| Turcios, L | 1 |
| Vilchez, V | 1 |
| Acosta, LF | 1 |
| Poyil, P | 1 |
| Butterfield, DA | 1 |
| Mitov, M | 1 |
| Marti, F | 1 |
| Yoshizumi, T | 1 |
| Kawasaki, J | 1 |
| Nagatsu, A | 1 |
| Uchiyama, H | 1 |
| Harada, N | 1 |
| Harimoto, N | 1 |
| Itoh, S | 1 |
| Motomura, T | 1 |
| Soejima, Y | 1 |
| Maehara, Y | 1 |
| Atkin, C | 1 |
| Earwaker, P | 1 |
| Pallan, A | 1 |
| Shetty, S | 1 |
| Punia, P | 1 |
| Howell, J | 2 |
| Ferrari, C | 2 |
| Gibbin, A | 2 |
| Guaschino, G | 2 |
| Black, J | 2 |
| Sellers, L | 2 |
| Liang, J | 1 |
| Meng, YM | 1 |
| Liu, CQ | 1 |
| Zhuang, SM | 1 |
| Teraoka, Y | 1 |
| Honda, F | 1 |
| Nagaoki, Y | 2 |
| Ohata, Y | 1 |
| Akiyama, Y | 1 |
| Mogushi, K | 1 |
| Nakao, K | 1 |
| Matsumura, S | 1 |
| Aihara, A | 1 |
| Ban, D | 1 |
| Ochiai, T | 1 |
| Kudo, A | 1 |
| Arii, S | 2 |
| Chiba, N | 1 |
| Ozawa, Y | 1 |
| Hikita, K | 1 |
| Okihara, M | 1 |
| Sano, T | 1 |
| Tomita, K | 1 |
| Takano, K | 1 |
| Kawachi, S | 1 |
| Cho, HJ | 1 |
| Kim, SS | 1 |
| Nam, JS | 1 |
| Oh, MJ | 1 |
| Kang, DR | 1 |
| Yang, MJ | 1 |
| Hwang, JC | 1 |
| Lim, SG | 1 |
| Shin, SJ | 1 |
| Lee, KM | 1 |
| Yoo, BM | 1 |
| Lee, KJ | 1 |
| Cho, SW | 1 |
| Cheong, JY | 1 |
| Zhong, BY | 1 |
| Ni, CF | 1 |
| Zhu, HD | 1 |
| Teng, GJ | 1 |
| Lee, SS | 3 |
| Cheong, H | 1 |
| Lee, CK | 1 |
| Son, WC | 1 |
| Hong, SM | 1 |
| Tan, W | 1 |
| Zhu, S | 1 |
| Jeng, KS | 2 |
| Chang, CF | 1 |
| Hsu, FF | 1 |
| Dima, S | 1 |
| Popescu, I | 1 |
| Flaherty, KT | 2 |
| Benes, CH | 1 |
| Majumdar, A | 1 |
| Thorburn, D | 1 |
| Davidson, BR | 1 |
| Tsochatzis, E | 1 |
| Gurusamy, KS | 1 |
| Gill, RM | 1 |
| Butte, AJ | 1 |
| Tandia, M | 1 |
| Mhiri, A | 1 |
| Saffroy, R | 1 |
| Cailliez, V | 1 |
| Noé, G | 1 |
| Farinotti, R | 1 |
| Bonhomme-Faivre, L | 1 |
| Rognoni, C | 1 |
| Ciani, O | 1 |
| Sommariva, S | 1 |
| Tarricone, R | 1 |
| Kuo, YH | 2 |
| Wu, IP | 1 |
| Kee, KM | 1 |
| Keating, GM | 3 |
| Lacouture, ME | 1 |
| Reilly, LM | 1 |
| Gerami, P | 1 |
| Guitart, J | 1 |
| Wu, SS | 1 |
| Chung, CY | 1 |
| Siemerink, EJ | 1 |
| Mulder, NH | 1 |
| Brouwers, AH | 1 |
| Hospers, GA | 1 |
| Pár, A | 1 |
| Pár, G | 1 |
| Ricci, S | 4 |
| Hilgard, P | 2 |
| de Oliveira, AC | 1 |
| Borbath, I | 1 |
| Giannaris, T | 1 |
| Shan, M | 3 |
| Moscovici, M | 4 |
| Voliotis, D | 6 |
| Alexandrescu, DT | 1 |
| McClure, R | 1 |
| Farzanmehr, H | 1 |
| Dasanu, CA | 1 |
| Palmer, D | 1 |
| Chaparro, M | 1 |
| González Moreno, L | 1 |
| Trapero-Marugán, M | 1 |
| Medina, J | 1 |
| Moreno-Otero, R | 1 |
| Chen, FS | 1 |
| Cui, YZ | 2 |
| Luo, RC | 3 |
| Gish, R | 1 |
| Marrero, JB | 1 |
| Tong, MJ | 2 |
| Park, BJ | 1 |
| So, BJ | 1 |
| Bekaii-Saab, T | 1 |
| Bloomston, MA | 1 |
| Patel, T | 2 |
| Roxburgh, P | 1 |
| Chan, P | 8 |
| Epstein, R | 2 |
| Muszbek, N | 2 |
| Shah, S | 1 |
| Carroll, S | 2 |
| McDonald, H | 1 |
| Dale, P | 1 |
| Maroun, J | 1 |
| Glimm, H | 1 |
| Richter, G | 1 |
| Heining, C | 1 |
| Schenkel, I | 1 |
| Zahlten-Hinguranage, A | 1 |
| Schirrmacher, P | 1 |
| Schmidt, J | 1 |
| Jaeger, D | 2 |
| Spinzi, G | 2 |
| Paggi, S | 1 |
| Copur, MS | 1 |
| Chen, CK | 1 |
| Lin, CP | 1 |
| Tai, HC | 1 |
| Wang, CH | 1 |
| Shueng, PW | 1 |
| Tsao, CJ | 3 |
| Liang, H | 1 |
| Burock, K | 1 |
| Zou, J | 2 |
| Llanos, L | 1 |
| Bellot, P | 1 |
| Zapater, P | 1 |
| Pérez-Mateo, M | 1 |
| Such, J | 1 |
| Richly, H | 2 |
| Schultheis, B | 1 |
| Adamietz, IA | 1 |
| Kupsch, P | 1 |
| Grubert, M | 1 |
| Hilger, RA | 2 |
| Ludwig, M | 1 |
| Brendel, E | 2 |
| Christensen, O | 2 |
| Strumberg, D | 3 |
| Ng, KK | 1 |
| Chok, SH | 1 |
| Cheung, TT | 4 |
| Fan, ST | 5 |
| Billingham, L | 1 |
| Kane, RC | 1 |
| Farrell, AT | 1 |
| Madabushi, R | 1 |
| Booth, B | 1 |
| Chattopadhyay, S | 1 |
| Sridhara, R | 1 |
| Justice, R | 1 |
| Pazdur, R | 1 |
| Sieghart, W | 6 |
| Graziadei, I | 3 |
| Maieron, A | 3 |
| Königsberg, R | 3 |
| Weissmann, A | 2 |
| Kornek, G | 2 |
| Plank, C | 1 |
| Clark, JW | 1 |
| Malek, N | 1 |
| Gogia, S | 1 |
| Befeler, AS | 1 |
| Latteri, F | 1 |
| Apostolidis, L | 1 |
| Kahlert, C | 1 |
| Siegmund, A | 1 |
| Thom, R | 1 |
| Horstmann, S | 1 |
| Lordick, F | 1 |
| Isabel Real, M | 1 |
| Robles, R | 1 |
| de la Mata, M | 3 |
| Buti, M | 1 |
| Martí-Bonmatí, L | 1 |
| Bru, C | 1 |
| Tabernero, J | 1 |
| Frigerio, M | 1 |
| Santi, V | 1 |
| Di Micoli, A | 1 |
| Wu, JM | 1 |
| Sheng, H | 1 |
| Saxena, R | 1 |
| Skill, NJ | 1 |
| Bhat-Nakshatri, P | 1 |
| Yu, M | 1 |
| Nakshatri, H | 1 |
| Hussain, K | 1 |
| Witjes, CD | 1 |
| Verheul, HM | 1 |
| Oseini, AM | 1 |
| Wei, L | 1 |
| Su, N | 1 |
| Zheng, DY | 1 |
| Cao, MR | 1 |
| Li, AM | 1 |
| Yan, X | 1 |
| Lü, CW | 1 |
| Chiang, D | 1 |
| Detry, O | 1 |
| Delwaide, J | 1 |
| De Roover, A | 1 |
| Meunier, P | 1 |
| Van Daele, D | 1 |
| Lamproye, A | 1 |
| Honoré, P | 1 |
| Polus, M | 1 |
| Kuiken, SD | 1 |
| van Delden, OM | 1 |
| Richel, DJ | 1 |
| Jansen, PL | 1 |
| Chappell, JA | 1 |
| Burkemper, NM | 1 |
| Semchyshyn, N | 1 |
| Li, P | 1 |
| Lin, XJ | 1 |
| Lee, JL | 2 |
| Chang, SE | 1 |
| Lee, MW | 1 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Koh, JK | 1 |
| Schraml, C | 3 |
| Berg, CP | 1 |
| Koppenhöfer, U | 1 |
| Claussen, CD | 4 |
| Gregor, M | 2 |
| Yu, L | 1 |
| Novi, M | 1 |
| Lauritano, EC | 1 |
| Piscaglia, AC | 1 |
| Barbaro, B | 1 |
| Mendizabal, M | 1 |
| Reddy, KR | 1 |
| Dudley, AC | 1 |
| Klagsbrun, M | 1 |
| Xiong, YQ | 3 |
| Newell, P | 3 |
| Toffanin, S | 4 |
| Chiang, DY | 1 |
| Melgar-Lesmes, P | 1 |
| Yea, S | 1 |
| Deniz, K | 1 |
| Fiel, MI | 1 |
| Friedman, SL | 3 |
| Meza-Junco, J | 1 |
| Chu, QS | 1 |
| Das, S | 1 |
| Stefanyschyn, R | 1 |
| Sawyer, MB | 1 |
| Perrone, F | 1 |
| Benten, D | 1 |
| Keller, G | 1 |
| Quaas, A | 1 |
| Schrader, J | 1 |
| Gontarewicz, A | 1 |
| Balabanov, S | 1 |
| Braig, M | 1 |
| Moll, J | 1 |
| Lohse, AW | 1 |
| Brummendorf, TH | 2 |
| Bai, S | 1 |
| Nasser, MW | 1 |
| Hsu, SH | 1 |
| Datta, J | 1 |
| Kutay, H | 1 |
| Yadav, A | 1 |
| Nuovo, G | 1 |
| Kumar, P | 2 |
| Liang, JD | 1 |
| Lu, YS | 1 |
| Yang, CH | 1 |
| Schwenzer, NF | 1 |
| Martirosian, P | 1 |
| Tai, CJ | 2 |
| Wang, YH | 3 |
| Liu, TZ | 2 |
| Jen, YM | 1 |
| Shiau, CY | 1 |
| Lapecorella, M | 1 |
| Napolitano, M | 1 |
| Tudini, M | 1 |
| Mariani, G | 1 |
| Printz, C | 1 |
| Huang, MT | 1 |
| Wei, PL | 1 |
| An, J | 1 |
| Chang, YJ | 1 |
| Marks, AB | 1 |
| Gerard, R | 1 |
| Fournier, P | 1 |
| Coupe, P | 1 |
| Gautier, S | 1 |
| Volk, ML | 1 |
| Lonardi, S | 1 |
| Angeli, P | 1 |
| Guillet, M | 1 |
| Walter, T | 2 |
| Scoazec, JY | 2 |
| Vial, T | 1 |
| Lombard-Bohas, C | 2 |
| Dumortier, J | 2 |
| Ngo, VC | 1 |
| Koong, HN | 1 |
| Poon, D | 1 |
| Chow, P | 1 |
| Ong, HS | 1 |
| Chung, A | 1 |
| Smith, PD | 1 |
| Liu, TH | 2 |
| Moretti, LV | 1 |
| Montalvo, RO | 1 |
| Cabrera, R | 6 |
| Nelson, DR | 6 |
| Lammer, J | 2 |
| Gusani, NJ | 1 |
| Kimchi, ET | 1 |
| Staveley-O'Carroll, KF | 1 |
| Ajani, JA | 1 |
| Mee, CJ | 1 |
| Farquhar, MJ | 1 |
| Harris, HJ | 1 |
| Hu, K | 1 |
| Ramma, W | 1 |
| Ahmed, A | 1 |
| Maurel, P | 1 |
| Bicknell, R | 1 |
| Balfe, P | 1 |
| McKeating, JA | 1 |
| Saif, MW | 2 |
| Dogan, E | 2 |
| Aksoy, S | 1 |
| Arslan, C | 1 |
| Dede, DS | 1 |
| Altundag, K | 1 |
| Wei, D | 1 |
| Cheng, P | 1 |
| Yeganeh, M | 1 |
| Wang, ZY | 1 |
| Wang, ZJ | 2 |
| Song, P | 2 |
| Maksimovic, O | 1 |
| Hartmann, JT | 1 |
| Pintoffl, J | 1 |
| Navasa, M | 1 |
| Matilla, A | 3 |
| Aracil, C | 1 |
| Del Val, A | 1 |
| Pascasio, JM | 1 |
| Prete, SD | 2 |
| Maiorino, L | 1 |
| Piai, G | 1 |
| Febbraro, A | 1 |
| Tarantino, L | 1 |
| Capasso, E | 1 |
| Guarrasi, R | 1 |
| Bianco, M | 1 |
| Mamone, R | 1 |
| Savastano, C | 1 |
| Pisano, A | 1 |
| Sabia, A | 1 |
| D'Agostino, A | 1 |
| Faiola, V | 1 |
| Braillon, A | 1 |
| Giuliani, F | 1 |
| Rizzo, S | 1 |
| Venditti, O | 1 |
| Frezza, AM | 1 |
| Colucci, G | 1 |
| Tonini, G | 2 |
| Boschetti, G | 1 |
| Hervieu, V | 1 |
| Cassier, P | 1 |
| Adham, M | 1 |
| Kohga, K | 1 |
| Tatsumi, T | 4 |
| Ishida, H | 4 |
| Miyagi, T | 4 |
| Hosui, A | 4 |
| Hayashi, N | 5 |
| Toonen, F | 1 |
| Smilde, T | 1 |
| Sinakos, E | 1 |
| Dedes, I | 1 |
| Papalavrentios, L | 1 |
| Drevelegas, A | 1 |
| Akriviadis, E | 1 |
| Perboni, G | 1 |
| Costa, P | 1 |
| Fibbia, GC | 1 |
| Morandini, B | 1 |
| Scalzini, A | 1 |
| Tagliani, A | 1 |
| Aitini, E | 1 |
| Zhao, JD | 1 |
| Gu, K | 3 |
| Zhou, ZH | 2 |
| Li, WT | 1 |
| Xu, ZY | 1 |
| Liu, LM | 2 |
| Jiang, GL | 2 |
| Reig, ME | 1 |
| de Lope, CR | 2 |
| Chevreau, C | 1 |
| Dielenseger, P | 1 |
| Ederhy, S | 1 |
| Goldwasser, F | 7 |
| Grange, JD | 1 |
| Mortier, L | 1 |
| Neidhardt-Berard, ME | 1 |
| Robert, C | 1 |
| Scotté, F | 1 |
| Tang, TC | 2 |
| Xu, P | 2 |
| Ozenne, V | 1 |
| Pernot, S | 1 |
| Castelnau, C | 1 |
| Vullierme, MP | 3 |
| Valla, D | 1 |
| Farges, O | 2 |
| Degos, F | 1 |
| Lee, JO | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Bang, YJ | 1 |
| Wang, SX | 1 |
| Byrnes, A | 1 |
| Verma, S | 1 |
| Pancoast, JR | 1 |
| Rixe, O | 1 |
| Verset, G | 1 |
| Maréchal, R | 1 |
| Bali, MA | 1 |
| Devière, J | 1 |
| Van Laethem, JL | 1 |
| Hikita, H | 3 |
| Kodama, T | 3 |
| Pellegrinelli, A | 1 |
| Lampis, A | 1 |
| Zangos, S | 1 |
| Kriener, S | 1 |
| Mönch, C | 1 |
| Ding, YH | 1 |
| Balsom, SM | 1 |
| Trolli, E | 1 |
| Rose, J | 1 |
| Bloomston, M | 1 |
| Bekaii-Saab, TS | 1 |
| Saadati, H | 1 |
| Vagefi, PA | 2 |
| Hirose, R | 2 |
| Porto, I | 1 |
| Leo, A | 1 |
| Crea, F | 1 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Yoon, DH | 1 |
| Lee, SG | 1 |
| Suh, DJ | 5 |
| Kim, TW | 1 |
| Ahn, CS | 1 |
| Moon, DB | 1 |
| Connock, M | 1 |
| Round, J | 1 |
| Bayliss, S | 1 |
| Tubeuf, S | 1 |
| Greenheld, W | 1 |
| Moore, D | 1 |
| Joshita, S | 1 |
| Yoshizawa, K | 1 |
| Sekiguchi, T | 1 |
| Kamijo, A | 1 |
| Komatsu, M | 1 |
| Umemura, T | 1 |
| Ichijo, T | 1 |
| Matsumoto, A | 1 |
| Tanaka, E | 1 |
| Lubomierski, N | 1 |
| Engels, K | 1 |
| Bechstein, WO | 2 |
| Olsen, SK | 1 |
| Magun, A | 1 |
| Brown, RS | 1 |
| Burak, KW | 2 |
| Schwarz, RE | 1 |
| Chirica, M | 1 |
| Castaing, D | 1 |
| Herden, U | 1 |
| Fischer, L | 2 |
| Schäfer, H | 1 |
| Nashan, B | 2 |
| von Baehr, V | 1 |
| Sterneck, M | 2 |
| Menon, N | 1 |
| Marrero, J | 1 |
| Venook, A | 1 |
| Nguyen-Khac, E | 1 |
| Descamps, V | 1 |
| Trouillet, N | 1 |
| Joly, JP | 1 |
| Duverlie, G | 1 |
| Wich, C | 1 |
| Agaimy, A | 1 |
| Strobel, D | 3 |
| Wissniowski, TT | 1 |
| Ocker, M | 2 |
| Terreni, N | 1 |
| Armstrong, C | 1 |
| Vignaud, A | 1 |
| Arrivé, L | 1 |
| Menu, Y | 1 |
| Horgan, AM | 1 |
| Swaminath, A | 1 |
| Knox, JJ | 2 |
| Duerden, M | 1 |
| Gomo, C | 1 |
| Faivre, L | 1 |
| Mir, O | 6 |
| Ropert, S | 6 |
| Billemont, B | 1 |
| Dauphin, A | 1 |
| Tod, M | 1 |
| Blanchet, B | 4 |
| Pang, R | 4 |
| Mornex, F | 2 |
| Dank, M | 1 |
| Shigekawa, M | 1 |
| Iwase, K | 1 |
| Hiramatsu, N | 2 |
| Maccaroni, E | 1 |
| Di Pietro Paolo, M | 1 |
| Berardi, R | 1 |
| Chelis, L | 1 |
| Ntinos, N | 1 |
| Souftas, V | 1 |
| Deftereos, S | 1 |
| Xenidis, N | 1 |
| Chamalidou, E | 1 |
| Maltezos, E | 1 |
| Kakolyris, S | 1 |
| Rowe, IA | 1 |
| Perrino, M | 1 |
| Viganò, M | 1 |
| Beck-Peccoz, P | 1 |
| Fugazzola, L | 1 |
| Moreno, JM | 1 |
| Josephs, DH | 1 |
| Wu, P | 1 |
| Li, PK | 1 |
| Spira, D | 1 |
| Fenchel, M | 1 |
| Heinz, WJ | 1 |
| Kahle, K | 1 |
| Helle-Beyersdorf, A | 1 |
| Schirmer, D | 1 |
| Lenker, U | 1 |
| Keller, D | 1 |
| Langmann, P | 1 |
| Klinker, H | 1 |
| Frederick, RT | 1 |
| Duffy, A | 2 |
| Greten, T | 1 |
| Leroux, C | 1 |
| Vauléon, E | 2 |
| Zoheir, Y | 1 |
| Hagymási, K | 1 |
| Tulassay, Z | 1 |
| Huang, GM | 1 |
| Wei, ZG | 1 |
| Hoppe, H | 1 |
| Helbling, B | 1 |
| Maurhofer, O | 1 |
| Szucs-Farkas, Z | 1 |
| Kickuth, R | 1 |
| Borner, M | 1 |
| Candinas, D | 1 |
| Saar, B | 1 |
| Gondek, K | 1 |
| Yeh, PY | 1 |
| Wang, CT | 1 |
| El-Gazzaz, G | 1 |
| Tan, A | 2 |
| Elson, P | 1 |
| Byrne, M | 2 |
| Chang, YD | 1 |
| Düber, C | 2 |
| Francia, G | 1 |
| Hashimoto, K | 1 |
| Emmenegger, U | 1 |
| Davidenko, I | 1 |
| Lacava, J | 1 |
| Leung, T | 1 |
| Speeg, KV | 1 |
| Washburn, WK | 1 |
| Halff, G | 1 |
| Lee, SA | 1 |
| Lee, MS | 1 |
| Ryu, HW | 1 |
| Kwak, TK | 1 |
| Jung, O | 1 |
| Park, KH | 1 |
| Lee, JW | 1 |
| TAN, WF | 1 |
| Qiu, ZQ | 1 |
| RAN, RZ | 1 |
| QIU, YH | 1 |
| FENG, FL | 1 |
| YAN, PN | 1 |
| ZHANG, BH | 2 |
| LUO, XJ | 1 |
| JIANG, XQ | 1 |
| Hofmann, WP | 1 |
| Franz, C | 1 |
| Mohr, E | 1 |
| Serba, S | 1 |
| Xu, LT | 2 |
| Lin, JH | 1 |
| Meng, ZQ | 2 |
| Gan, YH | 1 |
| Ge, NL | 1 |
| McTigue, M | 1 |
| Busuttil, RW | 1 |
| Fiume, L | 2 |
| Vettraino, M | 2 |
| Manerba, M | 2 |
| Di Stefano, G | 2 |
| Saidi, RF | 1 |
| Shah, SA | 1 |
| Rawson, AP | 1 |
| Grossman, S | 1 |
| Bozorgzadeh, A | 1 |
| Yoo, DJ | 1 |
| Jin, YJ | 1 |
| Yoon, HK | 1 |
| Chen, HL | 3 |
| Diaz-Sanchez, A | 1 |
| Rodriguez-Salas, N | 1 |
| Aramendi, T | 1 |
| Balbin, E | 1 |
| Nagai, T | 4 |
| Arao, T | 2 |
| Furuta, K | 1 |
| Kudo, K | 1 |
| Kaneda, H | 1 |
| Tamura, D | 1 |
| Aomatsu, K | 1 |
| Kimura, H | 2 |
| Fujita, Y | 1 |
| Matsumoto, K | 2 |
| Saijo, N | 1 |
| Amano, R | 1 |
| Yamada, N | 1 |
| Noda, E | 1 |
| Kubo, N | 1 |
| Muguruma, K | 1 |
| Takashima, T | 1 |
| Yashiro, M | 1 |
| Maeda, K | 1 |
| Onoda, N | 1 |
| Sawada, T | 1 |
| Nakata, B | 1 |
| Ohira, M | 1 |
| Hirakawa, K | 1 |
| Yanagimoto, Y | 1 |
| Nakatake, R | 3 |
| Guan, YS | 1 |
| He, Q | 1 |
| Lord, R | 1 |
| Girard, N | 1 |
| Gianluigi, G | 1 |
| Bozzi, E | 3 |
| Altomare, E | 3 |
| Bertoni, M | 3 |
| Capria, A | 1 |
| Donaldson, MR | 1 |
| Stetson, CL | 1 |
| Smith, JL | 1 |
| Kim, SO | 1 |
| Baek, YH | 1 |
| Han, JS | 1 |
| Cho, JH | 1 |
| Nam, KJ | 1 |
| Yoon, SH | 1 |
| Beljanski, V | 1 |
| Lewis, CS | 1 |
| Smith, CD | 2 |
| Curtit, E | 1 |
| Thiery-Vuillemin, A | 1 |
| Nguyen, T | 1 |
| Heyd, B | 1 |
| Pivot, X | 1 |
| Di Martino, V | 1 |
| Feng, YX | 1 |
| Yao, F | 1 |
| Zhu, YQ | 1 |
| Wang, XF | 1 |
| van der Lugt, A | 1 |
| Kim, KW | 1 |
| Choi, BI | 1 |
| Zimmermann, L | 1 |
| Bornschein, J | 1 |
| Csepregi, A | 1 |
| Rühl, R | 1 |
| Youn, JI | 1 |
| Gabrilovich, D | 1 |
| Yu, CW | 1 |
| Hu, FC | 1 |
| Wei, SY | 1 |
| Shih, TT | 1 |
| Shanbhogue, AK | 1 |
| Prasad, SR | 1 |
| Takahashi, N | 1 |
| Vikram, R | 1 |
| Sahani, DV | 1 |
| Gouya, H | 1 |
| Vignaux, O | 1 |
| Chaussade, S | 4 |
| Sogni, P | 2 |
| Pol, S | 3 |
| Legmann, P | 1 |
| Pazo Cid, RA | 1 |
| Lao, J | 1 |
| Lanzuela, M | 2 |
| Hardwigsen, J | 1 |
| Garcia, S | 1 |
| Durieux, O | 1 |
| Wei, G | 1 |
| Hyslop, T | 1 |
| Meng, F | 1 |
| Glaser, SS | 1 |
| Francis, H | 1 |
| DeMorrow, S | 1 |
| Passarini, JD | 1 |
| Stokes, A | 1 |
| Cleary, JP | 1 |
| Venter, J | 1 |
| Priester, S | 1 |
| Hubble, L | 1 |
| Staloch, D | 1 |
| Sharma, J | 1 |
| Liu, CG | 1 |
| Alpini, G | 1 |
| Lynch, MC | 1 |
| Straub, R | 1 |
| Adams, DR | 1 |
| Lee, JS | 1 |
| Ling-lin, Z | 1 |
| Jin-hui, T | 1 |
| Ke-hu, Y | 1 |
| Akladios, CY | 1 |
| Bour, G | 1 |
| Balboni, G | 1 |
| Mutter, D | 1 |
| Marescaux, J | 1 |
| Aprahamian, M | 1 |
| Jain, L | 1 |
| Woo, S | 1 |
| Gardner, ER | 1 |
| Dahut, WL | 1 |
| Kohn, EC | 1 |
| Kummar, S | 1 |
| Mould, DR | 1 |
| Giaccone, G | 1 |
| Yarchoan, R | 1 |
| Venitz, J | 1 |
| Breitbach, CJ | 1 |
| Moon, A | 1 |
| Kim, CW | 1 |
| Patt, R | 1 |
| Kim, MK | 1 |
| Lee, YK | 1 |
| Oh, SY | 1 |
| Parato, K | 1 |
| Rintoul, J | 1 |
| Falls, T | 1 |
| Hickman, T | 1 |
| Rhee, BG | 1 |
| Bell, JC | 1 |
| Kirn, DH | 1 |
| Hwang, TH | 1 |
| Kim, JE | 2 |
| Chang, HM | 2 |
| Irtan, S | 1 |
| Chopin-Laly, X | 1 |
| Abbass, K | 1 |
| Dewani, S | 1 |
| Markert, R | 1 |
| Kaplon, MK | 1 |
| Baumann, MA | 1 |
| Liang, CP | 1 |
| Yang, CS | 1 |
| Shen, JL | 1 |
| Lee, MJ | 1 |
| Bae, SC | 1 |
| Nam, BH | 2 |
| Kim, HK | 1 |
| Kim, TH | 1 |
| Kim, HB | 2 |
| Giuberti, G | 1 |
| Marra, M | 1 |
| Murolo, M | 1 |
| Naviglio, S | 1 |
| Abbruzzese, A | 1 |
| Hinojar-Gutiérrez, A | 1 |
| Nieto-Llanos, S | 1 |
| Mera-Menéndez, F | 1 |
| Fernández-Contreras, ME | 1 |
| Mendoza, J | 1 |
| Moreno, R | 1 |
| Ma, CY | 1 |
| Hua, SC | 1 |
| Yuan, Q | 1 |
| Byrne, MT | 1 |
| Razumilava, N | 1 |
| Ong, RW | 1 |
| Li, PY | 1 |
| Chong, LW | 1 |
| Luu, DA | 1 |
| Jong, CT | 1 |
| Lam, IW | 1 |
| Klinger, N | 1 |
| Sirma, H | 1 |
| Hashemolhosseini, S | 1 |
| Neureiter, D | 1 |
| Therneau, T | 1 |
| Orsini, LS | 1 |
| Qiao, YL | 1 |
| Rübsam, K | 1 |
| Flaig, MJ | 1 |
| Ruzicka, T | 1 |
| Prinz, JC | 1 |
| Holcombe, RF | 1 |
| Carter, WD | 1 |
| Melink, TJ | 1 |
| Gutheil, JC | 1 |
| Fernando, J | 1 |
| Sancho, P | 1 |
| Fernández-Rodriguez, CM | 1 |
| Caja, L | 1 |
| Campbell, JS | 1 |
| Fausto, N | 2 |
| Fabregat, I | 1 |
| Hirt, S | 1 |
| Daskalow, K | 1 |
| Cramer, T | 1 |
| Standop, J | 1 |
| Schmitz, V | 1 |
| Pannu, DS | 1 |
| Caridi, J | 1 |
| Firpi, RJ | 1 |
| Soldevila-Pico, C | 2 |
| Morelli, G | 2 |
| Clark, V | 2 |
| Suman, A | 1 |
| George, TJ | 1 |
| Li, HX | 1 |
| Xu, LY | 1 |
| Cohen, L | 1 |
| Yang, PY | 1 |
| Dubreuil, O | 1 |
| Boussaha, T | 1 |
| Trouilloud, I | 1 |
| Landi, B | 1 |
| Housset, M | 1 |
| Botti, M | 1 |
| Rougier, P | 1 |
| Taieb, J | 1 |
| Carrillo-Infante, C | 1 |
| Cucchi, E | 1 |
| Cuesta, L | 1 |
| Betlloch, I | 1 |
| Toledo, F | 1 |
| Latorre, N | 1 |
| Monteagudo, A | 1 |
| Edmonds, K | 1 |
| Spencer-Shaw, A | 1 |
| Koldenhof, J | 1 |
| Chrysou, M | 1 |
| Boers-Doets, C | 1 |
| Molassiotis, A | 1 |
| Airoldi, A | 2 |
| Vigano, R | 2 |
| Pinzello, G | 1 |
| Zhang, D | 1 |
| He, JT | 1 |
| Chida, N | 1 |
| Hori, T | 1 |
| Kumada, H | 1 |
| Tsubouchi, H | 1 |
| Wada, M | 1 |
| Yamaguchi, I | 1 |
| Ohya, T | 1 |
| Park, SH | 3 |
| Park, YS | 3 |
| Kang, WK | 3 |
| Yim, DS | 1 |
| Suchánková, G | 1 |
| Spicák, J | 1 |
| Baek, KK | 1 |
| Uhm, JE | 1 |
| Perrin, C | 1 |
| Le Roux, C | 1 |
| Ahn, HK | 1 |
| Sun, JM | 1 |
| Gallant, JN | 1 |
| Katz, SI | 1 |
| Dolloff, NG | 1 |
| Abdulghani, J | 1 |
| Allen, JE | 1 |
| Dicker, DT | 1 |
| Hong, B | 1 |
| Navaraj, A | 1 |
| El-Deiry, WS | 1 |
| Suo, A | 1 |
| Zhang, M | 2 |
| Yao, Y | 1 |
| Huang, C | 1 |
| Nan, K | 1 |
| Seo, HJ | 1 |
| Lucas, E | 1 |
| Aubourg, A | 1 |
| Bacq, Y | 1 |
| Truesdale, AE | 1 |
| Caldwell, SH | 1 |
| Shah, NL | 1 |
| Argo, CK | 1 |
| Al-Osaimi, AM | 1 |
| Schmitt, TM | 1 |
| Northup, PG | 1 |
| Manov, I | 1 |
| Pollak, Y | 1 |
| Broneshter, R | 1 |
| Iancu, TC | 1 |
| De Ruvo, N | 1 |
| D'Amico, G | 1 |
| Iemmolo, RM | 1 |
| Gerunda, GE | 1 |
| Huang, CS | 1 |
| Lyu, SC | 1 |
| Hu, ML | 1 |
| Tatsumi, C | 1 |
| Ueda, T | 1 |
| Ishikawa, E | 1 |
| Chung, H | 1 |
| Ong, R | 1 |
| Tsunematsu, H | 1 |
| Fujita, N | 1 |
| Yoshimori, T | 1 |
| Chenna, V | 1 |
| Hu, C | 1 |
| Khan, M | 1 |
| Bai, H | 1 |
| Hucke, F | 2 |
| Matejka, J | 1 |
| Stauber, R | 2 |
| Grünberger, B | 2 |
| Schöniger-Hekele, M | 1 |
| Yao, TJ | 4 |
| Wong, H | 4 |
| Takahara, T | 1 |
| Hasegawa, Y | 1 |
| Itou, N | 1 |
| Takahashi, M | 1 |
| Wakabayashi, G | 1 |
| Bhagat, N | 1 |
| Ichida, T | 1 |
| Fukumoto, M | 2 |
| Schmid, I | 1 |
| Häberle, B | 1 |
| Albert, MH | 1 |
| Corbacioglu, S | 1 |
| Fröhlich, B | 1 |
| Graf, N | 1 |
| Kammer, B | 1 |
| Kontny, U | 1 |
| Leuschner, I | 1 |
| Scheel-Walter, HG | 1 |
| Scheurlen, W | 1 |
| Werner, S | 1 |
| Wiesel, T | 1 |
| von Schweinitz, D | 1 |
| Castroagudin, JF | 1 |
| Salcedo, M | 1 |
| Garralda, E | 1 |
| Herrero, I | 1 |
| de Artaza Varasa, T | 1 |
| Ciampi Dopazo, JJ | 1 |
| Lanciego Pérez, C | 1 |
| Gómez Moreno, AZ | 1 |
| Li, XH | 1 |
| Zhong, KB | 1 |
| Yang, DH | 1 |
| Romano, O | 1 |
| Sergent, G | 1 |
| Mourad, A | 1 |
| Louvet, A | 1 |
| Dharancy, S | 1 |
| Boleslawski, E | 1 |
| Truant, S | 1 |
| Pruvot, FR | 1 |
| Hebbar, M | 1 |
| Ernst, O | 1 |
| Rastogi, A | 1 |
| Bihari, C | 1 |
| Jain, D | 1 |
| Gupta, NL | 1 |
| Sarin, SK | 1 |
| Asghar, U | 1 |
| Tumino, E | 3 |
| Di Biase, M | 1 |
| Trojniak, MP | 1 |
| Palozzo, AC | 1 |
| Mazurek, M | 1 |
| Jirillo, A | 1 |
| Gamstätter, T | 2 |
| Schadmand-Fischer, S | 1 |
| Spies, PR | 1 |
| Niederle, IM | 3 |
| Chen, TJ | 1 |
| Hirano, N | 1 |
| Hara, F | 1 |
| Iida, K | 2 |
| Tomoda, T | 1 |
| Toshimori, J | 1 |
| Gu, FM | 1 |
| Li, QL | 1 |
| Gao, Q | 1 |
| Jiang, JH | 1 |
| Pan, JF | 1 |
| Rohr-Udilova, N | 2 |
| Ferlitsch, A | 1 |
| Petrini, I | 1 |
| Lencioni, M | 1 |
| Ricasoli, M | 1 |
| Iannopollo, M | 1 |
| Orlandini, C | 1 |
| Oliveri, F | 1 |
| Arrondeau, J | 1 |
| Boudou-Rouquette, P | 3 |
| Dumas, G | 1 |
| Rodrigues, MJ | 1 |
| Lachenmayer, A | 3 |
| Rolle, E | 2 |
| Spada, F | 1 |
| Bobin-Dubigeon, C | 1 |
| Heurgue-Berlot, A | 1 |
| Bouché, O | 1 |
| Amiand, MB | 1 |
| Le Guellec, C | 1 |
| Bard, JM | 1 |
| Montagna, B | 1 |
| Melchiorre, F | 1 |
| Quaretti, P | 1 |
| Riccardi, A | 1 |
| Tagliaferri, B | 1 |
| Sottotetti, F | 1 |
| Di Cesare, P | 1 |
| Stella, MG | 1 |
| Villani, L | 1 |
| Zorzetto, M | 1 |
| Greco, G | 1 |
| Cornalba, G | 1 |
| Bernardo, G | 1 |
| Hoshioka, T | 1 |
| Tamaki, S | 1 |
| Kato, T | 2 |
| Tang, YF | 2 |
| Chiu, J | 2 |
| Leung, R | 2 |
| Chan, AC | 2 |
| Chen, HC | 1 |
| Yuan, RH | 1 |
| Hsu, HC | 2 |
| Ikuta, K | 1 |
| Addo, L | 1 |
| Akutsu, H | 1 |
| Sasaki, K | 1 |
| Ohtake, T | 1 |
| Fujiya, M | 1 |
| Torimoto, Y | 1 |
| Glass, J | 1 |
| Kohgo, Y | 1 |
| Yamanaka, K | 1 |
| Iida, T | 1 |
| Machimito, T | 1 |
| Isoda, H | 1 |
| Shibata, T | 1 |
| Sakaguchi, T | 2 |
| Nakahira, S | 1 |
| Suzuki, R | 1 |
| Nakata, K | 1 |
| Okishiro, M | 1 |
| Miki, H | 1 |
| Takatsuka, Y | 1 |
| Tamura, S | 1 |
| Masuda, T | 1 |
| Mima, K | 1 |
| Horino, K | 1 |
| Takamori, H | 1 |
| Nakahara, O | 1 |
| Inuzuka, T | 1 |
| Sekikawa, A | 1 |
| Henmi, S | 1 |
| Sakamoto, A | 1 |
| Saito, S | 1 |
| Kita, R | 1 |
| Ranieri, G | 1 |
| Goffredo, V | 1 |
| Patruno, R | 1 |
| Mangia, A | 1 |
| Rizzo, A | 1 |
| Sciorsci, RL | 1 |
| Gadaleta, CD | 1 |
| Reisegger, M | 1 |
| Ba-Ssalamah, A | 1 |
| Lentini, G | 1 |
| Scherubl, H | 1 |
| Germanidis, G | 1 |
| Dominguez, S | 1 |
| Nadel, A | 2 |
| Teufel, A | 1 |
| Wörns, M | 1 |
| Heise, M | 1 |
| Sanpei, A | 1 |
| Yano, M | 1 |
| Ohkoshi, S | 1 |
| Caravetta, A | 1 |
| Mollo, F | 1 |
| Peluso, L | 1 |
| Guarino, R | 1 |
| Li, XF | 1 |
| Gong, RY | 1 |
| Yan, ZL | 1 |
| Yuan, B | 1 |
| Shi, LH | 1 |
| Morioka, Y | 1 |
| Park, H | 1 |
| Han, SH | 1 |
| Park, K | 1 |
| Koh, YH | 1 |
| An, S | 1 |
| Burrel, M | 1 |
| Barrufet, M | 1 |
| Real, MI | 1 |
| Hsu, CL | 1 |
| Wu, MH | 1 |
| Huang, CK | 1 |
| Hung, YC | 1 |
| Lin, TY | 1 |
| Tsai, HW | 2 |
| Ward, SC | 2 |
| Russi, S | 1 |
| Conteduca, V | 1 |
| Sansonno, L | 1 |
| Dammacco, F | 1 |
| Teng, CL | 1 |
| Hwang, WL | 1 |
| Chang, KH | 1 |
| Lathia, CD | 1 |
| Nguyen, V | 1 |
| van der Poorten, D | 1 |
| Kaneko, T | 1 |
| Sclafani, F | 1 |
| Pedicini, V | 1 |
| Blivet-Van Eggelpoël, MJ | 1 |
| Chettouh, H | 1 |
| Aoudjehane, L | 1 |
| Barbu, V | 1 |
| Rey, C | 1 |
| Priam, S | 1 |
| Housset, C | 1 |
| Ramirez Morales, R | 2 |
| Fabries, P | 1 |
| Pauleau, G | 1 |
| Brardjanian, S | 1 |
| Artéaga, C | 1 |
| Guisset, M | 1 |
| Coton, T | 1 |
| Durand, JP | 2 |
| Cessot, A | 1 |
| Mallet, V | 1 |
| Mok, T | 1 |
| Ma, BB | 1 |
| Kölblinger, C | 1 |
| Xie, B | 1 |
| Wang, DH | 1 |
| Spechler, SJ | 1 |
| Chang, X | 1 |
| Lou, M | 1 |
| Lv, J | 1 |
| Kurniali, PC | 1 |
| O'Gara, K | 1 |
| Wang, LJ | 1 |
| Somasundar, P | 1 |
| Falanga, V | 1 |
| Espat, NJ | 1 |
| Katz, SC | 1 |
| Trécherel, E | 1 |
| Wong, A | 1 |
| Park, MS | 1 |
| Lee, DY | 1 |
| Estfan, B | 1 |
| Kim, GH | 1 |
| Song, GA | 1 |
| Iodice, L | 1 |
| Tartaglione, MT | 2 |
| Picciotto, FP | 2 |
| Mattera, S | 2 |
| De Luca, M | 2 |
| Lin, SD | 1 |
| Jia, D | 1 |
| Sun, Z | 1 |
| Ren, S | 1 |
| Ruan, Y | 1 |
| Dauser, B | 1 |
| Prager, G | 1 |
| Hayden, H | 1 |
| Dienes, HP | 1 |
| Scandurra, G | 1 |
| Aiello, RA | 1 |
| Alì, M | 1 |
| Taibi, E | 1 |
| Sanò, MV | 1 |
| Todaro, FM | 1 |
| La Rocca, R | 1 |
| Licciardello, P | 1 |
| Caruso, M | 1 |
| Michels, J | 1 |
| Vidal, M | 1 |
| Spârchez, Z | 1 |
| Moschouris, H | 1 |
| Malagari, K | 1 |
| Gkoutzios, P | 1 |
| Kalokairinou, M | 1 |
| Stamatiou, K | 1 |
| Chatzimichail, K | 1 |
| Kornezos, I | 1 |
| Karagiannis, E | 1 |
| Kiltenis, M | 1 |
| Papadaki, MG | 1 |
| Seewoo, V | 1 |
| Du, H | 1 |
| Lin, A | 1 |
| Shen, B | 1 |
| Peng, C | 1 |
| Cihon, F | 1 |
| Endo, Y | 1 |
| Miyamoto, M | 1 |
| Koujima, T | 1 |
| Kawai, T | 1 |
| Toda, K | 1 |
| Nobuhisa, T | 1 |
| Matsumoto, Y | 1 |
| Watanabe, N | 1 |
| Kai, K | 1 |
| Theysohn, JM | 1 |
| Schlaak, JF | 1 |
| Müller, S | 1 |
| Ertle, J | 1 |
| Schlosser, TW | 1 |
| Bockisch, A | 1 |
| Lauenstein, TC | 1 |
| Qu, XD | 1 |
| Chen, JM | 1 |
| Gong, GQ | 1 |
| Qian, S | 1 |
| Beaugrand, M | 1 |
| Kim, JA | 1 |
| Shin, ES | 1 |
| Park, NH | 1 |
| Horiuchi-Yamamoto, Y | 1 |
| Gemma, A | 1 |
| Inoue, Y | 1 |
| Sakai, F | 1 |
| Johkoh, T | 1 |
| Fujimoto, K | 1 |
| Kudoh, S | 1 |
| Federici, G | 2 |
| Metrangolo, S | 2 |
| Parisi, G | 2 |
| Neri, E | 1 |
| Sodini, E | 1 |
| Creasy, KT | 1 |
| Luo, XN | 1 |
| Yu, XY | 1 |
| Zhou, YM | 1 |
| Zhang, XF | 1 |
| Sui, CJ | 1 |
| Li, YM | 1 |
| Yin, ZF | 1 |
| Hu, S | 1 |
| Shi, B | 1 |
| Barretina, J | 1 |
| Subramanian, M | 1 |
| Yu, T | 1 |
| Zhuang, H | 1 |
| Barbero, C | 1 |
| Salizzoni, S | 1 |
| Centofanti, P | 1 |
| Molino, F | 1 |
| Campisi, P | 1 |
| Giorgi, M | 1 |
| Rinaldi, M | 1 |
| Scaramuzzino, A | 1 |
| Pazo-Cid, RA | 1 |
| Esquerdo, G | 1 |
| Pérez-Gracia, JL | 1 |
| Antón, A | 1 |
| Amigo, G | 1 |
| Trufero, JM | 1 |
| García-Otín, AL | 1 |
| Martín-Duque, P | 1 |
| Nakajima, J | 1 |
| Zugazagoitia, J | 1 |
| Manzano, A | 1 |
| Ladero, JM | 1 |
| Puente, J | 1 |
| Díaz-Rubio, E | 1 |
| Staufer, K | 1 |
| Seegers, B | 1 |
| Vettorazzi, E | 1 |
| Hu, AB | 1 |
| He, XS | 1 |
| Tai, Q | 1 |
| Zhu, XF | 1 |
| Wang, DP | 1 |
| Wang, GD | 1 |
| Wu, LW | 1 |
| Ju, WQ | 1 |
| Huang, JF | 1 |
| Iso, Y | 1 |
| Kubota, K | 1 |
| Utsunomiya, T | 1 |
| Toyoki, Y | 1 |
| Hakamada, K | 1 |
| Hisai, H | 1 |
| Imarisio, I | 1 |
| Paglino, C | 1 |
| Ganini, C | 1 |
| Magnani, L | 1 |
| Caccialanza, R | 1 |
| Nicco, C | 1 |
| Chéreau, C | 1 |
| Alexandre, J | 1 |
| Weill, B | 1 |
| Batteux, F | 1 |
| Lupescu, A | 1 |
| Shaik, N | 1 |
| Jilani, K | 1 |
| Zelenak, C | 1 |
| Lang, E | 1 |
| Pasham, V | 1 |
| Zbidah, M | 1 |
| Plate, A | 1 |
| Föller, M | 1 |
| Qadri, SM | 1 |
| Lang, F | 1 |
| Fínek, J | 1 |
| Shi, JH | 1 |
| Liu, SZ | 1 |
| Wierød, L | 1 |
| Scholz, H | 1 |
| Anmarkrud, JA | 1 |
| Huitfeldt, HS | 1 |
| Zhang, SJ | 1 |
| Line, PD | 1 |
| Liu, LP | 1 |
| Yalcin, S | 1 |
| Koca, D | 1 |
| Olmez, A | 1 |
| O'Reilly, EM | 1 |
| Gambacorti-Passerini, C | 1 |
| Rangwala, F | 1 |
| Williams, KP | 1 |
| Smith, GR | 1 |
| Thomas, Z | 1 |
| Allensworth, JL | 1 |
| Lyerly, HK | 1 |
| Diehl, AM | 1 |
| Morse, MA | 1 |
| Devi, GR | 1 |
| Ebert, MP | 1 |
| Boccagni, P | 1 |
| Kertusha, X | 1 |
| Zanus, G | 1 |
| D'Amico, F | 1 |
| Lodo, E | 1 |
| Ichikawa, K | 1 |
| Lesmana, LA | 2 |
| Gani, RA | 1 |
| Hasan, I | 1 |
| Waspodo, A | 1 |
| Boedi, P | 1 |
| Luwia, MS | 1 |
| Ganggaiswari, A | 1 |
| Anai, H | 1 |
| Sueyoshi, S | 1 |
| Masada, T | 1 |
| Kichikawa, K | 1 |
| Török, S | 1 |
| Cserepes T, M | 1 |
| Rényi-Vámos, F | 1 |
| Döme, B | 1 |
| Zhang, A | 1 |
| Fang, D | 1 |
| Rao, Z | 1 |
| Yi, P | 1 |
| Higa, A | 1 |
| Taouji, S | 1 |
| Bexiga, MG | 1 |
| Marza, E | 1 |
| Arma, D | 1 |
| Castain, C | 1 |
| Le Bail, B | 1 |
| Simpson, JC | 1 |
| Rosenbaum, J | 1 |
| Balabaud, C | 1 |
| Chevet, E | 1 |
| Ferrari, D | 1 |
| Mucciarini, C | 1 |
| Latini, L | 1 |
| Banzi, M | 1 |
| Lutman, FR | 1 |
| Tommasini, MA | 1 |
| Ceriani, R | 1 |
| Covini, G | 1 |
| Locopo, N | 1 |
| Naimo, S | 1 |
| Vangeli, M | 1 |
| Gentiluomo, M | 1 |
| Heindryckx, F | 1 |
| Coulon, S | 1 |
| Terrie, E | 1 |
| Casteleyn, C | 1 |
| Stassen, JM | 1 |
| Allemeersch, J | 1 |
| Carmeliet, P | 1 |
| Lulla, PD | 1 |
| Brammer, JE | 1 |
| Bandeali, S | 1 |
| Lynch, GR | 1 |
| Wang, WM | 1 |
| Shi, RY | 1 |
| Gotthardt, D | 1 |
| Koehler, C | 1 |
| Xi, M | 1 |
| Calvieri, A | 1 |
| Silletta, M | 1 |
| Vespasiani, U | 1 |
| Limaye, AR | 1 |
| Horne, P | 1 |
| Mills, R | 1 |
| Firpi, R | 1 |
| Zhao, X | 1 |
| Tian, C | 1 |
| Puszyk, WM | 1 |
| Ogunwobi, OO | 1 |
| van Malenstein, H | 1 |
| Windmolders, P | 1 |
| Nevens, F | 1 |
| Wilkerson, J | 1 |
| Compilato, D | 1 |
| Campisi, G | 1 |
| Nojiri, K | 1 |
| Shiraki, K | 1 |
| Tameda, M | 1 |
| Ogura, S | 1 |
| Kasai, C | 1 |
| Kusagawa, S | 1 |
| Yoneda, M | 1 |
| Yamamoto, N | 1 |
| Takei, Y | 1 |
| Nobori, T | 1 |
| Ito, M | 1 |
| Yuan, D | 1 |
| He, M | 1 |
| Lai, S | 1 |
| Shao, C | 1 |
| Sotiropoulos, GC | 1 |
| Nowak, KW | 1 |
| Vernadakis, S | 1 |
| Kykalos, S | 1 |
| Klein, CG | 1 |
| Paul, A | 1 |
| Sakata, K | 1 |
| Matsugaki, S | 1 |
| Kajiwara, M | 1 |
| Fukuizumi, K | 1 |
| Matsukuma, N | 1 |
| Sakai, T | 1 |
| Ono, N | 1 |
| Yano, Y | 1 |
| Kurogi, J | 1 |
| Sumie, S | 1 |
| Yamada, S | 1 |
| Sata, M | 1 |
| Hernandez-Gea, V | 1 |
| Maruyama, K | 1 |
| Iacovazzi, PA | 1 |
| Correale, M | 1 |
| Di Carlo, A | 1 |
| Psyrri, A | 1 |
| Arkadopoulos, N | 1 |
| Vassilakopoulou, M | 1 |
| Smyrniotis, V | 1 |
| Dimitriadis, G | 1 |
| Nguyen-Tat, M | 1 |
| Schulze-Bergkamen, H | 1 |
| Chang, AY | 1 |
| Ruan, ZP | 1 |
| Tian, T | 1 |
| Guo, H | 1 |
| Nan, KJ | 1 |
| Dal Maso, L | 1 |
| Cacopardo, B | 1 |
| Nasti, G | 1 |
| Facchini, G | 1 |
| Bearz, A | 1 |
| Spina, M | 1 |
| Garlassi, E | 1 |
| De Re, V | 1 |
| Fiorica, F | 1 |
| Lleshi, A | 1 |
| Tirelli, U | 1 |
| Cheng, YF | 1 |
| Ararat, M | 1 |
| Brusko, T | 1 |
| Wasserfall, C | 1 |
| Atkinson, MA | 1 |
| Chang, LJ | 1 |
| Shlomai, A | 1 |
| Schlemmer, HP | 1 |
| Schmidt, B | 1 |
| Höh, K | 1 |
| Knieling, F | 2 |
| Waldner, MJ | 2 |
| Goertz, RS | 2 |
| Lin, KL | 1 |
| Chang, CY | 1 |
| Zopf, S | 1 |
| Wildner, D | 1 |
| Neurath, MF | 1 |
| Bernatik, T | 1 |
| Brunocilla, PR | 1 |
| Brunello, F | 1 |
| Carucci, P | 1 |
| Gaia, S | 1 |
| Cantamessa, A | 1 |
| Castiglione, A | 1 |
| Ciccone, G | 1 |
| Rizzetto, M | 1 |
| Takagi, Y | 1 |
| Kametaka, H | 1 |
| Koyama, T | 1 |
| Seike, K | 1 |
| Hara, J | 1 |
| Hasegawa, A | 1 |
| Frampas, E | 1 |
| Lassau, N | 1 |
| Zappa, M | 1 |
| Koscielny, S | 1 |
| Ji, F | 1 |
| Hua, XD | 1 |
| He, ZY | 1 |
| Bruno, R | 1 |
| Stemmer, SM | 1 |
| Benjaminov, O | 1 |
| Medalia, G | 1 |
| Ciuraru, NB | 1 |
| Silverman, MH | 1 |
| Bar-Yehuda, S | 1 |
| Fishman, S | 1 |
| Harpaz, Z | 1 |
| Farbstein, M | 1 |
| Cohen, S | 1 |
| Patoka, R | 1 |
| Singer, B | 1 |
| Kerns, WD | 1 |
| Fishman, P | 1 |
| Zheng, T | 1 |
| Yin, D | 1 |
| Tian, L | 1 |
| Fang, X | 1 |
| Rognin, N | 1 |
| Kamiyama, N | 1 |
| Furuichi, Y | 1 |
| Imai, Y | 1 |
| Ahn, SY | 1 |
| Galeota Lanza, A | 1 |
| Ascione, A | 1 |
| Ye, W | 1 |
| Xiao, YS | 1 |
| Wang, YJ | 1 |
| Qi, XS | 1 |
| He, CY | 1 |
| Li, RJ | 1 |
| Wu, KC | 1 |
| Xia, JL | 1 |
| Amarapurkar, D | 1 |
| Tan, CK | 1 |
| Tanwandee, T | 1 |
| Burroughs, A | 1 |
| REVEL, M | 1 |
| MANDEL, L | 1 |
| WINTZERITH, M | 1 |
| KLEIN, N | 1 |
| MANDEL, P | 2 |
| CLARK, JB | 2 |
| GREENBAUM, AL | 2 |
| MCLEAN, P | 2 |
| REID, E | 1 |
| HAWTREY, AO | 1 |
| SCHOEMAN, CA | 1 |
| DIJKSTRA, J | 1 |
| SCHIRREN, V | 1 |
| NOURSE, L | 1 |
| NOGUCHI, S | 1 |
| NAKATA, Y | 1 |
| JINNAI, D | 1 |
| SAKAMOTO, Y | 1 |
| Hasmann, M | 1 |
| Schemainda, I | 1 |
| Schleucher, N | 1 |
| Korfee, S | 1 |
| Tewes, M | 1 |
| Faghih, M | 1 |
| Haase, CG | 1 |
| Schwartz, B | 2 |
| Awada, A | 1 |
| Voigtmann, R | 1 |
| Seeber, S | 1 |
| Rini, BI | 1 |
| Figer, A | 1 |
| De Greve, J | 1 |
| Douillard, JY | 1 |
| Lathia, C | 1 |
| Taylor, I | 1 |
| Burton, A | 1 |
| McNabola, A | 1 |
| Wilkie, D | 1 |
| Wilhelm, S | 1 |
| Lynch, M | 1 |
| Carter, C | 1 |
| Spangenberg, HC | 1 |
| Mohr, L | 1 |
| Blum, HE | 1 |
| Almhanna, K | 1 |
| Kalmadi, S | 1 |
| Pelley, R | 1 |
| Simpson, D | 1 |
| Michel, P | 1 |
| Lang, L | 1 |
| Fransvea, E | 1 |
| Angelotti, U | 1 |
| Antonaci, S | 1 |
| Yeh, YK | 1 |
| Hankes, LV | 1 |
| Wessels, LM | 1 |
| Wu, JC | 1 |
| Merlino, G | 1 |
| Cveklova, K | 1 |
| Mosinger, B | 1 |
| Schoental, R | 1 |
| Schmähl, D | 1 |
| Stackelberg, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330] | 129 participants (Actual) | Interventional | 2014-03-21 | Completed | |||
| Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma[NCT02504983] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-08-31 | Active, not recruiting | ||
| A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer[NCT02292173] | Phase 1 | 17 participants (Actual) | Interventional | 2015-02-18 | Completed | ||
| Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486] | Phase 2 | 160 participants (Actual) | Interventional | 2011-11-14 | Completed | ||
| Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer[NCT00813293] | Phase 2 | 20 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Neoadjuvant Combination Therapy of Lenvima Plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients With Large Hepatocellular Carcinoma[NCT05171335] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-06-20 | Enrolling by invitation | ||
| A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors[NCT00940225] | Phase 2 | 730 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Soraf[NCT01140347] | Phase 3 | 565 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma[NCT00872014] | Phase 2 | 60 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Transarterial Chemoembolization With Lenvatinib Versus Lenvatinib Alone in First-line Treatment of Advanced Hepatocellular Carcinoma: a Phase III, Multicenter, Randomized Controlled Trial[NCT03905967] | Phase 3 | 336 participants (Anticipated) | Interventional | 2019-06-16 | Recruiting | ||
| A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma[NCT00105443] | Phase 3 | 602 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Randomized, Double-blinded, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma[NCT00492752] | Phase 3 | 226 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma[NCT01032850] | Phase 2 | 15 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Low accrual rate) | ||
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial[NCT01545804] | Phase 2 | 55 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 1st Generation EGFR-TKI Due to Acquisition of EGFR T790M[NCT03543683] | 330 participants (Anticipated) | Observational | 2020-08-01 | Not yet recruiting | |||
| Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Epidermal Growth Factor Receptor(EGFR)-Mutation[NCT04184921] | 350 participants (Anticipated) | Observational | 2020-08-01 | Not yet recruiting | |||
| Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor（EGFR-TKI） Osimertinib[NCT03532698] | 100 participants (Anticipated) | Observational | 2020-08-01 | Not yet recruiting | |||
| A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma[NCT01482442] | Phase 3 | 496 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Randomized, Open, Two-cohort Phase 2 Study of Toripalimab(PD1) Combined With Lenvatnib, or Gemox Chemotherapy Combined With Lenvatinib as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma[NCT04361331] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-03-06 | Active, not recruiting | ||
| Drug-eluting Bead Transarterial Chemoembolization Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma: a Multicentric Prospective Study[NCT04229355] | Phase 3 | 90 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | ||
| a Single-arm Study of Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and Programmed Cell Death Protein 1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma[NCT03951597] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-05-10 | Active, not recruiting | ||
| A Prospective Cohort Study of the Effect of Lenvatinib Combined With TACE in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT03838796] | 297 participants (Actual) | Interventional | 2019-01-03 | Active, not recruiting | |||
| Combined Therapy Using Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma, a Single-arm Study[NCT04527679] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-10-31 | Not yet recruiting | ||
| Multicenter Phase 2 Trial of Lenvatinib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma After Progression on First-line Atezolizumab Plus Bevacizumab[NCT06138769] | Phase 2 | 50 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| The Efficacy and Safety of Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer[NCT04656249] | Phase 2 | 46 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma: A Single Arm, Nonrandomized, Single Center Clinical Study[NCT05048017] | Phase 2 | 20 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| A Single-arm, Non-randomized, Single-center Study to Evaluate Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma[NCT04443309] | Phase 1/Phase 2 | 53 participants (Anticipated) | Interventional | 2020-09-11 | Recruiting | ||
| Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma: a Single-center, Single-arm, Non-randomized Clinical Study[NCT04368078] | Phase 2 | 76 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study[NCT04211168] | Phase 2 | 44 participants (Anticipated) | Interventional | 2020-08-11 | Recruiting | ||
| Safety and Efficacy of Lenvatinib as an Adjuvant Therapy in Patients With Hepatocellular Carcinoma Following Radical Resection: A Single-Arm and Open-Label Prospective Study[NCT04227808] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949] | Phase 1/Phase 2 | 39 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical Study[NCT03895970] | Phase 2 | 32 participants (Actual) | Interventional | 2019-04-20 | Completed | ||
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.[NCT05171166] | Phase 2/Phase 3 | 156 participants (Anticipated) | Interventional | 2021-12-24 | Recruiting | ||
| Efficacy and Safety of PD-1 Antibody and Lenvatinib Plus TACE on Downstaging Hepatocellular Carcinoma With BCLC B/C[NCT04974281] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Lenvatinib in Neo-adjuvant and Adjuvant Therapy for Poor-prognosis BCLC A HepatoCellular Carcinoma Treated by Percutaneous Ablation Procedure in a Curative Intent: Multicentre Pilot Therapeutic Trial[NCT05113186] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.[NCT05166239] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-01-10 | Recruiting | ||
| A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma[NCT01761266] | Phase 3 | 954 participants (Actual) | Interventional | 2013-03-01 | Completed | ||
| Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With Hepatitis B Virus-related Hepatocellular Carcinoma Following Liver Transplantation: a Retrospective Case Control Study[NCT04415567] | 23 participants (Actual) | Observational | 2018-06-01 | Completed | |||
| Biomarker Discovery Through Multiomics Study in Advanced Hepatocellular Carcinoma Patients Who Received Atezolizumab and Bevacizumab Combination Therapy[NCT05197504] | 100 participants (Anticipated) | Observational | 2021-12-20 | Recruiting | |||
| Investigation of Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab[NCT05173298] | 100 participants (Anticipated) | Observational | 2021-08-02 | Recruiting | |||
| Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib[NCT00812175] | 3,371 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial[NCT01906216] | Phase 2/Phase 3 | 246 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| Transarterial Chemoembolization (TACE) With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma: a Multicenter Prospective Nonrandomized Study[NCT02529761] | 330 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | |||
| Randomized Continuation, Dose Escalation Trial of Sorafenib in Patients With Advanced HCC With Radiological Progression on Prior Sorafenib Treatment (Phase II Study)[NCT00490685] | Phase 2 | 142 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial[NCT00717756] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation.[NCT00846131] | Phase 1 | 24 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma[NCT00858871] | Phase 3 | 1,714 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Briva[NCT00825955] | Phase 3 | 587 participants (Actual) | Interventional | 2009-02-17 | Completed | ||
| A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma[NCT00699374] | Phase 3 | 1,075 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to See termination reason in detailed description.) | ||
| Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib[NCT02786342] | 160 participants (Anticipated) | Observational | 2016-02-15 | Active, not recruiting | |||
| Transarterial Chemoembolization With Lipiodol-Idarubicin Emulsion in the Treatment of Hepatocellular Carcinoma: a Prospective, Multicenter, Real-world Study[NCT05280444] | Phase 2/Phase 3 | 216 participants (Anticipated) | Interventional | 2022-05-28 | Recruiting | ||
| Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®[NCT03203837] | 4 participants (Actual) | Observational | 2017-07-05 | Terminated (stopped due to Funding Discontinued due to low accrual rate) | |||
| Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma[NCT00712790] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Composition for Treating Cirrhosis and Liver Cancer[NCT05178303] | 134 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)[NCT00882869] | Phase 1/Phase 2 | 75 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2021-07-01 | Enrolling by invitation | ||
| A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study[NCT01035229] | Phase 3 | 546 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability[NCT04601428] | Early Phase 1 | 43 participants (Anticipated) | Interventional | 2021-01-26 | Recruiting | ||
| START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial[NCT00990860] | Phase 2 | 36 participants (Anticipated) | Interventional | 2009-02-28 | Active, not recruiting | ||
| Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)[NCT00618384] | Phase 2 | 43 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)[NCT01204177] | Phase 2 | 70 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)[NCT01009593] | Phase 3 | 1,035 participants (Actual) | Interventional | 2010-01-31 | Terminated (stopped due to See termination reason in detailed description) | ||
| The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study[NCT03212625] | Phase 4 | 288 participants (Actual) | Interventional | 2016-01-28 | Completed | ||
| A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma[NCT01033240] | Phase 2 | 172 participants (Actual) | Interventional | 2010-07-09 | Completed | ||
| Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial[NCT04010071] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375] | Phase 2/Phase 3 | 192 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel-group, International Multicenter Phase III Trial of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection[NCT01402908] | Phase 3 | 520 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Due to Interim Analysis and business concerns) | ||
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial[NCT04521153] | 290 participants (Anticipated) | Interventional | 2021-03-25 | Recruiting | |||
| The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697] | Phase 3 | 290 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.[NCT00692770] | Phase 3 | 1,114 participants (Actual) | Interventional | 2008-08-15 | Completed | ||
| Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation in Curative Intent: French Multicenter Phase 2 Therapeutic[NCT06045975] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-12-04 | Not yet recruiting | ||
| Adjuvant Tislelizumab With or Without Lenvatinib for Patients at High-risk of Hepatocellular Carcinoma Recurrence After Curative Resection or Ablation: a Multicentric, Prospective Study[NCT05910970] | Phase 3 | 200 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| Immunotherapy by Nivolumab in Neoadjuvant and Adjuvant Setting in Patients With Advanced HCC Treated by Electroporation in Curative Intent: French Multicenter Phase 2 Therapeutic Trial.[NCT03630640] | Phase 2 | 43 participants (Actual) | Interventional | 2018-10-11 | Active, not recruiting | ||
| Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib[NCT01205828] | Phase 2 | 16 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Lack of efficacy) | ||
| Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma. A Randomized Controlled Trial[NCT04803019] | Phase 3 | 154 participants (Anticipated) | Interventional | 2019-12-04 | Recruiting | ||
| A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma[NCT01258608] | Phase 1/Phase 2 | 101 participants (Actual) | Interventional | 2011-02-08 | Completed | ||
| A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).[NCT00855218] | Phase 2 | 307 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma[NCT03149822] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2017-09-28 | Active, not recruiting | ||
| Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.[NCT01005199] | Phase 2 | 106 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)[NCT00855465] | Phase 3 | 262 participants (Actual) | Interventional | 2009-02-23 | Completed | ||
| Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma)[NCT01411436] | 1,637 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment[NCT00943449] | Phase 2 | 57 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma[NCT01348503] | Phase 1 | 5 participants (Actual) | Interventional | 2011-05-31 | Terminated (stopped due to Treatment was ineffective) | ||
| Real-world Study for Targeted Therapy and Immunotherapy in Patients With Advanced Hepatobiliary Tumors: a Multi-centers, Open-assess Observational Study.[NCT03892577] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2017-07-01 | Recruiting | |||
| "HAIC Combined With Second-line Target Immunity for Advanced Hepatocellular Carcinoma With Low Response or Failure of TACE Combined With First-line Target Immunity: A Prospective, Randomized- Control, Multicenter Clinical Trial"[NCT05233358] | 176 participants (Anticipated) | Interventional | 2022-02-01 | Not yet recruiting | |||
| A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma[NCT01029418] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to The phase II portion was not conducted due to funding issue.) | ||
| Hepatocellular Carcinoma in HIV-infected Patients[NCT02785835] | 477 participants (Actual) | Observational | 2014-05-31 | Completed | |||
| [NCT03026452] | Phase 1/Phase 2 | 400 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)[NCT01135056] | Phase 3 | 360 participants (Actual) | Interventional | 2010-07-31 | Active, not recruiting | ||
| Phase II Study of Regorafenib-nivolumab Combination Therapy for Chemotherapy-naïve Patients With Unresectable or Metastatic Hepatocellular Carcinoma[NCT04310709] | Phase 2 | 42 participants (Actual) | Interventional | 2020-06-16 | Completed | ||
| Evaluation of the Efficacy and Safety of Regorafenib in Patients With Refractory Primary Bone Tumors[NCT05395741] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-28 | Recruiting | ||
| Phase II Trial of Regorafenib in Patients With Unresectable Hepatocellular Carcinoma After Progression on First Line Atezolizumab Plus Bevacizumab (REGONEXT Trial)[NCT05134532] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-24 | Active, not recruiting | ||
| A Real World Study of Regogfinib in the Treatment of Advanced Hepatocellular Carcinoma[NCT05557656] | 800 participants (Anticipated) | Observational | 2023-01-05 | Not yet recruiting | |||
| A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib[NCT01774344] | Phase 3 | 573 participants (Actual) | Interventional | 2013-05-14 | Completed | ||
| Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma[NCT00867321] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-02 | Recruiting | ||
| A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).[NCT00976170] | Phase 1 | 42 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib[NCT01375569] | Phase 2 | 11 participants (Actual) | Interventional | 2011-06-22 | Completed | ||
| Combining Radiation Therapy With Anti-PD-1 for Patients With Advanced Hepatocellular Carcinoma (RT+PD-1-HCC)[NCT04193696] | Phase 2 | 39 participants (Anticipated) | Interventional | 2020-01-10 | Not yet recruiting | ||
| TACE Combined With Iodine-125 Seeds Implantation Versus TACE Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective, Multicenter, Randomized, Controlled Study[NCT03322280] | 270 participants (Anticipated) | Interventional | 2018-07-01 | Active, not recruiting | |||
| Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy Followed by ImmunoTherapy for Downstaging Hepatocellular Carcinoma for Hepatectomy (START-FIT)[NCT03817736] | Phase 2 | 33 participants (Actual) | Interventional | 2019-03-01 | Active, not recruiting | ||
| A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)[NCT02311205] | Phase 2 | 55 participants (Anticipated) | Interventional | 2014-12-31 | Active, not recruiting | ||
| Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma[NCT01897610] | Phase 2 | 40 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis[NCT03518502] | Phase 4 | 130 participants (Anticipated) | Interventional | 2012-03-01 | Recruiting | ||
| Adjuvant Transarterial Chemoembolization With or Without Sorafenib for Patients With Hepatocellular Carcinoma and Microvascular Invasion[NCT02436902] | Phase 3 | 240 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)[NCT01306058] | Phase 1/Phase 2 | 27 participants (Actual) | Interventional | 2011-02-11 | Completed | ||
| An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809] | Phase 4 | 40 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma[NCT02729506] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics[NCT02973204] | 167 participants (Actual) | Observational [Patient Registry] | 2016-11-30 | Completed | |||
| Maintenance of Sorafenib Following Combined Therapy of Three-dimensional Conformal Radiation Therapy/Intensity-modulated Radiation Therapy and Transcatheter Arterial Chemoembolization in Patients With Locally Advanced Hepatocellular Carcinoma: a Phase I/I[NCT00999843] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma[NCT00478374] | Phase 1 | 21 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.[NCT00108953] | Phase 2 | 96 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma[NCT00464919] | Phase 2 | 50 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study[NCT01831037] | 0 participants (Actual) | Observational | 2015-07-31 | Withdrawn (stopped due to Unable to obtain funding) | |||
| Radiofrequency Ablation Combined With Highly-purified CTL vs. Radiofrequency Ablation Alone for Recurrent HCC[NCT02678013] | Phase 3 | 210 participants (Anticipated) | Interventional | 2016-02-29 | Active, not recruiting | ||
| Prophylactic Minimally-invasive Local Ablation Therapies for the Hepatic Dysplastic Nodules in Patients With Positive Hepatitis B Surface Antigen (HBsAg).[NCT02793791] | 30 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | |||
| The Combination of Pembrolizumab and Lenvatinib as Neoadjuvant Treatment for Hepatocellular Carcinoma Patients: a Single Arm Phase II Study[NCT05389527] | Phase 2 | 43 participants (Anticipated) | Interventional | 2022-09-30 | Active, not recruiting | ||
| Stereotactic Image-Guided Microwave Ablation for Hepatocellular Carcinoma - Does Computer-assistance Broaden Eligibility and Efficacy of Ablative Treatment?[NCT03630068] | 87 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| A New Track Ablation Device for Liver Biopsy: A Feasibility Study[NCT02521129] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | ||
| A Randomized Controlled Trial of Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma[NCT02243384] | 150 participants (Actual) | Interventional | 2014-09-01 | Completed | |||
| A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin[NCT03452553] | 0 participants (Actual) | Interventional | 2018-07-01 | Withdrawn (stopped due to CMS disapproval, no alternative for sites/patient, risk of financial burden.) | |||
| Effectivity and Safety of Microwave Ablation Combined With Transcatheter Arterial Chemoembolization(TACE) for Huge Unresectable Hepatocellular Carcinoma: a Multicenter Analysis[NCT03277716] | 100 participants (Anticipated) | Interventional | 2017-12-01 | Recruiting | |||
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)[NCT00494299] | Phase 3 | 458 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging[NCT06144827] | 40 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.[NCT00619541] | Phase 2 | 46 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| Prospective Evaluation of Tumor Response to Cancer Treatment Therapies[NCT02787954] | 10 participants (Actual) | Observational [Patient Registry] | 2016-01-31 | Terminated (stopped due to PI transferred to another institution and did not take this study with him.) | |||
| Clinical Study of Transarterial Chemoembolization (TACE) Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma[NCT02630108] | Phase 3 | 280 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Radiofrequency Ablation or Surgical Resection Combined With Neo-MASCT for Primary Hepatocellular Carcinoma: a Randomised, Multicentre Phase II Trial[NCT03067493] | Phase 2 | 98 participants (Anticipated) | Interventional | 2017-07-25 | Recruiting | ||
| DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab[NCT04954339] | Phase 2 | 45 participants (Anticipated) | Interventional | 2021-10-29 | Recruiting | ||
| A Sorafenib-Regorafenib Sequence Treatment Monitoring Study Using Liquid Biopsy[NCT03956940] | 18 participants (Actual) | Interventional | 2019-10-04 | Terminated (stopped due to Change of the scientific and medical context that is no longer favorable to our study. This has resulted in the termination of inclusions.) | |||
| Longitudinal Immune-phenotyping of Surgically Resected HCC Following Neoadjuvant and Adjuvant Treatment With MK-3475[NCT04224480] | Phase 1 | 45 participants (Anticipated) | Interventional | 2019-12-10 | Recruiting | ||
| Establishing a Correlation Between Pre-treatment CT Perfusion Parameter Values and Post-treatment PET/CT Dosimetry to Aid in Tumor-specific Y-90 Radioembolization Treatment Planning for Hepatocellular Carcinoma[NCT02558205] | 0 participants (Actual) | Observational | 2015-07-31 | Withdrawn (stopped due to unable to rectuir) | |||
| A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma[NCT00790218] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis[NCT05201404] | Phase 3 | 471 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| The Efficacy and Safety of Retreatment With Transcatheter Arterial Infusion (TAI) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial[NCT02220088] | Phase 2/Phase 3 | 79 participants (Actual) | Interventional | 2014-12-31 | Terminated (stopped due to protocol violation) | ||
| A Multicenter, Open-label, Single-arm Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT Using SIR-Spheres for the Treatment of Patients With HepatoCellular Carcinoma That Are Candidates for Locoregional Therapies[NCT03380130] | Phase 2 | 41 participants (Actual) | Interventional | 2017-09-11 | Completed | ||
| Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study[NCT02636426] | Phase 1 | 17 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors[NCT00933777] | Phase 1 | 36 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase II Multicenter Uncontrolled Trial of Sorafenib (BAY43-9006) in Patients With Advanced Hepatocellular Carcinoma[NCT00044512] | Phase 2 | 137 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | millimeters (Mean) |
|---|---|
| Sorafenib | 42.4 |
| Placebo | 44.1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | millimeters (Mean) |
|---|---|
| Sorafenib | 36.0 |
| Placebo | 35.1 |
The size of the coagulation zone was determined on CT imaging obtained after RFA for the single index tumor. (NCT00813293)
Timeframe: Up to day 50 from study enrollment (target 30 days after RFA)
| Intervention | centimeters^3 (Mean) |
|---|---|
| Sorafenib | 30.7 |
| Placebo | 30.5 |
Feasibility rate is defined as the percentage of participants completing radiofrequency ablation following 9 days of sorafenib or placebo therapy. (NCT00813293)
Timeframe: Up to day 14 since enrollment
| Intervention | percentage of particpants (Number) |
|---|---|
| Sorafenib | 90 |
| Placebo | 90 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related up to day 9 of study drug treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple different AE types within a grade. (NCT00813293)
Timeframe: Day 9
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 8 |
| Placebo | 4 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related on day of RFA treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple AE types within a grade. (NCT00813293)
Timeframe: Up to day 14 (target day 10 RFA)
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 5 |
| Placebo | 4 |
AEs were assessed based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v3.0). The number of Grade 1-4 AEs with treatment attribution possibly, probably or definitely related one month after RFA treatment were counted for this outcome. Worst grade by patient within AE type was calculated. Participants could have multiple AE types within a grade. (NCT00813293)
Timeframe: Up to day 40 post RFA (target 30 days)
| Intervention | adverse events (Number) |
|---|---|
| Sorafenib | 8 |
| Placebo | 4 |
(NCT01140347)
Timeframe: 1 hour following completion of Cycle 4 (14-day cycles) infusion
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 189.5 |
(NCT01140347)
Timeframe: 1 hour following completion of Cycle 7 (14-day cycles) infusion
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 184.4 |
(NCT01140347)
Timeframe: 1 hour following the completion of Cycle 1 (14-day cycle) infusion
| Intervention | micrograms/milliliter (µg/mL) (Geometric Mean) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 149.6 |
Participants were considered positive for anti-ramucirumab antibodies [anti-drug antibodies (ADA)] if the post-treatment sample had an increase of at least 4-fold in titer from the pretreatment values. If the pretreatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence of ADA. (NCT01140347)
Timeframe: Prior to treatment and 1 hour post end of infusion for Cycles 1, 4 and 7 (14-day cycles)
| Intervention | participants (Number) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 10 |
| Placebo + BSC | 7 |
OS was defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up were censored on the last date the participant was known to be alive. (NCT01140347)
Timeframe: Randomization to death from any cause (up to 37 months)
| Intervention | months (Median) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 9.17 |
| Placebo + BSC | 7.62 |
ORR was defined, using RECIST v1.1 criteria, as the percentage of participants who achieved a best overall response of CR or PR. CR was defined as the disappearance of all lesions and any intratumor arterial enhancement in target lesions, the normalization of the tumor marker level and all lymph nodes short axis reduced to <10 mm. PR was defined as ≥30% decrease in the SOD of target lesions, including the short axes of any target lymph nodes, taking as reference the baseline SOD of target lesions, no new lesions and stable nontarget lesions. Percentage of participants was calculated as: (number of participants with CR or PR / number of participants randomized) * 100. (NCT01140347)
Timeframe: Baseline to the date of first evidence of confirmed CR or PR (up to 37 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 7.1 |
| Placebo + BSC | 0.7 |
PFS was defined as time from date of randomization until date of objectively determined progressive disease (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or death from any cause. PD was defined as ≥20% increase in sum of diameters (SOD) of target lesions, taking as reference smallest sum on study (including baseline sum if it was smallest). Sum must show a ≥5 millimeter (mm) increase. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. In primary analysis, participants alive and without PD were censored at day of last adequate tumor assessment; progression or deaths without progression occurring immediately after ≥2 missed tumor assessments, were censored at day of the last adequate tumor assessment prior to missing assessments; participants who began new anticancer therapy were censored at day of the last adequate tumor assessment prior to start of new anticancer therapy. (NCT01140347)
Timeframe: Randomization to PD (up to 36 months)
| Intervention | months (Median) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 2.79 |
| Placebo + BSC | 2.10 |
TTP was defined as the time from randomization to the first radiographically documented PD. PD was defined, using RECIST v1.1 criteria, as ≥20% increase in SOD of target lesions, taking as reference smallest sum on study (including baseline sum if it was the smallest). Sum must show an absolute increase of ≥5 mm. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. Participants without PD were censored at the day of the last adequate tumor assessment. Progression occurred immediately after ≥2 missed tumor assessments and were censored at the day of the last adequate tumor assessment prior to the missing assessments. Participants who began new anticancer therapy were censored at the day of their last adequate tumor assessment prior to start of new anticancer therapy. (NCT01140347)
Timeframe: Randomization to PD (up to 36 months)
| Intervention | months (Median) |
|---|---|
| Ramucirumab (IMC-1121B) + BSC | 3.48 |
| Placebo + BSC | 2.63 |
The EQ-5D is a self-reported, 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire related to the participant's current health state. Each question was scored using a 3 level scale (no problems, some problems, or extreme problems). EQ-5D health state was defined by combining responses from each of the 5 dimensions into a weighted health-state index score according to the United Kingdom (UK) population based algorithm where 0 = death and 1 = perfect health. (NCT01140347)
Timeframe: Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), end of treatment (up to 34 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Cycle 4 (n=166, 145) | Cycle 10 (n=71, 45) | Cycle 16 (n=47, 25) | End of Treatment (n=166, 190) | |
| Placebo + BSC | -0.046 | 0.003 | -0.012 | -0.144 |
| Ramucirumab (IMC-1121B) + BSC | -0.038 | -0.054 | -0.062 | -0.129 |
The FHSI-8 is a self-administered 8-item questionnaire that measures a participant's symptoms in the domains of jaundice, stomach pain/discomfort weight loss, and fatigue. Participants rated each item on a 5-point scale from 0 (not at all) to 4 (very much). Item scores were calculated as outlined in the FACIT manual. FHSI-8 total score was the sum of each item's score with a total score ranging from 0 (highly symptomatic) to 32 (asymptomatic). (NCT01140347)
Timeframe: Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), and end of treatment (up to 34 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Cycle 4 (n=166, 147) | Cycle 10 (n=70, 45) | Cycle 16 (n=47, 24) | End of Treatment (n=169, 199) | |
| Placebo + BSC | -0.81 | -0.01 | 0.75 | -2.86 |
| Ramucirumab (IMC-1121B) + BSC | -1.26 | -1.28 | -0.97 | -2.44 |
The number of participants with serious AEs (SAEs), other non-serious AEs and participants who died. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module. (NCT01140347)
Timeframe: Baseline to study completion (up to 37 months)
| Intervention | participants (Number) | ||
|---|---|---|---|
| SAEs | Other Non-SAEs | Died | |
| Placebo + BSC | 92 | 235 | 220 |
| Ramucirumab (IMC-1121B) + BSC | 123 | 254 | 215 |
The DC is defined as the number of subjects with a best response rating of complete response (CR), partial response (PR), or stable disease (SD) that is maintained at least 28 days from the first manifestation of that rating. Definitions: CR = disappearance of all clinical and radiological tumor lesions; PR = at least 30% decrease in sum of the longest diameters of tumor lesions; SD = neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease. (NCT00105443)
Timeframe: time from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment
| Intervention | Participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 130 |
| Placebo | 96 |
The DC is defined as the number of subjects with a best response rating of CR, PR, or SD that is maintained at least 28 days from the first manifestation of that rating. (NCT00105443)
Timeframe: from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment
| Intervention | Participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 130 |
| Placebo | 96 |
Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00105443)
Timeframe: from randomization to death due to any cause until an average 8.5 months later up to the data cut-off date approximately 23 months after start of enrollment
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 327 |
| Placebo | 243 |
Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00105443)
Timeframe: from randomization to death due to any cause until an average 7.2 months later up to the data cut-off date approximately 19 months after start of enrollment
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 324 |
| Placebo | 241 |
TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00105443)
Timeframe: from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 19 months after start of enrollment
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 168 |
| Placebo | 86 |
TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00105443)
Timeframe: from randomization to disease progression based on radiological assessment until an average 2.8 months later up to the data cut-off date approximately 23 months after start of enrollment
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 168 |
| Placebo | 86 |
TTSP was defined as the time from randomization to the first documented symptomatic progression (NCT00105443)
Timeframe: from randomization to the first documented symptomatic progression until an average 5.7 months later up to the data cut-off date approximately 23 months after start of enrollment
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 127 |
| Placebo | 148 |
TTSP was defined as the time from randomization to the first documented symptomatic progression. (NCT00105443)
Timeframe: from randomization to the first documented symptomatic progression until an average 4.8 months later up to the data cut-off date approximately 19 months after start of enrollment
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 126 |
| Placebo | 148 |
PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. (NCT00105443)
Timeframe: from randomization to end of treatment up to the data cutoff date approximately 19 months after start of enrollment
| Intervention | Participants (Number) | |
|---|---|---|
| Cycle 3 day 1 change <8 points | Cycle 3 day 1 change ≥8 points | |
| Placebo | 139 | 39 |
| Sorafenib (Nexavar, BAY43-9006) | 151 | 23 |
PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. At the cut-off date for this analysis, one more patient data has been gained. (NCT00105443)
Timeframe: from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment
| Intervention | Participants (Number) | |
|---|---|---|
| Cycle 3 day 1 change <8 points | Cycle 3 day 1 change ≥8 points | |
| Placebo | 139 | 40 |
| Sorafenib (Nexavar, BAY43-9006) | 151 | 23 |
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. A plot of concentration vs time after dosing is created, and the area under this curve is calculated by standard methods (eg, trapezoidal rule) to provide a measure of how much drug was in the bloodstream following dosing. (NCT00492752)
Timeframe: PK assessments made at following times: pre-dose, 1 h, 2h, 4h, 8h,and 12h after at least 21 consecutive doses during Cycle 1
| Intervention | mg*h/L (Geometric Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 35.7 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) is first documented, or to the date of death, whichever occurs first. Subjects still having CR or PR at the time of analysis were censored at their last tumor assessment. (NCT00492752)
Timeframe: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 210 |
| Placebo | 252 |
Cmax refers to the highest plasma concentration of drug reached after dosing. It is obtained by collecting a series of blood samples after dosing, and analyzing them for drug content by a sensitive and specific analytical method. The highest measured concentration is referred to as the Cmax. (NCT00492752)
Timeframe: PK assessments made at following times: pre-dose, 1 h, 2h, 4h, 8h,and 12h after at least 21 consecutive doses during Cycle 1
| Intervention | mg/L (Geometric Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 4.44 |
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. A plot of concentration vs time after dosing is created, and the area under this curve is calculated by standard methods (eg, trapezoidal rule) to provide a measure of how much drug was in the bloodstream following dosing. (NCT00492752)
Timeframe: PK assessments made at following times: pre-dose, 1 h, 2h, 4h, 8h,and 12h after at least 21 consecutive doses during Cycle 1
| Intervention | g*h/L (Geometric Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 6.6 |
Cmaxnorm refers to the maximum plasma concentration of Sorafenib corrected for dose and body weight (Cmaxnorm = Cmax/(mg/kg)). (NCT00492752)
Timeframe: PK assessments made at following times: pre-dose, 1 h, 2h, 4h, 8h,and 12h after at least 21 consecutive doses during Cycle 1
| Intervention | g/mL (Geometric Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.66 |
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00492752)
Timeframe: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 198 |
| Placebo | 127 |
Tmax refers to the time after dosing when a drug attains its maximum concentration in the blood. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. The time corresponding to the highest measurable concentration (Cmax) is referred to as Tmax. (NCT00492752)
Timeframe: PK assessments made at following times: pre-dose, 1 h, 2h, 4h, 8h,and 12h after at least 21 consecutive doses during Cycle 1
| Intervention | hours (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 4.0 |
Time to progression (TTP) was defined as the time from date of randomization to radiologically documented disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation。 (NCT00492752)
Timeframe: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 84 |
| Placebo | 41.5 |
Time to Response (TTR) for subjects who achieved a response (Complete Response (CR) or Partial Response (PR) ) was defined as the time from date of randomization to the earliest date that the response was first documented. (NCT00492752)
Timeframe: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 84 |
| Placebo | 42 |
Time to Symptomatic Progression (TTSP) was defined as the time from date of randomization to symptomatic progression. Subjects without symptomatic progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00492752)
Timeframe: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 105 |
| Placebo | 103 |
The FHSI-8 questionnaire was completed at baseline and every 3 weeks during treatment and at the end of treatment visit only for subjects who withdrew for reasons other than symptomatic progression. Patient reported outcome was measured using the FHSI-8 score changes from baseline throughout the study period. FHSI-8 assesses hepatobiliary cancer symptoms with total score ranges from 0 to 32 (0 = the best quality of life; 32 = the worst quality of life with severe symptoms).. (NCT00492752)
Timeframe: Baseline up to Cycle 1 and Cycle 3. From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| cycle 1 | cycle 3 | |
| Placebo | 26 | 25 |
| Sorafenib (Nexavar, BAY43-9006) | 26 | 24 |
"The FACT-Hep questionnaire was also completed to assess patient reported outcome. The FACT-Hep assesses hepatobiliary cancer-related quality of life. FACT-Hep total score ranges from 0 to 180 (0=All questions answered Not at all; 180=All questions answered Very much)." (NCT00492752)
Timeframe: Baseline up to Cycle 3 and end of treatment. From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| cycle 3 | end of treatment | |
| Placebo | -3 | -23 |
| Sorafenib (Nexavar, BAY43-9006) | -10 | -25 |
Disease Control (DC) was defined as the total number of subjects whose best response was not Progressive Disease (PD: an increase in the sum of tumor lesions sizes) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR: disappearance of tumor lesions) + total number of Partial Response (PR: a decrease of at least 30% in the sum of tumor lesion sizes) + total number of Stable Disease (SD: steady state of disease); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating). (NCT00492752)
Timeframe: From randomization of the first subject until the data cut-off date approximately 23 months after start of randomization
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Placebo | 12 | 64 |
| Sorafenib (Nexavar, BAY43-9006) | 53 | 97 |
Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR: disappearance of tumor lesions), confirmed* Partial Response (PR: a decrease of at least 30% in the sum of tumor lesion sizes), Stable Disease (SD: steady state of disease), or Progressive Disease (PD: an increase in the sum of tumor lesions sizes)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (NCT00492752)
Timeframe: From randomization/start of treatment of the first subject until approximately 23 months after randomization when the subjects on placebo were offered the option to crossover to sorafenib treatment
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not assessable | |
| Placebo | 0 | 1 | 21 | 41 | 13 |
| Sorafenib (Nexavar, BAY43-9006) | 0 | 5 | 81 | 46 | 18 |
The time from treatment initiation to death by any cause (NCT01032850)
Timeframe: 5 years
| Intervention | Months (Median) |
|---|---|
| Arm 1: Sorafenib & Capecitabine | 12.7 |
The time from treatment initiation to disease progression or death by any cause. Progression is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI:) Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient decrease in the sum of the longest diameter of target lesions to qualify for PR nor sufficient increase in the sum of the longest diameter of target lesions to qualify for Progressive Disease; Progressive Disease (PD), 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01032850)
Timeframe: 5 years
| Intervention | months (Median) |
|---|---|
| Arm 1: Sorafenib & Capecitabine | 4.15 |
Tumor response is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI:) Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient decrease in the sum of the longest diameter of target lesions to qualify for PR nor sufficient increase in the sum of the longest diameter of target lesions to qualify for Progressive Disease; Progressive Disease (PD), 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Disease control rate (DCR) is the sum of the percentages of patients achieving complete and partial responses and stable disease (NCT01032850)
Timeframe: 6 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Disease Control Rate of Response (DCR) | |
| Arm 1: Sorafenib & Capecitabine | 8 | 8 | 61 | 77 |
The primary objective of the study is to evaluate safety and tolerability of the study treatment regimen. The analyses will be descriptive and no formal hypotheses testing will be performed. Toxicities (i.e. Adverse Events) are evaluated prior to each treatment and during any clinical visit. (NCT01032850)
Timeframe: 6 months
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | Neutropenia | Low phosphate levels | Low magnesium levels | Low calcium levels | Low sodium levels | High bilirubin levels | Elevated aspartate aminotransferase | Hand and foot syndrome | Mucositis | Alopecia (Hair loss) | Skin rash | Deep vein thrombosis | Treatment related deaths | |
| Arm 1: Sorafenib & Capecitabine | 9 | 1 | 3 | 2 | 2 | 1 | 3 | 2 | 3 | 1 | 1 | 1 | 3 | 0 |
AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)
| Intervention | nanogram*hour per milliliter (ng*h/mL) (Mean) |
|---|---|
| Lenvatinib 8 mg | 1969.6 |
| Lenvatinib 12 mg | 2120.9 |
CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD >=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenvatinib | 59.0 |
| Sorafenib | 38.4 |
DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been >=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenvatinib | 75.5 |
| Sorafenib | 60.5 |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenvatinib | 24.1 |
| Sorafenib | 9.2 |
OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff. (NCT01761266)
Timeframe: From date of randomization until date of death from any cause (approximately up to 3.8 years)
| Intervention | months (Median) |
|---|---|
| Lenvatinib | 13.6 |
| Sorafenib | 12.3 |
PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
| Intervention | months (Median) |
|---|---|
| Lenvatinib | 7.4 |
| Sorafenib | 3.7 |
The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
| Intervention | months (Median) |
|---|---|
| Lenvatinib | 1.7 |
| Sorafenib | 1.8 |
TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)
| Intervention | months (Median) |
|---|---|
| Lenvatinib | 8.9 |
| Sorafenib | 3.7 |
The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date. (NCT01761266)
Timeframe: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)
| Intervention | percent change (Median) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANG 2: Cycle 1 Day 15 | ANG 2: Cycle 2 Day 1 | ANG 2: Cycle 3 Day 1 | ANG 2: Cycle 4 Day 1 | ANG 2: Cycle 5 Day 1 | ANG 2: Cycle 6 Day 1 | ANG 2: Cycle 7 Day 1 | ANG 2: Cycle 8 Day 1 | ANG 2: Cycle 9 Day 1 | ANG 2: Off-Treatment | FGF19: Cycle 1 Day 15 | FGF19: Cycle 2 Day 1 | FGF19: Cycle 3 Day 1 | FGF19: Cycle 4 Day 1 | FGF19: Cycle 5 Day 1 | FGF19: Cycle 6 Day 1 | FGF19: Cycle 7 Day 1 | FGF19: Cycle 8 Day 1 | FGF19: Cycle 9 Day 1 | FGF19: Off-Treatment | FGF 21: Cycle 1 Day 15 | FGF 21: Cycle 2 Day 1 | FGF 21: Cycle 3 Day 1 | FGF 21: Cycle 4 Day 1 | FGF 21: Cycle 5 Day 1 | FGF 21: Cycle 6 Day 1 | FGF 21: Cycle 7 Day 1 | FGF 21 : Cycle 8 Day1 | FGF 21: Cycle 9 Day1 | FGF 21: Off-Treatment | FGF 23: Cycle 1 Day15 | FGF 23: Cycle 2 Day 1 | FGF 23: Cycle 3 Day 1 | FGF 23: Cycle 4 Day 1 | FGF 23: Cycle 5 Day 1 | FGF 23: Cycle 6 Day 1 | FGF 23: Cycle 7 Day 1 | FGF 23: Cycle 8 Day 1 | FGF 23: Cycle 9 Day 1 | FGF 23: Off-Treatment | PIVKA-II: Cycle 1 Day 15 | PIVKA-II: Cycle 2 Day 1 | PIVKA-II: Cycle 3 Day 1 | PIVKA-II: Cycle 4 Day 1 | PIVKA-II: Cycle 5 Day 1 | PIVKA-II: Cycle 6 Day 1 | PIVKA-II: Cycle 7 Day 1 | PIVKA-II: Cycle 8 Day 1 | PIVKA-II: Cycle 9 Day 1 | PIVKA-II: Off-Treatment | VEGF: Cycle 1 Day 15 | VEGF: Cycle 2 Day 1 | VEGF: Cycle 3 Day 1 | VEGF: Cycle 4 Day 1 | VEGF: Cycle 5 Day 1 | VEGF: Cycle 6 Day 1 | VEGF: Cycle 7 Day 1 | VEGF: Cycle 8 Day 1 | VEGF: Cycle 9 Day 1 | VEGF: Off-Treatment | |
| Lenvatinib | -28.1 | -28.8 | -32.2 | -35.6 | -38.9 | -36.7 | -41.4 | -40.2 | -39.6 | 11.7 | 75.0 | 66.5 | 86.9 | 208.1 | 152.8 | 119.8 | 64.4 | 95.8 | 159.3 | 140.1 | 22.0 | 15.7 | 38.3 | 42.9 | 41.0 | 52.6 | 63.4 | 38.3 | 59.1 | 141.4 | 23.9 | 20.9 | 25.5 | 29.5 | 29.6 | 26.3 | 31.5 | 38.1 | 23.2 | 17.8 | 80.0 | 169.7 | 252.4 | 371.7 | 628.2 | 648.7 | 184.8 | 277.8 | 318.8 | 809.3 | 157.5 | 128.9 | 97.7 | 113.4 | 132.4 | 113.1 | 133.1 | 148.7 | 129.6 | 127.1 |
| Sorafenib | 8.9 | -0.9 | 0.5 | -4.5 | 7.0 | -3.6 | 1.0 | -6.7 | -1.1 | 16.8 | 1.3 | 36.6 | 22.8 | 46.8 | -1.0 | 26.9 | -5.9 | 53.9 | 56.6 | 9.0 | 4.0 | 18.6 | 49.4 | 32.8 | 31.1 | 23.2 | 23.7 | 17.0 | 68.9 | 104.9 | -16.3 | -6.2 | 17.3 | 14.2 | 1.0 | -10.6 | 0.7 | 2.8 | 0.5 | 14.2 | 166.9 | 243.8 | 218.7 | 196.2 | 369.5 | 415.7 | 703.6 | 724.0 | 859.1 | 272.5 | 97.4 | 94.0 | 66.0 | 76.1 | 116.2 | 130.9 | 96.9 | 181.1 | 135.6 | 147.8 |
"The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = not at all and 4 = very much. All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date." (NCT01761266)
Timeframe: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
| Intervention | months (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Fatigue | Jaundice | Body Image | Nutrition | Pain | Fever | Sex Life | Abdominal swelling | |
| Lenvatinib | 1.9 | 4.6 | 2.8 | 4.1 | 2.7 | 5.5 | 7.4 | 7.4 |
| Sorafenib | 1.8 | 3.7 | 1.9 | 2.8 | 2.8 | 3.7 | 6.7 | 7.4 |
"The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with 3 corresponding to no problems and 15 corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date." (NCT01761266)
Timeframe: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
| Intervention | months (Median) | |
|---|---|---|
| VAS | HUI | |
| Lenvatinib | 2.8 | 2.8 |
| Sorafenib | 1.9 | 1.9 |
"radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD~It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed." (NCT00717756)
Timeframe: on average about every 2 months until progression, on average about 4 months.
| Intervention | participants (Number) |
|---|---|
| Lenalidomide | 6 |
Overall survival is the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact. (NCT00699374)
Timeframe: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
| Intervention | Weeks (Median) |
|---|---|
| Sunitinib | 34.3 |
| Sorafenib | 43.9 |
The period from randomization until disease progression or death. (NCT00699374)
Timeframe: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
| Intervention | Weeks (Median) |
|---|---|
| Sunitinib | 15.3 |
| Sorafenib | 12.6 |
Time in weeks from randomization to first documentation of objective tumor progression or death due to cancer, whichever comes first. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]) (NCT00699374)
Timeframe: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
| Intervention | Weeks (Median) |
|---|---|
| Sunitinib | 17.7 |
| Sorafenib | 15.4 |
OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance. (NCT01035229)
Timeframe: When 454 OS events were observed
| Intervention | Months (Median) |
|---|---|
| Everolimus + Best Supportive Care (BSC) | 7.56 |
| Placebo + Best Supportive Care | 7.33 |
DCR is defined as the proportion of participants with a best objective response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST. The BOR was the best response recorded from the start of the treatment until disease progression. CR is disappearance of all target lesions; PR is at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters; SD is neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD is at least a 20% increase in the sum of the longest diameter of all measured target lesions, taking as reference the smallest sum of longest diameter of all target lesions recorded at or after baseline. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
| Intervention | Percentage of Participants (Number) |
|---|---|
| Everolimus + Best Supportive Care (BSC) | 56.1 |
| Placebo + Best Supportive Care | 45.1 |
Cmax is the maximum (peak) blood drug concentration after dose administration (ng/mL) calculated as the maximum of C1h and C2h. C1h was 1 hour post-dose blood concentration (ng/mL) and C2h was 2 hour post-dose blood concentration (ng/mL). C1h and C2h post-dose samples were collected from all patients in both arms at Visit 3. Steady-state for the C1h and C2h samples was defined as continuous administration of the same dose in the previous 4 days and the day on which the C1h and C2h samples were collected. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid C1h and C2h everolimus samples were included in the analysis. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
| Intervention | ng/mL (Mean) |
|---|---|
| Everolimus 7.5mg + Best Supportive Care (BSC) | 47.881 |
| Everolimus 5mg + Best Supportive Care (BSC) | 31.592 |
Cmin is the pre-dose blood concentration at steady-state (ng/mL). Pre-dose (Cmin) blood samples were collected from all patients in both arms at Visit 3. Steady-state for the Cmin sample was defined as continuous administration of the same dose in the last 4 days prior to the collection of the Cmin sample. Steady-state for the 5 mg every other day regimen was defined as the state when the 5 mg dose was taken 2 days and 4 days before sampling. PK samples were only drawn at visit 3, and only analyzed for patients receiving everolimus at steady state (if patients had received the dose the previous 4 days). In addition summary statistics were only done for each everolimus dose when 3 samples were available. Only valid pre-dose (Cmin) everolimus samples were included in the analysis. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
| Intervention | ng/mL (Mean) |
|---|---|
| Everolimus 7.5mg + Best Supportive Care (BSC) | 16.141 |
| Everolimus 5mg + Best Supportive Care (BSC) | 9.318 |
Change in Eastern Cooperative Oncology Group (ECOG) were assessed by time to definitive performance status deterioration by at least one category on the ECOG scale. Deterioration was considered definitive if no improvement in the ECOG PS was observed at a subsequent measurement. ECOG PS: 0=Fully active, able to carry on all pre-disease performance without restriction, 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2=Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3=Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4=Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair; 5=Dead (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient.
| Intervention | Months (Median) |
|---|---|
| Everolimus + Best Supportive Care (BSC) | 4.27 |
| Placebo + Best Supportive Care | 4.47 |
The primary quality of life endpoint was the time to definitive 5% deterioration from baseline in the global health status/quality of life scale of the EORTC QLQ-C30 questionnaire. Definitive deterioration by at least 5% is defined as a decrease in score by at least 5% compared to baseline, with no later observed increase above this threshold. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events - Estimate of 1 year for each patient.
| Intervention | Months (Median) |
|---|---|
| Everolimus + Best Supportive Care (BSC) | 2.86 |
| Placebo + Best Supportive Care | 3.45 |
TTP was defined as the time from the date of randomization to the date of the first documented radiologic confirmation of disease progression. Since the study did not meet the primary objective, TTP was not formally tested. (NCT01035229)
Timeframe: Until all patients have disease progression or leave study due to intolerable adverse events- Estimate of 1 year for each patient
| Intervention | Months (Median) |
|---|---|
| Everolimus + Best Supportive Care (BSC) | 2.96 |
| Placebo + Best Supportive Care | 2.60 |
Overall survival (OS) was defined as the time from randomization to the date of death. The factors in the final model were treatment, Eastern Cooperative Oncology Group (ECOG) performance status, presence of extrahepatic metastasis and/or macrovessel invasion, and region. (NCT01033240)
Timeframe: Baseline up to approximately 3 years 2 months post-dose.
| Intervention | months (Median) |
|---|---|
| Sorafenib | 8.2 |
| CS-1008 6/2 mg/kg + Sorafenib | 8.2 |
| CS-1008 6/6 mg/kg + Sorafenib | 12.2 |
Time to progression was defined as the time from randomization to the date of the first objective documentation of radiographic or symptomatic progression, whichever came first. (NCT01033240)
Timeframe: Baseline up to approximately 2 years post-dose.
| Intervention | months (Median) |
|---|---|
| Sorafenib | 2.8 |
| CS-1008 6/2 mg/kg + Sorafenib | 3.0 |
| CS-1008 6/6 mg/kg + Sorafenib | 3.9 |
The best overall response is the best response (in the order of confirmed complete response [CR], confirmed partial response [PR], unconfirmed CR, unconfirmed PR, stable disease [SD], and progressive disease [PD]) among all overall responses recorded from the start of treatment until the participant withdraws from the study based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If there is no tumor assessment after the first dose of study drug, the best overall response is classified as Inevaluable. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD defined as at least a 20% increase in the sum of diameters of target lesions. Objective response rate was defined as confirmed CR and confirmed PR. (NCT01033240)
Timeframe: Baseline up to disease progression, death, lost to follow up, or study discontinuation (whichever comes first), up to approximately 3 years 2 months post-dose.
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Objective Response Rate (CR+PR) | Stable Disease (SD) | Progressive Disease (PD) | Inevaluable | Best Overall Response of SD or Better | |
| CS-1008 6/2 mg/kg + Sorafenib | 0 | 3 | 3 | 26 | 14 | 10 | 29 |
| CS-1008 6/6 mg/kg + Sorafenib | 0 | 8 | 8 | 29 | 15 | 2 | 37 |
| Sorafenib | 0 | 6 | 6 | 24 | 20 | 5 | 30 |
Treatment-Emergent Adverse Events (TEAEs) were defined as those adverse events (AEs) that occurred, having been absent before the study, or worsened in severity after the initiation of study treatment administration. An AE that occurred more than 30 days after the last dose of study medication was not included as a TEAE unless it was considered related to treatment or the assessment of relatedness was missing. (NCT01033240)
Timeframe: Baseline up to 30 days after last dose, up to approximately 3 years 2 months post-dose.
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subjects with ≥1 TEAE | TEAEs by worst CTCAE grade: CTCAE grade: Grade ≥ 3 | TEAEs by worst CTCAE grade: Grade 5 | TEAEs related to CS-1008 | TEAEs related to sorafenib | Discontinued CS-1008 due to TEAE | Discontinued sorafenib due to TEAE | Treatment-Emergent SAEs | TEAEs leading to death | Deaths | |
| CS-1008 6/2 mg/kg + Sorafenib | 52 | 44 | 8 | 40 | 51 | 5 | 7 | 26 | 8 | 31 |
| CS-1008 6/6 mg/kg + Sorafenib | 54 | 46 | 5 | 39 | 54 | 8 | 9 | 20 | 6 | 29 |
| Sorafenib | 54 | 43 | 10 | NA | 53 | 0 | 18 | 25 | 11 | 34 |
"To evaluate the efficacy of daily administration of PI-88 versus placebo for the adjuvant treatment of study subjects as measured by DFS during study period.~As the median DFS could not be estimated, the overall 25 th percentile DFS was reported." (NCT01402908)
Timeframe: End of study
| Intervention | weeks (Mean) |
|---|---|
| PI-88 | 51.0 |
| Placebo | 75.6 |
Overall survival was defined as the time, in weeks, from randomization to death from any cause during the study period. (NCT01402908)
Timeframe: Overall survival was defined as the time, in weeks, from randomization to death from any cause during the study period (3 years).
| Intervention | weeks (Mean) |
|---|---|
| PI-88 | 71.7 |
| Placebo | 69.2 |
"As no subjects died without a preceding tumor recurrence , no median time to TTR could be estimated in the present study. And therefore the overall 25th percentile DFS was reported.~The results of time to recurrence (TTR) were the same as that of DFS, as no subjects died without a preceding tumor recurrence." (NCT01402908)
Timeframe: Time to recurrence (TTR) was defined as the time from randomization to the first time that tumor recurrence was observed or suspected during the study period (3 years).
| Intervention | weeks (Mean) |
|---|---|
| PI-88 | 51.0 |
| Placebo | 75.6 |
TR rate was to calculate number of subjects with recurrence among the analyzed population. (NCT01402908)
Timeframe: The cumulative tumor recurrence rate at weeks 5, 53, 101 and 149 was reported here.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cumulative Tumor Recurrence Rate at weeks 5 | Cumulative Tumor Recurrence Rate at weeks 53 | Cumulative Tumor Recurrence Rate at weeks 101 | Cumulative Tumor Recurrence Rate at weeks 149 | |
| PI-88 | 11 | 74 | 82 | 85 |
| Placebo | 8 | 58 | 70 | 74 |
"OS was defined as the time from randomization to date of death due to any cause. OS for subjects alive at the time of analysis was censored at their last date of contact. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization of the first subject until 4 years later.
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | NA |
| Placebo | NA |
The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D Index is a descriptive system of the following health dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Subjects were asked to choose any one of the 3 response levels for each dimension: no problems, some problems, and severe problems. The 5 health dimensions were summarized into a single score, the EQ-5D Index score which ranged from -0.59 to 1 with higher scores representing better health states (0=death, 1= perfect health, and -0.59=a health state worse than death). A change of at least 0.10 to 0.12 points was considered a minimally important difference using Eastern Cooperative Oncology Group Performance Status as the anchor. The results on the Analysis of covariance of timeadjusted Area under curve for the EQ-5D index score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.827 |
| Placebo | 0.866 |
The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D VAS is a measure that represents health status as a single value. It is a 20-centimetre vertical graduated visual analogue scale with scores that ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). The respondent rated his/her current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the EQ-5D VAS. A 3-digit number (including leading zeros) was read off the scale from the point where the respondent's line crossed the scale, which was the EQ-5D VAS score. A change of at least 7 points on the VAS was considered as minimally important. The results on the ANCOVA analysis of time-adjusted AUC for the EQ-5D VAS score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 77.203 |
| Placebo | 80.181 |
The PWB, FWB, SWB and EWB were summed to form the FACT-G total score. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). FACT-G scores ranged from 0 to 108 and the higher scores represented a better quality of life. The MID for the FACT-G total score was in the range of 6 to 7. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-G score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 80.46 |
| Placebo | 82.95 |
The FACT-HEP is a 45 item, self-administered, multi-dimensional, psychometrically sound questionnaire used extensively in oncology clinical trials. FACT-HEP consisted of five subscales: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The PWB, FWB, SWB and EWB were summed to form the FACTGeneral (FACT-G) total score. The FACT-G and HCS scores were summed to form the FACT-HEP total score. FACT-HEP scores ranged from 0 to 180 and the higher scores represented a better quality of life. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). The minimally important difference (MID) for the FACT-Hep total score was in the range of 8 to 9. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-HEP score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 138.7 |
| Placebo | 143.79 |
Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans. RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death. (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 1014 |
| Placebo | 1026 |
"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline
| Intervention | Days (Median) |
|---|---|
| AFP High Expression Group | 668 |
| AFP Low Expression Group | 1267 |
"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline
| Intervention | Days (Median) |
|---|---|
| ANG-2 High Expression Group | 588 |
| ANG-2 Low Expression Group | 1260 |
"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline
| Intervention | Days (Median) |
|---|---|
| MET High Expression Group | 841 |
| MET Low Expression Group | NA |
"TTR was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment. For subjects who had not recurred at the time of analysis, TTR was censored at their last date of evaluable scan before withdrawal for any other reason than recurrence. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 1172 |
| Placebo | 1089 |
complete response at any time + partial response at any time + stable disease after 8 weeks of treatment based on RECIST Criteria (NCT01205828)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| ABT-888 and Temozolomide | 3 |
Record of all toxicities graded according to the NCI CTCAE version 3.0 (NCT01205828)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| ABT-888 and Temozolomide | 5 |
the number of months between a patient's enrollment and his/her date of death (NCT01205828)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| ABT-888 and Temozolomide | 13.1 |
The number of months between a patient's enrollment and his/her disease progression (NCT01205828)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| ABT-888 and Temozolomide | 1.9 |
Duration of response is defined as time from first PR or CR to radiologic disease progression; in responders only. CR: Disappearance of intratumoral arterial enhancement in all target lesions. PR: At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the Baseline sum of the diameters of target lesions. Progressive disease (PD): An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started. (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Days (Median) |
|---|---|
| Sorafenib+Placebo | 123 |
| Sorafenib+Mapatumumab 30 mg/kg | 127 |
Overall survival is defined as time from randomization to death from any cause. The analysis was performed using Kaplan Meier methods. The median overall survival is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented. (NCT01258608)
Timeframe: Randomization to maximum of 52.9 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib+Placebo | 10.1 |
| Sorafenib+Mapatumumab 30 mg/kg | 10.0 |
An AE is any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. Severity of AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0. Grade 1 represents mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 represents moderate; minimal, local or non-invasive intervention indicated. Grade 3 represents severe or medically significant but not immediately life -threatening; hospitalization or prolongation of hospitalization indicated; disabling. Grade 4 represents life -threatening consequences; urgent intervention indicated. Grade 5 represents death related to AE. Severe AE is defined as AEs classified by investigator as severe (causing inability to carry out usual activities), life threatening or fatal using NCI-CTCAE Version 4.0 grading. (NCT01258608)
Timeframe: Start of study treatment to maximum of 52.9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sorafenib+Placebo | 42 |
| Sorafenib+Mapatumumab 30 mg/kg | 38 |
Disease control rate is the percentage of participants with complete response+partial response+stable disease according to mRECIST criteria for hepatocellular carcinoma. The end point was based on BICR assessment of imaging scans. The percentage of participants with disease control is presented along with 95% confidence interval. (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib+Placebo | 92.5 |
| Sorafenib+Mapatumumab 30 mg/kg | 71.8 |
Disease control rate is the percentage of participants with complete response+partial response+stable disease according to mRECIST criteria for hepatocellular carcinoma to investigator assessments. The percentage of participants with disease control is presented along with 95% confidence interval. (NCT01258608)
Timeframe: Randomization to maximum of 52.9 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib+Placebo | 74.5 |
| Sorafenib+Mapatumumab 30 mg/kg | 68.8 |
Objective response rate is defined as the percentage of participants with complete response+partial response according to mRECIST criteria for hepatocellular carcinoma using BICR assessment of imaging scans. The percentage of participants with objective response is reported along with 95% confidence interval. (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib+Placebo | 12.5 |
| Sorafenib+Mapatumumab 30 mg/kg | 17.9 |
Objective response rate is defined as the percentage of participants with complete response+partial response according to mRECIST criteria for hepatocellular carcinoma to investigator assessments. The percentage of participants with objective response is reported along with 95% confidence interval. (NCT01258608)
Timeframe: Randomization to maximum of 52.9 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib+Placebo | 7.8 |
| Sorafenib+Mapatumumab 30 mg/kg | 14.6 |
Progression free survival is defined as time from randomization to radiologic disease progression or death from any cause. The analysis was performed using Kaplan Meier methods using BICR assessment of imaging scans. The median progression free survival is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented. (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib+Placebo | 4.3 |
| Sorafenib+Mapatumumab 30 mg/kg | 3.2 |
Progression free survival is defined as time from randomization to radiologic disease progression or death from any cause. The analysis was performed using Kaplan Meier methods based on application of mRECIST for hepatocellular carcinoma to investigator assessments. The median progression free survival is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented. (NCT01258608)
Timeframe: Randomization to maximum of 52.9 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib+Placebo | 5.4 |
| Sorafenib+Mapatumumab 30 mg/kg | 4.0 |
Time to progression is defined as the time from randomization to radiologic disease progression based on blinded independent review (BICR) of imaging scans using modified Response Evaluation Criteria in Solid Tumors assessment (mRECIST) for hepatocellular carcinoma. The primary analysis was performed using Kaplan Meier methods. The median time to progression is reported with one-sided 90% confidence interval. Analysis was performed on the modified Intent to Treat (mITT) Population which comprised of all randomized participants who received at least part of 1 dose of study agent (mapatumumab/placebo and/or sorafenib) with participants analyzed according to the groups to which they were randomized. NA indicates upper limit was not measurable as one-sided confidence interval is presented. (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib+Placebo | 5.6 |
| Sorafenib+Mapatumumab 30 mg/kg | 4.1 |
Time to progression is defined as the time from randomization to radiologic disease progression. The primary analysis was performed using Kaplan Meier methods based on application of mRECIST for hepatocellular carcinoma to investigator assessments. The median time to progression is reported with one-sided 90% confidence interval. NA indicates upper limit was not measurable as one-sided confidence interval is presented. (NCT01258608)
Timeframe: Randomization to maximum of 52.9 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib+Placebo | 8.3 |
| Sorafenib+Mapatumumab 30 mg/kg | 6.4 |
Time to response is defined as time from randomization to first partial response or complete response in responders only. Complete Response (CR): Disappearance of intratumoral arterial enhancement in all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Days (Median) |
|---|---|
| Sorafenib+Placebo | 44 |
| Sorafenib+Mapatumumab 30 mg/kg | 48 |
Heart rate was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Beats per minute (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1, n=46, 44 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=33, 32 | CYCLE 5 DAY 1; n=27, 26 | CYCLE 6 DAY 1; n=24, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=22, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 8 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | |
| Sorafenib+Placebo | 0.7 | 1.7 | 1.0 | 1.3 | 0.2 | 2.0 | 0.5 | 2.1 | 2.3 | -0.8 | -0.7 | 0.9 | 1.6 | 5.6 | 3.3 | 3.1 | 6.4 | -2.5 | 0.3 | 0.5 | 0.5 | -3.8 | -2.5 | -1.8 | -0.5 | -2.0 | -1.8 | 0.0 | 0.3 | -2.7 | 2.0 | -2.0 | 0.0 |
Heart rate was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Beats per minute (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1, n=46, 44 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=33, 32 | CYCLE 5 DAY 1; n=27, 26 | CYCLE 6 DAY 1; n=24, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=22, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 8 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | CYCLE 35 DAY 1; n=0, 4 | CYCLE 36 DAY 1; n=0, 4 | CYCLE 37 DAY 1; n=0, 3 | CYCLE 38 DAY 1; n=0, 3 | CYCLE 39 DAY 1; n=0, 3 | CYCLE 40 DAY 1; n=0, 2 | CYCLE 41 DAY 1; n=0, 2 | CYCLE 42 DAY 1; n=0, 2 | CYCLE 43 DAY 1; n=0, 2 | CYCLE 44 DAY 1; n=0, 2 | CYCLE 45 DAY 1; n=0, 2 | CYCLE 46 DAY 1; n=0, 2 | CYCLE 47 DAY 1; n=0, 2 | CYCLE 48 DAY 1; n=0, 2 | CYCLE 49 DAY 1; n=0, 2 | CYCLE 50 DAY 1; n=0, 2 | CYCLE 51 DAY 1; n=0, 2 | CYCLE 52 DAY 1; n=0, 2 | CYCLE 53 DAY 1; n=0, 2 | CYCLE 54 DAY 1; n=0, 2 | CYCLE 55 DAY 1; n=0, 1 | CYCLE 56 DAY 1; n=0, 1 | CYCLE 57 DAY 1; n=0, 1 | CYCLE 58 DAY 1; n=0, 1 | CYCLE 59 DAY 1; n=0, 1 | CYCLE 60 DAY 1; n=0, 1 | CYCLE 61 DAY 1; n=0, 1 | CYCLE 62 DAY 1; n=0, 1 | CYCLE 63 DAY 1; n=0, 1 | CYCLE 64 DAY 1; n=0, 1 | CYCLE 65 DAY 1; n=0, 1 | CYCLE 66 DAY 1; n=0, 1 | CYCLE 67 DAY 1; n=0, 1 | CYCLE 68 DAY 1; n=0, 1 | CYCLE 69 DAY 1; n=0, 1 | CYCLE 70 DAY 1; n=0, 1 | CYCLE 71 DAY 1; n=0, 1 | CYCLE 72 DAY 1; n=0, 1 | CYCLE 73 DAY 1; n=0, 1 | CYCLE 74 DAY 1; n=0, 1 | CYCLE 75 DAY 1; n=0, 1 | |
| Sorafenib+Mapatumumab 30 mg/kg | -1.8 | -1.6 | 1.9 | 0.2 | 0.3 | -1.8 | -0.4 | 0.3 | 0.5 | -2.0 | 0.2 | 0.9 | 3.1 | 2.2 | 0.7 | 1.6 | -0.5 | 0.5 | 0.9 | -1.4 | 3.0 | 2.9 | 2.9 | 0.3 | 1.6 | 2.4 | -0.2 | -3.8 | -9.3 | -0.8 | -3.8 | -5.5 | -3.5 | -4.8 | -8.0 | -9.3 | -2.0 | -4.7 | -4.0 | -7.0 | -2.0 | -6.0 | -2.0 | -4.0 | -3.0 | -2.0 | -3.0 | -9.0 | -5.0 | -5.0 | -8.0 | -10.0 | -2.0 | -10.0 | -12.0 | -10.0 | -8.0 | -12.0 | -10.0 | -12.0 | -14.0 | -15.0 | -10.0 | -11.0 | -12.0 | -9.0 | -10.0 | -12.0 | -9.0 | -7.0 | -10.0 | -9.0 | -8.0 | -9.0 |
Respiratory rate was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose.Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Breaths per minute (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYCLE 2 Day 1, n=46, 44 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=32, 32 | CYCLE 5 DAY 1; n=26, 26 | CYCLE 6 DAY 1; n=24, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=21, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 8 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | |
| Sorafenib+Placebo | -0.1 | 0.2 | 0.2 | -0.1 | 0.5 | -0.1 | 0.6 | -0.5 | -1.7 | -0.8 | 0.0 | -0.2 | 0.4 | -0.5 | -0.5 | 0.0 | -0.4 | 0.7 | 0.2 | 0.8 | 0.0 | 0.5 | -0.3 | -0.3 | -0.5 | 0.0 | -0.3 | -0.7 | 0.0 | 0.7 | -0.7 | -2.0 | 0.0 |
Respiratory rate was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose.Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Breaths per minute (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYCLE 2 Day 1, n=46, 44 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=32, 32 | CYCLE 5 DAY 1; n=26, 26 | CYCLE 6 DAY 1; n=24, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=21, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 8 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | CYCLE 35 DAY 1; n=0, 4 | CYCLE 36 DAY 1; n=0, 4 | CYCLE 37 DAY 1; n=0, 3 | CYCLE 38 DAY 1; n=0, 3 | CYCLE 39 DAY 1; n=0, 3 | CYCLE 40 DAY 1; n=0, 2 | CYCLE 41 DAY 1; n=0, 2 | CYCLE 42 DAY 1; n=0, 2 | CYCLE 43 DAY 1; n=0, 2 | CYCLE 44 DAY 1; n=0, 2 | CYCLE 45 DAY 1; n=0, 2 | CYCLE 46 DAY 1; n=0, 2 | CYCLE 47 DAY 1; n=0, 2 | CYCLE 48 DAY 1; n=0, 2 | CYCLE 49 DAY 1; n=0, 2 | CYCLE 50 DAY 1; n=0, 2 | CYCLE 51 DAY 1; n=0, 2 | CYCLE 52 DAY 1; n=0, 2 | CYCLE 53 DAY 1; n=0, 2 | CYCLE 54 DAY 1; n=0, 2 | CYCLE 55 DAY 1; n=0, 1 | CYCLE 56 DAY 1; n=0, 1 | CYCLE 57 DAY 1; n=0, 1 | CYCLE 58 DAY 1; n=0, 1 | CYCLE 59 DAY 1; n=0, 1 | CYCLE 60 DAY 1; n=0, 1 | CYCLE 61 DAY 1; n=0, 1 | CYCLE 62 DAY 1; n=0, 1 | CYCLE 63 DAY 1; n=0, 1 | CYCLE 64 DAY 1; n=0, 1 | CYCLE 65 DAY 1; n=0, 1 | CYCLE 66 DAY 1; n=0, 1 | CYCLE 67 DAY 1; n=0, 1 | CYCLE 68 DAY 1; n=0, 1 | CYCLE 69 DAY 1; n=0, 1 | CYCLE 70 DAY 1; n=0, 1 | CYCLE 71 DAY 1; n=0, 1 | CYCLE 72 DAY 1; n=0, 1 | CYCLE 73 DAY 1; n=0, 1 | CYCLE 74 DAY 1; n=0, 1 | CYCLE 75 DAY 1; n=0, 1 | |
| Sorafenib+Mapatumumab 30 mg/kg | 0.1 | -0.2 | -0.3 | -0.3 | -0.3 | -0.2 | -0.1 | -0.2 | -0.4 | -0.8 | -1.0 | -0.7 | -1.0 | -0.9 | -0.9 | 0.1 | 0.4 | 0.0 | 0.0 | -0.1 | -0.1 | 0.4 | 0.0 | -0.3 | 0.0 | 0.0 | 0.2 | -0.3 | -0.3 | 0.3 | 0.0 | -0.8 | 0.8 | 0.0 | 0.3 | -1.0 | -0.3 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.5 | 0.0 | -0.5 | 1.0 | -1.0 | 0.0 | 0.0 | 0.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | -1.0 | -2.0 | -2.0 | -1.0 | -2.0 | -2.0 | -1.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
SBP and DBP were obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Millimeters of mercury (mmHg) (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP; Cycle 2 Day 1, n=46, 44 | SBP; CYCLE 3 DAY 1, n=39, 35 | SBP; CYCLE 4; DAY 1; n=33, 32 | SBP; CYCLE 5 DAY 1; n=27, 26 | SBP; CYCLE 6 DAY 1; n=24, 22 | SBP; CYCLE 7 DAY 1; n=24, 22 | SBP; CYCLE 8 DAY 1; n=22, 21 | SBP; CYCLE 9 DAY 1; n=19, 16 | SBP; CYCLE 10 DAY 1; n=18, 16 | SBP; CYCLE 11 DAY 1; n=16, 15 | SBP; CYCLE 12 DAY 1; n=15, 13 | SBP; CYCLE 13 DAY 1; n=13, 12 | SBP; CYCLE 14 DAY 1; n=12, 12 | SBP; CYCLE 15 DAY 1; n=10, 9 | SBP; CYCLE 16 DAY 1; n=10, 9 | SBP; CYCLE 17 DAY 1; n=8, 8 | SBP; CYCLE 18 DAY 1; n=8, 8 | SBP; CYCLE 19 DAY 1; n=6, 8 | SBP; CYCLE 20 DAY 1; n=6, 8 | SBP; CYCLE 21 DAY 1; n=4, 8 | SBP; CYCLE 22 DAY 1; n=4, 8 | SBP; CYCLE 23 DAY 1; n=4, 8 | SBP; CYCLE 24 DAY 1; n=4, 8 | SBP; CYCLE 25 DAY 1; n=4, 8 | SBP; CYCLE 26 DAY 1; n=4, 7 | SBP; CYCLE 27 DAY 1; n=4, 5 | SBP; CYCLE 28 DAY 1; n=4, 5 | SBP; CYCLE 29 DAY 1; n=3, 4 | SBP; CYCLE 30 DAY 1; n=3, 4 | SBP; CYCLE 31 DAY 1; n=3, 4 | SBP; CYCLE 32 DAY 1; n=3, 4 | SBP; CYCLE 33 DAY 1; n=2, 4 | SBP; CYCLE 34 DAY 1; n=1, 4 | SBP; CYCLE 35 DAY 1; n=0, 4 | SBP; CYCLE 36 DAY 1; n=0, 4 | SBP; CYCLE 37 DAY 1; n=0, 3 | SBP; CYCLE 38 DAY 1; n=0, 3 | SBP; CYCLE 39 DAY 1; n=0, 3 | SBP; CYCLE 40 DAY 1; n=0, 2 | SBP; CYCLE 41 DAY 1; n=0, 2 | SBP; CYCLE 42 DAY 1; n=0, 2 | SBP; CYCLE 43 DAY 1; n=0, 2 | SBP; CYCLE 44 DAY 1; n=0, 2 | SBP; CYCLE 45 DAY 1; n=0, 2 | SBP; CYCLE 46 DAY 1; n=0, 2 | SBP; CYCLE 47 DAY 1; n=0, 2 | SBP; CYCLE 48 DAY 1; n=0, 2 | SBP; CYCLE 49 DAY 1; n=0, 2 | SBP; CYCLE 50 DAY 1; n=0, 2 | SBP; CYCLE 51 DAY 1; n=0, 2 | SBP; CYCLE 52 DAY 1; n=0, 2 | SBP; CYCLE 53 DAY 1; n=0, 2 | SBP; CYCLE 54 DAY 1; n=0, 2 | SBP; CYCLE 55 DAY 1; n=0, 1 | SBP; CYCLE 56 DAY 1; n=0, 1 | SBP; CYCLE 57 DAY 1; n=0, 1 | SBP; CYCLE 58 DAY 1; n=0, 1 | SBP; CYCLE 59 DAY 1; n=0, 1 | SBP; CYCLE 60 DAY 1; n=0, 1 | SBP; CYCLE 61 DAY 1; n=0, 1 | SBP; CYCLE 62 DAY 1; n=0, 1 | SBP; CYCLE 63 DAY 1; n=0, 1 | SBP; CYCLE 64 DAY 1; n=0, 1 | SBP; CYCLE 65 DAY 1; n=0, 1 | SBP; CYCLE 66 DAY 1; n=0, 1 | SBP; CYCLE 67 DAY 1; n=0, 1 | SBP; CYCLE 68 DAY 1; n=0, 1 | SBP; CYCLE 69 DAY 1; n=0, 1 | SBP; CYCLE 70 DAY 1; n=0, 1 | SBP; CYCLE 71 DAY 1; n=0, 1 | SBP; CYCLE 72 DAY 1; n=0, 1 | SBP; CYCLE 73 DAY 1; n=0, 1 | SBP; CYCLE 74 DAY 1; n=0, 1 | SBP; CYCLE 75 DAY 1; n=0, 1 | DBP; Cycle 2 Day 1, n=46, 44 | DBP; CYCLE 3 DAY 1, n=39, 35 | DBP; CYCLE 4; DAY 1; n=33, 32 | DBP; CYCLE 5 DAY 1; n=27, 26 | DBP; CYCLE 6 DAY 1; n=24, 22 | DBP; CYCLE 7 DAY 1; n=24, 22 | DBP; CYCLE 8 DAY 1; n=22, 21 | DBP; CYCLE 9 DAY 1; n=19, 16 | DBP; CYCLE 10 DAY 1; n=18, 16 | DBP; CYCLE 11 DAY 1; n=16, 15 | DBP; CYCLE 12 DAY 1; n=15, 13 | DBP; CYCLE 13 DAY 1; n=13, 12 | DBP; CYCLE 14 DAY 1; n=12, 12 | DBP; CYCLE 15 DAY 1; n=10, 9 | DBP; CYCLE 16 DAY 1; n=10, 9 | DBP; CYCLE 17 DAY 1; n=8, 8 | DBP; CYCLE 18 DAY 1; n=8, 8 | DBP; CYCLE 19 DAY 1; n=6, 8 | DBP; CYCLE 20 DAY 1; n=6, 8 | DBP; CYCLE 21 DAY 1; n=4, 8 | DBP; CYCLE 22 DAY 1; n=4, 8 | DBP; CYCLE 23 DAY 1; n=4, 8 | DBP; CYCLE 24 DAY 1; n=4, 8 | DBP; CYCLE 25 DAY 1; n=4, 8 | DBP; CYCLE 26 DAY 1; n=4, 7 | DBP; CYCLE 27 DAY 1; n=4, 5 | DBP; CYCLE 28 DAY 1; n=4, 5 | DBP; CYCLE 29 DAY 1; n=3, 4 | DBP; CYCLE 30 DAY 1; n=3, 4 | DBP; CYCLE 31 DAY 1; n=3, 4 | DBP; CYCLE 32 DAY 1; n=3, 4 | DBP; CYCLE 33 DAY 1; n=2, 4 | DBP; CYCLE 34 DAY 1; n=1, 4 | DBP; CYCLE 35 DAY 1; n=0, 4 | DBP; CYCLE 36 DAY 1; n=0, 4 | DBP; CYCLE 37 DAY 1; n=0, 3 | DBP; CYCLE 38 DAY 1; n=0, 3 | DBP; CYCLE 39 DAY 1; n=0, 3 | DBP; CYCLE 40 DAY 1; n=0, 2 | DBP; CYCLE 41 DAY 1; n=0, 2 | DBP; CYCLE 42 DAY 1; n=0, 2 | DBP; CYCLE 43 DAY 1; n=0, 2 | DBP; CYCLE 44 DAY 1; n=0, 2 | DBP; CYCLE 45 DAY 1; n=0, 2 | DBP; CYCLE 46 DAY 1; n=0, 2 | DBP; CYCLE 47 DAY 1; n=0, 2 | DBP; CYCLE 48 DAY 1; n=0, 2 | DBP; CYCLE 49 DAY 1; n=0, 2 | DBP; CYCLE 50 DAY 1; n=0, 2 | DBP; CYCLE 51 DAY 1; n=0, 2 | DBP; CYCLE 52 DAY 1; n=0, 2 | DBP; CYCLE 53 DAY 1; n=0, 2 | DBP; CYCLE 54 DAY 1; n=0, 2 | DBP; CYCLE 55 DAY 1; n=0, 1 | DBP; CYCLE 56 DAY 1; n=0, 1 | DBP; CYCLE 57 DAY 1; n=0, 1 | DBP; CYCLE 58 DAY 1; n=0, 1 | DBP; CYCLE 59 DAY 1; n=0, 1 | DBP; CYCLE 60 DAY 1; n=0, 1 | DBP; CYCLE 61 DAY 1; n=0, 1 | DBP; CYCLE 62 DAY 1; n=0, 1 | DBP; CYCLE 63 DAY 1; n=0, 1 | DBP; CYCLE 64 DAY 1; n=0, 1 | DBP; CYCLE 65 DAY 1; n=0, 1 | DBP; CYCLE 66 DAY 1; n=0, 1 | DBP; CYCLE 67 DAY 1; n=0, 1 | DBP; CYCLE 68 DAY 1; n=0, 1 | DBP; CYCLE 69 DAY 1; n=0, 1 | DBP; CYCLE 70 DAY 1; n=0, 1 | DBP; CYCLE 71 DAY 1; n=0, 1 | DBP; CYCLE 72 DAY 1; n=0, 1 | DBP; CYCLE 73 DAY 1; n=0, 1 | DBP; CYCLE 74 DAY 1; n=0, 1 | DBP; CYCLE 75 DAY 1; n=0, 1 | |
| Sorafenib+Mapatumumab 30 mg/kg | 2.2 | 4.1 | 5.3 | 4.9 | 5.1 | 5.0 | 5.2 | 7.8 | 4.5 | 5.2 | 5.2 | 3.0 | 4.0 | 6.7 | 7.9 | 10.1 | 9.5 | 8.4 | 5.8 | 10.0 | 5.5 | 12.9 | 5.6 | 11.3 | 9.3 | 8.4 | 5.2 | 3.3 | -2.3 | 2.0 | 3.3 | -5.3 | -5.3 | -5.0 | -1.5 | -6.0 | -1.3 | -4.3 | -12.5 | -15.0 | -7.5 | -17.5 | -10.0 | -17.5 | -5.0 | -17.5 | -5.0 | -17.5 | -15.0 | -10.0 | -17.5 | -20.0 | -10.0 | -30.0 | -30.0 | -30.0 | -25.0 | -20.0 | -30.0 | -25.0 | -23.0 | -28.0 | -25.0 | -26.0 | -32.0 | -33.0 | -32.0 | -31.0 | -25.0 | -28.0 | -30.0 | -27.0 | -30.0 | -28.0 | 0.7 | 1.4 | 2.4 | 3.0 | 1.2 | 2.0 | 2.3 | 4.1 | 2.4 | 0.9 | 2.1 | -2.7 | 3.3 | 1.1 | 0.1 | 5.0 | 3.4 | 5.5 | 3.5 | 2.8 | 3.8 | 5.1 | 2.5 | 2.5 | 4.0 | 3.6 | 4.0 | -2.0 | -2.3 | 0.5 | -0.3 | -2.5 | -1.8 | -3.0 | 1.5 | 1.7 | -2.3 | 0.3 | 0.0 | -7.5 | 0.0 | -7.5 | -2.5 | -7.5 | -5.0 | -3.0 | -5.0 | -12.5 | -5.0 | -5.0 | -10.0 | -7.5 | -5.0 | -15.0 | -10.0 | -15.0 | -10.0 | -10.0 | -15.0 | -15.0 | -13.0 | -15.0 | -14.0 | -15.0 | -17.0 | -14.0 | -15.0 | -17.0 | -16.0 | -15.0 | -19.0 | -15.0 | -14.0 | -17.0 |
SBP and DBP were obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Millimeters of mercury (mmHg) (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP; Cycle 2 Day 1, n=46, 44 | SBP; CYCLE 3 DAY 1, n=39, 35 | SBP; CYCLE 4; DAY 1; n=33, 32 | SBP; CYCLE 5 DAY 1; n=27, 26 | SBP; CYCLE 6 DAY 1; n=24, 22 | SBP; CYCLE 7 DAY 1; n=24, 22 | SBP; CYCLE 8 DAY 1; n=22, 21 | SBP; CYCLE 9 DAY 1; n=19, 16 | SBP; CYCLE 10 DAY 1; n=18, 16 | SBP; CYCLE 11 DAY 1; n=16, 15 | SBP; CYCLE 12 DAY 1; n=15, 13 | SBP; CYCLE 13 DAY 1; n=13, 12 | SBP; CYCLE 14 DAY 1; n=12, 12 | SBP; CYCLE 15 DAY 1; n=10, 9 | SBP; CYCLE 16 DAY 1; n=10, 9 | SBP; CYCLE 17 DAY 1; n=8, 8 | SBP; CYCLE 18 DAY 1; n=8, 8 | SBP; CYCLE 19 DAY 1; n=6, 8 | SBP; CYCLE 20 DAY 1; n=6, 8 | SBP; CYCLE 21 DAY 1; n=4, 8 | SBP; CYCLE 22 DAY 1; n=4, 8 | SBP; CYCLE 23 DAY 1; n=4, 8 | SBP; CYCLE 24 DAY 1; n=4, 8 | SBP; CYCLE 25 DAY 1; n=4, 8 | SBP; CYCLE 26 DAY 1; n=4, 7 | SBP; CYCLE 27 DAY 1; n=4, 5 | SBP; CYCLE 28 DAY 1; n=4, 5 | SBP; CYCLE 29 DAY 1; n=3, 4 | SBP; CYCLE 30 DAY 1; n=3, 4 | SBP; CYCLE 31 DAY 1; n=3, 4 | SBP; CYCLE 32 DAY 1; n=3, 4 | SBP; CYCLE 33 DAY 1; n=2, 4 | SBP; CYCLE 34 DAY 1; n=1, 4 | DBP; Cycle 2 Day 1, n=46, 44 | DBP; CYCLE 3 DAY 1, n=39, 35 | DBP; CYCLE 4; DAY 1; n=33, 32 | DBP; CYCLE 5 DAY 1; n=27, 26 | DBP; CYCLE 6 DAY 1; n=24, 22 | DBP; CYCLE 7 DAY 1; n=24, 22 | DBP; CYCLE 8 DAY 1; n=22, 21 | DBP; CYCLE 9 DAY 1; n=19, 16 | DBP; CYCLE 10 DAY 1; n=18, 16 | DBP; CYCLE 11 DAY 1; n=16, 15 | DBP; CYCLE 12 DAY 1; n=15, 13 | DBP; CYCLE 13 DAY 1; n=13, 12 | DBP; CYCLE 14 DAY 1; n=12, 12 | DBP; CYCLE 15 DAY 1; n=10, 9 | DBP; CYCLE 16 DAY 1; n=10, 9 | DBP; CYCLE 17 DAY 1; n=8, 8 | DBP; CYCLE 18 DAY 1; n=8, 8 | DBP; CYCLE 19 DAY 1; n=6, 8 | DBP; CYCLE 20 DAY 1; n=6, 8 | DBP; CYCLE 21 DAY 1; n=4, 8 | DBP; CYCLE 22 DAY 1; n=4, 8 | DBP; CYCLE 23 DAY 1; n=4, 8 | DBP; CYCLE 24 DAY 1; n=4, 8 | DBP; CYCLE 25 DAY 1; n=4, 8 | DBP; CYCLE 26 DAY 1; n=4, 7 | DBP; CYCLE 27 DAY 1; n=4, 5 | DBP; CYCLE 28 DAY 1; n=4, 5 | DBP; CYCLE 29 DAY 1; n=3, 4 | DBP; CYCLE 30 DAY 1; n=3, 4 | DBP; CYCLE 31 DAY 1; n=3, 4 | DBP; CYCLE 32 DAY 1; n=3, 4 | DBP; CYCLE 33 DAY 1; n=2, 4 | DBP; CYCLE 34 DAY 1; n=1, 4 | |
| Sorafenib+Placebo | 2.3 | 6.0 | 2.1 | 1.7 | 1.3 | -0.8 | -1.6 | 1.2 | 1.4 | 2.4 | 2.7 | 2.3 | -1.0 | 1.4 | 1.8 | 1.3 | -2.0 | -4.8 | 1.2 | 2.5 | 6.0 | -1.0 | -3.0 | 1.3 | 6.0 | 3.3 | 3.3 | -0.7 | 2.7 | -3.0 | 5.0 | 0.0 | 13.0 | -0.6 | 2.1 | 1.8 | 0.9 | 3.5 | 0.5 | 0.5 | 2.7 | 2.7 | -0.1 | 0.6 | -2.2 | 0.7 | 2.1 | 0.1 | -1.5 | 0.1 | -2.5 | 2.3 | 0.8 | -1.8 | 2.5 | -3.0 | 3.5 | 0.0 | -3.3 | 2.0 | 1.7 | -0.3 | 6.7 | 2.7 | 0.5 | -15.0 |
Temperature was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Celsius (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1, n=46, 43 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=33, 32 | CYCLE 5 DAY 1; n=27, 26 | CYCLE 6 DAY 1; n=23, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=21, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 8 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | |
| Sorafenib+Placebo | 0.02 | -0.01 | 0.02 | 0.05 | -0.05 | 0.03 | 0.01 | 0.04 | 0.05 | -0.02 | 0.00 | 0.00 | 0.13 | 0.11 | 0.01 | 0.00 | -0.14 | -0.10 | -0.02 | 0.13 | 0.17 | 0.03 | 0.18 | 0.20 | 0.15 | 0.18 | 0.15 | 0.13 | 0.10 | -0.07 | 0.10 | 0.30 | 0.30 |
Temperature was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Celsius (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1, n=46, 43 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=33, 32 | CYCLE 5 DAY 1; n=27, 26 | CYCLE 6 DAY 1; n=23, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=21, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 8 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | CYCLE 35 DAY 1; n=0, 4 | CYCLE 36 DAY 1; n=0, 4 | CYCLE 37 DAY 1; n=0, 3 | CYCLE 38 DAY 1; n=0, 3 | CYCLE 39 DAY 1; n=0, 3 | CYCLE 40 DAY 1; n=0, 2 | CYCLE 41 DAY 1; n=0, 2 | CYCLE 42 DAY 1; n=0, 2 | CYCLE 43 DAY 1; n=0, 2 | CYCLE 44 DAY 1; n=0, 2 | CYCLE 45 DAY 1; n=0, 2 | CYCLE 46 DAY 1; n=0, 2 | CYCLE 47 DAY 1; n=0, 2 | CYCLE 48 DAY 1; n=0, 2 | CYCLE 49 DAY 1; n=0, 2 | CYCLE 50 DAY 1; n=0, 2 | CYCLE 51 DAY 1; n=0, 2 | CYCLE 52 DAY 1; n=0, 2 | CYCLE 53 DAY 1; n=0, 2 | CYCLE 54 DAY 1; n=0, 2 | CYCLE 55 DAY 1; n=0, 1 | CYCLE 56 DAY 1; n=0, 1 | CYCLE 57 DAY 1; n=0, 1 | CYCLE 58 DAY 1; n=0, 1 | CYCLE 59 DAY 1; n=0, 1 | CYCLE 60 DAY 1; n=0, 1 | CYCLE 61 DAY 1; n=0, 1 | CYCLE 62 DAY 1; n=0, 1 | CYCLE 63 DAY 1; n=0, 1 | CYCLE 64 DAY 1; n=0, 1 | CYCLE 65 DAY 1; n=0, 1 | CYCLE 66 DAY 1; n=0, 1 | CYCLE 67 DAY 1; n=0, 1 | CYCLE 68 DAY 1; n=0, 1 | CYCLE 69 DAY 1; n=0, 1 | CYCLE 70 DAY 1; n=0, 1 | CYCLE 71 DAY 1; n=0, 1 | CYCLE 72 DAY 1; n=0, 1 | CYCLE 73 DAY 1; n=0, 1 | CYCLE 74 DAY 1; n=0, 1 | CYCLE 75 DAY 1; n=0, 1 | |
| Sorafenib+Mapatumumab 30 mg/kg | -0.02 | -0.11 | -0.05 | -0.04 | -0.07 | -0.10 | 0.02 | 0.00 | 0.04 | -0.09 | 0.02 | 0.03 | -0.04 | -0.13 | -0.04 | 0.05 | -0.09 | 0.10 | 0.01 | -0.01 | 0.00 | 0.13 | 0.06 | 0.00 | -0.01 | 0.10 | -0.02 | -0.02 | 0.00 | 0.05 | -0.05 | -0.07 | -0.20 | -0.05 | -0.07 | -0.30 | 0.00 | -0.07 | 0.00 | -0.10 | 0.05 | -0.05 | 0.00 | 0.00 | -0.05 | 0.05 | 0.00 | -0.05 | 0.00 | -0.05 | -0.10 | 0.05 | -0.05 | -0.20 | -0.10 | 0.00 | -0.10 | 0.00 | -0.10 | -0.10 | 0.00 | -0.10 | -0.10 | 0.00 | -0.20 | -0.10 | 0.00 | -0.20 | 0.00 | -0.10 | -0.20 | -0.10 | -0.20 | -0.10 |
Weight was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Kilograms (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1, n=46, 44 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=33, 32 | CYCLE 5 DAY 1; n=27, 26 | CYCLE 6 DAY 1; n=24, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=22, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 7 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | |
| Sorafenib+Placebo | -1.51 | -2.54 | -3.02 | -3.31 | -3.25 | -3.75 | -3.89 | -4.14 | -5.50 | -5.70 | -5.85 | -6.54 | -7.03 | -7.21 | -7.59 | -8.49 | -8.25 | -8.78 | -9.22 | -3.03 | -3.50 | -4.13 | -3.38 | -3.88 | -3.88 | -4.88 | -5.13 | -5.50 | -5.83 | -5.50 | -5.50 | -1.75 | -2.50 |
Weight was obtained on Day 1 of each cycle. Baseline is the last assessment prior to first dose. Change from Baseline is the value at indicated time point minus the value at Baseline. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time point. (NCT01258608)
Timeframe: Baseline and Day 1 of Cycles 2 to 75 (each cycle of 21 days)
| Intervention | Kilograms (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1, n=46, 44 | CYCLE 3 DAY 1, n=39, 35 | CYCLE 4; DAY 1; n=33, 32 | CYCLE 5 DAY 1; n=27, 26 | CYCLE 6 DAY 1; n=24, 22 | CYCLE 7 DAY 1; n=24, 22 | CYCLE 8 DAY 1; n=22, 21 | CYCLE 9 DAY 1; n=19, 16 | CYCLE 10 DAY 1; n=18, 16 | CYCLE 11 DAY 1; n=16, 15 | CYCLE 12 DAY 1; n=15, 13 | CYCLE 13 DAY 1; n=13, 12 | CYCLE 14 DAY 1; n=12, 12 | CYCLE 15 DAY 1; n=10, 9 | CYCLE 16 DAY 1; n=10, 9 | CYCLE 17 DAY 1; n=8, 8 | CYCLE 18 DAY 1; n=8, 8 | CYCLE 19 DAY 1; n=6, 8 | CYCLE 20 DAY 1; n=6, 8 | CYCLE 21 DAY 1; n=4, 8 | CYCLE 22 DAY 1; n=4, 8 | CYCLE 23 DAY 1; n=4, 8 | CYCLE 24 DAY 1; n=4, 7 | CYCLE 25 DAY 1; n=4, 8 | CYCLE 26 DAY 1; n=4, 7 | CYCLE 27 DAY 1; n=4, 5 | CYCLE 28 DAY 1; n=4, 5 | CYCLE 29 DAY 1; n=3, 4 | CYCLE 30 DAY 1; n=3, 4 | CYCLE 31 DAY 1; n=3, 4 | CYCLE 32 DAY 1; n=3, 4 | CYCLE 33 DAY 1; n=2, 4 | CYCLE 34 DAY 1; n=1, 4 | CYCLE 35 DAY 1; n=0, 4 | CYCLE 36 DAY 1; n=0, 4 | CYCLE 37 DAY 1; n=0, 3 | CYCLE 38 DAY 1; n=0, 3 | CYCLE 39 DAY 1; n=0, 3 | CYCLE 40 DAY 1; n=0, 2 | CYCLE 41 DAY 1; n=0, 2 | CYCLE 42 DAY 1; n=0, 2 | CYCLE 43 DAY 1; n=0, 2 | CYCLE 44 DAY 1; n=0, 2 | CYCLE 45 DAY 1; n=0, 2 | CYCLE 46 DAY 1; n=0, 2 | CYCLE 47 DAY 1; n=0, 2 | CYCLE 48 DAY 1; n=0, 2 | CYCLE 49 DAY 1; n=0, 2 | CYCLE 50 DAY 1; n=0, 2 | CYCLE 51 DAY 1; n=0, 2 | CYCLE 52 DAY 1; n=0, 2 | CYCLE 53 DAY 1; n=0, 2 | CYCLE 54 DAY 1; n=0, 2 | CYCLE 55 DAY 1; n=0, 1 | CYCLE 56 DAY 1; n=0, 1 | CYCLE 57 DAY 1; n=0, 1 | CYCLE 58 DAY 1; n=0, 1 | CYCLE 59 DAY 1; n=0, 1 | CYCLE 60 DAY 1; n=0, 1 | CYCLE 61 DAY 1; n=0, 1 | CYCLE 62 DAY 1; n=0, 1 | CYCLE 63 DAY 1; n=0, 1 | CYCLE 64 DAY 1; n=0, 1 | CYCLE 65 DAY 1; n=0, 1 | CYCLE 66 DAY 1; n=0, 1 | CYCLE 67 DAY 1; n=0, 1 | CYCLE 68 DAY 1; n=0, 1 | CYCLE 69 DAY 1; n=0, 1 | CYCLE 70 DAY 1; n=0, 1 | CYCLE 71 DAY 1; n=0, 1 | CYCLE 72 DAY 1; n=0, 1 | CYCLE 73 DAY 1; n=0, 1 | CYCLE 74 DAY 1; n=0, 1 | CYCLE 75 DAY 1; n=0, 1 | |
| Sorafenib+Mapatumumab 30 mg/kg | -1.55 | -1.88 | -1.86 | -2.01 | -2.61 | -2.14 | -2.61 | -2.14 | -1.99 | -1.67 | -1.72 | -1.11 | -1.23 | -1.09 | -0.93 | -1.24 | -0.80 | -0.19 | -0.40 | -0.29 | -0.32 | -0.16 | -1.93 | 0.04 | 0.54 | -2.04 | -2.20 | -2.18 | -3.25 | -3.38 | -3.05 | -3.13 | -3.18 | -3.25 | -3.38 | -3.17 | -2.63 | -3.00 | -3.40 | -2.90 | -3.00 | -2.90 | -3.90 | -4.40 | -3.90 | -3.40 | -3.65 | -4.40 | -4.15 | -3.65 | -2.90 | -4.40 | -3.65 | -2.80 | -1.80 | -0.80 | -1.30 | -0.30 | -0.30 | 0.00 | -0.30 | -0.80 | -0.60 | -2.80 | -3.30 | -3.80 | -1.30 | -1.80 | 0.20 | -0.80 | -0.80 | -1.30 | -0.80 | -0.30 |
Blood samples were collected for the assessment of serum antibodies. The presence of anti-mapatumumab antibodies was assessed using a validated electrochemiluminescent immunoassay. The assay incorporated a tiered testing approach which used screening and confirmation steps. The anti-drug antibody (ADA) confirmed positive participants were separated into transient or persistent antibody positives. Persistent positive refers to positive immunogenic response at 2 or more assessments or at the final assessment. Transient positive refers to positive immunogenic response at only 1 assessment and negative at the final assessment. (NCT01258608)
Timeframe: Randomization to maximum of 24.1 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Transient positive | Persistent positive | Negative | |
| Sorafenib+Mapatumumab 30 mg/kg | 6 | 7 | 36 |
An AE is any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. An SAE is an adverse event resulting in any of the following outcomes: death, life-threatening, inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other medically important events that may jeopardize the participant or may require intervention to prevent one of the other outcomes mentioned before. A treatment-emergent AE is an AE that emerged during treatment, having been absent pre-treatment, or worsened relative to the pre-treatment state. As-Treated Population comprised of participants who received at least part of 1 dose of study agent analyzed according to the treatment that they actually received. (NCT01258608)
Timeframe: Start of study treatment to maximum of 52.9 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Non-serious AEs | SAEs | |
| Sorafenib+Mapatumumab 30 mg/kg | 49 | 21 |
| Sorafenib+Placebo | 47 | 27 |
Blood samples were collected for the evaluation of following chemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), amylase, bilirubin, gamma glutamyl transferase (GGT), calcium, potassium, magnesium, albumin, sodium and creatinine. Laboratory toxicities were graded based on the NCI-CTCAE version 4.0. Grade 1 represents mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 represents moderate; minimal, local or non-invasive intervention indicated. Grade 3 represents severe or medically significant but not immediately life -threatening; hospitalization or prolongation of hospitalization indicated; disabling. Grade 4 represents life -threatening consequences; urgent intervention indicated. Number of participants with worst toxicity grades for any abnormalities observed in any chemistry parameters during the study is presented. (NCT01258608)
Timeframe: Enrolment to maximum of 52.9 months
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT increased; Grade 0, n=51, 50 | ALT increased; Grade 1, n=51, 50 | ALT increased; Grade 2, n=51, 50 | ALT increased; Grade 3, n=51, 50 | ALT increased; Grade 4, n=51, 50 | AST increased; Grade 0, n=51, 50 | AST increased; Grade 1, n=51, 50 | AST increased; Grade 2, n=51, 50 | AST increased; Grade 3, n=51, 50 | AST increased; Grade 4, n=51, 50 | ALP increased; Grade 0, n=51, 50 | ALP increased; Grade 1, n=51, 50 | ALP increased; Grade 2, n=51, 50 | ALP increased; Grade 3, n=51, 50 | ALP increased; Grade 4, n=51, 50 | Amylase increased; Grade 0, n=51, 50 | Amylase increased; Grade 1, n=51, 50 | Amylase increased; Grade 2, n=51, 50 | Amylase increased; Grade 3, n=51, 50 | Amylase increased; Grade 4, n=51, 50 | Bilirubin increased; Grade 0, n=51, 50 | Bilirubin increased; Grade 1, n=51, 50 | Bilirubin increased; Grade 2, n=51, 50 | Bilirubin increased; Grade 3, n=51, 50 | Bilirubin increased; Grade 4, n=51, 50 | GGT increased; Grade 0, n=51, 50 | GGT increased; Grade 1, n=51, 50 | GGT increased; Grade 2, n=51, 50 | GGT increased; Grade 3, n=51, 50 | GGT increased; Grade 4, n=51, 50 | Hypercalcemia; Grade 0, n=49, 47 | Hypercalcemia; Grade 1, n=49, 47 | Hypercalcemia; Grade 2, n=49, 47 | Hypercalcemia; Grade 3, n=49, 47 | Hypercalcemia; Grade 4, n=49, 47 | Hyperkalemia; Grade 0; n=51, 50 | Hyperkalemia; Grade 1; n=51, 50 | Hyperkalemia; Grade 2; n=51, 50 | Hyperkalemia; Grade 3; n=51, 50 | Hyperkalemia; Grade 4; n=51, 50 | Hypermagnesemia; Grade 0; n=51, 50 | Hypermagnesemia; Grade 1; n=51, 50 | Hypermagnesemia; Grade 2; n=51, 50 | Hypermagnesemia; Grade 3; n=51, 50 | Hypermagnesemia; Grade 4; n=51, 50 | Hypernatremia; Grade 0, n=51, 50 | Hypernatremia; Grade 1, n=51, 50 | Hypernatremia; Grade 2, n=51, 50 | Hypernatremia; Grade 3, n=51, 50 | Hypernatremia; Grade 4, n=51, 50 | Hypoalbuminemia; Grade 0, n=51, 50 | Hypoalbuminemia; Grade 1, n=51, 50 | Hypoalbuminemia; Grade 2, n=51, 50 | Hypoalbuminemia; Grade 3, n=51, 50 | Hypoalbuminemia; Grade 4, n=51, 50 | Hypocalcemia; Grade 0, n=50, 50 | Hypocalcemia; Grade 1, n=50, 50 | Hypocalcemia; Grade 2, n=50, 50 | Hypocalcemia; Grade 3, n=50, 50 | Hypocalcemia; Grade 4, n=50, 50 | Hypokalemia; Grade 0, n=51, 50 | Hypokalemia; Grade 1, n=51, 50 | Hypokalemia; Grade 2, n=51, 50 | Hypokalemia; Grade 3, n=51, 50 | Hypokalemia; Grade 4, n=51, 50 | Hypomagnesemia; Grade 0, n=51, 50 | Hypomagnesemia; Grade 1, n=51, 50 | Hypomagnesemia; Grade 2, n=51, 50 | Hypomagnesemia; Grade 3, n=51, 50 | Hypomagnesemia; Grade 4, n=51, 50 | Hyponatremia; Grade 0, n=49, 47 | Hyponatremia; Grade 1, n=49, 47 | Hyponatremia; Grade 2, n=49, 47 | Hyponatremia; Grade 3, n=49, 47 | Hyponatremia; Grade 4, n=49, 47 | Lipase increased; Grade 0, n=51, 50 | Lipase increased; Grade 1, n=51, 50 | Lipase increased; Grade 2, n=51, 50 | Lipase increased; Grade 3, n=51, 50 | Lipase increased; Grade 4, n=51, 50 | Renal: Creatinine increased; Grade 0, n=51, 50 | Renal: Creatinine increased; Grade 1, n=51, 50 | Renal: Creatinine increased; Grade 2, n=51, 50 | Renal: Creatinine increased; Grade 3, n=51, 50 | Renal: Creatinine increased; Grade 4, n=51, 50 | |
| Sorafenib+Mapatumumab 30 mg/kg | 4 | 28 | 9 | 9 | 0 | 1 | 20 | 9 | 20 | 0 | 8 | 26 | 11 | 5 | 0 | 22 | 17 | 8 | 3 | 0 | 9 | 10 | 16 | 13 | 2 | 2 | 13 | 15 | 18 | 2 | 37 | 9 | 0 | 0 | 1 | 27 | 3 | 10 | 7 | 3 | 28 | 19 | 0 | 3 | 0 | 18 | 14 | 0 | 15 | 3 | 26 | 9 | 14 | 1 | 0 | 15 | 14 | 19 | 2 | 0 | 41 | 8 | 0 | 1 | 0 | 35 | 13 | 1 | 0 | 1 | 32 | 10 | 3 | 2 | 0 | 13 | 6 | 8 | 17 | 6 | 34 | 12 | 3 | 1 | 0 |
| Sorafenib+Placebo | 6 | 30 | 8 | 7 | 0 | 1 | 23 | 10 | 16 | 1 | 4 | 31 | 11 | 5 | 0 | 30 | 9 | 5 | 6 | 1 | 12 | 15 | 17 | 7 | 0 | 1 | 10 | 14 | 23 | 3 | 37 | 11 | 1 | 0 | 0 | 36 | 2 | 10 | 0 | 3 | 29 | 21 | 0 | 1 | 0 | 18 | 16 | 0 | 16 | 1 | 22 | 10 | 18 | 1 | 0 | 16 | 8 | 18 | 6 | 2 | 37 | 11 | 0 | 1 | 2 | 30 | 19 | 2 | 0 | 0 | 40 | 5 | 2 | 2 | 0 | 19 | 5 | 8 | 16 | 3 | 36 | 7 | 8 | 0 | 0 |
Blood samples were collected for assessment of the following hematology parameters: activated partial thromboplastin time (APTT), hemoglobin, international normalized ratio (INR), lymphocytes, neutrophils, platelets and white blood cells (WBC). Laboratory toxicities were graded based on the NCI-CTCAE version 4.0. Grade 1 represents mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 represents moderate; minimal, local or non-invasive intervention indicated. Grade 3 represents severe or medically significant but not immediately life -threatening; hospitalization or prolongation of hospitalization indicated; disabling. Grade 4 represents life -threatening consequences; urgent intervention indicated. Number of participants with worst toxicity grades for any abnormalities observed in any hematology parameters during the study is presented. (NCT01258608)
Timeframe: Enrolment to maximum of 52.9 months
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APTT prolonged; Grade 0, n=51, 50 | APTT prolonged; Grade 1, n=51, 50 | APTT prolonged; Grade 2, n=51, 50 | APTT prolonged; Grade 3, n=51, 50 | APTT prolonged; Grade 4, n=51, 50 | Anemia; Grade 0, n=51, 50 | Anemia; Grade 1, n=51, 50 | Anemia; Grade 2, n=51, 50 | Anemia; Grade 3, n=51, 50 | Anemia; Grade 4, n=51, 50 | Hemoglobin increased; Grade 0, n=46, 44 | Hemoglobin increased; Grade 1, n=46, 44 | Hemoglobin increased; Grade 2, n=46, 44 | Hemoglobin increased; Grade 3, n=46, 44 | Hemoglobin increased; Grade 4, n=46, 44 | INR increased; Grade 0, n=51, 50 | INR increased; Grade 1, n=51, 50 | INR increased; Grade 2, n=51, 50 | INR increased; Grade 3, n=51, 50 | INR increased; Grade 4, n=51, 50 | Lymphocytes decreased; Grade 0, n=51, 50 | Lymphocytes decreased; Grade 1, n=51, 50 | Lymphocytes decreased; Grade 2, n=51, 50 | Lymphocytes decreased; Grade 3, n=51, 50 | Lymphocytes decreased; Grade 4, n=51, 50 | Lymphocytes increased; Grade 0, n=51, 49 | Lymphocytes increased; Grade 1, n=51, 49 | Lymphocytes increased; Grade 2, n=51, 49 | Lymphocytes increased; Grade 3, n=51, 49 | Lymphocytes increased; Grade 4, n=51, 49 | Neutrophil count decreased; Grade 0, n=51, 50 | Neutrophil count decreased; Grade 1, n=51, 50 | Neutrophil count decreased; Grade 2, n=51, 50 | Neutrophil count decreased; Grade 3, n=51, 50 | Neutrophil count decreased; Grade 4, n=51, 50 | Platelets decreased; Grade 0, n=51, 50 | Platelets decreased; Grade 1, n=51, 50 | Platelets decreased; Grade 2, n=51, 50 | Platelets decreased; Grade 3, n=51, 50 | Platelets decreased; Grade 4, n=51, 50 | WBC decreased; Grade 0, n=51, 50 | WBC decreased; Grade 1, n=51, 50 | WBC decreased; Grade 2, n=51, 50 | WBC decreased; Grade 3, n=51, 50 | WBC decreased; Grade 4, n=51, 50 | |
| Sorafenib+Mapatumumab 30 mg/kg | 22 | 24 | 2 | 2 | 0 | 9 | 22 | 16 | 3 | 0 | 44 | 0 | 0 | 0 | 0 | 3 | 30 | 14 | 3 | 0 | 23 | 0 | 18 | 8 | 1 | 45 | 0 | 4 | 0 | 0 | 37 | 2 | 7 | 1 | 3 | 21 | 16 | 6 | 5 | 2 | 30 | 12 | 5 | 3 | 0 |
| Sorafenib+Placebo | 24 | 19 | 6 | 2 | 0 | 13 | 23 | 9 | 6 | 0 | 46 | 0 | 0 | 0 | 0 | 2 | 35 | 12 | 2 | 0 | 24 | 3 | 16 | 8 | 0 | 49 | 0 | 2 | 0 | 0 | 39 | 3 | 8 | 1 | 0 | 21 | 12 | 10 | 7 | 1 | 33 | 10 | 8 | 0 | 0 |
Blood samples were collected for determination of serum mapatumumab concentration at the indicated time points. NA indicates standard deviation could not be calculated as only one participant was analyzed at the specified time points. (NCT01258608)
Timeframe: Day1 pre-dose(Cycle 1,2,4,5,6,8,9,10,12,14,16,17,18,20,22,24,26,28,30,32,34);end of infusion (Cycle 1);Day8 pre-dose(Cycle 1);Day15 pre-dose (Cycle 1,2);Day21(Cycle 2,4,6,8,9,12,14,16,18,20,22,24,26,28,30,32,34);Cycle 99(end of treatment) (21-day cycles)
| Intervention | Nanograms per milliliter (Mean) | ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYCLE 1 Day 1, pre-dose, n=46 | CYCLE 1 DAY 1,end of infusion, n=46 | CYCLE 1; DAY 8, pre-dose; n=40 | CYCLE 1 DAY 15, pre-dose; n=1 | CYCLE 2 DAY 1, pre-dose; n=40 | CYCLE 2 DAY 15, pre-dose; n=3 | CYCLE 2 DAY 21; n=28 | CYCLE 4 DAY 1, pre-dose; n=31 | CYCLE 4, DAY 21; n=23 | CYCLE 5, DAY 1, pre-dose; n=1 | CYCLE 6, DAY 1, pre-dose; n=21 | CYCLE 6, DAY 21; n=20 | CYCLE 8, DAY 1, pre-dose; n=21 | CYCLE 8, DAY 21; n=17 | CYCLE 9, DAY 1, pre-dose; n=1 | CYCLE 10, DAY 1, pre-dose; n=16 | CYCLE 10, DAY 21; n=15 | CYCLE 12, DAY 1, pre-dose; n=12 | CYCLE 12, DAY 21; n=11 | CYCLE 14, DAY 1, pre-dose; n=9 | CYCLE 14, DAY 21 n=9 | CYCLE 16, DAY 1, pre-dose; n=9 | CYCLE 16, DAY 21; n=8 | CYCLE 17, DAY 1, pre-dose; n=1 | CYCLE 18, DAY 1, pre-dose; n=8 | CYCLE 18, DAY 21; n=7 | CYCLE 20 DAY 1, pre-dose; n=8 | CYCLE 20, DAY 21; n=7 | CYCLE 22 DAY 1, pre-dose; n=8 | CYCLE 22, DAY 21; n=7 | CYCLE 24 DAY 1, pre-dose; n=8 | CYCLE 24, DAY 21; n=7 | CYCLE 26 DAY 1, pre-dose; n=4 | CYCLE 26, DAY 21; n=4 | CYCLE 28 DAY 1, pre-dose; n=3 | CYCLE 28, DAY 21; n=2 | CYCLE 30 DAY 1, pre-dose; n=2 | CYCLE 30, DAY 21; n=2 | CYCLE 32 DAY 1, pre-dose; n=1 | CYCLE 32, DAY 21; n=1 | CYCLE 34 DAY 1, pre-dose; n=1 | CYCLE 34, DAY 21; n=1 | CYCLE 99, end of treatment; n=14 | |
| Sorafenib+Mapatumumab 30 mg/kg | 638.4 | 555157.6 | 250229.9 | 121556.0 | 126588.4 | 128839.0 | 180606.6 | 194936.8 | 183754.3 | 223681.0 | 160741.5 | 201237.7 | 246616.5 | 187927.6 | 136122.0 | 204147.1 | 219503.0 | 200141.1 | 256924.5 | 207930.6 | 256779.4 | 196074.3 | 253521.0 | 156161.0 | 199379.4 | 229539.1 | 189486.6 | 222443.7 | 208485.4 | 212481.1 | 219439.8 | 221249.1 | 223427.3 | 295941.5 | 219802.7 | 173018.5 | 173200.5 | 180484.5 | 178275.0 | 177496.0 | 150553.0 | 134781.0 | 86640.1 |
Overall Survival (OS) was defined as the time (days) from randomization to death due to any cause. Participants still alive at the time of analysis were censored at their last date of last contact. (NCT00855218)
Timeframe: From randomization of the first participant until 28 months later (cut-off date)
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + TACE | NA |
| Placebo + TACE | NA |
TTP is defined as the time (days) from randomization to radiological confirmed disease progression. Participants without progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00855218)
Timeframe: From randomization of the first participant until 28 months later (cut-off date)
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + TACE | 169 |
| Placebo + TACE | 166 |
Time to untreatable progression (TTUP) was defined as the time (days) from randomization to untreatable progression. Participants without untreatable progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00855218)
Timeframe: From randomization of the first participant until 28 months later (cut-off date)
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + TACE | 95 |
| Placebo + TACE | 224 |
Time to vascular invasion/extrahepatic spread (TTVI/ES) was defined as the time (days) from randomization to vascular invasion/extrahepatic spread. Participants without vascular invasion/extrahepatic spread at the time of analysis were censored at their last date of tumor evaluation. (NCT00855218)
Timeframe: From randomization of the first participant until 28 months later (cut-off date)
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + TACE | NA |
| Placebo + TACE | NA |
Tumor Response was defined as the number of participants with a confirmed Complete Response (CR)=disappearance of all clinical and radiological tumor lesions, Partial Response (PR)= at least 30% decrease in sum of the longest diameters (LD) of tumor lesions, Stable Disease (SD)= neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease, or Progressive Disease (PD)=at least 20% increase in the sum of LD of measured lesions, observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (NCT00855218)
Timeframe: From randomization of the first participant until 28 months later (cut-off date)
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Response (CR+PR) | Complete Response (CR) | Partial Response (PR) | Stable Disease | Progressive Disease | Not assessable | |
| Placebo + TACE | 43 | 17 | 26 | 56 | 36 | 18 |
| Sorafenib (Nexavar, BAY43-9006) + TACE | 55 | 20 | 35 | 52 | 20 | 27 |
Tumor Response was defined as the number of participants with a confirmed Complete Response (CR)=disappearance of all clinical and radiological tumor lesions, Partial Response (PR)= at least 30% decrease in sum of the longest diameters (LD) of tumor lesions, Stable Disease (SD)= neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease, or Progressive Disease (PD)=at least 20% increase in the sum of LD of measured lesions, observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (NCT00855218)
Timeframe: From randomization of the first participant until 28 months later (cut-off date)
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Response (CR+PR) | Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Assessable | |
| Placebo + TACE | 53 | 20 | 33 | 57 | 30 | 13 |
| Sorafenib (Nexavar, BAY43-9006) + TACE | 66 | 21 | 45 | 50 | 16 | 22 |
DCR is the sum of the complete response, partial response, and stable disease rates (NCT03149822)
Timeframe: Beginning of study to end of study, or death, whichever comes first, up to 5 years
| Intervention | % of patients (Number) |
|---|---|
| All Evaluable Patients Treated at Pembrolizumab 200 mg IV Q3W + Cabozantinib 60 mg PO QD | 97.4 |
"Assessed through Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. Dose Limiting Toxicity (DLT) was defined as any of the following events occurring during the DLT assessment window (21 days) and is assessed by the investigator to be likely related to study treatment (pembrolizumab and/or cabozantinib).~Grade ≥ 3 non-hematologic, non-hepatic adverse events~Grade 3 nausea, vomiting, or diarrhea lasting >72 hours despite maximal medical therapy.~Grade ≥ 4 neutropenia (ANC < 500 cells/μL) lasting > 7 days~Grade ≥ 3 febrile neutropenia~Grade ≥ 4 anemia~Grade ≥ 4 thrombocytopenia, or Grade 3 thrombocytopenia associated with clinically significant bleeding~Grade ≥ 3 elevation of serum hepatic transaminase (ALT or AST).~Grade ≥ 3 elevation of serum total bilirubin.~ALT or AST > 3 × upper limit of normal (ULN) AND total bilirubin >2 × ULN will require permanent treatment discontinuation." (NCT03149822)
Timeframe: Throughout Cycle 1, up to 21 days
| Intervention | events (Number) |
|---|---|
| Phase 1 Cohort 1: Pembrolizumab 200 mg Plus Cabozantinib 40mg | 0 |
| Phase 1 Cohort 2: Pembrolizumab 200 mg Plus Cabozantinib 60mg | 0 |
Duration of time that patients maintain RECIST response to treatment (NCT03149822)
Timeframe: Time of first response as measured by RECIST 1.1 to time of progression or death, whichever comes first, up to 5 years
| Intervention | months (Median) |
|---|---|
| All Patients Treated at the RP2D of Pembrolizumab 200 mg IM Q3W Plus Cabozantinib 60 mg PO QD | 8.3 |
Measured through the complete response (CR) + partial response (PR)] of pembrolizumab and cabozantinib when administered in combination in subjects with locally advanced or metastatic renal cell carcinoma. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT03149822)
Timeframe: Beginning of study to end of study, up to 5 years
| Intervention | % of patients (Number) |
|---|---|
| Phase 1/2: All Evaluable Patients Treated at Pembrolizumab 200 mg IV Q3W + Cabozantinib 60 mg PO QD | 65.8 |
| Phase 1 Dose Escalation Cohort: Pembrolizumab 200 mg IV Q3W Plus Cabozantinib 40mg PO QD | 0 |
"The MTD is defined as the highest dose level with no more than 1 DLT reported in 6 DLT-evaluable subjects.~The Recommended Phase 2 Dose (RP2D) of cabozantinib will be selected based on the clinical data and will not exceed the MTD. If < 2/6 subjects experience a DLT at 60 mg daily during dose escalation, then 60 mg daily will be considered the RP2D. If ≥ 2/6 subjects experience DLTs at 60 mg daily, and ≤ 1/6 subjects experience a DLT at 40 mg daily, then 40 mg daily will be considered the RP2D. The dose of pembrolizumab will be constant at 200 mg IV every 3 weeks." (NCT03149822)
Timeframe: Throughout Cycle 1, up to 21 days
| Intervention | mg (Number) |
|---|---|
| Phase 1: Pembrolizumab 200 mg IV Q3W Plus Cabozantinib 40mg or 60 mg PO QD | 60 |
Measured as the time it takes for an occurrence of death due to any cause (NCT03149822)
Timeframe: Beginning of study to end of study, or death, whichever comes first, up to 5 years
| Intervention | months (Median) |
|---|---|
| All Patients Treated at the RP2D of Pembrolizumab 200 mg IM Q3W Plus Cabozantinib 60 mg PO QD | 30.81 |
Measured as the time it takes for an occurrence of documented disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT03149822)
Timeframe: Beginning of study to end of study, or death, whichever comes first, up to 5 years
| Intervention | months (Median) |
|---|---|
| All Patients Treated at the RP2D of Pembrolizumab 200 mg IM Q3W Plus Cabozantinib 60 mg PO QD | 10.45 |
6-minute walking distance (6MWD) is a measure for the objective evaluation of a participant's functional exercise capacity. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Meters (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 38.9 |
| Placebo | -5.5 |
Alanine Aminotransferase (ALT) is a standard clinical chemistry parameter. Normal range: 0 to 45 U/L. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -1.2 |
| Placebo | 2.2 |
Alkaline phosphatase (AP) is a standard clinical chemistry parameter. Normal range: 40 to 129 U/L (males), 35 to 104 U/L (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -3.8 |
| Placebo | 2.5 |
"All cause mortality (including cardiovascular mortality) was one component of the composite endpoint time to clinical worsening." (NCT00855465)
Timeframe: At visit 6 (week 16)
| Intervention | Participants (Number) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 2 |
| Placebo | 3 |
Arterial partial pressure of oxygen (PaO2) is performed as part of the capillary or arterial blood gas analysis. If possible, no supplementary oxygen was given during the resting period and while blood samples were drawn. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -3.01 |
| Placebo | -4.95 |
Arterial partial pressure of carbon dioxide (PaCO2) is performed as part of the capillary or arterial blood gas analysis. If possible, no supplementary oxygen was given during the resting period and while blood samples were drawn. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.34 |
| Placebo | 0.56 |
Aspartate Aminotransferase (AST) is a standard clinical chemistry parameter. Normal range: 0 to 41 U/L. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.3 |
| Placebo | 2.8 |
Bilirubin is a standard clinical chemistry parameter. Normal range: 0.1 to 1.2 mg/dL (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mg/dL (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.010 |
| Placebo | 0.189 |
"The Borg CR10 Scale is a participant reported outcome measure used in clinical diagnosis of e.g. breathlessness and dyspnea. It documents the participant's exertion during a physical test. Low values indicate low levels of exertion; high values indicate more intense exertion reported by the participant. The score ranges from 0 (Nothing at all) to 10 (Extremely strong - Maximal)." (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Scores on a scale (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.83 |
| Placebo | 0.17 |
The cardiac index (CI) is a calculated hemodynamic parameter. CI is derived from the directly measured parameters cardiac output (CO), divided by the body surface area (BSA). BSA is a calculated parameter, using the subject's height and weight in the DuBois formula. Formula: BSA = (W [kg]*0.425)*(H [cm]*0.725)*0.007184 (m^2) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | L/min/m^2 (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.45 |
| Placebo | -0.01 |
Creatine Kinase is a standard clinical chemistry parameter. Normal range: 35 to 232 U/L (males), 26 to 145 U/L (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 7.9 |
| Placebo | 5.6 |
Creatinine is a standard clinical chemistry parameter. Normal range: 0.25 to 1.20 mg/dL (males), 0.46 to 1.00 mg/dL (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mg/dL (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.003 |
| Placebo | 0.032 |
Creatinine clearance is a standard clinical chemistry parameter. Normal range: 90 to 140 mL/min (males), 80 to 125 mL/min (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mL/min (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 2.25 |
| Placebo | -0.93 |
Cystatin C is a biomarker. Normal range: 0.53 to 1.01 ng/mL (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ng/ml (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 16.1 |
| Placebo | 62.9 |
Diastolic systemic arterial blood pressure (DBP) is a directly non-invasively measured hemodynamic parameter. Range allowed in this study at Visit 0 and/or Visit 1 before randomization: <= 110 mmHg. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -8.17 |
| Placebo | -3.40 |
EQ-5D utility score is a Quality-of-Life participant reported outcome measure. The utility score is calculated based on five questions concerning problems with mobility, self-care, usual activities, pain/discomfort and anxiety/depression. An increase in the utility score represents an improvement in quality of life. The score ranges from -0.594 (worst answer in all five questions) to 1 (best answer in all five questions). (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Scores on a scale (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.0615 |
| Placebo | -0.0819 |
Erythrocytes (red blood cells, RBC) is a standard clinical hematology parameter. Normal range: 4.6 to 5.8*10^12 cells/L (males), 4.1 to 5.2*10^12 cells/L (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | *10^12 cells/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.14 |
| Placebo | 0.04 |
Heart rate (HR) is a directly non-invasively measured hemodynamic parameter. Range allowed in this study at Visit 0 and/or Visit 1 before randomization: 50 -105 beats per minute (bpm) at rest. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Beats/min (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 0.83 |
| Placebo | 1.67 |
Hematocrit is a standard clinical hematology parameter. Normal range: 40 to 52% (males), 36 to 46% (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Volume percentage of red blood cells (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -2.0 |
| Placebo | 0.5 |
Hemoglobin is a standard clinical hematology parameter. Normal range: 13.5 to 17.5 g/dL (males), 12.0 to 16.0 g/dL (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | g/dL (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.69 |
| Placebo | 0.02 |
Leukocytes (white blood cells, WBC) is a standard clinical hematology parameter. Normal range: 4.0 to 10.7*10^9 cells/L (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | *10^9 cells/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.55 |
| Placebo | 0.23 |
The self-reported Living with Pulmonary Hypertension (LPH) questionnaire is designed to measure the effects of PH and PH-specific treatments on an individual's quality of life. The LPH total score can range from 0 (best) to 105 (worst). (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Scores on a scale (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -6.72 |
| Placebo | -2.09 |
Total lymphocytes is a standard clinical hematology parameter. Normal range: 1.0 to 4.0*10^9 cells/L (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | *10^9 cells/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.16 |
| Placebo | 0.00 |
PR duration was evaluated as part of the 12-lead electrocardiogram. electrocardiograms (ECGs) were recorded after the participant had been at rest for 15 minutes in a supine position. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ms (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.32 |
| Placebo | 0.87 |
Mean pulmonary arterial pressure (PAPmean) is a directly measured hemodynamic parameter. PAPmean is recorded during a right heart catheterization. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -4.31 |
| Placebo | 0.76 |
QRS duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ms (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.19 |
| Placebo | -0.05 |
QT duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ms (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 1.19 |
| Placebo | -2.00 |
Bazett-corrected QTcB duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ms (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -4.30 |
| Placebo | -0.51 |
Fridericia-corrected QTcF duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ms (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -2.34 |
| Placebo | -1.02 |
RR duration was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | ms (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 3.89 |
| Placebo | -14.00 |
Ventricular rate was evaluated as part of the 12-lead electrocardiogram. ECGs were recorded after the participant had been at rest for 15 minutes in a supine position (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | beats per minute (bpm) (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.70 |
| Placebo | 1.60 |
N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | pg/mL (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -290.69 |
| Placebo | 76.35 |
Neutrophils is a standard clinical hematology parameter. Normal range: 1.6 to 7.4*10^9 cells/L (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | *10^9 cells/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.31 |
| Placebo | 0.26 |
Oxygen saturation (SaO2) is measured as part of the capillary or arterial blood gas analysis. Normal blood oxygen saturation is considered 95-100 percent. If possible, no supplementary oxygen was given during the resting period and while blood samples were drawn. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Percentage of oxygen saturation (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -1.5 |
| Placebo | -3.1 |
Potassium is a standard clinical chemistry parameter. Normal range: 3.5 to 5.3 mmol/L (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mmol/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.08 |
| Placebo | -0.02 |
The pulmonary vascular resistance (PVR) is a calculated hemodynamic parameter. PVR is derived from the directly measured parameters mean pulmonary arterial pressure (PAPmean) and pulmonary capillary wedge pressure (PCWP), divided by the cardiac output (CO). PVR and PAPmean are acquired during a right heart catheterization. CO is a calculated hemodynamic parameter, too. Formula: PVR = 80*(PAPmean - PCWP)/CO (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | dyn*s*cm^-5 (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -225.68 |
| Placebo | 23.07 |
Systolic systemic arterial blood pressure (SBP) is a directly non-invasively measured hemodynamic parameter. Range allowed in this study at Visit 0 and/or Visit 1 before randomization: 95 - 180 mmHg. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -10.49 |
| Placebo | -5.28 |
Triacylglycerol lipase is a standard clinical chemistry parameter. Normal range: 7 to 60 U/L (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -4.2 |
| Placebo | 0.1 |
Urate is a standard clinical chemistry parameter. Normal range: 4.0 to 8.5 mg/dL (males, 16-59 years), 3.4 to 8.7 mg/dL (males, >60 years) 2.5 to 7.5 mg/dL (females) (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mg/dL (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.405 |
| Placebo | 0.209 |
Urea (blood urea nitrogen, BUN) is a standard clinical chemistry parameter. Normal range: 4 to 25 mg/dL (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | mg/dL (Mean) |
|---|---|
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | -0.60 |
| Placebo | 0.99 |
"The combined endpoint time to clinical worsening, made up of the following components, defined by the first occurrence: all-cause mortality; heart/lung transplantation; rescue endarterectomy; first hospitalization due to pulmonary hypertension; start of a new pulmonary hypertension treatment; persistent worsening of 6MWD or WHO functional class due to deterioration of PH." (NCT00855465)
Timeframe: At week 16
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any Event | Hospitalization due to pulmonary hypertension | Start of new pulmonary hypertension | Decrease in 6MWT due to pulmonary hypertension | Persistant worsening of functional class due to PH | Death | |
| Placebo | 5.7 | 1.1 | 1.1 | 2.3 | 1.1 | 3.4 |
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 2.3 | 0 | 1.2 | 0.6 | 0 | 1.2 |
The WHO functional assessment of pulmonary arterial hypertension ranged from functional class I (Patients with PH but without resulting limitation of physical activity) to class IV (Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-heart failure.). Changes to a lower WHO functional class resemble improvement; changes to a higher functional class resemble deterioration of PAH. (NCT00855465)
Timeframe: Baseline and week 16
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| -2 | -1 | 0 | 1 | 2 | 3 | |
| Placebo | 0 | 14.9 | 78.2 | 3.4 | 3.4 | 0 |
| Riociguat (Adempas, BAY63-2521)_individual Dose Titration | 2.3 | 30.6 | 61.8 | 4.0 | 0.6 | 0.6 |
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause (NCT01774344)
Timeframe: From randomization (Day 1) of the first subject to end of follow upto 1710 days
| Intervention | days (Median) |
|---|---|
| Placebo | 241 |
| Regorafenib 160 mg (BAY73-4506) | 326 |
Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT01774344)
Timeframe: From randomization (Day 1) of the first subject until 419 days later
| Intervention | days (Median) |
|---|---|
| Placebo | 237 |
| Regorafenib 160 mg (BAY73-4506) | 323 |
Disease control rate (DCR) was defined as the percentage of subjects whose best response was CR (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), PR (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or stable disease (SD) (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST and RECIST 1.1 criteria. SD had to be maintained for at least 6 weeks from the first demonstration of that rating. (NCT01774344)
Timeframe: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| mRECIST | RECIST 1.1 | |
| Placebo | 36.1 | 34.5 |
| Regorafenib 160 mg (BAY73-4506) | 65.2 | 65.7 |
Objective tumor response rate (ORR) was defined as the percentage of subjects whose best tumor response CR or Partial Response (PR) observed during trial period assessed according to the mRECIST criteria and RECIST 1.1. CR= Disappearance of all clinical and radiological evidence of tumor (both target and non-target). Any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to < 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non target lesions and no appearance of new lesions. Subjects prematurely discontinuing without an assessment were to be considered non-responders for the analysis. (NCT01774344)
Timeframe: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| mRECIST | RECIST 1.1 | |
| Placebo | 4.1 | 2.6 |
| Regorafenib 160 mg (BAY73-4506) | 10.8 | 6.6 |
Progression Free Survival (PFS) was defined as the time (days) from date of randomization to date of disease progression (radiological or clinical) or death due to any cause, if death occurs before progression was documented. Death in the absence of progression was a PFS event only if it occurred within the 12+1 weeks for subjects who discontinued treatment prior to cycle 8 and 24+2 weeks for subjects who discontinued treatment after to cycle 8 of the last evaluable tumor assessment; PFS were censored at the date of the last evaluable tumor assessment, if it occurred later. Median and 95% confidence interval 95% were reported for the mRECIST and RECIST 1.1 analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT01774344)
Timeframe: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks)
| Intervention | days (Median) | |
|---|---|---|
| mRECIST | RECIST 1.1 | |
| Placebo | 45 | 45 |
| Regorafenib 160 mg (BAY73-4506) | 95 | 102 |
TTP was the time (days) from randomization to radiological or clinical disease progression assessed by independent radiological review. Median and 95% confidence interval were reported for the modified response evaluation criteria in solid tumors (mRECIST) and response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT01774344)
Timeframe: From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)
| Intervention | days (Median) | |
|---|---|---|
| mRECIST | RECIST 1.1 | |
| Placebo | 45 | 45 |
| Regorafenib 160 mg (BAY73-4506) | 97 | 119 |
MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients). If dose level (-1) is not tolerable, but dose (-3) or (-2) is below or at MTD, testing of alternate dose levels (-2a, -3a, -3b) will occur as outlined in the table. The number of dose limiting toxicities will be reported here. (NCT00867321)
Timeframe: From baseline up to 3 years post treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level 0 | 2 |
| Phase I: Dose Level -1 | 3 |
| Phase I: Dose Level -2a (Maximum Tolerated Dose) | 0 |
| Phase I: Dose Level -2 | 0 |
Overall survival (OS) is defined as the length of time from date of registration to a) date of death due to any cause or b) last follow-up. Kaplan-Meier survival curves will be used to estimate the distribution of OS. (NCT00867321)
Timeframe: Up to 3 years post treatment
| Intervention | Months (Median) |
|---|---|
| All Patients | 13.3 |
Time to progression is defined to be the length of time from study registration to a) date of disease progression as defined by section 11.0, or b) last follow-up. If a patient dies without documentation of disease progression, the patient will be considered to have had a tumor progression at the time of death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Kaplan-Meier survival curves will be used to estimate the distribution of TTP. (NCT00867321)
Timeframe: From baseline up to 3 years post treatment
| Intervention | years (Median) |
|---|---|
| Arm I (Phase II) | 8.6 |
| Arm II (Phase II) | 13.3 |
here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01375569)
Timeframe: 25 months, 15 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TRC105 in Liver Cancer | 11 |
Time to tumor progression is defined as the proportion of participants who are progression free after 4 months on study. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01375569)
Timeframe: 2 years
| Intervention | Weeks (Mean) |
|---|---|
| TRC105 in Liver Cancer | 12 |
OS was calculated from the on-study date until the date of death or the date the patient was last known to be alive. Probabilities were determined using the Kaplan-Meier method. (NCT01306058)
Timeframe: up to 2 years
| Intervention | Months (Median) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 15.5 |
PFS was calculated from the on-study date until date of progression, death, or an event that would render the patient inevaluable for further follow-up (liver dysfunction), or end of study. Probabilities were determined using the Kaplan-Meier method. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01306058)
Timeframe: up to 6 months
| Intervention | Months (Median) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 3.8 |
DLT was assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. DLT criteria included treatment-related grade 3 non-hematological toxicities or grade 4 hematological toxicities occurring within the first 28 days of treatment. Grade 3 electrolyte toxicities to be corrected to Grade 1 or less within 24 hours will be considered dose limiting (proteinuria >3.5g/24 hour will be defined as a DLT). Drug-related Grade 4 hematological toxicity will be considered dose limiting. Toxicity requiring a dose reduction or a delay in treatment for >7 days will be considered dose limiting. Other Grade 3 or higher toxicity related to TRC105 will be considered dose limiting. (NCT01306058)
Timeframe: First 28 days of treatment (cycle 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 1 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01306058)
Timeframe: 4 years and 10.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 27 |
Overall response (Complete Response (CR) + Partial Response (PR) was assessed by the European Association for the Study of the Liver (EASL)-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for target lesions and assessed by magnetic resonance imaging (MRI). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT01306058)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 21 |
Overall response (Complete Response (CR) + Partial Response (PR) was assessed by the Standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria for target lesions and assessed by magnetic resonance imaging (MRI). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT01306058)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 21 |
Patients who develop antidrug antibodies is measured by human anti-chimeric antibody (HACA) formation (e.g. immunogenicity of TRC105). (NCT01306058)
Timeframe: Cycle 1 Day 1, 28 days post end of study (up to 2 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 7 |
MTD is the highest dose studied for which the incidence of DLT was less than 33%. DLT criteria included treatment-related grade 3 non-hematological toxicities or grade 4 hematological toxicities occurring within the first 28 days of treatment. Grade 3 electrolyte toxicities to be corrected to Grade 1 or less within 24 hours will be considered dose limiting (proteinuria >3.5g/24 hour will be defined as a DLT). Drug-related Grade 4 hematological toxicity will be considered dose limiting. Toxicity requiring a dose reduction or a delay in treatment for >7 days will be considered dose limiting. Other Grade 3 or higher toxicity related to TRC105 will be considered dose limiting. (NCT01306058)
Timeframe: Completed in the first 28 days of treatment (cycle 1)
| Intervention | mg/kg (Number) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 15 |
TTP is the time between the first day of treatment to the day of disease progression. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01306058)
Timeframe: 2 years
| Intervention | Months (Median) |
|---|---|
| Sorafenib & TRC105 in Hepatocellular CA | 3.8 |
Mean peak TRC105 serum trough concentrations were plotted over time by dose level to assess accumulation. (e.g. drug absorption). The lower limit of quantification (LLOQ) is 200 ng/mL. (NCT01306058)
Timeframe: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, and prior to start of TRC105 infusion
| Intervention | Hr*ng/mL (Mean) | |||
|---|---|---|---|---|
| Dose level 1 | Dose level 2 | Dose level 3 | Dose level 4 | |
| Sorafenib & TRC105 in Hepatocellular CA | 75933 | 152900 | 242882 | 362611 |
Blood samples were collected and analyzed by the enzyme-linked immunosorbent assay (ELISA). Serum samples were measured using a validated ELISA with a lower limit of quantification (LLOQ) of 200 ng/ml. Soluble endoglin was only assessed in patient samples without detectable TRC105 concentrations. (NCT01306058)
Timeframe: Cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, or end of study (eos), an average of 12 weeks
| Intervention | ng/ml (Median) | |||
|---|---|---|---|---|
| Cycel 1 Day 1 | Cycle 1 Day 15 | Cycel 2 day 1 | End of study (eos) | |
| Sorafenib & TRC105 in Hepatocellular CA | 27.5 | 60.4 | 64.5 | 66.6 |
Plasma biomarker tests were performed for VEGF and PIGF using assay plates from Meso-Scale Discovery according to the product manual. The concentrations of the cytokines were determined with recombinant standards. Changes in biomarkers were determined by a Wilcoxon signed rank test. (NCT01306058)
Timeframe: Cycle 1 day 1, cycle 1 day 15, cycle 2 day 1, or end of study, an average of 12 weeks
| Intervention | pg/ml (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| VEGF cycle 1 day 1 | PIGF cycle 1 day 1 | VEGF cycle 1 day 15 | PIGF cycle 1 day 15 | VEGF cycle 2 day 1 | PIGF cycle 2 day 1 | VEGF end of study (eos) | PIGF end of study (eos) | |
| Sorafenib & TRC105 in Hepatocellular CA | 202.5 | 44.6 | 299 | 81.6 | 243.4 | 68.8 | 184.3 | 53.5 |
A 5mL blood sample will be collected to assess immunogenicity. Immunogenicity will be measured by the enzyme-linked immunosorbent assay (ELISA) and expressed in titres. The higher the titre, the higher the formation of HAMA antibody in the blood. A higher concentration of HAMA (higher titre result) is a negative finding. A higher level means the drug elimination is faster and the TRC 105 is then less effective. Lower level is 0-2 titre. Any value above 2 titre would be a positive HAMA result. The HAMA ( Human anti-mouse antibody) measurement at 28 days post treatment levels provides information as to the rate of drug elimination and effectiveness. Patients with 0 to < 2.0 titre. eliminates the TRC 105 slower and the drug may be more effective than patients who have a low(>2.0 titres) or high level of HAMA. Higher levels of HAMA reflect the TRC 105 elimination from the body faster and the drug potentially not as effective as negative HAMA titres. (NCT01306058)
Timeframe: Baseline and then 28 days following the end of the study treatment, approximately two years
| Intervention | titres (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | no evidence of HAMA 28 days post treatment | Low level of HAMA 28 days post treatment | High level of HAMA 28 days post treatment | |
| Sorafenib & TRC105 in Hepatocellular CA | 0.02 | 0 | 65 | 515 |
Response is defined as per the Response Evaluation Criteria in Solid Tumors (RECIST). Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. To be assigned a confirmed PR, changes in tumor measurements must be confirmed by repeat assessments that should be performed at least 4 weeks after the criteria for response are first met. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01306058)
Timeframe: Every 8 weeks, up to 180 days
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Phase I - Stable disease | Phase I - Progressive disease | Phase I - Partial response | Phase 2 - Stable disease | Phase 2 - Partial response | Phase 2 - Progressive disease | |
| Sorafenib & TRC105 in Hepatocellular CA | 9 | 2 | 4 | 3 | 1 | 2 |
Percentage of participants last known to be alive at 6 and 12 months. (NCT01306058)
Timeframe: 6 and 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 month OS | 12 month OS | |
| Sorafenib & TRC105 in Hepatocellular CA | 74.0 | 59.2 |
Percentage of participants who were progression free at 3 and 6 months. Progressive disease was measured by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01306058)
Timeframe: 3 and 6 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 3 month PFS | 6 month PFS | |
| Sorafenib & TRC105 in Hepatocellular CA | 75.0 | 16.7 |
Here are the number of treatment-emergent adverse events categorized by Any grade, Grade 3, Grade 4 and Grade 5 adverse events. Adverse events was assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v4.0. Grade 1 is mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 is moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) (e.g. preparing meals, shopping for groceries or clothes). Grade 3 is severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL (e.g. bathing, dressing and undressing). Grade 4 is life-threatening consequences; urgent intervention indicated. Grade 5 is death related to adverse event. (NCT01306058)
Timeframe: 4 years and 10.5 months
| Intervention | treatment-emergent adverse events (Number) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Grade Headache | Any Grade Epistaxis | Any Grade Increased aspartate aminotransaminase | Grade 3 Increased aspartate aminotransaminase | Any Grade Rash, other | Grade 3 Rash, other | Any Grade Hypophosphatemia | Grade 3 Hypophosphatemia | Any Grade Hypoalbuminemia | Grade 3 Hypoalbuminemia | Any Grade Anemia | Grade 3 Anemia | Any Grade Fatigue | Any Grade Increased alkaline phosphatase | Grade 3 Increased alkaline phosphatase | Any Grade Diarrhea | Grade 3 Diarrhea | Any Grade Increased blood bilirubin | Grade 3 Increased blood bilirubin | Grade 4 Increased blood bilirubin | Any Grade Nausea | Any Grade Increased alanine transaminase | Any Grade Oral mucositis/pain | Any Grade Thrombocytopenia | Grade 3 Thrombocytopenia | Any Grade Amylase | Grade 3 Amylase | Grade 4 Amylase | Any Grade Abdominal pain | Any Grade Hand-foot skin reaction | Grade 3 Hand-foot skin reaction | Any Grade Infusion reaction | Grade 3 infusion reaction | Any Grade Neutropenia | Any Grade Weight loss | Any Grade Hypertension | Grade 3 Hypertension | Any Grade Vomiting | Any Grade Hypomagnesemia | Any Grade Alopecia | Any Grade Insomnia | Any Grade Constipation | Grade 3 Intracranial hemorrhage | Grade 5 Myocardial ischemia | Grade 4 Lipase | Any Grade Hyperglycemia | Grade 3 Hyperglycemia | Grade 4 Hyperuricemia | |
| Sorafenib & TRC105 in Hepatocellular CA | 20 | 19 | 18 | 5 | 18 | 3 | 18 | 7 | 17 | 2 | 16 | 1 | 15 | 15 | 5 | 15 | 1 | 14 | 6 | 1 | 14 | 13 | 12 | 10 | 1 | 10 | 2 | 1 | 9 | 8 | 2 | 8 | 1 | 8 | 8 | 6 | 1 | 6 | 5 | 5 | 4 | 3 | 1 | 1 | 1 | 1 | 2 | 2 |
Time from date of first objective response (complete response [CR] or partial response [PR]) to date progression is first documented (as defined per independent central radiological assessment) or death, whichever occurs first (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib + Doxorubicin | 199 |
| Placebo + Doxorubicin | 68 |
The time from date of randomization to date of death (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib + Doxorubicin | 418 |
| Placebo + Doxorubicin | 199 |
Participants with disease control: those who have as best response complete response (CR), partial response (PR) or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease) according to Response Evaluation Criteria in Solid Tumors (RECIST) (NCT00108953)
Timeframe: from date of randomization to end of treatment plus 30 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib + Doxorubicin | 63.8 |
| Placebo + Doxorubicin | 30.6 |
Time from the date of randomization to the date of the first documented radiological progression (as defined per independent central radiological assessment) or death, whichever occurs first (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib + Doxorubicin | 242 |
| Placebo + Doxorubicin | 85 |
TTP was defined as the time from randomization to radiological disease progression by independent assessment. (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib + Doxorubicin | 263 |
| Placebo + Doxorubicin | 147 |
Time from date of randomization to date of first objective response (complete response [CR] or partial response [PR]) is documented and confirmed according to RECIST criteria (NCT00108953)
Timeframe: from date of randomization until 3 years later at end of study
| Intervention | days (Median) |
|---|---|
| Sorafenib + Doxorubicin | 134 |
| Placebo + Doxorubicin | 40 |
Time from date of randomization to date of first documented symptomatic progression defined by Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index-8 (FHSI-8) assessment (NCT00108953)
Timeframe: from date of randomization of the first patient until 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib + Doxorubicin | 208 |
| Placebo + Doxorubicin | 152 |
Percentage of participants with complete or partial response (CR or PR) confirmed according to Response Evaluation Criteria in Solid Tumors (RECIST) and achieved during treatment or 30 days after end of treatment. CR: disappearance of all clinical and radiological tumor lesions. PR: at least 30% decrease in sum of the longest diameters of tumor lesions. Stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease. (NCT00108953)
Timeframe: achieved during treatment or within 30 days after termination of active therapy
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | |
| Placebo + Doxorubicin | 2.0 | 0.0 | 49.0 |
| Sorafenib + Doxorubicin | 0.0 | 4.3 | 66.0 |
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. (NCT00494299)
Timeframe: From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 164 |
| Placebo | 112 |
(NCT00494299)
Timeframe: From randomization of the first subject until death due to any cause assessed up to 55 months.
| Intervention | Participants (Number) | |
|---|---|---|
| up to 39 months | up to 55 months | |
| Placebo | 41 | 56 |
| Sorafenib (Nexavar, BAY43-9006) | 43 | 50 |
Dose-limiting toxicity was defined as a clinically significant AE or laboratory abnormality occurring in Cycle 1 (NCT00790218)
Timeframe: From start of treatment until Day 28 of Cycle 1
| Intervention | Participants (Count of Participants) |
|---|---|
| CF102 1mg | 0 |
| CF102 5mg | 0 |
| CF102 25mg | 0 |
The MTD was defined as the highest dose level at which < 2 of 6 patients developed Cycle 1 DLT. (NCT00790218)
Timeframe: first 28 days (Cycle 1)
| Intervention | milligrams (Number) |
|---|---|
| CF102 1mg | NA |
| CF102 5mg | NA |
| CF102 25mg | NA |
Therapeutic effect of CF102 in hepatocellular carcinoma measured by number of subjects with objective tumor response (NCT00790218)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| CF102 1mg | 0 |
| CF102 5mg | 0 |
| CF102 25mg | 0 |
Blood samples were collected and plasma concentrations determined using a high-pressure liquid chromatography method. (NCT00790218)
Timeframe: Dose Escalation Phase on Day 1 and Day 29 pre-dose and at 1, 2, 3, 4, 6, 8 hours post-dose
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 1 | Day 29 | |
| CF102 1mg | 4.455 | 10.46 |
| CF102 25mg | 98.36 | 330.6 |
| CF102 5mg | 25.10 | 53.69 |
Time from the date that MR was first documented to the date that PD was first documented. (NCT00044512)
Timeframe: Time from MR to PD
| Intervention | days (Mean) |
|---|---|
| Sorafenib 400 mg b.i.d. | 122 |
Duration of response was calculated from the first drug treatment date until documented progressive disease (PD). PD was 1) 25% or more increase in the sum of all target lesion areas taking as reference the smallest sum recorded at or following baseline, 2) unequivocal progression of an existing non-target lesion, or 3) appearance of a new lesion. (NCT00044512)
Timeframe: up to 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib 400 mg b.i.d. | 374 |
Time from the first day of receiving study drug until there was a documented PD or response. (NCT00044512)
Timeframe: up to 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib 400 mg b.i.d. | 166 |
Time from the first date of receiving study medication to death. (NCT00044512)
Timeframe: Start of treatment to death
| Intervention | days (Median) |
|---|---|
| Sorafenib 400 mg b.i.d. | 280 |
Time from the first day of receiving study drug to the date the MR was first documented (with confirmation). Minor response = >25% regression. (NCT00044512)
Timeframe: up to 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib 400 mg b.i.d. | 84 |
Time from the first date of receiving study drug until the first documented PD. (NCT00044512)
Timeframe: up to 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib 400 mg b.i.d. | 167 |
Time from the first day of receiving study drug to the date the CR or PR was documented (with confirmation). (NCT00044512)
Timeframe: up to 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib 400 mg b.i.d. | 144 |
Objective response rate of sorafenib assessed as the proportion of subjects with confirmed complete or partial response as per modified World Health Organization (WHO) criteria. (NCT00044512)
Timeframe: Until 30 days after termination of active therapy
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Minor response (MR) | Stable disease (SD) | Progressive disease (PD) | Not available for independent review (NA) | Not evaluable (NE) | |
| Sorafenib 400 mg b.i.d. | 0 | 2.2 | 5.8 | 54.7 | 13.9 | 22.6 | 0.7 |
252 reviews available for niacinamide and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; | 2022 |
Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.
Topics: Antineoplastic Agents; Biological Products; Carcinoma, Hepatocellular; Chemoembolization, Therapeuti | 2022 |
The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2020 |
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Loca | 2021 |
New knowledge of the mechanisms of sorafenib resistance in liver cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal | 2017 |
Tivantinib for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2017 |
Update on Embolization Therapies for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver; Liver Neoplasms; Neoplasm Stagi | 2017 |
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mes | 2017 |
Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Design; Drug Resistance, N | 2017 |
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Niacinamid | 2017 |
Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms | 2017 |
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolizatio | 2017 |
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cl | 2017 |
Bridging to liver transplantation in HCC patients.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver | 2017 |
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm | 2017 |
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Hand | 2018 |
New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistan | 2017 |
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2017 |
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Drug Resist | 2017 |
Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2017 |
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; | 2018 |
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2018 |
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2018 |
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Hepatocellular; Chemoembolization, Thera | 2018 |
Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; D | 2013 |
Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Discover | 2013 |
Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; | 2013 |
[Current status of molecular targeted therapies in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mitogen-Activated Protein | 2013 |
Antiangiogenic therapies for advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Fibroblast Growth Factors; Humans; Liver Neoplas | 2013 |
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Di | 2013 |
Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
Topics: Biological Products; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Com | 2013 |
Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2013 |
Sorafenib: from literature to clinical practice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Evidence-Based Medicine; Humans; Liver Ne | 2013 |
A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver | 2013 |
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Com | 2013 |
Targeted therapies in hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; H | 2014 |
Met as a therapeutic target in HCC: facts and hopes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocyte Growth Factor; Humans; Liver Neopla | 2014 |
Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as | 2013 |
Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2013 |
Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; | 2013 |
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2013 |
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Topics: Antineoplastic Agents; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glucocorticoids; Graft Rej | 2014 |
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2014 |
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod | 2014 |
Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms | 2013 |
Newer treatments for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 2014 |
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2014 |
Systemic therapy of hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatoce | 2014 |
Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Top | 2014 |
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2014 |
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2014 |
Sorafenib use in the transplant setting.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Immunosuppressive | 2014 |
Advances in managing hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transp | 2014 |
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Progression; | 2014 |
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as | 2014 |
Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2014 |
Treating advanced hepatocellular carcinoma: How to get out of first gear.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2014 |
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy | 2014 |
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Re | 2014 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2014 |
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2014 |
Management of hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Mana | 2015 |
Hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niaci | 2014 |
Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2014 |
A short update on cancer chemoresistance.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatectomy; Humans | 2014 |
Systemic treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Patient Sele | 2014 |
Refining sorafenib therapy: lessons from clinical practice.
Topics: Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Mo | 2015 |
Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoem | 2014 |
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Down-Regulation; Humans; Liver | 2014 |
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2014 |
Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2014 |
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Di | 2014 |
Managing localized unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2015 |
New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cytoprotection; Drug Therapy, Combinati | 2014 |
Treatment of hepatocellular carcinoma: beyond international guidelines.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Guidelines as | 2015 |
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; D | 2015 |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; | 2015 |
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ne | 2015 |
Is Notch Signaling a Specific Target in Hepatocellular Carcinoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Humans; Liver Neoplasms; Ma | 2015 |
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal | 2015 |
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The | 2014 |
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; | 2015 |
Management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contraindications; | 2015 |
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod | 2015 |
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neopl | 2015 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Liquid biopsy in liver cancer.
Topics: Alleles; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; DNA, Neopla | 2015 |
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoe | 2015 |
Novel drugs in clinical development for hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Design; Humans; Live | 2015 |
[Advanced hepatocellular carcinoma: importance of clinical trials].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disea | 2015 |
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver | 2015 |
Sorafenib: 10 years after the first pivotal trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Ni | 2015 |
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
New molecular therapies for hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II | 2015 |
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; DNA Methylation; Drug Design; Epigenesis, | 2015 |
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2015 |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Liv | 2015 |
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epige | 2015 |
Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeuti | 2015 |
Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined | 2016 |
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Diseas | 2015 |
Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.
Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans | 2015 |
Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms | 2015 |
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ne | 2015 |
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoc | 2015 |
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposit | 2016 |
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compo | 2016 |
Treatment of hepatocellular carcinoma: beyond international guidelines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2016 |
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
Topics: ADAM17 Protein; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy | 2016 |
Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2016 |
Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2016 |
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Differentiation; Dendritic Cells; Humans; Immun | 2016 |
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Ther | 2016 |
Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Midd | 2016 |
The use of genetic alterations in the development of liver cancer drugs.
Topics: Animals; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Huma | 2015 |
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2016 |
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility S | 2018 |
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Liver Neopla | 2016 |
Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Immunotherapy; Infusions, | 2016 |
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Discovery; ErbB Rece | 2016 |
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Design; Humans; Liver Ne | 2016 |
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niac | 2016 |
Targeted Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms | 2016 |
Challenges of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinic | 2016 |
Hepatocellular carcinoma in patients with HIV.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B, Chronic; Hepatitis C, Ch | 2017 |
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Patho | 2017 |
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Humans; Liver Neoplasms; | 2017 |
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free S | 2016 |
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Human | 2017 |
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; | 2017 |
Recent advances in hepatocellular carcinoma therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality | 2017 |
Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Mid | 2017 |
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chr | 2017 |
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2017 |
Sorafenib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide | 2017 |
Contemporary management of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hep | 2008 |
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans; Li | 2008 |
Molecular targeted therapies in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neop | 2008 |
Medical therapies to extend survival in hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Male; Neoplasm | 2008 |
Systemic therapy of hepatocellular carcinoma: are we making progress?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoemboliz | 2008 |
Molecular therapy for the treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2009 |
Evolution of systemic therapy of advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; | 2008 |
Management of advanced hepatocellular carcinoma in the era of targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma | 2009 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Ne | 2009 |
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Controlled Clinical Trials as T | 2009 |
Multimodal approaches to the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoemboliz | 2009 |
New drugs for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; ErbB Receptors; Humans; Mitogen | 2009 |
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hum | 2009 |
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
Topics: Algorithms; alpha-Fetoproteins; Anti-Infective Agents, Local; Antineoplastic Agents; Benzenesulfonat | 2009 |
Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2009 |
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellula | 2009 |
Pathogenesis of hepatocellular carcinoma and molecular therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2009 |
Selection of patients with hepatocellular carcinoma for sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2009 |
[The treatment of hepatocellular carcinoma. New developments].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2009 |
[Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Proliferati | 2009 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Ther | 2009 |
Molecular targeting for treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovas | 2009 |
Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neopla | 2010 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2009 |
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecu | 2010 |
Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Pharmacological; Biomarkers, Tumor; C | 2010 |
Current strategy for staging and treatment: the BCLC update and future prospects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as T | 2010 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2010 |
[Chemotherapy].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Liver Neoplasms; Niacinamide; P | 2010 |
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as T | 2010 |
Novel inhibitors in development for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Top | 2010 |
Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2010 |
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C | 2010 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Deve | 2010 |
Sorafenib for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease | 2010 |
[Current therapy for hepatocellular carcinoma].
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Emboliza | 2010 |
The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neoplasm Staging | 2010 |
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug D | 2010 |
Sorafenib: where do we go from here?
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Intracellular Signali | 2010 |
Hepatocellular carcinoma--what's new?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neop | 2010 |
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocell | 2010 |
Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Topics: Algorithms; Asia; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Li | 2010 |
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
[Nonsurgical management of hepatocellular carcinoma].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembol | 2010 |
[Treatment of primary hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans | 2010 |
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; | 2011 |
Sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neopla | 2010 |
Developing better treatments in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Top | 2010 |
[Multimodality treatment for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoemboliz | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[Hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecu | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; | 2010 |
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; | 2010 |
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2010 |
Novel molecular therapies in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecu | 2011 |
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Clinical Tr | 2011 |
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Epide | 2011 |
[Sorafenib and radiotherapy association for hepatocellular carcinoma].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Ex | 2011 |
Assessment of the treatment response of HCC.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoemboliz | 2011 |
Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
Topics: Adenoma, Liver Cell; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cyt | 2011 |
Sorafenib for advanced hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2011 |
[Hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecu | 2011 |
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2011 |
Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2011 |
Sorafenib for HCC: a pragmatic perspective.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2011 |
Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compo | 2011 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2012 |
[Sorafenib in the treatment of hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2011 |
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Mol | 2011 |
Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2011 |
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Topics: Antibiotics, Antineoplastic; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Humans; Live | 2012 |
Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; D | 2011 |
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Management; Humans; Liv | 2011 |
Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, The | 2012 |
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Synergism; Endoplasmic Ret | 2011 |
Signaling pathways in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Interce | 2011 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, | 2011 |
Radiotherapeutic strategies in the management of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2011 |
Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug | 2012 |
[Hepatocellular carcinoma: what's new?].
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatoce | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Advanced HCC: emerging molecular therapies.
Topics: Antibodies, Monoclonal; Benzenesulfonates; California; Carcinoma, Hepatocellular; Catheter Ablation; | 2012 |
Management of hepatocellular carcinoma: beyond sorafenib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug T | 2012 |
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoemb | 2012 |
[Treatment of advanced hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms | 2012 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluoro | 2012 |
[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellula | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Hepati | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Dose- | 2012 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB | 2013 |
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Dru | 2012 |
Impact of restricting access to high-cost medications for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision | 2012 |
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transpl | 2013 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Tri | 2012 |
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2013 |
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2012 |
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Incid | 2013 |
Extrahepatic spread of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Target | 2012 |
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2013 |
Pathways and targets in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver N | 2012 |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Huma | 2013 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2005 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2006 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2007 |
[The hepatocellular carcinoma: alternative therapeutical strategies].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female | 2007 |
Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoemboliz | 2007 |
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Sorafenib: in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinic | 2008 |
Novel advancements in the management of hepatocellular carcinoma in 2008.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod | 2008 |
174 trials available for niacinamide and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niaci | 2022 |
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2022 |
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; | 2022 |
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
Topics: Carcinoma, Hepatocellular; Extracellular Vesicles; Humans; Liver Neoplasms; Niacinamide; Phenylurea | 2022 |
Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Japan; Liv | 2019 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Ph | 2020 |
Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female | 2020 |
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepato | 2020 |
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Leukocytes, Monon | 2020 |
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver | 2021 |
Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compo | 2022 |
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Surviva | 2017 |
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Drug-R | 2017 |
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan- | 2017 |
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Area Under Curve; Biomarker | 2017 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2017 |
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-F | 2017 |
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Hepatocellular; C | 2017 |
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Surv | 2017 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Coun | 2017 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Coun | 2017 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Coun | 2017 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Coun | 2017 |
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Hum | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Mod | 2017 |
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate | 2017 |
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; L | 2017 |
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; | 2017 |
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Com | 2017 |
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hand-Foot | 2017 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2018 |
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kap | 2018 |
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
Topics: Aged; Asian People; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; | 2018 |
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antin | 2018 |
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2018 |
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Huma | 2013 |
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Ther | 2013 |
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tu | 2013 |
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Sid | 2013 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplas | 2013 |
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Adolescent; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; | 2013 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepato | 2013 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Everolimus; | 2013 |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Fol | 2013 |
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resist | 2013 |
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diseas | 2013 |
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Fe | 2014 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit | 2013 |
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female | 2014 |
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea | 2013 |
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2014 |
The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohor | 2014 |
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2014 |
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2014 |
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization | 2014 |
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Adm | 2014 |
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rej | 2014 |
Sorafenib in liver function impaired advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cross- | 2014 |
Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Female; Humans; Liver Fun | 2014 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2014 |
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2014 |
Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; L | 2014 |
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Fr | 2014 |
Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Femal | 2014 |
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Europe; Follow-Up S | 2015 |
Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Confidence Intervals; | 2016 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2014 |
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2015 |
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembol | 2014 |
Poor results for everolimus in patients with liver cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; | 2014 |
Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Delayed-Action Pre | 2015 |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Carcinoma, He | 2014 |
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administratio | 2015 |
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Erlo | 2015 |
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therap | 2015 |
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; | 2015 |
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance i
Topics: Amino Acids; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line | 2015 |
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Germany; Humans; Liver Neopla | 2015 |
SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, | 2015 |
Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contr | 2015 |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, | 2015 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma | 2015 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma | 2015 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma | 2015 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma | 2015 |
Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female | 2015 |
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Femal | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C | 2015 |
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Li | 2015 |
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hum | 2015 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellul | 2015 |
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue | 2015 |
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Drug Administration Schedule; Female | 2016 |
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neo | 2016 |
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2016 |
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Double-Blind Metho | 2016 |
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease- | 2016 |
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2016 |
Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Female; Human | 2016 |
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2016 |
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Hydroxamic Acids; | 2016 |
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2016 |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asia, Eastern; Benzimidazoles; Bioma | 2016 |
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocel | 2016 |
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Le | 2016 |
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulatio | 2016 |
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therap | 2016 |
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbo | 2016 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2017 |
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2016 |
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellul | 2016 |
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; F | 2017 |
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy | 2016 |
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Clinical Protocols; Combined Modali | 2016 |
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Age | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan- | 2017 |
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Female; Huma | 2017 |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distrib | 2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2017 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Dou | 2008 |
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
Topics: Antineoplastic Agents; Benzenesulfonates; Canada; Carcinoma, Hepatocellular; Disease-Free Survival; | 2008 |
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Thera | 2008 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocel | 2009 |
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Fema | 2009 |
[Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2009 |
[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; | 2009 |
New pharmacological developments in the treatment of hepatocellular cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neo | 2009 |
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom | 2010 |
Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2010 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2010 |
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Clini | 2010 |
[Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoe | 2010 |
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cathe | 2010 |
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoe | 2010 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2011 |
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio | 2011 |
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Be | 2011 |
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinom | 2011 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2012 |
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular | 2011 |
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocell | 2012 |
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Di | 2012 |
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re | 2011 |
Sorafenib in hepatocellular carcinoma - a post marketing evaluation.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Follow-Up Studies | 2012 |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2011 |
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2012 |
Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; M | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; M | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; M | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; M | 2012 |
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; alpha-Fetoproteins; Antineoplastic Agents; Asp | 2012 |
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, | 2012 |
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progress | 2012 |
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Topics: Alkaline Phosphatase; alpha-Fetoproteins; Angiopoietin-2; Benzenesulfonates; Biomarkers, Tumor; Carc | 2012 |
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2012 |
Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Cryo | 2012 |
The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatic Ar | 2012 |
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Cont | 2012 |
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatopulmonary Syndrom | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; F | 2012 |
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
Topics: Advanced Oxidation Protein Products; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular | 2012 |
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Feasibility Studies; | 2013 |
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Asian People; Carcinoma, Hepatocellular; Catheterization; | 2013 |
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; H | 2013 |
Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2013 |
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Med | 2013 |
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mon | 2013 |
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mon | 2013 |
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mon | 2013 |
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mon | 2013 |
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolizati | 2013 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcino | 2006 |
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationshi | 2008 |
1212 other studies available for niacinamide and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2021 |
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; F | 2021 |
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Sta | 2022 |
Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Cell Proli | 2022 |
Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance; Humans; Liver Neoplasms; Niacinamide; | 2022 |
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neop | 2022 |
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Ni | 2022 |
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinam | 2023 |
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver | 2022 |
The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Liver Neoplasms; Mice; Nia | 2022 |
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolife | 2022 |
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Drug Resistance, Neoplasm; Hep G2 Cells; Huma | 2022 |
FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Ion Channels; Liver | 2022 |
[Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Core Binding Factor Alpha 3 Subu | 2022 |
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Li | 2022 |
Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhi | 2022 |
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Pro | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; L | 2022 |
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liv | 2022 |
Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neopla | 2023 |
Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2022 |
A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Genome-Wide Association Study; Humans; Liver Neopl | 2023 |
Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; N | 2023 |
Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Prospective | 2023 |
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2023 |
[E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2019 |
Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinam | 2020 |
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Carcinoma, Hepatocellular; Cell Prol | 2019 |
Letter: are sorafenib-related adverse events associated with prolonged survival?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Response to: Prognostication of HCC patients under sorafenib is not always possible.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; So | 2020 |
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Europe; Humans; Liver Neoplasms; Niacinamide | 2020 |
The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hispanic or Latino; Humans; Liver Neoplasms; | 2020 |
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Live | 2020 |
Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Disease-Free Survi | 2021 |
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Exocrine Pancreatic Insufficiency; Female; Humans; | 2021 |
Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiopia; Humans; | 2020 |
Modulation of antioxidant enzymes, SIRT1 and NF-κB by resveratrol and nicotinamide in alcohol-aflatoxin B1-induced hepatocellular carcinoma.
Topics: Aflatoxin B1; Animals; Antioxidants; Carcinoma, Hepatocellular; Ethanol; Liver Neoplasms, Experiment | 2021 |
Management of intermediate-stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy?
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Live | 2021 |
Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bismuth; Carcinoma, Hepatocellular; Cell Line, Tumor; Cel | 2020 |
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Pharmacogene | 2020 |
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Comp | 2021 |
Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; | 2021 |
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacin | 2021 |
Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Databases, | 2021 |
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Humans; Liver Neoplasms; | 2021 |
Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Topics: Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifera | 2021 |
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Tr | 2017 |
Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line; Cell Line | 2017 |
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell | 2017 |
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease P | 2017 |
Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipi | 2017 |
TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Exome; Female; High-Throughput Nucleotide | 2017 |
Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Adenine Nucleotide Translocator 2; Carcinoma, Hepatocellular; Cell Line, Tu | 2017 |
3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
Topics: Anoikis; Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Epithelial-Mesenc | 2017 |
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma | 2017 |
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2017 |
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2017 |
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2018 |
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Prolif | 2017 |
Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular | 2017 |
Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Prolif | 2017 |
Immune oncology in hepatocellular carcinoma-hype and hope.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms | 2017 |
Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cohort Studies; Disease Models | 2017 |
Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality | 2017 |
Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect.
Topics: Adult; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Re | 2018 |
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyc | 2017 |
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relatio | 2018 |
Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular | 2017 |
Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female | 2017 |
[Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Hep G2 Cells; Humans | 2017 |
Immortal time bias or sorafenib effect in elderly patients with HCC?
Topics: Aged; Antineoplastic Agents; Bias; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; | 2017 |
Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Fe | 2018 |
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2017 |
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis Regulatory Prot | 2017 |
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Gene Expressio | 2017 |
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
Topics: Aged; Amino Acid Transport Systems, Neutral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellul | 2017 |
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
Topics: Blood Volume; Carcinoma, Hepatocellular; Feasibility Studies; Humans; Liver Neoplasms; Niacinamide; | 2017 |
PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neopla | 2017 |
Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; France; Humans; Liver; Liver Neoplas | 2017 |
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Topics: Apoptosis; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA (Cyto | 2017 |
Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2017 |
Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Endoplasmic Reticulum S | 2017 |
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Humans; Liver Neop | 2017 |
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, | 2018 |
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2017 |
Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agen | 2017 |
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Sid | 2017 |
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Pro | 2017 |
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; France; | 2017 |
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms | 2018 |
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
Topics: Abies; Animals; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell | 2017 |
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2017 |
Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Haloperidol; | 2017 |
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2017 |
Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expres | 2017 |
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumo | 2017 |
Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.
Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Chlorocebus aeth | 2017 |
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2017 |
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; | 2018 |
6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Blotti | 2017 |
Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; H | 2017 |
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver | 2017 |
A typical presentation of a hepatocellular carcinoma in a middle-aged patient.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bone Neoplasms; Carcinoma, Hepatocellular; Clavicle; Fat | 2017 |
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
Topics: Analysis of Variance; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; | 2018 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dr | 2017 |
Might Sorafenib combined with radiotherapy be better option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms | 2018 |
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Do | 2017 |
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; D | 2017 |
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed- | 2017 |
Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver; Li | 2018 |
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Sur | 2017 |
The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disea | 2017 |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Hu | 2017 |
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Topics: Acrylamides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; | 2018 |
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual | 2017 |
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hep | 2017 |
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analy | 2017 |
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modalit | 2017 |
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Hel | 2017 |
Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Ce | 2017 |
The treatment path in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Liver Ne | 2017 |
Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Carcinoma, Hepatocellular; Depr | 2018 |
Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular | 2017 |
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Predictors of sorafenib benefit in patients with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; So | 2018 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellul | 2017 |
Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Ferric Compounds; Heterografts; Humans; | 2017 |
Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; Drug D | 2017 |
Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Topics: Antineoplastic Agents; Apoptosis; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Cycle | 2018 |
Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; | 2018 |
Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma.
Topics: Acetates; Acidosis; Aged, 80 and over; Carbon Radioisotopes; Carcinoma, Hepatocellular; Humans; Live | 2018 |
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neop | 2018 |
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision- | 2018 |
Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellu | 2018 |
Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, | 2018 |
Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Mod | 2017 |
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Discovery; Drug Re | 2017 |
High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cytosol; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockd | 2017 |
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Topics: Administration, Metronomic; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatoce | 2018 |
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Fre | 2017 |
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Humans; Liver Neoplasms; | 2018 |
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality | 2018 |
The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Surv | 2018 |
Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model.
Topics: Animals; Antineoplastic Agents; Blood Flow Velocity; Blood Vessels; Carcinoma, Hepatocellular; Histi | 2018 |
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.
Topics: Carcinoma, Hepatocellular; Cell Survival; Elastic Modulus; Exome; Fluorescent Antibody Technique; Hu | 2018 |
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Costs; Drug Prescriptions; Female; Gast | 2018 |
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene | 2018 |
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; | 2018 |
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, | 2018 |
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; | 2018 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Clusterin; Gene Silen | 2018 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell | 2018 |
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Huma | 2018 |
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reacti | 2018 |
Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafe | 2018 |
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2018 |
Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoem | 2018 |
Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Co | 2018 |
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up | 2018 |
Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Huma | 2018 |
Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contra | 2018 |
Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biflavonoids; Carcinoma, H | 2018 |
Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Ne | 2018 |
Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cel | 2018 |
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Competence; Diag | 2018 |
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolizati | 2018 |
Rupture of a Small Hepatocellular Carcinoma in a Stable Disease State in a Patient Receiving Sorafenib Treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2018 |
Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, | 2018 |
Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Topics: Activating Transcription Factor 2; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell | 2018 |
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Hepatocellular; Diterpenes; | 2018 |
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
Topics: Adult; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease-Free Survival; Female; H | 2018 |
Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Cost-Benefit Analysis; | 2018 |
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2018 |
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Drug | 2018 |
[Hepatocellular Carcinoma: New multimodal therapy concepts].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therap | 2018 |
Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance | 2018 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineop | 2018 |
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents; Caproates; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2018 |
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome | 2018 |
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplas | 2018 |
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver | 2018 |
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Drug Syn | 2018 |
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; F | 2018 |
Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; CASP8 and | 2018 |
Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Prolife | 2018 |
The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB.
Topics: Animals; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neopla | 2019 |
[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recu | 2019 |
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
Topics: Carcinoma, Hepatocellular; Humans; Leukemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sor | 2019 |
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
Topics: Aged; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Cognition Disorders; Electroencephalogra | 2013 |
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Carcinoma, He | 2013 |
Label-retaining liver cancer cells are relatively resistant to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neop | 2013 |
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2013 |
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Drug Evaluation, Pr | 2013 |
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Disease Prog | 2013 |
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembo | 2013 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellula | 2013 |
Liver tumors and loco-regional therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2013 |
Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neopla | 2013 |
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
Topics: alpha-Fetoproteins; Animals; Autophagy-Related Protein 5; Carcinoma, Hepatocellular; Cell Line, Tumo | 2013 |
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Res | 2013 |
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Chemoradiotherapy; Cyclin D1; Humans; I | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocel | 2013 |
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea C | 2013 |
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Coh | 2013 |
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclo | 2013 |
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
[Molecular targeted agent for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 2012 |
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2013 |
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regu | 2014 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; | 2013 |
Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide | 2013 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellu | 2013 |
Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, | 2013 |
Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neopl | 2013 |
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re | 2013 |
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diseas | 2013 |
Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohor | 2013 |
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Caspase 3; Cell | 2013 |
The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Epigenesis, Genetic; Er | 2013 |
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis | 2013 |
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease | 2013 |
Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Deli | 2013 |
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.
Topics: AC133 Antigen; alpha-Fetoproteins; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Biomarke | 2013 |
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular; | 2013 |
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Topics: Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carcinoma, Hepatocellular; CASP8 | 2013 |
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA Repair; Extra | 2013 |
Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Graft Survival; Humans; Liver Neopla | 2013 |
Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Li | 2014 |
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, Hepatocellular; | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diph | 2013 |
Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell | 2013 |
Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Synergism; Endo | 2013 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferatio | 2013 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatic | 2013 |
Hepatocellular carcinoma: perspective of an oncologist.
Topics: Antineoplastic Agents; Attitude of Health Personnel; Carcinoma, Hepatocellular; Humans; Liver Neopla | 2013 |
Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; | 2013 |
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; | 2013 |
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Therapy | 2013 |
Long-term treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Niacinamide | 2013 |
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Prolifera | 2013 |
Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; F | 2013 |
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle | 2013 |
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2014 |
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Diethy | 2013 |
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; F | 2013 |
Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
Topics: Aged, 80 and over; Antineoplastic Agents; Capsule Endoscopy; Carcinoma, Hepatocellular; Female; Gast | 2013 |
Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Cyclin G1; Drug Resistan | 2013 |
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Carcinoma, Hepatocellu | 2013 |
Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Fe | 2013 |
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Prog | 2013 |
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; | 2013 |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolif | 2014 |
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2013 |
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell | 2014 |
Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Dr | 2013 |
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Ki | 2013 |
[Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma].
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Femal | 2013 |
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; British Columbia; Carcinoma, Hepatocellular; Diseas | 2013 |
MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
Topics: Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gen | 2014 |
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphospho | 2013 |
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2013 |
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort | 2013 |
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Molecular Targeted | 2013 |
[The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2013 |
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell C | 2013 |
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms | 2013 |
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, T | 2014 |
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; P | 2013 |
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Femal | 2013 |
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Topics: AC133 Antigen; Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Antineoplastic Agents; B | 2013 |
Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neo | 2013 |
Sorafenib for hepatocellular carcinoma before liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplanta | 2013 |
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, | 2013 |
Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; | 2014 |
Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dat | 2013 |
Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma".
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re | 2014 |
Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re | 2014 |
In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Combined Modality Therapy; Humans; | 2013 |
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fl | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2014 |
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Co | 2013 |
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; | 2013 |
Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver N | 2013 |
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; L | 2013 |
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin-Dependent Kinase | 2013 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carc | 2014 |
Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans | 2013 |
Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Topics: Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, N | 2014 |
The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neo | 2013 |
A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; C | 2013 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined C | 2014 |
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Topics: Allografts; Allosteric Regulation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diphen | 2013 |
Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
Topics: Adult; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Chem | 2013 |
Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue".
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re | 2014 |
Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re | 2014 |
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, | 2013 |
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Fem | 2014 |
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Thera | 2013 |
SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Prol | 2013 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Move | 2014 |
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell L | 2013 |
High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Hum | 2014 |
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Topics: Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Humans; Liver Neoplasms; N | 2014 |
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
Topics: Aged; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Iopamidol; Liver Neoplasms; Magneti | 2014 |
[A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; | 2013 |
Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Communic | 2014 |
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.
Topics: Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Combined Mod | 2014 |
Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatoc | 2013 |
Interplay between cancer cells, macrophages and natural killer cells may actually decide the outcome of therapy with sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Macrophage Activ | 2014 |
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2013 |
[Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; F | 2013 |
[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The | 2013 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2014 |
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2014 |
Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Liver; Liver Neoplasms, Experimental; Nia | 2014 |
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Sid | 2013 |
Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Clostridium; Clostridium In | 2014 |
Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; | 2014 |
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellu | 2014 |
Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Drug Resistance, Neoplasm; Humans; Inhibitor of Apop | 2014 |
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studi | 2014 |
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Ad | 2014 |
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease-Free Surv | 2014 |
Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?
Topics: Alanine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male | 2014 |
Reply to X. Qi et al.
Topics: Alanine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male | 2014 |
Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2014 |
Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; D | 2014 |
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diseas | 2014 |
NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Apo | 2014 |
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedul | 2014 |
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lymphocytes; Neutrophils; | 2014 |
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distrib | 2014 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue | 2014 |
[Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2014 |
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis.
Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cells, Cultured; Endopl | 2014 |
[Diagnostics and treatment of hepatocellular carcinoma: trends in the Netherlands in the period 2003-2011].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therap | 2014 |
Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell P | 2014 |
Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dermatomycoses; Humans; Liver Neoplasms; Mal | 2015 |
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2014 |
Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
Topics: Actins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Gene Ex | 2014 |
Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, | 2014 |
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver | 2014 |
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette | 2014 |
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Co | 2014 |
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cel | 2014 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Everolimus; Humans; Immunosuppr | 2014 |
RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; DNA Methylation; Drug Resistanc | 2014 |
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Topics: Anilides; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolife | 2014 |
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2014 |
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; H | 2014 |
Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; G | 2014 |
Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Cell Line, Tumor; Cell P | 2014 |
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Fema | 2015 |
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cau | 2015 |
A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2014 |
Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Gene Expressi | 2014 |
Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinami | 2014 |
Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Fema | 2014 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2014 |
Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Sur | 2014 |
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Mod | 2014 |
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 C | 2014 |
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Protein | 2014 |
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular | 2015 |
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, He | 2014 |
The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver N | 2014 |
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Hepatocellular; Cell Proliferati | 2014 |
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; D | 2014 |
A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
Topics: Acetonitriles; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Huma | 2014 |
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatoc | 2014 |
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Kaplan-Meier | 2014 |
VEGFA genomic amplification tailors treatment of HCCs with sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Ni | 2014 |
Multidisciplinary management of hepatocellular carcinoma in clinical practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Fe | 2014 |
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Anima | 2014 |
Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cell | 2014 |
Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Gene | 2014 |
Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans.
Topics: Acetylcarnitine; Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; alpha-Fetoproteins; Bi | 2014 |
Value of neutrophil lymphocyte ratio in patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphocyte Co | 2014 |
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspa | 2014 |
Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell | 2014 |
Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug | 2014 |
Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Feasibility Studies; Female; | 2015 |
Systemic therapy in HCC: lessons from brivanib.
Topics: Alanine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male | 2014 |
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dos | 2014 |
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neopl | 2014 |
Invasive hepatocellular carcinoma with recurrent pulmonary embolism: use of AngioVac cannula thrombectomy device for mechanical aspiration.
Topics: Adult; Angiography; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Fa | 2014 |
Earlier presentation and application of curative treatments in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2014 |
[Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erythema Multiforme; Female; Humans; Liver N | 2014 |
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib.
Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular | 2014 |
Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Genom | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Topics: 3' Untranslated Regions; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Survival; Dose-Respon | 2014 |
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Hep G2 Ce | 2015 |
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2014 |
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Coculture Techniques; Culture | 2014 |
Network features suggest new hepatocellular carcinoma treatment strategies.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neopla | 2014 |
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Fema | 2014 |
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Human | 2015 |
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Hep | 2014 |
miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; D | 2014 |
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans | 2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Model | 2014 |
Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Carcinoma, | 2014 |
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clopidogrel; Dose-Response Relationship, Drug; Dru | 2014 |
The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immu | 2014 |
Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2014 |
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Human | 2015 |
Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Move | 2014 |
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Topics: Activating Transcription Factor 2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug R | 2014 |
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Rel | 2014 |
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic | 2014 |
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2015 |
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2014 |
Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middl | 2014 |
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinas | 2014 |
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dise | 2014 |
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Damage; | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, H | 2016 |
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplas | 2017 |
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2014 |
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2014 |
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2015 |
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2014 |
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; He | 2015 |
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecip | 2014 |
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male | 2014 |
Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Confounding Factors, Epidemiologic; Data Int | 2014 |
Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocyte | 2015 |
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival | 2014 |
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Stu | 2014 |
Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cohort Studies; Combined | 2014 |
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
Topics: Activities of Daily Living; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and | 2014 |
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Dru | 2015 |
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2014 |
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; | 2014 |
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Female | 2015 |
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolif | 2015 |
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Topics: Adult; Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Chil | 2015 |
A rare primary liver tumor that responded to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Eukaryotic Initiation Factor-3 | 2014 |
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm | 2015 |
Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; DNA-Binding Proteins; Dose-Response Rel | 2015 |
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Carcinoma, Hepatocel | 2015 |
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemo | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbid | 2015 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; In | 2015 |
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2015 |
[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice].
Topics: Aged; Aged, 80 and over; Alcoholism; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization | 2015 |
Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Chemoembolizati | 2014 |
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dr | 2015 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined | 2014 |
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Femal | 2015 |
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; M | 2015 |
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Prolif | 2014 |
Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Injections, Intra | 2014 |
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; F | 2015 |
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Dr | 2015 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethan | 2015 |
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carcinoma, Hepa | 2015 |
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; | 2015 |
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Tec | 2015 |
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Apoptosis; Binding Sites; Carcinoma, Hepato | 2015 |
Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Co | 2015 |
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Liver | 2014 |
Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Thera | 2015 |
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-R | 2015 |
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control | 2015 |
Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Femal | 2015 |
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis | 2015 |
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Europe; False Positive Reactions; Female | 2015 |
Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Proliferati | 2015 |
Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 2014 |
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocol | 2015 |
PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Nucleus; Cell Pr | 2015 |
Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Ass | 2015 |
Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Topics: Age Factors; Aged; Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Th | 2015 |
Sorafenib- or 90Y-loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver N | 2015 |
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Jaundice; Liver Failu | 2015 |
Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney Neoplasms; Male; Middle Aged; Neopl | 2015 |
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidin | 2015 |
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumo | 2015 |
Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcino | 2014 |
[A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Li | 2014 |
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms | 2015 |
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Kerat | 2015 |
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dr | 2015 |
Reply to: "Sorafenib or (90) Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?".
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver N | 2015 |
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; | 2015 |
Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; | 2015 |
PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drugs, Chi | 2015 |
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.
Topics: Animals; Apoptosis; Arginine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm | 2015 |
Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Duodenitis; Gastrointestinal Hemorrhage; Humans; L | 2015 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2015 |
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembol | 2015 |
Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatectomy; Hospita | 2015 |
Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Female; Humans; Liver Neoplasms | 2015 |
Response to Yang et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Female; Humans; Liver Neoplasms | 2015 |
Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver | 2015 |
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2015 |
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Fe | 2015 |
The endless SEARCH for a better medical treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neo | 2015 |
Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Topics: Carcinoma, Hepatocellular; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulat | 2015 |
Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Topics: Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Synergism; Hep G2 Cells; Hepatocy | 2015 |
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Ci | 2015 |
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Human | 2015 |
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Li | 2015 |
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; Female; Humans; | 2015 |
Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
Topics: Animals; Carcinoma, Hepatocellular; CD13 Antigens; Cell Differentiation; Cell Line, Tumor; Cell Line | 2015 |
Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2015 |
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Stag | 2015 |
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Bl | 2015 |
Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplanta | 2015 |
RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Endoribonucle | 2015 |
Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD47 Antigen; Disease Models, Animal; Dru | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell P | 2015 |
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Surviva | 2015 |
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease | 2015 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Ne | 2015 |
Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aging; Carcinoma, Hepatocellular; Demography; Dose-Response Relationship, Drug; Female; Humans | 2015 |
Combination therapy with sorafenib and radiofrequency ablation for hepatocellular carcinoma: a glimmer of light after the storm trial?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Female; Humans; Liver Neoplasms | 2015 |
Response to Facciorusso et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Female; Humans; Liver Neoplasms | 2015 |
Pattern of tumor progression in liver cancer: The missing partner in trial design.
Topics: Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Ne | 2015 |
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; | 2015 |
Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway.
Topics: Actins; Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2015 |
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2014 |
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; It | 2015 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellul | 2015 |
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Loss, Surgical; Carcinoma, Hepatocellular; Combined | 2015 |
Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Re | 2015 |
Reply to M. Bouattour et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Indazoles; Liver Neoplasms; Male; | 2015 |
Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Indazoles; Liver Neoplasms; Male; | 2015 |
CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassett | 2015 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma | 2015 |
Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dextrans; Drug Carr | 2015 |
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; | 2015 |
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neo | 2015 |
Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Gene Expression Profiling; Gene Expression Regulat | 2015 |
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers; Biomarkers, Tumor; Biopsy, | 2015 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep | 2015 |
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep | 2015 |
Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Synergis | 2015 |
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2015 |
Does ramucirumab deserve a second chance for liver cancer?
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamid | 2015 |
Long-term therapy with sorafenib is associated with pancreatic atrophy.
Topics: Aged; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Huma | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carci | 2015 |
Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Jejunum; Liver Neoplasms; Male; Niac | 2015 |
Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Middle Aged; Niac | 2015 |
Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distributio | 2014 |
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diseas | 2014 |
MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
Topics: Adult; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cells, Cu | 2015 |
Systemic Treatment: Expecting Further Success.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; L | 2015 |
Next Generation of Preclinical Liver Cancer Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Genomic Hybridization; Diseas | 2015 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, He | 2015 |
The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2014 |
[Hepatocellular Carcinoma: therapeutic options 2015].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; | 2015 |
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cervical Cord; Chemoembolization, | 2015 |
[Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The | 2015 |
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Topics: Age Factors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Activation; Gene Expr | 2015 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Hu | 2015 |
Reply to F.V. Negri et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Emulsions; Female; Hand-Foot Syndrome; Humans; Liv | 2015 |
Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Emulsions; Female; Hand-Foot Syndrome; Humans; Liv | 2015 |
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery | 2015 |
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combi | 2015 |
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Ve | 2015 |
Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2015 |
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeuti | 2015 |
Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecul | 2015 |
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver | 2015 |
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2015 |
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemoki | 2015 |
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboxymethylcellulose Sodium; C | 2015 |
LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, | 2015 |
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; | 2015 |
Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Calorimetry, Differential Scanning; Carcinoma, Hepatocellular; Cell Survival; Dr | 2015 |
[Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Huma | 2015 |
An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Topics: AC133 Antigen; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Aporphines; ATP Bin | 2015 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver; Liv | 2015 |
Hepatocellular carcinoma: current questions and future directions.
Topics: Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Comb | 2015 |
The role of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cl | 2015 |
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenc | 2015 |
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell L | 2015 |
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Topics: Apoptosis; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; En | 2015 |
The Eltrombopag antitumor effect on hepatocellular carcinoma.
Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prol | 2015 |
Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Female; Hepatectomy; Humans; Li | 2015 |
Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free | 2015 |
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; L | 2016 |
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Foll | 2015 |
Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2015 |
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans | 2015 |
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hum | 2015 |
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Ka | 2015 |
Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Re | 2015 |
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Kaplan-Me | 2015 |
The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylure | 2015 |
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2015 |
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Resistance, Neopla | 2015 |
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
Topics: Adipose Tissue; Adult; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepa | 2015 |
Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; | 2015 |
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Pr | 2015 |
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2015 |
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; C | 2016 |
Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2016 |
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumo | 2015 |
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separa | 2015 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy | 2015 |
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aporphines; Carcinoma, Hepatocellular; CCAAT- | 2016 |
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyc | 2016 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyc | 2015 |
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell | 2015 |
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver | 2015 |
MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma, Hepato | 2016 |
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progressi | 2017 |
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, H | 2016 |
LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepat | 2016 |
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2016 |
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
Topics: Aged; Algorithms; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Chi-Square D | 2016 |
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Bindin | 2016 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2016 |
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2016 |
MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatoce | 2016 |
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Pro | 2015 |
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasm | 2016 |
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2016 |
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; | 2016 |
JAMA PATIENT PAGE. Treatment of Liver Cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Hepa | 2016 |
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene E | 2016 |
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Dyspnea; Em | 2016 |
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; | 2016 |
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phen | 2016 |
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Antibodies, Neutralizing; Apoptosis; Autocrine Communication; Carcinoma, Hepatocellular; Cell Line, | 2016 |
[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectom | 2015 |
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; | 2015 |
[Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Mod | 2015 |
[A Case of Multiple HCC with Vp2 and Vv3 Invasion Controlled by Multidisciplinary Treatment Including Surgery].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cisplatin; Combined Modal | 2015 |
[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Embolization, | 2015 |
Transketolase counteracts oxidative stress to drive cancer development.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Death; Cell Line, Tu | 2016 |
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Ceramides; Dru | 2016 |
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diff | 2016 |
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; M | 2016 |
Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2016 |
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cation Transport Proteins; Female; Gene Expressi | 2016 |
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA-Binding Pro | 2016 |
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellu | 2015 |
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Electrolytes; Female; Follow-Up Studies; | 2016 |
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoe | 2016 |
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chem | 2015 |
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse | 2016 |
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Huma | 2016 |
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2016 |
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Dr | 2016 |
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemic | 2016 |
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Dise | 2016 |
New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated | 2016 |
Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cross-Se | 2016 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carrier Proteins; Drug Resistance, Neopla | 2016 |
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; | 2016 |
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fem | 2016 |
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; | 2016 |
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Mo | 2016 |
Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Candidiasis; Carcinoma, Hepatocel | 2016 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Fema | 2016 |
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver | 2016 |
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; He | 2016 |
Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.
Topics: Apoptosis; Ascorbic Acid; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cell | 2016 |
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeuti | 2016 |
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2016 |
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherap | 2016 |
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studi | 2016 |
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Co | 2016 |
[Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid].
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Contr | 2016 |
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2016 |
Iron depletion enhances the effect of sorafenib in hepatocarcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Iron | 2016 |
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2016 |
Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferat | 2016 |
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; | 2016 |
CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.
Topics: Animals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Lineage; Chromatin; DNA Helicases; DN | 2016 |
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance | 2016 |
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Humans | 2016 |
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoe | 2016 |
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2016 |
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit | 2016 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; | 2016 |
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neopl | 2016 |
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver N | 2016 |
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Human | 2016 |
The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Ther | 2016 |
Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Hydrogen-Ion Conce | 2016 |
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; | 2016 |
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2016 |
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepato | 2016 |
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Gene Expre | 2016 |
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; | 2016 |
Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Combined Modali | 2016 |
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Disease Progression; Diseas | 2016 |
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Mo | 2016 |
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithe | 2016 |
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; France | 2016 |
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver | 2016 |
Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality | 2016 |
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Huma | 2017 |
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2017 |
Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Comput | 2016 |
Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopla | 2016 |
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hep | 2016 |
Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Sche | 2016 |
Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male | 2016 |
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors | 2016 |
Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ni | 2016 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
[Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus].
Topics: Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Endo | 2016 |
Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Gene | 2016 |
Severe adverse skin reaction and desensitization to sorafenib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Growth Processes; Desensitization, Imm | 2016 |
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Femal | 2016 |
miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor | 2016 |
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neopl | 2016 |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; b | 2016 |
[Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female | 2016 |
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neopl | 2016 |
Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; | 2016 |
Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellu | 2016 |
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2016 |
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacin | 2016 |
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Niacinamide; Pheny | 2016 |
Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumo | 2016 |
[Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma].
Topics: Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Immunotherapy; Interferons; Li | 2016 |
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; C | 2016 |
Capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; F | 2016 |
Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neop | 2017 |
Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
Topics: Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplas | 2016 |
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Co | 2016 |
The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoe | 2016 |
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Decision- | 2016 |
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Li | 2016 |
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Protein | 2016 |
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Complicat | 2017 |
Response to Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy by Borentain et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ni | 2016 |
The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C | 2016 |
Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
Topics: Angiopoietin-Like Protein 1; Angiopoietin-like Proteins; Angiopoietins; Animals; Antineoplastic Agen | 2016 |
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2016 |
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2017 |
Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Carcin | 2016 |
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ne | 2016 |
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distrib | 2016 |
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Huma | 2017 |
Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Dru | 2016 |
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survi | 2016 |
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Apoptos | 2016 |
Sorafenib plus cisplatin for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial | 2016 |
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Fe | 2016 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-S | 2017 |
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Focal Adhesion Protein- | 2016 |
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular | 2017 |
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Pro | 2016 |
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease M | 2016 |
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Surviva | 2016 |
Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; | 2016 |
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cohort St | 2016 |
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Databases, Factual; F | 2017 |
Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Diffusion Magnetic Reso | 2017 |
C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niaci | 2017 |
[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Diarrhea; Fe | 2016 |
The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diethylnitrosami | 2017 |
Painful Rashes on the Palms and Soles.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; | 2016 |
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Me | 2016 |
Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocel | 2017 |
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tu | 2017 |
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neop | 2017 |
Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Chemoradiotherapy; Dose-Re | 2016 |
Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dru | 2017 |
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepati | 2016 |
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor | 2016 |
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver | 2016 |
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disea | 2016 |
Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Glucose; Humans; Liver Neoplasms; Neoplastic Stem | 2017 |
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
Topics: Aged; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembol | 2016 |
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2017 |
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2017 |
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hyd | 2017 |
Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Live | 2017 |
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2017 |
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cel | 2017 |
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinic | 2017 |
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Fucose; | 2016 |
Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2017 |
MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regu | 2017 |
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Cell Prolifer | 2017 |
Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.
Topics: Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; C | 2017 |
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?
Topics: Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niaci | 2017 |
Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survi | 2017 |
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Card | 2017 |
An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Female; Humans; Live | 2017 |
CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplas | 2017 |
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, An | 2017 |
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fibroblast Gr | 2017 |
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3 | 2017 |
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Female; Hep G2 Cells; Humans; Liver Neop | 2017 |
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellula | 2017 |
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tum | 2017 |
[Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Diseases, Inte | 2016 |
[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 2016 |
Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Humans; Infusi | 2017 |
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2017 |
Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dual Specificity Phosphatase 1; | 2017 |
Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Aortic Aneurysm, Abdominal; Aortic Dissection; Carcinoma, Hepatocellular; End | 2017 |
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neopla | 2017 |
Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
Topics: Anthracenes; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Dru | 2017 |
The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cell Membrane; Female; Humans; Liver Neoplasms; | 2017 |
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Topics: Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Energy Met | 2017 |
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studie | 2017 |
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Human | 2017 |
Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Topics: Adult; Aged; Animals; Biomarkers, Tumor; Blood Vessels; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2017 |
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease | 2017 |
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor | 2017 |
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Liver Neopl | 2017 |
Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Fe | 2017 |
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines | 2017 |
Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2017 |
Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
Topics: Animals; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; He | 2017 |
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2017 |
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line; Drug Delivery Systems; Humans; Liver | 2017 |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ce | 2017 |
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B | 2017 |
Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Topics: Aged; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Hepatocellular; Cohort Studies; Cost | 2017 |
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Topics: Aged; Albuminuria; Antineoplastic Agents; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; | 2017 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; | 2008 |
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Niaci | 2008 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Tria | 2008 |
Sorafenib in liver cancer--just the beginning.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Costs; Humans; Liver Neoplasms; Niacinamide; Phen | 2008 |
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Wes | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, R | 2008 |
[Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; C | 2008 |
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; | 2009 |
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Human | 2008 |
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as To | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Hypertension; Incidence; Liver Neoplasms; Niac | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; H | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans | 2008 |
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2009 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical a | 2009 |
Sorafenib for liver cancer: the horizon broadens.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2009 |
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacin | 2009 |
Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Ne | 2009 |
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver | 2009 |
Treating hepatocellular carcinoma without liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cathet | 2009 |
Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Benzenesulfonates; Carcinoma, Hepatoce | 2009 |
Major achievements in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2009 |
Major achievements in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2009 |
Major achievements in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2009 |
Major achievements in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2009 |
[Diagnosis and treatment of hepatocellular carcinoma].
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Early Detection of Cancer; Hepatectomy; Hu | 2009 |
Hyperkeratosis of nipple skin during sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Breast Diseases; Carcinoma, Hepatocellular; Humans; | 2009 |
NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Ce | 2009 |
[Hepatocellular carcinoma management in the era of sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2009 |
[Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; B | 2009 |
[Prospect of hepatocellular carcinoma in 2008].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diagnosis, Differential; Humans | 2009 |
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II | 2009 |
Localized dyskeratotic plaque with milia associated with sorafenib.
Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepat | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfon | 2009 |
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Li | 2009 |
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Ad | 2009 |
Tumor endothelial cells join the resistance.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonate | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellu | 2009 |
[Expert consensus on standardization of the management of primary liver cancer].
Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Che | 2009 |
[Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzenesulfonates; Carcinoma, H | 2009 |
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellula | 2009 |
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinic | 2009 |
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; | 2009 |
Hepatocellular carcinoma: The beginning of a long journey.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Human | 2009 |
Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Clinical Trials, Ph | 2009 |
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as T | 2009 |
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B | 2009 |
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cel | 2009 |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; | 2009 |
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle A | 2009 |
Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, | 2009 |
Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Calcium; Carcinoma, Hepatocellular; Caspase 3; | 2009 |
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor V | 2010 |
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Protocols; Humans; Li | 2009 |
Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; C | 2010 |
Sorafenib-induced hepatic encephalopathy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Dru | 2009 |
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; | 2010 |
Sorafenib-induced bilateral osteonecrosis of femoral heads.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Femur Head Necrosis; Humans; Li | 2010 |
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellu | 2010 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, | 2010 |
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; H | 2009 |
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; | 2010 |
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
Topics: Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Polarity; Hep G2 Cells; | 2010 |
Baying for a flexible drug price.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Ind | 2009 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver | 2010 |
Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; | 2010 |
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hep | 2009 |
[Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, | 2009 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; | 2010 |
Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Liver | 2010 |
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2010 |
Hepatocellular carcinoma: sorafenib before liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; | 2010 |
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2010 |
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Be | 2010 |
Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Topics: ADAM Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dipeptides; Down-Regu | 2010 |
A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Hepatocellular; Cho | 2010 |
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2010 |
Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Carcinoma, Hepatocellular; Chemotherapy, | 2009 |
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Hepatitis C | 2010 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cir | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2011 |
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis | 2010 |
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Topics: Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures | 2010 |
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepato | 2010 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcin | 2010 |
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tu | 2010 |
Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2010 |
Drug therapy: sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasm | 2010 |
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
Topics: Actins; Benzenesulfonates; Carcinoma, Hepatocellular; Cofilin 1; Cytoskeleton; Enzyme Activation; Hu | 2010 |
Sorafenib-induced acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Ne | 2010 |
A case of variant angina in a patient under chronic treatment with sorafenib.
Topics: Angina Pectoris, Variant; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardi | 2010 |
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Dru | 2010 |
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phe | 2010 |
Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, | 2010 |
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cl | 2010 |
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2010 |
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2010 |
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemi | 2010 |
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis B virus; | 2010 |
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver | 2011 |
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Biomarkers, Tumor; Biphenyl Compounds; Blotting | 2010 |
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Health-related quality of life and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; | 2010 |
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Car | 2010 |
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Mag | 2011 |
Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Live | 2012 |
From a cancer drug fund to value based pricing of drugs.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; England; | 2010 |
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Calcium Channel Blockers; Carcinoma, He | 2011 |
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Immunosuppressive Agents; | 2011 |
The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Car | 2010 |
Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
Topics: Aged; Antiretroviral Therapy, Highly Active; Benzenesulfonates; Carcinoma, Hepatocellular; Coinfecti | 2011 |
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Li | 2010 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, C | 2010 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovas | 2010 |
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brachytherapy; Carcinoma, Hepatocellular; Cause of | 2010 |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, He | 2010 |
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular | 2011 |
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal | 2011 |
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; F | 2011 |
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male | 2011 |
Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Animals; Anthracenes; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Benzenesulfonates | 2010 |
Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as T | 2010 |
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Administration Sched | 2010 |
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio | 2010 |
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2010 |
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Huma | 2010 |
Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2011 |
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Thera | 2010 |
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Combin | 2011 |
Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell P | 2010 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoemb | 2010 |
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease | 2010 |
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Li | 2011 |
Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Fema | 2010 |
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenes | 2011 |
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell G | 2010 |
How I manage my patients with hepatocellular carcinoma.
Topics: Ablation Techniques; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; D | 2011 |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistan | 2011 |
Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; | 2011 |
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulati | 2011 |
[The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female | 2010 |
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2010 |
Complete response for advanced liver cancer during sorafenib therapy: case report.
Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatoce | 2011 |
Invasive squamous cell carcinoma and sorafenib in a black patient.
Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamo | 2011 |
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Topics: Aged; Antineoplastic Agents; Aspirin; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; | 2011 |
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, P | 2012 |
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcino | 2011 |
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Chemother | 2011 |
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, | 2011 |
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Atrophy; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; | 2011 |
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hep | 2011 |
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Topics: Animals; Benzenesulfonates; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Division; Cell Line, | 2011 |
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Doxorubici | 2011 |
Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Fata | 2011 |
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Functional analysis of microRNAs in human hepatocellular cancer stem cells.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2012 |
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; | 2011 |
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, S | 2011 |
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Fem | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cont | 2011 |
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcin | 2011 |
Which treatment modality should we choose for advanced hepatocellular carcinoma?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2010 |
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Fema | 2011 |
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherap | 2011 |
All that glitters: sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Ne | 2011 |
Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hep | 2011 |
Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Disease Models, Animal; Di | 2012 |
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chi-Square | 2011 |
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hep | 2011 |
Laryngeal metastasis as first presentation of hepatocellular carcinoma.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined | 2011 |
microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
Topics: ADAM Proteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Down-Regulation; | 2011 |
The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Topics: Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Eukaryotic Initiation Fac | 2011 |
Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Casein | 2011 |
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; China; Disease Progression; Hum | 2011 |
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; M | 2011 |
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Topics: Ablation Techniques; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Li | 2010 |
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autocrine | 2012 |
Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, | 2012 |
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2011 |
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; | 2012 |
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxyc | 2011 |
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Dise | 2011 |
Severe sorafenib-induced hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Dis | 2011 |
Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Gastrointestinal | 2011 |
[In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2011 |
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2011 |
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms | 2012 |
Targeting STAT3 in hepatocellular carcinoma: sorafenib again….
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylu | 2011 |
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Dea | 2011 |
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatography, High Pressure L | 2012 |
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellul | 2011 |
Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; | 2011 |
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hu | 2011 |
Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Autophagy; Benzenesulfonates; Carcinoma, Hepatoc | 2011 |
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therap | 2012 |
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell A | 2012 |
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progressi | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; B | 2011 |
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophag | 2012 |
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line | 2012 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fem | 2011 |
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug | 2011 |
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; | 2011 |
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.
Topics: Adenosine Triphosphate; Aerobiosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellu | 2011 |
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Earl | 2011 |
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Fem | 2011 |
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mal | 2013 |
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dose-Response Relationshi | 2012 |
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatoce | 2011 |
[Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Topics: Anticoagulants; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, C | 2011 |
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms | 2011 |
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Bioma | 2011 |
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzy | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirr | 2012 |
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Disease Progression | 2012 |
A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Calibration; Carcinoma, Hepatocellular; Chromatography, Hi | 2011 |
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; C | 2011 |
The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohor | 2011 |
SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineo | 2012 |
Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2011 |
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Topics: Animals; Apoptosis; Benzenesulfonates; Benzimidazoles; Blotting, Western; Carcinoma, Hepatocellular; | 2012 |
Iron facilitator LS081 reduces hypoxia-inducible factor-1α protein and functions as anticancer agent in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; HEK293 Cells; Hep G2 Cells; Human | 2012 |
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoe | 2012 |
[Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neo | 2011 |
[Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 2011 |
[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy | 2011 |
Multidisciplinary management of nonresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2011 |
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, | 2011 |
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neo | 2011 |
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Ce | 2012 |
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Im | 2012 |
Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzenesulfonates; Caffeine; Carcinom | 2012 |
Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver | 2011 |
Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, | 2012 |
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2012 |
A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiomyopathies; Coronary Angiography; Fema | 2012 |
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, The | 2012 |
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; D | 2012 |
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzene | 2012 |
Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellul | 2012 |
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2012 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular | 2012 |
TACE with or without systemic therapy?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; H | 2012 |
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomar | 2012 |
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Bio | 2012 |
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms | 2012 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, H | 2013 |
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidin | 2012 |
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2012 |
The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationshi | 2012 |
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistan | 2012 |
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2012 |
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
Topics: Antineoplastic Agents; Benzenesulfonates; Bronchial Arteries; Carcinoma, Hepatocellular; Chemoemboli | 2012 |
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hep | 2012 |
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Fa | 2013 |
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease | 2012 |
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2012 |
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
Topics: AC133 Antigen; Adult; Aged; Animals; Antigens, CD; Benzenesulfonates; Carcinoma, Hepatocellular; Cel | 2012 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Mon | 2012 |
Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Protocols; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cell | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug | 2012 |
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcin | 2012 |
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell C | 2012 |
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Rela | 2012 |
Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neovascularizat | 2012 |
The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines.
Topics: Antigens, Differentiation; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Casp | 2012 |
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Decision Making; Female; Humans | 2012 |
[A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Hum | 2012 |
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Thera | 2012 |
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Genetic Pr | 2013 |
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Co | 2013 |
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Fo | 2012 |
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellula | 2012 |
[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; D | 2012 |
MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma.
Topics: Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tum | 2012 |
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hep | 2012 |
[Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neo | 2012 |
Molecular mechanisms of sorafenib action in liver cancer cells.
Topics: Apoptosis; Benzenesulfonates; Biological Transport; Carcinoma, Hepatocellular; Cell Adhesion; Cell C | 2012 |
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Lin | 2012 |
Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 2013 |
Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Down-Regulation; F | 2013 |
Right sided heart mass reveals hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Live | 2012 |
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, He | 2012 |
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials, Phase I | 2012 |
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; | 2012 |
Closing remarks.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; | 2012 |
Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kapla | 2013 |
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carci | 2012 |
[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; | 2012 |
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomar | 2012 |
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line | 2013 |
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbid | 2012 |
Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Size; Cer | 2012 |
[Hepatocellular carcinoma - long-term treatable disease].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; | 2012 |
Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Anima | 2012 |
RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2013 |
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulat | 2012 |
Clinicopathological characteristics of hepatocellular carcinoma in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Bioma | 2012 |
[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male | 2012 |
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fibroblast Growth Factor 3; Fibro | 2013 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, | 2012 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver | 2012 |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2013 |
Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Financial | 2012 |
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2012 |
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellula | 2012 |
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; C | 2012 |
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamin | 2013 |
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Magnetic Resonance Imagin | 2013 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up S | 2013 |
Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Surv | 2012 |
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Hum | 2012 |
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; H | 2013 |
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochromes c; Down-Regulation; Gen | 2013 |
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Topics: Anilides; Antineoplastic Agents; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; | 2013 |
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; | 2013 |
Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; DNA Dama | 2013 |
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplanta | 2012 |
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Disease | 2013 |
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease P | 2012 |
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferat | 2013 |
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Li | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2013 |
PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; C | 2012 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular | 2013 |
Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Humans; Liver Neoplas | 2013 |
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; CD4-Positive T-Lymphocytes; | 2013 |
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed?
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Hepatocellular; Cell Death; Clinical Trial | 2012 |
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fat | 2012 |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolys | 2013 |
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neop | 2012 |
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female | 2012 |
[A case of hepatocellular carcinoma treated by resection of metachronous rib metastasis after primary hepatectomy].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; H | 2012 |
[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispla | 2012 |
Letter: The antiviral activity of sorafenib in patients with hepatitis C-related hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C; Humans; Liver Neoplasms; Male | 2013 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemo | 2012 |
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; K | 2013 |
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Li | 2013 |
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Contr | 2013 |
Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; | 2013 |
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Femal | 2013 |
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin | 2013 |
αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
Topics: 14-3-3 Proteins; alpha-Crystallin B Chain; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Li | 2013 |
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2013 |
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Beclin-1; Carcinoma, Hepat | 2013 |
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, T | 2013 |
[Regulation of the biosynthesis of ribonucleic acids. Action of nicotinamide].
Topics: Animals; Carcinoma, Hepatocellular; Kidney; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; N | 1961 |
[SOME ASPECTS OF THE REGULATION OF RIBONUCLEIC ACID BIOSYNTHESES IN HIGHER ANIMALS].
Topics: Carcinoma, Hepatocellular; Chromatography; Leucine; Liver; Liver Neoplasms; Metabolism; NAD; Neoplas | 1964 |
CONCENTRATIONS AND RATES OF SYNTHESIS OF NICOTINAMIDE-ADENINE-DINUCLEODIDE PHOSPHATE IN PRECANCEROUS LIVERS AND HEPATOMAS INDUCED BY AZO-DYE FEEDING.
Topics: Adenine; Carcinogens; Carcinoma, Hepatocellular; Liver; Liver Neoplasms; NADP; Neoplasms; Neoplasms, | 1964 |
THE EFFECT OF SHORT-TERM FEEDING EXPERIMENTS WITH 3'-METHYL-4-DIMETHYLAMINOAZOBENZENE OF RAT-LIVER MITOCHONDRIAL FUNCTION.
Topics: Carcinoma, Hepatocellular; Citrates; Citric Acid Cycle; Glutamates; Hydroxybutyrates; Isocitrate Deh | 1964 |
[STUDIES ON NICOTINAMIDE METHYLPHERASE ACTIVITY IN THE LIVER OF TUMOR-BEARING RAT].
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Carcinoma, Hepatocellular; Cortisone; Endotoxins; Fluoro | 1964 |
THE ESTIMATION OF THE OXIDIZED AND REDUCED FORMS OF THE NICOTINAMIDE NUCLEOTIDES.
Topics: Adipose Tissue; Alcohol Oxidoreductases; Animals; Carcinoma, Hepatocellular; Glucosephosphate Dehydr | 1965 |
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Topics: Acrylamides; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Ce | 2003 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as To | 2006 |
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Death | 2006 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinom | 2007 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2008 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Comb | 2008 |
FDA approves sorafenib for patients with inoperable liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Ne | 2008 |
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tum | 2008 |
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Protocols; Contraindic | 2008 |
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western | 2008 |
Pyridine nucleotide metabolism in the erythrocyte of South African blacks with primary hepatoma.
Topics: Black People; Carcinoma, Hepatocellular; Erythrocytes; Humans; Liver Neoplasms; Models, Biological; | 1982 |
Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1.
Topics: alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cell Transformatio | 1994 |
Pancreatic islet-cell and other tumors in rats given heliotrine, a monoester pyrrolizidine alkaloid, and nicotinamide.
Topics: Adenoma; Adenoma, Islet Cell; Animals; Carcinoma, Hepatocellular; Hyperplasia; Liver Neoplasms; Male | 1975 |
[The effect of lactoflavin, nicotinic acid amide or dipyridamol on the cancerogenic action of diethylnitrosamine in rats].
Topics: Animals; Carcinogens; Carcinoma, Hepatocellular; Dipyridamole; Female; Kidney; Liver; Liver Neoplasm | 1968 |